{"5fb7bd615184ada5f4ed81103f9eaf3bc950fd2a": [["IntroductionHuman bocavirus (HBoV) is a newly recognised respiratory pathogen that mainly affects children aged <2 years.", [["respiratory pathogen", "DISEASE", 57, 77], ["IntroductionHuman bocavirus", "ORGANISM", 0, 27], ["HBoV", "ORGANISM", 29, 33], ["children", "ORGANISM", 98, 106], ["children", "SPECIES", 98, 106], ["HBoV", "SPECIES", 29, 33], ["IntroductionHuman bocavirus (HBoV", "PROBLEM", 0, 33], ["respiratory pathogen", "OBSERVATION", 57, 77]]], ["1 It is a member of the Parvoviridae family, subfamily Parvovirinae, genus bocavirus.", [["Parvoviridae", "GENE_OR_GENE_PRODUCT", 24, 36], ["Parvovirinae", "GENE_OR_GENE_PRODUCT", 55, 67], ["Parvoviridae family", "PROTEIN", 24, 43], ["bocavirus", "PROTEIN", 75, 84], ["Parvovirinae", "TREATMENT", 55, 67], ["genus bocavirus", "PROBLEM", 69, 84], ["genus bocavirus", "OBSERVATION", 69, 84]]], ["Since its first description in 2005 by Allander et al., it has been found worldwide in respiratory specimens from children with lower respiratory tract (LRT) infection with a prevalence varying from 1.5% to 19%.", [["respiratory specimens", "ANATOMY", 87, 108], ["lower respiratory tract", "ANATOMY", 128, 151], ["lower respiratory tract (LRT) infection", "DISEASE", 128, 167], ["children", "ORGANISM", 114, 122], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 128, 151], ["children", "SPECIES", 114, 122], ["lower respiratory tract (LRT) infection", "PROBLEM", 128, 167], ["worldwide", "OBSERVATION_MODIFIER", 74, 83], ["respiratory specimens", "OBSERVATION", 87, 108], ["lower", "ANATOMY_MODIFIER", 128, 133], ["respiratory tract", "ANATOMY", 134, 151], ["infection", "OBSERVATION", 158, 167]]], ["2, 3 HBoV has also been isolated from faeces of children with gastroenteritis, with or without respiratory symptoms.", [["faeces", "ANATOMY", 38, 44], ["respiratory", "ANATOMY", 95, 106], ["gastroenteritis", "DISEASE", 62, 77], ["respiratory symptoms", "DISEASE", 95, 115], ["HBoV", "ORGANISM", 5, 9], ["faeces", "ORGANISM_SUBDIVISION", 38, 44], ["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["HBoV", "SPECIES", 5, 9], ["gastroenteritis", "PROBLEM", 62, 77], ["respiratory symptoms", "PROBLEM", 95, 115], ["gastroenteritis", "OBSERVATION", 62, 77]]], ["4 Recent studies have described two novel HBoV groups, named HBoV2 and HBoV3.", [["HBoV", "ORGANISM", 42, 46], ["HBoV2", "GENE_OR_GENE_PRODUCT", 61, 66], ["HBoV3", "GENE_OR_GENE_PRODUCT", 71, 76], ["HBoV2", "PROTEIN", 61, 66], ["HBoV3", "PROTEIN", 71, 76], ["Recent studies", "TEST", 2, 16]]], ["5 Publications addressing the epidemiology of nosocomial respiratory virus infection are scarce.", [["nosocomial respiratory virus infection", "DISEASE", 46, 84], ["nosocomial respiratory virus", "ORGANISM", 46, 74], ["nosocomial respiratory virus", "SPECIES", 46, 74], ["nosocomial respiratory virus infection", "PROBLEM", 46, 84], ["nosocomial", "OBSERVATION_MODIFIER", 46, 56], ["respiratory virus infection", "OBSERVATION", 57, 84]]], ["A few authors have reported cases of nosocomial HBoV infection, mostly acquired in intensive care units.", [["HBoV infection", "DISEASE", 48, 62], ["HBoV", "ORGANISM", 48, 52], ["HBoV", "SPECIES", 48, 52], ["nosocomial HBoV infection", "PROBLEM", 37, 62], ["nosocomial", "OBSERVATION_MODIFIER", 37, 47], ["HBoV infection", "OBSERVATION", 48, 62]]], ["6e8 As a potential new agent of nosocomial childhood infection, we screened for HBoV in young children with respiratory tract infection.MethodsThe data presented are part of a prospective study on the aetiology of childhood respiratory infections being carried out at Santa Casa de Miseric\u00f3rdia Hospital, S\u00e3o Paulo, Brazil.", [["respiratory tract", "ANATOMY", 108, 125], ["respiratory", "ANATOMY", 224, 235], ["6e8", "CHEMICAL", 0, 3], ["nosocomial childhood infection", "DISEASE", 32, 62], ["HBoV", "DISEASE", 80, 84], ["respiratory tract infection", "DISEASE", 108, 135], ["respiratory infections", "DISEASE", 224, 246], ["HBoV", "ORGANISM", 80, 84], ["children", "ORGANISM", 94, 102], ["tract", "ORGANISM_SUBDIVISION", 120, 125], ["children", "SPECIES", 94, 102], ["HBoV", "SPECIES", 80, 84], ["nosocomial childhood infection", "PROBLEM", 32, 62], ["HBoV", "PROBLEM", 80, 84], ["respiratory tract infection", "PROBLEM", 108, 135], ["a prospective study", "TEST", 174, 193], ["childhood respiratory infections", "PROBLEM", 214, 246], ["new", "OBSERVATION_MODIFIER", 19, 22], ["nosocomial", "OBSERVATION_MODIFIER", 32, 42], ["infection", "OBSERVATION", 53, 62], ["respiratory tract", "ANATOMY", 108, 125], ["infection", "OBSERVATION", 126, 135], ["respiratory", "ANATOMY", 224, 235], ["infections", "OBSERVATION", 236, 246]]], ["Santa Casa is a tertiary reference hospital located in the central region of S\u00e3o Paulo City.MethodsFrom January 2008 to December 2008, nasopharyngeal aspirates (NPAs) were collected from children aged <2 years and screened for respiratory viruses including HBoV.", [["nasopharyngeal aspirates", "ANATOMY", 135, 159], ["NPAs", "ANATOMY", 161, 165], ["respiratory viruses", "DISEASE", 227, 246], ["HBoV", "DISEASE", 257, 261], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 135, 159], ["NPAs", "CANCER", 161, 165], ["children", "ORGANISM", 187, 195], ["HBoV", "ORGANISM", 257, 261], ["children", "SPECIES", 187, 195], ["HBoV", "SPECIES", 257, 261], ["Methods", "TREATMENT", 92, 99], ["nasopharyngeal aspirates", "TEST", 135, 159], ["respiratory viruses", "PROBLEM", 227, 246], ["HBoV", "PROBLEM", 257, 261], ["central", "ANATOMY_MODIFIER", 59, 66], ["nasopharyngeal", "ANATOMY", 135, 149], ["aspirates", "OBSERVATION", 150, 159], ["respiratory", "ANATOMY", 227, 238], ["viruses", "OBSERVATION", 239, 246]]], ["Two groups of children were screened: (1) children on the paediatric ward or intensive care unit (ICU) with clinically suspected LRT infection (either community-or hospital-acquired), and (2) infants who had been in the neonatal ICU (NICU) since birth.", [["infection", "DISEASE", 133, 142], ["children", "ORGANISM", 14, 22], ["children", "ORGANISM", 42, 50], ["infants", "ORGANISM", 192, 199], ["children", "SPECIES", 14, 22], ["children", "SPECIES", 42, 50], ["infants", "SPECIES", 192, 199], ["LRT infection", "PROBLEM", 129, 142], ["infection", "OBSERVATION", 133, 142]]], ["On the NICU, NPAs were collected from those with suspected LRT infection, and once a week from asymptomatic infants who were receiving mechanical ventilation.MethodsNPAs were stored in liquid nitrogen and sent weekly to the virology laboratory of the University of S\u00e3o Paulo for detection of respiratory virus by polymerase chain reaction (PCR).", [["LRT infection", "DISEASE", 59, 72], ["nitrogen", "CHEMICAL", 192, 200], ["NPAs", "SIMPLE_CHEMICAL", 13, 17], ["infants", "ORGANISM", 108, 115], ["MethodsNPAs", "SIMPLE_CHEMICAL", 158, 169], ["infants", "SPECIES", 108, 115], ["respiratory virus", "SPECIES", 292, 309], ["LRT infection", "PROBLEM", 59, 72], ["mechanical ventilation", "TREATMENT", 135, 157], ["liquid nitrogen", "TREATMENT", 185, 200], ["respiratory virus", "PROBLEM", 292, 309], ["polymerase chain reaction", "PROBLEM", 313, 338], ["PCR", "TEST", 340, 343], ["infection", "OBSERVATION", 63, 72], ["respiratory virus", "OBSERVATION", 292, 309]]], ["9 All samples were tested for the following respiratory viruses: respiratory syncytial virus, human metapneumovirus, parainfluenza virus 1, 2 and 3, influenza virus A and B and adenovirus.", [["samples", "ANATOMY", 6, 13], ["respiratory viruses", "DISEASE", 44, 63], ["respiratory syncytial virus", "DISEASE", 65, 92], ["human metapneumovirus", "DISEASE", 94, 115], ["parainfluenza virus", "DISEASE", 117, 136], ["respiratory syncytial virus", "ORGANISM", 65, 92], ["human metapneumovirus", "ORGANISM", 94, 115], ["parainfluenza virus 1", "ORGANISM", 117, 138], ["3", "GENE_OR_GENE_PRODUCT", 146, 147], ["influenza virus A", "ORGANISM", 149, 166], ["B", "GENE_OR_GENE_PRODUCT", 171, 172], ["adenovirus", "ORGANISM", 177, 187], ["respiratory syncytial virus", "SPECIES", 65, 92], ["human", "SPECIES", 94, 99], ["metapneumovirus", "SPECIES", 100, 115], ["parainfluenza virus 1", "SPECIES", 117, 138], ["influenza virus", "SPECIES", 149, 164], ["respiratory syncytial virus", "SPECIES", 65, 92], ["human metapneumovirus", "SPECIES", 94, 115], ["parainfluenza virus 1", "SPECIES", 117, 138], ["influenza virus A", "SPECIES", 149, 166], ["All samples", "TEST", 2, 13], ["respiratory syncytial virus", "PROBLEM", 65, 92], ["human metapneumovirus", "TEST", 94, 115], ["parainfluenza virus", "PROBLEM", 117, 136], ["influenza virus A", "PROBLEM", 149, 166], ["adenovirus", "PROBLEM", 177, 187], ["respiratory syncytial", "ANATOMY", 65, 86]]], ["PCR and reverse transcription (RT)ePCR assays were developed based on previous publications using GeneScan analysis with primers previously described.", [["PCR", "TEST", 0, 3], ["reverse transcription (RT)ePCR assays", "TEST", 8, 45], ["GeneScan analysis", "TEST", 98, 115], ["primers", "TREATMENT", 121, 128]]], ["10e12 PCR for HBoV was performed using primers previously described targeting the NS1 gene.", [["HBoV", "ORGANISM", 14, 18], ["NS1", "GENE_OR_GENE_PRODUCT", 82, 85], ["NS1 gene", "DNA", 82, 90], ["HBoV", "SPECIES", 14, 18], ["PCR", "TEST", 6, 9], ["HBoV", "PROBLEM", 14, 18], ["primers", "TREATMENT", 39, 46]]], ["13 All HBoV-positive samples were amplified by a second PCR using primers based on a conserved region of the VP1/VP2 gene: HBoVP1 (5 0 4128 ACCACCAAGTACTTAGAACTGG 4149 3 0 ) and HBoVP2 (3 0 4785 AATAGTGCCTGGAGGATGATCC 4765 5 0 ).", [["samples", "ANATOMY", 21, 28], ["HBoV", "ORGANISM", 7, 11], ["VP1", "GENE_OR_GENE_PRODUCT", 109, 112], ["VP2", "GENE_OR_GENE_PRODUCT", 113, 116], ["VP1/VP2 gene", "DNA", 109, 121], ["HBoVP1", "DNA", 123, 129], ["All HBoV", "TEST", 3, 11], ["a second PCR", "TEST", 47, 59], ["the VP1", "TEST", 105, 112], ["HBoVP1", "TEST", 123, 129], ["ACCACCAAGTACTTAGAACTGG", "TEST", 140, 162], ["HBoVP2", "TEST", 178, 184], ["AATAGTGCCTGGAGGATGATCC", "TEST", 195, 217]]], ["The expected product size was 657 bp.", [["bp", "TEST", 34, 36], ["size", "OBSERVATION_MODIFIER", 21, 25]]], ["In most cases these products were sequenced for phylogenetic analysis.", [["phylogenetic analysis", "TEST", 48, 69]]], ["Sequences were edited with the sequence navigator program version 1.0 (Applied Biosystems, Inc., Foster City, CA, USA) and the phylogenetic tree was created by the clustal method using Megalign (Lacergene, DNA STAR, Inc., Madison, WI, USA).MethodsThe study was approved by the Research Ethics Committee of Santa Casa de Miseric\u00f3rdia Hospital and by the University of S\u00e3o Paulo.", [["DNA", "CELLULAR_COMPONENT", 206, 209], ["Megalign (Lacergene", "TREATMENT", 185, 204]]], ["Written informed consent was obtained from the parent or guardian of each child enrolled in the study.ResultsA total of 511 NPA were collected from 406 children: 381 samples were collected from 359 children in the paediatric ward and ICU, while 130 were collected from 47 infants in the NICU.", [["samples", "ANATOMY", 166, 173], ["NPA", "CHEMICAL", 124, 127], ["NPA", "CANCER", 124, 127], ["children", "ORGANISM", 152, 160], ["children", "ORGANISM", 198, 206], ["infants", "ORGANISM", 272, 279], ["children", "SPECIES", 152, 160], ["children", "SPECIES", 198, 206], ["infants", "SPECIES", 272, 279], ["the study", "TEST", 92, 101], ["NPA", "TEST", 124, 127]]], ["Fiftyfive samples (10.7%) were positive for HBoV, with a higher prevalence between May and August.ResultsTen of the HBoV infections were definitely or probably acquired in the hospital.", [["samples", "ANATOMY", 10, 17], ["HBoV", "DISEASE", 44, 48], ["HBoV infections", "DISEASE", 116, 131], ["Fiftyfive samples", "CANCER", 0, 17], ["HBoV", "ORGANISM", 44, 48], ["HBoV", "ORGANISM", 116, 120], ["HBoV", "SPECIES", 44, 48], ["HBoV", "SPECIES", 116, 120], ["Fiftyfive samples", "TEST", 0, 17], ["HBoV", "PROBLEM", 44, 48], ["the HBoV infections", "PROBLEM", 112, 131], ["HBoV infections", "OBSERVATION", 116, 131]]], ["Four infants had been in the NICU since birth (patients 1, 2, 3 and 10) while four infants admitted from the community had previously tested negative for HBoV (patients 4, 6, 7 and 9).", [["HBoV", "DISEASE", 154, 158], ["infants", "ORGANISM", 5, 12], ["patients", "ORGANISM", 47, 55], ["infants", "ORGANISM", 83, 90], ["HBoV", "ORGANISM", 154, 158], ["patients", "ORGANISM", 160, 168], ["infants", "SPECIES", 5, 12], ["patients", "SPECIES", 47, 55], ["infants", "SPECIES", 83, 90], ["patients", "SPECIES", 160, 168], ["HBoV", "SPECIES", 154, 158], ["HBoV", "PROBLEM", 154, 158]]], ["One infant (patient 8) was in the paediatric ICU following liver transplantation and developed respiratory distress 28 days after admission.", [["liver", "ANATOMY", 59, 64], ["respiratory", "ANATOMY", 95, 106], ["respiratory distress", "DISEASE", 95, 115], ["infant", "ORGANISM", 4, 10], ["patient", "ORGANISM", 12, 19], ["liver", "ORGAN", 59, 64], ["infant", "SPECIES", 4, 10], ["patient", "SPECIES", 12, 19], ["liver transplantation", "TREATMENT", 59, 80], ["respiratory distress", "PROBLEM", 95, 115], ["liver", "ANATOMY", 59, 64], ["transplantation", "OBSERVATION", 65, 80], ["respiratory", "ANATOMY", 95, 106], ["distress", "OBSERVATION", 107, 115]]], ["The final patient (patient 5) was in the paediatric ward being treated for visceral leishmaniasis and developed LRT infection 17 days after admission.", [["visceral", "ANATOMY", 75, 83], ["visceral leishmaniasis", "DISEASE", 75, 97], ["LRT infection", "DISEASE", 112, 125], ["patient", "ORGANISM", 10, 17], ["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 10, 17], ["patient", "SPECIES", 19, 26], ["visceral leishmaniasis", "PROBLEM", 75, 97], ["LRT infection", "PROBLEM", 112, 125], ["visceral", "ANATOMY", 75, 83], ["leishmaniasis", "OBSERVATION", 84, 97], ["LRT", "OBSERVATION_MODIFIER", 112, 115], ["infection", "OBSERVATION", 116, 125]]], ["The characteristics of the patients with hospital-acquired HBoV are described in Table I .ResultsAmong the 45 presumed community-acquired HBoV infections, 23 (51.1%) were coinfected with at least one other respiratory virus, particularly adenovirus and respiratory syncytial virus (RSV) (in nine cases each).", [["HBoV", "DISEASE", 59, 63], ["HBoV infections", "DISEASE", 138, 153], ["respiratory virus", "DISEASE", 206, 223], ["respiratory syncytial virus", "DISEASE", 253, 280], ["patients", "ORGANISM", 27, 35], ["HBoV", "ORGANISM", 59, 63], ["HBoV", "ORGANISM", 138, 142], ["adenovirus", "ORGANISM", 238, 248], ["respiratory syncytial virus", "ORGANISM", 253, 280], ["RSV", "ORGANISM", 282, 285], ["patients", "SPECIES", 27, 35], ["respiratory syncytial virus", "SPECIES", 253, 280], ["HBoV", "SPECIES", 138, 142], ["respiratory syncytial virus", "SPECIES", 253, 280], ["RSV", "SPECIES", 282, 285], ["acquired HBoV", "PROBLEM", 50, 63], ["acquired HBoV infections", "PROBLEM", 129, 153], ["other respiratory virus", "PROBLEM", 200, 223], ["adenovirus", "PROBLEM", 238, 248], ["respiratory syncytial virus", "PROBLEM", 253, 280], ["HBoV", "OBSERVATION", 59, 63], ["respiratory virus", "OBSERVATION", 206, 223], ["respiratory", "ANATOMY", 253, 264], ["syncytial virus", "OBSERVATION", 265, 280]]], ["Of the 10 hospital-acquired infections, only one was coinfected (adenovirus).ResultsPhylogenetic analysis of eight of the 10 HBoV amplicons revealed three different strains of HBoV group 1 with 99.6e99.8% similarity (Figure 1 ).", [["infections", "DISEASE", 28, 38], ["adenovirus", "ORGANISM", 65, 75], ["HBoV", "ORGANISM", 125, 129], ["HBoV", "ORGANISM", 176, 180], ["HBoV amplicons", "DNA", 125, 139], ["HBoV group", "SPECIES", 176, 186], ["HBoV group 1", "SPECIES", 176, 188], ["acquired infections", "PROBLEM", 19, 38], ["Phylogenetic analysis", "TEST", 84, 105], ["the 10 HBoV amplicons", "TEST", 118, 139], ["HBoV group", "TEST", 176, 186], ["infections", "OBSERVATION", 28, 38]]], ["Two amplicons (representing patients 8 and 10) were not sequenced.DiscussionNosocomial HBoV infection has been recently described.", [["HBoV infection", "DISEASE", 87, 101], ["patients", "ORGANISM", 28, 36], ["HBoV", "ORGANISM", 87, 91], ["patients", "SPECIES", 28, 36], ["Nosocomial HBoV", "SPECIES", 76, 91], ["Two amplicons", "TREATMENT", 0, 13], ["Nosocomial HBoV infection", "PROBLEM", 76, 101], ["infection", "OBSERVATION", 92, 101]]], ["Kesebir et al. reported three children who were infected in the hospital, all of whom had a history of premature birth and chronic lung disease.", [["lung", "ANATOMY", 131, 135], ["premature birth", "DISEASE", 103, 118], ["chronic lung disease", "DISEASE", 123, 143], ["children", "ORGANISM", 30, 38], ["lung", "ORGAN", 131, 135], ["children", "SPECIES", 30, 38], ["premature birth", "PROBLEM", 103, 118], ["chronic lung disease", "PROBLEM", 123, 143], ["infected", "OBSERVATION", 48, 56], ["chronic", "OBSERVATION_MODIFIER", 123, 130], ["lung", "ANATOMY", 131, 135], ["disease", "OBSERVATION", 136, 143]]], ["6 Chow et al. reported three cases of nosocomial HBoV, two in the NICU.", [["HBoV", "DISEASE", 49, 53], ["HBoV", "ORGANISM", 49, 53], ["HBoV", "SPECIES", 49, 53], ["nosocomial HBoV", "PROBLEM", 38, 53]]], ["8 Calvo et al. described two newborns with HBoV in the NICU, both premature and receiving mechanical ventilation.", [["HBoV", "DISEASE", 43, 47], ["newborns", "ORGANISM", 29, 37], ["HBoV", "ORGANISM", 43, 47], ["HBoV", "SPECIES", 43, 47], ["HBoV", "PROBLEM", 43, 47], ["mechanical ventilation", "TREATMENT", 90, 112], ["HBoV", "OBSERVATION", 43, 47], ["mechanical ventilation", "OBSERVATION", 90, 112]]], ["7 In this paper we describe 10 further cases of nosocomial HBoV infection in children and infants.", [["HBoV infection", "DISEASE", 59, 73], ["HBoV", "ORGANISM", 59, 63], ["children", "ORGANISM", 77, 85], ["infants", "ORGANISM", 90, 97], ["children", "SPECIES", 77, 85], ["infants", "SPECIES", 90, 97], ["HBoV", "SPECIES", 59, 63], ["nosocomial HBoV infection", "PROBLEM", 48, 73], ["nosocomial", "OBSERVATION_MODIFIER", 48, 58], ["HBoV infection", "OBSERVATION", 59, 73]]], ["Sequence analysis of eight of the infecting viruses revealed three different strains of HBoV group 1, denominated A (six cases), B (one case) and C (one case).DiscussionAmong these 10 children, only one was coinfected with another respiratory virus (adenovirus).", [["HBoV", "ORGANISM", 88, 92], ["children", "ORGANISM", 184, 192], ["respiratory virus", "ORGANISM", 231, 248], ["adenovirus", "ORGANISM", 250, 260], ["HBoV group", "SPECIES", 88, 98], ["children", "SPECIES", 184, 192], ["HBoV group 1", "SPECIES", 88, 100], ["Sequence analysis", "TEST", 0, 17], ["the infecting viruses", "PROBLEM", 30, 51], ["HBoV group 1", "PROBLEM", 88, 100], ["another respiratory virus (adenovirus", "PROBLEM", 223, 260]]], ["Previous reports of HBoV infection suggest rates of coinfection with other respiratory viruses of up to 75%.", [["HBoV infection", "DISEASE", 20, 34], ["coinfection", "DISEASE", 52, 63], ["respiratory viruses", "DISEASE", 75, 94], ["HBoV", "ORGANISM", 20, 24], ["HBoV", "SPECIES", 20, 24], ["HBoV infection", "PROBLEM", 20, 34], ["coinfection", "PROBLEM", 52, 63], ["other respiratory viruses", "PROBLEM", 69, 94], ["HBoV infection", "OBSERVATION", 20, 34], ["coinfection", "OBSERVATION", 52, 63], ["respiratory viruses", "OBSERVATION", 75, 94]]], ["14 The low rate of coinfection in hospital-acquired compared with community-acquired HBoV may reflect the diminished circulation of respiratory virus in the hospital setting.", [["coinfection", "DISEASE", 19, 30], ["HBoV", "DISEASE", 85, 89], ["HBoV", "ORGANISM", 85, 89], ["HBoV", "SPECIES", 85, 89], ["acquired HBoV", "PROBLEM", 76, 89], ["the diminished circulation of respiratory virus", "PROBLEM", 102, 149], ["low", "OBSERVATION_MODIFIER", 7, 10], ["coinfection", "OBSERVATION", 19, 30], ["HBoV", "OBSERVATION", 85, 89], ["may reflect", "UNCERTAINTY", 90, 101], ["diminished", "OBSERVATION", 106, 116], ["respiratory virus", "OBSERVATION", 132, 149]]], ["We did not screen our samples for rhinovirus or coronavirus.DiscussionOne child had undergone liver transplantation 27 days before HBoV was detected and was under intense immunosuppression.", [["liver", "ANATOMY", 94, 99], ["rhinovirus or coronavirus", "DISEASE", 34, 59], ["rhinovirus", "ORGANISM", 34, 44], ["coronavirus", "ORGANISM", 48, 59], ["child", "ORGANISM", 74, 79], ["liver", "ORGAN", 94, 99], ["HBoV", "ORGANISM", 131, 135], ["coronavirus", "SPECIES", 48, 59], ["HBoV", "SPECIES", 131, 135], ["our samples", "TEST", 18, 29], ["rhinovirus", "PROBLEM", 34, 44], ["coronavirus", "PROBLEM", 48, 59], ["liver transplantation", "TREATMENT", 94, 115], ["HBoV", "PROBLEM", 131, 135], ["intense immunosuppression", "TREATMENT", 163, 188], ["liver", "ANATOMY", 94, 99], ["transplantation", "OBSERVATION", 100, 115], ["intense", "OBSERVATION_MODIFIER", 163, 170], ["immunosuppression", "OBSERVATION", 171, 188]]], ["The role of HBoV infection in immunocompromised children is not well-defined.", [["HBoV infection", "DISEASE", 12, 26], ["HBoV", "ORGANISM", 12, 16], ["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["HBoV", "SPECIES", 12, 16], ["HBoV infection", "PROBLEM", 12, 26], ["HBoV", "OBSERVATION_MODIFIER", 12, 16], ["infection", "OBSERVATION", 17, 26], ["not", "UNCERTAINTY", 60, 63], ["well-defined", "OBSERVATION_MODIFIER", 64, 76]]], ["Recent studies report persistence of HBoV DNA in NPA of healthy individuals up to four months after infection.", [["infection", "DISEASE", 100, 109], ["HBoV", "ORGANISM", 37, 41], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["NPA", "CANCER", 49, 52], ["HBoV DNA", "DNA", 37, 45], ["HBoV", "SPECIES", 37, 41], ["Recent studies", "TEST", 0, 14], ["HBoV DNA", "PROBLEM", 37, 45], ["infection", "PROBLEM", 100, 109], ["HBoV DNA", "OBSERVATION", 37, 45], ["infection", "OBSERVATION", 100, 109]]], ["15 In this case, since no previous sample was available, it is possible that the infection represented reactivation of previous community HBoV infection due to immunosuppression.DiscussionThe finding of HBoV in four NICU infants hospitalised since birth raises the question of maternalefetal transmission.", [["infection", "DISEASE", 81, 90], ["HBoV infection", "DISEASE", 138, 152], ["HBoV", "DISEASE", 203, 207], ["HBoV", "ORGANISM", 138, 142], ["HBoV", "ORGANISM", 203, 207], ["infants", "ORGANISM", 221, 228], ["maternalefetal", "CANCER", 277, 291], ["infants", "SPECIES", 221, 228], ["HBoV", "SPECIES", 138, 142], ["HBoV", "SPECIES", 203, 207], ["the infection", "PROBLEM", 77, 90], ["previous community HBoV infection", "PROBLEM", 119, 152], ["immunosuppression", "TREATMENT", 160, 177], ["HBoV", "PROBLEM", 203, 207], ["maternalefetal transmission", "PROBLEM", 277, 304], ["infection", "OBSERVATION", 81, 90], ["community HBoV infection", "OBSERVATION", 128, 152]]], ["However, three of these children (patients 2, 3 and 10) had been in the NICU for more than two weeks when the virus was detected, and the fourth (patient 1) was seven months old, so it is more likely to have been acquired postnatally.DiscussionHospital-acquired respiratory virus infection can increase morbidity and mortality in hospitalised children, mainly the younger ones and those with underlying conditions.", [["respiratory virus infection", "DISEASE", 262, 289], ["children", "ORGANISM", 24, 32], ["patients", "ORGANISM", 34, 42], ["patient", "ORGANISM", 146, 153], ["DiscussionHospital-acquired respiratory virus", "ORGANISM", 234, 279], ["children", "ORGANISM", 343, 351], ["children", "SPECIES", 24, 32], ["patients", "SPECIES", 34, 42], ["patient", "SPECIES", 146, 153], ["children", "SPECIES", 343, 351], ["the virus", "PROBLEM", 106, 115], ["acquired respiratory virus infection", "PROBLEM", 253, 289], ["underlying conditions", "PROBLEM", 392, 413], ["more likely", "UNCERTAINTY", 188, 199], ["respiratory virus", "OBSERVATION", 262, 279]]], ["We have demonstrated that HBoV can be detected from infants with clinical evidence of nosocomial respiratory infection as well as those with community-acquired infection.Conflict of interest statementNone declared.Funding sourceThis study has been partially supported by grants from the CNPq e Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico, Brazil; project number 472537/2007-5.", [["respiratory", "ANATOMY", 97, 108], ["nosocomial respiratory infection", "DISEASE", 86, 118], ["infection", "DISEASE", 160, 169], ["HBoV", "ORGANISM", 26, 30], ["infants", "ORGANISM", 52, 59], ["infants", "SPECIES", 52, 59], ["HBoV", "SPECIES", 26, 30], ["HBoV", "PROBLEM", 26, 30], ["nosocomial respiratory infection", "PROBLEM", 86, 118], ["community-acquired infection", "PROBLEM", 141, 169], ["This study", "TEST", 228, 238], ["HBoV", "OBSERVATION", 26, 30], ["nosocomial", "OBSERVATION_MODIFIER", 86, 96], ["respiratory infection", "OBSERVATION", 97, 118], ["infection", "OBSERVATION", 160, 169]]]], "PMC7176175": [["IntroductionHigh-density resequencing microarrays were developed to detect single nucleotide polymorphisms (SNP) and so produce detailed genetic sequence reads.", [["SNP", "CHEMICAL", 108, 111], ["IntroductionHigh-density resequencing microarrays", "TREATMENT", 0, 49], ["single nucleotide polymorphisms", "PROBLEM", 75, 106]]], ["A resequencing microarray comprises \u201cprobe sets\u201d \u2013 high-density arrangements of short highly specific oligonucleotide probes (25 and 29 used currently) where each base in a reference sequence is queried by four probes.", [["oligonucleotide probes", "DNA", 102, 124], ["A resequencing microarray", "TEST", 0, 25], ["probe sets", "TEST", 37, 47], ["short highly specific oligonucleotide probes", "PROBLEM", 80, 124], ["high", "OBSERVATION_MODIFIER", 51, 55], ["density", "OBSERVATION", 56, 63], ["short", "OBSERVATION_MODIFIER", 80, 85], ["base", "ANATOMY_MODIFIER", 163, 167]]], ["One probe is an exact match of the reference sequence and the other three represent the same section of reference sequence with the central base position replaced by one of the possible SNP variants.", [["SNP", "CHEMICAL", 186, 189], ["SNP variants", "DNA", 186, 198], ["the reference sequence", "TEST", 31, 53], ["SNP variants", "PROBLEM", 186, 198], ["central", "OBSERVATION_MODIFIER", 132, 139], ["base", "OBSERVATION_MODIFIER", 140, 144], ["position", "OBSERVATION_MODIFIER", 145, 153], ["possible", "UNCERTAINTY", 177, 185], ["SNP variants", "OBSERVATION", 186, 198]]], ["In practical use, the number of probes is doubled so that for each base both the forward (sense) and reverse (antisense) directions are contained in a probe set.", [["reverse (antisense) directions", "TREATMENT", 101, 131]]], ["It is possible to completely \u201cresequence,\u201d resolve every base in the sequence of an unknown sample, the reference sequence itself or any other sequence that differs from the reference by one mismatch or fewer per 25 base pair (bp) (1).", [["sample", "ANATOMY", 92, 98]]], ["At higher mismatch rates, a large number of bases can still be identified, but an increasing number will fail as the differences increase.", [["mismatch", "OBSERVATION_MODIFIER", 10, 18], ["rates", "OBSERVATION_MODIFIER", 19, 24], ["large", "OBSERVATION_MODIFIER", 28, 33], ["number", "OBSERVATION_MODIFIER", 34, 40], ["bases", "ANATOMY_MODIFIER", 44, 49], ["increasing", "OBSERVATION_MODIFIER", 82, 92]]], ["This array-based format, combined with specific PCR, has proven ideal for SNP genotyping and phylogenetic analysis (2\u20136).", [["SNP", "CHEMICAL", 74, 77], ["specific PCR", "TEST", 39, 51], ["SNP genotyping", "TEST", 74, 88], ["phylogenetic analysis", "TEST", 93, 114]]], ["Initial work demonstrated the advantages of using a resequencing array with many short reference sequences to detect multiple bacterial and viral pathogens (7\u201311).", [["a resequencing array", "TREATMENT", 50, 70], ["multiple bacterial and viral pathogens", "PROBLEM", 117, 155], ["multiple", "OBSERVATION_MODIFIER", 117, 125], ["bacterial", "OBSERVATION", 126, 135], ["viral pathogens", "OBSERVATION", 140, 155]]], ["Taking full advantage of the sequential base resolution capability of resequencing microarrays, similarity searches of DNA databases have been incorporated into the analysis allowing for fine detailed discrimination of closely related pathogens and tracking mutations within the targeted pathogen even with only partial base call resolution in a reference sequence (8,10\u201312).IntroductionThe effective use of resequencing microarrays for respiratory pathogen detection or any large collection of organisms relies on the integration of several components.", [["DNA", "CELLULAR_COMPONENT", 119, 122], ["resequencing microarrays", "TEST", 70, 94], ["DNA databases", "TEST", 119, 132], ["the analysis", "TEST", 161, 173], ["closely related pathogens", "PROBLEM", 219, 244], ["tracking mutations", "PROBLEM", 249, 267], ["the targeted pathogen", "PROBLEM", 275, 296], ["a reference sequence", "TEST", 344, 364], ["resequencing microarrays", "TEST", 408, 432], ["respiratory pathogen detection", "TEST", 437, 467], ["any large collection of organisms", "PROBLEM", 471, 504], ["large", "OBSERVATION_MODIFIER", 475, 480], ["collection", "OBSERVATION", 481, 491], ["several", "OBSERVATION_MODIFIER", 534, 541], ["components", "OBSERVATION_MODIFIER", 542, 552]]], ["The overall design for the resequencing microarray and selection of primers for amplification must occur first.", [["the resequencing microarray", "TEST", 23, 50], ["selection of primers", "TREATMENT", 55, 75], ["amplification", "PROBLEM", 80, 93]]], ["This consists of several tasks: First, selection of organisms and desired level of discrimination for each organism and whether specific nucleic acid markers must be tested for; second, determination from known sequence data of sequence regions to choose reference sequences from; third, selection of reference sequences and check for possible conflicts; fourth, primer selection.", [["nucleic acid", "CHEMICAL", 137, 149], ["nucleic acid markers", "PROTEIN", 137, 157], ["organisms", "PROBLEM", 52, 61], ["each organism", "PROBLEM", 102, 115], ["specific nucleic acid markers", "TEST", 128, 157], ["reference sequences", "TEST", 255, 274], ["reference sequences", "TEST", 301, 320]]], ["The order of several of these steps can be interchanged and refinements consist of repeating several of these steps after making changes.", [["these steps", "TREATMENT", 24, 35]]], ["Once fabricated, an amplification method is required in order to achieve the sensitivity required for diagnosis/surveillance applications, so that any of the target pathogens can be detected directly from collected samples.", [["samples", "ANATOMY", 215, 222], ["an amplification method", "TEST", 17, 40], ["surveillance applications", "TEST", 112, 137], ["the target pathogens", "PROBLEM", 154, 174]]], ["Finally, because so many potential organism detection events are to be dealt with, a standardized algorithm is applied to determine if pathogens are detected and report the maximum level of detail possible using the resolved base sequence information from the multiple-pathogen resequencing microarrays.Controls ::: Materials", [["many potential organism detection events", "PROBLEM", 20, 60], ["a standardized algorithm", "TEST", 83, 107], ["pathogens", "PROBLEM", 135, 144]]]], "997d29fc8bd027729135ca4fb2b1943d5cf6a4ba": [["IntroductionAcute respiratory infections (ARIs) are caused by respiratory viruses and bacteria, being the most infectious disease in humans [1, 2] .", [["respiratory", "ANATOMY", 18, 29], ["respiratory infections", "DISEASE", 18, 40], ["ARIs", "DISEASE", 42, 46], ["respiratory viruses", "DISEASE", 62, 81], ["humans", "ORGANISM", 133, 139], ["humans", "SPECIES", 133, 139], ["humans", "SPECIES", 133, 139], ["IntroductionAcute respiratory infections (ARIs)", "PROBLEM", 0, 47], ["respiratory viruses", "PROBLEM", 62, 81], ["bacteria", "PROBLEM", 86, 94], ["respiratory", "ANATOMY", 18, 29], ["infections", "OBSERVATION", 30, 40], ["respiratory viruses", "OBSERVATION", 62, 81]]], ["These can be caused by more than 200 different viruses, with rhinovirus being the most common etiological agent [3] [4] [5] .", [["rhinovirus", "ORGANISM", 61, 71], ["different viruses", "PROBLEM", 37, 54], ["rhinovirus", "PROBLEM", 61, 71]]], ["In December 2019, a new coronavirus outbreak was reported in China, being called the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), spreading rapidly and infecting more than 14 million people, being declared a Health Emergency International Public Service on January 30, 2020 [6, 7] .IntroductionThe main mode of transmission is contact with droplets containing viral particles eliminated through the cough or sneeze of an infected person, and the incubation period usually varies from 2 to 14 days.", [["coronavirus", "DISEASE", 24, 35], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 92, 130], ["SARS-CoV-2", "CHEMICAL", 134, 144], ["cough", "DISEASE", 416, 421], ["coronavirus", "ORGANISM", 24, 35], ["SARS-CoV-2", "ORGANISM", 134, 144], ["people", "ORGANISM", 200, 206], ["people", "SPECIES", 200, 206], ["person", "SPECIES", 447, 453], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 85, 144], ["a new coronavirus outbreak", "PROBLEM", 18, 44], ["the Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 81, 130], ["SARS-CoV", "TEST", 134, 142], ["viral particles", "PROBLEM", 377, 392], ["the cough", "PROBLEM", 412, 421], ["new", "OBSERVATION_MODIFIER", 20, 23], ["coronavirus", "OBSERVATION", 24, 35], ["Severe", "OBSERVATION_MODIFIER", 85, 91], ["Acute", "OBSERVATION_MODIFIER", 92, 97], ["Respiratory Syndrome", "OBSERVATION", 98, 118], ["main", "OBSERVATION_MODIFIER", 315, 319], ["viral particles", "OBSERVATION", 377, 392], ["cough", "OBSERVATION", 416, 421], ["infected", "OBSERVATION", 438, 446]]], ["Approximately 80% of the cases are asymptomatic or with mild symptoms, and the others can be severe or critical and can lead to death [8] .", [["death", "DISEASE", 128, 133], ["asymptomatic", "PROBLEM", 35, 47], ["mild symptoms", "PROBLEM", 56, 69], ["mild", "OBSERVATION_MODIFIER", 56, 60], ["symptoms", "OBSERVATION", 61, 69]]], ["The development of Coronavirus Disease 2019 (COVID-19) is dependent on the interaction between SARS-CoV-2 and the host's immune system, the immune response being influenced by genetics (HLA genes), age, sex, nutritional status and status physical [9] .IntroductionThe immune response includes two stages, innate immunity and adaptive immunity.", [["immune system", "ANATOMY", 121, 134], ["Coronavirus Disease", "DISEASE", 19, 38], ["COVID-19", "CHEMICAL", 45, 53], ["COVID-19", "CELL", 45, 53], ["SARS-CoV-2", "ORGANISM", 95, 105], ["immune system", "ANATOMICAL_SYSTEM", 121, 134], ["HLA genes", "DNA", 186, 195], ["Coronavirus Disease 2019 (COVID-19", "SPECIES", 19, 53], ["SARS-CoV", "SPECIES", 95, 103], ["Coronavirus Disease", "PROBLEM", 19, 38], ["COVID", "TEST", 45, 50], ["SARS", "TEST", 95, 99], ["CoV", "TEST", 100, 103], ["adaptive immunity", "TREATMENT", 325, 342], ["Coronavirus Disease", "OBSERVATION", 19, 38]]], ["The first one comprises physical and chemical barriers and the action of cells such as macrophages, dendritic cells (DCs), natural killer cells (NKs), neutrophils and molecules such as cytokines, interleukins (ILs), nitric oxide (NO) and superoxide anion (O2-).", [["cells", "ANATOMY", 73, 78], ["macrophages", "ANATOMY", 87, 98], ["dendritic cells", "ANATOMY", 100, 115], ["DCs", "ANATOMY", 117, 120], ["natural killer cells", "ANATOMY", 123, 143], ["NKs", "ANATOMY", 145, 148], ["neutrophils", "ANATOMY", 151, 162], ["nitric oxide", "CHEMICAL", 216, 228], ["NO", "CHEMICAL", 230, 232], ["superoxide", "CHEMICAL", 238, 248], ["O2-", "CHEMICAL", 256, 259], ["nitric oxide", "CHEMICAL", 216, 228], ["NO", "CHEMICAL", 230, 232], ["superoxide", "CHEMICAL", 238, 248], ["O2", "CHEMICAL", 256, 258], ["cells", "CELL", 73, 78], ["macrophages", "CELL", 87, 98], ["dendritic cells", "CELL", 100, 115], ["DCs", "CELL", 117, 120], ["natural killer cells", "CELL", 123, 143], ["NKs", "CELL", 145, 148], ["neutrophils", "CELL", 151, 162], ["interleukins", "GENE_OR_GENE_PRODUCT", 196, 208], ["ILs", "GENE_OR_GENE_PRODUCT", 210, 213], ["nitric oxide", "SIMPLE_CHEMICAL", 216, 228], ["NO", "SIMPLE_CHEMICAL", 230, 232], ["superoxide anion", "SIMPLE_CHEMICAL", 238, 254], ["O2", "SIMPLE_CHEMICAL", 256, 258], ["macrophages", "CELL_TYPE", 87, 98], ["dendritic cells", "CELL_TYPE", 100, 115], ["DCs", "CELL_TYPE", 117, 120], ["natural killer cells", "CELL_TYPE", 123, 143], ["NKs", "CELL_TYPE", 145, 148], ["neutrophils", "CELL_TYPE", 151, 162], ["cytokines", "PROTEIN", 185, 194], ["interleukins", "PROTEIN", 196, 208], ["ILs", "PROTEIN", 210, 213], ["macrophages", "PROBLEM", 87, 98], ["dendritic cells", "PROBLEM", 100, 115], ["natural killer cells", "PROBLEM", 123, 143], ["NKs", "TEST", 145, 148], ["neutrophils", "TEST", 151, 162], ["cytokines, interleukins (ILs)", "TREATMENT", 185, 214], ["nitric oxide", "TREATMENT", 216, 228], ["superoxide anion (O2", "TREATMENT", 238, 258], ["dendritic cells", "OBSERVATION", 100, 115], ["natural killer cells", "OBSERVATION", 123, 143]]], ["The second one has as mechanism of action the T lymphocytes (TCD4 + and TCD8 +) and B lymphocytes and their products, such as antibodies and cytokines.", [["T lymphocytes", "ANATOMY", 46, 59], ["TCD4 + and TCD8 +)", "ANATOMY", 61, 79], ["B lymphocytes", "ANATOMY", 84, 97], ["T lymphocytes", "CELL", 46, 59], ["TCD4", "GENE_OR_GENE_PRODUCT", 61, 65], ["TCD8", "GENE_OR_GENE_PRODUCT", 72, 76], ["B lymphocytes", "CELL", 84, 97], ["T lymphocytes", "CELL_TYPE", 46, 59], ["TCD4", "CELL_TYPE", 61, 65], ["TCD8", "PROTEIN", 72, 76], ["B lymphocytes", "CELL_TYPE", 84, 97], ["antibodies", "PROTEIN", 126, 136], ["cytokines", "PROTEIN", 141, 150], ["the T lymphocytes", "TEST", 42, 59], ["TCD4", "TEST", 61, 65], ["TCD8", "TEST", 72, 76], ["B lymphocytes", "PROBLEM", 84, 97], ["cytokines", "PROBLEM", 141, 150], ["lymphocytes", "ANATOMY", 86, 97]]], ["Furthermore, the adaptive immune response can be subdivided into cellular immunity (mediate by cells as macrophages and lymphocytes) and humoral immunity (mediates by cells as macrophages and lymphocytes) and humoral immunity (mediated by antibodies) [10, 11] .", [["cellular", "ANATOMY", 65, 73], ["cells", "ANATOMY", 95, 100], ["macrophages", "ANATOMY", 104, 115], ["lymphocytes", "ANATOMY", 120, 131], ["cells", "ANATOMY", 167, 172], ["macrophages", "ANATOMY", 176, 187], ["lymphocytes", "ANATOMY", 192, 203], ["cellular", "CELL", 65, 73], ["cells", "CELL", 95, 100], ["macrophages", "CELL", 104, 115], ["lymphocytes", "CELL", 120, 131], ["cells", "CELL", 167, 172], ["macrophages", "CELL", 176, 187], ["lymphocytes", "CELL", 192, 203], ["macrophages", "CELL_TYPE", 104, 115], ["lymphocytes", "CELL_TYPE", 120, 131], ["macrophages", "CELL_TYPE", 176, 187], ["lymphocytes", "CELL_TYPE", 192, 203], ["antibodies", "PROTEIN", 239, 249], ["lymphocytes", "TEST", 120, 131], ["lymphocytes", "TEST", 192, 203], ["humoral immunity", "TEST", 209, 225]]], ["The regular practice of physical exercises promotes improvements in quality of life and can act in the immune response, reducing the risk of developing systemic inflammatory processes and stimulating cellular immunity [12] .IntroductionTherefore, the present article aims to perform an integrative review of the literature relating the role of physical exercise on the immune system in the fight against COVID-19.", [["cellular", "ANATOMY", 200, 208], ["cellular", "CELL", 200, 208], ["physical exercises", "TREATMENT", 24, 42], ["developing systemic inflammatory processes", "PROBLEM", 141, 183], ["COVID", "TEST", 404, 409], ["systemic", "OBSERVATION_MODIFIER", 152, 160], ["inflammatory", "OBSERVATION", 161, 173]]], ["For this purpose, the bibliographic study included knowledge about respiratory infections, influences of physical exercise on the immune system and proposed the comprehension of the most recent information about the immunopathogenesis of SARS-CoV-2 infection, also comprising its relationship with the host's physical and health conditions.Influence of physical exercise on the immunological responsePhysical activity is considered one of the main components of healthy living.", [["respiratory", "ANATOMY", 67, 78], ["immune system", "ANATOMY", 130, 143], ["respiratory infections", "DISEASE", 67, 89], ["SARS-CoV-2 infection", "DISEASE", 238, 258], ["SARS-CoV-2", "ORGANISM", 238, 248], ["CoV-2", "SPECIES", 243, 248], ["SARS-CoV-2", "SPECIES", 238, 248], ["the bibliographic study", "TEST", 18, 41], ["respiratory infections", "PROBLEM", 67, 89], ["SARS", "PROBLEM", 238, 242], ["CoV-2 infection", "PROBLEM", 243, 258], ["infections", "OBSERVATION", 79, 89], ["infection", "OBSERVATION", 249, 258]]], ["In addition to the functions related to the prevention of excess body weight, systemic inflammation and chronic non-communicable diseases, a potential benefit of physical exercise in reducing communicable diseases, including viral pathologies, is suggested [13] .Influence of physical exercise on the immunological responseThe practice of physical exercise, both in its acute form and in its chronic form, significantly alters the immune system [14, 15] .", [["body", "ANATOMY", 65, 69], ["inflammation", "DISEASE", 87, 99], ["chronic non-communicable diseases", "DISEASE", 104, 137], ["communicable diseases", "DISEASE", 192, 213], ["viral pathologies", "DISEASE", 225, 242], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["excess body weight", "PROBLEM", 58, 76], ["systemic inflammation", "PROBLEM", 78, 99], ["chronic non-communicable diseases", "PROBLEM", 104, 137], ["reducing communicable diseases", "PROBLEM", 183, 213], ["viral pathologies", "PROBLEM", 225, 242], ["physical exercise", "TEST", 339, 356], ["systemic", "OBSERVATION_MODIFIER", 78, 86], ["inflammation", "OBSERVATION", 87, 99], ["chronic", "OBSERVATION_MODIFIER", 104, 111], ["non-communicable diseases", "OBSERVATION", 112, 137], ["acute", "OBSERVATION_MODIFIER", 370, 375]]], ["Studies indicate that the modulation of the immune response related to exercise depends on factors such as regularity, intensity, duration and type of effort applied [13, 16] .Influence of physical exercise on the immunological responseModerate-intensity physical exercises stimulate cellular immunity, while prolonged or high-intensity practices without appropriate rest can trigger decreased cellular immunity, increasing the propensity for infectious diseases [14, 15] .", [["cellular", "ANATOMY", 284, 292], ["cellular", "ANATOMY", 394, 402], ["infectious diseases", "DISEASE", 443, 462], ["cellular", "CELL", 284, 292], ["cellular", "CELL", 394, 402], ["Studies", "TEST", 0, 7], ["the immune response", "PROBLEM", 40, 59], ["high-intensity practices", "TREATMENT", 322, 346], ["decreased cellular immunity", "PROBLEM", 384, 411], ["infectious diseases", "PROBLEM", 443, 462], ["immune response", "OBSERVATION", 44, 59]]], ["According to the International Society for Exercise and Immunology (ISEI), the immunological decrease occurs after the practice of prolonged physical exercise, that is, after 90 min of moderate-to high-intensity physical activity [17] .", [["the immunological decrease", "PROBLEM", 75, 101]]], ["Cellular changes due to physical activity are illustrated in Fig. 1 .CytokinesCytokines are classified as anti-inflammatory and proinflammatory according to their functions.", [["Cytokines", "PROTEIN", 69, 78], ["Cytokines", "PROTEIN", 78, 87], ["Cellular changes", "PROBLEM", 0, 16], ["CytokinesCytokines", "TREATMENT", 69, 87], ["anti-inflammatory", "OBSERVATION_MODIFIER", 106, 123]]], ["Among the antiinflammatory cytokines, we highlight IL-10 and transforming growth factor-beta (TGF-\u03b2), responsible for inhibiting the production of pro-inflammatory cytokines [18] .", [["IL-10", "GENE_OR_GENE_PRODUCT", 51, 56], ["transforming growth factor-beta", "GENE_OR_GENE_PRODUCT", 61, 92], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 94, 99], ["antiinflammatory cytokines", "PROTEIN", 10, 36], ["IL-10", "PROTEIN", 51, 56], ["TGF-\u03b2", "PROTEIN", 94, 99], ["pro-inflammatory cytokines", "PROTEIN", 147, 173], ["the antiinflammatory cytokines", "TEST", 6, 36], ["IL", "TEST", 51, 53], ["transforming growth factor", "TEST", 61, 87], ["beta (TGF", "TEST", 88, 97], ["pro-inflammatory cytokines", "PROBLEM", 147, 173], ["antiinflammatory cytokines", "OBSERVATION", 10, 36]]], ["Among the pro-inflammatory cytokines, we highlight IL-1, IL-2, IL-12, IL-18, interferon-gamma (IFN-\u03b3) and tumor necrosis factor-alpha (TNF-\u03b1) [19] .", [["necrosis", "DISEASE", 112, 120], ["IL-1", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL-2", "GENE_OR_GENE_PRODUCT", 57, 61], ["IL-12", "GENE_OR_GENE_PRODUCT", 63, 68], ["IL-18", "GENE_OR_GENE_PRODUCT", 70, 75], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 77, 93], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 95, 100], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 106, 133], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 135, 140], ["pro-inflammatory cytokines", "PROTEIN", 10, 36], ["interferon-gamma (IFN-\u03b3", "PROTEIN", 77, 100], ["tumor necrosis factor-alpha", "PROTEIN", 106, 133], ["TNF", "PROTEIN", 135, 138], ["the pro-inflammatory cytokines", "TEST", 6, 36], ["IL", "TEST", 51, 53], ["IL", "TEST", 57, 59], ["IL", "TEST", 63, 65], ["IL", "TEST", 70, 72], ["interferon", "TREATMENT", 77, 87], ["IFN", "TEST", 95, 98], ["tumor necrosis factor", "PROBLEM", 106, 127], ["alpha (TNF", "TEST", 128, 138], ["pro-inflammatory cytokines", "OBSERVATION", 10, 36], ["gamma", "ANATOMY", 88, 93], ["tumor", "OBSERVATION_MODIFIER", 106, 111], ["necrosis", "OBSERVATION", 112, 120]]], ["Cytokine production can be modified due to hormonal or oxidative stress and physical exercise.", [["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["Cytokine", "PROTEIN", 0, 8], ["Cytokine production", "TREATMENT", 0, 19], ["hormonal or oxidative stress", "PROBLEM", 43, 71]]], ["The muscle contraction has the effect of increasing the release of antinflammatory and pro-inflammatory cytokines at levels that vary according to the volume of contractile mass involved, duration and intensity of exercise [20] .NeutrophilsDuring the practice of physical exercise, the activation of the muscle fiber is responsible for increasing the release of calcium (Ca2 +) and, therefore, promoting the synthesis of proinflammatory cytokines, namely TNF-\u03b1 and IL-1\u03b2, which act in the regulation of selectins, which, in turn, attract neutrophils to the site [21] .", [["muscle", "ANATOMY", 4, 10], ["contractile mass", "ANATOMY", 161, 177], ["Neutrophils", "ANATOMY", 229, 240], ["muscle fiber", "ANATOMY", 304, 316], ["neutrophils", "ANATOMY", 538, 549], ["muscle contraction", "DISEASE", 4, 22], ["calcium", "CHEMICAL", 362, 369], ["Ca2", "CHEMICAL", 371, 374], ["calcium", "CHEMICAL", 362, 369], ["Ca2 +)", "CHEMICAL", 371, 377], ["muscle", "ORGAN", 4, 10], ["Neutrophils", "CELL", 229, 240], ["muscle fiber", "TISSUE", 304, 316], ["calcium", "SIMPLE_CHEMICAL", 362, 369], ["Ca2 +", "SIMPLE_CHEMICAL", 371, 376], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 455, 460], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 465, 470], ["selectins", "GENE_OR_GENE_PRODUCT", 503, 512], ["neutrophils", "CELL", 538, 549], ["antinflammatory and pro-inflammatory cytokines", "PROTEIN", 67, 113], ["Neutrophils", "CELL_TYPE", 229, 240], ["proinflammatory cytokines", "PROTEIN", 421, 446], ["TNF", "PROTEIN", 455, 458], ["IL-1\u03b2", "PROTEIN", 465, 470], ["selectins", "PROTEIN", 503, 512], ["neutrophils", "CELL_TYPE", 538, 549], ["antinflammatory and pro-inflammatory cytokines at levels", "PROBLEM", 67, 123], ["contractile mass", "PROBLEM", 161, 177], ["Neutrophils", "TEST", 229, 240], ["physical exercise", "TEST", 263, 280], ["calcium (Ca2", "TEST", 362, 374], ["proinflammatory cytokines", "TEST", 421, 446], ["TNF", "TEST", 455, 458], ["IL", "TEST", 465, 467], ["muscle", "ANATOMY", 4, 10], ["contraction", "OBSERVATION", 11, 22], ["pro-inflammatory cytokines", "OBSERVATION", 87, 113], ["contractile mass", "OBSERVATION", 161, 177], ["muscle", "ANATOMY", 304, 310]]], ["The neutrophilia induced by physical activity is due to the release of neutrophils from the bone marrow due to the influence of cortisol [22] .NeutrophilsAfter aerobic physical exercise (approximately 24 h), there is a significant reduction in neutrophil chemotaxis, however, without compromising bactericidal activity.", [["neutrophils", "ANATOMY", 71, 82], ["bone marrow", "ANATOMY", 92, 103], ["Neutrophils", "ANATOMY", 143, 154], ["neutrophil", "ANATOMY", 244, 254], ["neutrophilia", "DISEASE", 4, 16], ["cortisol", "CHEMICAL", 128, 136], ["cortisol", "CHEMICAL", 128, 136], ["neutrophils", "CELL", 71, 82], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 92, 103], ["cortisol", "SIMPLE_CHEMICAL", 128, 136], ["Neutrophils", "CELL", 143, 154], ["neutrophil", "CELL", 244, 254], ["neutrophils", "CELL_TYPE", 71, 82], ["Neutrophils", "CELL_TYPE", 143, 154], ["neutrophil", "CELL_TYPE", 244, 254], ["The neutrophilia", "PROBLEM", 0, 16], ["the release of neutrophils", "PROBLEM", 56, 82], ["cortisol", "TEST", 128, 136], ["Neutrophils", "TEST", 143, 154], ["a significant reduction in neutrophil chemotaxis", "PROBLEM", 217, 265], ["compromising bactericidal activity", "PROBLEM", 284, 318], ["neutrophilia", "OBSERVATION", 4, 16], ["bone marrow", "ANATOMY", 92, 103], ["significant", "OBSERVATION_MODIFIER", 219, 230], ["reduction", "OBSERVATION_MODIFIER", 231, 240], ["neutrophil chemotaxis", "OBSERVATION", 244, 265], ["without", "UNCERTAINTY", 276, 283], ["bactericidal activity", "OBSERVATION", 297, 318]]], ["The reduction in neutrophil chemotaxis is reversed within 48 h after physical activity, during which the opportunistic activity of infectious microorganisms can occur [23] .LeukocytesPhysical activity is also responsible for increasing the concentration of circulating leukocytes [24] .", [["neutrophil", "ANATOMY", 17, 27], ["Leukocytes", "ANATOMY", 173, 183], ["leukocytes", "ANATOMY", 269, 279], ["neutrophil", "CELL", 17, 27], ["Leukocytes", "CELL", 173, 183], ["leukocytes", "CELL", 269, 279], ["neutrophil", "CELL_TYPE", 17, 27], ["Leukocytes", "CELL_TYPE", 173, 183], ["circulating leukocytes", "CELL_TYPE", 257, 279], ["The reduction in neutrophil chemotaxis", "TREATMENT", 0, 38], ["infectious microorganisms", "PROBLEM", 131, 156], ["Leukocytes", "TEST", 173, 183], ["circulating leukocytes", "PROBLEM", 257, 279], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["neutrophil chemotaxis", "OBSERVATION", 17, 38], ["circulating leukocytes", "OBSERVATION", 257, 279]]], ["This is due to shearing of immune cells in blood vessels, especially secondary lymphoid tissues such as liver, spleen and lung [25] .", [["immune cells", "ANATOMY", 27, 39], ["blood vessels", "ANATOMY", 43, 56], ["lymphoid tissues", "ANATOMY", 79, 95], ["liver", "ANATOMY", 104, 109], ["spleen", "ANATOMY", 111, 117], ["lung", "ANATOMY", 122, 126], ["immune cells", "CELL", 27, 39], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 43, 56], ["lymphoid tissues", "TISSUE", 79, 95], ["liver", "ORGAN", 104, 109], ["spleen", "ORGAN", 111, 117], ["lung", "ORGAN", 122, 126], ["immune cells", "CELL_TYPE", 27, 39], ["shearing of immune cells in blood vessels", "PROBLEM", 15, 56], ["secondary lymphoid tissues", "PROBLEM", 69, 95], ["due to", "UNCERTAINTY", 8, 14], ["immune cells", "OBSERVATION", 27, 39], ["blood vessels", "ANATOMY", 43, 56], ["secondary lymphoid tissues", "OBSERVATION", 69, 95], ["liver", "ANATOMY", 104, 109], ["spleen", "ANATOMY", 111, 117], ["lung", "ANATOMY", 122, 126]]], ["The leukocyte concentration remains high with a peak of 30-120 min after constant physical activity, which may persist for up to 24 h after [24] .Antigen-presenting cells (APCs)The practice of aerobic physical exercise in an exacerbated manner is responsible for decreasing the expression of Tolllike receptors (TLRs) in macrophages, considerably reducing the presentation of antigens to T lymphocytes, thus causing the suppression of the inflammatory T helper type 1 (Th1) response.", [["leukocyte", "ANATOMY", 4, 13], ["Antigen-presenting cells", "ANATOMY", 146, 170], ["APCs", "ANATOMY", 172, 176], ["macrophages", "ANATOMY", 321, 332], ["T lymphocytes", "ANATOMY", 388, 401], ["leukocyte", "CELL", 4, 13], ["Antigen-presenting cells", "CELL", 146, 170], ["APCs", "CELL", 172, 176], ["Tolllike receptors", "GENE_OR_GENE_PRODUCT", 292, 310], ["TLRs", "GENE_OR_GENE_PRODUCT", 312, 316], ["macrophages", "CELL", 321, 332], ["T lymphocytes", "CELL", 388, 401], ["T helper type 1", "GENE_OR_GENE_PRODUCT", 452, 467], ["Th1", "GENE_OR_GENE_PRODUCT", 469, 472], ["Antigen-presenting cells", "CELL_TYPE", 146, 170], ["APCs", "CELL_TYPE", 172, 176], ["Tolllike receptors", "PROTEIN", 292, 310], ["TLRs", "PROTEIN", 312, 316], ["macrophages", "CELL_TYPE", 321, 332], ["T lymphocytes", "CELL_TYPE", 388, 401], ["The leukocyte concentration", "TEST", 0, 27], ["aerobic physical exercise", "TREATMENT", 193, 218], ["leukocyte concentration", "OBSERVATION", 4, 27], ["high", "OBSERVATION_MODIFIER", 36, 40], ["macrophages", "ANATOMY", 321, 332], ["inflammatory", "OBSERVATION_MODIFIER", 439, 451]]], ["Thus, the failure to develop an inflammatory activity precludes possible tissue damage resulting from inflammatory mediators and, consequently, the risk of chronic inflammatory processes.", [["tissue", "ANATOMY", 73, 79], ["tissue", "TISSUE", 73, 79], ["inflammatory mediators", "PROTEIN", 102, 124], ["the failure", "PROBLEM", 6, 17], ["an inflammatory activity", "PROBLEM", 29, 53], ["tissue damage", "PROBLEM", 73, 86], ["inflammatory mediators", "PROBLEM", 102, 124], ["chronic inflammatory processes", "PROBLEM", 156, 186], ["failure", "OBSERVATION", 10, 17], ["inflammatory", "OBSERVATION", 32, 44], ["possible", "UNCERTAINTY", 64, 72], ["tissue", "OBSERVATION_MODIFIER", 73, 79], ["damage", "OBSERVATION", 80, 86], ["inflammatory", "OBSERVATION_MODIFIER", 102, 114], ["chronic", "OBSERVATION_MODIFIER", 156, 163], ["inflammatory", "OBSERVATION", 164, 176]]], ["However, the susceptibility to infections due to intracellular microorganisms increases [26] .Natural killer cells (NKs)During physical activity, blood flow increases in order to supply the metabolic demands of the human body.", [["intracellular", "ANATOMY", 49, 62], ["Natural killer cells", "ANATOMY", 94, 114], ["NKs", "ANATOMY", 116, 119], ["blood", "ANATOMY", 146, 151], ["body", "ANATOMY", 221, 225], ["infections", "DISEASE", 31, 41], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 62], ["Natural killer cells", "CELL", 94, 114], ["NKs", "CELL", 116, 119], ["blood", "ORGANISM_SUBSTANCE", 146, 151], ["human", "ORGANISM", 215, 220], ["body", "ORGANISM_SUBDIVISION", 221, 225], ["Natural killer cells", "CELL_TYPE", 94, 114], ["NKs", "CELL_TYPE", 116, 119], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["the susceptibility to infections", "PROBLEM", 9, 41], ["intracellular microorganisms increases", "PROBLEM", 49, 87], ["Natural killer cells", "TREATMENT", 94, 114], ["blood flow", "TEST", 146, 156], ["killer cells", "OBSERVATION", 102, 114], ["metabolic demands", "OBSERVATION", 190, 207], ["human body", "ANATOMY_MODIFIER", 215, 225]]], ["The recruitment of NK cells occurs through cellular stress promoted by exercise and a consequent decrease in adhesion molecules induced by catecholamines [27] .", [["NK cells", "ANATOMY", 19, 27], ["cellular", "ANATOMY", 43, 51], ["catecholamines", "CHEMICAL", 139, 153], ["catecholamines", "CHEMICAL", 139, 153], ["NK cells", "CELL", 19, 27], ["cellular", "CELL", 43, 51], ["catecholamines", "SIMPLE_CHEMICAL", 139, 153], ["NK cells", "CELL_TYPE", 19, 27], ["adhesion molecules", "PROTEIN", 109, 127], ["NK cells", "TREATMENT", 19, 27], ["cellular stress", "PROBLEM", 43, 58], ["a consequent decrease in adhesion molecules", "PROBLEM", 84, 127], ["catecholamines", "TEST", 139, 153], ["recruitment", "OBSERVATION_MODIFIER", 4, 15], ["NK cells", "OBSERVATION", 19, 27], ["decrease", "OBSERVATION_MODIFIER", 97, 105], ["adhesion molecules", "OBSERVATION", 109, 127]]], ["However, physical activity lasting more than three hours causes the concentration of NK cells to return to the pre-exercise state or even lower than this.", [["NK cells", "ANATOMY", 85, 93], ["NK cells", "CELL", 85, 93], ["NK cells", "CELL_TYPE", 85, 93], ["NK cells", "PROBLEM", 85, 93], ["NK cells", "OBSERVATION", 85, 93]]], ["This is because the NK cells migrate to the muscle injury site [28] .LymphocytesDuring moderate physical exercise, the concentration of lymphocytes increases in the vascular bed and, after strenuous exercise, decreases to levels below the pre-exercise period [29, 30] .", [["NK cells", "ANATOMY", 20, 28], ["muscle", "ANATOMY", 44, 50], ["Lymphocytes", "ANATOMY", 69, 80], ["lymphocytes", "ANATOMY", 136, 147], ["vascular bed", "ANATOMY", 165, 177], ["NK cells", "CELL", 20, 28], ["muscle", "ORGAN", 44, 50], ["Lymphocytes", "CELL", 69, 80], ["lymphocytes", "CELL", 136, 147], ["vascular bed", "MULTI-TISSUE_STRUCTURE", 165, 177], ["NK cells", "CELL_TYPE", 20, 28], ["Lymphocytes", "CELL_TYPE", 69, 80], ["lymphocytes", "CELL_TYPE", 136, 147], ["the NK cells", "TREATMENT", 16, 28], ["the muscle injury site", "PROBLEM", 40, 62], ["Lymphocytes", "TEST", 69, 80], ["lymphocytes", "PROBLEM", 136, 147], ["strenuous exercise", "TEST", 189, 207], ["NK cells", "OBSERVATION", 20, 28], ["muscle", "ANATOMY", 44, 50], ["injury", "OBSERVATION", 51, 57], ["moderate", "OBSERVATION_MODIFIER", 87, 95], ["lymphocytes", "OBSERVATION", 136, 147], ["vascular bed", "ANATOMY", 165, 177]]], ["The CD4 +:CD8 + ratio decreases as TCD8 + cells increase [14] .LymphocytesTCD4 + cells decrease due to the increase in NK cells [14, 31] .", [["CD4 +:CD8 +", "ANATOMY", 4, 15], ["TCD8 + cells", "ANATOMY", 35, 47], ["LymphocytesTCD4 + cells", "ANATOMY", 63, 86], ["NK cells", "ANATOMY", 119, 127], ["CD4", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD8", "GENE_OR_GENE_PRODUCT", 10, 13], ["LymphocytesTCD4 + cells", "CELL", 63, 86], ["NK cells", "CELL", 119, 127], ["CD4", "PROTEIN", 4, 7], ["CD8", "PROTEIN", 10, 13], ["TCD8", "PROTEIN", 35, 39], ["LymphocytesTCD4", "PROTEIN", 63, 78], ["NK cells", "CELL_TYPE", 119, 127], ["The CD4", "TEST", 0, 7], ["CD8", "TEST", 10, 13], ["TCD8", "TEST", 35, 39], ["LymphocytesTCD4", "TEST", 63, 78], ["cells decrease", "PROBLEM", 81, 95], ["the increase in NK cells", "PROBLEM", 103, 127], ["decreases", "OBSERVATION_MODIFIER", 22, 31], ["cells decrease", "OBSERVATION", 81, 95], ["increase", "OBSERVATION_MODIFIER", 107, 115], ["NK cells", "OBSERVATION", 119, 127]]], ["After physical activity, the lymphocyte concentration decreases due to the apoptosis mechanism [32] .", [["lymphocyte", "ANATOMY", 29, 39], ["lymphocyte", "CELL", 29, 39], ["the lymphocyte concentration", "TEST", 25, 53], ["the apoptosis mechanism", "PROBLEM", 71, 94]]], ["Thus, the increase in lymphocyte concentrations favors the Th1mediated immune response, preventing infections by intracellular microorganisms [24] (Fig. 2 ).SARS-COV-2 virology and the role of the immune system in COVID-19 infectionSARS-CoV-2 is constituted by single-strand positivesense RNA and belongs to the genus Betacoronavirus, lineage B and subgenus Sarbecovirus.", [["lymphocyte", "ANATOMY", 22, 32], ["intracellular", "ANATOMY", 113, 126], ["infections", "DISEASE", 99, 109], ["SARS", "DISEASE", 157, 161], ["lymphocyte", "CELL", 22, 32], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 126], ["COVID-19 infectionSARS-CoV-2", "ORGANISM", 214, 242], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 318, 333], ["lineage B", "CELL", 335, 344], ["COVID-19 infectionSARS-CoV-2", "DNA", 214, 242], ["single-strand positivesense RNA", "RNA", 261, 292], ["COVID-19", "SPECIES", 214, 222], ["the increase in lymphocyte concentrations", "PROBLEM", 6, 47], ["infections", "PROBLEM", 99, 109], ["intracellular microorganisms", "PROBLEM", 113, 141], ["SARS", "TEST", 157, 161], ["the immune system", "TEST", 193, 210], ["COVID", "TEST", 214, 219], ["infectionSARS", "TEST", 223, 236], ["CoV", "TEST", 237, 240], ["single-strand positivesense RNA", "PROBLEM", 261, 292], ["lineage B and subgenus Sarbecovirus", "PROBLEM", 335, 370], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["lymphocyte concentrations", "OBSERVATION", 22, 47], ["genus Betacoronavirus", "ANATOMY", 312, 333], ["subgenus Sarbecovirus", "OBSERVATION", 349, 370]]], ["Viral genome studies have identified similarity of SARS-CoV-2 with bat coronaviruses, as well as coronaviruses responsible for two previous pandemics: the Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV) and the Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) [33, 34] .SARS-COV-2 virology and the role of the immune system in COVID-19 infectionSimilar to SARS-CoV, the novel coronavirus uses a structural glycoprotein to infect cells: the envelope Spike protein (S), using the Angiotensin-Converting Enzyme-2 (ACE2) as entry receptor [33, 34] .", [["cells", "ANATOMY", 456, 461], ["Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV)", "DISEASE", 162, 219], ["Respiratory Syndrome Coronavirus", "DISEASE", 243, 275], ["SARS", "DISEASE", 297, 301], ["SARS", "DISEASE", 383, 387], ["Angiotensin", "CHEMICAL", 505, 516], ["SARS-CoV-2", "ORGANISM", 51, 61], ["bat coronaviruses", "ORGANISM", 67, 84], ["SARS-CoV", "ORGANISM", 210, 218], ["Middle Eastern Respiratory Syndrome Coronavirus", "ORGANISM", 228, 275], ["MERS-CoV", "ORGANISM", 277, 285], ["COVID-19 infectionSimilar", "ORGANISM", 354, 379], ["SARS-CoV", "ORGANISM", 383, 391], ["coronavirus", "ORGANISM", 403, 414], ["cells", "CELL", 456, 461], ["Spike", "GENE_OR_GENE_PRODUCT", 476, 481], ["Angiotensin-Converting Enzyme-2", "GENE_OR_GENE_PRODUCT", 505, 536], ["ACE2", "GENE_OR_GENE_PRODUCT", 538, 542], ["structural glycoprotein", "PROTEIN", 422, 445], ["envelope Spike protein", "PROTEIN", 467, 489], ["S", "PROTEIN", 491, 492], ["Angiotensin-Converting Enzyme-2", "PROTEIN", 505, 536], ["ACE2", "PROTEIN", 538, 542], ["entry receptor", "PROTEIN", 547, 561], ["SARS-CoV", "SPECIES", 51, 59], ["bat coronaviruses", "SPECIES", 67, 84], ["Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV", "SPECIES", 155, 218], ["Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 228, 285], ["SARS-CoV", "SPECIES", 383, 391], ["Viral genome studies", "TEST", 0, 20], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["bat coronaviruses", "PROBLEM", 67, 84], ["coronaviruses", "PROBLEM", 97, 110], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 151, 188], ["Related Coronavirus (SARS-CoV)", "PROBLEM", 189, 219], ["the Middle Eastern Respiratory Syndrome Coronavirus", "PROBLEM", 224, 275], ["SARS", "TEST", 297, 301], ["the immune system", "TEST", 333, 350], ["COVID", "TEST", 354, 359], ["SARS", "PROBLEM", 383, 387], ["CoV", "PROBLEM", 388, 391], ["the novel coronavirus", "PROBLEM", 393, 414], ["a structural glycoprotein to infect cells", "PROBLEM", 420, 461], ["the Angiotensin-Converting Enzyme-", "TREATMENT", 501, 535], ["Severe", "OBSERVATION_MODIFIER", 155, 161], ["Acute", "OBSERVATION_MODIFIER", 162, 167], ["Respiratory Syndrome", "OBSERVATION", 168, 188], ["Middle Eastern", "ANATOMY", 228, 242], ["Respiratory Syndrome", "OBSERVATION", 243, 263]]], ["ACE2 consists of a cell membrane protein abundantly expressed in the organism, which is present in cardiac, pulmonary, renal, intestinal and vascular cells, and the binding of SARS-CoV-2 with this enzyme has a strong affinity, which may explain the high transmissibility of the virus [8, 9, 34] .SARS-COV-2 virology and the role of the immune system in COVID-19 infectionDue to mainly respiratory symptoms, it is believed that the target cells of SARS-CoV-2 are in lower airways [35] , as is the case of type 2 pneumocytes or alveolar cells, the main site of expression of ACE2 receptors [8] .", [["cell membrane", "ANATOMY", 19, 32], ["cardiac", "ANATOMY", 99, 106], ["pulmonary", "ANATOMY", 108, 117], ["renal", "ANATOMY", 119, 124], ["intestinal", "ANATOMY", 126, 136], ["vascular cells", "ANATOMY", 141, 155], ["immune system", "ANATOMY", 336, 349], ["respiratory", "ANATOMY", 385, 396], ["cells", "ANATOMY", 438, 443], ["lower airways", "ANATOMY", 465, 478], ["type 2 pneumocytes", "ANATOMY", 504, 522], ["alveolar cells", "ANATOMY", 526, 540], ["SARS", "DISEASE", 176, 180], ["SARS", "DISEASE", 296, 300], ["respiratory symptoms", "DISEASE", 385, 405], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell membrane", "CELLULAR_COMPONENT", 19, 32], ["cardiac", "ORGAN", 99, 106], ["pulmonary", "ORGAN", 108, 117], ["renal", "CELL", 119, 124], ["intestinal", "CELL", 126, 136], ["vascular cells", "CELL", 141, 155], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 176, 186], ["COVID-19", "CELL", 353, 361], ["cells", "CELL", 438, 443], ["SARS-CoV-2", "ORGANISM", 447, 457], ["type 2 pneumocytes", "CELL", 504, 522], ["alveolar cells", "CELL", 526, 540], ["ACE2", "GENE_OR_GENE_PRODUCT", 573, 577], ["ACE2", "PROTEIN", 0, 4], ["cell membrane protein", "PROTEIN", 19, 40], ["intestinal and vascular cells", "CELL_TYPE", 126, 155], ["enzyme", "PROTEIN", 197, 203], ["type 2 pneumocytes", "CELL_TYPE", 504, 522], ["alveolar cells", "CELL_TYPE", 526, 540], ["ACE2 receptors", "PROTEIN", 573, 587], ["COVID-19", "SPECIES", 353, 361], ["SARS-CoV", "SPECIES", 447, 455], ["a cell membrane protein", "TREATMENT", 17, 40], ["cardiac, pulmonary, renal, intestinal and vascular cells", "PROBLEM", 99, 155], ["CoV", "TEST", 181, 184], ["this enzyme", "TEST", 192, 203], ["the high transmissibility of the virus", "PROBLEM", 245, 283], ["SARS", "TEST", 296, 300], ["COVID", "TEST", 353, 358], ["mainly respiratory symptoms", "PROBLEM", 378, 405], ["SARS", "TEST", 447, 451], ["CoV", "TEST", 452, 455], ["type 2 pneumocytes", "PROBLEM", 504, 522], ["alveolar cells", "PROBLEM", 526, 540], ["ACE2 receptors", "TREATMENT", 573, 587], ["cell membrane", "OBSERVATION", 19, 32], ["organism", "OBSERVATION", 69, 77], ["cardiac", "ANATOMY", 99, 106], ["pulmonary", "ANATOMY", 108, 117], ["renal", "ANATOMY", 119, 124], ["intestinal", "ANATOMY", 126, 136], ["vascular cells", "ANATOMY", 141, 155], ["lower", "ANATOMY_MODIFIER", 465, 470], ["airways", "ANATOMY", 471, 478], ["pneumocytes", "OBSERVATION", 511, 522], ["alveolar cells", "OBSERVATION", 526, 540], ["main", "OBSERVATION_MODIFIER", 546, 550]]], ["The result of the interaction between the S receptor binding domain (RBD) and ACE2 is the fusion of the viral and host membranes, which proceeds for viral replication and dissemination and may reach the other cells with ACE2 expression in the organism [8] .SARS-COV-2 virology and the role of the immune system in COVID-19 infectionWith the purpose of containing the infection, the innate and adaptive immune system is activated by mechanisms that are not yet completely elucidated.", [["membranes", "ANATOMY", 119, 128], ["cells", "ANATOMY", 209, 214], ["immune system", "ANATOMY", 297, 310], ["SARS", "DISEASE", 257, 261], ["infection", "DISEASE", 367, 376], ["ACE2", "GENE_OR_GENE_PRODUCT", 78, 82], ["host membranes", "CELLULAR_COMPONENT", 114, 128], ["cells", "CELL", 209, 214], ["ACE2", "GENE_OR_GENE_PRODUCT", 220, 224], ["COVID-19", "CELL", 314, 322], ["immune system", "ANATOMICAL_SYSTEM", 402, 415], ["S receptor binding domain", "PROTEIN", 42, 67], ["RBD", "PROTEIN", 69, 72], ["ACE2", "PROTEIN", 78, 82], ["ACE2", "PROTEIN", 220, 224], ["COVID-19", "SPECIES", 314, 322], ["ACE2", "TREATMENT", 78, 82], ["the fusion", "TREATMENT", 86, 96], ["the viral and host membranes", "PROBLEM", 100, 128], ["viral replication", "PROBLEM", 149, 166], ["ACE2 expression", "PROBLEM", 220, 235], ["SARS", "TEST", 257, 261], ["COVID", "TEST", 314, 319], ["the infection", "PROBLEM", 363, 376], ["the innate and adaptive immune system", "TREATMENT", 378, 415], ["viral", "OBSERVATION", 104, 109], ["host membranes", "OBSERVATION", 114, 128], ["infection", "OBSERVATION", 367, 376]]], ["In spite of this, it is known that effective immunological actions are essential to control viral replication and dissemination, cellular inflammation and tissue injury, and many studies have reported that the immune response of the host influences the severity of COVID-19 [9, [36] [37] [38] .Immune response to coronavirus infectionsTo initiate the antiviral response, cells of the innate immune system need to recognize the infection, a process performed through pattern-recognition receptors (PRRs) such as TLR, NOD-like receptor (NLR), C-type lectinlike receptor (CLR), RIG-I-like receptor (RLR) and freemolecule receptors in the cytoplasm, which detect pathogen-associated molecular patterns (PAMPs).", [["cellular", "ANATOMY", 129, 137], ["tissue", "ANATOMY", 155, 161], ["cells", "ANATOMY", 371, 376], ["cytoplasm", "ANATOMY", 635, 644], ["inflammation", "DISEASE", 138, 150], ["tissue injury", "DISEASE", 155, 168], ["coronavirus infections", "DISEASE", 313, 335], ["infection", "DISEASE", 427, 436], ["COVID-19", "CHEMICAL", 265, 273], ["cellular", "CELL", 129, 137], ["tissue", "TISSUE", 155, 161], ["coronavirus", "ORGANISM", 313, 324], ["cells", "CELL", 371, 376], ["pattern-recognition receptors", "GENE_OR_GENE_PRODUCT", 466, 495], ["PRRs", "GENE_OR_GENE_PRODUCT", 497, 501], ["TLR", "GENE_OR_GENE_PRODUCT", 511, 514], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 516, 533], ["NLR", "GENE_OR_GENE_PRODUCT", 535, 538], ["C-type lectinlike receptor", "GENE_OR_GENE_PRODUCT", 541, 567], ["CLR", "GENE_OR_GENE_PRODUCT", 569, 572], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 575, 594], ["RLR", "GENE_OR_GENE_PRODUCT", 596, 599], ["freemolecule receptors", "GENE_OR_GENE_PRODUCT", 605, 627], ["cytoplasm", "ORGANISM_SUBSTANCE", 635, 644], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 659, 697], ["PAMPs", "GENE_OR_GENE_PRODUCT", 699, 704], ["pattern-recognition receptors", "PROTEIN", 466, 495], ["PRRs", "PROTEIN", 497, 501], ["TLR", "PROTEIN", 511, 514], ["NOD-like receptor", "PROTEIN", 516, 533], ["NLR", "PROTEIN", 535, 538], ["C-type lectinlike receptor", "PROTEIN", 541, 567], ["CLR", "PROTEIN", 569, 572], ["RIG-I-like receptor", "PROTEIN", 575, 594], ["RLR", "PROTEIN", 596, 599], ["freemolecule receptors", "PROTEIN", 605, 627], ["pathogen-associated molecular patterns", "PROTEIN", 659, 697], ["PAMPs", "PROTEIN", 699, 704], ["effective immunological actions", "PROBLEM", 35, 66], ["viral replication", "PROBLEM", 92, 109], ["cellular inflammation", "PROBLEM", 129, 150], ["tissue injury", "PROBLEM", 155, 168], ["many studies", "TEST", 174, 186], ["COVID", "TEST", 265, 270], ["Immune response", "PROBLEM", 294, 309], ["coronavirus infections", "PROBLEM", 313, 335], ["the antiviral response", "TREATMENT", 347, 369], ["the innate immune system", "TREATMENT", 380, 404], ["the infection", "PROBLEM", 423, 436], ["TLR", "TEST", 511, 514], ["NOD", "TEST", 516, 519], ["NLR", "TEST", 535, 538], ["C-type lectinlike receptor", "PROBLEM", 541, 567], ["freemolecule receptors in the cytoplasm", "PROBLEM", 605, 644], ["pathogen", "PROBLEM", 659, 667], ["cellular inflammation", "OBSERVATION", 129, 150], ["coronavirus infections", "OBSERVATION", 313, 335], ["infection", "OBSERVATION", 427, 436]]], ["Once viral nucleic acids are recognized as PAMPs, PRRs activate molecular pathways of inflammatory response, stimulating chemotaxis, maturation of immune cells, phagocytosis and expression of inflammatory factors [39] .Immune response to coronavirus infectionsViral recognition by TLR3, TLR7 and RIG-I receptors leads to activation of the nuclear factor-\u03baB (NF-\u03baB) and IRF3 signaling cascade, with nuclear transcription and expression of type I interferons (IFNs-I) and pro-inflammatory cytokines, creating the first line of defense against viral infections.", [["immune cells", "ANATOMY", 147, 159], ["nuclear", "ANATOMY", 398, 405], ["nucleic acids", "CHEMICAL", 11, 24], ["coronavirus infections", "DISEASE", 238, 260], ["viral infections", "DISEASE", 541, 557], ["PAMPs", "GENE_OR_GENE_PRODUCT", 43, 48], ["PRRs", "GENE_OR_GENE_PRODUCT", 50, 54], ["immune cells", "CELL", 147, 159], ["coronavirus", "ORGANISM", 238, 249], ["TLR3", "GENE_OR_GENE_PRODUCT", 281, 285], ["TLR7", "GENE_OR_GENE_PRODUCT", 287, 291], ["RIG-I", "GENE_OR_GENE_PRODUCT", 296, 301], ["nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 339, 356], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 358, 363], ["IRF3", "GENE_OR_GENE_PRODUCT", 369, 373], ["nuclear", "CELLULAR_COMPONENT", 398, 405], ["type I interferons", "GENE_OR_GENE_PRODUCT", 438, 456], ["IFNs-I", "GENE_OR_GENE_PRODUCT", 458, 464], ["PAMPs", "PROTEIN", 43, 48], ["PRRs", "PROTEIN", 50, 54], ["immune cells", "CELL_TYPE", 147, 159], ["inflammatory factors", "PROTEIN", 192, 212], ["TLR3", "PROTEIN", 281, 285], ["TLR7", "PROTEIN", 287, 291], ["RIG-I receptors", "PROTEIN", 296, 311], ["NF-\u03baB", "PROTEIN", 358, 363], ["IRF3", "PROTEIN", 369, 373], ["type I interferons", "PROTEIN", 438, 456], ["IFNs", "PROTEIN", 458, 462], ["I", "PROTEIN", 463, 464], ["pro-inflammatory cytokines", "PROTEIN", 470, 496], ["viral nucleic acids", "TEST", 5, 24], ["PAMPs", "PROBLEM", 43, 48], ["inflammatory response", "PROBLEM", 86, 107], ["stimulating chemotaxis", "PROBLEM", 109, 131], ["immune cells", "PROBLEM", 147, 159], ["phagocytosis", "PROBLEM", 161, 173], ["inflammatory factors", "PROBLEM", 192, 212], ["Immune response", "PROBLEM", 219, 234], ["coronavirus infections", "PROBLEM", 238, 260], ["Viral recognition", "TEST", 260, 277], ["TLR3", "TEST", 281, 285], ["TLR7", "TEST", 287, 291], ["RIG-I receptors", "TREATMENT", 296, 311], ["the nuclear factor", "TEST", 335, 353], ["\u03baB", "TEST", 354, 356], ["NF", "TEST", 358, 360], ["IRF3 signaling cascade", "PROBLEM", 369, 391], ["nuclear transcription", "TREATMENT", 398, 419], ["type I interferons", "PROBLEM", 438, 456], ["pro-inflammatory cytokines", "PROBLEM", 470, 496], ["viral infections", "PROBLEM", 541, 557], ["inflammatory", "OBSERVATION_MODIFIER", 86, 98], ["immune cells", "OBSERVATION", 147, 159], ["inflammatory", "OBSERVATION_MODIFIER", 192, 204], ["coronavirus infections", "OBSERVATION", 238, 260], ["viral", "OBSERVATION_MODIFIER", 541, 546], ["infections", "OBSERVATION", 547, 557]]], ["The IFNs-I (IFN-\u03b1 and IFN-\u03b2) are the most important antiviral cytokines, and they act as immunomodulators influencing the activities of macrophages and lymphocytes, performing actions such as protection of non-infected cells, containment of viral replication and effective activation of the adaptive immune system [8, 9, 39] .Immune response to coronavirus infectionsA suppression or delay of IFNs-I response-due to viral evasion mechanisms-results in impairment of early infection control, hyperinflammatory infiltrate of neutrophils, macrophages and monocytes into the lungs, production of cytokines by these cells and lung tissue damage.", [["macrophages", "ANATOMY", 136, 147], ["lymphocytes", "ANATOMY", 152, 163], ["cells", "ANATOMY", 219, 224], ["neutrophils", "ANATOMY", 523, 534], ["macrophages", "ANATOMY", 536, 547], ["monocytes", "ANATOMY", 552, 561], ["lungs", "ANATOMY", 571, 576], ["cells", "ANATOMY", 611, 616], ["lung tissue", "ANATOMY", 621, 632], ["coronavirus infections", "DISEASE", 345, 367], ["impairment of early infection", "DISEASE", 452, 481], ["tissue damage", "DISEASE", 626, 639], ["IFNs-I", "GENE_OR_GENE_PRODUCT", 4, 10], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 12, 17], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 22, 27], ["macrophages", "CELL", 136, 147], ["lymphocytes", "CELL", 152, 163], ["cells", "CELL", 219, 224], ["coronavirus", "ORGANISM", 345, 356], ["IFNs-I", "GENE_OR_GENE_PRODUCT", 393, 399], ["neutrophils", "CELL", 523, 534], ["macrophages", "CELL", 536, 547], ["monocytes", "CELL", 552, 561], ["lungs", "ORGAN", 571, 576], ["cells", "CELL", 611, 616], ["lung tissue", "TISSUE", 621, 632], ["IFNs", "PROTEIN", 4, 8], ["IFN", "PROTEIN", 12, 15], ["\u03b1", "PROTEIN", 16, 17], ["IFN-\u03b2", "PROTEIN", 22, 27], ["antiviral cytokines", "PROTEIN", 52, 71], ["macrophages", "CELL_TYPE", 136, 147], ["lymphocytes", "CELL_TYPE", 152, 163], ["non-infected cells", "CELL_TYPE", 206, 224], ["IFNs", "PROTEIN", 393, 397], ["neutrophils", "CELL_TYPE", 523, 534], ["macrophages", "CELL_TYPE", 536, 547], ["monocytes", "CELL_TYPE", 552, 561], ["cytokines", "PROTEIN", 592, 601], ["IFN", "TEST", 12, 15], ["immunomodulators", "TREATMENT", 89, 105], ["lymphocytes", "PROBLEM", 152, 163], ["protection of non-infected cells", "TREATMENT", 192, 224], ["viral replication", "TREATMENT", 241, 258], ["Immune response", "PROBLEM", 326, 341], ["coronavirus infections", "PROBLEM", 345, 367], ["viral evasion mechanisms", "PROBLEM", 416, 440], ["early infection control", "PROBLEM", 466, 489], ["hyperinflammatory infiltrate of neutrophils", "PROBLEM", 491, 534], ["macrophages", "PROBLEM", 536, 547], ["monocytes into the lungs", "PROBLEM", 552, 576], ["cytokines", "PROBLEM", 592, 601], ["these cells", "PROBLEM", 605, 616], ["lung tissue damage", "PROBLEM", 621, 639], ["non-infected cells", "OBSERVATION", 206, 224], ["viral replication", "OBSERVATION", 241, 258], ["coronavirus infections", "OBSERVATION", 345, 367], ["early", "OBSERVATION_MODIFIER", 466, 471], ["infection", "OBSERVATION", 472, 481], ["infiltrate", "OBSERVATION", 509, 519], ["neutrophils", "ANATOMY", 523, 534], ["lungs", "ANATOMY", 571, 576], ["lung", "ANATOMY", 621, 625], ["tissue", "ANATOMY_MODIFIER", 626, 632], ["damage", "OBSERVATION", 633, 639]]], ["This process, described in SARS-CoV and MERS-CoV, has been suggested as a possible strategy to trigger or collaborate to the pathology of COVID-19 [8, 9] .Immune response to coronavirus infectionsMacrophages and DCs act as APCs for lymphocytes via MHC and produce a microenvironment of signaling cytokines, activating the adaptive immune system.", [["Macrophages", "ANATOMY", 196, 207], ["DCs", "ANATOMY", 212, 215], ["APCs", "ANATOMY", 223, 227], ["lymphocytes", "ANATOMY", 232, 243], ["coronavirus infections", "DISEASE", 174, 196], ["COVID-19", "CHEMICAL", 138, 146], ["SARS-CoV", "ORGANISM", 27, 35], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 40, 48], ["coronavirus", "ORGANISM", 174, 185], ["Macrophages", "CELL", 196, 207], ["DCs", "CELL", 212, 215], ["APCs", "CELL", 223, 227], ["lymphocytes", "CELL", 232, 243], ["MHC", "GENE_OR_GENE_PRODUCT", 248, 251], ["Macrophages", "CELL_TYPE", 196, 207], ["DCs", "CELL_TYPE", 212, 215], ["APCs", "CELL_TYPE", 223, 227], ["lymphocytes", "CELL_TYPE", 232, 243], ["MHC", "PROTEIN", 248, 251], ["signaling cytokines", "PROTEIN", 286, 305], ["coronavirus", "SPECIES", 174, 185], ["SARS-CoV", "SPECIES", 27, 35], ["MERS-CoV", "SPECIES", 40, 48], ["COVID", "TEST", 138, 143], ["Immune response", "PROBLEM", 155, 170], ["coronavirus infectionsMacrophages", "PROBLEM", 174, 207], ["lymphocytes", "PROBLEM", 232, 243], ["signaling cytokines", "PROBLEM", 286, 305], ["the adaptive immune system", "TREATMENT", 318, 344], ["coronavirus infections", "OBSERVATION", 174, 196]]], ["T lymphocytes perform important functions against viral microorganisms, since TCD8 + can cause direct cytotoxicity against infected cells and TCD4 + stimulate B lymphocytes to produce neutralizing antibodies.", [["T lymphocytes", "ANATOMY", 0, 13], ["cells", "ANATOMY", 132, 137], ["B lymphocytes", "ANATOMY", 159, 172], ["TCD8", "CHEMICAL", 78, 82], ["T lymphocytes", "CELL", 0, 13], ["TCD8 +", "SIMPLE_CHEMICAL", 78, 84], ["cells", "CELL", 132, 137], ["TCD4 +", "SIMPLE_CHEMICAL", 142, 148], ["B lymphocytes", "CELL", 159, 172], ["T lymphocytes", "CELL_TYPE", 0, 13], ["TCD8", "PROTEIN", 78, 82], ["infected cells", "CELL_TYPE", 123, 137], ["TCD4", "PROTEIN", 142, 146], ["B lymphocytes", "CELL_TYPE", 159, 172], ["neutralizing antibodies", "PROTEIN", 184, 207], ["T lymphocytes", "TEST", 0, 13], ["viral microorganisms", "PROBLEM", 50, 70], ["TCD8", "TEST", 78, 82], ["direct cytotoxicity", "PROBLEM", 95, 114], ["infected cells", "PROBLEM", 123, 137], ["TCD4", "TEST", 142, 146], ["stimulate B lymphocytes", "PROBLEM", 149, 172], ["neutralizing antibodies", "PROBLEM", 184, 207], ["neutralizing antibodies", "OBSERVATION", 184, 207]]], ["In turn, T helper lymphocytes (Th)-predominantly Th1-contribute to the organization of the adaptive response and release cytokines that are able to recruit monocytes and neutrophils and to promote other cascades of pro-inflammatory molecules, amplifying the immune response [8, 39] (Fig. 3 ).Immune response to coronavirus infectionsThe complement system can also be activated and has an important role in coronavirus infections, because it helps the innate immune system to identify antigens.", [["T helper lymphocytes", "ANATOMY", 9, 29], ["monocytes", "ANATOMY", 156, 165], ["neutrophils", "ANATOMY", 170, 181], ["coronavirus infections", "DISEASE", 311, 333], ["coronavirus infections", "DISEASE", 406, 428], ["T helper lymphocytes", "CELL", 9, 29], ["Th", "CELL", 31, 33], ["Th1", "GENE_OR_GENE_PRODUCT", 49, 52], ["monocytes", "CELL", 156, 165], ["neutrophils", "CELL", 170, 181], ["coronavirus", "ORGANISM", 311, 322], ["coronavirus", "ORGANISM", 406, 417], ["T helper lymphocytes", "CELL_TYPE", 9, 29], ["Th", "CELL_TYPE", 31, 33], ["cytokines", "PROTEIN", 121, 130], ["monocytes", "CELL_TYPE", 156, 165], ["neutrophils", "CELL_TYPE", 170, 181], ["pro-inflammatory molecules", "PROTEIN", 215, 241], ["antigens", "PROTEIN", 484, 492], ["coronavirus", "SPECIES", 406, 417], ["release cytokines", "TEST", 113, 130], ["monocytes", "TEST", 156, 165], ["neutrophils", "TEST", 170, 181], ["pro-inflammatory molecules", "PROBLEM", 215, 241], ["Immune response", "PROBLEM", 292, 307], ["coronavirus infections", "PROBLEM", 311, 333], ["coronavirus infections", "PROBLEM", 406, 428], ["coronavirus infections", "OBSERVATION", 311, 333], ["coronavirus infections", "OBSERVATION", 406, 428]]], ["However, its activation can contribute to the disease due to its potent capacity to stimulate neutrophils and to recruit inflammatory cells, which can trigger tissue damage [39] .Unbalanced immunological responses at COVID-19Studies suggest that in mild cases, pulmonary tissue macrophages are capable of containing SARS-CoV-2 and innate and adaptive immune responses are efficiently activated against viral replication.", [["neutrophils", "ANATOMY", 94, 105], ["inflammatory cells", "ANATOMY", 121, 139], ["tissue", "ANATOMY", 159, 165], ["pulmonary tissue macrophages", "ANATOMY", 261, 289], ["tissue damage", "DISEASE", 159, 172], ["neutrophils", "CELL", 94, 105], ["cells", "CELL", 134, 139], ["tissue", "TISSUE", 159, 165], ["pulmonary tissue macrophages", "CELL", 261, 289], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 316, 326], ["neutrophils", "CELL_TYPE", 94, 105], ["inflammatory cells", "CELL_TYPE", 121, 139], ["pulmonary tissue macrophages", "CELL_TYPE", 261, 289], ["the disease", "PROBLEM", 42, 53], ["its potent capacity", "PROBLEM", 61, 80], ["neutrophils", "PROBLEM", 94, 105], ["inflammatory cells", "PROBLEM", 121, 139], ["tissue damage", "PROBLEM", 159, 172], ["Unbalanced immunological responses", "PROBLEM", 179, 213], ["COVID", "TEST", 217, 222], ["mild cases, pulmonary tissue macrophages", "PROBLEM", 249, 289], ["SARS", "PROBLEM", 316, 320], ["CoV", "TEST", 321, 324], ["viral replication", "TREATMENT", 402, 419], ["inflammatory cells", "OBSERVATION", 121, 139], ["mild", "OBSERVATION_MODIFIER", 249, 253], ["cases", "OBSERVATION", 254, 259], ["pulmonary tissue", "ANATOMY", 261, 277], ["macrophages", "OBSERVATION", 278, 289]]], ["However, severe cases of COVID-19 are associated with an imbalance in antiviral immunity, characterized by two main situations: a pro-inflammatory cytokine storm and a lymphopenia state [37, 38] .Unbalanced immunological responses at COVID-19The degree of lymphopenia and cytokine storm was related to the severity of COVID-19 [7] , and similar situations had already been reported in other respiratory viral infections, including influenza, SARS-CoV and MERS-CoV.", [["COVID-19", "CHEMICAL", 25, 33], ["lymphopenia", "DISEASE", 168, 179], ["lymphopenia", "DISEASE", 256, 267], ["respiratory viral infections", "DISEASE", 391, 419], ["influenza", "DISEASE", 431, 440], ["SARS", "DISEASE", 442, 446], ["COVID-19", "CHEMICAL", 25, 33], ["COVID-19", "CHEMICAL", 234, 242], ["COVID-19", "CHEMICAL", 318, 326], ["COVID-19", "GENE_OR_GENE_PRODUCT", 25, 33], ["SARS-CoV", "ORGANISM", 442, 450], ["MERS-CoV", "ORGANISM", 455, 463], ["pro-inflammatory cytokine", "PROTEIN", 130, 155], ["cytokine", "PROTEIN", 272, 280], ["SARS-CoV", "SPECIES", 442, 450], ["MERS-CoV", "SPECIES", 455, 463], ["COVID", "TEST", 25, 30], ["an imbalance in antiviral immunity", "PROBLEM", 54, 88], ["a pro-inflammatory cytokine storm", "PROBLEM", 128, 161], ["a lymphopenia state", "PROBLEM", 166, 185], ["Unbalanced immunological responses", "PROBLEM", 196, 230], ["COVID", "TEST", 234, 239], ["lymphopenia", "PROBLEM", 256, 267], ["cytokine storm", "PROBLEM", 272, 286], ["COVID", "TEST", 318, 323], ["other respiratory viral infections", "PROBLEM", 385, 419], ["influenza", "PROBLEM", 431, 440], ["SARS", "PROBLEM", 442, 446], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["imbalance", "OBSERVATION", 57, 66], ["antiviral immunity", "OBSERVATION", 70, 88], ["pro-inflammatory cytokine storm", "OBSERVATION", 130, 161], ["lymphopenia", "OBSERVATION", 168, 179], ["degree", "OBSERVATION_MODIFIER", 246, 252], ["lymphopenia", "OBSERVATION", 256, 267], ["cytokine storm", "OBSERVATION", 272, 286], ["respiratory", "ANATOMY", 391, 402], ["viral infections", "OBSERVATION", 403, 419]]], ["Activation of the complement system and abnormalities in coagulation were also observed in severe patients with markers such as C-reactive protein (CRP), dimero-D and fibrin degradation products, which are usually elevated in advanced stages of the disease [37, 38] .Unbalanced immunological responses at COVID-19The mechanism of cytokine storm and lymphopenia associated with circulatory alterations and viral dissemination to several organs was proposed as being responsible for viral sepsis.", [["organs", "ANATOMY", 436, 442], ["abnormalities in coagulation", "DISEASE", 40, 68], ["lymphopenia", "DISEASE", 349, 360], ["circulatory alterations", "DISEASE", 377, 400], ["sepsis", "DISEASE", 487, 493], ["COVID-19", "CHEMICAL", 305, 313], ["patients", "ORGANISM", 98, 106], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 128, 146], ["CRP", "GENE_OR_GENE_PRODUCT", 148, 151], ["dimero-D", "SIMPLE_CHEMICAL", 154, 162], ["fibrin", "GENE_OR_GENE_PRODUCT", 167, 173], ["organs", "ORGAN", 436, 442], ["C-reactive protein", "PROTEIN", 128, 146], ["CRP", "PROTEIN", 148, 151], ["fibrin", "PROTEIN", 167, 173], ["cytokine", "PROTEIN", 330, 338], ["patients", "SPECIES", 98, 106], ["abnormalities in coagulation", "PROBLEM", 40, 68], ["markers", "TEST", 112, 119], ["C-reactive protein", "TEST", 128, 146], ["CRP", "TEST", 148, 151], ["dimero", "TEST", 154, 160], ["fibrin degradation products", "PROBLEM", 167, 194], ["the disease", "PROBLEM", 245, 256], ["Unbalanced immunological responses", "PROBLEM", 267, 301], ["COVID", "TEST", 305, 310], ["cytokine storm", "PROBLEM", 330, 344], ["lymphopenia", "PROBLEM", 349, 360], ["circulatory alterations", "PROBLEM", 377, 400], ["viral dissemination", "PROBLEM", 405, 424], ["viral sepsis", "PROBLEM", 481, 493], ["fibrin degradation", "OBSERVATION", 167, 185], ["elevated", "OBSERVATION_MODIFIER", 214, 222], ["advanced stages", "OBSERVATION_MODIFIER", 226, 241], ["disease", "OBSERVATION", 249, 256], ["cytokine storm", "OBSERVATION", 330, 344], ["lymphopenia", "OBSERVATION", 349, 360], ["circulatory alterations", "OBSERVATION", 377, 400], ["viral dissemination", "OBSERVATION", 405, 424], ["sepsis", "OBSERVATION", 487, 493]]], ["Among the complications of this condition are acute respiratory distress syndrome (ARDS), septic shock, multiple organ failure (MOF) and death [8, 38] .Cytokine stormIn patients with severe COVID-19, increased levels of cytokines were observed, including IL-1\u03b2, IL-2, IL-6, IL-8, IL-10, IL-17, interferon-gamma (IFN-\u03b3), tumor necrosis factor alpha (TNF-\u03b1), granulocyte-colony stimulating factor (G-CSF), gamma-induced protein 10 (IP10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1 alpha (MIP1-\u03b1) and other molecules, characterizing the cytokine storm [37, 38] .", [["respiratory", "ANATOMY", 52, 63], ["organ", "ANATOMY", 113, 118], ["acute respiratory distress syndrome", "DISEASE", 46, 81], ["ARDS", "DISEASE", 83, 87], ["septic shock", "DISEASE", 90, 102], ["multiple organ failure", "DISEASE", 104, 126], ["MOF", "DISEASE", 128, 131], ["death", "DISEASE", 137, 142], ["necrosis", "DISEASE", 326, 334], ["organ", "ORGAN", 113, 118], ["patients", "ORGANISM", 169, 177], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 255, 260], ["IL-2", "GENE_OR_GENE_PRODUCT", 262, 266], ["IL-6", "GENE_OR_GENE_PRODUCT", 268, 272], ["IL-8", "GENE_OR_GENE_PRODUCT", 274, 278], ["IL-10", "GENE_OR_GENE_PRODUCT", 280, 285], ["IL-17", "GENE_OR_GENE_PRODUCT", 287, 292], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 294, 310], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 312, 317], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 320, 347], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 349, 354], ["granulocyte-colony stimulating factor", "GENE_OR_GENE_PRODUCT", 357, 394], ["G-CSF", "GENE_OR_GENE_PRODUCT", 396, 401], ["gamma-induced protein 10", "GENE_OR_GENE_PRODUCT", 404, 428], ["IP10", "GENE_OR_GENE_PRODUCT", 430, 434], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 437, 471], ["MCP1", "GENE_OR_GENE_PRODUCT", 473, 477], ["macrophage inflammatory protein 1 alpha", "GENE_OR_GENE_PRODUCT", 480, 519], ["MIP1-\u03b1", "GENE_OR_GENE_PRODUCT", 521, 527], ["cytokines", "PROTEIN", 220, 229], ["interferon-gamma (IFN-\u03b3", "PROTEIN", 294, 317], ["tumor necrosis factor alpha", "PROTEIN", 320, 347], ["TNF", "PROTEIN", 349, 352], ["\u03b1", "PROTEIN", 353, 354], ["granulocyte-colony stimulating factor", "PROTEIN", 357, 394], ["G-CSF), gamma-induced protein 10", "PROTEIN", 396, 428], ["IP10", "PROTEIN", 430, 434], ["monocyte chemoattractant protein 1", "PROTEIN", 437, 471], ["MCP1", "PROTEIN", 473, 477], ["macrophage inflammatory protein 1 alpha", "PROTEIN", 480, 519], ["MIP1", "PROTEIN", 521, 525], ["\u03b1", "PROTEIN", 526, 527], ["cytokine", "PROTEIN", 569, 577], ["patients", "SPECIES", 169, 177], ["this condition", "PROBLEM", 27, 41], ["acute respiratory distress syndrome", "PROBLEM", 46, 81], ["ARDS", "PROBLEM", 83, 87], ["septic shock", "PROBLEM", 90, 102], ["multiple organ failure", "PROBLEM", 104, 126], ["death", "PROBLEM", 137, 142], ["Cytokine stormIn", "TREATMENT", 152, 168], ["severe COVID", "PROBLEM", 183, 195], ["increased levels of cytokines", "PROBLEM", 200, 229], ["IL", "TEST", 255, 257], ["IL", "TEST", 262, 264], ["IL", "TEST", 268, 270], ["IL", "TEST", 274, 276], ["IL", "TEST", 280, 282], ["IL", "TEST", 287, 289], ["interferon", "TREATMENT", 294, 304], ["IFN", "TEST", 312, 315], ["tumor necrosis factor", "PROBLEM", 320, 341], ["alpha", "TEST", 342, 347], ["TNF", "TEST", 349, 352], ["granulocyte", "TEST", 357, 368], ["colony stimulating factor", "TEST", 369, 394], ["G-CSF", "TEST", 396, 401], ["gamma-induced protein", "TEST", 404, 425], ["IP10", "TEST", 430, 434], ["monocyte chemoattractant protein", "TEST", 437, 469], ["MCP1", "TEST", 473, 477], ["macrophage inflammatory protein", "TEST", 480, 511], ["alpha", "TEST", 514, 519], ["MIP1", "TEST", 521, 525], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory distress", "OBSERVATION", 52, 72], ["septic shock", "OBSERVATION", 90, 102], ["multiple", "OBSERVATION_MODIFIER", 104, 112], ["organ", "ANATOMY", 113, 118], ["failure", "OBSERVATION", 119, 126], ["severe", "OBSERVATION_MODIFIER", 183, 189], ["gamma", "ANATOMY", 305, 310], ["tumor", "OBSERVATION_MODIFIER", 320, 325], ["necrosis", "OBSERVATION", 326, 334], ["granulocyte", "ANATOMY", 357, 368], ["macrophage", "OBSERVATION_MODIFIER", 480, 490], ["inflammatory", "OBSERVATION_MODIFIER", 491, 503], ["cytokine storm", "OBSERVATION", 569, 583]]], ["Additionally, elevations of IL-1\u03b2, IFN-\u03b3, IP10 and MCP1 in infections by the novel coronavirus were associated with the Th1 response; however, an increase in interleukins of the T helper type 2 (Th2) profile, such as IL-4, IL-5, IL10, which suppress the inflammation, was also associated with a greater severity of COVID-19, which may demonstrate an imbalance in immune regulation and an attempt to minimize tissue inflammatory damage [35, 40] .Cytokine stormThe cytokine storm generates an immunological system attack against the organism, which can cause substantial lesions in organs such as the lung, heart, brain, kidneys, spleen, liver and lymph nodes.", [["tissue", "ANATOMY", 408, 414], ["lesions", "ANATOMY", 569, 576], ["organs", "ANATOMY", 580, 586], ["lung", "ANATOMY", 599, 603], ["heart", "ANATOMY", 605, 610], ["brain", "ANATOMY", 612, 617], ["kidneys", "ANATOMY", 619, 626], ["spleen", "ANATOMY", 628, 634], ["liver", "ANATOMY", 636, 641], ["lymph nodes", "ANATOMY", 646, 657], ["infections", "DISEASE", 59, 69], ["inflammation", "DISEASE", 254, 266], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 28, 33], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 35, 40], ["IP10", "GENE_OR_GENE_PRODUCT", 42, 46], ["MCP1", "GENE_OR_GENE_PRODUCT", 51, 55], ["coronavirus", "ORGANISM", 83, 94], ["interleukins", "GENE_OR_GENE_PRODUCT", 158, 170], ["T helper type 2", "GENE_OR_GENE_PRODUCT", 178, 193], ["Th2", "GENE_OR_GENE_PRODUCT", 195, 198], ["IL-4", "GENE_OR_GENE_PRODUCT", 217, 221], ["IL-5", "GENE_OR_GENE_PRODUCT", 223, 227], ["IL10", "GENE_OR_GENE_PRODUCT", 229, 233], ["tissue", "TISSUE", 408, 414], ["Cytokine", "GENE_OR_GENE_PRODUCT", 445, 453], ["lesions", "PATHOLOGICAL_FORMATION", 569, 576], ["organs", "ORGAN", 580, 586], ["lung", "ORGAN", 599, 603], ["heart", "ORGAN", 605, 610], ["brain", "ORGAN", 612, 617], ["kidneys", "ORGAN", 619, 626], ["spleen", "ORGAN", 628, 634], ["liver", "ORGAN", 636, 641], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 646, 657], ["IL-1\u03b2", "PROTEIN", 28, 33], ["IFN-\u03b3", "PROTEIN", 35, 40], ["IP10", "PROTEIN", 42, 46], ["MCP1", "PROTEIN", 51, 55], ["interleukins", "PROTEIN", 158, 170], ["IL", "PROTEIN", 223, 225], ["IL10", "PROTEIN", 229, 233], ["Cytokine", "PROTEIN", 445, 453], ["cytokine", "PROTEIN", 463, 471], ["IL", "TEST", 28, 30], ["IFN", "TEST", 35, 38], ["IP10", "TREATMENT", 42, 46], ["MCP1 in infections", "PROBLEM", 51, 69], ["the novel coronavirus", "PROBLEM", 73, 94], ["IL", "TEST", 217, 219], ["IL", "TEST", 223, 225], ["IL10", "TREATMENT", 229, 233], ["the inflammation", "PROBLEM", 250, 266], ["COVID", "TEST", 315, 320], ["an imbalance in immune regulation", "PROBLEM", 347, 380], ["tissue inflammatory damage", "PROBLEM", 408, 434], ["Cytokine storm", "PROBLEM", 445, 459], ["substantial lesions in organs such as the lung, heart, brain, kidneys, spleen, liver and lymph nodes", "PROBLEM", 557, 657], ["elevations", "OBSERVATION_MODIFIER", 14, 24], ["infections", "OBSERVATION", 59, 69], ["increase", "OBSERVATION_MODIFIER", 146, 154], ["inflammation", "OBSERVATION", 254, 266], ["imbalance", "OBSERVATION", 350, 359], ["inflammatory", "OBSERVATION_MODIFIER", 415, 427], ["cytokine storm", "OBSERVATION", 463, 477], ["substantial", "OBSERVATION_MODIFIER", 557, 568], ["lesions", "OBSERVATION", 569, 576], ["lung", "ANATOMY", 599, 603], ["heart", "ANATOMY", 605, 610], ["brain", "ANATOMY", 612, 617], ["kidneys", "ANATOMY", 619, 626], ["spleen", "ANATOMY", 628, 634], ["liver", "ANATOMY", 636, 641], ["lymph nodes", "OBSERVATION", 646, 657]]], ["The increase of neutrophils, macrophages and monocytes in association with a dysfunction of the IFN-I response has been reported as the main cause of lethality in SARS-CoV and MERS-CoV pneumonia, and a similar conclusion has been suggested for SARS-CoV-2 [9, 37, 38] .Cytokine stormIn the lungs, alveolar macrophages and epithelial cells are the most responsible for the production of cytokines and chemokines.", [["neutrophils", "ANATOMY", 16, 27], ["macrophages", "ANATOMY", 29, 40], ["monocytes", "ANATOMY", 45, 54], ["lungs", "ANATOMY", 289, 294], ["alveolar macrophages", "ANATOMY", 296, 316], ["epithelial cells", "ANATOMY", 321, 337], ["SARS-CoV", "DISEASE", 163, 171], ["pneumonia", "DISEASE", 185, 194], ["neutrophils", "CELL", 16, 27], ["macrophages", "CELL", 29, 40], ["monocytes", "CELL", 45, 54], ["IFN-I", "GENE_OR_GENE_PRODUCT", 96, 101], ["SARS-CoV", "ORGANISM", 163, 171], ["MERS-CoV", "ORGANISM", 176, 184], ["SARS-CoV-2", "ORGANISM", 244, 254], ["Cytokine stormIn", "GENE_OR_GENE_PRODUCT", 268, 284], ["lungs", "ORGAN", 289, 294], ["alveolar macrophages", "CELL", 296, 316], ["epithelial cells", "CELL", 321, 337], ["neutrophils", "CELL_TYPE", 16, 27], ["macrophages", "CELL_TYPE", 29, 40], ["monocytes", "CELL_TYPE", 45, 54], ["IFN", "PROTEIN", 96, 99], ["Cytokine stormIn", "PROTEIN", 268, 284], ["alveolar macrophages", "CELL_TYPE", 296, 316], ["epithelial cells", "CELL_TYPE", 321, 337], ["cytokines", "PROTEIN", 385, 394], ["chemokines", "PROTEIN", 399, 409], ["SARS-CoV", "SPECIES", 163, 171], ["MERS-CoV", "SPECIES", 176, 184], ["SARS-CoV", "SPECIES", 244, 252], ["The increase of neutrophils", "PROBLEM", 0, 27], ["macrophages", "PROBLEM", 29, 40], ["monocytes", "PROBLEM", 45, 54], ["a dysfunction of the IFN", "PROBLEM", 75, 99], ["lethality", "PROBLEM", 150, 159], ["SARS", "PROBLEM", 163, 167], ["CoV", "PROBLEM", 168, 171], ["MERS", "PROBLEM", 176, 180], ["CoV pneumonia", "PROBLEM", 181, 194], ["SARS", "PROBLEM", 244, 248], ["CoV", "TEST", 249, 252], ["Cytokine stormIn the lungs, alveolar macrophages", "PROBLEM", 268, 316], ["epithelial cells", "PROBLEM", 321, 337], ["cytokines and chemokines", "TREATMENT", 385, 409], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["neutrophils", "OBSERVATION", 16, 27], ["macrophages", "OBSERVATION_MODIFIER", 29, 40], ["monocytes", "OBSERVATION_MODIFIER", 45, 54], ["lethality", "OBSERVATION", 150, 159], ["pneumonia", "OBSERVATION", 185, 194], ["lungs", "ANATOMY", 289, 294], ["alveolar", "ANATOMY", 296, 304], ["macrophages", "OBSERVATION", 305, 316], ["epithelial cells", "OBSERVATION", 321, 337], ["most responsible for", "UNCERTAINTY", 346, 366], ["cytokines", "OBSERVATION", 385, 394]]], ["During infection by the novel coronavirus, excessive secretion of these molecules by the immune cells mediates a massive pulmonary infiltrate of neutrophils, monocytes and macrophages, which results in alveolar damage due to wall thickening and formation of hyaline membranes.", [["immune cells", "ANATOMY", 89, 101], ["pulmonary", "ANATOMY", 121, 130], ["neutrophils", "ANATOMY", 145, 156], ["monocytes", "ANATOMY", 158, 167], ["macrophages", "ANATOMY", 172, 183], ["alveolar", "ANATOMY", 202, 210], ["wall", "ANATOMY", 225, 229], ["hyaline membranes", "ANATOMY", 258, 275], ["infection", "DISEASE", 7, 16], ["alveolar damage", "DISEASE", 202, 217], ["coronavirus", "ORGANISM", 30, 41], ["immune cells", "CELL", 89, 101], ["pulmonary", "ORGAN", 121, 130], ["neutrophils", "CELL", 145, 156], ["monocytes", "CELL", 158, 167], ["macrophages", "CELL", 172, 183], ["alveolar", "TISSUE", 202, 210], ["wall", "TISSUE", 225, 229], ["hyaline membranes", "CELLULAR_COMPONENT", 258, 275], ["immune cells", "CELL_TYPE", 89, 101], ["neutrophils", "CELL_TYPE", 145, 156], ["monocytes", "CELL_TYPE", 158, 167], ["macrophages", "CELL_TYPE", 172, 183], ["infection", "PROBLEM", 7, 16], ["the novel coronavirus", "PROBLEM", 20, 41], ["excessive secretion of these molecules", "PROBLEM", 43, 81], ["the immune cells", "TEST", 85, 101], ["a massive pulmonary infiltrate of neutrophils", "PROBLEM", 111, 156], ["monocytes", "TEST", 158, 167], ["macrophages", "PROBLEM", 172, 183], ["alveolar damage", "PROBLEM", 202, 217], ["wall thickening", "PROBLEM", 225, 240], ["hyaline membranes", "PROBLEM", 258, 275], ["infection", "OBSERVATION", 7, 16], ["massive", "OBSERVATION_MODIFIER", 113, 120], ["pulmonary", "ANATOMY", 121, 130], ["infiltrate", "OBSERVATION", 131, 141], ["neutrophils", "ANATOMY", 145, 156], ["macrophages", "OBSERVATION", 172, 183], ["alveolar damage", "OBSERVATION", 202, 217], ["wall", "ANATOMY_MODIFIER", 225, 229], ["thickening", "OBSERVATION", 230, 240], ["hyaline membranes", "OBSERVATION", 258, 275]]], ["In addition, the accumulation of neutrophils in the lungs increases the production of reactive oxygen species (ROS) and pro-inflammatory molecules, predisposing to injury [41] .", [["neutrophils", "ANATOMY", 33, 44], ["lungs", "ANATOMY", 52, 57], ["oxygen", "CHEMICAL", 95, 101], ["ROS", "CHEMICAL", 111, 114], ["oxygen", "CHEMICAL", 95, 101], ["neutrophils", "CELL", 33, 44], ["lungs", "ORGAN", 52, 57], ["reactive oxygen species", "SIMPLE_CHEMICAL", 86, 109], ["ROS", "SIMPLE_CHEMICAL", 111, 114], ["neutrophils", "CELL_TYPE", 33, 44], ["pro-inflammatory molecules", "PROTEIN", 120, 146], ["the accumulation of neutrophils in the lungs", "PROBLEM", 13, 57], ["reactive oxygen species", "PROBLEM", 86, 109], ["pro-inflammatory molecules", "PROBLEM", 120, 146], ["injury", "PROBLEM", 164, 170], ["accumulation", "OBSERVATION_MODIFIER", 17, 29], ["neutrophils", "OBSERVATION", 33, 44], ["lungs", "ANATOMY", 52, 57], ["production", "OBSERVATION_MODIFIER", 72, 82], ["reactive", "OBSERVATION_MODIFIER", 86, 94], ["oxygen species", "OBSERVATION", 95, 109], ["pro-inflammatory molecules", "OBSERVATION", 120, 146]]], ["Therefore, high levels of pro-inflammatory cytokines are associated with respiratory insufficiency, ARDS and may lead to shock, MOF and death in the COVID-19 [37, 38] .Cytokine stormIn comparison, pulmonary disease caused by SARS-CoV also presents with formation of hyaline membranes, desquamation of alveolar space pneumocytes and interstitial infiltration with lymphocytes and mononuclear cells.", [["respiratory", "ANATOMY", 73, 84], ["pulmonary", "ANATOMY", 197, 206], ["hyaline membranes", "ANATOMY", 266, 283], ["alveolar space pneumocytes", "ANATOMY", 301, 327], ["interstitial", "ANATOMY", 332, 344], ["lymphocytes", "ANATOMY", 363, 374], ["mononuclear cells", "ANATOMY", 379, 396], ["respiratory insufficiency", "DISEASE", 73, 98], ["ARDS", "DISEASE", 100, 104], ["shock", "DISEASE", 121, 126], ["MOF", "DISEASE", 128, 131], ["death", "DISEASE", 136, 141], ["pulmonary disease", "DISEASE", 197, 214], ["SARS", "DISEASE", 225, 229], ["pulmonary", "ORGAN", 197, 206], ["SARS-CoV", "ORGANISM", 225, 233], ["hyaline membranes", "CELLULAR_COMPONENT", 266, 283], ["alveolar space pneumocytes", "CELL", 301, 327], ["lymphocytes", "CELL", 363, 374], ["mononuclear cells", "CELL", 379, 396], ["pro-inflammatory cytokines", "PROTEIN", 26, 52], ["Cytokine stormIn", "PROTEIN", 168, 184], ["lymphocytes", "CELL_TYPE", 363, 374], ["mononuclear cells", "CELL_TYPE", 379, 396], ["SARS-CoV", "SPECIES", 225, 233], ["pro-inflammatory cytokines", "TREATMENT", 26, 52], ["respiratory insufficiency", "PROBLEM", 73, 98], ["ARDS", "PROBLEM", 100, 104], ["shock", "PROBLEM", 121, 126], ["MOF", "PROBLEM", 128, 131], ["death", "PROBLEM", 136, 141], ["the COVID", "TEST", 145, 154], ["Cytokine stormIn comparison", "TREATMENT", 168, 195], ["pulmonary disease", "PROBLEM", 197, 214], ["SARS", "PROBLEM", 225, 229], ["hyaline membranes", "PROBLEM", 266, 283], ["alveolar space pneumocytes", "PROBLEM", 301, 327], ["interstitial infiltration", "PROBLEM", 332, 357], ["lymphocytes", "PROBLEM", 363, 374], ["mononuclear cells", "PROBLEM", 379, 396], ["pro-inflammatory cytokines", "OBSERVATION", 26, 52], ["respiratory insufficiency", "OBSERVATION", 73, 98], ["ARDS", "OBSERVATION", 100, 104], ["pulmonary", "ANATOMY", 197, 206], ["disease", "OBSERVATION", 207, 214], ["hyaline membranes", "OBSERVATION", 266, 283], ["desquamation", "OBSERVATION_MODIFIER", 285, 297], ["alveolar", "ANATOMY_MODIFIER", 301, 309], ["space pneumocytes", "OBSERVATION", 310, 327], ["interstitial", "ANATOMY_MODIFIER", 332, 344], ["infiltration", "OBSERVATION", 345, 357], ["lymphocytes", "ANATOMY", 363, 374], ["mononuclear cells", "OBSERVATION", 379, 396]]], ["In the serum of patients who develop SARS, there are high levels of cytokines and pro-inflammatory chemokines [42] .Cytokine stormAdditionally, it has been observed that during viral infections, pro-inflammatory cytokines can stimulate an increase in the levels of ACE2 protein, the receptor for SARS-CoV-2.", [["serum", "ANATOMY", 7, 12], ["SARS", "DISEASE", 37, 41], ["viral infections", "DISEASE", 177, 193], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["patients", "ORGANISM", 16, 24], ["Cytokine", "GENE_OR_GENE_PRODUCT", 116, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 265, 269], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 296, 306], ["cytokines", "PROTEIN", 68, 77], ["pro-inflammatory chemokines", "PROTEIN", 82, 109], ["Cytokine", "PROTEIN", 116, 124], ["pro-inflammatory cytokines", "PROTEIN", 195, 221], ["ACE2 protein", "PROTEIN", 265, 277], ["patients", "SPECIES", 16, 24], ["SARS", "PROBLEM", 37, 41], ["high levels of cytokines", "PROBLEM", 53, 77], ["pro-inflammatory chemokines", "TEST", 82, 109], ["Cytokine stormAdditionally", "PROBLEM", 116, 142], ["viral infections", "PROBLEM", 177, 193], ["pro-inflammatory cytokines", "PROBLEM", 195, 221], ["ACE2 protein", "TREATMENT", 265, 277], ["SARS", "TEST", 296, 300], ["CoV", "TEST", 301, 304], ["SARS", "OBSERVATION", 37, 41], ["increase", "OBSERVATION_MODIFIER", 239, 247]]], ["A larger quantity of this protein may accelerate the entry of the novel coronavirus into the host cells and contribute to its dissemination in the organism, negatively influencing the antiviral response [34] .Changes in cellular countsIn critically ill patients, a state of immune suppression is also described, with a significant and sustained decrease in the absolute number of TCD4 + and TCD8 + lymphocytes, possible reduction of B lymphocytes, NK cells, monocytes, eosinophils and basophils [37, 38] .", [["cells", "ANATOMY", 98, 103], ["cellular", "ANATOMY", 220, 228], ["TCD4 +", "ANATOMY", 380, 386], ["TCD8 + lymphocytes", "ANATOMY", 391, 409], ["B lymphocytes", "ANATOMY", 433, 446], ["NK cells", "ANATOMY", 448, 456], ["monocytes", "ANATOMY", 458, 467], ["eosinophils", "ANATOMY", 469, 480], ["basophils", "ANATOMY", 485, 494], ["critically ill", "DISEASE", 238, 252], ["coronavirus", "ORGANISM", 72, 83], ["host cells", "CELL", 93, 103], ["cellular", "CELL", 220, 228], ["patients", "ORGANISM", 253, 261], ["TCD4", "GENE_OR_GENE_PRODUCT", 380, 384], ["TCD8", "GENE_OR_GENE_PRODUCT", 391, 395], ["B lymphocytes", "CELL", 433, 446], ["NK cells", "CELL", 448, 456], ["monocytes", "CELL", 458, 467], ["eosinophils", "CELL", 469, 480], ["basophils", "CELL", 485, 494], ["host cells", "CELL_TYPE", 93, 103], ["TCD4", "PROTEIN", 380, 384], ["TCD8", "PROTEIN", 391, 395], ["lymphocytes", "CELL_TYPE", 398, 409], ["B lymphocytes", "CELL_TYPE", 433, 446], ["NK cells", "CELL_TYPE", 448, 456], ["monocytes", "CELL_TYPE", 458, 467], ["eosinophils", "CELL_TYPE", 469, 480], ["basophils", "CELL_TYPE", 485, 494], ["patients", "SPECIES", 253, 261], ["this protein", "PROBLEM", 21, 33], ["the novel coronavirus into the host cells", "PROBLEM", 62, 103], ["its dissemination in the organism", "PROBLEM", 122, 155], ["the antiviral response", "TEST", 180, 202], ["Changes in cellular counts", "PROBLEM", 209, 235], ["immune suppression", "PROBLEM", 274, 292], ["TCD4", "TEST", 380, 384], ["TCD8", "TEST", 391, 395], ["lymphocytes", "TEST", 398, 409], ["reduction of B lymphocytes", "PROBLEM", 420, 446], ["NK cells", "TEST", 448, 456], ["monocytes", "TEST", 458, 467], ["eosinophils", "TEST", 469, 480], ["basophils", "TEST", 485, 494], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["quantity", "OBSERVATION_MODIFIER", 9, 17], ["host cells", "OBSERVATION", 93, 103], ["dissemination", "OBSERVATION", 126, 139], ["cellular counts", "OBSERVATION", 220, 235], ["significant", "OBSERVATION_MODIFIER", 319, 330], ["sustained", "OBSERVATION_MODIFIER", 335, 344], ["decrease", "OBSERVATION_MODIFIER", 345, 353], ["absolute", "OBSERVATION_MODIFIER", 361, 369], ["lymphocytes", "ANATOMY", 398, 409], ["possible", "UNCERTAINTY", 411, 419], ["reduction", "OBSERVATION_MODIFIER", 420, 429], ["B lymphocytes", "OBSERVATION", 433, 446], ["NK cells", "OBSERVATION", 448, 456]]], ["The study conducted by Liu et al. [7] did not observe significant changes in the total counts of B lymphocytes, NK cells and monocytes; however, there was a considerable reduction in the lymphocyte count in peripheral blood of patients with severe COVID-19 at the beginning of the disease, especially cytotoxic TCD8 + cells [7] .Changes in cellular countsActivation markers for TCD4 + and TCD8 + lymphocytes showed excessive stimulation and exhaustion markers for TCD8 + lymphocytes were elevated in the disease, suggesting lymphocyte dysfunction [9, 37] .", [["B lymphocytes", "ANATOMY", 97, 110], ["NK cells", "ANATOMY", 112, 120], ["monocytes", "ANATOMY", 125, 134], ["lymphocyte", "ANATOMY", 187, 197], ["peripheral blood", "ANATOMY", 207, 223], ["cytotoxic TCD8 + cells", "ANATOMY", 301, 323], ["cellular", "ANATOMY", 340, 348], ["TCD4 +", "ANATOMY", 378, 384], ["TCD8 + lymphocytes", "ANATOMY", 389, 407], ["TCD8 + lymphocytes", "ANATOMY", 464, 482], ["lymphocyte", "ANATOMY", 524, 534], ["COVID-19", "CHEMICAL", 248, 256], ["lymphocyte dysfunction", "DISEASE", 524, 546], ["B lymphocytes", "CELL", 97, 110], ["NK cells", "CELL", 112, 120], ["monocytes", "CELL", 125, 134], ["lymphocyte", "CELL", 187, 197], ["peripheral blood", "ORGANISM_SUBSTANCE", 207, 223], ["patients", "ORGANISM", 227, 235], ["TCD8 + cells", "CELL", 311, 323], ["cellular", "CELL", 340, 348], ["TCD4", "GENE_OR_GENE_PRODUCT", 378, 382], ["TCD8", "GENE_OR_GENE_PRODUCT", 389, 393], ["TCD8", "GENE_OR_GENE_PRODUCT", 464, 468], ["lymphocyte", "CELL", 524, 534], ["B lymphocytes", "CELL_TYPE", 97, 110], ["NK cells", "CELL_TYPE", 112, 120], ["monocytes", "CELL_TYPE", 125, 134], ["cytotoxic TCD8 + cells", "CELL_TYPE", 301, 323], ["TCD4", "PROTEIN", 378, 382], ["TCD8", "PROTEIN", 389, 393], ["TCD8", "PROTEIN", 464, 468], ["lymphocytes", "CELL_TYPE", 471, 482], ["patients", "SPECIES", 227, 235], ["The study", "TEST", 0, 9], ["significant changes", "PROBLEM", 54, 73], ["the total counts", "TEST", 77, 93], ["B lymphocytes", "TEST", 97, 110], ["NK cells", "TEST", 112, 120], ["monocytes", "TEST", 125, 134], ["a considerable reduction", "PROBLEM", 155, 179], ["the lymphocyte count", "TEST", 183, 203], ["severe COVID", "PROBLEM", 241, 253], ["the disease", "PROBLEM", 277, 288], ["cytotoxic TCD8 + cells", "PROBLEM", 301, 323], ["Changes in cellular counts", "PROBLEM", 329, 355], ["Activation markers", "TEST", 355, 373], ["TCD4", "TEST", 378, 382], ["TCD8", "TEST", 389, 393], ["lymphocytes", "PROBLEM", 396, 407], ["excessive stimulation", "PROBLEM", 415, 436], ["exhaustion markers", "TEST", 441, 459], ["TCD8", "TEST", 464, 468], ["lymphocytes", "PROBLEM", 471, 482], ["the disease", "PROBLEM", 500, 511], ["lymphocyte dysfunction", "PROBLEM", 524, 546], ["lymphocytes", "ANATOMY", 99, 110], ["NK cells", "OBSERVATION", 112, 120], ["considerable", "OBSERVATION_MODIFIER", 157, 169], ["reduction", "OBSERVATION_MODIFIER", 170, 179], ["lymphocyte count", "OBSERVATION", 187, 203], ["peripheral", "ANATOMY_MODIFIER", 207, 217], ["blood", "ANATOMY", 218, 223], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["disease", "OBSERVATION", 281, 288], ["cellular counts", "OBSERVATION", 340, 355], ["excessive stimulation", "OBSERVATION", 415, 436], ["elevated", "OBSERVATION_MODIFIER", 488, 496], ["disease", "OBSERVATION", 504, 511], ["suggesting", "UNCERTAINTY", 513, 523], ["lymphocyte dysfunction", "OBSERVATION", 524, 546]]], ["Additionally, an increase in the number of neutrophils and a greater neutrophil-to-CD8 + T cell ratio (N8R) was associated with severe COVID-19 and proposed as the most significant predictor of poor prognosis [7, 37] .Changes in cellular countsCell death induced by interaction between Fas and Fas ligand by activation of the TNF-related apoptosis inducing ligand axis and by direct infection of T lymphocytes by SARS-CoV-2 may be responsible for the origin of lymphopenia in COVID-19 [38] .", [["neutrophils", "ANATOMY", 43, 54], ["neutrophil-to-CD8 + T cell", "ANATOMY", 69, 95], ["cellular", "ANATOMY", 229, 237], ["Cell", "ANATOMY", 244, 248], ["T lymphocytes", "ANATOMY", 396, 409], ["death", "DISEASE", 249, 254], ["infection", "DISEASE", 383, 392], ["lymphopenia", "DISEASE", 461, 472], ["neutrophils", "CELL", 43, 54], ["neutrophil", "CELL", 69, 79], ["to-CD8", "GENE_OR_GENE_PRODUCT", 80, 86], ["cellular", "CELL", 229, 237], ["Cell", "CELL", 244, 248], ["Fas", "GENE_OR_GENE_PRODUCT", 286, 289], ["Fas ligand", "GENE_OR_GENE_PRODUCT", 294, 304], ["TNF-related apoptosis inducing ligand", "GENE_OR_GENE_PRODUCT", 326, 363], ["T lymphocytes", "CELL", 396, 409], ["SARS-CoV-2", "ORGANISM", 413, 423], ["neutrophils", "CELL_TYPE", 43, 54], ["neutrophil", "CELL_TYPE", 69, 79], ["to-CD8", "PROTEIN", 80, 86], ["Fas", "PROTEIN", 286, 289], ["Fas ligand", "PROTEIN", 294, 304], ["TNF", "PROTEIN", 326, 329], ["T lymphocytes", "CELL_TYPE", 396, 409], ["neutrophils", "TEST", 43, 54], ["a greater neutrophil", "TEST", 59, 79], ["T cell ratio", "TEST", 89, 101], ["severe COVID", "PROBLEM", 128, 140], ["Changes in cellular counts", "PROBLEM", 218, 244], ["Cell death", "PROBLEM", 244, 254], ["Fas ligand", "TEST", 294, 304], ["the TNF", "TEST", 322, 329], ["apoptosis inducing ligand axis", "PROBLEM", 338, 368], ["direct infection of T lymphocytes", "PROBLEM", 376, 409], ["SARS", "PROBLEM", 413, 417], ["CoV", "TEST", 418, 421], ["lymphopenia", "PROBLEM", 461, 472], ["COVID", "TEST", 476, 481], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["number", "OBSERVATION_MODIFIER", 33, 39], ["neutrophils", "OBSERVATION", 43, 54], ["greater", "OBSERVATION_MODIFIER", 61, 68], ["neutrophil", "OBSERVATION_MODIFIER", 69, 79], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["cellular counts", "OBSERVATION", 229, 244], ["ligand axis", "OBSERVATION", 357, 368], ["infection", "OBSERVATION", 383, 392], ["lymphopenia", "OBSERVATION", 461, 472]]], ["The cytokine storm can also influence the lymphopenia, since in the study of Liu et al. [7] , the peaks in cytokine levels IL-2, IL-4, IL-10, TNF-\u03b1 and IFN-\u03b3 coincided with the lowest T lymphocyte counts, about 4-6 days after the onset of severe COVID-19; therefore, the restoration of T cell numbers was associated with reductions in circulating cytokines [7] .Changes in cellular countsThe fact that T cells are important regulators of the activation of the immune system during a viral infection may explain how lymphopenia is related to the worsening of inflammatory responses [7] .", [["T lymphocyte", "ANATOMY", 184, 196], ["T cell", "ANATOMY", 286, 292], ["cellular", "ANATOMY", 373, 381], ["T cells", "ANATOMY", 402, 409], ["immune system", "ANATOMY", 460, 473], ["lymphopenia", "DISEASE", 42, 53], ["viral infection", "DISEASE", 483, 498], ["lymphopenia", "DISEASE", 515, 526], ["IL-2", "GENE_OR_GENE_PRODUCT", 123, 127], ["IL-4", "GENE_OR_GENE_PRODUCT", 129, 133], ["IL-10", "GENE_OR_GENE_PRODUCT", 135, 140], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 142, 147], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 152, 157], ["T lymphocyte", "CELL", 184, 196], ["T cell", "CELL", 286, 292], ["cellular", "CELL", 373, 381], ["T cells", "CELL", 402, 409], ["cytokine", "PROTEIN", 4, 12], ["cytokine", "PROTEIN", 107, 115], ["TNF", "PROTEIN", 142, 145], ["IFN-\u03b3", "PROTEIN", 152, 157], ["cytokines", "PROTEIN", 347, 356], ["T cells", "CELL_TYPE", 402, 409], ["the lymphopenia", "PROBLEM", 38, 53], ["the study", "TEST", 64, 73], ["the peaks", "TEST", 94, 103], ["cytokine levels IL", "TEST", 107, 125], ["IL", "TEST", 129, 131], ["IL", "TEST", 135, 137], ["TNF", "TEST", 142, 145], ["IFN", "TEST", 152, 155], ["the lowest T lymphocyte counts", "TEST", 173, 203], ["severe COVID", "PROBLEM", 239, 251], ["T cell numbers", "PROBLEM", 286, 300], ["circulating cytokines", "TEST", 335, 356], ["Changes in cellular counts", "PROBLEM", 362, 388], ["T cells", "PROBLEM", 402, 409], ["a viral infection", "PROBLEM", 481, 498], ["lymphopenia", "PROBLEM", 515, 526], ["the worsening of inflammatory responses", "PROBLEM", 541, 580], ["cytokine storm", "OBSERVATION", 4, 18], ["lymphopenia", "OBSERVATION", 42, 53], ["severe", "OBSERVATION_MODIFIER", 239, 245], ["cellular counts", "OBSERVATION", 373, 388], ["lymphopenia", "OBSERVATION", 515, 526], ["worsening", "OBSERVATION_MODIFIER", 545, 554], ["inflammatory", "OBSERVATION", 558, 570]]], ["In consequence of lymphopenia and lymphocyte dysfunction, the adaptive immune response is ineffective and the infection is not adequately controlled, further increasing the stimulation of cytokines and cellular infiltrations [38] .Coagulation disordersIt was observed that patients with SARS-CoV-2 infection present increased risk of venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC).", [["lymphocyte", "ANATOMY", 34, 44], ["cellular", "ANATOMY", 202, 210], ["venous", "ANATOMY", 334, 340], ["intravascular", "ANATOMY", 380, 393], ["lymphopenia", "DISEASE", 18, 29], ["lymphocyte dysfunction", "DISEASE", 34, 56], ["infection", "DISEASE", 110, 119], ["Coagulation disorders", "DISEASE", 231, 252], ["SARS-CoV-2 infection", "DISEASE", 287, 307], ["venous thromboembolism", "DISEASE", 334, 356], ["VTE", "DISEASE", 358, 361], ["disseminated intravascular coagulation", "DISEASE", 367, 405], ["DIC", "DISEASE", 407, 410], ["lymphocyte", "CELL", 34, 44], ["cellular", "CELL", 202, 210], ["patients", "ORGANISM", 273, 281], ["SARS-CoV-2", "ORGANISM", 287, 297], ["venous", "PATHOLOGICAL_FORMATION", 334, 340], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 380, 393], ["cytokines", "PROTEIN", 188, 197], ["patients", "SPECIES", 273, 281], ["CoV-", "SPECIES", 292, 296], ["SARS-CoV-2", "SPECIES", 287, 297], ["lymphopenia", "PROBLEM", 18, 29], ["lymphocyte dysfunction", "PROBLEM", 34, 56], ["the infection", "PROBLEM", 106, 119], ["the stimulation of cytokines", "TREATMENT", 169, 197], ["cellular infiltrations", "PROBLEM", 202, 224], ["Coagulation disorders", "PROBLEM", 231, 252], ["SARS", "PROBLEM", 287, 291], ["CoV-2 infection", "PROBLEM", 292, 307], ["venous thromboembolism", "PROBLEM", 334, 356], ["VTE", "PROBLEM", 358, 361], ["disseminated intravascular coagulation", "PROBLEM", 367, 405], ["consequence of", "UNCERTAINTY", 3, 17], ["lymphopenia", "OBSERVATION", 18, 29], ["lymphocyte dysfunction", "OBSERVATION", 34, 56], ["ineffective", "OBSERVATION_MODIFIER", 90, 101], ["infection", "OBSERVATION", 110, 119], ["cellular", "OBSERVATION_MODIFIER", 202, 210], ["infiltrations", "OBSERVATION", 211, 224], ["infection", "OBSERVATION", 298, 307], ["increased", "OBSERVATION_MODIFIER", 316, 325], ["venous", "ANATOMY", 334, 340], ["thromboembolism", "OBSERVATION", 341, 356], ["disseminated", "OBSERVATION_MODIFIER", 367, 379], ["intravascular coagulation", "OBSERVATION", 380, 405]]], ["Coagulopathy associated with COVID-19, as it may be named, is characterized by hypercoagulability and thrombosis and is associated with worse prognosis in infection.", [["Coagulopathy", "DISEASE", 0, 12], ["COVID-19", "CHEMICAL", 29, 37], ["hypercoagulability", "DISEASE", 79, 97], ["thrombosis", "DISEASE", 102, 112], ["infection", "DISEASE", 155, 164], ["COVID-19", "CHEMICAL", 29, 37], ["Coagulopathy", "PROBLEM", 0, 12], ["COVID", "TEST", 29, 34], ["hypercoagulability", "PROBLEM", 79, 97], ["thrombosis", "PROBLEM", 102, 112], ["infection", "PROBLEM", 155, 164], ["hypercoagulability", "OBSERVATION", 79, 97], ["thrombosis", "OBSERVATION", 102, 112], ["infection", "OBSERVATION", 155, 164]]], ["Among the altered coagulation parameters in patients with severe COVID-19 are exacerbated coagulation activation, coagulation factor consumption, prolongation of prothrombin time (PT) and activated partial thromboplastin time (aPPT), moderate to severe thrombocytopenia, increased D-dimer and reduction of fibrinogen [43] .Coagulation disordersThrough a retrospective analysis of 183 patients with coronavirus pneumonia, high levels of the D-dimer and fibrin degradation product have been identified, in addition to prolonged PT, as well as aPPT in patients who had deceased.", [["thrombocytopenia", "DISEASE", 253, 269], ["Coagulation disorders", "DISEASE", 323, 344], ["coronavirus pneumonia", "DISEASE", 398, 419], ["COVID-19", "CHEMICAL", 65, 73], ["patients", "ORGANISM", 44, 52], ["coagulation factor", "GENE_OR_GENE_PRODUCT", 114, 132], ["prothrombin", "GENE_OR_GENE_PRODUCT", 162, 173], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 206, 220], ["D-dimer", "SIMPLE_CHEMICAL", 281, 288], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 306, 316], ["patients", "ORGANISM", 384, 392], ["coronavirus", "ORGANISM", 398, 409], ["D-dimer", "GENE_OR_GENE_PRODUCT", 440, 447], ["fibrin", "GENE_OR_GENE_PRODUCT", 452, 458], ["patients", "ORGANISM", 549, 557], ["coagulation factor", "PROTEIN", 114, 132], ["prothrombin", "PROTEIN", 162, 173], ["D-dimer", "PROTEIN", 281, 288], ["fibrinogen", "PROTEIN", 306, 316], ["D-dimer", "PROTEIN", 440, 447], ["fibrin", "PROTEIN", 452, 458], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 384, 392], ["coronavirus", "SPECIES", 398, 409], ["patients", "SPECIES", 549, 557], ["the altered coagulation parameters", "PROBLEM", 6, 40], ["severe COVID", "PROBLEM", 58, 70], ["exacerbated coagulation activation", "PROBLEM", 78, 112], ["coagulation factor consumption", "PROBLEM", 114, 144], ["prothrombin time", "TEST", 162, 178], ["PT", "TEST", 180, 182], ["activated partial thromboplastin time", "TREATMENT", 188, 225], ["moderate to severe thrombocytopenia", "PROBLEM", 234, 269], ["increased D-dimer", "PROBLEM", 271, 288], ["fibrinogen", "TEST", 306, 316], ["Coagulation disorders", "PROBLEM", 323, 344], ["a retrospective analysis", "TEST", 352, 376], ["coronavirus pneumonia", "PROBLEM", 398, 419], ["the D-dimer", "TREATMENT", 436, 447], ["fibrin degradation product", "TREATMENT", 452, 478], ["altered", "OBSERVATION_MODIFIER", 10, 17], ["coagulation", "OBSERVATION", 18, 29], ["moderate", "OBSERVATION_MODIFIER", 234, 242], ["severe", "OBSERVATION_MODIFIER", 246, 252], ["thrombocytopenia", "OBSERVATION", 253, 269], ["increased", "OBSERVATION_MODIFIER", 271, 280], ["D-dimer", "OBSERVATION_MODIFIER", 281, 288], ["coronavirus", "OBSERVATION_MODIFIER", 398, 409], ["pneumonia", "OBSERVATION", 410, 419], ["fibrin degradation", "OBSERVATION", 452, 470]]], ["Tang et al. [44] considered the D-dimer as an important coagulopathy marker in cases of SARS-COV-2 infection.", [["coagulopathy", "DISEASE", 56, 68], ["SARS", "DISEASE", 88, 92], ["infection", "DISEASE", 99, 108], ["D-dimer", "SIMPLE_CHEMICAL", 32, 39], ["the D-dimer", "TREATMENT", 28, 39], ["SARS", "PROBLEM", 88, 92], ["COV", "PROBLEM", 93, 96], ["2 infection", "PROBLEM", 97, 108], ["coagulopathy", "OBSERVATION", 56, 68], ["SARS", "OBSERVATION", 88, 92], ["infection", "OBSERVATION", 99, 108]]], ["The same findings were found in the studies by Han et al. [45] who see the use of hemostasis tests as tools to be used in early diagnosis and in monitoring disease progression [46] .Coagulation disordersBlood coagulation is the fastest mechanism in the confinement and inactivation of infections, being the first and the last defense line of the innate immune system to take place in tissues and blood circulation.", [["Blood", "ANATOMY", 203, 208], ["tissues", "ANATOMY", 384, 391], ["blood", "ANATOMY", 396, 401], ["Coagulation disorders", "DISEASE", 182, 203], ["Blood coagulation", "DISEASE", 203, 220], ["infections", "DISEASE", 285, 295], ["Blood", "ORGANISM_SUBSTANCE", 203, 208], ["immune system", "ANATOMICAL_SYSTEM", 353, 366], ["tissues", "TISSUE", 384, 391], ["blood", "ORGANISM_SUBSTANCE", 396, 401], ["hemostasis tests", "TEST", 82, 98], ["Coagulation disorders", "PROBLEM", 182, 203], ["Blood coagulation", "TEST", 203, 220], ["infections", "PROBLEM", 285, 295], ["the innate immune system", "TREATMENT", 342, 366], ["blood circulation", "TEST", 396, 413], ["infections", "OBSERVATION", 285, 295], ["blood", "ANATOMY", 396, 401]]], ["The sore promotes the activation of the endothelial cells and the dysfunction of the endothelium, thus generating a pro-thrombotic state [47] .", [["endothelial cells", "ANATOMY", 40, 57], ["endothelium", "ANATOMY", 85, 96], ["endothelial cells", "CELL", 40, 57], ["endothelium", "TISSUE", 85, 96], ["endothelial cells", "CELL_TYPE", 40, 57], ["The sore", "PROBLEM", 0, 8], ["the endothelial cells", "PROBLEM", 36, 57], ["the dysfunction of the endothelium", "PROBLEM", 62, 96], ["a pro-thrombotic state", "PROBLEM", 114, 136], ["sore", "OBSERVATION", 4, 8], ["endothelial cells", "OBSERVATION", 40, 57], ["dysfunction", "OBSERVATION", 66, 77], ["endothelium", "ANATOMY", 85, 96]]], ["In cases hyperactivation of the immune system, the coagulation may become intravascular and disseminated, therefore causing multiple organ failure.", [["immune system", "ANATOMY", 32, 45], ["intravascular", "ANATOMY", 74, 87], ["organ", "ANATOMY", 133, 138], ["organ failure", "DISEASE", 133, 146], ["organ", "ORGAN", 133, 138], ["hyperactivation of the immune system", "PROBLEM", 9, 45], ["intravascular", "PROBLEM", 74, 87], ["multiple organ failure", "PROBLEM", 124, 146], ["disseminated", "OBSERVATION", 92, 104], ["multiple", "OBSERVATION_MODIFIER", 124, 132], ["organ", "ANATOMY", 133, 138], ["failure", "OBSERVATION", 139, 146]]], ["After all, the amount of vascular endothelial lesions of organs and tissues is, due to their activation intent, inversely proportional to the amount of existing coagulation factors [48] .Coagulation disordersThereupon, the first clinical studies carried out in patients with pneumonia caused by the Coronavirus confirmed the occurrence of organ dysfunction and coagulopathy as possible causes of the negative outcomes of the disease [44] .", [["vascular endothelial lesions", "ANATOMY", 25, 53], ["organs", "ANATOMY", 57, 63], ["tissues", "ANATOMY", 68, 75], ["organ", "ANATOMY", 339, 344], ["Coagulation disorders", "DISEASE", 187, 208], ["pneumonia", "DISEASE", 275, 284], ["organ dysfunction", "DISEASE", 339, 356], ["coagulopathy", "DISEASE", 361, 373], ["vascular endothelial lesions", "PATHOLOGICAL_FORMATION", 25, 53], ["organs", "ORGAN", 57, 63], ["tissues", "TISSUE", 68, 75], ["patients", "ORGANISM", 261, 269], ["organ", "ORGAN", 339, 344], ["coagulation factors", "PROTEIN", 161, 180], ["patients", "SPECIES", 261, 269], ["vascular endothelial lesions of organs and tissues", "PROBLEM", 25, 75], ["existing coagulation factors", "PROBLEM", 152, 180], ["Coagulation disorders", "PROBLEM", 187, 208], ["the first clinical studies", "TEST", 219, 245], ["pneumonia", "PROBLEM", 275, 284], ["the Coronavirus", "PROBLEM", 295, 310], ["organ dysfunction", "PROBLEM", 339, 356], ["coagulopathy", "PROBLEM", 361, 373], ["the disease", "PROBLEM", 421, 432], ["amount", "OBSERVATION_MODIFIER", 15, 21], ["vascular endothelial", "ANATOMY", 25, 45], ["lesions", "OBSERVATION", 46, 53], ["organs", "ANATOMY", 57, 63], ["tissues", "ANATOMY", 68, 75], ["pneumonia", "OBSERVATION", 275, 284], ["coagulopathy", "OBSERVATION", 361, 373]]], ["The activation of the immune system, in response to the infection, leads the production of cytokines and tissue factor expression.", [["immune system", "ANATOMY", 22, 35], ["infection", "DISEASE", 56, 65], ["tissue factor", "GENE_OR_GENE_PRODUCT", 105, 118], ["cytokines", "PROTEIN", 91, 100], ["tissue factor", "PROTEIN", 105, 118], ["the infection", "PROBLEM", 52, 65], ["cytokines and tissue factor expression", "PROBLEM", 91, 129], ["immune system", "OBSERVATION", 22, 35], ["infection", "OBSERVATION", 56, 65]]], ["The cytokines, in large amounts, harm the gas exchange and lead not only to inflammation but fibrinolysis, thus increasing D-dimer concentration [49] .Coagulation disordersThe tissue factor is related to an increase in thrombin generation and fibrin deposition, leading to hypercoagulability and CIVD and, thus, a worse prognosis [46, 49] .", [["tissue", "ANATOMY", 176, 182], ["inflammation", "DISEASE", 76, 88], ["Coagulation disorders", "DISEASE", 151, 172], ["hypercoagulability", "DISEASE", 273, 291], ["CIVD", "DISEASE", 296, 300], ["D-dimer", "CHEMICAL", 123, 130], ["D-dimer", "SIMPLE_CHEMICAL", 123, 130], ["tissue", "TISSUE", 176, 182], ["thrombin", "GENE_OR_GENE_PRODUCT", 219, 227], ["fibrin", "GENE_OR_GENE_PRODUCT", 243, 249], ["cytokines", "PROTEIN", 4, 13], ["tissue factor", "PROTEIN", 176, 189], ["thrombin", "PROTEIN", 219, 227], ["The cytokines", "TEST", 0, 13], ["the gas exchange", "PROBLEM", 38, 54], ["inflammation", "PROBLEM", 76, 88], ["fibrinolysis", "PROBLEM", 93, 105], ["Coagulation disorders", "PROBLEM", 151, 172], ["The tissue factor", "PROBLEM", 172, 189], ["an increase in thrombin generation", "PROBLEM", 204, 238], ["fibrin deposition", "PROBLEM", 243, 260], ["hypercoagulability", "PROBLEM", 273, 291], ["cytokines", "OBSERVATION", 4, 13], ["large", "OBSERVATION_MODIFIER", 18, 23], ["amounts", "OBSERVATION_MODIFIER", 24, 31], ["gas exchange", "OBSERVATION", 42, 54], ["not only to", "UNCERTAINTY", 64, 75], ["inflammation", "OBSERVATION", 76, 88], ["fibrinolysis", "OBSERVATION", 93, 105], ["is related to", "UNCERTAINTY", 190, 203], ["increase", "OBSERVATION_MODIFIER", 207, 215], ["thrombin generation", "OBSERVATION", 219, 238], ["fibrin deposition", "OBSERVATION", 243, 260], ["hypercoagulability", "OBSERVATION", 273, 291]]], ["As a contributor to the coagulation process, there is the presence of polymorphonuclear leukocytes (PMN) that are activated during the inflammatory process, releasing extracellular neutrophil traps (NETs) which contain proteases that generate the inactivation of endogenous anticoagulants and the propagation of a procoagulant state.", [["polymorphonuclear leukocytes", "ANATOMY", 70, 98], ["PMN", "ANATOMY", 100, 103], ["extracellular neutrophil", "ANATOMY", 167, 191], ["NETs", "ANATOMY", 199, 203], ["polymorphonuclear leukocytes", "CELL", 70, 98], ["PMN", "CELL", 100, 103], ["extracellular neutrophil traps", "GENE_OR_GENE_PRODUCT", 167, 197], ["polymorphonuclear leukocytes", "CELL_TYPE", 70, 98], ["PMN", "CELL_TYPE", 100, 103], ["NETs", "CELL_TYPE", 199, 203], ["proteases", "PROTEIN", 219, 228], ["the coagulation process", "PROBLEM", 20, 43], ["polymorphonuclear leukocytes", "PROBLEM", 70, 98], ["PMN", "TEST", 100, 103], ["the inflammatory process", "PROBLEM", 131, 155], ["releasing extracellular neutrophil traps", "TREATMENT", 157, 197], ["proteases", "TREATMENT", 219, 228], ["endogenous anticoagulants", "TREATMENT", 263, 288], ["a procoagulant state", "PROBLEM", 312, 332], ["polymorphonuclear leukocytes", "OBSERVATION", 70, 98], ["inflammatory", "OBSERVATION_MODIFIER", 135, 147], ["neutrophil traps", "OBSERVATION", 181, 197], ["endogenous anticoagulants", "OBSERVATION", 263, 288]]], ["The interaction of activated platelets with PMN can form vaso-occlusive thrombotic complexes [47] .Coagulation disordersSome authors also elucidate the virus's relationship with the ECA2 functional receptor, present in the arterial and venous endothelial cells of most human organs and part of both axes of the renin-angiotensin system, the vasoconstrictor ECA/Ang/AT1R and the vasodilator ECA2/Ang-(1-7)/MAS [50, 51] .", [["platelets", "ANATOMY", 29, 38], ["PMN", "ANATOMY", 44, 47], ["arterial", "ANATOMY", 223, 231], ["venous endothelial cells", "ANATOMY", 236, 260], ["organs", "ANATOMY", 275, 281], ["thrombotic", "DISEASE", 72, 82], ["Coagulation disorders", "DISEASE", 99, 120], ["angiotensin", "CHEMICAL", 317, 328], ["Ang", "CHEMICAL", 361, 364], ["Ang", "CHEMICAL", 395, 398], ["platelets", "CELL", 29, 38], ["PMN", "CELL", 44, 47], ["ECA2", "GENE_OR_GENE_PRODUCT", 182, 186], ["arterial", "CELL", 223, 231], ["venous endothelial cells", "CELL", 236, 260], ["human", "ORGANISM", 269, 274], ["organs", "ORGAN", 275, 281], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 311, 328], ["ECA", "GENE_OR_GENE_PRODUCT", 357, 360], ["Ang", "GENE_OR_GENE_PRODUCT", 361, 364], ["AT1R", "GENE_OR_GENE_PRODUCT", 365, 369], ["ECA2", "GENE_OR_GENE_PRODUCT", 390, 394], ["Ang-(1-7)", "GENE_OR_GENE_PRODUCT", 395, 404], ["activated platelets", "CELL_TYPE", 19, 38], ["PMN", "CELL_TYPE", 44, 47], ["vaso-occlusive thrombotic complexes", "PROTEIN", 57, 92], ["ECA2 functional receptor", "PROTEIN", 182, 206], ["arterial and venous endothelial cells", "CELL_TYPE", 223, 260], ["renin", "PROTEIN", 311, 316], ["Ang", "PROTEIN", 361, 364], ["AT1R", "PROTEIN", 365, 369], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 269, 274], ["activated platelets", "TREATMENT", 19, 38], ["PMN", "TREATMENT", 44, 47], ["vaso-occlusive thrombotic complexes", "PROBLEM", 57, 92], ["Coagulation disorders", "PROBLEM", 99, 120], ["the virus", "PROBLEM", 148, 157], ["the renin", "TEST", 307, 316], ["the vasoconstrictor ECA", "TEST", 337, 360], ["Ang", "TEST", 361, 364], ["AT1R", "TEST", 365, 369], ["the vasodilator ECA2", "TEST", 374, 394], ["Ang", "TEST", 395, 398], ["arterial", "ANATOMY", 223, 231], ["venous endothelial", "ANATOMY", 236, 254], ["angiotensin system", "OBSERVATION", 317, 335]]], ["Dalan et al. [52] cite that both aging and metabolic disorders positively regulate the ECA/Ang/AT1R axis, leading to inflammatory, oxidative, vasoconstrictor and fibrotic effects.", [["metabolic disorders", "DISEASE", 43, 62], ["Ang", "CHEMICAL", 91, 94], ["ECA", "GENE_OR_GENE_PRODUCT", 87, 90], ["Ang", "GENE_OR_GENE_PRODUCT", 91, 94], ["AT1R", "GENE_OR_GENE_PRODUCT", 95, 99], ["AT1R", "PROTEIN", 95, 99], ["metabolic disorders", "PROBLEM", 43, 62], ["the ECA", "TEST", 83, 90], ["Ang/AT1R axis", "PROBLEM", 91, 104], ["inflammatory, oxidative", "PROBLEM", 117, 140], ["vasoconstrictor", "TREATMENT", 142, 157], ["fibrotic effects", "PROBLEM", 162, 178], ["AT1R axis", "ANATOMY", 95, 104], ["inflammatory", "OBSERVATION", 117, 129], ["fibrotic", "OBSERVATION", 162, 170]]], ["Therefore, the ECA2/ Ang-(1-7)/MAS axis is negatively regulated, resulting in a decrease in the anti-inflammatory and anti-fibrotic effects [52] .", [["Ang", "CHEMICAL", 21, 24], ["ECA2", "GENE_OR_GENE_PRODUCT", 15, 19], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 21, 29], ["MAS", "GENE_OR_GENE_PRODUCT", 31, 34], ["ECA2", "PROTEIN", 15, 19], ["the ECA2", "TEST", 11, 19], ["Ang", "TEST", 21, 24], ["a decrease in the anti-inflammatory and anti-fibrotic effects", "PROBLEM", 78, 139], ["decrease", "OBSERVATION_MODIFIER", 80, 88], ["anti-inflammatory", "OBSERVATION_MODIFIER", 96, 113]]], ["The connection of SARS-COV-2 to the ECA2 receiver affects the balance between ECA/Ang/AT1R and ECA2/Ang-(1-7)/MAS, making the effects of the ECA/ Ang/AT1R axis even more prominent [53] .AgingThe different immune responses of the host to the SARS-CoV-2 infection may explain the reason why men and women, young and old, infected by the virus can suffer a different severity of the disease [54] .", [["SARS", "DISEASE", 18, 22], ["Ang", "CHEMICAL", 82, 85], ["Ang", "CHEMICAL", 100, 103], ["Ang", "CHEMICAL", 146, 149], ["SARS", "DISEASE", 241, 245], ["infection", "DISEASE", 252, 261], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 18, 28], ["ECA2", "GENE_OR_GENE_PRODUCT", 36, 40], ["ECA", "GENE_OR_GENE_PRODUCT", 78, 81], ["Ang", "GENE_OR_GENE_PRODUCT", 82, 85], ["AT1R", "GENE_OR_GENE_PRODUCT", 86, 90], ["ECA2", "GENE_OR_GENE_PRODUCT", 95, 99], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 100, 108], ["ECA", "GENE_OR_GENE_PRODUCT", 141, 144], ["Ang", "GENE_OR_GENE_PRODUCT", 146, 149], ["AT1R", "GENE_OR_GENE_PRODUCT", 150, 154], ["SARS-CoV-2", "ORGANISM", 241, 251], ["men", "ORGANISM", 289, 292], ["women", "ORGANISM", 297, 302], ["COV", "PROTEIN", 23, 26], ["ECA2 receiver", "DNA", 36, 49], ["ECA", "PROTEIN", 78, 81], ["Ang", "PROTEIN", 82, 85], ["AT1R", "PROTEIN", 86, 90], ["ECA2", "PROTEIN", 95, 99], ["Ang", "PROTEIN", 146, 149], ["AT1R", "PROTEIN", 150, 154], ["CoV-2", "SPECIES", 246, 251], ["men", "SPECIES", 289, 292], ["women", "SPECIES", 297, 302], ["SARS-CoV-2", "SPECIES", 241, 251], ["SARS", "PROBLEM", 18, 22], ["COV", "TEST", 23, 26], ["ECA", "TEST", 78, 81], ["Ang", "TEST", 82, 85], ["AT1R", "TEST", 86, 90], ["ECA2", "TEST", 95, 99], ["Ang", "TEST", 100, 103], ["the ECA/ Ang/AT1R axis", "TEST", 137, 159], ["the SARS", "PROBLEM", 237, 245], ["CoV-2 infection", "PROBLEM", 246, 261], ["the virus", "PROBLEM", 331, 340], ["the disease", "PROBLEM", 376, 387], ["SARS", "OBSERVATION", 18, 22], ["disease", "OBSERVATION", 380, 387]]], ["Therefore, a considerably higher mortality rate was observed in patients with advanced chronological age [55] .AgingImmune aging is related to an increase in individuals' susceptibility to infections, due to the decline in immune function, which can occur at any stage of the immune response.", [["infections", "DISEASE", 189, 199], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["a considerably higher mortality rate", "PROBLEM", 11, 47], ["AgingImmune aging", "PROBLEM", 111, 128], ["an increase in individuals' susceptibility to infections", "PROBLEM", 143, 199], ["the decline in immune function", "PROBLEM", 208, 238], ["increase", "OBSERVATION_MODIFIER", 146, 154], ["infections", "OBSERVATION", 189, 199], ["immune function", "OBSERVATION", 223, 238], ["immune response", "OBSERVATION", 276, 291]]], ["Immune senescence is associated with the suppression of the activation and presentation of antigens by macrophages, which consequently prevent the migration of dendritic cells and the activation made by Toll receptors with less effect [56, 57] .", [["macrophages", "ANATOMY", 103, 114], ["dendritic cells", "ANATOMY", 160, 175], ["macrophages", "CELL", 103, 114], ["dendritic cells", "CELL", 160, 175], ["Toll", "GENE_OR_GENE_PRODUCT", 203, 207], ["antigens", "PROTEIN", 91, 99], ["macrophages", "CELL_TYPE", 103, 114], ["dendritic cells", "CELL_TYPE", 160, 175], ["Toll receptors", "PROTEIN", 203, 217], ["Immune senescence", "PROBLEM", 0, 17], ["macrophages", "PROBLEM", 103, 114], ["dendritic cells", "PROBLEM", 160, 175], ["migration", "OBSERVATION_MODIFIER", 147, 156], ["dendritic cells", "OBSERVATION", 160, 175]]], ["Ewers et al. [58] mention the decline and proliferation of T cells, in addition to the increased production of pro-inflammatory cytokines IL-1, IL-6 and TNF-\u03b1 in the elderly.AgingAnother point is the imbalance between Th1 and Th2 cytokines, generating an increase in the susceptibility of these individuals as infections by viruses and extracellular bacteria [58] .", [["T cells", "ANATOMY", 59, 66], ["extracellular", "ANATOMY", 336, 349], ["infections", "DISEASE", 310, 320], ["T cells", "CELL", 59, 66], ["IL-1", "GENE_OR_GENE_PRODUCT", 138, 142], ["IL-6", "GENE_OR_GENE_PRODUCT", 144, 148], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 153, 158], ["Th1", "GENE_OR_GENE_PRODUCT", 218, 221], ["Th2", "GENE_OR_GENE_PRODUCT", 226, 229], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 336, 349], ["T cells", "CELL_TYPE", 59, 66], ["pro-inflammatory cytokines", "PROTEIN", 111, 137], ["IL-1, IL-6", "PROTEIN", 138, 148], ["TNF-\u03b1", "PROTEIN", 153, 158], ["Th1 and Th2 cytokines", "PROTEIN", 218, 239], ["the decline", "PROBLEM", 26, 37], ["proliferation of T cells", "PROBLEM", 42, 66], ["pro-inflammatory cytokines IL", "TEST", 111, 140], ["IL", "TEST", 144, 146], ["TNF", "TEST", 153, 156], ["the imbalance between Th1 and Th2 cytokines", "PROBLEM", 196, 239], ["infections", "PROBLEM", 310, 320], ["extracellular bacteria", "PROBLEM", 336, 358], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["pro-inflammatory", "OBSERVATION_MODIFIER", 111, 127], ["increase", "OBSERVATION_MODIFIER", 255, 263]]], ["In view of this, aging is associated with a constitutive pro-inflammatory environment due to persistent and low-grade immune activation, which can lead to increased tissue damage caused by infections [57] .AgingAlso, there should be taken into account the positive regulation of the ACE-Ang-II-AT axis that leads to proinflammatory and pro-fibrotic effects.", [["tissue", "ANATOMY", 165, 171], ["tissue damage", "DISEASE", 165, 178], ["infections", "DISEASE", 189, 199], ["Ang", "CHEMICAL", 287, 290], ["tissue", "TISSUE", 165, 171], ["ACE", "GENE_OR_GENE_PRODUCT", 283, 286], ["Ang-II", "GENE_OR_GENE_PRODUCT", 287, 293], ["AT", "GENE_OR_GENE_PRODUCT", 294, 296], ["ACE", "PROTEIN", 283, 286], ["a constitutive pro-inflammatory environment", "PROBLEM", 42, 85], ["persistent and low-grade immune activation", "PROBLEM", 93, 135], ["increased tissue damage", "PROBLEM", 155, 178], ["infections", "PROBLEM", 189, 199], ["the ACE", "TEST", 279, 286], ["proinflammatory and pro-fibrotic effects", "PROBLEM", 316, 356], ["persistent", "OBSERVATION_MODIFIER", 93, 103], ["low-grade", "OBSERVATION_MODIFIER", 108, 117], ["immune activation", "OBSERVATION", 118, 135], ["increased tissue", "OBSERVATION_MODIFIER", 155, 171], ["damage", "OBSERVATION", 172, 178], ["infections", "OBSERVATION", 189, 199], ["positive", "OBSERVATION", 256, 264], ["proinflammatory", "OBSERVATION_MODIFIER", 316, 331], ["pro-fibrotic", "OBSERVATION_MODIFIER", 336, 348]]], ["Although not very detailed, it is still suggested the occurrence of a greater number of ECA2 receptors associated with aging, which would increase this imbalance.", [["ECA2 receptors", "GENE_OR_GENE_PRODUCT", 88, 102], ["ECA2 receptors", "PROTEIN", 88, 102], ["this imbalance", "PROBLEM", 147, 161], ["greater", "OBSERVATION_MODIFIER", 70, 77]]], ["After all, it is through this receptor that SARS-COV-2 infects humans and thus contributes to the development of COVID-19 in older people [52] .Obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)The precarious metabolic health is considered the main risk factor for the development of severe forms of COVID-19.", [["Obesity", "DISEASE", 144, 151], ["type 2 diabetes mellitus", "DISEASE", 153, 177], ["T2DM", "DISEASE", 179, 183], ["metabolic syndrome", "DISEASE", 189, 207], ["MS", "DISEASE", 209, 211], ["COVID-19", "CHEMICAL", 318, 326], ["SARS-COV-2", "ORGANISM", 44, 54], ["humans", "ORGANISM", 63, 69], ["people", "ORGANISM", 131, 137], ["humans", "SPECIES", 63, 69], ["people", "SPECIES", 131, 137], ["humans", "SPECIES", 63, 69], ["SARS", "PROBLEM", 44, 48], ["COVID", "TEST", 113, 118], ["Obesity", "PROBLEM", 144, 151], ["type 2 diabetes mellitus", "PROBLEM", 153, 177], ["T2DM)", "PROBLEM", 179, 184], ["metabolic syndrome", "PROBLEM", 189, 207], ["severe forms of COVID", "PROBLEM", 302, 323], ["diabetes mellitus", "OBSERVATION", 160, 177], ["metabolic syndrome", "OBSERVATION", 189, 207], ["severe", "OBSERVATION_MODIFIER", 302, 308]]], ["This may occur in T2DM, obesity and MS, possibly due to immune dysfunction in synergism with pathophysiological complications of these comorbidities [59] .Obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)Increased ACE2 expression is a protective adaptive mechanism in T2DM; however, it may facilitate the viral entry and spread of SARS-CoV-2 in the body [59] .", [["body", "ANATOMY", 368, 372], ["T2DM", "DISEASE", 18, 22], ["obesity", "DISEASE", 24, 31], ["MS", "DISEASE", 36, 38], ["immune dysfunction", "DISEASE", 56, 74], ["Obesity", "DISEASE", 155, 162], ["type 2 diabetes mellitus", "DISEASE", 164, 188], ["T2DM", "DISEASE", 190, 194], ["metabolic syndrome", "DISEASE", 200, 218], ["MS", "DISEASE", 220, 222], ["T2DM", "DISEASE", 287, 291], ["SARS", "DISEASE", 350, 354], ["ACE2", "GENE_OR_GENE_PRODUCT", 233, 237], ["SARS-CoV-2", "ORGANISM", 350, 360], ["body", "ORGANISM_SUBDIVISION", 368, 372], ["ACE2", "PROTEIN", 233, 237], ["SARS-CoV", "SPECIES", 350, 358], ["T2DM", "PROBLEM", 18, 22], ["obesity", "PROBLEM", 24, 31], ["MS", "PROBLEM", 36, 38], ["immune dysfunction", "PROBLEM", 56, 74], ["synergism", "PROBLEM", 78, 87], ["pathophysiological complications", "PROBLEM", 93, 125], ["these comorbidities", "PROBLEM", 129, 148], ["Obesity", "PROBLEM", 155, 162], ["type 2 diabetes mellitus", "PROBLEM", 164, 188], ["T2DM)", "PROBLEM", 190, 195], ["metabolic syndrome (MS)", "PROBLEM", 200, 223], ["Increased ACE2 expression", "PROBLEM", 223, 248], ["T2DM", "PROBLEM", 287, 291], ["the viral entry", "PROBLEM", 320, 335], ["SARS", "PROBLEM", 350, 354], ["CoV", "TEST", 355, 358], ["obesity", "OBSERVATION", 24, 31], ["possibly due to", "UNCERTAINTY", 40, 55], ["immune dysfunction", "OBSERVATION", 56, 74], ["diabetes mellitus", "OBSERVATION", 171, 188], ["metabolic syndrome", "OBSERVATION", 200, 218]]], ["Adipose tissue also exhibits high expression of ACE2, so the population with obesity may present greater vulnerability to COVID-19 [43] .Obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)It was observed that the expression of ACE2 in the adipose tissue of obese patients allows viral entry in adipocytes and makes this tissue a reservoir for the viral dissemination of SARS-CoV-2, since it is viscerally distributed [43, 51] .", [["Adipose tissue", "ANATOMY", 0, 14], ["adipose tissue", "ANATOMY", 256, 270], ["adipocytes", "ANATOMY", 311, 321], ["tissue", "ANATOMY", 337, 343], ["obesity", "DISEASE", 77, 84], ["Obesity", "DISEASE", 137, 144], ["type 2 diabetes mellitus", "DISEASE", 146, 170], ["T2DM", "DISEASE", 172, 176], ["metabolic syndrome", "DISEASE", 182, 200], ["MS", "DISEASE", 202, 204], ["SARS", "DISEASE", 387, 391], ["COVID-19", "CHEMICAL", 122, 130], ["Adipose tissue", "TISSUE", 0, 14], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["ACE2", "GENE_OR_GENE_PRODUCT", 244, 248], ["adipose tissue", "TISSUE", 256, 270], ["patients", "ORGANISM", 280, 288], ["adipocytes", "CELL", 311, 321], ["tissue", "TISSUE", 337, 343], ["SARS-CoV-2", "ORGANISM", 387, 397], ["ACE2", "PROTEIN", 48, 52], ["ACE2", "PROTEIN", 244, 248], ["adipocytes", "CELL_TYPE", 311, 321], ["patients", "SPECIES", 280, 288], ["SARS-CoV", "SPECIES", 387, 395], ["Adipose tissue", "PROBLEM", 0, 14], ["high expression of ACE2", "PROBLEM", 29, 52], ["obesity", "PROBLEM", 77, 84], ["COVID", "TEST", 122, 127], ["Obesity", "PROBLEM", 137, 144], ["type 2 diabetes mellitus", "PROBLEM", 146, 170], ["T2DM)", "PROBLEM", 172, 177], ["metabolic syndrome", "PROBLEM", 182, 200], ["obese patients", "PROBLEM", 274, 288], ["viral entry in adipocytes", "PROBLEM", 296, 321], ["this tissue a reservoir", "TREATMENT", 332, 355], ["SARS", "PROBLEM", 387, 391], ["high expression", "OBSERVATION_MODIFIER", 29, 44], ["obesity", "OBSERVATION", 77, 84], ["diabetes mellitus", "OBSERVATION", 153, 170], ["metabolic syndrome", "OBSERVATION", 182, 200], ["adipose tissue", "ANATOMY", 256, 270], ["obese", "OBSERVATION", 274, 279], ["adipocytes", "ANATOMY", 311, 321]]], ["In addition, obesity is an important factor for the development of T2DM-especially when associated with low levels of physical activity and poor physical conditioning-and as mentioned, both diseases are related to higher expression of ACE2, increasing the risk of advanced infection by SARS-CoV-2 [43] .Obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)Metabolic disorders lead to immune activation of tissues such as the adipose, increasing the concentration of lowgrade chronic inflammation plasma markers, called metabolic inflammation or meta-inflammation [61] .", [["tissues", "ANATOMY", 420, 427], ["adipose", "ANATOMY", 440, 447], ["plasma", "ANATOMY", 511, 517], ["obesity", "DISEASE", 13, 20], ["T2DM", "DISEASE", 67, 71], ["infection", "DISEASE", 273, 282], ["SARS", "DISEASE", 286, 290], ["Obesity", "DISEASE", 303, 310], ["type 2 diabetes mellitus", "DISEASE", 312, 336], ["T2DM", "DISEASE", 338, 342], ["metabolic syndrome", "DISEASE", 348, 366], ["MS", "DISEASE", 368, 370], ["Metabolic disorders", "DISEASE", 371, 390], ["inflammation", "DISEASE", 498, 510], ["metabolic inflammation", "DISEASE", 534, 556], ["ACE2", "GENE_OR_GENE_PRODUCT", 235, 239], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 286, 296], ["tissues", "TISSUE", 420, 427], ["adipose", "TISSUE", 440, 447], ["plasma", "ORGANISM_SUBSTANCE", 511, 517], ["ACE2", "PROTEIN", 235, 239], ["plasma markers", "PROTEIN", 511, 525], ["SARS-CoV", "SPECIES", 286, 294], ["obesity", "PROBLEM", 13, 20], ["T2DM", "PROBLEM", 67, 71], ["low levels of physical activity", "PROBLEM", 104, 135], ["poor physical conditioning", "PROBLEM", 140, 166], ["ACE2", "PROBLEM", 235, 239], ["advanced infection", "PROBLEM", 264, 282], ["CoV", "TEST", 291, 294], ["Obesity", "PROBLEM", 303, 310], ["type 2 diabetes mellitus", "PROBLEM", 312, 336], ["T2DM)", "PROBLEM", 338, 343], ["metabolic syndrome", "PROBLEM", 348, 366], ["MS)", "PROBLEM", 368, 371], ["Metabolic disorders", "PROBLEM", 371, 390], ["immune activation of tissues", "PROBLEM", 399, 427], ["the adipose", "PROBLEM", 436, 447], ["lowgrade chronic inflammation plasma markers", "PROBLEM", 481, 525], ["metabolic inflammation", "PROBLEM", 534, 556], ["meta-inflammation", "PROBLEM", 560, 577], ["obesity", "OBSERVATION", 13, 20], ["T2DM", "OBSERVATION", 67, 71], ["advanced", "OBSERVATION_MODIFIER", 264, 272], ["infection", "OBSERVATION", 273, 282], ["diabetes mellitus", "OBSERVATION", 319, 336], ["metabolic syndrome", "OBSERVATION", 348, 366], ["adipose", "ANATOMY", 440, 447], ["chronic", "OBSERVATION_MODIFIER", 490, 497], ["inflammation", "OBSERVATION", 498, 510]]], ["In this sense, the release of pro-inflammatory adipokines such as leptin, TNF-\u03b1, IL-6 and IL-1b is observed, with a reduction in antiinflammatory action through the suppression of adiponectins [62, 63] .", [["adiponectins", "CHEMICAL", 180, 192], ["leptin", "GENE_OR_GENE_PRODUCT", 66, 72], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL-6", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-1b", "GENE_OR_GENE_PRODUCT", 90, 95], ["adiponectins", "GENE_OR_GENE_PRODUCT", 180, 192], ["pro-inflammatory adipokines", "PROTEIN", 30, 57], ["leptin", "PROTEIN", 66, 72], ["TNF", "PROTEIN", 74, 77], ["IL-6 and IL-1b", "PROTEIN", 81, 95], ["pro-inflammatory adipokines", "TEST", 30, 57], ["leptin", "TEST", 66, 72], ["TNF", "TEST", 74, 77], ["IL", "TEST", 81, 83], ["a reduction in antiinflammatory action", "TREATMENT", 114, 152], ["antiinflammatory", "OBSERVATION_MODIFIER", 129, 145]]], ["The presented relationship is directly proportional to the presence of adipose tissue, the same that can be regulated through the practice of physical activity [64] .Obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)The pro-inflammatory state found in metabolic syndrome and T2DM may increase the probability of an unbalanced inflammatory response in COVID-19, like the cytokine storm described in patients with severe disease [59] .", [["adipose tissue", "ANATOMY", 71, 85], ["Obesity", "DISEASE", 166, 173], ["type 2 diabetes mellitus", "DISEASE", 175, 199], ["T2DM", "DISEASE", 201, 205], ["metabolic syndrome", "DISEASE", 211, 229], ["MS", "DISEASE", 231, 233], ["metabolic syndrome", "DISEASE", 270, 288], ["T2DM", "DISEASE", 293, 297], ["adipose tissue", "TISSUE", 71, 85], ["COVID-19", "CELL", 369, 377], ["patients", "ORGANISM", 416, 424], ["cytokine", "PROTEIN", 388, 396], ["patients", "SPECIES", 416, 424], ["adipose tissue", "PROBLEM", 71, 85], ["Obesity", "PROBLEM", 166, 173], ["type 2 diabetes mellitus", "PROBLEM", 175, 199], ["T2DM)", "PROBLEM", 201, 206], ["metabolic syndrome", "PROBLEM", 211, 229], ["MS)", "PROBLEM", 231, 234], ["The pro-inflammatory state", "PROBLEM", 234, 260], ["metabolic syndrome", "PROBLEM", 270, 288], ["T2DM", "PROBLEM", 293, 297], ["an unbalanced inflammatory response", "PROBLEM", 330, 365], ["COVID", "TEST", 369, 374], ["severe disease", "PROBLEM", 430, 444], ["adipose tissue", "OBSERVATION", 71, 85], ["diabetes mellitus", "OBSERVATION", 182, 199], ["metabolic syndrome", "OBSERVATION", 211, 229], ["metabolic syndrome", "OBSERVATION", 270, 288], ["unbalanced", "OBSERVATION_MODIFIER", 333, 343], ["inflammatory", "OBSERVATION", 344, 356], ["cytokine storm", "OBSERVATION", 388, 402], ["severe", "OBSERVATION_MODIFIER", 430, 436], ["disease", "OBSERVATION", 437, 444]]], ["Similarly, as obesity is a state of low-grade chronic inflammation, it shows a potential for immune amplification of pathogens, as the regulatory elements of the immune response are absent or dysfunctional and this may contribute to the cytokine storm, which is already in greater concentration in obese individuals and which sustains and activates multiple cytokine pathways for a long time after the viral insult [65, 66] .Obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)Damage to blood vessels caused by chronic diseases, such as T2DM, associated with hypercoagulability present in COVID-19 may intensify the risk of infection complications [59] .", [["blood vessels", "ANATOMY", 503, 516], ["obesity", "DISEASE", 14, 21], ["inflammation", "DISEASE", 54, 66], ["Obesity", "DISEASE", 425, 432], ["type 2 diabetes mellitus", "DISEASE", 434, 458], ["T2DM", "DISEASE", 460, 464], ["metabolic syndrome", "DISEASE", 470, 488], ["MS", "DISEASE", 490, 492], ["blood vessels", "DISEASE", 503, 516], ["chronic diseases", "DISEASE", 527, 543], ["T2DM", "DISEASE", 553, 557], ["hypercoagulability", "DISEASE", 575, 593], ["infection", "DISEASE", 640, 649], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 503, 516], ["regulatory elements", "DNA", 135, 154], ["cytokine", "PROTEIN", 237, 245], ["cytokine", "PROTEIN", 358, 366], ["obesity", "PROBLEM", 14, 21], ["low-grade chronic inflammation", "PROBLEM", 36, 66], ["immune amplification of pathogens", "PROBLEM", 93, 126], ["dysfunctional", "PROBLEM", 192, 205], ["obese individuals", "PROBLEM", 298, 315], ["multiple cytokine pathways", "TREATMENT", 349, 375], ["the viral insult", "PROBLEM", 398, 414], ["Obesity", "PROBLEM", 425, 432], ["type 2 diabetes mellitus", "PROBLEM", 434, 458], ["T2DM)", "PROBLEM", 460, 465], ["metabolic syndrome", "PROBLEM", 470, 488], ["MS)", "PROBLEM", 490, 493], ["Damage to blood vessels", "PROBLEM", 493, 516], ["chronic diseases", "PROBLEM", 527, 543], ["T2DM", "PROBLEM", 553, 557], ["hypercoagulability", "PROBLEM", 575, 593], ["COVID", "TEST", 605, 610], ["infection complications", "PROBLEM", 640, 663], ["obesity", "OBSERVATION", 14, 21], ["low-grade", "OBSERVATION_MODIFIER", 36, 45], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["inflammation", "OBSERVATION", 54, 66], ["greater concentration", "OBSERVATION_MODIFIER", 273, 294], ["obese", "OBSERVATION", 298, 303], ["diabetes mellitus", "OBSERVATION", 441, 458], ["metabolic syndrome", "OBSERVATION", 470, 488], ["blood vessels", "ANATOMY", 503, 516], ["chronic", "OBSERVATION_MODIFIER", 527, 534], ["diseases", "OBSERVATION", 535, 543], ["hypercoagulability", "OBSERVATION", 575, 593], ["infection", "OBSERVATION", 640, 649]]], ["Obesity can also aggravate endothelial dysfunction present in COVID-19 due to inflammation triggered by perivascular and vascular adipose tissue, combined with changes in the synthesis of endogenous vasoactive agents, leading to platelet hyperactivation, leukocyte adhesion and other modifications related to endothelial inflammation, prothrombosis and proatherogenesis [43] .Obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)Hypercoagulability is directly proportional to the severity of overweight in obese patients.", [["endothelial", "ANATOMY", 27, 38], ["perivascular", "ANATOMY", 104, 116], ["vascular adipose tissue", "ANATOMY", 121, 144], ["platelet", "ANATOMY", 229, 237], ["leukocyte", "ANATOMY", 255, 264], ["endothelial", "ANATOMY", 309, 320], ["Obesity", "DISEASE", 0, 7], ["endothelial dysfunction", "DISEASE", 27, 50], ["inflammation", "DISEASE", 78, 90], ["inflammation", "DISEASE", 321, 333], ["prothrombosis", "DISEASE", 335, 348], ["proatherogenesis", "DISEASE", 353, 369], ["Obesity", "DISEASE", 376, 383], ["type 2 diabetes mellitus", "DISEASE", 385, 409], ["T2DM", "DISEASE", 411, 415], ["metabolic syndrome", "DISEASE", 421, 439], ["MS", "DISEASE", 441, 443], ["Hypercoagulability", "DISEASE", 444, 462], ["overweight", "DISEASE", 507, 517], ["endothelial", "CELL", 27, 38], ["perivascular", "TISSUE", 104, 116], ["vascular adipose tissue", "TISSUE", 121, 144], ["platelet", "CELL", 229, 237], ["leukocyte", "CELL", 255, 264], ["endothelial", "CELL", 309, 320], ["patients", "ORGANISM", 527, 535], ["patients", "SPECIES", 527, 535], ["Obesity", "PROBLEM", 0, 7], ["endothelial dysfunction", "PROBLEM", 27, 50], ["COVID", "TEST", 62, 67], ["inflammation", "PROBLEM", 78, 90], ["perivascular and vascular adipose tissue", "PROBLEM", 104, 144], ["endogenous vasoactive agents", "TREATMENT", 188, 216], ["platelet hyperactivation", "PROBLEM", 229, 253], ["leukocyte adhesion", "PROBLEM", 255, 273], ["other modifications", "PROBLEM", 278, 297], ["endothelial inflammation", "PROBLEM", 309, 333], ["prothrombosis", "PROBLEM", 335, 348], ["proatherogenesis", "PROBLEM", 353, 369], ["Obesity", "PROBLEM", 376, 383], ["type 2 diabetes mellitus", "PROBLEM", 385, 409], ["T2DM)", "PROBLEM", 411, 416], ["metabolic syndrome", "PROBLEM", 421, 439], ["MS)", "PROBLEM", 441, 444], ["Hypercoagulability", "PROBLEM", 444, 462], ["inflammation", "OBSERVATION", 78, 90], ["perivascular", "ANATOMY_MODIFIER", 104, 116], ["vascular", "ANATOMY", 121, 129], ["adipose tissue", "OBSERVATION", 130, 144], ["platelet hyperactivation", "OBSERVATION", 229, 253], ["leukocyte adhesion", "OBSERVATION", 255, 273], ["endothelial", "ANATOMY", 309, 320], ["inflammation", "OBSERVATION", 321, 333], ["diabetes mellitus", "OBSERVATION", 392, 409], ["metabolic syndrome", "OBSERVATION", 421, 439]]], ["Among the pathophysiological mechanisms are the action of adipocytokinins, with leptin and adiponectin, overactivity of coagulation factors, reduction of fibrinolytic function and, once again, increased inflammation (TNF and IL-6).", [["inflammation", "DISEASE", 203, 215], ["adipocytokinins", "GENE_OR_GENE_PRODUCT", 58, 73], ["leptin", "GENE_OR_GENE_PRODUCT", 80, 86], ["adiponectin", "GENE_OR_GENE_PRODUCT", 91, 102], ["coagulation factors", "GENE_OR_GENE_PRODUCT", 120, 139], ["TNF", "GENE_OR_GENE_PRODUCT", 217, 220], ["IL-6", "GENE_OR_GENE_PRODUCT", 225, 229], ["leptin", "PROTEIN", 80, 86], ["adiponectin", "PROTEIN", 91, 102], ["coagulation factors", "PROTEIN", 120, 139], ["TNF", "PROTEIN", 217, 220], ["IL-6", "PROTEIN", 225, 229], ["adipocytokinins", "TREATMENT", 58, 73], ["leptin", "TREATMENT", 80, 86], ["adiponectin", "TREATMENT", 91, 102], ["overactivity of coagulation factors", "PROBLEM", 104, 139], ["fibrinolytic function", "TEST", 154, 175], ["increased inflammation", "PROBLEM", 193, 215], ["TNF and IL", "TREATMENT", 217, 227], ["fibrinolytic function", "OBSERVATION", 154, 175], ["increased", "OBSERVATION_MODIFIER", 193, 202], ["inflammation", "OBSERVATION", 203, 215]]], ["Other contributors include elevated oxidative stress, lipid and glucose tolerance disorders, MS and venous stasis.", [["venous", "ANATOMY", 100, 106], ["glucose tolerance disorders", "DISEASE", 64, 91], ["MS", "DISEASE", 93, 95], ["venous stasis", "DISEASE", 100, 113], ["glucose", "CHEMICAL", 64, 71], ["lipid", "SIMPLE_CHEMICAL", 54, 59], ["glucose", "SIMPLE_CHEMICAL", 64, 71], ["venous", "PATHOLOGICAL_FORMATION", 100, 106], ["elevated oxidative stress", "PROBLEM", 27, 52], ["lipid and glucose tolerance disorders", "PROBLEM", 54, 91], ["MS", "PROBLEM", 93, 95], ["venous stasis", "PROBLEM", 100, 113], ["elevated", "OBSERVATION_MODIFIER", 27, 35], ["oxidative stress", "OBSERVATION", 36, 52], ["glucose tolerance", "OBSERVATION", 64, 81], ["venous", "ANATOMY", 100, 106], ["stasis", "OBSERVATION", 107, 113]]], ["Thus, it is considered a synergic effect of obesity and MS on the state of hypercoagulability in COVID-19, aggravating the risk of VTE and DIC even more [43] .Obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)There is also a greater amount of macrophages in the adipose tissue of obese individuals due to areas of microhypoxia, which lead to the nuclear factor-\u03baB (NF-\u03baB) pathway activation, thus increasing the expression of genes involved in inflammation [61] .", [["macrophages", "ANATOMY", 261, 272], ["adipose tissue", "ANATOMY", 280, 294], ["obesity", "DISEASE", 44, 51], ["MS", "DISEASE", 56, 58], ["hypercoagulability", "DISEASE", 75, 93], ["VTE", "DISEASE", 131, 134], ["DIC", "DISEASE", 139, 142], ["Obesity", "DISEASE", 159, 166], ["type 2 diabetes mellitus", "DISEASE", 168, 192], ["T2DM", "DISEASE", 194, 198], ["metabolic syndrome", "DISEASE", 204, 222], ["MS", "DISEASE", 224, 226], ["microhypoxia", "DISEASE", 332, 344], ["inflammation", "DISEASE", 462, 474], ["macrophages", "CELL", 261, 272], ["adipose tissue", "TISSUE", 280, 294], ["nuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 364, 381], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 383, 388], ["macrophages", "CELL_TYPE", 261, 272], ["nuclear factor-\u03baB", "PROTEIN", 364, 381], ["NF-\u03baB", "PROTEIN", 383, 388], ["obesity", "PROBLEM", 44, 51], ["MS", "PROBLEM", 56, 58], ["hypercoagulability", "PROBLEM", 75, 93], ["COVID", "TEST", 97, 102], ["VTE", "PROBLEM", 131, 134], ["DIC", "PROBLEM", 139, 142], ["Obesity", "PROBLEM", 159, 166], ["type 2 diabetes mellitus", "PROBLEM", 168, 192], ["T2DM)", "PROBLEM", 194, 199], ["metabolic syndrome (MS)", "PROBLEM", 204, 227], ["obese individuals", "PROBLEM", 298, 315], ["microhypoxia", "PROBLEM", 332, 344], ["the nuclear factor", "TEST", 360, 378], ["pathway activation", "PROBLEM", 390, 408], ["inflammation", "PROBLEM", 462, 474], ["obesity", "OBSERVATION", 44, 51], ["diabetes mellitus", "OBSERVATION", 175, 192], ["metabolic syndrome", "OBSERVATION", 204, 222], ["greater", "OBSERVATION_MODIFIER", 243, 250], ["amount", "OBSERVATION_MODIFIER", 251, 257], ["macrophages", "OBSERVATION", 261, 272], ["adipose tissue", "ANATOMY", 280, 294], ["obese", "OBSERVATION", 298, 303], ["microhypoxia", "OBSERVATION", 332, 344]]], ["This condition is the result of the attraction of monocytes in the circulation made by chemokines; when they infiltrate the adipose tissue, they transform into macrophages, which, in turn, release TNF-\u03b1 and IL-6 which induce the tissue's resistance to insulin [63] .", [["monocytes", "ANATOMY", 50, 59], ["adipose tissue", "ANATOMY", 124, 138], ["macrophages", "ANATOMY", 160, 171], ["tissue", "ANATOMY", 229, 235], ["monocytes", "CELL", 50, 59], ["adipose tissue", "TISSUE", 124, 138], ["macrophages", "CELL", 160, 171], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 197, 202], ["IL-6", "GENE_OR_GENE_PRODUCT", 207, 211], ["tissue", "TISSUE", 229, 235], ["insulin", "GENE_OR_GENE_PRODUCT", 252, 259], ["monocytes", "CELL_TYPE", 50, 59], ["chemokines", "PROTEIN", 87, 97], ["macrophages", "CELL_TYPE", 160, 171], ["TNF", "PROTEIN", 197, 200], ["IL-6", "PROTEIN", 207, 211], ["they infiltrate the adipose tissue", "PROBLEM", 104, 138], ["TNF", "TEST", 197, 200], ["IL", "TREATMENT", 207, 209], ["insulin", "TEST", 252, 259], ["monocytes", "OBSERVATION", 50, 59], ["adipose tissue", "ANATOMY", 124, 138], ["macrophages", "OBSERVATION", 160, 171]]], ["Insulin resistance is also related to the host's immune response, as it can inhibit the resolution of T cell-mediated inflammation [61] .Obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS)The adipose tissue is not the only one affected by the deposition of fats, because of that, bone marrow and thymus also present significant changes to the immune system of obese individuals and those with MS [67] .", [["T cell", "ANATOMY", 102, 108], ["adipose tissue", "ANATOMY", 209, 223], ["fats", "ANATOMY", 274, 278], ["bone marrow", "ANATOMY", 297, 308], ["thymus", "ANATOMY", 313, 319], ["immune system", "ANATOMY", 360, 373], ["Insulin", "CHEMICAL", 0, 7], ["inflammation", "DISEASE", 118, 130], ["Obesity", "DISEASE", 137, 144], ["type 2 diabetes mellitus", "DISEASE", 146, 170], ["T2DM", "DISEASE", 172, 176], ["metabolic syndrome", "DISEASE", 182, 200], ["MS", "DISEASE", 202, 204], ["MS", "DISEASE", 410, 412], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cell", "CELL", 102, 108], ["adipose tissue", "TISSUE", 209, 223], ["fats", "SIMPLE_CHEMICAL", 274, 278], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 297, 308], ["thymus", "ORGAN", 313, 319], ["immune system", "ANATOMICAL_SYSTEM", 360, 373], ["Insulin resistance", "TREATMENT", 0, 18], ["T cell-mediated inflammation", "PROBLEM", 102, 130], ["Obesity", "PROBLEM", 137, 144], ["type 2 diabetes mellitus", "PROBLEM", 146, 170], ["T2DM)", "PROBLEM", 172, 177], ["metabolic syndrome", "PROBLEM", 182, 200], ["The adipose tissue", "PROBLEM", 205, 223], ["bone marrow and thymus", "PROBLEM", 297, 319], ["significant changes", "PROBLEM", 333, 352], ["obese individuals", "PROBLEM", 377, 394], ["MS", "TEST", 410, 412], ["diabetes mellitus", "OBSERVATION", 153, 170], ["metabolic syndrome", "OBSERVATION", 182, 200], ["bone marrow", "ANATOMY", 297, 308], ["thymus", "ANATOMY", 313, 319], ["significant", "OBSERVATION_MODIFIER", 333, 344]]], ["Thus, there is a marked deregulation of immune responses, which leads to a lower presence of circulating T cells, reducing the response to pathogens [60, 61, 65] .Physical exercise and COVID-19Despite the lack of accurate data on how physical activity improves the immune response against the new coronavirus, there is evidence of lower rates of ARI incidence, duration and intensity of symptoms and risk of mortality from infectious respiratory diseases in individuals who exercise at high levels appropriate.", [["T cells", "ANATOMY", 105, 112], ["respiratory", "ANATOMY", 434, 445], ["coronavirus", "DISEASE", 297, 308], ["ARI", "DISEASE", 346, 349], ["infectious respiratory diseases", "DISEASE", 423, 454], ["T cells", "CELL", 105, 112], ["coronavirus", "ORGANISM", 297, 308], ["circulating T cells", "CELL_TYPE", 93, 112], ["a marked deregulation of immune responses", "PROBLEM", 15, 56], ["circulating T cells", "PROBLEM", 93, 112], ["COVID", "TEST", 185, 190], ["the new coronavirus", "PROBLEM", 289, 308], ["ARI incidence", "PROBLEM", 346, 359], ["symptoms", "PROBLEM", 387, 395], ["infectious respiratory diseases", "PROBLEM", 423, 454], ["marked", "OBSERVATION_MODIFIER", 17, 23], ["deregulation", "OBSERVATION", 24, 36], ["immune responses", "OBSERVATION", 40, 56], ["circulating T cells", "OBSERVATION", 93, 112], ["lower", "OBSERVATION_MODIFIER", 331, 336], ["infectious", "OBSERVATION_MODIFIER", 423, 433]]], ["Furthermore, different studies suggest that regular physical exercise is directly related to decreased mortality from pneumonia and influenza, improvements in cardiorespiratory function, vaccine response, metabolism of glucose, lipids and insulin [13, 16] .Physical exercise and COVID-19Increased immune surveillance against infections has been proposed as a mechanism responsible for improving the immune response related to physical exercise.", [["pneumonia", "DISEASE", 118, 127], ["influenza", "DISEASE", 132, 141], ["glucose", "CHEMICAL", 219, 226], ["infections", "DISEASE", 325, 335], ["glucose", "CHEMICAL", 219, 226], ["glucose", "SIMPLE_CHEMICAL", 219, 226], ["lipids", "SIMPLE_CHEMICAL", 228, 234], ["insulin", "GENE_OR_GENE_PRODUCT", 239, 246], ["different studies", "TEST", 13, 30], ["decreased mortality", "PROBLEM", 93, 112], ["pneumonia", "PROBLEM", 118, 127], ["influenza", "PROBLEM", 132, 141], ["cardiorespiratory function", "TEST", 159, 185], ["vaccine response", "TEST", 187, 203], ["glucose", "TEST", 219, 226], ["lipids", "TEST", 228, 234], ["insulin", "TREATMENT", 239, 246], ["COVID", "TEST", 279, 284], ["infections", "PROBLEM", 325, 335], ["pneumonia", "OBSERVATION", 118, 127]]], ["Moderateintensity physical activity is responsible for providing an increase in the anti-pathogenic activity of macrophages, at the same time as elevations in the circulation of immune cells, immunoglobulins and anti-inflammatory cytokines occur, thereby reducing the burden of pathogen on organs such as the lung and the risk of lung damage due to the influx of inflammatory cells [12] .Physical exercise and COVID-19During regular physical exercise practices, inflammatory responses and stress hormones are decreased; in contrast, lymphocytes, NK cells, immature B cells and monocytes are at high levels.", [["macrophages", "ANATOMY", 112, 123], ["immune cells", "ANATOMY", 178, 190], ["organs", "ANATOMY", 290, 296], ["lung", "ANATOMY", 309, 313], ["lung", "ANATOMY", 330, 334], ["inflammatory cells", "ANATOMY", 363, 381], ["lymphocytes", "ANATOMY", 533, 544], ["NK cells", "ANATOMY", 546, 554], ["B cells", "ANATOMY", 565, 572], ["monocytes", "ANATOMY", 577, 586], ["lung damage", "DISEASE", 330, 341], ["COVID-19During", "CHEMICAL", 410, 424], ["macrophages", "CELL", 112, 123], ["immune cells", "CELL", 178, 190], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 192, 207], ["organs", "ORGAN", 290, 296], ["lung", "ORGAN", 309, 313], ["lung", "ORGAN", 330, 334], ["cells", "CELL", 376, 381], ["lymphocytes", "CELL", 533, 544], ["NK cells", "CELL", 546, 554], ["B cells", "CELL", 565, 572], ["monocytes", "CELL", 577, 586], ["macrophages", "CELL_TYPE", 112, 123], ["immune cells", "CELL_TYPE", 178, 190], ["immunoglobulins", "PROTEIN", 192, 207], ["anti-inflammatory cytokines", "PROTEIN", 212, 239], ["inflammatory cells", "CELL_TYPE", 363, 381], ["lymphocytes", "CELL_TYPE", 533, 544], ["NK cells", "CELL_TYPE", 546, 554], ["immature B cells", "CELL_TYPE", 556, 572], ["monocytes", "CELL_TYPE", 577, 586], ["Moderateintensity physical activity", "PROBLEM", 0, 35], ["an increase in the anti-pathogenic activity of macrophages", "PROBLEM", 65, 123], ["elevations in the circulation of immune cells", "PROBLEM", 145, 190], ["immunoglobulins", "TREATMENT", 192, 207], ["anti-inflammatory cytokines", "TREATMENT", 212, 239], ["pathogen on organs", "PROBLEM", 278, 296], ["lung damage", "PROBLEM", 330, 341], ["inflammatory cells", "PROBLEM", 363, 381], ["COVID", "TEST", 410, 415], ["inflammatory responses", "TEST", 462, 484], ["stress hormones", "TEST", 489, 504], ["lymphocytes", "TEST", 533, 544], ["NK cells", "TEST", 546, 554], ["monocytes", "TEST", 577, 586], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["macrophages", "OBSERVATION", 112, 123], ["immune cells", "OBSERVATION", 178, 190], ["anti-inflammatory cytokines", "OBSERVATION", 212, 239], ["pathogen", "OBSERVATION", 278, 286], ["lung", "ANATOMY", 309, 313], ["lung", "ANATOMY", 330, 334], ["damage", "OBSERVATION", 335, 341], ["inflammatory cells", "OBSERVATION", 363, 381], ["NK cells", "OBSERVATION", 546, 554], ["immature B cells", "OBSERVATION", 556, 572], ["monocytes", "OBSERVATION_MODIFIER", 577, 586]]], ["Thus, there is an improvement in immunovigilance, as well as a reduction in the systemic inflammatory process, factors that corroborate that regular physical activity helps to improve the immune system, while helping to prevent respiratory diseases and thus protect against infections such as COVID-19 [68] .Physical exercise and COVID-19Dynamic exercises that generate cardiorespiratory overload promote the mobilization and redistribution of effector lymphocytes, mediated by catecholamines.", [["immune system", "ANATOMY", 188, 201], ["respiratory", "ANATOMY", 228, 239], ["effector lymphocytes", "ANATOMY", 444, 464], ["respiratory diseases", "DISEASE", 228, 248], ["infections", "DISEASE", 274, 284], ["cardiorespiratory overload", "DISEASE", 370, 396], ["catecholamines", "CHEMICAL", 478, 492], ["COVID-19", "CHEMICAL", 293, 301], ["catecholamines", "CHEMICAL", 478, 492], ["lymphocytes", "CELL", 453, 464], ["catecholamines", "SIMPLE_CHEMICAL", 478, 492], ["effector lymphocytes", "CELL_TYPE", 444, 464], ["immunovigilance", "TREATMENT", 33, 48], ["a reduction", "TREATMENT", 61, 72], ["the systemic inflammatory process", "PROBLEM", 76, 109], ["respiratory diseases", "PROBLEM", 228, 248], ["infections", "PROBLEM", 274, 284], ["COVID", "TEST", 293, 298], ["COVID-19Dynamic exercises", "TREATMENT", 330, 355], ["cardiorespiratory overload", "PROBLEM", 370, 396], ["the mobilization", "TREATMENT", 405, 421], ["effector lymphocytes", "PROBLEM", 444, 464], ["improvement", "OBSERVATION_MODIFIER", 18, 29], ["reduction", "OBSERVATION_MODIFIER", 63, 72], ["systemic", "OBSERVATION_MODIFIER", 80, 88], ["inflammatory", "OBSERVATION", 89, 101], ["mobilization", "OBSERVATION", 409, 421], ["redistribution", "OBSERVATION_MODIFIER", 426, 440], ["effector lymphocytes", "OBSERVATION", 444, 464]]], ["This action primarily stimulates subtypes of lymphocytes capable of migrating from reservoirs-such as blood vessels, spleen and bone marrow-to lymphoid tissues and organs-such as the upper respiratory tract, lungs and intestines, aiming at recognizing and fighting pathogens and, thus, increasing immune surveillance and improving the antiviral response [16] .Physical exercise and COVID-19Similarly, regular exercise practices at moderate levels favor the function of the human body's immune surveillance against pathogens, as they stimulate an exchange of white blood cells between the circulatory system and tissues, a fact that reduces morbidity and mortality from acute respiratory disease and infections viral.", [["lymphocytes", "ANATOMY", 45, 56], ["blood vessels", "ANATOMY", 102, 115], ["spleen", "ANATOMY", 117, 123], ["bone marrow", "ANATOMY", 128, 139], ["lymphoid tissues", "ANATOMY", 143, 159], ["organs", "ANATOMY", 164, 170], ["upper respiratory tract", "ANATOMY", 183, 206], ["lungs", "ANATOMY", 208, 213], ["intestines", "ANATOMY", 218, 228], ["body", "ANATOMY", 479, 483], ["white blood cells", "ANATOMY", 558, 575], ["circulatory system", "ANATOMY", 588, 606], ["tissues", "ANATOMY", 611, 618], ["respiratory", "ANATOMY", 675, 686], ["acute respiratory disease", "DISEASE", 669, 694], ["infections", "DISEASE", 699, 709], ["lymphocytes", "CELL", 45, 56], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 102, 115], ["spleen", "ORGAN", 117, 123], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 128, 139], ["lymphoid tissues", "TISSUE", 143, 159], ["organs", "ORGAN", 164, 170], ["upper", "ORGANISM_SUBDIVISION", 183, 188], ["respiratory tract", "ORGANISM_SUBDIVISION", 189, 206], ["lungs", "ORGAN", 208, 213], ["intestines", "ORGAN", 218, 228], ["human", "ORGANISM", 473, 478], ["body", "ORGANISM_SUBDIVISION", 479, 483], ["white blood cells", "CELL", 558, 575], ["circulatory system", "ANATOMICAL_SYSTEM", 588, 606], ["tissues", "TISSUE", 611, 618], ["lymphocytes", "CELL_TYPE", 45, 56], ["white blood cells", "CELL_TYPE", 558, 575], ["human", "SPECIES", 473, 478], ["human", "SPECIES", 473, 478], ["lymphocytes", "PROBLEM", 45, 56], ["blood vessels", "TEST", 102, 115], ["the upper respiratory tract, lungs and intestines", "PROBLEM", 179, 228], ["fighting pathogens", "PROBLEM", 256, 274], ["increasing immune surveillance", "PROBLEM", 286, 316], ["COVID", "TEST", 382, 387], ["regular exercise practices", "TREATMENT", 401, 427], ["pathogens", "PROBLEM", 514, 523], ["white blood cells", "TREATMENT", 558, 575], ["acute respiratory disease", "PROBLEM", 669, 694], ["infections viral", "PROBLEM", 699, 715], ["lymphocytes", "OBSERVATION", 45, 56], ["vessels", "ANATOMY", 108, 115], ["spleen", "ANATOMY", 117, 123], ["bone marrow", "ANATOMY", 128, 139], ["lymphoid tissues", "OBSERVATION", 143, 159], ["organs", "ANATOMY", 164, 170], ["upper", "ANATOMY_MODIFIER", 183, 188], ["respiratory tract", "ANATOMY", 189, 206], ["lungs", "ANATOMY", 208, 213], ["intestines", "ANATOMY", 218, 228], ["circulatory system", "ANATOMY", 588, 606], ["tissues", "ANATOMY", 611, 618], ["acute", "OBSERVATION_MODIFIER", 669, 674], ["respiratory disease", "OBSERVATION", 675, 694], ["infections", "OBSERVATION", 699, 709]]], ["They are also capable of promoting protection against infections triggered by intracellular microorganisms, as viral agents, given that the predominant immune response is mediated by Th1 cells [68] .Physical exercise and COVID-19Regular exercise of moderate intensity has already been associated with a reduction in respiratory infections compared to sedentariness.", [["intracellular", "ANATOMY", 78, 91], ["Th1 cells", "ANATOMY", 183, 192], ["respiratory", "ANATOMY", 316, 327], ["infections", "DISEASE", 54, 64], ["respiratory infections", "DISEASE", 316, 338], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 91], ["Th1 cells", "CELL", 183, 192], ["Th1 cells", "CELL_TYPE", 183, 192], ["infections", "PROBLEM", 54, 64], ["intracellular microorganisms", "PROBLEM", 78, 106], ["viral agents", "TREATMENT", 111, 123], ["COVID", "TEST", 221, 226], ["moderate intensity", "PROBLEM", 249, 267], ["a reduction in respiratory infections", "PROBLEM", 301, 338], ["sedentariness", "PROBLEM", 351, 364], ["moderate intensity", "OBSERVATION_MODIFIER", 249, 267], ["respiratory", "ANATOMY", 316, 327], ["infections", "OBSERVATION", 328, 338]]], ["However, exhaustive physical practices before or during an infectious condition, such as influenza or COVID-19, can trigger severe illness due to changes in the immune system [40, 68] .", [["influenza", "DISEASE", 89, 98], ["COVID-19", "CHEMICAL", 102, 110], ["illness", "DISEASE", 131, 138], ["an infectious condition", "PROBLEM", 56, 79], ["influenza", "PROBLEM", 89, 98], ["COVID", "TEST", 102, 107], ["severe illness", "PROBLEM", 124, 138], ["changes in the immune system", "PROBLEM", 146, 174]]], ["This occurs due to the production of Th2 anti-inflammatory cytokines in order to reduce muscle tissue damage, but in strenuous activities this effect can reach immunosuppression levels, thus providing the opportunity for infections [12, 40] .", [["muscle tissue", "ANATOMY", 88, 101], ["muscle tissue damage", "DISEASE", 88, 108], ["infections", "DISEASE", 221, 231], ["muscle tissue", "TISSUE", 88, 101], ["Th2 anti-inflammatory cytokines", "PROTEIN", 37, 68], ["Th2 anti-inflammatory cytokines", "TREATMENT", 37, 68], ["muscle tissue damage", "PROBLEM", 88, 108], ["immunosuppression levels", "TREATMENT", 160, 184], ["infections", "PROBLEM", 221, 231], ["muscle tissue", "ANATOMY", 88, 101], ["damage", "OBSERVATION", 102, 108]]], ["Therefore, attention should be paid to the importance of developing physical training at appropriate levels of execution.Physical exercise and COVID-19To the detriment of the world demographic change and the habits arising from the technological revolution, the population is aging more, becoming more obese and, consequently, less active when it comes to physical exercise.", [["COVID-19To", "CHEMICAL", 143, 153], ["developing physical training", "TREATMENT", 57, 85], ["COVID", "TEST", 143, 148], ["more", "OBSERVATION_MODIFIER", 297, 301], ["obese", "OBSERVATION", 302, 307]]], ["In this way, the immune system undergoes negative changes; that is, there is a functional impairment of innate immunity and adaptive immunity called immunosenescence, which results in greater susceptibility to infectious diseases and systemic inflammatory processes, decreased response to antibodies and, therefore, compromised immunological surveillance [68] .Physical exercise and COVID-19Therefore, for the elderly population, physical activity is even more essential, as these individuals generally have greater comorbidities and, in relation to the new coronavirus, are more vulnerable to contracting the disease [69] .", [["immune system", "ANATOMY", 17, 30], ["infectious diseases", "DISEASE", 210, 229], ["COVID-19Therefore", "CHEMICAL", 383, 400], ["coronavirus", "DISEASE", 558, 569], ["antibodies", "PROTEIN", 289, 299], ["greater susceptibility to infectious diseases", "PROBLEM", 184, 229], ["systemic inflammatory processes", "PROBLEM", 234, 265], ["decreased response to antibodies", "PROBLEM", 267, 299], ["greater comorbidities", "PROBLEM", 508, 529], ["the new coronavirus", "PROBLEM", 550, 569], ["negative", "OBSERVATION", 41, 49], ["greater susceptibility", "OBSERVATION_MODIFIER", 184, 206], ["infectious", "OBSERVATION", 210, 220], ["systemic", "OBSERVATION_MODIFIER", 234, 242], ["inflammatory", "OBSERVATION", 243, 255], ["new", "OBSERVATION_MODIFIER", 554, 557], ["coronavirus", "OBSERVATION", 558, 569]]], ["Damiot et al. [70] suggested that individuals who have remained active throughout their lives have less pronounced immunosenescence characteristics, which may be a possible protective factor against the development of complications caused by COVID-19.Physical exercise and COVID-19In this sense, beneficial effects of regular physical exercise have been reported in the elderly population, including reduction in oxidative stress, improvement in immune competence and reduction in cellular changes related to immunosenescence [13, 16] .", [["cellular", "ANATOMY", 481, 489], ["COVID-19", "CHEMICAL", 242, 250], ["COVID-19", "CHEMICAL", 242, 250], ["COVID-19In", "CHEMICAL", 273, 283], ["individuals", "ORGANISM", 34, 45], ["cellular", "CELL", 481, 489], ["complications", "PROBLEM", 218, 231], ["COVID", "TEST", 242, 247], ["COVID", "TREATMENT", 273, 278], ["oxidative stress", "PROBLEM", 413, 429], ["immune competence", "PROBLEM", 446, 463], ["cellular changes", "PROBLEM", 481, 497], ["active", "OBSERVATION", 64, 70], ["cellular changes", "OBSERVATION", 481, 497]]], ["Elderly individuals who maintain continued physical activity have levels of TCD4 + and TCD8 + lymphocytes similar to younger individuals, in addition to not having harmful defects in the recruitment of lymphocytes during the infectious process [58] .Physical exercise and COVID-19According to the study by Ferrer et al. [71] with 116 elderly volunteers, through physical activity there is a decrease in the current levels of IL-6, as well as an increase in the expression of IL-10 in active individuals [71] .", [["TCD8 + lymphocytes", "ANATOMY", 87, 105], ["lymphocytes", "ANATOMY", 202, 213], ["individuals", "ORGANISM", 8, 19], ["TCD4", "GENE_OR_GENE_PRODUCT", 76, 80], ["TCD8", "GENE_OR_GENE_PRODUCT", 87, 91], ["lymphocytes", "CELL", 202, 213], ["volunteers", "ORGANISM", 342, 352], ["IL-6", "GENE_OR_GENE_PRODUCT", 425, 429], ["IL-10", "GENE_OR_GENE_PRODUCT", 475, 480], ["TCD4", "PROTEIN", 76, 80], ["TCD8", "PROTEIN", 87, 91], ["lymphocytes", "CELL_TYPE", 94, 105], ["lymphocytes", "CELL_TYPE", 202, 213], ["IL-6", "PROTEIN", 425, 429], ["IL-10", "PROTEIN", 475, 480], ["TCD4", "TEST", 76, 80], ["TCD8", "PROBLEM", 87, 91], ["lymphocytes", "PROBLEM", 94, 105], ["harmful defects", "PROBLEM", 164, 179], ["COVID", "TEST", 272, 277], ["the study", "TEST", 293, 302], ["a decrease", "PROBLEM", 389, 399], ["the expression of IL", "TREATMENT", 457, 477], ["harmful", "OBSERVATION_MODIFIER", 164, 171], ["defects", "OBSERVATION", 172, 179], ["recruitment", "OBSERVATION_MODIFIER", 187, 198], ["lymphocytes", "OBSERVATION", 202, 213], ["infectious", "OBSERVATION_MODIFIER", 225, 235], ["decrease", "OBSERVATION_MODIFIER", 391, 399], ["increase", "OBSERVATION_MODIFIER", 445, 453]]], ["A low presence of circulating pro-inflammatory cytokines is observed in contrast to the increase in anti-inflammatory cytokines.", [["pro-inflammatory cytokines", "PROTEIN", 30, 56], ["anti-inflammatory cytokines", "PROTEIN", 100, 127], ["circulating pro-inflammatory cytokines", "PROBLEM", 18, 56], ["anti-inflammatory cytokines", "TREATMENT", 100, 127], ["low", "OBSERVATION_MODIFIER", 2, 5], ["circulating", "OBSERVATION_MODIFIER", 18, 29], ["pro-inflammatory cytokines", "OBSERVATION", 30, 56], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["anti-inflammatory cytokines", "OBSERVATION", 100, 127]]], ["Thus, there are positive changes in the immune system of these individuals, including enhancements in host response and vaccine immunoprotection [70] .Physical exercise and COVID-19Similarly, while prolonged maintenance or worsening of obesity and MS perpetuates deregulation of immune responses, promoting greater risks of the individual developing diseases and increasing their vulnerability to infection by the novel coronavirus [43, 59, 61 ].", [["immune system", "ANATOMY", 40, 53], ["COVID-19Similarly", "CHEMICAL", 173, 190], ["obesity", "DISEASE", 236, 243], ["MS", "DISEASE", 248, 250], ["infection", "DISEASE", 397, 406], ["coronavirus", "ORGANISM", 420, 431], ["positive changes in the immune system", "PROBLEM", 16, 53], ["vaccine immunoprotection", "TREATMENT", 120, 144], ["COVID", "TREATMENT", 173, 178], ["obesity", "PROBLEM", 236, 243], ["MS", "PROBLEM", 248, 250], ["immune responses", "PROBLEM", 279, 295], ["the individual developing diseases", "PROBLEM", 324, 358], ["increasing their vulnerability to infection", "PROBLEM", 363, 406], ["the novel coronavirus", "PROBLEM", 410, 431], ["positive", "OBSERVATION", 16, 24], ["host response", "OBSERVATION", 102, 115], ["worsening", "OBSERVATION_MODIFIER", 223, 232], ["obesity", "OBSERVATION", 236, 243], ["diseases", "OBSERVATION", 350, 358], ["infection", "OBSERVATION", 397, 406]]], ["An association between physical activity and reduction of inflammatory markers in obese and overweight patients is suggested [13] .Physical exercise and COVID-19Luzi and Radaelli [72] add the lack of physical activity as an important factor among obese patients, as it impairs the immune response against microbial agents, from the activation of macrophages to the inhibition of pro-inflammatory cytokines.", [["macrophages", "ANATOMY", 346, 357], ["overweight", "DISEASE", 92, 102], ["COVID-19Luzi", "CHEMICAL", 153, 165], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 253, 261], ["macrophages", "CELL", 346, 357], ["inflammatory markers", "PROTEIN", 58, 78], ["macrophages", "CELL_TYPE", 346, 357], ["pro-inflammatory cytokines", "PROTEIN", 379, 405], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 253, 261], ["inflammatory markers in obese", "PROBLEM", 58, 87], ["Physical exercise", "TEST", 131, 148], ["COVID", "TEST", 153, 158], ["Radaelli", "TREATMENT", 170, 178], ["microbial agents", "TREATMENT", 305, 321], ["pro-inflammatory cytokines", "TREATMENT", 379, 405], ["inflammatory", "OBSERVATION_MODIFIER", 58, 70], ["pro-inflammatory cytokines", "OBSERVATION", 379, 405]]], ["On the other hand, both metabolic health and immune health benefit from the practice of physical activity, which reduces the risk of infectious complications.", [["infectious complications", "PROBLEM", 133, 157], ["infectious", "OBSERVATION", 133, 143]]], ["Thus, regular physical exercise appears as a preventive measure in the defense of the host against viral infection [72] .Physical exercise and COVID-19Muscle contraction is responsible for the transient increase in circulating levels of IL-6 cytokine, in proportion to the duration of physical activity and the amount of muscle mass recruited.", [["muscle mass", "ANATOMY", 321, 332], ["viral infection", "DISEASE", 99, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 237, 241], ["muscle", "ORGAN", 321, 327], ["IL-6 cytokine", "PROTEIN", 237, 250], ["viral infection", "PROBLEM", 99, 114], ["Physical exercise", "TEST", 121, 138], ["COVID", "TEST", 143, 148], ["the transient increase in circulating levels of IL", "PROBLEM", 189, 239], ["muscle mass", "PROBLEM", 321, 332], ["transient", "OBSERVATION_MODIFIER", 193, 202], ["increase", "OBSERVATION_MODIFIER", 203, 211], ["amount", "OBSERVATION_MODIFIER", 311, 317], ["muscle", "ANATOMY", 321, 327], ["mass", "OBSERVATION", 328, 332]]], ["The elevation of this interleukin seems to be followed by increases in antinflammatory cytokines, such as IL-10, released by cells of innate immunity and responsible for promoting an antinflammatory environment, inhibiting inflammatory mediators to limit tissue damage.", [["cells", "ANATOMY", 125, 130], ["tissue", "ANATOMY", 255, 261], ["interleukin", "GENE_OR_GENE_PRODUCT", 22, 33], ["IL-10", "GENE_OR_GENE_PRODUCT", 106, 111], ["cells", "CELL", 125, 130], ["tissue", "TISSUE", 255, 261], ["interleukin", "PROTEIN", 22, 33], ["antinflammatory cytokines", "PROTEIN", 71, 96], ["IL-10", "PROTEIN", 106, 111], ["inflammatory mediators", "PROTEIN", 223, 245], ["The elevation", "PROBLEM", 0, 13], ["this interleukin", "TREATMENT", 17, 33], ["antinflammatory cytokines", "TREATMENT", 71, 96], ["an antinflammatory environment", "TREATMENT", 180, 210], ["inflammatory mediators", "PROBLEM", 223, 245], ["tissue damage", "PROBLEM", 255, 268], ["elevation", "OBSERVATION_MODIFIER", 4, 13], ["increases", "OBSERVATION_MODIFIER", 58, 67], ["limit tissue", "OBSERVATION_MODIFIER", 249, 261], ["damage", "OBSERVATION", 262, 268]]], ["This effect may be beneficial in cases of chronic inflammation, such as obesity, T2DM and MS, and may reduce the risk of a pathogenic inflammatory response such as the cytokine storm present in severe COVID-19 [40, 59] .Physical exercise and COVID-19In addition, IL-10 is associated with enhanced insulin sensibility and glycemic metabolism [40] .", [["inflammation", "DISEASE", 50, 62], ["obesity", "DISEASE", 72, 79], ["T2DM", "DISEASE", 81, 85], ["MS", "DISEASE", 90, 92], ["COVID-19In", "CHEMICAL", 242, 252], ["COVID-19", "CHEMICAL", 201, 209], ["COVID-19In", "CHEMICAL", 242, 252], ["COVID-19In", "GENE_OR_GENE_PRODUCT", 242, 252], ["IL-10", "GENE_OR_GENE_PRODUCT", 263, 268], ["insulin", "GENE_OR_GENE_PRODUCT", 297, 304], ["cytokine", "PROTEIN", 168, 176], ["IL-10", "PROTEIN", 263, 268], ["chronic inflammation", "PROBLEM", 42, 62], ["obesity", "PROBLEM", 72, 79], ["T2DM", "PROBLEM", 81, 85], ["MS", "PROBLEM", 90, 92], ["a pathogenic inflammatory response", "PROBLEM", 121, 155], ["the cytokine storm", "PROBLEM", 164, 182], ["severe COVID", "TEST", 194, 206], ["COVID", "TEST", 242, 247], ["enhanced insulin sensibility", "TEST", 288, 316], ["may be", "UNCERTAINTY", 12, 18], ["chronic", "OBSERVATION_MODIFIER", 42, 49], ["inflammation", "OBSERVATION", 50, 62], ["obesity", "OBSERVATION", 72, 79], ["pathogenic", "OBSERVATION_MODIFIER", 123, 133], ["inflammatory", "OBSERVATION", 134, 146], ["severe", "OBSERVATION_MODIFIER", 194, 200]]], ["Physical practice is able to reduce the excessive concentration of pro-inflammatory adipocin leptin and improve sensitivity to leptin and insulin [72, 73] .", [["adipocin", "GENE_OR_GENE_PRODUCT", 84, 92], ["leptin", "GENE_OR_GENE_PRODUCT", 93, 99], ["leptin", "GENE_OR_GENE_PRODUCT", 127, 133], ["insulin", "GENE_OR_GENE_PRODUCT", 138, 145], ["pro-inflammatory adipocin", "PROTEIN", 67, 92], ["pro-inflammatory adipocin leptin", "TREATMENT", 67, 99], ["leptin and insulin", "TREATMENT", 127, 145]]], ["In patients with T2DM and new coronavirus infection, good glycemic control has been associated with better prognosis in COVID-19 [59] .Physical exercise and COVID-19Thus, physical exercise is shown to be an immunomodulatory and non-pharmacological intervention, achieving positive immunomodulation through exercises of light to moderate intensity [72] .", [["T2DM", "DISEASE", 17, 21], ["coronavirus infection", "DISEASE", 30, 51], ["COVID-19Thus", "CHEMICAL", 157, 169], ["patients", "ORGANISM", 3, 11], ["coronavirus", "ORGANISM", 30, 41], ["patients", "SPECIES", 3, 11], ["T2DM", "PROBLEM", 17, 21], ["new coronavirus infection", "PROBLEM", 26, 51], ["COVID", "TEST", 120, 125], ["COVID", "TEST", 157, 162], ["an immunomodulatory", "TREATMENT", 204, 223], ["non-pharmacological intervention", "TREATMENT", 228, 260], ["T2DM", "OBSERVATION", 17, 21], ["new", "OBSERVATION_MODIFIER", 26, 29], ["coronavirus", "OBSERVATION_MODIFIER", 30, 41], ["infection", "OBSERVATION", 42, 51]]], ["Through exercise, there is an improvement in the response to infection in obese individuals, due to immune and cellular restoration [74] .", [["cellular", "ANATOMY", 111, 119], ["infection", "DISEASE", 61, 70], ["cellular", "CELL", 111, 119], ["infection in obese individuals", "PROBLEM", 61, 91], ["immune and cellular restoration", "PROBLEM", 100, 131], ["improvement", "OBSERVATION_MODIFIER", 30, 41], ["infection", "OBSERVATION", 61, 70], ["cellular restoration", "OBSERVATION", 111, 131]]], ["Although COVID-19 is not primarily a metabolic disease, there is a need to maintain metabolic control of glucose, lipid levels and blood pressure in order to prevent metabolic and cardiovascular complications, as well as to reduce the local inflammatory response and block the virus entering the cells [75] .Physical exercise and COVID-19As seen, innate immunity has an important role in the pathogenesis of COVID-19 and ARDS, due to inflammatory cascades, recruitment of neutrophils, macrophages and DC cells and increased production of ROSs.", [["blood", "ANATOMY", 131, 136], ["cardiovascular", "ANATOMY", 180, 194], ["cells", "ANATOMY", 296, 301], ["neutrophils", "ANATOMY", 472, 483], ["macrophages", "ANATOMY", 485, 496], ["DC cells", "ANATOMY", 501, 509], ["metabolic disease", "DISEASE", 37, 54], ["glucose", "CHEMICAL", 105, 112], ["metabolic and cardiovascular complications", "DISEASE", 166, 208], ["COVID-19As", "CHEMICAL", 330, 340], ["ARDS", "DISEASE", 421, 425], ["glucose", "CHEMICAL", 105, 112], ["COVID-19", "GENE_OR_GENE_PRODUCT", 9, 17], ["glucose", "SIMPLE_CHEMICAL", 105, 112], ["lipid", "SIMPLE_CHEMICAL", 114, 119], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["cardiovascular", "ANATOMICAL_SYSTEM", 180, 194], ["cells", "CELL", 296, 301], ["COVID-19As", "GENE_OR_GENE_PRODUCT", 330, 340], ["COVID-19", "CELL", 408, 416], ["neutrophils", "CELL", 472, 483], ["macrophages", "CELL", 485, 496], ["DC cells", "CELL", 501, 509], ["ROSs", "GENE_OR_GENE_PRODUCT", 538, 542], ["COVID-19", "DNA", 9, 17], ["neutrophils", "CELL_TYPE", 472, 483], ["macrophages", "CELL_TYPE", 485, 496], ["DC cells", "CELL_TYPE", 501, 509], ["ROSs", "PROTEIN", 538, 542], ["COVID", "TEST", 9, 14], ["a metabolic disease", "PROBLEM", 35, 54], ["lipid levels", "TEST", 114, 126], ["blood pressure", "TEST", 131, 145], ["metabolic and cardiovascular complications", "PROBLEM", 166, 208], ["the local inflammatory response", "PROBLEM", 231, 262], ["block the virus", "PROBLEM", 267, 282], ["COVID", "TEST", 330, 335], ["COVID", "TEST", 408, 413], ["ARDS", "PROBLEM", 421, 425], ["inflammatory cascades", "PROBLEM", 434, 455], ["neutrophils", "PROBLEM", 472, 483], ["macrophages", "PROBLEM", 485, 496], ["DC cells", "PROBLEM", 501, 509], ["increased production of ROSs", "PROBLEM", 514, 542], ["metabolic disease", "OBSERVATION", 37, 54], ["cardiovascular", "ANATOMY", 180, 194], ["complications", "OBSERVATION", 195, 208], ["local", "OBSERVATION_MODIFIER", 235, 240], ["inflammatory", "OBSERVATION", 241, 253], ["ARDS", "OBSERVATION", 421, 425], ["inflammatory", "OBSERVATION_MODIFIER", 434, 446], ["increased", "OBSERVATION_MODIFIER", 514, 523], ["production", "OBSERVATION_MODIFIER", 524, 534]]], ["In turn, by the modulation mechanism of chemokine production, physical training and therapeutic exercises can attenuate alveolar neutrophilia in the face of lung injury [41] .Physical exercise and COVID-19Furthermore, the expression of the extracellular superoxide dismutase enzyme (EcSOD), an important antioxidant in the body and highly present in the lungs, is enhanced by resistance physical activity and was associated with inhibition of endothelial activation and inflammatory adhesion, with potential benefit to reduce oxidative stress and tissue damage in COVID-19 [41] .", [["alveolar", "ANATOMY", 120, 128], ["lung", "ANATOMY", 157, 161], ["extracellular", "ANATOMY", 240, 253], ["body", "ANATOMY", 323, 327], ["lungs", "ANATOMY", 354, 359], ["endothelial", "ANATOMY", 443, 454], ["tissue", "ANATOMY", 547, 553], ["neutrophilia", "DISEASE", 129, 141], ["lung injury", "DISEASE", 157, 168], ["superoxide", "CHEMICAL", 254, 264], ["superoxide", "CHEMICAL", 254, 264], ["COVID-19", "CHEMICAL", 564, 572], ["alveolar", "MULTI-TISSUE_STRUCTURE", 120, 128], ["lung", "ORGAN", 157, 161], ["extracellular superoxide dismutase enzyme", "GENE_OR_GENE_PRODUCT", 240, 281], ["EcSOD", "GENE_OR_GENE_PRODUCT", 283, 288], ["body", "ORGANISM_SUBDIVISION", 323, 327], ["lungs", "ORGAN", 354, 359], ["endothelial", "CELL", 443, 454], ["tissue", "TISSUE", 547, 553], ["chemokine", "PROTEIN", 40, 49], ["extracellular superoxide dismutase enzyme", "PROTEIN", 240, 281], ["EcSOD", "PROTEIN", 283, 288], ["chemokine production", "PROBLEM", 40, 60], ["physical training", "TREATMENT", 62, 79], ["therapeutic exercises", "TREATMENT", 84, 105], ["alveolar neutrophilia", "PROBLEM", 120, 141], ["lung injury", "PROBLEM", 157, 168], ["COVID", "TEST", 197, 202], ["the extracellular superoxide dismutase enzyme", "TEST", 236, 281], ["endothelial activation", "PROBLEM", 443, 465], ["inflammatory adhesion", "PROBLEM", 470, 491], ["oxidative stress", "PROBLEM", 526, 542], ["tissue damage", "PROBLEM", 547, 560], ["COVID", "TEST", 564, 569], ["alveolar neutrophilia", "OBSERVATION", 120, 141], ["lung", "ANATOMY", 157, 161], ["injury", "OBSERVATION", 162, 168], ["antioxidant", "OBSERVATION_MODIFIER", 304, 315], ["body", "ANATOMY_MODIFIER", 323, 327], ["lungs", "ANATOMY", 354, 359], ["endothelial", "ANATOMY", 443, 454], ["inflammatory adhesion", "OBSERVATION", 470, 491]]], ["The amplification of the antioxidant defense generated by routine physical activity also contributes to immunological surveillance [13] .Physical exercise and COVID-19Moreover, Womack, Nagelkirk and Coughlin [76] point out that through the intensity of physical exercise, a change in the potential for coagulation, platelet aggregation and fibrinolysis can be seen.", [["platelet", "ANATOMY", 315, 323], ["platelet aggregation", "DISEASE", 315, 335], ["platelet", "CELL", 315, 323], ["immunological surveillance", "TEST", 104, 130], ["COVID", "TEST", 159, 164], ["coagulation", "TEST", 302, 313], ["platelet aggregation", "PROBLEM", 315, 335], ["fibrinolysis", "TREATMENT", 340, 352], ["platelet aggregation", "OBSERVATION", 315, 335], ["fibrinolysis", "OBSERVATION", 340, 352]]], ["As an example, there is long-term training through aerobic exercises where a decrease in the clotting potential is observed in healthy individuals.", [["long-term training", "TREATMENT", 24, 42], ["aerobic exercises", "TREATMENT", 51, 68], ["a decrease in the clotting potential", "PROBLEM", 75, 111], ["decrease", "OBSERVATION_MODIFIER", 77, 85], ["clotting", "OBSERVATION", 93, 101]]], ["Thus, it is suggested that the practice of physical exercises contributes to reducing the risk of ischemic events depending on their intensity and duration [76] and may contribute to attenuating coagulation disorders associated with SARS-CoV-2 infection.Physical exercise and COVID-19The anti-inflammatory, antioxidant and endothelial activation inhibitor benefits may also be linked to the reduction in hypercoagulability related to COVID-19.", [["endothelial", "ANATOMY", 323, 334], ["coagulation disorders", "DISEASE", 195, 216], ["SARS-CoV-2 infection", "DISEASE", 233, 253], ["COVID-19", "CHEMICAL", 276, 284], ["hypercoagulability", "DISEASE", 404, 422], ["COVID-19", "CHEMICAL", 276, 284], ["COVID-19", "CHEMICAL", 434, 442], ["CoV-2", "ORGANISM", 238, 243], ["endothelial", "CELL", 323, 334], ["COVID-19", "GENE_OR_GENE_PRODUCT", 434, 442], ["physical exercises", "TREATMENT", 43, 61], ["ischemic events", "PROBLEM", 98, 113], ["attenuating coagulation disorders", "PROBLEM", 183, 216], ["SARS", "PROBLEM", 233, 237], ["CoV-2 infection", "PROBLEM", 238, 253], ["COVID", "TEST", 276, 281], ["The anti-inflammatory", "TREATMENT", 284, 305], ["antioxidant", "TREATMENT", 307, 318], ["endothelial activation inhibitor", "TREATMENT", 323, 355], ["the reduction in hypercoagulability", "PROBLEM", 387, 422], ["COVID", "TEST", 434, 439], ["ischemic", "OBSERVATION", 98, 106], ["attenuating", "OBSERVATION_MODIFIER", 183, 194], ["coagulation", "OBSERVATION", 195, 206], ["infection", "OBSERVATION", 244, 253], ["anti-inflammatory", "OBSERVATION_MODIFIER", 288, 305], ["reduction", "OBSERVATION_MODIFIER", 391, 400], ["hypercoagulability", "OBSERVATION", 404, 422]]], ["This is because, as previously mentioned, the exacerbated activation of the immune system increases the expression of the tissue factor and, consequently, the predisposition to the formation of thrombi; in addition, metabolic disorders, oxidant stress and changes in senescence positively stimulate the vasoconstrictor axis ECA/Ang/AT1R, contributing to endothelial imbalances [46, 47, [49] [50] [51] [52] [53] 69] .", [["immune system", "ANATOMY", 76, 89], ["tissue", "ANATOMY", 122, 128], ["thrombi", "ANATOMY", 194, 201], ["endothelial", "ANATOMY", 354, 365], ["thrombi", "DISEASE", 194, 201], ["metabolic disorders", "DISEASE", 216, 235], ["Ang", "CHEMICAL", 328, 331], ["tissue", "TISSUE", 122, 128], ["thrombi", "PATHOLOGICAL_FORMATION", 194, 201], ["ECA", "GENE_OR_GENE_PRODUCT", 324, 327], ["Ang", "GENE_OR_GENE_PRODUCT", 328, 331], ["AT1R", "GENE_OR_GENE_PRODUCT", 332, 336], ["endothelial", "CELL", 354, 365], ["tissue factor", "PROTEIN", 122, 135], ["Ang", "PROTEIN", 328, 331], ["AT1R", "PROTEIN", 332, 336], ["the exacerbated activation of the immune system", "PROBLEM", 42, 89], ["the tissue factor", "PROBLEM", 118, 135], ["thrombi", "PROBLEM", 194, 201], ["metabolic disorders", "PROBLEM", 216, 235], ["oxidant stress", "PROBLEM", 237, 251], ["changes in senescence", "PROBLEM", 256, 277], ["the vasoconstrictor axis ECA", "TEST", 299, 327], ["Ang/AT1R", "TEST", 328, 336], ["endothelial imbalances", "TEST", 354, 376], ["thrombi", "OBSERVATION", 194, 201], ["metabolic disorders", "OBSERVATION", 216, 235], ["endothelial", "ANATOMY", 354, 365]]], ["Therefore, the immunometabolic improvements promoted by physical exercise may help in the control of coagulation disorders in the COVID-19 (Fig. 4) .Physical exercise and COVID-19Finally, in view of the quarantine status adopted in several countries as a measure to prevent and control the spread of SARS-CoV-2 during the COVID-19 pandemic, social isolation and restrictions on the movement of people reduced the practice of physical activity, predisposing the population to adopt sedentary behavior [77] .", [["coagulation disorders", "DISEASE", 101, 122], ["SARS", "DISEASE", 300, 304], ["SARS-CoV-2", "ORGANISM", 300, 310], ["people", "ORGANISM", 394, 400], ["people", "SPECIES", 394, 400], ["SARS-CoV", "SPECIES", 300, 308], ["the immunometabolic improvements", "PROBLEM", 11, 43], ["coagulation disorders", "PROBLEM", 101, 122], ["the COVID", "TEST", 126, 135], ["COVID", "TREATMENT", 171, 176], ["SARS", "PROBLEM", 300, 304], ["social isolation", "TREATMENT", 341, 357]]], ["Social distancing is a sine qua non in reducing the speed of contagion of COVID-19 and associated deaths.", [["deaths", "DISEASE", 98, 104]]], ["However, due to these measures, sports clubs, gyms and fitness spaces have suspended their activities in order to reduce agglomerations; thus, difficulties regarding physical exercise were imposed [78] .Physical exercise and COVID-19Therefore, despite being one of the main strategies against COVID-19, social isolation has been related to behavioral and physiological changes, including the increased prevalence of sedentarism and eating disorders (food compulsion, hyperphagia), resulting in negative consequences for metabolic health, such as weight gain, growth of fat tissue, hyperglycemia and insulin resistance and loss of muscle tissue [59] .", [["fat tissue", "ANATOMY", 569, 579], ["muscle tissue", "ANATOMY", 630, 643], ["sedentarism", "DISEASE", 416, 427], ["eating disorders", "DISEASE", 432, 448], ["food compulsion", "DISEASE", 450, 465], ["hyperphagia", "DISEASE", 467, 478], ["weight gain", "DISEASE", 546, 557], ["hyperglycemia", "DISEASE", 581, 594], ["fat tissue", "TISSUE", 569, 579], ["insulin", "GENE_OR_GENE_PRODUCT", 599, 606], ["muscle tissue", "TISSUE", 630, 643], ["agglomerations", "PROBLEM", 121, 135], ["COVID", "TEST", 225, 230], ["COVID", "TEST", 293, 298], ["social isolation", "TREATMENT", 303, 319], ["behavioral and physiological changes", "PROBLEM", 340, 376], ["sedentarism", "PROBLEM", 416, 427], ["eating disorders", "PROBLEM", 432, 448], ["hyperphagia", "PROBLEM", 467, 478], ["weight gain", "PROBLEM", 546, 557], ["fat tissue", "PROBLEM", 569, 579], ["hyperglycemia", "PROBLEM", 581, 594], ["insulin resistance", "PROBLEM", 599, 617], ["loss of muscle tissue", "PROBLEM", 622, 643], ["fat tissue", "OBSERVATION", 569, 579], ["hyperglycemia", "OBSERVATION", 581, 594], ["insulin resistance", "OBSERVATION", 599, 617], ["muscle tissue", "ANATOMY", 630, 643]]], ["Since this condition can harm the body's defenses and contribute significantly to the reduction in individuals' physical condition, functional and health loss, the adoption of healthy habits and an exercise routine can help in maintaining health [59, 69] .Physical exercise and COVID-19It is significant to consider that contexts like this increase the susceptibility to stressful events and elevations of glucocorticoids (cortisol), with consequent inhibition of the functions of NK cells and TCD8 + lymphocytes in the antiviral response.", [["body", "ANATOMY", 34, 38], ["NK cells", "ANATOMY", 481, 489], ["TCD8 + lymphocytes", "ANATOMY", 494, 512], ["COVID-19It", "CHEMICAL", 278, 288], ["glucocorticoids", "CHEMICAL", 406, 421], ["cortisol", "CHEMICAL", 423, 431], ["COVID-19It", "CHEMICAL", 278, 288], ["cortisol", "CHEMICAL", 423, 431], ["body", "ORGANISM_SUBDIVISION", 34, 38], ["glucocorticoids", "SIMPLE_CHEMICAL", 406, 421], ["cortisol", "SIMPLE_CHEMICAL", 423, 431], ["NK cells", "CELL", 481, 489], ["TCD8 + lymphocytes", "CELL", 494, 512], ["NK cells", "CELL_TYPE", 481, 489], ["TCD8 + lymphocytes", "CELL_TYPE", 494, 512], ["the reduction in individuals' physical condition", "PROBLEM", 82, 130], ["functional and health loss", "PROBLEM", 132, 158], ["an exercise routine", "TREATMENT", 195, 214], ["COVID", "TEST", 278, 283], ["stressful events", "PROBLEM", 371, 387], ["elevations of glucocorticoids", "PROBLEM", 392, 421], ["cortisol", "TEST", 423, 431], ["NK cells", "PROBLEM", 481, 489], ["TCD8", "PROBLEM", 494, 498], ["lymphocytes", "PROBLEM", 501, 512], ["NK cells", "OBSERVATION", 481, 489], ["antiviral response", "OBSERVATION", 520, 538]]], ["However, good physical conditioning was associated with lower risks of reactivation of latent viral infections in situations of isolation and confinement, indicating a favored immune system compared to individuals with less physical fitness [16] .Physical exercise and COVID-19Physical activity is considered a non-medication practice for the prevention and treatment of diseases of psychological, physical and/or metabolic origin [78] .", [["viral infections", "DISEASE", 94, 110], ["diseases of psychological, physical and/or metabolic origin", "DISEASE", 371, 430], ["latent viral infections", "PROBLEM", 87, 110], ["a favored immune system", "PROBLEM", 166, 189], ["a non-medication practice", "TREATMENT", 309, 334], ["the prevention", "TREATMENT", 339, 353], ["diseases", "PROBLEM", 371, 379], ["good", "OBSERVATION_MODIFIER", 9, 13], ["reactivation", "OBSERVATION", 71, 83], ["latent", "OBSERVATION_MODIFIER", 87, 93], ["viral", "OBSERVATION_MODIFIER", 94, 99], ["infections", "OBSERVATION", 100, 110]]], ["Regular physical exercise should be encouraged during social isolation as a preventive measure for health, given that exercise is essential during the period of fight against the spread of coronavirus [69] .Physical exercise and COVID-19The American College of Sports Medicine (ACSM) recommends that the practice of moderate physical exercise should be maintained during the quarantine period, since it helps in the immune reinforcement against SARS-CoV-2.", [["coronavirus", "DISEASE", 189, 200], ["SARS", "DISEASE", 445, 449], ["coronavirus", "ORGANISM", 189, 200], ["SARS-CoV-2", "ORGANISM", 445, 455], ["SARS-CoV", "SPECIES", 445, 453], ["social isolation", "TREATMENT", 54, 70], ["coronavirus", "PROBLEM", 189, 200], ["moderate physical exercise", "TREATMENT", 316, 342], ["the immune reinforcement", "TREATMENT", 412, 436], ["SARS", "PROBLEM", 445, 449]]], ["The WHO recommends that asymptomatic and healthy individuals should exercise at least 150 min per week for adults and 300 min per week for children and adolescents.", [["children", "ORGANISM", 139, 147], ["children", "SPECIES", 139, 147], ["adolescents", "SPECIES", 152, 163]]], ["These times can be distributed during the days of the week and according to the person's routine [69] .", [["person", "SPECIES", 80, 86]]], ["It is important to emphasize that physical activity should be interrupted and a health professional should be consulted in case symptoms such as fever, dyspnea at rest and dry cough are manifested, because these symptoms can be related to COVID-19 [69, 79] .Physical exercise and COVID-19In social isolation, the home environment has become the ideal and necessary place for physical activity.", [["fever", "DISEASE", 145, 150], ["dyspnea", "DISEASE", 152, 159], ["dry cough", "DISEASE", 172, 181], ["COVID-19In", "CHEMICAL", 280, 290], ["COVID-19", "CHEMICAL", 239, 247], ["symptoms", "PROBLEM", 128, 136], ["fever", "PROBLEM", 145, 150], ["dyspnea", "PROBLEM", 152, 159], ["dry cough", "PROBLEM", 172, 181], ["these symptoms", "PROBLEM", 206, 220], ["COVID", "TEST", 239, 244], ["social isolation", "TREATMENT", 291, 307]]], ["Activities that are satisfactory and that allow better exploring the home space should be sought.", [["the home space", "TREATMENT", 65, 79]]], ["Activities of daily living such as organization of spaces, cleaning and maintenance also help in coping with COVID-19.", [["COVID-19", "CHEMICAL", 109, 117], ["cleaning", "TREATMENT", 59, 67], ["COVID", "TEST", 109, 114]]], ["In environments with children, playing and exercising with them is a great way to promote energy expenditure, thus leaving the beginning of sedentary rest.", [["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29]]], ["Meditation, stretching and relaxation are allies in combating a sedentary lifestyle.", [["Meditation", "TREATMENT", 0, 10], ["stretching and relaxation", "TREATMENT", 12, 37]]], ["It is important to avoid long rest periods, which should be intercalated with active practices [69] .Physical exercise and COVID-19The ACSM has published guidelines for moderate-intensity activities that can be practiced during the pandemic period, including aerobic exercises and strength training, indoors, like at home, or outdoors, when permitted by Fig. 4 Benefits of regular moderate-intensity physical activity on factors that influence the response against to COVID-19.", [["COVID-19", "CHEMICAL", 468, 476], ["COVID", "TEST", 123, 128], ["aerobic exercises", "TREATMENT", 259, 276], ["strength training", "TREATMENT", 281, 298], ["COVID", "TEST", 468, 473], ["regular moderate", "OBSERVATION_MODIFIER", 373, 389]]], ["Options for aerobic activities to be performed at home include walk briskly around the house, up-and downstairs, dancing and jumping rope.", [["aerobic activities", "TREATMENT", 12, 30]]], ["When possible, walking or running outdoors, cycling, gardening work and family games are interesting alternatives, as long as infection prevention measures are maintained [79] .Physical exercise and COVID-19Among the strength activities, ACSM indicates downloading a strength workout app that does not require any equipment and suggests exercises such as squat, sit-ups, push-ups, lunges and yoga practice, which can also help in anxious states [79] .", [["infection", "DISEASE", 126, 135], ["infection prevention measures", "TREATMENT", 126, 155], ["Physical exercise", "TEST", 177, 194], ["COVID", "TEST", 199, 204], ["any equipment", "TREATMENT", 310, 323]]], ["Oliveira Neto et al. [80] suggest resistance exercises based on ACSM recommendations to be performed at home, including exercises involving the muscles of the lower body, upper body and limbs, and lower limbs, which can be adapted for beginners in physical practice or experienced people.Physical exercise and COVID-19Activities that make use of the individual's own body weight, associated with resistance training as well as the use of elastic bands, provide excellent health results, results similar to those achieved by traditional gyms.", [["muscles", "ANATOMY", 144, 151], ["lower body", "ANATOMY", 159, 169], ["upper body", "ANATOMY", 171, 181], ["limbs", "ANATOMY", 186, 191], ["lower limbs", "ANATOMY", 197, 208], ["body", "ANATOMY", 367, 371], ["muscles", "ORGANISM_SUBDIVISION", 144, 151], ["lower body", "ORGANISM_SUBDIVISION", 159, 169], ["upper body", "ORGANISM_SUBDIVISION", 171, 181], ["limbs", "ORGANISM_SUBDIVISION", 186, 191], ["lower limbs", "ORGANISM_SUBDIVISION", 197, 208], ["people", "ORGANISM", 281, 287], ["body", "ORGANISM_SUBDIVISION", 367, 371], ["people", "SPECIES", 281, 287], ["resistance exercises", "TREATMENT", 34, 54], ["ACSM recommendations", "TREATMENT", 64, 84], ["resistance training", "TREATMENT", 396, 415], ["elastic bands", "TREATMENT", 438, 451], ["muscles", "ANATOMY", 144, 151], ["lower", "ANATOMY_MODIFIER", 159, 164], ["body", "ANATOMY", 165, 169], ["upper", "ANATOMY_MODIFIER", 171, 176], ["body", "ANATOMY", 177, 181], ["limbs", "ANATOMY", 186, 191], ["lower limbs", "ANATOMY", 197, 208]]], ["Thus, objects such as backpacks, books, market bags and water bottles can be used as an auxiliary tool in resistance physical activity.", [["market bags and water bottles", "TREATMENT", 40, 69]]], ["Exercises such as squats, jumping jacks and going up and down steps can be effective in physical training [78] .Physical exercise and COVID-19As for the intensity and volume of physical exercise practices, these must be moderate, as they exceed both the volume and the intensity, effects such as momentary immunosuppression are achieved, thus providing greater vulnerability as to the contagion of the novel coronavirus.", [["COVID-19As", "CHEMICAL", 134, 144], ["coronavirus", "DISEASE", 408, 419], ["coronavirus", "ORGANISM", 408, 419], ["jumping jacks", "PROBLEM", 26, 39], ["COVID", "TEST", 134, 139], ["physical exercise practices", "TREATMENT", 177, 204], ["momentary immunosuppression", "TREATMENT", 296, 323], ["the novel coronavirus", "PROBLEM", 398, 419], ["moderate", "OBSERVATION_MODIFIER", 220, 228]]], ["If individuals want to practice high-intensity exercises, a reduction in exercise volume should be adopted as a preventive measure, in order to avoid strenuous exercises [78] .Physical exercise and COVID-19In addition, technological tools can contribute to the better performance of these activities in the home environment, as video calls with a physical education professional facilitate the orientation of the exercises to be performed, providing support that has, as a consequence, better results and greater safety in the execution of the exercises.", [["COVID-19In", "CHEMICAL", 198, 208], ["COVID-19In", "CHEMICAL", 198, 208], ["practice high-intensity exercises", "TREATMENT", 23, 56], ["a reduction in exercise volume", "TREATMENT", 58, 88], ["COVID", "TREATMENT", 198, 203]]], ["Regardless of whether or not you are in the risk group for COVID-19, regular exercise, according to the ACSM, should be regularly performed, given that it aims to improve the immune system, reduce stress perceived and decrease anxiety disorders [78] .ConclusionThere are still gaps in the knowledge regarding the pathogenic mechanisms involved in SARS-CoV-2 infection.", [["immune system", "ANATOMY", 175, 188], ["anxiety disorders", "DISEASE", 227, 244], ["SARS-CoV-2 infection", "DISEASE", 347, 367], ["SARS-CoV-2", "ORGANISM", 347, 357], ["SARS-CoV-2", "SPECIES", 347, 357], ["COVID", "TEST", 59, 64], ["decrease anxiety disorders", "PROBLEM", 218, 244], ["the pathogenic mechanisms", "PROBLEM", 309, 334], ["SARS", "PROBLEM", 347, 351], ["2 infection", "PROBLEM", 356, 367], ["gaps", "OBSERVATION", 277, 281], ["SARS", "OBSERVATION", 347, 351], ["infection", "OBSERVATION", 358, 367]]], ["However, there is consensus in the scientific literature about the important involvement of the immune system in the susceptibility, progression and outcome of COVID-19.", [["immune system", "ANATOMY", 96, 109], ["COVID", "TEST", 160, 165], ["progression", "OBSERVATION_MODIFIER", 133, 144]]], ["The imbalance in innate and adaptive immune responses, characterized mainly by changes such as cytokine storm and lymphopenia, in addition to the disorders in coagulation-and host-related conditions, including obesity, metabolic syndrome and aging (immunosenescence), is among the factors notoriously associated with a worse prognosis of infection.ConclusionThe benefits of exercise-regular and at appropriate intensity levels-for the immune system in respiratory infections such as COVID-19 include increased immunovigilance and improved immune competence, which help in the control of pathogens, a fact that becomes more important considering the immunosenescence and susceptibility of the elderly population to severe infection.", [["immune system", "ANATOMY", 435, 448], ["respiratory", "ANATOMY", 452, 463], ["lymphopenia", "DISEASE", 114, 125], ["obesity", "DISEASE", 210, 217], ["metabolic syndrome", "DISEASE", 219, 237], ["infection", "DISEASE", 338, 347], ["respiratory infections", "DISEASE", 452, 474], ["COVID-19", "CHEMICAL", 483, 491], ["infection", "DISEASE", 721, 730], ["COVID-19", "CHEMICAL", 483, 491], ["cytokine", "PROTEIN", 95, 103], ["The imbalance", "PROBLEM", 0, 13], ["cytokine storm", "PROBLEM", 95, 109], ["lymphopenia", "PROBLEM", 114, 125], ["the disorders in coagulation", "PROBLEM", 142, 170], ["obesity", "PROBLEM", 210, 217], ["metabolic syndrome", "PROBLEM", 219, 237], ["infection", "PROBLEM", 338, 347], ["appropriate intensity levels", "TEST", 398, 426], ["the immune system", "PROBLEM", 431, 448], ["respiratory infections", "PROBLEM", 452, 474], ["COVID", "TEST", 483, 488], ["increased immunovigilance", "PROBLEM", 500, 525], ["pathogens", "PROBLEM", 587, 596], ["severe infection", "PROBLEM", 714, 730], ["imbalance", "OBSERVATION", 4, 13], ["cytokine storm", "OBSERVATION", 95, 109], ["lymphopenia", "OBSERVATION", 114, 125], ["obesity", "OBSERVATION", 210, 217], ["metabolic syndrome", "OBSERVATION", 219, 237], ["infection", "OBSERVATION", 338, 347], ["respiratory", "ANATOMY", 452, 463], ["infections", "OBSERVATION", 464, 474], ["severe", "OBSERVATION_MODIFIER", 714, 720], ["infection", "OBSERVATION", 721, 730]]], ["Other favorable effects in relation to host factors, such as prevention or reduction of overweight, increased physical and cardiopulmonary conditioning, attenuation of the systemic pro-inflammatory and pro-thrombotic states, decrease in oxidative stress, improvements in glycemic, insulinic and lipidic metabolisms, besides the enhancement of the vaccination response, also indicate how adequately physical activity can help the organism's immune response against COVID-19.ConclusionIn the COVID-19 pandemic situation, adopting mitigation practices is an essential strategy to reduce the risks related to the novel coronavirus infection.", [["overweight", "DISEASE", 88, 98], ["coronavirus infection", "DISEASE", 615, 636], ["COVID-19", "CHEMICAL", 464, 472], ["insulinic", "SIMPLE_CHEMICAL", 281, 290], ["coronavirus", "ORGANISM", 615, 626], ["overweight", "PROBLEM", 88, 98], ["increased physical and cardiopulmonary conditioning", "PROBLEM", 100, 151], ["the systemic pro-inflammatory and pro-thrombotic states", "PROBLEM", 168, 223], ["oxidative stress", "PROBLEM", 237, 253], ["glycemic, insulinic and lipidic metabolisms", "PROBLEM", 271, 314], ["COVID", "TEST", 464, 469], ["adopting mitigation practices", "TREATMENT", 519, 548], ["the novel coronavirus infection", "PROBLEM", 605, 636], ["favorable", "OBSERVATION_MODIFIER", 6, 15], ["cardiopulmonary conditioning", "OBSERVATION", 123, 151], ["systemic", "OBSERVATION_MODIFIER", 172, 180], ["pro-inflammatory", "OBSERVATION_MODIFIER", 181, 197], ["oxidative stress", "OBSERVATION", 237, 253], ["lipidic metabolisms", "OBSERVATION", 295, 314], ["coronavirus", "OBSERVATION_MODIFIER", 615, 626], ["infection", "OBSERVATION", 627, 636]]], ["These interventions include the use of personal protective equipment (PPE), adherence to hygiene procedures and social isolation measures, as well as actions that lead to a healthier lifestyle, minimize stress factors and strengthen the immune system, such as regular physical activity.ConclusionHowever, remaining active at appropriate levels seems to be a challenge in a context of confinement and social isolation, which emphasizes the importance of developing training with recommendations adapted to the new routine of the population.", [["immune system", "ANATOMY", 237, 250], ["These interventions", "TREATMENT", 0, 19], ["personal protective equipment", "TREATMENT", 39, 68], ["hygiene procedures", "TREATMENT", 89, 107], ["social isolation measures", "TREATMENT", 112, 137], ["stress factors", "PROBLEM", 203, 217], ["social isolation", "TREATMENT", 400, 416], ["active", "OBSERVATION_MODIFIER", 315, 321]]], ["Fortunately, there are viable alternatives for performing physical exercises in restricted environments, enabling the population to enjoy the advantages of physical training for health in the context of OVID-19.ConclusionFinally, future studies that deepen the relationship between physical activity and infection by SARS-CoV-2, including the influences of exercise on metabolic and immunological disorders present in COVID-19, will certainly be relevant in view of the probable benefits already mentioned and considering the impacts of infection by the novel coronavirus in the global context.", [["infection", "DISEASE", 304, 313], ["SARS", "DISEASE", 317, 321], ["metabolic and immunological disorders", "DISEASE", 369, 406], ["infection", "DISEASE", 537, 546], ["SARS-CoV-2", "ORGANISM", 317, 327], ["coronavirus", "ORGANISM", 560, 571], ["SARS-CoV", "SPECIES", 317, 325], ["performing physical exercises", "TREATMENT", 47, 76], ["physical training", "TREATMENT", 156, 173], ["future studies", "TEST", 230, 244], ["infection", "PROBLEM", 304, 313], ["SARS", "PROBLEM", 317, 321], ["CoV", "TEST", 322, 325], ["immunological disorders", "PROBLEM", 383, 406], ["infection", "PROBLEM", 537, 546], ["the novel coronavirus", "PROBLEM", 550, 571], ["infection", "OBSERVATION", 304, 313], ["infection", "OBSERVATION", 537, 546]]], ["Faced with the possibility of new pandemics by previously unknown microorganisms, without totally effective prevention measures, vaccines or specific treatments of proven efficacy, the host organism's capacity against infections becomes the most important line of defense, thus emphasizing the importance of investing in lifestyle habits that promote health and well-being, such as the practice of physical activity.", [["infections", "DISEASE", 218, 228], ["new pandemics", "PROBLEM", 30, 43], ["vaccines", "TREATMENT", 129, 137], ["specific treatments", "TREATMENT", 141, 160], ["the host organism's capacity", "PROBLEM", 181, 209], ["infections", "PROBLEM", 218, 228]]]], "defb3d3bd1f210f27426c5f20d48c398f6600587": [["1 Reducing accidents and errors is a major focus of hospital quality programs and an international policy imperative.", [["accidents", "DISEASE", 11, 20]]], ["2 Engaging patients is increasingly recognized to be an important component of safety initiatives [3] [4] [5] and a logical extension of efforts to involve patients in the health care process.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 156, 164]]], ["6 Patients are present at the point of care where errors may occur, able to detect medically relevant incidents, 7 concerned about their safety, [8] [9] [10] and correspondence: charles e cunningham ron Joyce children's health centre, child and Youth Mental health Program, 237 Barton street east, hamilton, On l8l 2X2, canada Tel +1 905 521 2100 ext 77307 Fax +1 905 577 8453 email cunnic@hhsc.ca motivated to improve the quality of the care they receive.", [["Patients", "ORGANISM", 2, 10], ["children", "ORGANISM", 209, 217], ["Patients", "SPECIES", 2, 10], ["children", "SPECIES", 209, 217]]], ["11 Patients have been encouraged to reduce hospital-acquired infections by cleaning their hands and reminding service providers to observe hand hygiene protocols.", [["hand", "ANATOMY", 139, 143], ["infections", "DISEASE", 61, 71], ["Patients", "ORGANISM", 3, 11], ["hand", "ORGANISM_SUBDIVISION", 139, 143], ["Patients", "SPECIES", 3, 11], ["acquired infections", "PROBLEM", 52, 71], ["hand hygiene protocols", "TREATMENT", 139, 161]]], ["12 They have been asked to contribute to the prevention of diagnostic errors, 13 check medications, 14, 15 join safety committees, 6, 16 voice their safety concerns, 17 and notify health care workers if errors are detected.", [["medications", "TREATMENT", 87, 98]]], ["18 The likelihood of engaging patients in safety partnerships varies as a function of the demographics of both patients and their service providers.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 111, 119]]], ["Younger patients with higher levels of education, greater health literacy, and more accurate information about potential risks prefer a more active role in the delivery of safe care.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["the delivery of safe care", "TREATMENT", 156, 181]]], ["8 Engagement in safety initiatives also varies with the professional background of the health service providers with whom patients must partner.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130]]], ["Patients, for example, are much more likely to direct questions regarding hand hygiene to nursing staff than to physicians.", [["hand", "ANATOMY", 74, 78], ["Patients", "ORGANISM", 0, 8], ["hand", "ORGANISM_SUBDIVISION", 74, 78], ["Patients", "SPECIES", 0, 8]]], ["12 Davis et al 12 reported that, across three studies, 90%-100% of participants questioned nurses about hand hygiene, whereas only 32%-40% asked physicians.IntroductionParticipation in safety partnerships is also linked to the experiences and attitudes of patients.", [["hand", "ANATOMY", 104, 108], ["participants", "ORGANISM", 67, 79], ["hand", "ORGANISM_SUBDIVISION", 104, 108], ["patients", "ORGANISM", 256, 264], ["participants", "SPECIES", 67, 79], ["patients", "SPECIES", 256, 264]]], ["Although many patients believe that they can contribute to safer hospital care, 19 their willingness to participate in safety initiatives varies as a function of their risk perceptions, 3 exposure to medical errors, 3 and beliefs regarding their role in safety.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["12, 20 Cognitive models, such as the Theory of Planned Behavior, predict that the intent to participate would reflect expectations regarding the effectiveness of risk reduction strategies, encouragement by significant individuals, and confidence in one's ability to contribute to prevention.", [["risk reduction strategies", "TREATMENT", 162, 187]]], ["11, 12 The type of safety partnership patients are asked to participate in exerts a strong influence on their engagement.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46]]], ["11, 19 Discharged inpatients would be more comfortable questioning nurses and doctors about medications than asking whether they had cleaned their hands.", [["inpatients", "ORGANISM", 18, 28], ["medications", "TREATMENT", 92, 103]]], ["6 Indeed, while 75.2% reported that they had inquired about medications, only 4.6% asked whether staff had cleaned their hands.", [["medications", "TREATMENT", 60, 71], ["hands", "ANATOMY", 121, 126]]], ["6 Patients are reluctant to make comments that might be perceived to challenge the authority or competence of service providers.", [["Patients", "ORGANISM", 2, 10], ["Patients", "SPECIES", 2, 10]]], ["8, 21 They are concerned that health service providers may respond negatively, 11 patients may be labeled as difficult, 3 their relationship with service providers may be compromised, and the quality of the care they receive may be affected.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90]]], ["17 Studies of the attitudes of professionals provide some support for these concerns.", [["some support", "TREATMENT", 53, 65]]], ["22 Efforts to engage patients in safety initiatives have included badges encouraging patients to ask whether health care providers cleaned their hands, 12 posters depicting the correct administration of key health care strategies, 23 or personal requests from health care professionals.", [["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 85, 93]]], ["12 In one study, patients felt that they would be more than twice as likely to ask whether nurses or physicians had cleaned their hands if health care workers provided an invitation.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["one study", "TEST", 6, 15]]], ["This issue is one focus of the current study.IntroductionAlthough the mechanisms via which patients might contribute to a reduction in medical errors seem clear, Berger et al concluded that \"while patient engagement in safety is appealing, there is insufficient high quality evidence informing real-world implementation.\" 25 Systematic reviews suggest that there is a need for research regarding the effectiveness of efforts to engage patients, the contribution of patients to a reduction in errors, improvements in health outcomes, or the potential risks of engaging patients in safety partnerships.", [["patients", "ORGANISM", 91, 99], ["patient", "ORGANISM", 197, 204], ["patients", "ORGANISM", 435, 443], ["patients", "ORGANISM", 465, 473], ["patients", "ORGANISM", 568, 576], ["patients", "SPECIES", 91, 99], ["patient", "SPECIES", 197, 204], ["patients", "SPECIES", 435, 443], ["patients", "SPECIES", 465, 473], ["patients", "SPECIES", 568, 576], ["the current study", "TEST", 27, 44], ["a reduction in medical errors", "PROBLEM", 120, 149], ["a reduction in errors", "PROBLEM", 477, 498], ["one focus", "OBSERVATION_MODIFIER", 14, 23]]], ["11, 12, 16, 25 Ultimately, an effective engagement strategy is a prerequisite to a successful patient safety partnership.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["an effective engagement strategy", "TREATMENT", 27, 59]]], ["To engage patients, the design of safety partnerships needs to be informed by the preferences of potential participants.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["participants", "SPECIES", 107, 119]]], ["11, 26 Although studies have asked patients for feedback on safety initiatives, few have included patients in the design and development process.", [["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 98, 106], ["safety initiatives", "TREATMENT", 60, 78]]], ["12 Davis et al 12 reported that only two of 23 studies included in a systematic review indicated that patients had been engaged in the design process.The current studyWe extend research in this area by using a discrete choice conjoint experiment (DCE) to engage a large sample of patients, or those acting on their behalf, in the design of an approach to hospital safety partnerships.", [["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 280, 288], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 280, 288], ["23 studies", "TEST", 44, 54], ["The current study", "TEST", 150, 167], ["large", "OBSERVATION_MODIFIER", 264, 269]]], ["27 Although DCEs have been applied to the design of other risk reduction strategies, 28 this is, to our knowledge, the first application of these methods to the study of hospital safety partnerships.", [["other risk reduction strategies", "TREATMENT", 52, 83], ["the study", "TEST", 157, 166]]], ["12 we examined relative preferences for partnerships that might include medication and identity double checks or membership on hospital safety committees.", [["medication", "TREATMENT", 72, 82], ["double checks", "TEST", 96, 109]]], ["Previous studies suggest that, while patients respond positively to safety partnerships focusing on strategies to ensure the accuracy of medication administration, 6 they are uncomfortable in addressing staff compliance with hand hygiene protocols.", [["hand", "ANATOMY", 225, 229], ["patients", "ORGANISM", 37, 45], ["hand", "ORGANISM_SUBDIVISION", 225, 229], ["patients", "SPECIES", 37, 45], ["Previous studies", "TEST", 0, 16], ["strategies", "TREATMENT", 100, 110], ["medication administration", "TREATMENT", 137, 162], ["uncomfortable", "PROBLEM", 175, 188], ["hand hygiene protocols", "TREATMENT", 225, 247]]], ["6 We predicted, therefore, that: HYP 1.", [["HYP 1", "GENE_OR_GENE_PRODUCT", 33, 38]]], ["Patients would show a stronger preference for partnerships involving medication double checks than for those asking staff to clean their hands.The current studyAlthough patients recognize the value of hand hygiene, 24 they are hesitant to participate in safety partnerships that involve questioning staff.", [["hand", "ANATOMY", 201, 205], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 169, 177], ["hand", "ORGANISM_SUBDIVISION", 201, 205], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 169, 177], ["medication double checks", "TREATMENT", 69, 93], ["The current study", "TEST", 143, 160], ["hands", "ANATOMY", 137, 142]]], ["8, 21 We predicted that: HYP 2.", [["HYP 2", "GENE_OR_GENE_PRODUCT", 25, 30], ["HYP", "OBSERVATION", 25, 28]]], ["Participants would prefer partnerships focusing on hand hygiene for patients rather than an approach encouraging patients to remind staff to clean their hands.The current studyAlthough previous studies do not provide a basis for specific HYPs, we extend research in this area by exploring a set of partnership features that might influence the decision to participate.", [["hand", "ANATOMY", 51, 55], ["hand", "ORGANISM_SUBDIVISION", 51, 55], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 113, 121], ["hands", "ORGANISM_SUBDIVISION", 153, 158], ["Participants", "SPECIES", 0, 12], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 113, 121], ["The current study", "TEST", 159, 176], ["previous studies", "TEST", 185, 201], ["hands", "ANATOMY", 153, 158]]], ["These included the way in which risk information is communicated to patients, sources of evidence regarding the benefits of safety partnerships, the process via which patients are engaged in safety partnerships, strategies for providing the training needed to participate, processes for reporting errors, and organizational responses to safety concerns.", [["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 167, 175], ["the training", "TREATMENT", 237, 249]]], ["Patients hold different attitudes regarding their role in their health 32 and safety.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["6, 20, 33, 34 A patient-centered approach to safety partnerships needs to reflect these differences.", [["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23]]], ["Using latent class analysis, 35ParticipantsThis study was approved by the Hamilton Integrated Research Ethics Board.", [["This study", "TEST", 43, 53]]], ["In outpatient waiting areas and inpatient rooms, a hospital staff member asked patients or those acting on their behalf (eg, parents of children, partners, or friends) if they would consider participating.", [["patients", "ORGANISM", 79, 87], ["children", "ORGANISM", 136, 144], ["patients", "SPECIES", 79, 87], ["children", "SPECIES", 136, 144]]], ["If they agreed, a research team member explained the study, obtained electronic consent, and administered the survey on a laptop computer.", [["the study", "TEST", 49, 58]]], ["A member of the research team presented the study to 1,567 potential participants (42 of 1,609 were called for an appointment before the study was presented).", [["participants", "SPECIES", 69, 81], ["the study", "TEST", 40, 49], ["the study", "TEST", 133, 142]]], ["Overall, 1,084 completed the DCE.", [["DCE", "CHEMICAL", 29, 32], ["the DCE", "TEST", 25, 32]]], ["Our sample size is consistent with the recommendation of 200 participants per segment.", [["participants", "SPECIES", 61, 73], ["Our sample size", "TEST", 0, 15], ["size", "OBSERVATION_MODIFIER", 11, 15], ["consistent with", "UNCERTAINTY", 19, 34]]], ["41 Focus groups or individual interviews were conducted with patients (n=18), family members or support persons (n=6), a Family Advisory Council (n=6), staff (n=18), and physicians (n=1).", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["persons", "SPECIES", 104, 111]]], ["Staff participating in focus groups or interviews included registered nurses, physiotherapists, occupational therapists, imaging technologists, clinical managers, and environmental aides.", [["imaging technologists", "TEST", 121, 142]]], ["Recordings were transcribed and summarized thematically.", [["Recordings", "TEST", 0, 10]]], ["Next, we identified widely disseminated safety partnerships and attributes of the implementation process that might influence patient decisions (eg, safety partnership decision making or training).", [["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133], ["widely", "OBSERVATION_MODIFIER", 20, 26], ["disseminated", "OBSERVATION_MODIFIER", 27, 39]]], ["Attributes ranged from the point of care (eg, medication and identity double checks) to policy and governance (safety committee membership).", [["care (eg", "TREATMENT", 36, 44], ["medication", "TREATMENT", 46, 56], ["identity double checks)", "TREATMENT", 61, 84]]], ["31 experimental design and procedureDce developmentEach participant completed 17 choice sets.", [["participant", "SPECIES", 56, 67]]], ["Participants were instructed that \"Below are three ways to make health care safer.", [["Participants", "SPECIES", 0, 12]]], ["We used a partial profile design to simplify choices and improve the performance of participants.", [["participants", "SPECIES", 84, 96], ["a partial profile design", "TREATMENT", 8, 32]]], ["Sawtooth Software's experimental design algorithm created the attribute combinations appearing in each choice set.", [["design algorithm", "PROBLEM", 33, 49]]], ["The term \"patients\" was defined as patients or their family members.", [["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 35, 43]]], ["41 Participants completed one warm-up task, 17 choice sets, the Safety Partnership Attitudes Questionnaire described in Figure S1 , and demographic questions (a median completion time of 13.4 minutes).Other measuresTo explore attitudes that might influence safety partnership preferences, we developed a Safety Partnership Attitudes Questionnaire reflecting the components of the Theory of Planned Behavior, a model linked to participation in safety initiatives.", [["Participants", "SPECIES", 3, 15]]], ["Attitudes measured the anticipated benefits of patient safety behaviors.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54]]], ["Questions from the Safety Partnership Attitudes Questionnaire and internal consistency scores from this study appear in the Supplementary material.Data analysisAs described elsewhere, 46 we used a latent class program (Latent Gold Choice 4.5) to group participants with similar safety partnership preferences into classes.", [["participants", "SPECIES", 252, 264], ["internal consistency scores", "TEST", 66, 93], ["this study", "TEST", 99, 109], ["Data analysisAs", "TEST", 147, 162]]], ["Utility coefficients, reflecting preference for the levels of each safety partnership attribute, were estimated for each class.", [["Utility coefficients", "TEST", 0, 20]]], ["47 Three covariates were included in the latent class model: 35, 47 intent to participate in safety partnerships (from the Safety Partnership Questionnaire), education (high school or less versus some college or higher), and status as a patient versus parent or person acting on behalf of a patient.", [["patient", "ORGANISM", 237, 244], ["patient", "ORGANISM", 291, 298], ["patient", "SPECIES", 237, 244], ["person", "SPECIES", 262, 268], ["patient", "SPECIES", 291, 298]]], ["A maximum likelihood solution with 1, 2, 3, 4, and 5 classes was estimated.", [["A maximum likelihood solution", "TREATMENT", 0, 29], ["maximum", "OBSERVATION_MODIFIER", 2, 9]]], ["To avoid an unrepresentative model, each solution was computed ten times from different starting points.", [["an unrepresentative model, each solution", "TREATMENT", 9, 49]]], ["47 Importance scores reflect the relative influence of variation in the levels of each safety partnership attribute on choices.Data analysisAs described elsewhere, 46 HYPs 5 and 6 were examined by entering Latent Gold Choice 4.5's individual utility coefficients into Sawtooth Software's Randomized First Choice simulator.", [["Data analysisAs", "TEST", 127, 142]]], ["48, 49 Simulations predict each participant's response to hypothetical safety partnerships created by combining the levels of several attributes.", [["participant", "SPECIES", 32, 43]]], ["Across 200,000 iterations estimating two sources of error, the simulator assumes that participants would choose a safety partnership with a combination of attribute levels yielding the greatest utility.", [["participants", "SPECIES", 86, 98]]], ["48, 50 reliability and validityData analysisWe included identical \"hold-out\" choice sets at positions 7 and 13 in the 17 set sequences.", [["17 set sequences", "DNA", 118, 134]]], ["31 Reliability analysis showed that 96% of participants made identical choices to the two hold-out sets.", [["participants", "SPECIES", 43, 55], ["Reliability analysis", "TEST", 3, 23]]], ["Simulations based on the remaining choice data predicted the percentage of participants choosing each option.", [["participants", "SPECIES", 75, 87]]], ["This measure, mean absolute error, shows high predictive validity.", [["mean absolute error", "TEST", 14, 33], ["high predictive validity", "PROBLEM", 41, 65], ["absolute error", "OBSERVATION", 19, 33], ["high", "OBSERVATION_MODIFIER", 41, 45], ["predictive validity", "OBSERVATION", 46, 65]]], ["31ResultsBased on modeling studies, our goal was to identify a latent class model that minimized Bayesian Information Criterion values and yielded an interpretable solution with administratively manageable sample sizes.", [["modeling studies", "TEST", 18, 34], ["administratively manageable sample sizes", "TREATMENT", 178, 218]]], ["Both segments preferred that patients and staff double check patient's identity and medication accuracy.", [["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 61, 68], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 61, 68], ["medication accuracy", "TEST", 84, 103], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Consistent with HYP 2, an initiative encouraging patients to clean their hands was more important than asking patients to remind staff to clean their hands.", [["HYP 2", "GENE_OR_GENE_PRODUCT", 16, 21], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 110, 118], ["HYP 2", "PROBLEM", 16, 21], ["hands", "ANATOMY", 150, 155]]], ["Both segments preferred signs (versus staff or volunteers) reminding patients to wash their hands and to ask staff if they had washed their hands (Table 3) .Resultscommunicating risk and safety information to patientsResultsDisclosure of risks exerted an important influence on choices ( Table 2 ).", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 209, 217], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Both segments preferred that all patients were informed of risks and that staff encourage patients to ask about safety (Table 3) .safety partnership processThe safety reporting process and the hospital's response to safety questions exerted a moderate influence on choices ( Table 2 ).", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 90, 98], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Both segments preferred that patients report safety concerns directly to staff and that those reporting concerns were thanked and informed about the hospital's response ( decide whether to give their names when reporting safety concerns (Table 3) , variations in the anonymity afforded patients reporting concerns exerted little influence on choices ( Table 2) .", [["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 286, 294], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Although utility values suggest that a collaborative approach to safety partnership decisions was preferred (Table 3) , variations in the levels of this attribute exerted a limited influence on choices (Table 2 ). rQ 2: Are there segments preferring different safety partnerships?safety partnership processActively engaged and passively engaged segments of the two-segment latent class solution were consistent with HYP 3's predictions.", [["HYP 3", "GENE_OR_GENE_PRODUCT", 416, 421], ["utility values", "TEST", 9, 23], ["consistent with", "UNCERTAINTY", 400, 415]]], ["We consider differences in these segments subsequently.Actively engagedCovariate analysis suggests that membership in the actively engaged segment was linked to higher education, P,0.001, and a greater intent to participate in safety partnerships, P,0.01.", [["Covariate analysis", "TEST", 71, 89]]], ["The status of informants as patients versus those acting on behalf of patients was not associated with segment membership, P=0.09.", [["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 70, 78]]], ["The actively engaged segment was likely to be younger, outpatients, born in Canada (Table 1) .", [["likely to be", "UNCERTAINTY", 33, 45]]], ["Scores from the Safety Partnership Attitudes scale (Table 4) address HYP 4.", [["Scores", "TEST", 0, 6]]], ["As predicted, actively engaged participants anticipated greater benefits to partnerships, reported more confidence in their ability to contribute, and expressed a stronger intent to participate.", [["participants", "SPECIES", 31, 43]]], ["The actively engaged segment preferred that staff, rather than signs, encourage patients to report safety concerns and that staff disclose all mistakes.Passively engagedMembership in the passively engaged segment was associated with lower education and a lower intent to participate in safety partnerships.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88]]], ["Participants who were immigrants were more likely to reside in this segment ( was less confident in their ability to contribute ( Table 4 ).", [["Participants", "SPECIES", 0, 12]]], ["The utility values show that they preferred staff to decide whether patients were informed of mistakes (Table 3 ).", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["The utility values", "TEST", 0, 18]]], ["In contrast to the evidence-informed approach preferred by the actively engaged segment, passively engaged participants preferred that staff explain why they (rather than research) felt patients should participate in safety partnerships.", [["patients", "ORGANISM", 186, 194], ["participants", "SPECIES", 107, 119], ["patients", "SPECIES", 186, 194]]], ["Patient representation on hospital safety committees was more important to the passively engaged segment than to the actively engaged segment; they preferred that patients were represented on all safety committees. rQ 3: To what extent do patients prefer a collaborative approach to safety?Passively engagedTo explore this question, we simulated each participant's response to three approaches to safety.", [["patients", "ORGANISM", 163, 171], ["patients", "ORGANISM", 239, 247], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 239, 247], ["participant", "SPECIES", 351, 362]]], ["According to the safety partnership model, patients received safety training that 1) included readings, videos, and checklists.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["safety training", "TREATMENT", 61, 76]]], ["Both patients and staff double checked that 2) staff helped the right patient and 3) medications were correct.", [["patients", "ORGANISM", 5, 13], ["patient", "ORGANISM", 70, 77], ["patients", "SPECIES", 5, 13], ["patient", "SPECIES", 70, 77], ["medications", "TREATMENT", 85, 96]]], ["According to the staff safety model: 1) patients did not learn to make care safer.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["Staff double checked that 2) they were helping the right patient and 3) medications were correct.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["medications", "TREATMENT", 72, 83]]], ["In the control condition, 1) patients did not learn to make care safer, and no one double checked that 2) staff were helping the right patient, and 3) medications were correct.", [["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 135, 142], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 135, 142], ["medications", "TREATMENT", 151, 162]]], ["Consistent with HYP 5 simulations predicted that both actively (100%) and passively engaged (91%) participants would prefer partnerships with staff rather than a model delegating safety to staff alone (Table 5 ).Passively engagedrQ 4: What type of engagement strategy do patients prefer?Passively engagedWe used Randomized First Choice simulations to address this question and to examine HYP 6's prediction that patients would prefer that staff personally engage them in safety partnerships.", [["patients", "ORGANISM", 271, 279], ["patients", "ORGANISM", 412, 420], ["participants", "SPECIES", 98, 110], ["patients", "SPECIES", 271, 279], ["patients", "SPECIES", 412, 420], ["HYP 5 simulations", "PROBLEM", 16, 33]]], ["According to the personal engagement model, staff encouraged patients to 1) ask about safety, 2) report concerns, 3) clean their hands, and 4) remind staff to wash their hands.", [["patients", "ORGANISM", 61, 69], ["hands", "ORGANISM_SUBDIVISION", 170, 175], ["patients", "SPECIES", 61, 69], ["hands", "ANATOMY", 170, 175]]], ["According to the visual engagement model, signs encouraged patients to 1) ask about safety, 2) report concerns, 3) clean their hands, and 4) remind staff to clean their hands.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["hands", "ANATOMY", 169, 174]]], ["In the control condition, patients were notDiscussionThis study modeled the safety partnership preferences of health service users.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["This study", "TEST", 53, 63]]], ["Although DCEs represent a standard approach to the assessment of health service preferences, 27 we believe this is their first application to the study of safety partnerships.", [["the assessment", "TEST", 47, 61], ["the study", "TEST", 142, 151]]], ["Our findings contribute to research on this topic by estimating the relative value of the different features of multicomponent approaches to safety, demonstrating important individual differences in preferences, and simulating the response of participants to different engagement strategies.DiscussionrQ 1: What features of safety partnerships are most important to each segment?DiscussionAs predicted, participants preferred point of care initiatives such as medication and identity double checks that might contribute to an immediate reduction in personal risk.", [["participants", "SPECIES", 243, 255], ["participants", "SPECIES", 403, 415], ["care initiatives", "TREATMENT", 435, 451], ["medication", "TREATMENT", 460, 470], ["identity double checks", "TEST", 475, 497], ["an immediate reduction in personal risk", "PROBLEM", 523, 562], ["reduction", "OBSERVATION_MODIFIER", 536, 545]]], ["The administration of medications, for example, represents a significant source of error.", [["medications", "TREATMENT", 22, 33], ["significant", "OBSERVATION_MODIFIER", 61, 72]]], ["52 Double-checking medications exerted a stronger influence on choices than any other attribute.", [["Double-checking medications", "TREATMENT", 3, 30]]], ["This is consistent with studies suggesting that patients rate double checks, and related approaches to the prevention of medication errors, very positively.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["studies", "TEST", 24, 31], ["patients rate double checks", "TEST", 48, 75], ["medication errors", "PROBLEM", 121, 138], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Consistent with HYP 2, participants were more likely to choose partnerships prompting patients to wash their hands than those encouraging patients to remind staff to wash their hands.", [["HYP 2", "GENE_OR_GENE_PRODUCT", 16, 21], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 138, 146], ["hands", "ORGANISM_SUBDIVISION", 177, 182], ["participants", "SPECIES", 23, 35], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 138, 146]]], ["This finding is consistent with research suggesting that patients consider asking staff whether they have cleaned their hands to be less effective than other strategies and themselves to be less likely to participate in these programs than in other risk reduction initiatives.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["consistent with", "UNCERTAINTY", 16, 31]]], ["21, 53 Waterman et al 19 reported that only 5% of 2,078 post-discharge inpatients asked nurses or doctors whether they had cleaned their hands.", [["inpatients", "ORGANISM", 71, 81]]], ["This is consistent with evidence that patients are reluctant to engage in partnerships that might be perceived to challenge the competence of service providers.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Consistent with HYP 3, latent class analysis revealed two segments that might be expected to respond to different safety partnerships.", [["HYP 3", "GENE_OR_GENE_PRODUCT", 16, 21], ["latent class analysis", "TEST", 23, 44]]], ["Younger outpatients with higher education were more likely to be members of an actively engaged segment that valued scientific evidence that patients could improve safety.", [["outpatients", "ORGANISM", 8, 19], ["patients", "ORGANISM", 141, 149], ["outpatients", "SPECIES", 8, 19], ["patients", "SPECIES", 141, 149]]], ["In previous studies, patients with higher activation scores engage in more preventive activities, are more likely to follow treatment protocols, evidence better health outcomes, incur fewer costs, and evaluate care experiences more positively.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["previous studies", "TEST", 3, 19], ["higher activation scores", "PROBLEM", 35, 59], ["treatment protocols", "TREATMENT", 124, 143]]], ["32 Passively engaged participants anticipated fewer benefits to safety partnerships, were less confident in their ability to contribute, and less intent on participating.", [["participants", "SPECIES", 21, 33]]], ["They preferred that staff give a rationale for safety partnerships and decide whether patients were informed of errors.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94]]], ["In comparison to the actively engaged segment, patient representation on safety committees was more important to the passively engaged segment.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54]]], ["Passively engaged participants, who may be less comfortable expressing their concerns, may value patient representatives who can speak on their behalf.", [["participants", "ORGANISM", 18, 30], ["patient", "ORGANISM", 97, 104], ["participants", "SPECIES", 18, 30], ["patient", "SPECIES", 97, 104]]], ["Participants with immigrant backgrounds, less education, and receiving services as inpatients were more likely to be members of the passively engaged segment.", [["Participants", "SPECIES", 0, 12]]], ["These findings are consistent with studies linking limited education and lower levels of health literacy 54 to a preference for a less active role in health 32,36 and safety.", [["consistent with", "UNCERTAINTY", 19, 34]]], ["11 Although utility values showed that actively engaged participants preferred to read how to make care safer, they also responded positively to a more comprehensive multimodal approach to safety education utilizing readings, videos, and checklists.", [["participants", "ORGANISM", 56, 68], ["participants", "SPECIES", 56, 68], ["utility values", "TEST", 12, 26]]], ["Passively engaged participants, in contrast, preferred to simply read about safety strategies.", [["participants", "SPECIES", 18, 30]]], ["However, when the medication and identity double-checks participants valued were included in a multicomponent (readings, videos, and checklists) educational strategy, simulations predicted that 91% of the passively engaged segment would choose an approach including this active learning option.", [["participants", "SPECIES", 56, 68], ["the medication", "TREATMENT", 14, 28], ["an approach", "TREATMENT", 244, 255], ["this active learning option", "TREATMENT", 266, 293]]], ["The results of simulations reveal attitudinal processes via which highly valued attributes Consistent with HYP 5, simulations predicted that, rather than delegating responsibility for safety to hospital staff, 97.6% of our study participants would prefer partnerships between staff and patients.", [["patients", "ORGANISM", 286, 294], ["participants", "SPECIES", 229, 241], ["patients", "SPECIES", 286, 294], ["attitudinal processes", "PROBLEM", 34, 55], ["HYP 5", "PROBLEM", 107, 112], ["our study", "TEST", 219, 228], ["Consistent with", "UNCERTAINTY", 91, 106]]], ["The strength of this finding is consistent with a study reporting that 91% of a sample of discharged inpatients agreed that patients could contribute to the prevention of health service errors.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["a study", "TEST", 48, 55], ["consistent with", "UNCERTAINTY", 32, 47]]], ["19 rQ 4: What type of engagement strategy do patients prefer?DiscussionHYP 6 postulated that patients would prefer a personal engagement strategy rather than visual safety prompts.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 93, 101], ["a personal engagement strategy", "TREATMENT", 115, 145]]], ["Simulations predicted that 57.5% of the study participants would prefer a personal strategy in which staff engaged patients in safety partnerships.", [["patients", "ORGANISM", 115, 123], ["participants", "SPECIES", 46, 58], ["patients", "SPECIES", 115, 123], ["the study", "TEST", 36, 45]]], ["This is consistent with evidence that encouragement by doctors and nurses may increase participation.", [["consistent with", "UNCERTAINTY", 8, 23]]], ["12 In contrast, 42.4% would prefer an approach with signage reminding patients to ask about safety, report safety concerns, and wash their hands.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["Preference for a visual communication strategy was strongest in the passively engaged segment.", [["a visual communication strategy", "TREATMENT", 15, 46]]], ["We were surprised by the number of participants predicted to choose a visual strategy.", [["participants", "SPECIES", 35, 47]]], ["There may be several explanations for this finding.", [["may be", "UNCERTAINTY", 6, 12]]], ["Patients, for example, may perceive signs to be less of a burden to staff than a personal discussion.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["3 In a sample of 277 health care workers, 26% felt there was insufficient time to encourage patients to ask about hand washing.", [["hand", "ANATOMY", 114, 118], ["patients", "ORGANISM", 92, 100], ["hand", "ORGANISM_SUBDIVISION", 114, 118], ["patients", "SPECIES", 92, 100], ["hand washing", "TREATMENT", 114, 126]]], ["22 Signs may also put less pressure on those who find safety partnerships inconsistent with their perception of the patient's role.", [["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 116, 123], ["less pressure", "OBSERVATION_MODIFIER", 22, 35]]], ["In addition to their alignment with the preferences of a significant number of participants, the signage and visual prompts included in a range of health, safety, and infection control initiatives 56, 57 can simultaneously inform patients, family members, staff, and the administrators who are critical to the success of large-scale safety initiatives.", [["infection", "DISEASE", 167, 176], ["patients", "ORGANISM", 230, 238], ["participants", "SPECIES", 79, 91], ["patients", "SPECIES", 230, 238], ["the signage", "TEST", 93, 104], ["infection control initiatives", "TREATMENT", 167, 196], ["large-scale safety initiatives", "TREATMENT", 321, 351]]], ["39, 58 Signs can be prepared in multiple languages, use an array of interactive strategies, allow patients to review safety recommendations, and facilitate the positioning of reminders at key points along the health service pathway.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["interactive strategies", "TREATMENT", 68, 90]]], ["59 Despite these advantages, effective signage requires careful attention to visual appeal, content, health literacy, and culture; 39,60,61 evidence regarding its unique contribution to hospital safety is lacking.", [["effective signage", "TREATMENT", 29, 46], ["culture", "TEST", 122, 129]]], ["Systematic reviews show that patients are more likely to adhere to health services that are consistent with their preferences.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["Systematic reviews", "TEST", 0, 18]]], ["62, 63 Collaborative decisions, therefore, are more likely to promote the engagement that enhances the patient experience and improves outcome.", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110]]], ["Both segments preferred that all patients were informed about risks to safety.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["segments", "ANATOMY_MODIFIER", 5, 13]]], ["Awareness of risks is associated with greater confidence in one's ability to prevent medical errors.", [["medical errors", "PROBLEM", 85, 99]]], ["21 Confidence in one's ability to prevent medical errors (self-efficacy), in turn, predicts the intent to act preventively.", [["medical errors", "PROBLEM", 42, 56]]], ["21 Both segments preferred that patients report safety concerns directly to staff and that those conveying safety concerns were thanked and told how the hospital will respond.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["Although both segments preferred that patients decide whether to give their names when reporting safety concerns, variations in the anonymity afforded those reporting safety concerns exerted relatively little influence on choices.Discussionlimitations This study was conducted in Ontario, Canada, a province in which local media coverage of issues such as SARS (severe acute respiratory syndrome) and Avian flu might have altered public perceptions of the risks of hospital-acquired infection and the importance of participation in infection control strategies.", [["SARS", "DISEASE", 356, 360], ["acute respiratory syndrome", "DISEASE", 369, 395], ["Avian flu", "DISEASE", 401, 410], ["infection", "DISEASE", 483, 492], ["infection", "DISEASE", 532, 541], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Avian flu", "SPECIES", 401, 410], ["This study", "TEST", 252, 262], ["local media coverage", "TREATMENT", 317, 337], ["SARS (severe acute respiratory syndrome", "PROBLEM", 356, 395], ["Avian flu", "PROBLEM", 401, 410], ["acquired infection", "PROBLEM", 474, 492], ["infection control strategies", "TREATMENT", 532, 560], ["severe", "OBSERVATION_MODIFIER", 362, 368], ["acute", "OBSERVATION_MODIFIER", 369, 374], ["respiratory syndrome", "OBSERVATION", 375, 395], ["infection", "OBSERVATION", 483, 492]]], ["The finding that patients are more likely to engage in safety partnerships that may challenge nurses rather than doctors 66 suggests that future studies should examine preferences for partnerships with different health service providers.DiscussionAlthough the waiting areas in which most surveys were completed may have increased the survey's contextual validity, return rates were reduced: 26% of those prepared to consider participation were called for appointments before completing the survey.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["future studies", "TEST", 138, 152], ["more likely", "UNCERTAINTY", 30, 41]]], ["Because this sample loss was related to organizational factors beyond patient control, it did not, in all probability, represent a systematic enrollment bias.ConclusionParticipants preferred point of contact safety partnerships that might afford an immediate reduction in risk.", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["this sample loss", "PROBLEM", 8, 24], ["organizational factors", "PROBLEM", 40, 62], ["enrollment bias", "OBSERVATION", 142, 157]]], ["Health service providers need to ask patients about their goals and preferences, ensure the safety partnerships available reflect the views of different segments, teach the skills needed to participate, enhance self efficacy, and ensure a receptive response when patients participate or raise safety concerns.", [["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 263, 271]]], ["Respecting individual differences in safety partnership preferences should enhance engagement, improve health outcomes, and contribute to a more positive patient experience.", [["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161]]]], "963898d7cd9a860c0ee13859f33ad0880c03b116": [["MSCs include bone marrow-derived stem cells (BMSCs), MSCs in umbilical cord blood, and adipose-derived stem cells (ASCs).", [["MSCs", "ANATOMY", 0, 4], ["bone marrow-derived stem cells", "ANATOMY", 13, 43], ["BMSCs", "ANATOMY", 45, 50], ["MSCs", "ANATOMY", 53, 57], ["umbilical cord blood", "ANATOMY", 61, 81], ["adipose-derived stem cells", "ANATOMY", 87, 113], ["ASCs", "ANATOMY", 115, 119], ["MSCs", "CELL", 0, 4], ["bone marrow-derived stem cells", "CELL", 13, 43], ["BMSCs", "CELL", 45, 50], ["MSCs", "CELL", 53, 57], ["cord blood", "ORGANISM_SUBSTANCE", 71, 81], ["adipose-derived stem cells", "CELL", 87, 113], ["ASCs", "CELL", 115, 119], ["MSCs", "CELL_TYPE", 0, 4], ["bone marrow-derived stem cells", "CELL_TYPE", 13, 43], ["BMSCs", "CELL_TYPE", 45, 50], ["MSCs", "CELL_TYPE", 53, 57], ["adipose-derived stem cells", "CELL_TYPE", 87, 113], ["ASCs", "CELL_TYPE", 115, 119], ["MSCs", "PROBLEM", 0, 4], ["bone marrow", "TEST", 13, 24], ["BMSCs", "TEST", 45, 50], ["MSCs in umbilical cord blood", "TEST", 53, 81], ["bone", "ANATOMY", 13, 17], ["marrow", "ANATOMY", 18, 24], ["stem cells", "OBSERVATION", 33, 43], ["umbilical cord", "ANATOMY", 61, 75], ["adipose", "ANATOMY", 87, 94], ["stem cells", "OBSERVATION", 103, 113]]], ["In the fi eld of ALI/ARDS cell-based therapeutics, most attention has focused on BMSCs, which have therapeutic effi cacy in rodent and human tissue models of ALI and sepsis [3, 4] .", [["cell", "ANATOMY", 26, 30], ["BMSCs", "ANATOMY", 81, 86], ["tissue", "ANATOMY", 141, 147], ["ALI", "DISEASE", 17, 20], ["ARDS", "DISEASE", 21, 25], ["ALI", "DISEASE", 158, 161], ["sepsis", "DISEASE", 166, 172], ["cell", "CELL", 26, 30], ["BMSCs", "CELL", 81, 86], ["human", "ORGANISM", 135, 140], ["tissue", "TISSUE", 141, 147], ["BMSCs", "CELL_TYPE", 81, 86], ["rodent", "SPECIES", 124, 130], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 135, 140], ["ALI", "PROBLEM", 17, 20], ["ARDS cell", "PROBLEM", 21, 30], ["BMSCs", "TREATMENT", 81, 86], ["ALI", "PROBLEM", 158, 161], ["sepsis", "PROBLEM", 166, 172], ["ALI", "ANATOMY", 17, 20], ["ARDS cell", "OBSERVATION", 21, 30], ["human tissue", "OBSERVATION_MODIFIER", 135, 147], ["ALI", "OBSERVATION", 158, 161], ["sepsis", "OBSERVATION", 166, 172]]], ["However, a number of barriers that may limit the clinical usefulness of BMSCs in human ALI/ARDS have been identifi ed [5, 6] ( Table 1) .", [["BMSCs", "ANATOMY", 72, 77], ["ALI", "DISEASE", 87, 90], ["ARDS", "DISEASE", 91, 95], ["BMSCs", "CELL", 72, 77], ["human", "ORGANISM", 81, 86], ["BMSCs", "CELL_TYPE", 72, 77], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["BMSCs", "PROBLEM", 72, 77], ["ARDS", "PROBLEM", 91, 95], ["ARDS", "OBSERVATION", 91, 95]]], ["Like BMSCs, ASCs have anti-infl ammatory and immuno-suppressive activities.", [["BMSCs", "ANATOMY", 5, 10], ["ASCs", "ANATOMY", 12, 16], ["BMSCs", "CELL", 5, 10], ["ASCs", "CELL", 12, 16], ["BMSCs", "CELL_TYPE", 5, 10], ["ASCs", "CELL_TYPE", 12, 16], ["ASCs", "PROBLEM", 12, 16], ["anti-infl ammatory", "TREATMENT", 22, 40], ["immuno-suppressive activities", "TREATMENT", 45, 74]]], ["ASCs inhibit immune cell activation and proliferation by inducing cell-to-cell contact and signaling and releasing mediators that limit tissue injury [7] .", [["ASCs", "ANATOMY", 0, 4], ["immune cell", "ANATOMY", 13, 24], ["cell", "ANATOMY", 66, 70], ["cell", "ANATOMY", 74, 78], ["tissue", "ANATOMY", 136, 142], ["ASCs", "CELL", 0, 4], ["immune cell", "CELL", 13, 24], ["cell", "CELL", 66, 70], ["cell", "CELL", 74, 78], ["tissue", "TISSUE", 136, 142], ["ASCs", "CELL_TYPE", 0, 4], ["ASCs", "PROBLEM", 0, 4], ["immune cell activation", "PROBLEM", 13, 35], ["proliferation", "PROBLEM", 40, 53], ["tissue injury", "PROBLEM", 136, 149], ["immune cell activation", "OBSERVATION", 13, 35], ["limit tissue", "OBSERVATION_MODIFIER", 130, 142]]], ["ASCs have greater anti-infl ammatory potential than BMSCs because they secrete higher levels of bioactive mediators [8] .", [["ASCs", "ANATOMY", 0, 4], ["BMSCs", "ANATOMY", 52, 57], ["ASCs", "CELL", 0, 4], ["BMSCs", "CELL", 52, 57], ["ASCs", "CELL_TYPE", 0, 4], ["BMSCs", "CELL_TYPE", 52, 57], ["ASCs", "PROBLEM", 0, 4], ["BMSCs", "TREATMENT", 52, 57]]], ["Th is and other properties of ASCs (Table 1 ) make them an attractive alternative to BMSCs as cell-based therapeutics for human ALI/ARDS.", [["ASCs", "ANATOMY", 30, 34], ["BMSCs", "ANATOMY", 85, 90], ["cell", "ANATOMY", 94, 98], ["ALI", "DISEASE", 128, 131], ["ARDS", "DISEASE", 132, 136], ["ASCs", "CELL", 30, 34], ["BMSCs", "CELL", 85, 90], ["cell", "CELL", 94, 98], ["human", "ORGANISM", 122, 127], ["ASCs", "CELL_TYPE", 30, 34], ["BMSCs", "CELL_TYPE", 85, 90], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 122, 127], ["human ALI", "PROBLEM", 122, 131], ["ARDS", "PROBLEM", 132, 136], ["ARDS", "OBSERVATION", 132, 136]]], ["Consistent with this concept, recent studies have shown that transplantation of autologous ASCs attenuates ischemia-reperfusion lung injury in rodents [9, 10] .", [["ASCs", "ANATOMY", 91, 95], ["lung", "ANATOMY", 128, 132], ["lung injury", "DISEASE", 128, 139], ["ASCs", "CELL", 91, 95], ["lung", "ORGAN", 128, 132], ["autologous ASCs", "CELL_TYPE", 80, 95], ["recent studies", "TEST", 30, 44], ["transplantation of autologous ASCs", "TREATMENT", 61, 95], ["ischemia-reperfusion lung injury", "PROBLEM", 107, 139], ["autologous ASCs", "OBSERVATION", 80, 95], ["ischemia-reperfusion", "OBSERVATION_MODIFIER", 107, 127], ["lung", "ANATOMY", 128, 132], ["injury", "OBSERVATION", 133, 139]]]], "PMC3503966": [["IntroductionSevere Acute Respiratory Syndrome Coronavirus (SARS-CoV) infection in humans results in Acute Respiratory Distress Syndrome (ARDS) in 20\u201330% of patients with 10% mortality [1].", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 19, 57], ["SARS-CoV) infection", "DISEASE", 59, 78], ["Acute Respiratory Distress Syndrome", "DISEASE", 100, 135], ["ARDS", "DISEASE", 137, 141], ["SARS-CoV", "ORGANISM", 59, 67], ["humans", "ORGANISM", 82, 88], ["patients", "ORGANISM", 156, 164], ["humans", "SPECIES", 82, 88], ["patients", "SPECIES", 156, 164], ["Acute Respiratory Syndrome Coronavirus (SARS-CoV", "SPECIES", 19, 67], ["humans", "SPECIES", 82, 88], ["Acute Respiratory Syndrome", "PROBLEM", 19, 45], ["Coronavirus (SARS-CoV) infection in humans", "PROBLEM", 46, 88], ["Acute Respiratory Distress Syndrome", "PROBLEM", 100, 135], ["ARDS", "PROBLEM", 137, 141], ["Acute", "OBSERVATION_MODIFIER", 19, 24], ["Respiratory Syndrome", "OBSERVATION", 25, 45], ["Acute", "OBSERVATION_MODIFIER", 100, 105], ["Respiratory Distress", "OBSERVATION", 106, 126]]], ["Passive antibody therapy has been successfully used to treat patients infected with SARS-CoV [2]\u2013[4], and to confer protection against lethal challenge in experimental animals [5].", [["SARS", "DISEASE", 84, 88], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 84, 92], ["Passive antibody therapy", "TREATMENT", 0, 24], ["SARS", "PROBLEM", 84, 88]]], ["Re-emergence of SARS in humans remains a credible health threat because of the animal reservoirs [6]\u2013[9].", [["SARS", "DISEASE", 16, 20], ["humans", "ORGANISM", 24, 30], ["humans", "SPECIES", 24, 30], ["humans", "SPECIES", 24, 30], ["SARS", "PROBLEM", 16, 20], ["the animal reservoirs", "TREATMENT", 75, 96], ["SARS", "OBSERVATION", 16, 20]]], ["As of now, there is no effective treatment for SARS.", [["SARS", "DISEASE", 47, 51], ["effective treatment", "TREATMENT", 23, 42], ["SARS", "PROBLEM", 47, 51], ["no", "UNCERTAINTY", 20, 22], ["effective", "OBSERVATION_MODIFIER", 23, 32]]], ["However, since virus titer peaks 10 days post-infection [1], [10], post-exposure treatment that is effective against a broad spectrum of viral variants remains a viable option.", [["infection", "DISEASE", 46, 55], ["virus titer peaks", "PROBLEM", 15, 32], ["post-infection", "PROBLEM", 41, 55], ["post-exposure treatment", "TREATMENT", 67, 90], ["viral variants", "PROBLEM", 137, 151], ["viral variants", "OBSERVATION", 137, 151]]], ["Many of the reported HmAbs against SARS-CoV fail to neutralize all of the clinical isolates [11]\u2013[13].", [["SARS", "DISEASE", 35, 39], ["HmAbs", "GENE_OR_GENE_PRODUCT", 21, 26], ["SARS-CoV", "ORGANISM", 35, 43], ["HmAbs", "PROTEIN", 21, 26], ["SARS-CoV", "SPECIES", 35, 43], ["SARS", "PROBLEM", 35, 39], ["CoV fail", "PROBLEM", 40, 48], ["the clinical isolates", "TEST", 70, 91]]], ["Therefore, there is a need for a clinically usable therapy against SARS-CoV infection.IntroductionThe Spike (S) glycoprotein plays an essential role in receptor binding and membrane fusion critical for the virus entry, and contains epitopes that elicit neutralizing Abs [14]\u2013[17].", [["membrane", "ANATOMY", 173, 181], ["SARS-CoV infection", "DISEASE", 67, 85], ["SARS-CoV", "ORGANISM", 67, 75], ["Spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 102, 124], ["membrane", "CELLULAR_COMPONENT", 173, 181], ["Spike (S) glycoprotein", "PROTEIN", 102, 124], ["epitopes", "PROTEIN", 232, 240], ["SARS-CoV", "SPECIES", 67, 75], ["a clinically usable therapy", "TREATMENT", 31, 58], ["SARS", "PROBLEM", 67, 71], ["CoV infection", "PROBLEM", 72, 85], ["The Spike (S) glycoprotein", "TREATMENT", 98, 124], ["receptor binding", "TREATMENT", 152, 168], ["membrane fusion", "TREATMENT", 173, 188], ["the virus entry", "TREATMENT", 202, 217], ["neutralizing Abs", "TEST", 253, 269], ["infection", "OBSERVATION", 76, 85]]], ["The SARS-CoV S protein consists of two functional domains, S1 (amino acids 12\u2013680) and S2 (amino acids 681\u20131255) [18].", [["amino acids 12\u2013680", "CHEMICAL", 63, 81], ["amino acids 681\u20131255", "CHEMICAL", 91, 111], ["amino acids", "CHEMICAL", 63, 74], ["amino acids", "CHEMICAL", 91, 102], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["amino acids", "AMINO_ACID", 63, 74], ["12\u2013680", "AMINO_ACID", 75, 81], ["amino acids", "AMINO_ACID", 91, 102], ["SARS-CoV S protein", "PROTEIN", 4, 22], ["S1", "PROTEIN", 59, 61], ["amino acids 12\u2013680", "PROTEIN", 63, 81], ["S2", "PROTEIN", 87, 89], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV S protein", "TEST", 9, 22], ["amino acids", "TEST", 63, 74], ["S2 (amino acids", "TEST", 87, 102]]], ["The receptor binding domain (RBD) (amino acids 318\u2013510) contained within the S1 domain is required for binding to ACE-2 receptor on the cell surface and is thought to contain the majority of neutralizing epitopes [14], [19], [20].", [["cell surface", "ANATOMY", 136, 148], ["amino acids 318\u2013510", "CHEMICAL", 35, 54], ["amino acids", "CHEMICAL", 35, 46], ["amino acids", "AMINO_ACID", 35, 46], ["318\u2013510", "AMINO_ACID", 47, 54], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 114, 128], ["cell surface", "CELLULAR_COMPONENT", 136, 148], ["[19]", "SIMPLE_CHEMICAL", 219, 223], ["[20]", "SIMPLE_CHEMICAL", 225, 229], ["receptor binding domain", "PROTEIN", 4, 27], ["RBD", "PROTEIN", 29, 32], ["amino acids 318\u2013510", "PROTEIN", 35, 54], ["S1 domain", "PROTEIN", 77, 86], ["ACE-2 receptor", "PROTEIN", 114, 128], ["amino acids", "TEST", 35, 46], ["ACE", "TEST", 114, 117], ["neutralizing epitopes", "PROBLEM", 191, 212], ["S1", "ANATOMY", 77, 79]]], ["Co-crystallization of the RBD and human ACE-2 identified the receptor binding motif (RBM) (amino acids 424\u2013494) in direct contact with ACE2 [18].", [["amino acids 424\u2013494", "CHEMICAL", 91, 110], ["amino acids", "CHEMICAL", 91, 102], ["human", "ORGANISM", 34, 39], ["ACE-2", "GENE_OR_GENE_PRODUCT", 40, 45], ["amino acids", "AMINO_ACID", 91, 102], ["424\u2013494", "AMINO_ACID", 103, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["RBD", "PROTEIN", 26, 29], ["human ACE-2", "PROTEIN", 34, 45], ["receptor binding motif", "PROTEIN", 61, 83], ["RBM", "PROTEIN", 85, 88], ["ACE2", "PROTEIN", 135, 139], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["the RBD", "PROBLEM", 22, 29], ["human ACE", "TREATMENT", 34, 43], ["the receptor binding motif (RBM", "TREATMENT", 57, 88], ["amino acids", "TEST", 91, 102], ["ACE2", "TEST", 135, 139], ["RBD", "OBSERVATION", 26, 29]]], ["The S2 domain contains the fusion peptide followed by two conserved heptad repeats (i.e. HR1 and HR2), which upon cleavage by cathepsin-L associate to form a fusion core [15], [18], [21]\u2013[23], and facilitate fusion with the cell membrane required for the virus entry [24].", [["cell membrane", "ANATOMY", 224, 237], ["HR1", "GENE_OR_GENE_PRODUCT", 89, 92], ["HR2", "GENE_OR_GENE_PRODUCT", 97, 100], ["cathepsin-L", "GENE_OR_GENE_PRODUCT", 126, 137], ["[18], [21]\u2013[23]", "SIMPLE_CHEMICAL", 176, 191], ["cell membrane", "CELLULAR_COMPONENT", 224, 237], ["S2 domain", "PROTEIN", 4, 13], ["heptad repeats", "PROTEIN", 68, 82], ["HR1", "PROTEIN", 89, 92], ["HR2", "PROTEIN", 97, 100], ["cathepsin-L", "PROTEIN", 126, 137], ["the fusion peptide", "TREATMENT", 23, 41], ["heptad repeats", "TEST", 68, 82], ["cathepsin", "TEST", 126, 135], ["a fusion core", "TEST", 156, 169], ["the cell membrane", "TREATMENT", 220, 237], ["fusion", "OBSERVATION", 27, 33]]], ["Synthetic HR2 peptides as well as HR2 specific antibodies have been shown to block SARS-CoV infection [25]\u2013[27].", [["SARS-CoV infection", "DISEASE", 83, 101], ["HR2 peptides", "GENE_OR_GENE_PRODUCT", 10, 22], ["HR2", "GENE_OR_GENE_PRODUCT", 34, 37], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 83, 91], ["HR2", "PROTEIN", 10, 13], ["HR2 specific antibodies", "PROTEIN", 34, 57], ["SARS-CoV", "SPECIES", 83, 91], ["Synthetic HR2 peptides", "TREATMENT", 0, 22], ["HR2 specific antibodies", "TEST", 34, 57], ["block SARS", "PROBLEM", 77, 87], ["CoV infection", "PROBLEM", 88, 101]]], ["The RBD shows high rates of mutation which allows the virus to escape neutralization by Abs without losing its ability to infect cells [13], [28].", [["cells", "ANATOMY", 129, 134], ["RBD", "DISEASE", 4, 7], ["cells", "CELL", 129, 134], ["RBD", "PROTEIN", 4, 7], ["Abs", "PROTEIN", 88, 91], ["The RBD", "TEST", 0, 7], ["high rates of mutation", "PROBLEM", 14, 36], ["the virus", "PROBLEM", 50, 59], ["escape neutralization", "TREATMENT", 63, 84], ["high rates", "OBSERVATION", 14, 24]]], ["In contrast, the S2 domain is highly conserved among different clinical isolates of the SARS-CoV [29], [30], and thus raise the possibility that Abs against this region may confer better protection against a broad spectrum of clinical isolates.IntroductionPreviously, using Xenomouse (mouse immunoglobulin genes were replaced by human immunoglobulin genes) immunized with SARS-CoV Urbani strain S protein ectodomain, we produced a panel of 19 neutralizing HmAbs and found that they all bound to the S1 region of the S protein [19].", [["SARS", "DISEASE", 88, 92], ["S2", "GENE_OR_GENE_PRODUCT", 17, 19], ["SARS-CoV", "ORGANISM", 88, 96], ["Abs", "GENE_OR_GENE_PRODUCT", 145, 148], ["mouse", "ORGANISM", 285, 290], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 291, 305], ["human", "ORGANISM", 329, 334], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 335, 349], ["SARS-CoV Urbani", "ORGANISM", 372, 387], ["HmAbs", "GENE_OR_GENE_PRODUCT", 456, 461], ["S2 domain", "PROTEIN", 17, 26], ["Abs", "PROTEIN", 145, 148], ["Xenomouse", "DNA", 274, 283], ["mouse immunoglobulin genes", "DNA", 285, 311], ["human immunoglobulin genes", "DNA", 329, 355], ["SARS-CoV Urbani strain S protein ectodomain", "PROTEIN", 372, 415], ["HmAbs", "PROTEIN", 456, 461], ["S1 region", "PROTEIN", 499, 508], ["S protein", "PROTEIN", 516, 525], ["mouse", "SPECIES", 285, 290], ["human", "SPECIES", 329, 334], ["CoV Urbani", "SPECIES", 377, 387], ["SARS-CoV", "SPECIES", 88, 96], ["mouse", "SPECIES", 285, 290], ["human", "SPECIES", 329, 334], ["SARS-CoV", "SPECIES", 372, 380], ["the SARS", "TEST", 84, 92], ["Abs against this region", "PROBLEM", 145, 168], ["Xenomouse (mouse immunoglobulin genes", "TREATMENT", 274, 311], ["human immunoglobulin genes", "TREATMENT", 329, 355], ["SARS", "PROBLEM", 372, 376], ["a panel", "TEST", 429, 436], ["neutralizing HmAbs", "TEST", 443, 461], ["S2", "ANATOMY", 17, 19], ["raise the possibility", "UNCERTAINTY", 118, 139], ["S1", "ANATOMY", 499, 501]]], ["We found that 18 HmAbs bound to RBD and neutralized the virus by blocking virus binding to the ACE-2 receptor, while one HmAb (4D4) neutralized the virus by inhibiting a post-binding event [11].", [["HmAbs", "CHEMICAL", 17, 22], ["HmAbs", "GENE_OR_GENE_PRODUCT", 17, 22], ["RBD", "GENE_OR_GENE_PRODUCT", 32, 35], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 95, 109], ["HmAb", "GENE_OR_GENE_PRODUCT", 121, 125], ["HmAbs", "PROTEIN", 17, 22], ["RBD", "PROTEIN", 32, 35], ["ACE-2 receptor", "PROTEIN", 95, 109], ["HmAb (4D4)", "PROTEIN", 121, 131], ["18 HmAbs bound to RBD", "PROBLEM", 14, 35], ["the virus", "PROBLEM", 52, 61], ["blocking virus binding", "PROBLEM", 65, 87], ["the ACE", "TEST", 91, 98], ["the virus", "PROBLEM", 144, 153]]], ["In this study, we describe neutralizing HmAbs that specifically bind to S2 region and found that these HmAbs, unlike S1 specific HmAbs, were better able to neutralize a broader range of surrogate clinical isolates.Construction of Expression Plasmids for SARS-CoV 12-510 S1-IgG and Full Length Spike (S) Protein Mutants ::: Materials and MethodsThe expression plasmid encoding 12-510 S1 fragment of SARS-CoV Urbani Spike (S) protein, with an N terminal C5 signal sequence and a C-terminal human IgG Fc [14], was used as a template in site directed mutagenesis PCR using QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene) to generate Sin845, GZ-C, GDO1, and GZ0402 mutants.", [["N", "CHEMICAL", 441, 442], ["C", "CHEMICAL", 477, 478], ["HmAbs", "GENE_OR_GENE_PRODUCT", 40, 45], ["S2", "GENE_OR_GENE_PRODUCT", 72, 74], ["HmAbs", "GENE_OR_GENE_PRODUCT", 103, 108], ["HmAbs", "GENE_OR_GENE_PRODUCT", 129, 134], ["IgG", "GENE_OR_GENE_PRODUCT", 273, 276], ["SARS-CoV Urbani Spike (S)", "GENE_OR_GENE_PRODUCT", 398, 423], ["human", "ORGANISM", 488, 493], ["Sin845", "GENE_OR_GENE_PRODUCT", 645, 651], ["GZ-C", "GENE_OR_GENE_PRODUCT", 653, 657], ["GDO1", "GENE_OR_GENE_PRODUCT", 659, 663], ["GZ0402", "GENE_OR_GENE_PRODUCT", 669, 675], ["HmAbs", "PROTEIN", 40, 45], ["S2 region", "PROTEIN", 72, 81], ["HmAbs", "PROTEIN", 103, 108], ["S1", "PROTEIN", 117, 119], ["HmAbs", "PROTEIN", 129, 134], ["Expression Plasmids", "DNA", 230, 249], ["SARS-CoV 12-510 S1-IgG and Full Length Spike (S) Protein Mutants", "DNA", 254, 318], ["expression plasmid", "DNA", 348, 366], ["12-510 S1 fragment", "DNA", 376, 394], ["SARS-CoV Urbani Spike (S) protein", "PROTEIN", 398, 431], ["N terminal C5 signal sequence", "PROTEIN", 441, 470], ["C-terminal human IgG Fc", "PROTEIN", 477, 500], ["human", "SPECIES", 488, 493], ["SARS-CoV", "SPECIES", 254, 262], ["SARS-CoV", "SPECIES", 398, 406], ["human", "SPECIES", 488, 493], ["this study", "TEST", 3, 13], ["neutralizing HmAbs", "PROBLEM", 27, 45], ["these HmAbs", "TEST", 97, 108], ["Expression Plasmids", "TREATMENT", 230, 249], ["SARS", "TEST", 254, 258], ["CoV", "TEST", 259, 262], ["S1-IgG", "TEST", 270, 276], ["Full Length Spike", "TEST", 281, 298], ["Protein Mutants", "TEST", 303, 318], ["SARS", "TEST", 398, 402], ["CoV Urbani Spike (S) protein", "TEST", 403, 431], ["an N terminal C5 signal sequence", "TEST", 438, 470], ["a C-terminal human IgG Fc", "TREATMENT", 475, 500], ["a template in site directed mutagenesis PCR", "TREATMENT", 519, 562], ["Directed Mutagenesis Kit (Stratagene)", "TREATMENT", 595, 632], ["GZ", "TEST", 653, 655], ["GDO1", "TEST", 659, 663]]], ["The same procedure and primers were used for the generation of the full length S protein mutant constructs using the pcDNA3.1- S, coding for the full length SARS-CoV S protein with a C-terminal (C9) tag derived from human rhodopsin protein, as a template.Construction of S-ectodomain, S2, HR1 and HR2 Domains Expression Plasmids ::: Materials and MethodsThe pcDNA3.1 S encoding the full length S protein of SARS-CoV was used as a template in a PCR reaction to amplify the S-ectodomain (residues 12-1184), the S2 (residues 700-1184), the HR1 (residues 901-1040), and the HR2 (residues 1141-1184) domains.", [["C", "CHEMICAL", 183, 184], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 117, 123], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 157, 167], ["human", "ORGANISM", 216, 221], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 222, 231], ["S-ectodomain", "GENE_OR_GENE_PRODUCT", 271, 283], ["S2", "GENE_OR_GENE_PRODUCT", 285, 287], ["HR1", "GENE_OR_GENE_PRODUCT", 289, 292], ["HR2", "GENE_OR_GENE_PRODUCT", 297, 300], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 358, 366], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 407, 415], ["full length S protein mutant constructs", "DNA", 67, 106], ["pcDNA3", "DNA", 117, 123], ["full length SARS-CoV S protein", "PROTEIN", 145, 175], ["C-terminal (C9) tag", "PROTEIN", 183, 202], ["human rhodopsin protein", "PROTEIN", 216, 239], ["S-ectodomain", "PROTEIN", 271, 283], ["S2", "PROTEIN", 285, 287], ["HR1", "PROTEIN", 289, 292], ["HR2", "PROTEIN", 297, 300], ["pcDNA3.1", "DNA", 358, 366], ["full length S protein", "PROTEIN", 382, 403], ["SARS-CoV", "PROTEIN", 407, 415], ["S-ectodomain", "DNA", 472, 484], ["residues 12-1184", "PROTEIN", 486, 502], ["S2", "PROTEIN", 509, 511], ["HR1", "PROTEIN", 537, 540], ["HR2", "PROTEIN", 570, 573], ["residues 1141-1184) domains", "PROTEIN", 575, 602], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 216, 221], ["SARS-CoV", "SPECIES", 407, 415], ["The same procedure", "TREATMENT", 0, 18], ["primers", "TREATMENT", 23, 30], ["the full length S protein mutant constructs", "TREATMENT", 63, 106], ["the pcDNA3", "TREATMENT", 113, 123], ["the full length SARS", "TEST", 141, 161], ["CoV S protein", "TEST", 162, 175], ["a C-terminal (C9) tag", "TREATMENT", 181, 202], ["human rhodopsin protein", "TREATMENT", 216, 239], ["SARS", "PROBLEM", 407, 411], ["CoV", "PROBLEM", 412, 415], ["a PCR reaction", "PROBLEM", 442, 456], ["the HR2 (residues", "TEST", 566, 583], ["S2", "ANATOMY", 285, 287]]], ["All the forward primers were designed with a 5\u2032 NheI site while the reverse primers were designed with a 5\u2032 BamHI site.", [["NheI", "GENE_OR_GENE_PRODUCT", 48, 52], ["BamHI", "GENE_OR_GENE_PRODUCT", 108, 113], ["NheI site", "DNA", 48, 57], ["reverse primers", "DNA", 68, 83], ["BamHI site", "DNA", 108, 118], ["BamHI site", "PROBLEM", 108, 118]]], ["The PCR products were then cloned in frame into the C-terminus IgG tag mammalian expression vector [14].Expression and Purification of SARS-CoV12-510 S1-IgG Urbani and Mutant Proteins as well as S-ectodomain, S1, S2, HR1 and HR2 Domain Proteins ::: Materials and MethodsThe plasmids coding for 12-510 S1-IgG proteins as well as the S protein truncations (S-ectodomain, S2, HR1 and HR2 domains) were used to transfect 293FT cells by calcium phosphate transfection method and the proteins were purified using protein A agarose beads as described previously [19].", [["plasmids", "ANATOMY", 274, 282], ["293FT cells", "ANATOMY", 417, 428], ["calcium phosphate", "CHEMICAL", 432, 449], ["calcium phosphate", "CHEMICAL", 432, 449], ["IgG", "GENE_OR_GENE_PRODUCT", 153, 156], ["S-ectodomain", "GENE_OR_GENE_PRODUCT", 195, 207], ["S1", "GENE_OR_GENE_PRODUCT", 209, 211], ["S2", "GENE_OR_GENE_PRODUCT", 213, 215], ["HR1", "GENE_OR_GENE_PRODUCT", 217, 220], ["HR2", "GENE_OR_GENE_PRODUCT", 225, 228], ["IgG", "GENE_OR_GENE_PRODUCT", 304, 307], ["HR1", "GENE_OR_GENE_PRODUCT", 373, 376], ["HR2", "GENE_OR_GENE_PRODUCT", 381, 384], ["293FT cells", "CELL", 417, 428], ["calcium", "SIMPLE_CHEMICAL", 432, 439], ["PCR products", "DNA", 4, 16], ["C-terminus IgG tag mammalian expression vector", "DNA", 52, 98], ["SARS-CoV12-510 S1-IgG Urbani", "PROTEIN", 135, 163], ["Mutant Proteins", "PROTEIN", 168, 183], ["S-ectodomain", "PROTEIN", 195, 207], ["S1", "PROTEIN", 209, 211], ["S2", "PROTEIN", 213, 215], ["HR1", "PROTEIN", 217, 220], ["HR2", "PROTEIN", 225, 228], ["plasmids", "DNA", 274, 282], ["12-510 S1", "DNA", 294, 303], ["IgG proteins", "PROTEIN", 304, 316], ["S protein truncations", "PROTEIN", 332, 353], ["S-ectodomain", "PROTEIN", 355, 367], ["S2", "PROTEIN", 369, 371], ["HR1", "PROTEIN", 373, 376], ["HR2 domains", "PROTEIN", 381, 392], ["293FT cells", "CELL_LINE", 417, 428], ["The PCR products", "TREATMENT", 0, 16], ["the C-terminus IgG tag mammalian expression vector", "TREATMENT", 48, 98], ["SARS", "TEST", 135, 139], ["CoV12", "TEST", 140, 145], ["S1", "TEST", 150, 152], ["IgG Urbani", "TEST", 153, 163], ["Mutant Proteins", "TEST", 168, 183], ["S-ectodomain", "TEST", 195, 207], ["S1-IgG proteins", "TEST", 301, 316], ["the S protein truncations", "TEST", 328, 353], ["S-ectodomain", "TEST", 355, 367], ["S2", "TEST", 369, 371], ["HR1", "TEST", 373, 376], ["calcium phosphate transfection method", "TREATMENT", 432, 469], ["the proteins", "TEST", 474, 486], ["protein A agarose beads", "TREATMENT", 507, 530], ["S1", "ANATOMY", 209, 211], ["S2", "ANATOMY", 213, 215]]], ["The purified proteins were concentrated through Centricon filters (Millipore, Bedford, MA) then detected by Coomassie blue staining (Bio-Rad, Hercules, CA) following separation on a 4\u201315% SDS/PAGE gel.", [["Coomassie blue", "CHEMICAL", 108, 122], ["SDS", "CHEMICAL", 188, 191], ["Coomassie", "SIMPLE_CHEMICAL", 108, 117], ["purified proteins", "PROTEIN", 4, 21], ["The purified proteins", "TREATMENT", 0, 21], ["Centricon filters", "TREATMENT", 48, 65], ["Coomassie blue staining", "TEST", 108, 131], ["Bio", "TEST", 133, 136], ["a 4\u201315% SDS/PAGE gel", "TREATMENT", 180, 200]]], ["The expression was further confirmed by western blot using polyclonal goat anti-human IgG Fc HRP antibody (Promega).Purification of the Non S1 Binding and Neutralizing Human mAbs ::: Materials and MethodsHybridomas of 56 neutralizing non S1 binding HmAbs were cloned by limiting dilution and the clones were cultured in DMEM medium supplemented with 10% Fetal clone (Hyclone laboratories, Logan, Utah) to produce large quantities of HmAbs.", [["clones", "ANATOMY", 296, 302], ["HRP", "GENE_OR_GENE_PRODUCT", 93, 96], ["Human", "ORGANISM", 168, 173], ["HmAbs", "GENE_OR_GENE_PRODUCT", 249, 254], ["clones", "CELL", 296, 302], ["Fetal clone", "CELL", 354, 365], ["HmAbs", "GENE_OR_GENE_PRODUCT", 433, 438], ["polyclonal goat anti-human IgG Fc HRP antibody", "PROTEIN", 59, 105], ["Non S1 Binding and Neutralizing Human mAbs", "PROTEIN", 136, 178], ["S1 binding HmAbs", "DNA", 238, 254], ["HmAbs", "PROTEIN", 433, 438], ["goat", "SPECIES", 70, 74], ["Human", "SPECIES", 168, 173], ["goat", "SPECIES", 70, 74], ["Human", "SPECIES", 168, 173], ["western blot", "TEST", 40, 52], ["polyclonal goat anti-human IgG", "TREATMENT", 59, 89], ["HRP antibody", "TEST", 93, 105], ["MethodsHybridomas", "TEST", 197, 214], ["neutralizing non S1 binding HmAbs", "TREATMENT", 221, 254], ["the clones", "TREATMENT", 292, 302], ["large quantities of HmAbs", "PROBLEM", 413, 438], ["large", "OBSERVATION_MODIFIER", 413, 418]]], ["The HmAbs were purified using protein-A agarose beads.", [["HmAbs", "GENE_OR_GENE_PRODUCT", 4, 9], ["HmAbs", "PROTEIN", 4, 9], ["The HmAbs", "TEST", 0, 9], ["protein", "TEST", 30, 37], ["A agarose beads", "TREATMENT", 38, 53]]], ["Thirty nine HmAbs were successfully purified and the Ab production was confirmed by 4\u201315% SDS/PAGE followed by Coomassie blue staining.", [["Coomassie blue", "CHEMICAL", 111, 125], ["HmAbs", "GENE_OR_GENE_PRODUCT", 12, 17], ["Ab", "GENE_OR_GENE_PRODUCT", 53, 55], ["Coomassie", "SIMPLE_CHEMICAL", 111, 120], ["HmAbs", "PROTEIN", 12, 17], ["the Ab production", "TEST", 49, 66]]], ["The antibody concentration was measured at 280 nm using the Biomate3S UV-Visible Spectrophotometer (ThermoScientific).", [["The antibody concentration", "TEST", 0, 26], ["the Biomate3S UV", "TREATMENT", 56, 72], ["Visible Spectrophotometer", "OBSERVATION", 73, 98]]], ["All HmAbs were diluted to a final concentration of 50 \u00b5g/ml.Enzyme Linked Immunosorbent Assay (ELISA) ::: Materials and MethodsMedisorp ELISA plates (Nunc, Roskilde, Denmark) were coated with 100 ng/well of 12-510 S1-IgG Urbani protein as well as mutant proteins (Sin845, GZ-C, GD01 and GZ0402) overnight at 4\u00b0C. The binding of the 18 HmAbs were tested by ELISA as described previously using antihuman IgG2 HRP mouse monoclonal antibody as the secondary antibody (SouthernBiotech, Birmingham, AL) [19].", [["HmAbs", "SIMPLE_CHEMICAL", 4, 9], ["GZ-C", "SIMPLE_CHEMICAL", 272, 276], ["GZ0402", "SIMPLE_CHEMICAL", 287, 293], ["HmAbs", "GENE_OR_GENE_PRODUCT", 335, 340], ["IgG2", "GENE_OR_GENE_PRODUCT", 402, 406], ["mouse", "ORGANISM", 411, 416], ["HmAbs", "PROTEIN", 4, 9], ["IgG Urbani protein", "PROTEIN", 217, 235], ["mutant proteins", "PROTEIN", 247, 262], ["Sin845", "PROTEIN", 264, 270], ["GZ", "PROTEIN", 272, 274], ["C", "PROTEIN", 275, 276], ["GD01", "PROTEIN", 278, 282], ["GZ0402", "PROTEIN", 287, 293], ["18 HmAbs", "PROTEIN", 332, 340], ["antihuman IgG2 HRP mouse monoclonal antibody", "PROTEIN", 392, 436], ["secondary antibody", "PROTEIN", 444, 462], ["mouse", "SPECIES", 411, 416], ["mouse", "SPECIES", 411, 416], ["All HmAbs", "TREATMENT", 0, 9], ["Enzyme", "TEST", 60, 66], ["Immunosorbent Assay", "TEST", 74, 93], ["MethodsMedisorp ELISA plates", "TREATMENT", 120, 148], ["IgG Urbani protein", "TEST", 217, 235], ["mutant proteins", "TEST", 247, 262], ["GZ", "TEST", 272, 274], ["GD01", "TEST", 278, 282], ["GZ0402", "TEST", 287, 293], ["ELISA", "TEST", 356, 361], ["antihuman IgG2", "TEST", 392, 406], ["monoclonal antibody", "TEST", 417, 436]]], ["The same procedure was followed for testing the binding of 39 non S1 neutralizing HmAbs against S protein ectodomain, S2, HR1, HR2 and S1 domain proteins.Production of Urbani and Different Mutant Pseudotyped Viruses ::: Materials and MethodsPseudotyped viruses were generated by co-transfection of 293FT producer cells (grown in DMEM with 10% FBS) with pHIV-GFP-luc expression vector, pgagpol HIV vector, pHIV-Rev and pHIV-TAT [31], along with the pcDNA3.1-S coding for the SARS-CoV S protein using calcium phosphate transfection according to the previously described protocol [19].", [["293FT producer cells", "ANATOMY", 298, 318], ["FBS", "ANATOMY", 343, 346], ["calcium phosphate", "CHEMICAL", 499, 516], ["calcium phosphate", "CHEMICAL", 499, 516], ["HmAbs", "GENE_OR_GENE_PRODUCT", 82, 87], ["S2", "GENE_OR_GENE_PRODUCT", 118, 120], ["HR1", "GENE_OR_GENE_PRODUCT", 122, 125], ["HR2", "GENE_OR_GENE_PRODUCT", 127, 130], ["293FT producer cells", "CELL", 298, 318], ["FBS", "ORGANISM_SUBSTANCE", 343, 346], ["GFP", "GENE_OR_GENE_PRODUCT", 358, 361], ["luc", "GENE_OR_GENE_PRODUCT", 362, 365], ["pgagpol", "GENE_OR_GENE_PRODUCT", 385, 392], ["pHIV-Rev", "GENE_OR_GENE_PRODUCT", 405, 413], ["pHIV-TAT", "GENE_OR_GENE_PRODUCT", 418, 426], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 448, 454], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 474, 484], ["calcium", "SIMPLE_CHEMICAL", 499, 506], ["HmAbs", "PROTEIN", 82, 87], ["S protein ectodomain", "PROTEIN", 96, 116], ["S2", "PROTEIN", 118, 120], ["HR1", "PROTEIN", 122, 125], ["HR2", "PROTEIN", 127, 130], ["S1 domain proteins", "PROTEIN", 135, 153], ["293FT producer cells", "CELL_LINE", 298, 318], ["pHIV-GFP-luc expression vector", "DNA", 353, 383], ["pgagpol HIV vector", "DNA", 385, 403], ["pHIV", "DNA", 405, 409], ["Rev", "DNA", 410, 413], ["pHIV", "DNA", 418, 422], ["TAT [31]", "DNA", 423, 431], ["pcDNA3", "DNA", 448, 454], ["SARS-CoV S protein", "PROTEIN", 474, 492], ["HIV", "SPECIES", 393, 396], ["SARS-CoV", "SPECIES", 474, 482], ["The same procedure", "TREATMENT", 0, 18], ["testing the binding", "TEST", 36, 55], ["S1 neutralizing HmAbs", "TEST", 66, 87], ["S protein ectodomain", "TEST", 96, 116], ["S2", "TEST", 118, 120], ["HR1", "TEST", 122, 125], ["HR2", "TEST", 127, 130], ["Production of Urbani", "PROBLEM", 154, 174], ["MethodsPseudotyped viruses", "PROBLEM", 234, 260], ["DMEM", "TEST", 329, 333], ["FBS", "TEST", 343, 346], ["pHIV", "TEST", 353, 357], ["GFP", "TEST", 358, 361], ["pHIV", "TEST", 405, 409], ["the pcDNA3", "TREATMENT", 444, 454], ["the SARS", "TEST", 470, 478], ["CoV S protein", "TREATMENT", 479, 492], ["calcium phosphate transfection", "TREATMENT", 499, 529], ["S1", "ANATOMY", 135, 137], ["Pseudotyped Viruses", "OBSERVATION", 196, 215]]], ["For the production of HIV/\u0394E, only HIV vectors were transfected into the cells.", [["cells", "ANATOMY", 73, 78], ["HIV/\u0394E", "ORGANISM", 22, 28], ["HIV", "ORGANISM", 35, 38], ["cells", "CELL", 73, 78], ["HIV", "SPECIES", 22, 25], ["HIV/\u0394E", "SPECIES", 22, 28], ["HIV", "SPECIES", 35, 38], ["HIV/\u0394E", "PROBLEM", 22, 28], ["HIV vectors", "TREATMENT", 35, 46], ["cells", "ANATOMY", 73, 78]]], ["The media were changed the following morning and the supernatants were collected 24 and 48 hrs later and pooled.", [["supernatants", "ANATOMY", 53, 65], ["The media", "TREATMENT", 0, 9]]], ["The pseudotyped viruses were concentrated through a 20% sucrose cushion at 41,000 rpm using Beckman Ultracentrifuge.", [["sucrose", "CHEMICAL", 56, 63], ["sucrose", "CHEMICAL", 56, 63], ["pseudotyped", "ORGANISM", 4, 15], ["The pseudotyped viruses", "PROBLEM", 0, 23], ["a 20% sucrose cushion", "TREATMENT", 50, 71], ["Beckman Ultracentrifuge", "TREATMENT", 92, 115], ["pseudotyped viruses", "OBSERVATION", 4, 23]]], ["The incorporation of the S proteins in the virus particles was confirmed by western blot using 1D4 anti-rhodopsin mouse monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA), while the virus p24Ag content was confirmed by mouse anti-HIV1 p24 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA).In vitro Pseudotyped Virus Neutralization Assay ::: Materials and MethodsEntry inhibition was performed by pre-incubating Urbani and mutant pseudoviruses, [equivalent to 10 nanograms of p24 Ag, quantified by HIV-1 p24 ELISA kit (Express Biotech International, MD)], with purified mAbs individually or in combinations at 37\u00b0C for 1 hr.", [["Ag", "CHEMICAL", 504, 506], ["1D4", "GENE_OR_GENE_PRODUCT", 95, 98], ["mouse", "ORGANISM", 114, 119], ["CA", "GENE_OR_GENE_PRODUCT", 179, 181], ["p24Ag", "GENE_OR_GENE_PRODUCT", 200, 205], ["mouse", "ORGANISM", 231, 236], ["Virus", "ORGANISM", 335, 340], ["p24 Ag", "GENE_OR_GENE_PRODUCT", 500, 506], ["S proteins", "PROTEIN", 25, 35], ["1D4 anti-rhodopsin mouse monoclonal antibody", "PROTEIN", 95, 139], ["Santa Cruz Biotechnology", "PROTEIN", 141, 165], ["Santa Cruz", "PROTEIN", 167, 177], ["CA", "PROTEIN", 179, 181], ["p24Ag", "PROTEIN", 200, 205], ["mouse anti-HIV1 p24 monoclonal antibody", "PROTEIN", 231, 270], ["Santa Cruz Biotechnology", "PROTEIN", 272, 296], ["Santa Cruz, CA", "PROTEIN", 298, 312], ["p24 Ag", "PROTEIN", 500, 506], ["purified mAbs", "PROTEIN", 585, 598], ["mouse", "SPECIES", 114, 119], ["mouse", "SPECIES", 231, 236], ["mouse", "SPECIES", 114, 119], ["mouse", "SPECIES", 231, 236], ["anti-HIV1", "SPECIES", 237, 246], ["HIV-1", "SPECIES", 522, 527], ["the S proteins", "TREATMENT", 21, 35], ["the virus particles", "PROBLEM", 39, 58], ["the virus p24Ag content", "TEST", 190, 213], ["mutant pseudoviruses", "PROBLEM", 447, 467], ["purified mAbs", "TREATMENT", 585, 598], ["Pseudotyped Virus", "OBSERVATION", 323, 340]]], ["The pseudovirus/mAb mixture or pseudovirus alone was added to the target 293/ACE2 stable cell line plated at a density of 60,000 cells/well in 12 well plate, and incubated overnight at 37\u00b0C and the medium was replaced the following morning.", [["cell line", "ANATOMY", 89, 98], ["cells", "ANATOMY", 129, 134], ["pseudovirus", "ORGANISM", 4, 15], ["mAb", "GENE_OR_GENE_PRODUCT", 16, 19], ["pseudovirus", "ORGANISM", 31, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["cell line", "CELL", 89, 98], ["cells", "CELL", 129, 134], ["target 293", "CELL_LINE", 66, 76], ["ACE2", "PROTEIN", 77, 81], ["60,000 cells", "CELL_LINE", 122, 134], ["The pseudovirus/mAb mixture", "TREATMENT", 0, 27], ["pseudovirus", "TREATMENT", 31, 42], ["ACE2 stable cell line", "TREATMENT", 77, 98], ["stable", "OBSERVATION_MODIFIER", 82, 88], ["cell line", "OBSERVATION", 89, 98], ["medium", "OBSERVATION_MODIFIER", 198, 204]]], ["Forty eight hours later, the cells were lysed and luciferase expression was determined using luciferase assay kit (Promega, WI) according to the manufacturer\u2019s instructions.", [["cells", "ANATOMY", 29, 34], ["cells", "CELL", 29, 34], ["luciferase", "GENE_OR_GENE_PRODUCT", 50, 60], ["luciferase", "GENE_OR_GENE_PRODUCT", 93, 103], ["luciferase", "PROTEIN", 50, 60], ["luciferase", "PROTEIN", 93, 103], ["the cells", "PROBLEM", 25, 34], ["luciferase expression", "TEST", 50, 71], ["luciferase assay", "TEST", 93, 109]]], ["The rabbit immune serum was used as a positive control for entry inhibition.", [["immune serum", "ANATOMY", 11, 23], ["rabbit", "ORGANISM", 4, 10], ["immune serum", "ORGANISM_SUBSTANCE", 11, 23], ["rabbit", "SPECIES", 4, 10], ["rabbit", "SPECIES", 4, 10], ["The rabbit immune serum", "TEST", 0, 23], ["entry inhibition", "TREATMENT", 59, 75]]], ["The percentage entry inhibition was calculated using the following equation:The antibody mediated inhibitions of different mutant pseudoviruses were then normalized to HIV/Urbani-S inhibitions.Expression of SARS-CoV 12-510 S1 IgG Urbani and Mutant Proteins ::: ResultsThe SARS-CoV S protein consists of S1 domain in which RBD contains the major neutralizing epitopes, and S2 domain which consists mainly of HR1 and HR2 domains (Fig. S1A).", [["HIV", "ORGANISM", 168, 171], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 207, 215], ["HR1", "GENE_OR_GENE_PRODUCT", 407, 410], ["HR2 domains (Fig. S1A", "GENE_OR_GENE_PRODUCT", 415, 436], ["SARS-CoV 12-510 S1 IgG Urbani and Mutant Proteins", "PROTEIN", 207, 256], ["SARS-CoV S protein", "PROTEIN", 272, 290], ["S1 domain", "PROTEIN", 303, 312], ["RBD", "PROTEIN", 322, 325], ["major neutralizing epitopes", "PROTEIN", 339, 366], ["S2 domain", "PROTEIN", 372, 381], ["HR1", "PROTEIN", 407, 410], ["HR2 domains", "PROTEIN", 415, 426], ["Fig. S1A", "PROTEIN", 428, 436], ["HIV", "SPECIES", 168, 171], ["SARS-CoV", "SPECIES", 207, 215], ["SARS-CoV", "SPECIES", 272, 280], ["The antibody mediated inhibitions", "TREATMENT", 76, 109], ["different mutant pseudoviruses", "PROBLEM", 113, 143], ["HIV", "TEST", 168, 171], ["SARS", "PROBLEM", 207, 211], ["CoV", "TEST", 212, 215], ["The SARS", "TEST", 268, 276], ["CoV S protein", "TEST", 277, 290], ["S1 domain", "PROBLEM", 303, 312], ["the major neutralizing epitopes", "PROBLEM", 335, 366], ["S2 domain", "PROBLEM", 372, 381], ["HR1", "TEST", 407, 410], ["major", "OBSERVATION_MODIFIER", 339, 344], ["neutralizing epitopes", "OBSERVATION", 345, 366]]], ["To identify broadly neutralizing HmAbs, we wanted to test our HmAbs against a relatively large panel of variants.", [["HmAbs", "SIMPLE_CHEMICAL", 33, 38], ["HmAbs", "GENE_OR_GENE_PRODUCT", 62, 67], ["HmAbs", "PROTEIN", 33, 38], ["HmAbs", "PROTEIN", 62, 67], ["broadly", "OBSERVATION_MODIFIER", 12, 19], ["neutralizing", "OBSERVATION", 20, 32]]], ["We aligned the RBD amino acid sequences available from 94 SARS-CoV late clinical isolates and found mutations in the RBD region of only four clinical isolates relative to the Urbani RBD sequence (Fig. S1B).", [["amino acid", "CHEMICAL", 19, 29], ["amino acid", "CHEMICAL", 19, 29], ["amino acid", "AMINO_ACID", 19, 29], ["RBD amino acid sequences", "PROTEIN", 15, 39], ["RBD region", "PROTEIN", 117, 127], ["Urbani RBD sequence", "DNA", 175, 194], ["SARS-CoV", "SPECIES", 58, 66], ["the RBD amino acid sequences", "TEST", 11, 39], ["CoV late clinical isolates", "PROBLEM", 63, 89], ["mutations in the RBD region", "PROBLEM", 100, 127], ["the Urbani RBD sequence", "TEST", 171, 194], ["RBD", "ANATOMY", 117, 120]]], ["The clinical isolates with the identified RBD mutations are named Sin845, GZ-C, GD01 and GZ0402 (GenBank accession number: AY559093.1, AY394979.1, AY278489.2 and AY613947.1 respectively).", [["RBD", "GENE_OR_GENE_PRODUCT", 42, 45], ["GZ-C", "GENE_OR_GENE_PRODUCT", 74, 78], ["RBD", "PROTEIN", 42, 45], ["The clinical isolates", "TEST", 0, 21], ["RBD mutations", "TEST", 42, 55], ["GZ", "TEST", 74, 76], ["GD01", "TEST", 80, 84], ["AY", "TEST", 135, 137]]], ["We inserted the identified mutations within the RBD by site directed mutagenesis into the Urbani 12-510 S1 sequence that is fused to human IgG1 Fc tag at the C-terminus [14].", [["RBD", "DISEASE", 48, 51], ["human", "ORGANISM", 133, 138], ["IgG1 Fc tag", "GENE_OR_GENE_PRODUCT", 139, 150], ["RBD", "DNA", 48, 51], ["Urbani 12-510 S1 sequence", "DNA", 90, 115], ["human IgG1 Fc tag", "PROTEIN", 133, 150], ["C-terminus", "PROTEIN", 158, 168], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["the identified mutations within the RBD", "PROBLEM", 12, 51]]], ["The Urbani and the mutated 12-510 S1-IgG proteins were expressed in 293FT cells, purified and analyzed by SDS/PAGE (Fig. S2A) followed by western blot (Fig. S2B).S1 Proteins Containing RBD Sequences of Sin845, GD01, and GZ0402 Isolates Show Low Binding to S1 Specific Neutralizing HmAbs, While that of GZ-C Isolate Shows Higher Binding ::: ResultsRelative binding of HmAbs to different S1 proteins at different concentrations of antibodies was determined.", [["293FT cells", "ANATOMY", 68, 79], ["IgG", "GENE_OR_GENE_PRODUCT", 37, 40], ["293FT cells", "CELL", 68, 79], ["S2A", "GENE_OR_GENE_PRODUCT", 121, 124], ["S2B", "GENE_OR_GENE_PRODUCT", 157, 160], ["Sin845", "GENE_OR_GENE_PRODUCT", 202, 208], ["HmAbs", "GENE_OR_GENE_PRODUCT", 367, 372], ["mutated 12-510 S1-IgG proteins", "PROTEIN", 19, 49], ["293FT cells", "CELL_LINE", 68, 79], ["S2A", "PROTEIN", 121, 124], ["S2B", "PROTEIN", 157, 160], ["S1", "PROTEIN", 256, 258], ["Neutralizing HmAbs", "PROTEIN", 268, 286], ["HmAbs", "PROTEIN", 367, 372], ["S1 proteins", "PROTEIN", 386, 397], ["antibodies", "PROTEIN", 429, 439], ["The Urbani", "TEST", 0, 10], ["S1-IgG proteins", "TEST", 34, 49], ["RBD Sequences", "TEST", 185, 198], ["Sin845", "TEST", 202, 208], ["GD01", "TEST", 210, 214], ["GZ0402 Isolates", "TEST", 220, 235], ["Low Binding", "PROBLEM", 241, 252], ["Neutralizing HmAbs", "TEST", 268, 286], ["GZ", "TEST", 302, 304], ["different S1 proteins", "PROBLEM", 376, 397], ["different concentrations of antibodies", "PROBLEM", 401, 439]]], ["Interestingly, the Sin845-S1 protein failed to react with 16/18 HmAbs (OD \u223c 0.2) when compared to the control OD of \u223c0.156.", [["Sin845-S1", "GENE_OR_GENE_PRODUCT", 19, 28], ["Sin845", "PROTEIN", 19, 25], ["S1 protein", "PROTEIN", 26, 36]]], ["However, HmAbs 4D4 and 6B1 showed about 50% binding to Sin845 S1 protein relative to their binding to Urbani S1 protein (Fig. 1A).", [["HmAbs 4D4", "GENE_OR_GENE_PRODUCT", 9, 18], ["6B1", "GENE_OR_GENE_PRODUCT", 23, 26], ["Sin845 S1", "GENE_OR_GENE_PRODUCT", 55, 64], ["Urbani S1", "GENE_OR_GENE_PRODUCT", 102, 111], ["4D4", "PROTEIN", 15, 18], ["6B1", "PROTEIN", 23, 26], ["Sin845 S1 protein", "PROTEIN", 55, 72], ["Urbani S1 protein", "PROTEIN", 102, 119], ["HmAbs", "TEST", 9, 14], ["S1 protein", "TEST", 62, 72], ["Urbani S1 protein", "TEST", 102, 119]]], ["The GD01-S1 protein showed a diminished binding to 16/18 HmAbs and binding of about 40% and 60% to 4D4 and 3C7 HmAbs respectively (Fig. 1B).", [["GD01-S1", "GENE_OR_GENE_PRODUCT", 4, 11], ["HmAbs", "GENE_OR_GENE_PRODUCT", 57, 62], ["GD01", "PROTEIN", 4, 8], ["S1 protein", "PROTEIN", 9, 19], ["16/18 HmAbs", "PROTEIN", 51, 62], ["4D4", "PROTEIN", 99, 102], ["3C7 HmAbs", "PROTEIN", 107, 116], ["The GD01-S1 protein", "TEST", 0, 19], ["a diminished binding", "PROBLEM", 27, 47], ["binding", "TEST", 67, 74], ["diminished", "OBSERVATION", 29, 39]]], ["The GZ0402-S1 protein showed minimal binding to 15/18 HmAbs, and 57%, 52% and 69% binding to HmAbs 4D4, 6B1 and 3C7 respectively (Fig. 1C).", [["GZ0402-S1", "GENE_OR_GENE_PRODUCT", 4, 13], ["HmAbs", "GENE_OR_GENE_PRODUCT", 54, 59], ["GZ0402-S1 protein", "PROTEIN", 4, 21], ["6B1", "PROTEIN", 104, 107], ["3C7", "PROTEIN", 112, 115], ["The GZ0402-S1 protein", "TEST", 0, 21], ["minimal binding", "PROBLEM", 29, 44], ["HmAbs", "TEST", 54, 59], ["HmAbs", "TEST", 93, 98], ["6B1", "TEST", 104, 107], ["minimal", "OBSERVATION_MODIFIER", 29, 36]]], ["Surprisingly, the GZ-C S1 protein showed an increased binding to all 18 HmAbs (Fig. 1D).S1 Proteins Containing RBD Sequences of Sin845, GD01, and GZ0402 Isolates Show Low Binding to S1 Specific Neutralizing HmAbs, While that of GZ-C Isolate Shows Higher Binding ::: ResultsThe diminished binding to the Sin845, GD01 and GZ0402 mutants was further confirmed by the minimal to no binding of the HmAbs 5A5, 5D6 and 4G2, even when the wells were coated with an excessive amount of mutant S1 proteins (i.e. 600 ng) relative to their significant binding to only 100 ngs of the Urbani-S1 protein (data not shown).S1 Proteins Containing RBD Sequences of Sin845, GD01, and GZ0402 Isolates Show Low Binding to S1 Specific Neutralizing HmAbs, While that of GZ-C Isolate Shows Higher Binding ::: ResultsThe validity of these findings was confirmed when we found that an anti-SARS-CoV-S Urbani polyclonal serum showed strong reactivity (OD \u223c 0.4) against the GZ-C-S1 mutant even at a high dilution (1/1280) while it showed much lower binding to Sin845-S1, GD01-S1 and GZ0402-S1 proteins relative to its binding to the Urbani-S1 protein (Fig. 2A).", [["serum", "ANATOMY", 892, 897], ["GZ-C S1", "GENE_OR_GENE_PRODUCT", 18, 25], ["Sin845", "GENE_OR_GENE_PRODUCT", 128, 134], ["Sin845", "GENE_OR_GENE_PRODUCT", 303, 309], ["GD01", "GENE_OR_GENE_PRODUCT", 311, 315], ["GZ0402", "GENE_OR_GENE_PRODUCT", 320, 326], ["Urbani-S1", "GENE_OR_GENE_PRODUCT", 571, 580], ["Sin845", "GENE_OR_GENE_PRODUCT", 646, 652], ["anti-SARS-CoV", "ORGANISM", 858, 871], ["serum", "ORGANISM_SUBSTANCE", 892, 897], ["GZ-C-S1", "GENE_OR_GENE_PRODUCT", 946, 953], ["Sin845-S1", "GENE_OR_GENE_PRODUCT", 1032, 1041], ["GD01-S1", "GENE_OR_GENE_PRODUCT", 1043, 1050], ["GZ0402-S1", "GENE_OR_GENE_PRODUCT", 1055, 1064], ["Urbani-S1", "GENE_OR_GENE_PRODUCT", 1105, 1114], ["GZ-C S1 protein", "PROTEIN", 18, 33], ["HmAbs", "PROTEIN", 72, 77], ["S1", "PROTEIN", 182, 184], ["Neutralizing HmAbs", "PROTEIN", 194, 212], ["Sin845, GD01 and GZ0402 mutants", "PROTEIN", 303, 334], ["5A5", "PROTEIN", 399, 402], ["5D6", "PROTEIN", 404, 407], ["4G2", "PROTEIN", 412, 415], ["mutant S1 proteins", "PROTEIN", 477, 495], ["Urbani-S1 protein", "PROTEIN", 571, 588], ["S1", "PROTEIN", 700, 702], ["Neutralizing HmAbs", "PROTEIN", 712, 730], ["Sin845", "PROTEIN", 1032, 1038], ["S1", "PROTEIN", 1039, 1041], ["GD01", "PROTEIN", 1043, 1047], ["S1", "PROTEIN", 1048, 1050], ["GZ0402", "PROTEIN", 1055, 1061], ["S1 proteins", "PROTEIN", 1062, 1073], ["Urbani-S1 protein", "PROTEIN", 1105, 1122], ["Fig. 2A", "PROTEIN", 1124, 1131], ["the GZ-C S1 protein", "TEST", 14, 33], ["an increased binding", "PROBLEM", 41, 61], ["RBD Sequences", "TEST", 111, 124], ["Sin845", "TEST", 128, 134], ["GD01", "TEST", 136, 140], ["GZ0402 Isolates", "TEST", 146, 161], ["Low Binding", "PROBLEM", 167, 178], ["Neutralizing HmAbs", "TEST", 194, 212], ["GZ", "TEST", 228, 230], ["The diminished binding", "PROBLEM", 273, 295], ["mutant S1 proteins", "PROBLEM", 477, 495], ["the Urbani", "TEST", 567, 577], ["RBD Sequences", "TEST", 629, 642], ["Sin845", "TEST", 646, 652], ["GD01", "TEST", 654, 658], ["GZ0402 Isolates", "TEST", 664, 679], ["Low Binding", "PROBLEM", 685, 696], ["Neutralizing HmAbs", "TEST", 712, 730], ["GZ", "TEST", 746, 748], ["an anti-SARS", "TEST", 855, 867], ["CoV", "TEST", 868, 871], ["S Urbani polyclonal serum", "TEST", 872, 897], ["the GZ", "TEST", 942, 948], ["much lower binding", "PROBLEM", 1010, 1028], ["GD01", "TEST", 1043, 1047], ["GZ0402", "TEST", 1055, 1061], ["S1 proteins", "PROBLEM", 1062, 1073], ["the Urbani", "TEST", 1101, 1111], ["increased", "OBSERVATION", 44, 53], ["diminished", "OBSERVATION", 277, 287], ["S1", "ANATOMY", 951, 953], ["S1", "ANATOMY", 1048, 1050]]], ["Enhanced binding to GZ-C-S1 protein was further validated when we found that as little as 25 ng of the GZ-C protein could block HmAb 5A7 binding to the Urbani-S1 protein while as much as 200 ng of Urbani protein was significantly less efficient in blocking the HmAb 5A7 binding to GZ-C-S1 protein (Fig. 2B).S Proteins Containing RBD Sequences of Sin845, GD01, GZ0402 and GZ-C Isolates do not Affect Pseudovirus Entry ::: ResultsWe prepared pseudoviruses expressing S proteins containing RBD sequences of Sin845, GD01, GZ0402 and GZ-C isolates to serve as \u201cRBD surrogates\u201d for those clinical isolates.", [["HmAb", "CHEMICAL", 128, 132], ["GZ-C-S1", "GENE_OR_GENE_PRODUCT", 20, 27], ["GZ-C", "GENE_OR_GENE_PRODUCT", 103, 107], ["HmAb 5A7", "GENE_OR_GENE_PRODUCT", 128, 136], ["Urbani-S1", "GENE_OR_GENE_PRODUCT", 152, 161], ["Urbani", "GENE_OR_GENE_PRODUCT", 197, 203], ["HmAb 5A7", "GENE_OR_GENE_PRODUCT", 261, 269], ["GZ-C-S1", "GENE_OR_GENE_PRODUCT", 281, 288], ["Sin845", "GENE_OR_GENE_PRODUCT", 346, 352], ["Sin845", "GENE_OR_GENE_PRODUCT", 504, 510], ["GD01", "GENE_OR_GENE_PRODUCT", 512, 516], ["GZ-C", "GENE_OR_GENE_PRODUCT", 529, 533], ["GZ-C-S1 protein", "PROTEIN", 20, 35], ["GZ-C protein", "PROTEIN", 103, 115], ["5A7", "PROTEIN", 133, 136], ["Urbani-S1 protein", "PROTEIN", 152, 169], ["Urbani protein", "PROTEIN", 197, 211], ["5A7", "PROTEIN", 266, 269], ["GZ-C-S1 protein", "PROTEIN", 281, 296], ["Fig. 2B", "PROTEIN", 298, 305], ["S proteins", "PROTEIN", 465, 475], ["RBD sequences", "DNA", 487, 500], ["Enhanced binding", "PROBLEM", 0, 16], ["GZ", "TEST", 20, 22], ["S1 protein", "PROBLEM", 25, 35], ["the GZ", "TEST", 99, 105], ["the Urbani", "TEST", 148, 158], ["Urbani protein", "TEST", 197, 211], ["GZ", "TEST", 281, 283], ["S Proteins", "TEST", 307, 317], ["RBD Sequences", "TEST", 329, 342], ["Sin845", "TEST", 346, 352], ["GD01", "TEST", 354, 358], ["GZ0402", "TEST", 360, 366], ["GZ", "TEST", 371, 373], ["RBD sequences", "TEST", 487, 500], ["Sin845", "TEST", 504, 510], ["GD01", "TEST", 512, 516], ["GZ0402", "TEST", 518, 524], ["GZ", "TEST", 529, 531], ["RBD surrogates", "TEST", 556, 570], ["those clinical isolates", "PROBLEM", 576, 599]]], ["The S protein and the HIV p24 Ag incorporation into the viral particles were confirmed by western blot (Fig. S3A).", [["Ag", "CHEMICAL", 30, 32], ["Ag", "CHEMICAL", 30, 32], ["Ag", "GENE_OR_GENE_PRODUCT", 30, 32], ["S3A", "GENE_OR_GENE_PRODUCT", 109, 112], ["S protein", "PROTEIN", 4, 13], ["HIV p24 Ag", "PROTEIN", 22, 32], ["S3A", "PROTEIN", 109, 112], ["HIV", "SPECIES", 22, 25], ["HIV", "SPECIES", 22, 25], ["The S protein", "TEST", 0, 13], ["the HIV p24 Ag incorporation", "TREATMENT", 18, 46], ["the viral particles", "TEST", 52, 71], ["viral particles", "OBSERVATION", 56, 71]]], ["In HIV/\u0394E, as expected, no surface glycoprotein was detected.", [["surface", "ANATOMY", 27, 34], ["HIV/\u0394E", "ORGANISM", 3, 9], ["surface glycoprotein", "PROTEIN", 27, 47], ["HIV", "SPECIES", 3, 6], ["HIV/\u0394E", "SPECIES", 3, 9], ["surface glycoprotein", "PROBLEM", 27, 47]]], ["Pseudoviruses expressing the mutant S proteins entered 293 cells, stably expressing ACE2, with equal efficiency when compared to the HIV/S positive control (Fig. S3B).Pseudoviruses Containing S Proteins with RBD Sequences of Sin845, GD01 and GZ0402 Isolates Escape Neutralization While GZ-C Shows Enhanced Neutralization by S1 Specific HmAbs ::: ResultsConsistent with the binding data shown above, entry inhibition of Sin845-S, GD01-S and GZ0402-S pseudoviruses ranged from 10\u201345%, except for the HmAb, 4D4, which showed 78\u201385% inhibition, relative to that seen with Urbani-S pseudovirus by the corresponding antibodies (Fig. 3A, 3B).", [["293 cells", "ANATOMY", 55, 64], ["GZ-C", "CHEMICAL", 286, 290], ["293 cells", "CELL", 55, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["S3B", "GENE_OR_GENE_PRODUCT", 162, 165], ["Sin845", "GENE_OR_GENE_PRODUCT", 225, 231], ["Sin845-S", "GENE_OR_GENE_PRODUCT", 419, 427], ["GD01-S", "GENE_OR_GENE_PRODUCT", 429, 435], ["GZ0402-S", "GENE_OR_GENE_PRODUCT", 440, 448], ["HmAb", "GENE_OR_GENE_PRODUCT", 498, 502], ["Urbani-S pseudovirus", "ORGANISM", 568, 588], ["mutant S proteins", "PROTEIN", 29, 46], ["293 cells", "CELL_LINE", 55, 64], ["ACE2", "PROTEIN", 84, 88], ["S3B", "PROTEIN", 162, 165], ["S1", "PROTEIN", 324, 326], ["HmAbs", "PROTEIN", 336, 341], ["Sin845", "PROTEIN", 419, 425], ["antibodies", "PROTEIN", 610, 620], ["Fig. 3A, 3B", "PROTEIN", 622, 633], ["HIV", "SPECIES", 133, 136], ["Urbani-S pseudovirus", "SPECIES", 568, 588], ["the mutant S proteins", "PROBLEM", 25, 46], ["ACE2", "TEST", 84, 88], ["the HIV", "TEST", 129, 136], ["RBD Sequences", "TEST", 208, 221], ["Sin845", "TEST", 225, 231], ["GD01", "TEST", 233, 237], ["Isolates Escape", "TEST", 249, 264], ["Neutralization", "TEST", 265, 279], ["GZ", "TEST", 286, 288], ["the binding data", "TEST", 369, 385], ["Sin845", "TEST", 419, 425], ["GD01", "TEST", 429, 433], ["GZ0402", "TEST", 440, 446], ["S pseudoviruses", "TEST", 447, 462], ["the HmAb", "TEST", 494, 502], ["Urbani", "TEST", 568, 574], ["equal efficiency", "OBSERVATION_MODIFIER", 95, 111]]], ["In contrast, these antibodies showed more efficient inhibition of GZ-C mutant (Fig. 3A).", [["GZ-C", "GENE_OR_GENE_PRODUCT", 66, 70], ["antibodies", "PROTEIN", 19, 29], ["GZ-C mutant", "PROTEIN", 66, 77], ["these antibodies", "TEST", 13, 29]]], ["The HmAbs did not show significant inhibition of VSV-G pseudotyped virus which ensures the specificity of the HmAbs (data not shown).Differential Reactivity of Non-S1 Binding HmAbs with S Ectodomain, S2 Domain, HR1 and HR2 Regions Suggest Multiple Mechanisms of Virus Neutralization ::: ResultsThe recombinant S protein ectodomain, S2 domain, HR1 and HR2 proteins were expressed in 293FT cells and purified using protein-A agarose beads (Fig. S4).", [["293FT cells", "ANATOMY", 382, 393], ["HmAbs", "SIMPLE_CHEMICAL", 4, 9], ["VSV-G pseudotyped virus", "ORGANISM", 49, 72], ["HmAbs", "GENE_OR_GENE_PRODUCT", 110, 115], ["Virus", "ORGANISM", 262, 267], ["S2", "GENE_OR_GENE_PRODUCT", 332, 334], ["HR1", "GENE_OR_GENE_PRODUCT", 343, 346], ["HR2", "GENE_OR_GENE_PRODUCT", 351, 354], ["293FT cells", "CELL", 382, 393], ["HmAbs", "PROTEIN", 110, 115], ["Non-S1", "PROTEIN", 160, 166], ["HmAbs", "PROTEIN", 175, 180], ["S Ectodomain", "PROTEIN", 186, 198], ["HR1", "PROTEIN", 211, 214], ["HR2", "PROTEIN", 219, 222], ["recombinant S protein ectodomain", "PROTEIN", 298, 330], ["S2 domain", "PROTEIN", 332, 341], ["HR1", "PROTEIN", 343, 346], ["HR2 proteins", "PROTEIN", 351, 363], ["293FT cells", "CELL_LINE", 382, 393], ["VSV-G pseudotyped virus", "SPECIES", 49, 72], ["The HmAbs", "TEST", 0, 9], ["significant inhibition of VSV", "PROBLEM", 23, 52], ["G pseudotyped virus", "PROBLEM", 53, 72], ["Differential Reactivity", "TEST", 133, 156], ["Non-S1 Binding HmAbs", "TEST", 160, 180], ["S Ectodomain", "TEST", 186, 198], ["HR1 and HR2 Regions", "TREATMENT", 211, 230], ["The recombinant S protein ectodomain", "TEST", 294, 330], ["S2 domain", "TEST", 332, 341], ["HR1", "TEST", 343, 346], ["HR2 proteins", "TEST", 351, 363], ["protein", "TEST", 413, 420], ["A agarose beads", "TREATMENT", 421, 436], ["HR1", "ANATOMY", 211, 214], ["Multiple", "OBSERVATION_MODIFIER", 239, 247], ["Virus", "OBSERVATION", 262, 267]]], ["Thirty nine non-S1 binding but Urbani strain S-ectodomain binding and neutralizing HmAbs [19], were successfully purified and tested for binding to different regions of the S protein, including S1 domain as a negative control and full-length S-ectodomain as a positive control.", [["S-ectodomain", "GENE_OR_GENE_PRODUCT", 242, 254], ["S protein", "PROTEIN", 173, 182], ["S1 domain", "PROTEIN", 194, 203], ["negative control and full-length S-ectodomain", "PROTEIN", 209, 254], ["Thirty nine non-S1 binding", "PROBLEM", 0, 26], ["Urbani strain S-ectodomain binding", "PROBLEM", 31, 65], ["neutralizing HmAbs", "TEST", 70, 88], ["the S protein", "TEST", 169, 182], ["S1 domain", "TREATMENT", 194, 203], ["full-length S-ectodomain", "TREATMENT", 230, 254], ["a positive control", "TREATMENT", 258, 276], ["negative", "OBSERVATION", 209, 217]]], ["OD which is 3x negative control (control OD \u223c 0.13) was considered positive.", [["positive", "OBSERVATION", 67, 75]]], ["Twenty two HmAbs bound to S2 domain out of which nine and thirteen bound specifically to the HR1 and the HR2 regions respectively (Table S1).", [["HmAbs", "GENE_OR_GENE_PRODUCT", 11, 16], ["HR1", "GENE_OR_GENE_PRODUCT", 93, 96], ["HmAbs", "PROTEIN", 11, 16], ["S2 domain", "PROTEIN", 26, 35], ["HR1", "PROTEIN", 93, 96], ["HR2 regions", "PROTEIN", 105, 116], ["HR2", "ANATOMY", 105, 108], ["regions", "ANATOMY_MODIFIER", 109, 116]]], ["Interestingly, seventeen HmAbs bound to S-ectodomain but failed to bind to HR1 and HR2 regions of the S2 domain.Differential Reactivity of Non-S1 Binding HmAbs with S Ectodomain, S2 Domain, HR1 and HR2 Regions Suggest Multiple Mechanisms of Virus Neutralization ::: ResultsInhibition of different pseudoviruses entry by HR1 and HR2 binding HmAbs ranged from 60 to 110% of the Urbani-S pseudovirus inhibition at an antibody concentration of 25 \u00b5g/ml (Table 1).", [["HmAbs", "GENE_OR_GENE_PRODUCT", 25, 30], ["S-ectodomain", "GENE_OR_GENE_PRODUCT", 40, 52], ["HR1", "GENE_OR_GENE_PRODUCT", 75, 78], ["HR2", "GENE_OR_GENE_PRODUCT", 83, 86], ["Virus", "ORGANISM", 241, 246], ["HR1", "GENE_OR_GENE_PRODUCT", 320, 323], ["HR2", "GENE_OR_GENE_PRODUCT", 328, 331], ["HmAbs", "GENE_OR_GENE_PRODUCT", 340, 345], ["pseudovirus", "ORGANISM", 385, 396], ["HmAbs", "PROTEIN", 25, 30], ["S-ectodomain", "PROTEIN", 40, 52], ["HR1", "PROTEIN", 75, 78], ["HR2 regions", "PROTEIN", 83, 94], ["S2 domain", "PROTEIN", 102, 111], ["Non-S1", "PROTEIN", 139, 145], ["HmAbs", "PROTEIN", 154, 159], ["S Ectodomain", "PROTEIN", 165, 177], ["HR1", "PROTEIN", 190, 193], ["HR2", "PROTEIN", 198, 201], ["HR1", "PROTEIN", 320, 323], ["HR2 binding HmAbs", "PROTEIN", 328, 345], ["Urbani-S pseudovirus", "SPECIES", 376, 396], ["S-ectodomain", "TREATMENT", 40, 52], ["Differential Reactivity", "TEST", 112, 135], ["Non-S1 Binding HmAbs", "TEST", 139, 159], ["S Ectodomain", "TEST", 165, 177], ["HR1 and HR2 Regions", "TREATMENT", 190, 209], ["HR1", "TEST", 320, 323], ["HR2 binding HmAbs", "TEST", 328, 345], ["the Urbani", "TEST", 372, 382], ["an antibody concentration", "TREATMENT", 411, 436], ["S2", "ANATOMY", 102, 104], ["HR1", "ANATOMY", 190, 193], ["Multiple", "OBSERVATION_MODIFIER", 218, 226], ["Virus", "OBSERVATION", 241, 246]]], ["In contrast, the S-ectodomain binding HmAbs were less effective and showed entry inhibition ranging from 10\u201345% of Urbani-S inhibition, except for the HmAb 4G10 which showed \u223c76% neutralization of Sin845-S virus, and the HmAbs 3F1 and 2G11 which showed 92% and 98.4% neutralization of the GZ-C-S virus (Table 1).", [["HmAbs", "GENE_OR_GENE_PRODUCT", 38, 43], ["Urbani-S", "SIMPLE_CHEMICAL", 115, 123], ["4G10", "GENE_OR_GENE_PRODUCT", 156, 160], ["Sin845-S virus", "ORGANISM", 197, 211], ["HmAbs 3F1", "CELL", 221, 230], ["GZ-C-S virus", "ORGANISM", 289, 301], ["S-ectodomain binding HmAbs", "PROTEIN", 17, 43], ["HmAb 4G10", "PROTEIN", 151, 160], ["Sin845", "PROTEIN", 197, 203], ["S virus", "SPECIES", 294, 301], ["Sin845-S virus", "SPECIES", 197, 211], ["GZ-C-S virus", "SPECIES", 289, 301], ["the S-ectodomain binding HmAbs", "TEST", 13, 43], ["entry inhibition", "TEST", 75, 91], ["Urbani", "TEST", 115, 121], ["the HmAb", "TEST", 147, 155], ["neutralization", "TEST", 179, 193], ["the HmAbs", "TEST", 217, 226], ["neutralization", "TEST", 267, 281], ["the GZ", "TEST", 285, 291]]], ["Collectively, the above results showed that the HR1 and HR2 binding HmAbs are more effective in inhibiting the entry of the RBD surrogate clinical isolates.", [["HR1", "GENE_OR_GENE_PRODUCT", 48, 51], ["HR2", "GENE_OR_GENE_PRODUCT", 56, 59], ["HmAbs", "GENE_OR_GENE_PRODUCT", 68, 73], ["HR1", "PROTEIN", 48, 51], ["HR2", "PROTEIN", 56, 59], ["RBD", "PROTEIN", 124, 127], ["the HR1 and HR2 binding HmAbs", "PROBLEM", 44, 73], ["more effective", "OBSERVATION_MODIFIER", 78, 92]]], ["Those HmAbs did not inhibit the entry of VSV-G pseudotyped virus (data not shown).Combinations of SARS-CoV HmAbs Targeted to Different Regions of the S Glycoprotein More Efficiently Inhibit the Entry of RBD Surrogate Clinical Isolates ::: ResultsNext, we tested combinations of 4D4 (binds to S1, N-terminal of RBD), 1F8 (binds to HR1) and 5E9 (binds to HR2) HmAbs to see if they can more effectively inhibit viral entry.", [["SARS", "DISEASE", 98, 102], ["N", "CHEMICAL", 296, 297], ["HmAbs", "GENE_OR_GENE_PRODUCT", 6, 11], ["VSV-G pseudotyped virus", "ORGANISM", 41, 64], ["SARS-CoV", "ORGANISM", 98, 106], ["4D4", "GENE_OR_GENE_PRODUCT", 278, 281], ["RBD", "GENE_OR_GENE_PRODUCT", 310, 313], ["1F8", "GENE_OR_GENE_PRODUCT", 316, 319], ["HR1", "GENE_OR_GENE_PRODUCT", 330, 333], ["5E9", "GENE_OR_GENE_PRODUCT", 339, 342], ["HR2", "GENE_OR_GENE_PRODUCT", 353, 356], ["SARS-CoV HmAbs", "PROTEIN", 98, 112], ["RBD", "PROTEIN", 203, 206], ["4D4", "PROTEIN", 278, 281], ["S1", "PROTEIN", 292, 294], ["N-terminal", "PROTEIN", 296, 306], ["RBD", "PROTEIN", 310, 313], ["1F8", "PROTEIN", 316, 319], ["HR1", "PROTEIN", 330, 333], ["5E9", "PROTEIN", 339, 342], ["HR2", "PROTEIN", 353, 356], ["HmAbs", "PROTEIN", 358, 363], ["VSV-G pseudotyped virus", "SPECIES", 41, 64], ["SARS-CoV", "SPECIES", 98, 106], ["VSV", "TEST", 41, 44], ["G pseudotyped virus", "PROBLEM", 45, 64], ["SARS-CoV HmAbs", "TREATMENT", 98, 112], ["the S Glycoprotein", "TREATMENT", 146, 164], ["S1", "TEST", 292, 294], ["HR2", "TEST", 353, 356], ["HmAbs", "TEST", 358, 363], ["SARS", "OBSERVATION", 98, 102]]], ["The combinations of 4D4/1F8, 4D4/5E9 and 1F8/5E9 HmAbs were more effective in blocking Urbani pseudovirus entry compared to the individual antibodies (p value <0.05).", [["1F8", "GENE_OR_GENE_PRODUCT", 24, 27], ["5E9", "GENE_OR_GENE_PRODUCT", 33, 36], ["1F8", "GENE_OR_GENE_PRODUCT", 41, 44], ["5E9", "GENE_OR_GENE_PRODUCT", 45, 48], ["Urbani pseudovirus", "ORGANISM", 87, 105], ["4D4/1F8, 4D4/5E9 and 1F8/5E9 HmAbs", "DNA", 20, 54], ["Urbani pseudovirus", "SPECIES", 87, 105], ["the individual antibodies", "TEST", 124, 149]]], ["The same pattern of inhibition was seen with the Sin845-S, GZ-C-S and GZ0402-S pseudoviruses (p values = 0.005\u20130.04).", [["GZ", "TEST", 59, 61], ["GZ0402", "TEST", 70, 76], ["values", "TEST", 96, 102]]], ["However, these HmAb combinations exhibited similar levels of GD01 pseudovirus blocking as seen with the 1F8 or 5E9 HmAbs when used individually.", [["HmAb", "GENE_OR_GENE_PRODUCT", 15, 19], ["GD01", "GENE_OR_GENE_PRODUCT", 61, 65], ["5E9 HmAbs", "SIMPLE_CHEMICAL", 111, 120], ["GD01 pseudovirus blocking", "TREATMENT", 61, 86]]], ["Maximum inhibition of 90\u201395% (p values = 0.003\u20130.04) was noted when a combination of 4D4/1F8/5E9 HmAbs was used (Fig. 4).", [["4D4", "PROTEIN", 85, 88], ["1F8", "PROTEIN", 89, 92], ["5E9", "PROTEIN", 93, 96], ["Maximum inhibition", "TEST", 0, 18], ["values", "TEST", 32, 38], ["4D4/1F8/5E9 HmAbs", "TREATMENT", 85, 102]]], ["These results indicated that a cocktail of HmAbs targeting different conserved regions of the S protein is likely to be more effective in neutralizing different SARS-CoV clinical isolates than individual antibodies with specificity to those regions.DiscussionTherapies that are directed towards RNA viruses, including SARS-CoV, must consider the quasispecies nature of the viral population, the ability of the virus to mutate and recombine in response to host selection pressure [32].", [["HmAbs", "CHEMICAL", 43, 48], ["HmAbs", "GENE_OR_GENE_PRODUCT", 43, 48], ["SARS-CoV", "ORGANISM", 161, 169], ["SARS-CoV", "ORGANISM", 318, 326], ["HmAbs", "PROTEIN", 43, 48], ["S protein", "PROTEIN", 94, 103], ["antibodies", "PROTEIN", 204, 214], ["SARS-CoV", "SPECIES", 161, 169], ["SARS-CoV", "SPECIES", 318, 326], ["a cocktail of HmAbs", "TREATMENT", 29, 48], ["the S protein", "TEST", 90, 103], ["neutralizing different SARS", "PROBLEM", 138, 165], ["CoV clinical isolates", "PROBLEM", 166, 187], ["individual antibodies", "TEST", 193, 214], ["DiscussionTherapies", "TREATMENT", 249, 268], ["RNA viruses", "PROBLEM", 295, 306], ["SARS", "PROBLEM", 318, 322], ["the viral population", "PROBLEM", 369, 389], ["the virus", "PROBLEM", 406, 415], ["host selection pressure", "TEST", 455, 478], ["likely to be", "UNCERTAINTY", 107, 119], ["more effective", "OBSERVATION_MODIFIER", 120, 134]]], ["Such changes likely allowed the SARS-CoV to jump from the intermediate hosts to humans and resulted in the 2002\u20132003 outbreak [33].", [["SARS", "DISEASE", 32, 36], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["humans", "ORGANISM", 80, 86], ["humans", "SPECIES", 80, 86], ["SARS-CoV", "SPECIES", 32, 40], ["humans", "SPECIES", 80, 86], ["Such changes", "PROBLEM", 0, 12], ["the SARS", "PROBLEM", 28, 36]]], ["Therefore, therapies against SARS-CoV, including passive immunotherapy with HmAbs, must be able to neutralize a wide range of clinical isolates and prevent or minimize generation of escape mutants.DiscussionIn this study, we found that the anti-S1 HmAbs were unable to bind to the recombinant mutant 12-510 S1 fragments (i.e. Sin845, GD01 and GZ0402) except for the 4D4 antibody, which showed only a decreased binding.", [["SARS", "DISEASE", 29, 33], ["SARS-CoV", "ORGANISM", 29, 37], ["HmAbs", "GENE_OR_GENE_PRODUCT", 76, 81], ["anti-S1", "GENE_OR_GENE_PRODUCT", 240, 247], ["HmAbs", "GENE_OR_GENE_PRODUCT", 248, 253], ["anti-S1 HmAbs", "PROTEIN", 240, 253], ["recombinant mutant 12-510 S1 fragments", "DNA", 281, 319], ["Sin845", "PROTEIN", 326, 332], ["GD01", "PROTEIN", 334, 338], ["GZ0402", "PROTEIN", 343, 349], ["4D4 antibody", "PROTEIN", 366, 378], ["SARS-CoV", "SPECIES", 29, 37], ["therapies", "TREATMENT", 11, 20], ["SARS", "PROBLEM", 29, 33], ["passive immunotherapy", "TREATMENT", 49, 70], ["HmAbs", "TREATMENT", 76, 81], ["clinical isolates", "TREATMENT", 126, 143], ["escape mutants", "PROBLEM", 182, 196], ["this study", "TEST", 210, 220], ["the anti-S1 HmAbs", "PROBLEM", 236, 253], ["the 4D4 antibody", "TEST", 362, 378], ["a decreased binding", "PROBLEM", 398, 417], ["escape mutants", "OBSERVATION", 182, 196], ["decreased", "OBSERVATION", 400, 409]]], ["All anti-S1 HmAbs showed enhanced binding to the GZ-C-S1 fragment.DiscussionThe 4D4 HmAb binds to an epitope that resides N-terminal to RBD and neutralizes the SARS-CoV by inhibiting a post-binding step in the viral entry [11], [19].", [["SARS", "DISEASE", 160, 164], ["N", "CHEMICAL", 122, 123], ["anti-S1 HmAbs", "SIMPLE_CHEMICAL", 4, 17], ["HmAb", "GENE_OR_GENE_PRODUCT", 84, 88], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 160, 168], ["anti-S1 HmAbs", "PROTEIN", 4, 17], ["GZ-C-S1 fragment", "DNA", 49, 65], ["4D4 HmAb", "PROTEIN", 80, 88], ["N-terminal", "PROTEIN", 122, 132], ["RBD", "PROTEIN", 136, 139], ["SARS-CoV", "SPECIES", 160, 168], ["All anti-S1 HmAbs", "TEST", 0, 17], ["enhanced binding", "PROBLEM", 25, 41], ["an epitope", "TREATMENT", 98, 108], ["terminal to RBD", "PROBLEM", 124, 139], ["the SARS", "PROBLEM", 156, 164], ["CoV", "PROBLEM", 165, 168], ["enhanced binding", "OBSERVATION", 25, 41], ["S1", "ANATOMY", 54, 56], ["fragment", "OBSERVATION", 57, 65]]], ["This HmAb continued to react albeit to a lesser extent with surrogate clinical isolates.", [["HmAb", "CHEMICAL", 5, 9], ["HmAb", "GENE_OR_GENE_PRODUCT", 5, 9], ["HmAb", "PROTEIN", 5, 9], ["lesser extent", "OBSERVATION_MODIFIER", 41, 54]]], ["Moreover, when used in combination with other HmAbs, such as HmAb 3C7, it showed a synergistic effect [11].", [["HmAbs", "SIMPLE_CHEMICAL", 46, 51], ["HmAb 3C7", "GENE_OR_GENE_PRODUCT", 61, 69], ["HmAb 3C7", "PROTEIN", 61, 69]]], ["Accordingly, our earlier as well as current results highlight the importance of the HmAb 4D4 in neutralizing SARS-CoV mutants and its ability to compliment other HmAbs.DiscussionThe Identification of S2 domain specific neutralizing HmAbs is consistent with a previous study which showed B-cell responses against the S2 domain in patients who recovered from SARS-CoV infection [34], and other studies which showed that a fragment consisting of amino acids 1055 to 1192 can induce neutralizing antibodies [29], [30].", [["B-cell", "ANATOMY", 287, 293], ["SARS", "DISEASE", 109, 113], ["SARS-CoV infection", "DISEASE", 357, 375], ["amino acids 1055 to 1192", "CHEMICAL", 443, 467], ["amino acids", "CHEMICAL", 443, 454], ["HmAb 4D4", "GENE_OR_GENE_PRODUCT", 84, 92], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 109, 117], ["HmAbs", "GENE_OR_GENE_PRODUCT", 162, 167], ["S2", "GENE_OR_GENE_PRODUCT", 200, 202], ["HmAbs", "GENE_OR_GENE_PRODUCT", 232, 237], ["B-cell", "CELL", 287, 293], ["patients", "ORGANISM", 329, 337], ["SARS-CoV", "ORGANISM", 357, 365], ["amino acids", "AMINO_ACID", 443, 454], ["HmAb 4D4", "PROTEIN", 84, 92], ["HmAbs", "PROTEIN", 162, 167], ["S2 domain", "PROTEIN", 200, 209], ["HmAbs", "PROTEIN", 232, 237], ["S2 domain", "PROTEIN", 316, 325], ["amino acids 1055 to 1192", "PROTEIN", 443, 467], ["neutralizing antibodies", "PROTEIN", 479, 502], ["patients", "SPECIES", 329, 337], ["SARS-CoV", "SPECIES", 109, 117], ["SARS-CoV", "SPECIES", 357, 365], ["the HmAb", "TREATMENT", 80, 88], ["neutralizing SARS", "PROBLEM", 96, 113], ["CoV mutants", "TREATMENT", 114, 125], ["a previous study", "TEST", 257, 273], ["B-cell responses", "PROBLEM", 287, 303], ["SARS", "PROBLEM", 357, 361], ["CoV infection", "PROBLEM", 362, 375], ["other studies", "TEST", 386, 399], ["a fragment", "PROBLEM", 418, 428], ["amino acids", "TEST", 443, 454], ["neutralizing antibodies", "TEST", 479, 502], ["consistent with", "UNCERTAINTY", 241, 256]]], ["Therefore, our finding of thirteen neutralizing HmAbs that bind to HR2 domain is consistent with the previous reports on mouse HR2 specific monoclonal antibodies.", [["HmAbs", "CHEMICAL", 48, 53], ["HmAbs", "GENE_OR_GENE_PRODUCT", 48, 53], ["HR2", "GENE_OR_GENE_PRODUCT", 67, 70], ["mouse", "ORGANISM", 121, 126], ["HR2", "GENE_OR_GENE_PRODUCT", 127, 130], ["HmAbs", "PROTEIN", 48, 53], ["HR2 domain", "PROTEIN", 67, 77], ["mouse HR2 specific monoclonal antibodies", "PROTEIN", 121, 161], ["mouse", "SPECIES", 121, 126], ["mouse", "SPECIES", 121, 126], ["thirteen neutralizing HmAbs", "PROBLEM", 26, 53], ["mouse HR2 specific monoclonal antibodies", "PROBLEM", 121, 161], ["consistent with", "UNCERTAINTY", 81, 96], ["monoclonal antibodies", "OBSERVATION", 140, 161]]], ["However those Abs were neither of human origin nor were tested for their ability to neutralize different clinical isolates [27], [35].", [["Abs", "GENE_OR_GENE_PRODUCT", 14, 17], ["human", "ORGANISM", 34, 39], ["Abs", "PROTEIN", 14, 17], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["those Abs", "TEST", 8, 17]]], ["Our finding of nine HR1 binding neutralizing HmAbs is novel as there are no reported HR1 specific neutralizing antibodies to date.DiscussionWe believe that the HmAbs targeted to epitopes within the S1 domain failed to bind and neutralize because of the mutations which most likely disrupted the conformation of the protein and resulted in the loss of expression of specific epitopes.", [["HmAbs", "CHEMICAL", 160, 165], ["HR1", "GENE_OR_GENE_PRODUCT", 20, 23], ["HmAbs", "GENE_OR_GENE_PRODUCT", 45, 50], ["HR1", "GENE_OR_GENE_PRODUCT", 85, 88], ["HmAbs", "GENE_OR_GENE_PRODUCT", 160, 165], ["HR1", "PROTEIN", 20, 23], ["HmAbs", "PROTEIN", 45, 50], ["HR1", "PROTEIN", 85, 88], ["neutralizing antibodies", "PROTEIN", 98, 121], ["HmAbs", "PROTEIN", 160, 165], ["epitopes", "PROTEIN", 178, 186], ["S1 domain", "PROTEIN", 198, 207], ["epitopes", "PROTEIN", 374, 382], ["nine HR1 binding neutralizing HmAbs", "PROBLEM", 15, 50], ["HR1 specific neutralizing antibodies", "PROBLEM", 85, 121], ["the HmAbs", "PROBLEM", 156, 165], ["the mutations", "PROBLEM", 249, 262], ["specific epitopes", "PROBLEM", 365, 382]]], ["In contrast, S2 domain reactive HmAbs were able to neutralize different RBD surrogate isolates even better than the 4D4 HmAb.", [["S2 domain reactive HmAbs", "SIMPLE_CHEMICAL", 13, 37], ["S2 domain reactive HmAbs", "PROTEIN", 13, 37], ["RBD", "PROTEIN", 72, 75], ["4D4 HmAb", "PROTEIN", 116, 124], ["S2 domain reactive HmAbs", "PROBLEM", 13, 37]]], ["Interestingly, analyses of the amino acid sequences of the S protein of 94 SARS-CoV clinical isolates revealed no mutations that are localized to HR1, and only K1163E mutation in the HR2 of six isolates (i.e. SZ3, GZ0402, HSZ-Cb, SZ16, A022, and GZ02), and Q1183R and Q1183K mutations in the HR2 of BJ182-12 and GZ-C isolates respectively.", [["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "AMINO_ACID", 31, 41], ["SARS-CoV", "ORGANISM", 75, 83], ["HR1", "GENE_OR_GENE_PRODUCT", 146, 149], ["K1163E", "GENE_OR_GENE_PRODUCT", 160, 166], ["HSZ-Cb", "GENE_OR_GENE_PRODUCT", 222, 228], ["GZ-C isolates", "CELL", 312, 325], ["amino acid sequences", "PROTEIN", 31, 51], ["S protein", "PROTEIN", 59, 68], ["HR1", "PROTEIN", 146, 149], ["HR2", "PROTEIN", 183, 186], ["HSZ", "PROTEIN", 222, 225], ["GZ02", "PROTEIN", 246, 250], ["HR2", "PROTEIN", 292, 295], ["SARS-CoV", "SPECIES", 75, 83], ["the amino acid sequences", "TEST", 27, 51], ["the S protein", "TEST", 55, 68], ["SARS", "TEST", 75, 79], ["CoV clinical isolates", "TEST", 80, 101], ["mutations", "PROBLEM", 114, 123], ["HR1", "TEST", 146, 149], ["SZ3", "TEST", 209, 212], ["GZ0402", "TEST", 214, 220], ["HSZ", "TEST", 222, 225], ["Cb", "TEST", 226, 228], ["SZ16", "TEST", 230, 234], ["A022", "TEST", 236, 240], ["GZ02", "TEST", 246, 250], ["the HR2", "TEST", 288, 295], ["BJ182", "TEST", 299, 304], ["GZ", "TEST", 312, 314], ["no", "UNCERTAINTY", 111, 113]]], ["Other isolates were found to be free of any mutations in either HR1 or HR2 domains.DiscussionMost of the previously reported HmAbs recognize epitopes within the RBD in which mutations that allow viruses to escape neutralization without loss of infectivity are often found [12], [36].", [["loss of infectivity", "DISEASE", 236, 255], ["HR2", "GENE_OR_GENE_PRODUCT", 71, 74], ["HmAbs", "GENE_OR_GENE_PRODUCT", 125, 130], ["HR1", "PROTEIN", 64, 67], ["HR2 domains", "PROTEIN", 71, 82], ["HmAbs", "PROTEIN", 125, 130], ["epitopes", "PROTEIN", 141, 149], ["RBD", "PROTEIN", 161, 164], ["Other isolates", "TEST", 0, 14], ["any mutations in either HR1 or HR2 domains", "PROBLEM", 40, 82], ["the RBD", "PROBLEM", 157, 164], ["escape neutralization", "PROBLEM", 206, 227], ["loss of infectivity", "PROBLEM", 236, 255]]], ["This is further substantiated in the current study by the loss of neutralization by different RBD binding antibodies due to a single mutation in the S protein.", [["RBD binding antibodies", "PROTEIN", 94, 116], ["S protein", "PROTEIN", 149, 158], ["the current study", "TEST", 33, 50], ["the loss of neutralization", "PROBLEM", 54, 80], ["different RBD binding antibodies", "PROBLEM", 84, 116], ["a single mutation in the S protein", "PROBLEM", 124, 158]]], ["However, HR1 and HR2 regions contain highly conserved neutralization epitopes in which mutations are likely lethal due to their critical role in the membrane fusion required for virus entry.", [["membrane", "ANATOMY", 149, 157], ["HR1", "GENE_OR_GENE_PRODUCT", 9, 12], ["HR2", "GENE_OR_GENE_PRODUCT", 17, 20], ["membrane", "CELLULAR_COMPONENT", 149, 157], ["HR1", "PROTEIN", 9, 12], ["HR2 regions", "PROTEIN", 17, 28], ["neutralization epitopes", "PROTEIN", 54, 77], ["HR1 and HR2 regions", "PROBLEM", 9, 28], ["conserved neutralization epitopes", "PROBLEM", 44, 77], ["lethal", "PROBLEM", 108, 114], ["the membrane fusion", "TREATMENT", 145, 164], ["virus entry", "PROBLEM", 178, 189], ["neutralization epitopes", "OBSERVATION", 54, 77], ["membrane fusion", "OBSERVATION", 149, 164]]], ["Consequently, as shown by our results, the HR1 and HR2 specific antibodies can neutralize a broad spectrum of SARS-CoV variants with very limited potential, if any, for the emergence of escape mutants, especially when they are used in combination.DiscussionBased on results obtained using a combination of mAbs against HBV and RSV, and our previous demonstration of highly efficient neutralization of SARS-CoV using combinations of HmAbs [11], [37], we reasoned that a combination of HmAbs targeting different regions of the S protein would likely confer better protection against different isolates.", [["SARS", "DISEASE", 110, 114], ["SARS", "DISEASE", 401, 405], ["HmAbs", "CHEMICAL", 484, 489], ["HR1", "GENE_OR_GENE_PRODUCT", 43, 46], ["HR2", "GENE_OR_GENE_PRODUCT", 51, 54], ["SARS-CoV", "ORGANISM", 110, 118], ["HBV", "ORGANISM", 319, 322], ["RSV", "ORGANISM", 327, 330], ["SARS-CoV", "ORGANISM", 401, 409], ["HmAbs [11]", "SIMPLE_CHEMICAL", 432, 442], ["[37]", "SIMPLE_CHEMICAL", 444, 448], ["HmAbs", "GENE_OR_GENE_PRODUCT", 484, 489], ["HR1", "PROTEIN", 43, 46], ["HR2", "PROTEIN", 51, 54], ["mAbs", "PROTEIN", 306, 310], ["HmAbs", "PROTEIN", 484, 489], ["S protein", "PROTEIN", 525, 534], ["SARS-CoV", "SPECIES", 110, 118], ["HBV", "SPECIES", 319, 322], ["RSV", "SPECIES", 327, 330], ["SARS-CoV", "SPECIES", 401, 409], ["the HR1 and HR2 specific antibodies", "TEST", 39, 74], ["SARS-CoV variants", "PROBLEM", 110, 127], ["escape mutants", "PROBLEM", 186, 200], ["mAbs", "TREATMENT", 306, 310], ["HBV", "PROBLEM", 319, 322], ["RSV", "PROBLEM", 327, 330], ["SARS", "PROBLEM", 401, 405], ["HmAbs", "TEST", 432, 437], ["HmAbs", "TREATMENT", 484, 489], ["the S protein", "TREATMENT", 521, 534]]], ["Combining the S1 binding 4D4 HmAb with either 1F8 (HR1) or 5E9 (HR2) resulted in increased virus neutralization of the mutants Sin845, GZ-C and GZ0402 compared to the individual HmAbs.", [["4D4 HmAb", "GENE_OR_GENE_PRODUCT", 25, 33], ["1F8 (HR1)", "GENE_OR_GENE_PRODUCT", 46, 55], ["5E9", "GENE_OR_GENE_PRODUCT", 59, 62], ["HR2", "GENE_OR_GENE_PRODUCT", 64, 67], ["GZ-C", "SIMPLE_CHEMICAL", 135, 139], ["GZ0402", "SIMPLE_CHEMICAL", 144, 150], ["HmAbs", "GENE_OR_GENE_PRODUCT", 178, 183], ["S1 binding 4D4 HmAb", "PROTEIN", 14, 33], ["1F8", "PROTEIN", 46, 49], ["HR1", "PROTEIN", 51, 54], ["5E9", "PROTEIN", 59, 62], ["HR2", "PROTEIN", 64, 67], ["HmAbs", "PROTEIN", 178, 183], ["increased virus neutralization", "PROBLEM", 81, 111], ["GZ", "TEST", 135, 137], ["GZ0402", "TEST", 144, 150], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["virus", "OBSERVATION", 91, 96]]], ["Failure of the 4D4/1F8, 4D4/5E9 and 1F8/5E9 combinations to increase GD01 pseudovirus inhibition, when compared to the inhibition seen either with 5E9 or 1F8 alone, was likely due to enhanced binding and neutralization of this virus by these HmAbs when used individually.", [["GD01", "CHEMICAL", 69, 73], ["5E9", "GENE_OR_GENE_PRODUCT", 28, 31], ["1F8", "GENE_OR_GENE_PRODUCT", 36, 39], ["5E9", "GENE_OR_GENE_PRODUCT", 40, 43], ["GD01", "GENE_OR_GENE_PRODUCT", 69, 73], ["1F8", "GENE_OR_GENE_PRODUCT", 154, 157], ["HmAbs", "GENE_OR_GENE_PRODUCT", 242, 247], ["4D4/1F8, 4D4/5E9 and 1F8/5E9 combinations", "DNA", 15, 56], ["HmAbs", "PROTEIN", 242, 247], ["enhanced binding", "PROBLEM", 183, 199], ["this virus", "PROBLEM", 222, 232], ["likely due to", "UNCERTAINTY", 169, 182], ["enhanced binding", "OBSERVATION", 183, 199]]], ["However, a combination comprising of HmAbs 4D4, 1F8 and 5E9 showed further significant increase in virus neutralization compared to each of the individual HmAbs or any of the pairs.", [["HmAbs 4D4, 1F8 and 5E9", "CHEMICAL", 37, 59], ["HmAbs 4D4", "SIMPLE_CHEMICAL", 37, 46], ["1F8", "GENE_OR_GENE_PRODUCT", 48, 51], ["5E9", "GENE_OR_GENE_PRODUCT", 56, 59], ["HmAbs", "GENE_OR_GENE_PRODUCT", 155, 160], ["4D4", "PROTEIN", 43, 46], ["1F8", "PROTEIN", 48, 51], ["5E9", "PROTEIN", 56, 59], ["HmAbs", "PROTEIN", 155, 160], ["HmAbs", "TEST", 37, 42], ["further significant increase in virus neutralization", "PROBLEM", 67, 119], ["significant", "OBSERVATION_MODIFIER", 75, 86], ["increase", "OBSERVATION_MODIFIER", 87, 95], ["virus neutralization", "OBSERVATION", 99, 119]]], ["These results suggested that the use of a cocktail consisting of HmAbs that can bind to different conserved regions of the S protein may be more desirable for therapeutic use against SARS-CoV infection.", [["HmAbs", "CHEMICAL", 65, 70], ["SARS-CoV infection", "DISEASE", 183, 201], ["HmAbs", "GENE_OR_GENE_PRODUCT", 65, 70], ["S protein", "GENE_OR_GENE_PRODUCT", 123, 132], ["SARS-CoV", "ORGANISM", 183, 191], ["HmAbs", "PROTEIN", 65, 70], ["S protein", "PROTEIN", 123, 132], ["SARS-CoV", "SPECIES", 183, 191], ["a cocktail", "TREATMENT", 40, 50], ["HmAbs", "TREATMENT", 65, 70], ["the S protein", "TEST", 119, 132], ["SARS", "PROBLEM", 183, 187], ["CoV infection", "PROBLEM", 188, 201], ["infection", "OBSERVATION", 192, 201]]], ["This speculation is supported by earlier studies that have shown that it is far more difficult to select for viral variants in the presence of either a polyclonal neutralizing antibody or a cocktail of monoclonal neutralizing antibodies [36], [38]\u2013[40].DiscussionAlthough others have demonstrated the utility of cocktails consisting of mAbs with similar mode of action [12], [36], [41], the present study shows the utility of a cocktail of HmAbs with different specificities and likely with different mechanisms of action for neutralizing a broad spectrum of SARS-CoV clinical isolates.", [["SARS", "DISEASE", 559, 563], ["[38]\u2013[40]", "SIMPLE_CHEMICAL", 243, 252], ["[36]", "SIMPLE_CHEMICAL", 375, 379], ["[41]", "SIMPLE_CHEMICAL", 381, 385], ["HmAbs", "SIMPLE_CHEMICAL", 440, 445], ["SARS-CoV", "ORGANISM", 559, 567], ["polyclonal neutralizing antibody", "PROTEIN", 152, 184], ["monoclonal neutralizing antibodies", "PROTEIN", 202, 236], ["mAbs", "PROTEIN", 336, 340], ["SARS-CoV", "SPECIES", 559, 567], ["earlier studies", "TEST", 33, 48], ["viral variants", "PROBLEM", 109, 123], ["a polyclonal neutralizing antibody", "TEST", 150, 184], ["monoclonal neutralizing antibodies", "TEST", 202, 236], ["cocktails", "TREATMENT", 312, 321], ["mAbs", "TREATMENT", 336, 340], ["the present study", "TEST", 387, 404], ["SARS", "PROBLEM", 559, 563], ["CoV clinical isolates", "PROBLEM", 564, 585]]], ["SARS-CoV S protein is a class I fusion protein that contains HR1 and HR2 regions [16], which are highly conserved.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["HR1", "GENE_OR_GENE_PRODUCT", 61, 64], ["HR2", "GENE_OR_GENE_PRODUCT", 69, 72], ["SARS-CoV S protein", "PROTEIN", 0, 18], ["class I fusion protein", "PROTEIN", 24, 46], ["HR1", "PROTEIN", 61, 64], ["HR2 regions", "PROTEIN", 69, 80], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV S protein", "TEST", 5, 18], ["a class I fusion protein", "PROBLEM", 22, 46]]], ["Presence of similar structures in many other class I viral fusion proteins [42], point to a common fusion mechanism used by different viruses.", [["class I viral fusion proteins", "PROTEIN", 45, 74], ["similar structures", "PROBLEM", 12, 30], ["viral fusion proteins", "TEST", 53, 74], ["a common fusion mechanism", "TREATMENT", 90, 115], ["similar", "OBSERVATION_MODIFIER", 12, 19], ["common fusion", "ANATOMY", 92, 105], ["different viruses", "OBSERVATION", 124, 141]]], ["Therefore, monoclonal antibodies against such conserved regions might constitute the most effective passive therapy.", [["monoclonal antibodies", "PROTEIN", 11, 32], ["monoclonal antibodies", "TREATMENT", 11, 32], ["passive therapy", "TREATMENT", 100, 115]]], ["Our findings are not only relevant to designing a highly effective passive therapy for SARS-CoV but have implications for the development of passive therapy for other viral infections including influenza and HIV [38], [39], [43].", [["SARS-CoV", "DISEASE", 87, 95], ["viral infections", "DISEASE", 167, 183], ["influenza", "DISEASE", 194, 203], ["SARS-CoV", "ORGANISM", 87, 95], ["HIV", "SPECIES", 208, 211], ["SARS-CoV", "SPECIES", 87, 95], ["HIV", "SPECIES", 208, 211], ["a highly effective passive therapy", "TREATMENT", 48, 82], ["SARS", "PROBLEM", 87, 91], ["passive therapy", "TREATMENT", 141, 156], ["other viral infections", "PROBLEM", 161, 183], ["influenza", "PROBLEM", 194, 203], ["HIV", "PROBLEM", 208, 211]]]], "e1c6d85e866ce75b1d465804e8d9341605973ec5": [["Ozone is a highly oxidizing gas easily generated from atmospheric oxygen with inexpensive equipment and is commonly used for the disinfection of municipal water, foods, and surfaces.", [["Ozone", "CHEMICAL", 0, 5], ["oxygen", "CHEMICAL", 66, 72], ["Ozone", "CHEMICAL", 0, 5], ["oxygen", "CHEMICAL", 66, 72], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["oxygen", "SIMPLE_CHEMICAL", 66, 72], ["atmospheric oxygen", "TREATMENT", 54, 72], ["inexpensive equipment", "TREATMENT", 78, 99]]], ["We report tests of the ability of ozone to inactivate enveloped respiratory viruses (influenza A virus and respiratory syncytial virus), chosen as more easily handled surrogates for SARS-CoV-2, on N95 respirators and other personal protective equipment (PPE) commonly used in hospitals.", [["ozone", "CHEMICAL", 34, 39], ["respiratory viruses", "DISEASE", 64, 83], ["influenza A", "DISEASE", 85, 96], ["respiratory syncytial virus", "DISEASE", 107, 134], ["SARS", "DISEASE", 182, 186], ["ozone", "CHEMICAL", 34, 39], ["ozone", "SIMPLE_CHEMICAL", 34, 39], ["enveloped respiratory viruses", "ORGANISM", 54, 83], ["influenza A virus", "ORGANISM", 85, 102], ["respiratory syncytial virus", "ORGANISM", 107, 134], ["influenza A virus", "SPECIES", 85, 102], ["respiratory syncytial virus", "SPECIES", 107, 134], ["influenza A virus", "SPECIES", 85, 102], ["respiratory syncytial virus", "SPECIES", 107, 134], ["SARS-CoV", "SPECIES", 182, 190], ["enveloped respiratory viruses", "PROBLEM", 54, 83], ["influenza A virus", "PROBLEM", 85, 102], ["respiratory syncytial virus", "PROBLEM", 107, 134], ["SARS", "PROBLEM", 182, 186], ["CoV", "TEST", 187, 190], ["N95 respirators", "TREATMENT", 197, 212], ["respiratory viruses", "OBSERVATION", 64, 83]]], ["At 20 ppm, an ozone concentration easily achieved by standard commercial equipment, the viruses were inactivated with high efficiency as long as the relative humidity was above a threshold value of approximately 50%.", [["ozone", "CHEMICAL", 14, 19], ["ozone", "CHEMICAL", 14, 19], ["ozone", "SIMPLE_CHEMICAL", 14, 19], ["an ozone concentration", "TREATMENT", 11, 33], ["the viruses", "PROBLEM", 84, 95], ["high efficiency", "PROBLEM", 118, 133], ["viruses", "OBSERVATION", 88, 95]]], ["In the absence of humidity control, disinfection is more variable and requires considerably longer exposure under relatively dry conditions.", [["humidity control", "TREATMENT", 18, 34], ["disinfection", "PROBLEM", 36, 48], ["more variable", "OBSERVATION_MODIFIER", 52, 65]]], ["This report extends the observations of a previous publication (http://doi.org/10.1080/01919510902747969) to hospital-relevant materials and provides additional details about the relationship of humidity to the antiviral activity of ozone.", [["ozone", "CHEMICAL", 233, 238], ["ozone", "CHEMICAL", 233, 238], ["ozone", "SIMPLE_CHEMICAL", 233, 238], ["antiviral activity", "OBSERVATION", 211, 229]]], ["Home CPAP disinfection devices using ozone can provide effective results for individuals.", [["ozone", "CHEMICAL", 37, 42], ["ozone", "CHEMICAL", 37, 42], ["ozone", "SIMPLE_CHEMICAL", 37, 42], ["Home CPAP disinfection devices", "TREATMENT", 0, 30], ["ozone", "TREATMENT", 37, 42], ["individuals", "PROBLEM", 77, 88]]], ["Ozone did not appear to degrade any of the materials tested except for elastic bands if strained during treatment (such as by the pressure exerted by stapled attachment to N95 respirators).", [["Ozone", "CHEMICAL", 0, 5], ["Ozone", "CHEMICAL", 0, 5], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["elastic bands", "PROBLEM", 71, 84], ["treatment", "TREATMENT", 104, 113], ["stapled attachment to N95 respirators", "TREATMENT", 150, 187]]], ["The filtration efficiency of N95 respirator material was not compromised.", [["The filtration efficiency", "TREATMENT", 0, 25], ["N95 respirator material", "TREATMENT", 29, 52], ["filtration", "OBSERVATION_MODIFIER", 4, 14], ["efficiency", "OBSERVATION_MODIFIER", 15, 25], ["N95 respirator material", "OBSERVATION", 29, 52]]], ["Overall, we recommend exposures of at least 40 minutes to 20 ppm ozone and >70% relative humidity at ambient temperatures (21-24\u00b0C) for 4-log (99.99%) reduction of viral infectivity on a variety of PPE, including gowns, face shields, and respirators.", [["ozone", "CHEMICAL", 65, 70], ["ozone", "CHEMICAL", 65, 70], ["ambient temperatures", "TEST", 101, 121], ["viral infectivity", "PROBLEM", 164, 181], ["a variety of PPE", "TREATMENT", 185, 201], ["gowns, face shields", "TREATMENT", 213, 232], ["viral infectivity", "OBSERVATION", 164, 181]]], ["Shorter exposure times are likely to be effective under these conditions, but at the risk of some variability for different materials.", [["likely to be", "UNCERTAINTY", 27, 39]]], ["Higher ozone concentrations and higher humidity levels promoted faster inactivation of viruses.", [["ozone", "CHEMICAL", 7, 12], ["ozone", "CHEMICAL", 7, 12], ["ozone", "SIMPLE_CHEMICAL", 7, 12], ["Higher ozone concentrations", "PROBLEM", 0, 27], ["higher humidity levels", "PROBLEM", 32, 54], ["viruses", "PROBLEM", 87, 94], ["ozone", "OBSERVATION_MODIFIER", 7, 12], ["concentrations", "OBSERVATION_MODIFIER", 13, 27], ["higher", "OBSERVATION_MODIFIER", 32, 38], ["viruses", "OBSERVATION", 87, 94]]], ["Our work suggests that ozone exposure can be a widely accessible method for disinfecting PPE, permitting safer re-use for healthcare workers and patients alike in times of shortage.IntroductionUnder conventional circumstances in high-resource environments, personal protective equipment (PPE), necessary to protect wearers from a variety of harmful substances such as biological waste, bacteria, and viruses, 1 is often designed to be discarded after a single use.", [["ozone", "CHEMICAL", 23, 28], ["ozone", "CHEMICAL", 23, 28], ["ozone", "SIMPLE_CHEMICAL", 23, 28], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["disinfecting PPE", "TREATMENT", 76, 92], ["healthcare workers", "TREATMENT", 122, 140], ["personal protective equipment (PPE)", "TREATMENT", 257, 292], ["harmful substances", "TREATMENT", 341, 359], ["biological waste", "TREATMENT", 368, 384], ["bacteria", "PROBLEM", 386, 394], ["viruses", "PROBLEM", 400, 407]]], ["2 However, high demand during the SARS-CoV-2 pandemic has led to shortages in PPE and created the need for its safe reuse.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-2", "ORGANISM", 34, 44], ["SARS-CoV", "SPECIES", 34, 42], ["high demand", "PROBLEM", 11, 22], ["the SARS", "TEST", 30, 38], ["CoV", "TEST", 39, 42], ["pandemic", "PROBLEM", 45, 53], ["its safe reuse", "TREATMENT", 107, 121]]], ["While a great deal has been published on the disinfection of materials and surfaces for a wide variety of industries, only a few reports exist that are focused on the effectiveness of disinfectants on PPE.", [["PPE", "TREATMENT", 201, 204], ["great", "OBSERVATION_MODIFIER", 8, 13]]], ["[3] [4] [5] Numerous possibilities exist, including alcohols, heat, and ultraviolet light.", [["alcohols", "CHEMICAL", 52, 60], ["[3] [4] [5", "SIMPLE_CHEMICAL", 0, 10], ["alcohols", "SIMPLE_CHEMICAL", 52, 60], ["alcohols", "TREATMENT", 52, 60], ["ultraviolet light", "TREATMENT", 72, 89]]], ["[5] [6] [7] [8] [9] We focus here on ozone, an easily generated and highly oxidative gas that is widely employed in a variety of applications, including for industrial-scale food disinfection 10 and municipal wastewater treatment.", [["ozone", "CHEMICAL", 37, 42], ["ozone", "CHEMICAL", 37, 42], ["[5] [6] [7] [8] [9", "SIMPLE_CHEMICAL", 0, 18], ["ozone", "SIMPLE_CHEMICAL", 37, 42], ["highly oxidative gas", "PROBLEM", 68, 88], ["industrial-scale food disinfection", "TREATMENT", 157, 191], ["municipal wastewater treatment", "TREATMENT", 199, 229]]], ["11, 12 To our knowledge, only one report has recently appeared concerning the use of ozone for the disinfection of PPE, focusing on N95 respirators.", [["ozone", "CHEMICAL", 85, 90], ["ozone", "CHEMICAL", 85, 90], ["ozone", "SIMPLE_CHEMICAL", 85, 90], ["ozone", "TREATMENT", 85, 90], ["the disinfection of PPE", "TREATMENT", 95, 118], ["N95 respirators", "TREATMENT", 132, 147]]], ["13 We describe a similar study here, extended to other relevant PPE materials and exploring the role of humidity in the effectiveness of ozone treatment.IntroductionSARS-CoV-2 is an enveloped virus, as are all other coronaviruses and many other respiratory viruses.", [["ozone", "CHEMICAL", 137, 142], ["respiratory viruses", "DISEASE", 245, 264], ["ozone", "CHEMICAL", 137, 142], ["ozone", "SIMPLE_CHEMICAL", 137, 142], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 153, 175], ["coronaviruses", "ORGANISM", 216, 229], ["a similar study", "TEST", 15, 30], ["relevant PPE materials", "TREATMENT", 55, 77], ["ozone treatment", "TREATMENT", 137, 152], ["IntroductionSARS", "TEST", 153, 169], ["an enveloped virus", "PROBLEM", 179, 197], ["all other coronaviruses", "PROBLEM", 206, 229], ["many other respiratory viruses", "PROBLEM", 234, 264], ["virus", "OBSERVATION", 192, 197], ["respiratory viruses", "OBSERVATION", 245, 264]]], ["14 We were surprised to find that the vast majority of the disinfectant products recommended by the U.S. Environmental Protection Agency for use against coronavirus contamination have been tested only on nonenveloped viruses (those lacking an outer lipid membrane).", [["outer lipid membrane", "ANATOMY", 243, 263], ["coronavirus contamination", "DISEASE", 153, 178], ["coronavirus", "ORGANISM", 153, 164], ["lipid membrane", "CELLULAR_COMPONENT", 249, 263], ["the disinfectant products", "TREATMENT", 55, 80], ["coronavirus contamination", "PROBLEM", 153, 178], ["nonenveloped viruses", "PROBLEM", 204, 224], ["an outer lipid membrane", "TREATMENT", 240, 263]]], ["15 Similarly, ozone disinfection has also been tested more frequently on nonenveloped viruses than enveloped ones, 9, [16] [17] [18] [19] [20] [21] and only rarely has the deactivation of coronaviruses by multiple methods been studied.", [["ozone", "CHEMICAL", 14, 19], ["9, [16] [17] [18] [19] [20] [21]", "CHEMICAL", 115, 147], ["ozone", "CHEMICAL", 14, 19], ["ozone", "SIMPLE_CHEMICAL", 14, 19], ["[16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 118, 147], ["coronaviruses", "ORGANISM", 188, 201], ["ozone disinfection", "TREATMENT", 14, 32], ["coronaviruses", "PROBLEM", 188, 201], ["ozone disinfection", "OBSERVATION", 14, 32], ["coronaviruses", "OBSERVATION", 188, 201]]], ["22, 23 We wished to explore the parameters for ozone deactivation of a respiratory virus that would serve as a reasonable surrogate for the highly infectious SARS-CoV-2.", [["ozone", "CHEMICAL", 47, 52], ["SARS", "DISEASE", 158, 162], ["ozone", "CHEMICAL", 47, 52], ["ozone", "SIMPLE_CHEMICAL", 47, 52], ["SARS-CoV-2", "ORGANISM", 158, 168], ["SARS-CoV", "SPECIES", 158, 166], ["ozone deactivation", "TREATMENT", 47, 65], ["a respiratory virus", "PROBLEM", 69, 88], ["the highly infectious SARS", "PROBLEM", 136, 162], ["respiratory virus", "OBSERVATION", 71, 88], ["infectious", "OBSERVATION", 147, 157]]], ["We chose influenza A virus (IAV; strain A/WSN/33) as our primary test pathogen, and human respiratory syncytial virus (RSV; strain A2) as a secondary target, both of which are handled under BSL-2 (biosafety level 2) conditions.", [["influenza A virus", "DISEASE", 9, 26], ["respiratory syncytial virus", "DISEASE", 90, 117], ["influenza A virus", "ORGANISM", 9, 26], ["IAV", "ORGANISM", 28, 31], ["WSN/33", "ORGANISM", 42, 48], ["human", "ORGANISM", 84, 89], ["respiratory syncytial virus", "ORGANISM", 90, 117], ["RSV", "ORGANISM", 119, 122], ["influenza A virus", "SPECIES", 9, 26], ["human", "SPECIES", 84, 89], ["respiratory syncytial virus", "SPECIES", 90, 117], ["influenza A virus", "SPECIES", 9, 26], ["IAV", "SPECIES", 28, 31], ["A/WSN/33", "SPECIES", 40, 48], ["human respiratory syncytial virus", "SPECIES", 84, 117], ["RSV", "SPECIES", 119, 122], ["influenza A virus", "PROBLEM", 9, 26], ["our primary test pathogen", "TEST", 53, 78], ["human respiratory syncytial virus", "PROBLEM", 84, 117], ["respiratory syncytial", "ANATOMY", 90, 111]]], ["As summarized in Table 1 , these pathogens are similar in form and function to SARS-CoV-2, although not without some differences.", [["SARS", "DISEASE", 79, 83], ["SARS-CoV", "SPECIES", 79, 87], ["these pathogens", "PROBLEM", 27, 42], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["pathogens", "OBSERVATION", 33, 42], ["not without", "UNCERTAINTY", 100, 111]]], ["We explored three questions regarding ozone disinfection.", [["ozone", "CHEMICAL", 38, 43], ["ozone", "CHEMICAL", 38, 43], ["ozone", "SIMPLE_CHEMICAL", 38, 43], ["ozone disinfection", "TREATMENT", 38, 56]]], ["(1) Does ozone successfully neutralize virions, such that they are no longer infectious? (2) Does the PPE mechanically survive ozone treatment? (3) Does ozone treatment negatively impact the proper protective function of the PPE, especially the filtration properties of N95 respirators?", [["ozone", "CHEMICAL", 9, 14], ["ozone", "CHEMICAL", 127, 132], ["ozone", "CHEMICAL", 153, 158], ["ozone", "CHEMICAL", 9, 14], ["ozone", "CHEMICAL", 127, 132], ["ozone", "CHEMICAL", 153, 158], ["ozone", "SIMPLE_CHEMICAL", 9, 14], ["ozone", "SIMPLE_CHEMICAL", 127, 132], ["ozone", "SIMPLE_CHEMICAL", 153, 158], ["neutralize virions", "TREATMENT", 28, 46], ["the PPE mechanically survive ozone treatment", "TREATMENT", 98, 142], ["ozone treatment", "TREATMENT", 153, 168], ["the PPE", "TREATMENT", 221, 228], ["N95 respirators", "TREATMENT", 270, 285], ["no longer", "UNCERTAINTY", 67, 76]]], ["We examined these questions using several commercially available ozone treatment units marketed for use in other contexts.", [["ozone", "CHEMICAL", 65, 70], ["ozone", "CHEMICAL", 65, 70], ["ozone treatment units", "TREATMENT", 65, 86]]], ["We hope this will be of value to potential users considering the feasibility of the safe reuse of PPE.", [["PPE", "PROBLEM", 98, 101]]], ["A 2009 report described similar findings for the inactivation of 12 viruses, including seven enveloped viruses (influenza, herpes simplex virus, sindbis virus, yellow fever virus, vesicular stomatitis virus, vaccinia virus, and mouse coronavirus) when deposited on a hard surface.", [["surface", "ANATOMY", 272, 279], ["influenza, herpes simplex virus", "DISEASE", 112, 143], ["yellow fever", "DISEASE", 160, 172], ["vesicular stomatitis", "DISEASE", 180, 200], ["influenza,", "ORGANISM", 112, 122], ["herpes simplex virus", "ORGANISM", 123, 143], ["sindbis virus", "ORGANISM", 145, 158], ["yellow fever virus", "ORGANISM", 160, 178], ["vesicular stomatitis virus", "ORGANISM", 180, 206], ["vaccinia virus", "ORGANISM", 208, 222], ["mouse", "ORGANISM", 228, 233], ["coronavirus", "ORGANISM", 234, 245], ["herpes simplex virus", "SPECIES", 123, 143], ["sindbis virus", "SPECIES", 145, 158], ["yellow fever virus", "SPECIES", 160, 178], ["vesicular stomatitis virus", "SPECIES", 180, 206], ["vaccinia virus", "SPECIES", 208, 222], ["mouse", "SPECIES", 228, 233], ["coronavirus", "SPECIES", 234, 245], ["herpes simplex virus", "SPECIES", 123, 143], ["sindbis virus", "SPECIES", 145, 158], ["yellow fever virus", "SPECIES", 160, 178], ["vesicular stomatitis virus", "SPECIES", 180, 206], ["vaccinia virus", "SPECIES", 208, 222], ["mouse coronavirus", "SPECIES", 228, 245], ["the inactivation of 12 viruses", "PROBLEM", 45, 75], ["seven enveloped viruses", "PROBLEM", 87, 110], ["influenza", "PROBLEM", 112, 121], ["herpes simplex virus", "PROBLEM", 123, 143], ["sindbis virus", "PROBLEM", 145, 158], ["yellow fever virus", "PROBLEM", 160, 178], ["vesicular stomatitis virus", "PROBLEM", 180, 206], ["vaccinia virus", "PROBLEM", 208, 222], ["mouse coronavirus", "PROBLEM", 228, 245], ["vesicular stomatitis", "ANATOMY", 180, 200]]], ["24Assay ValidationIn the literature, virus survival post-disinfection is typically measured by determining viral titer by plaque assays or TCID50 (median tissue culture infectious dose) on permissive cells, or by measuring viral RNA loads via RT-qPCR.", [["plaque", "ANATOMY", 122, 128], ["tissue", "ANATOMY", 154, 160], ["cells", "ANATOMY", 200, 205], ["cells", "CELL", 200, 205], ["permissive cells", "CELL_TYPE", 189, 205], ["viral RNA", "RNA", 223, 232], ["virus survival", "TREATMENT", 37, 51], ["viral titer", "PROBLEM", 107, 118], ["plaque assays", "TEST", 122, 135], ["TCID50", "TREATMENT", 139, 145], ["median tissue culture", "TEST", 147, 168], ["permissive cells", "PROBLEM", 189, 205]]], ["18, 25 We sought to maintain viral infectivity as the primary readout, but to do so in a simpler and faster way.", [["viral infectivity", "PROBLEM", 29, 46], ["viral infectivity", "OBSERVATION", 29, 46]]], ["Accordingly, we employed the reporter strains WSN/33-PA-2A-NLuc and RSV-luc5, replication-competent influenza A virus and respiratory syncytial virus, respectively, modified to have a cleavable NanoLuc (NLuc) reporter on the PA protein (IAV) and a luciferase between the P and M genes (RSV).", [["respiratory syncytial virus", "DISEASE", 122, 149], ["PA-2A", "GENE_OR_GENE_PRODUCT", 53, 58], ["NLuc", "GENE_OR_GENE_PRODUCT", 59, 63], ["RSV", "ORGANISM", 68, 71], ["-luc5", "ORGANISM", 71, 76], ["influenza A virus", "ORGANISM", 100, 117], ["respiratory syncytial virus", "ORGANISM", 122, 149], ["NanoLuc", "GENE_OR_GENE_PRODUCT", 194, 201], ["PA", "GENE_OR_GENE_PRODUCT", 225, 227], ["IAV", "ORGANISM", 237, 240], ["luciferase", "GENE_OR_GENE_PRODUCT", 248, 258], ["RSV", "ORGANISM", 286, 289], ["cleavable NanoLuc (NLuc) reporter", "DNA", 184, 217], ["PA protein", "PROTEIN", 225, 235], ["IAV", "PROTEIN", 237, 240], ["luciferase", "PROTEIN", 248, 258], ["P and M genes", "DNA", 271, 284], ["influenza A virus", "SPECIES", 100, 117], ["respiratory syncytial virus", "SPECIES", 122, 149], ["RSV-luc5", "SPECIES", 68, 76], ["influenza A virus", "SPECIES", 100, 117], ["respiratory syncytial virus", "SPECIES", 122, 149], ["RSV", "SPECIES", 286, 289], ["RSV", "TEST", 68, 71], ["replication", "TREATMENT", 78, 89], ["competent influenza A virus", "PROBLEM", 90, 117], ["respiratory syncytial virus", "PROBLEM", 122, 149], ["a cleavable NanoLuc (NLuc)", "TREATMENT", 182, 208], ["the PA protein (IAV", "TREATMENT", 221, 240], ["RSV", "ANATOMY", 68, 71], ["luc5", "ANATOMY", 72, 76]]], ["26, 27 Overnight passage of any remaining virus after ozone treatment on MDCK cells (for IAV) or HEp-2 cells (for RSV) followed by cell lysis and NLuc or luciferase signal quantification provided a fast and convenient readout of viral protein load, and thereby of viral replication.Assay ValidationTesting with known concentrations of IAV and RSV demonstrated the dynamic range of the NLuc reporter assay (factors of 10 6 or greater in virus dilution) to exceed those of RT-qPCR and plaque assays (10 4 -fold range) in our hands (Figure 1a -c, f-g).", [["MDCK cells", "ANATOMY", 73, 83], ["HEp-2 cells", "ANATOMY", 97, 108], ["cell", "ANATOMY", 131, 135], ["plaque", "ANATOMY", 483, 489], ["ozone", "CHEMICAL", 54, 59], ["ozone", "CHEMICAL", 54, 59], ["ozone", "SIMPLE_CHEMICAL", 54, 59], ["MDCK cells", "CELL", 73, 83], ["HEp-2 cells", "CELL", 97, 108], ["RSV", "ORGANISM", 114, 117], ["cell", "CELL", 131, 135], ["NLuc", "GENE_OR_GENE_PRODUCT", 146, 150], ["luciferase", "GENE_OR_GENE_PRODUCT", 154, 164], ["IAV", "ORGANISM", 335, 338], ["RSV", "ORGANISM", 343, 346], ["NLuc", "GENE_OR_GENE_PRODUCT", 385, 389], ["MDCK cells", "CELL_LINE", 73, 83], ["HEp-2 cells", "CELL_LINE", 97, 108], ["luciferase", "PROTEIN", 154, 164], ["IAV", "SPECIES", 89, 92], ["RSV", "SPECIES", 114, 117], ["IAV", "SPECIES", 335, 338], ["RSV", "SPECIES", 343, 346], ["any remaining virus", "PROBLEM", 28, 47], ["ozone treatment", "TREATMENT", 54, 69], ["MDCK cells", "TEST", 73, 83], ["IAV", "PROBLEM", 89, 92], ["HEp-2 cells", "TREATMENT", 97, 108], ["RSV", "PROBLEM", 114, 117], ["cell lysis", "TEST", 131, 141], ["luciferase signal quantification", "TEST", 154, 186], ["viral protein load", "TREATMENT", 229, 247], ["viral replication", "TREATMENT", 264, 281], ["IAV", "PROBLEM", 335, 338], ["RSV", "PROBLEM", 343, 346], ["RT", "TEST", 471, 473], ["qPCR", "TEST", 474, 478], ["plaque assays", "TEST", 483, 496], ["HEp", "ANATOMY", 97, 100], ["cell lysis", "OBSERVATION", 131, 141], ["viral replication", "OBSERVATION", 264, 281], ["plaque", "OBSERVATION", 483, 489], ["hands", "ANATOMY", 523, 528]]], ["Asterisks in Fig. 1b indicate dilutions where large cytopathic effects were observed, such that plaques were uncountable.", [["plaques", "ANATOMY", 96, 103], ["plaques", "PATHOLOGICAL_FORMATION", 96, 103], ["large cytopathic effects", "PROBLEM", 46, 70], ["plaques", "PROBLEM", 96, 103], ["large", "OBSERVATION_MODIFIER", 46, 51], ["cytopathic", "OBSERVATION", 52, 62], ["plaques", "OBSERVATION", 96, 103]]], ["We also treated representative IAV samples with ozone in a standard manner (see below), and analyzed half of the samples by RT-qPCR and the other half with the NLuc reporter assay.", [["samples", "ANATOMY", 35, 42], ["samples", "ANATOMY", 113, 120], ["ozone", "CHEMICAL", 48, 53], ["ozone", "CHEMICAL", 48, 53], ["IAV", "ORGANISM", 31, 34], ["ozone", "SIMPLE_CHEMICAL", 48, 53], ["NLuc", "GENE_OR_GENE_PRODUCT", 160, 164], ["IAV", "SPECIES", 31, 34]]], ["As shown in Fig. 1d -e, the observed trends were similar; these results with a small number of samples in each group also illustrate the general observation that the NLuc assay provided somewhat smaller variance among replicates.Effects of exposure time, humidity, and ozone concentration on virus inactivationWe selected three types of materials in common use in healthcare environments for testing of virus deactivation by ozone: cloth face masks, Tyvek (spun high-density polyethylene) fabric used in disposable gowns and PAPR (powered air purifying respirator) hoods, and N95 respirators (Supplemental Information, Table S1 ).", [["samples", "ANATOMY", 95, 102], ["ozone", "CHEMICAL", 269, 274], ["ozone", "CHEMICAL", 425, 430], ["Tyvek", "CHEMICAL", 450, 455], ["ozone", "CHEMICAL", 269, 274], ["ozone", "CHEMICAL", 425, 430], ["polyethylene", "CHEMICAL", 475, 487], ["ozone", "SIMPLE_CHEMICAL", 269, 274], ["ozone", "SIMPLE_CHEMICAL", 425, 430], ["the NLuc assay", "TEST", 162, 176], ["humidity", "TREATMENT", 255, 263], ["ozone concentration", "TREATMENT", 269, 288], ["virus inactivationWe", "TREATMENT", 292, 312], ["virus deactivation", "PROBLEM", 403, 421], ["cloth face masks", "TREATMENT", 432, 448], ["Tyvek (spun high-density polyethylene) fabric", "TREATMENT", 450, 495], ["disposable gowns", "TREATMENT", 504, 520], ["PAPR (powered air purifying respirator", "TREATMENT", 525, 563], ["small", "OBSERVATION_MODIFIER", 79, 84]]], ["In each case, a measured amount of virus was applied to small (1 cm square) pieces of material, allowed to dry, and then subjected to disinfection.", [["a measured amount of virus", "PROBLEM", 14, 40], ["material", "PROBLEM", 86, 94], ["virus", "OBSERVATION", 35, 40], ["small", "OBSERVATION_MODIFIER", 56, 61], ["(1 cm square", "OBSERVATION_MODIFIER", 62, 74], ["disinfection", "OBSERVATION", 134, 146]]], ["Any remaining virus was recovered by immersion of the treated material in growth media, followed by passage through susceptible cells in culture.", [["cells", "ANATOMY", 128, 133], ["cells", "CELL", 128, 133], ["susceptible cells", "CELL_TYPE", 116, 133], ["Any remaining virus", "PROBLEM", 0, 19], ["the treated material in growth media", "PROBLEM", 50, 86], ["susceptible cells in culture", "PROBLEM", 116, 144], ["virus", "OBSERVATION", 14, 19], ["growth", "OBSERVATION_MODIFIER", 74, 80]]], ["For multi-layered materials such as the N95 respirators, the virus solution did not remain on the surface layer, but rather were absorbed into the material.", [["surface layer", "ANATOMY", 98, 111], ["multi-layered materials", "TREATMENT", 4, 27], ["the N95 respirators", "TREATMENT", 36, 55], ["the virus solution", "TREATMENT", 57, 75]]], ["For negative disinfection controls, the same types of samples were treated with virus, left to dry, and were kept at room temperature without treatment.", [["samples", "ANATOMY", 54, 61], ["virus", "TREATMENT", 80, 85], ["treatment", "TREATMENT", 142, 151], ["disinfection", "OBSERVATION", 13, 25]]], ["Virus-laden samples sprayed with 70% ethanol were allowed to dry and served as positive disinfection controls.", [["samples", "ANATOMY", 12, 19], ["ethanol", "CHEMICAL", 37, 44], ["ethanol", "CHEMICAL", 37, 44], ["Virus", "ORGANISM", 0, 5], ["ethanol", "SIMPLE_CHEMICAL", 37, 44], ["Virus-laden samples", "TREATMENT", 0, 19], ["laden", "OBSERVATION_MODIFIER", 6, 11], ["positive disinfection", "OBSERVATION", 79, 100]]], ["Minimum assay response was defined by the signal generated by processing of materials not treated with any virus.", [["Minimum assay response", "TEST", 0, 22], ["any virus", "PROBLEM", 103, 112]]], ["In each experiment, 4-6 replicates of each sample type were used.", [["each sample type", "TREATMENT", 38, 54]]], ["To account for experiment-to-experiment variation in absolute values, results are reported as % reduction vs. ethanol treatment, which consistently provided more than 10 4 -fold reduction in viral infectivity.Effects of exposure time, humidity, and ozone concentration on virus inactivationOzone exposure was performed using three commercial instruments.", [["ethanol", "CHEMICAL", 110, 117], ["ozone", "CHEMICAL", 249, 254], ["Ozone", "CHEMICAL", 290, 295], ["ethanol", "CHEMICAL", 110, 117], ["ozone", "CHEMICAL", 249, 254], ["Ozone", "CHEMICAL", 290, 295], ["ethanol", "SIMPLE_CHEMICAL", 110, 117], ["ozone", "SIMPLE_CHEMICAL", 249, 254], ["Ozone", "SIMPLE_CHEMICAL", 290, 295], ["absolute values", "TEST", 53, 68], ["ethanol treatment", "TREATMENT", 110, 127], ["viral infectivity", "PROBLEM", 191, 208], ["humidity", "TREATMENT", 235, 243], ["ozone concentration", "TREATMENT", 249, 268], ["virus inactivationOzone exposure", "TREATMENT", 272, 304], ["viral infectivity", "OBSERVATION", 191, 208]]], ["Two (manufactured and provided by Global Ozone Innovations and Zono Technologies) were cabinets used primarily to disinfect sports and playground equipment in schools, daycare centers, and the like.", [["Ozone", "CHEMICAL", 41, 46], ["Global Ozone Innovations", "TREATMENT", 34, 58], ["Zono Technologies", "TREATMENT", 63, 80]]], ["The third was a disinfection device for home PAP (positive airway pressure) equipment (VirtuCLEAN, provided by Healthcare Logiix Systems).", [["airway", "ANATOMY", 59, 65], ["airway", "MULTI-TISSUE_STRUCTURE", 59, 65], ["a disinfection device", "TREATMENT", 14, 35], ["home PAP (positive airway pressure) equipment", "TREATMENT", 40, 85], ["disinfection", "OBSERVATION", 16, 28], ["airway pressure", "OBSERVATION", 59, 74]]], ["These devices were obtained by virtue of personal contacts with company representatives, not because of any particular technical features, and we believe they are representative of the types of equipment that can be widely obtained.", [["These devices", "TREATMENT", 0, 13]]], ["Ozone and .", [["Ozone", "CHEMICAL", 0, 5], ["Ozone", "CHEMICAL", 0, 5], ["Ozone", "SIMPLE_CHEMICAL", 0, 5]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Effects of exposure time, humidity, and ozone concentration on virus inactivationThe copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint humidity were monitored with built-in or externally-introduced sensors.", [["CC", "CHEMICAL", 0, 2], ["ozone", "CHEMICAL", 242, 247], ["ozone", "CHEMICAL", 242, 247], ["ozone", "SIMPLE_CHEMICAL", 242, 247], ["ND", "PROBLEM", 9, 11], ["humidity", "TREATMENT", 228, 236], ["ozone concentration", "TREATMENT", 242, 261], ["virus inactivation", "TREATMENT", 265, 283], ["The copyright holder", "TREATMENT", 283, 303], ["medRxiv preprint humidity", "TREATMENT", 407, 432], ["med", "ANATOMY", 105, 108]]], ["Hardware details are given in Tables S2 and S3; Figure S1 shows representative time courses of changes in ozone and humidity levels through a typical run.", [["ozone", "CHEMICAL", 106, 111], ["ozone", "CHEMICAL", 106, 111], ["ozone", "SIMPLE_CHEMICAL", 106, 111], ["Hardware details", "TREATMENT", 0, 16], ["changes in ozone", "TREATMENT", 95, 111], ["humidity levels", "TEST", 116, 131], ["S3", "ANATOMY", 44, 46]]], ["One of the instruments (made by Zono Technologies) was able to simultaneously control ozone concentration, humidity, and temperature, and so this was used for most of the experiments investigating changes in these parameters.Effects of exposure time, humidity, and ozone concentration on virus inactivationA standard ozone concentration of approximately 20 ppm was produced by all of the units.", [["ozone", "CHEMICAL", 86, 91], ["ozone", "CHEMICAL", 265, 270], ["ozone", "CHEMICAL", 317, 322], ["ozone", "CHEMICAL", 86, 91], ["ozone", "CHEMICAL", 265, 270], ["ozone", "CHEMICAL", 317, 322], ["ozone", "SIMPLE_CHEMICAL", 86, 91], ["ozone", "SIMPLE_CHEMICAL", 265, 270], ["ozone", "SIMPLE_CHEMICAL", 317, 322], ["humidity", "TREATMENT", 107, 115], ["humidity", "TREATMENT", 251, 259], ["ozone concentration", "TREATMENT", 265, 284], ["virus inactivationA standard ozone concentration", "TREATMENT", 288, 336]]], ["Under humid conditions (80% relative humidity, RH, at room temperature), effective inactivation of influenza virus (>70% of the ethanol control) was achieved even at the shortest exposure time tested (18 min), with a tendency to increase at longer times (up to 90 min), as shown in Figure 2a .", [["influenza", "DISEASE", 99, 108], ["ethanol", "CHEMICAL", 128, 135], ["ethanol", "CHEMICAL", 128, 135], ["influenza virus", "ORGANISM", 99, 114], ["ethanol", "SIMPLE_CHEMICAL", 128, 135], ["influenza virus", "SPECIES", 99, 114], ["influenza virus", "SPECIES", 99, 114], ["influenza virus", "PROBLEM", 99, 114], ["the ethanol control", "TREATMENT", 124, 143], ["a tendency", "PROBLEM", 215, 225], ["increase", "OBSERVATION_MODIFIER", 229, 237]]], ["In contrast, when the humidity was not controlled, disinfection was much more variable and required up to 4 h of ozone treatment to achieve results comparable to 70% ethanol for all three materials tested (Fig. 2b) .Effects of exposure time, humidity, and ozone concentration on virus inactivationThe results of a series of experiments controlling relative humidity (Fig. 2c ) demonstrated the critical nature of this parameter.", [["ozone", "CHEMICAL", 113, 118], ["ethanol", "CHEMICAL", 166, 173], ["ozone", "CHEMICAL", 256, 261], ["ozone", "CHEMICAL", 113, 118], ["ethanol", "CHEMICAL", 166, 173], ["ozone", "CHEMICAL", 256, 261], ["ozone", "SIMPLE_CHEMICAL", 113, 118], ["ethanol", "SIMPLE_CHEMICAL", 166, 173], ["ozone", "SIMPLE_CHEMICAL", 256, 261], ["the humidity", "TEST", 18, 30], ["disinfection", "PROBLEM", 51, 63], ["ozone treatment", "TREATMENT", 113, 128], ["humidity", "TREATMENT", 242, 250], ["ozone concentration", "TREATMENT", 256, 275], ["virus inactivation", "TREATMENT", 279, 297]]], ["A clear threshold was observed for all three materials, with 40% RH being ineffective and 50-70% RH giving maximum performance.", [["40% RH", "TREATMENT", 61, 67], ["clear", "OBSERVATION", 2, 7]]], ["These results are quite similar to those reported recently by Duchaine and colleagues on the deactivation of aerosolized nonenveloped viruses (phage and norovirus examples).", [["aerosolized nonenveloped viruses", "PROBLEM", 109, 141]]], ["Increasing ozone concentration from 20 ppm to 50 ppm gave a predictably better response, but the lower concentration was nevertheless quite effective ( Fig. 2d) .", [["ozone", "CHEMICAL", 11, 16], ["ozone", "CHEMICAL", 11, 16], ["ozone", "SIMPLE_CHEMICAL", 11, 16], ["Increasing ozone concentration", "TREATMENT", 0, 30], ["ozone", "OBSERVATION_MODIFIER", 11, 16], ["concentration", "OBSERVATION_MODIFIER", 17, 30]]], ["Higher temperature (48\u00b0C vs. room temperature) under humid conditions allowed for significant reduction of IAV infectivity on both Tyvek and N95 material in only 5 minutes, but this of course is less convenient to perform in practice (Fig. 2e) .", [["IAV", "ORGANISM", 107, 110], ["IAV", "SPECIES", 107, 110], ["Higher temperature", "PROBLEM", 0, 18], ["humid conditions", "TREATMENT", 53, 69], ["IAV infectivity", "PROBLEM", 107, 122], ["IAV infectivity", "OBSERVATION", 107, 122]]], ["In this experiment, a higher water vapor concentration was maintained at the higher temperature even though the relative humidity value was lower.", [["water", "SIMPLE_CHEMICAL", 29, 34], ["a higher water vapor concentration", "TREATMENT", 20, 54], ["the relative humidity value", "TEST", 108, 135], ["higher temperature", "OBSERVATION_MODIFIER", 77, 95]]], ["In contrast, increasing the temperature to 45\u00b0C while maintaining humidity at a relatively low level did not significantly enhance the rate of virus inactivation by ozone ( Figure S2 ).Effects of exposure time, humidity, and ozone concentration on virus inactivationExtended (90 min) ozone treatment under humid conditions also successfully inactivated IAV on samples of Tyvek from a standard disposable coverall (\"bunny suit\") and a hospital PAPR hood, as well as the polycarbonate PAPR face shield (Fig. 2f) .", [["samples", "ANATOMY", 360, 367], ["ozone", "CHEMICAL", 165, 170], ["ozone", "CHEMICAL", 225, 230], ["ozone", "CHEMICAL", 284, 289], ["ozone", "CHEMICAL", 165, 170], ["ozone", "CHEMICAL", 225, 230], ["ozone", "CHEMICAL", 284, 289], ["polycarbonate", "CHEMICAL", 469, 482], ["C", "GENE_OR_GENE_PRODUCT", 46, 47], ["ozone", "SIMPLE_CHEMICAL", 165, 170], ["ozone", "SIMPLE_CHEMICAL", 225, 230], ["ozone", "SIMPLE_CHEMICAL", 284, 289], ["IAV", "SPECIES", 353, 356], ["the temperature", "TEST", 24, 39], ["virus inactivation", "PROBLEM", 143, 161], ["humidity", "TREATMENT", 211, 219], ["ozone concentration", "TREATMENT", 225, 244], ["virus inactivation", "TREATMENT", 248, 266], ["ozone treatment", "TREATMENT", 284, 299], ["a hospital PAPR hood", "TREATMENT", 432, 452], ["the polycarbonate PAPR face shield", "TREATMENT", 465, 499]]], ["Lastly, RSV was completely deactivated by ozone under the same conditions, after either 40 or 90 minutes exposure (Fig. 2g) .", [["ozone", "CHEMICAL", 42, 47], ["ozone", "CHEMICAL", 42, 47], ["RSV", "ORGANISM", 8, 11], ["ozone", "SIMPLE_CHEMICAL", 42, 47], ["RSV", "SPECIES", 8, 11], ["RSV", "PROBLEM", 8, 11], ["RSV", "OBSERVATION", 8, 11]]], ["Therefore, if IAV and RSV are representative, these results suggest that ozone treatment at 20 ppm or greater, 70% or greater relative humidity at room temperature, and for at least 40 minutes should reliably inactivate enveloped viruses on a variety of materials of use in medical PPE.Effects of exposure time, humidity, and ozone concentration on virus inactivation.", [["ozone", "CHEMICAL", 73, 78], ["ozone", "CHEMICAL", 326, 331], ["ozone", "CHEMICAL", 73, 78], ["ozone", "CHEMICAL", 326, 331], ["IAV", "ORGANISM", 14, 17], ["RSV", "ORGANISM", 22, 25], ["ozone", "SIMPLE_CHEMICAL", 73, 78], ["ozone", "SIMPLE_CHEMICAL", 326, 331], ["IAV", "SPECIES", 14, 17], ["RSV", "SPECIES", 22, 25], ["IAV", "PROBLEM", 14, 17], ["RSV", "PROBLEM", 22, 25], ["ozone treatment", "TREATMENT", 73, 88], ["enveloped viruses", "PROBLEM", 220, 237], ["humidity", "TREATMENT", 312, 320], ["ozone concentration", "TREATMENT", 326, 345], ["virus inactivation", "TREATMENT", 349, 367], ["viruses", "OBSERVATION", 230, 237]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint Figure 2 . (a-f) Inactivation of influenza A virus by ozone under various conditions.", [["CC", "CHEMICAL", 0, 2], ["influenza A virus", "DISEASE", 375, 392], ["ozone", "CHEMICAL", 396, 401], ["ozone", "CHEMICAL", 396, 401], ["influenza A virus", "ORGANISM", 375, 392], ["ozone", "SIMPLE_CHEMICAL", 396, 401], ["influenza A virus", "SPECIES", 375, 392], ["influenza A virus", "SPECIES", 375, 392], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["influenza A virus", "PROBLEM", 375, 392], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["influenza", "OBSERVATION", 375, 384]]], ["Vertical axis = decrease in IAV infectivity relative to the results obtained from saturation of virus-deposited materials with 70% ethyl alcohol relative to samples receiving no disinfection treatment. (e) 80% RH at 24 \u00b0C = approx.", [["samples", "ANATOMY", 157, 164], ["ethyl alcohol", "CHEMICAL", 131, 144], ["ethyl alcohol", "CHEMICAL", 131, 144], ["ethyl alcohol", "SIMPLE_CHEMICAL", 131, 144], ["Vertical axis", "PROBLEM", 0, 13], ["decrease in IAV infectivity", "PROBLEM", 16, 43], ["virus", "PROBLEM", 96, 101], ["disinfection treatment", "TREATMENT", 178, 200], ["axis", "OBSERVATION_MODIFIER", 9, 13], ["decrease", "OBSERVATION_MODIFIER", 16, 24], ["IAV infectivity", "OBSERVATION", 28, 43]]], ["17.4 g/m 3 water vapor; 53% RH at 48\u00b0C = approx.", [["water vapor", "TEST", 11, 22]]], ["40 g/m 3 . (g) Inactivation of RSV by ozone.", [["RSV", "DISEASE", 31, 34], ["ozone", "CHEMICAL", 38, 43], ["ozone", "CHEMICAL", 38, 43], ["RSV", "ORGANISM", 31, 34], ["ozone", "SIMPLE_CHEMICAL", 38, 43], ["RSV", "SPECIES", 31, 34], ["RSV", "PROBLEM", 31, 34], ["RSV", "OBSERVATION", 31, 34]]], ["RH = relative humidity.", [["relative", "OBSERVATION_MODIFIER", 5, 13], ["humidity", "OBSERVATION_MODIFIER", 14, 22]]], ["2way ANOVAs with Tukey's multiple comparison tests were performed for the data in panels a, c-e, and g.", [["Tukey's multiple comparison tests", "TEST", 17, 50], ["the data", "TEST", 70, 78]]], ["A 2way ANOVA with a Tukey's multiple comparison test was run for panel b, except for N95 samples, for which a t-test was performed.", [["N95 samples", "ANATOMY", 85, 96], ["a Tukey's multiple comparison test", "TEST", 18, 52], ["panel b", "TEST", 65, 72], ["N95 samples", "TEST", 85, 96], ["a t-test", "TEST", 108, 116]]], ["A Brown-Forsythe and Welch ANOVA with a Dunnet's T3 multiple comparisons test was run for panel f. * p < 0.02, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.Effects of ozone on materials propertiesWe exposed larger swaths of Tyvek fabric from various sources, as well as cloth masks, N95 respirator material, and polycarbonate face shields to multiple cycles of ozone exposure (20 ppm) adding up to two hours or more.", [["ozone", "CHEMICAL", 170, 175], ["ozone", "CHEMICAL", 364, 369], ["ozone", "CHEMICAL", 170, 175], ["polycarbonate", "CHEMICAL", 315, 328], ["ozone", "CHEMICAL", 364, 369], ["ozone", "SIMPLE_CHEMICAL", 170, 175], ["ozone", "SIMPLE_CHEMICAL", 364, 369], ["a Dunnet's T3", "TREATMENT", 38, 51], ["p", "TEST", 101, 102], ["ozone on materials properties", "TREATMENT", 170, 199], ["Tyvek fabric", "TREATMENT", 227, 239], ["cloth masks", "TREATMENT", 273, 284], ["N95 respirator material", "TREATMENT", 286, 309], ["polycarbonate face shields", "TREATMENT", 315, 341], ["ozone exposure", "TREATMENT", 364, 378], ["Brown", "OBSERVATION_MODIFIER", 2, 7], ["ozone", "OBSERVATION_MODIFIER", 170, 175], ["larger", "OBSERVATION_MODIFIER", 210, 216], ["Tyvek fabric", "OBSERVATION_MODIFIER", 227, 239], ["various sources", "OBSERVATION", 245, 260], ["respirator material", "OBSERVATION", 290, 309]]], ["With one important exception, no perceptible changes occurred in any material, including goggle transparency, the integrity of seams and glued components, and the appearance and function valve assemblies and other plastic components (such as zippers).", [["perceptible changes", "PROBLEM", 33, 52], ["goggle transparency", "PROBLEM", 89, 108], ["function valve assemblies", "TREATMENT", 178, 203], ["other plastic components", "TREATMENT", 208, 232], ["no", "UNCERTAINTY", 30, 32], ["perceptible", "OBSERVATION_MODIFIER", 33, 44], ["changes", "OBSERVATION", 45, 52], ["integrity", "OBSERVATION_MODIFIER", 114, 123], ["glued", "OBSERVATION_MODIFIER", 137, 142], ["components", "OBSERVATION_MODIFIER", 143, 153], ["function valve", "OBSERVATION", 178, 192], ["plastic components", "OBSERVATION", 214, 232]]], ["While we did not perform quantitative fit testing of the respirators post-treatment, no deformations were observed following any of the ozone treatment variations.", [["deformations", "DISEASE", 88, 100], ["ozone", "CHEMICAL", 136, 141], ["ozone", "CHEMICAL", 136, 141], ["the respirators", "TREATMENT", 53, 68], ["treatment", "TREATMENT", 74, 83], ["deformations", "PROBLEM", 88, 100], ["the ozone treatment variations", "TREATMENT", 132, 162]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint assessments is provided in Table S4 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint assessments", "TEST", 325, 353], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Quantitative rheological measurements were not performed.(which was not certified by peer review)Only the elastic headbands of some N95 respirators were found to be degraded by ozone treatment, and only when the material was strained during exposure, either by function of a stapled attachment to the respirator or by tying off in a stretched state in the ozone cabinet ( Figure S3 ).", [["ozone", "CHEMICAL", 177, 182], ["ozone", "CHEMICAL", 356, 361], ["ozone", "CHEMICAL", 177, 182], ["ozone", "CHEMICAL", 356, 361], ["ozone", "SIMPLE_CHEMICAL", 177, 182], ["Quantitative rheological measurements", "TEST", 0, 37], ["some N95 respirators", "TREATMENT", 127, 147], ["ozone treatment", "TREATMENT", 177, 192], ["a stapled attachment to the respirator", "TREATMENT", 273, 311], ["elastic", "OBSERVATION_MODIFIER", 106, 113], ["stapled", "OBSERVATION", 275, 282]]], ["The degradation of strained rubber upon exposure to ozone has been previously described, 28 presumably due to scission of C=C double bonds in the polymers which results in cracking orthogonal to the strain.", [["ozone", "CHEMICAL", 52, 57], ["ozone", "CHEMICAL", 52, 57], ["C=C", "CHEMICAL", 122, 125], ["ozone", "SIMPLE_CHEMICAL", 52, 57], ["C=C double bonds", "SIMPLE_CHEMICAL", 122, 138], ["strained rubber", "PROBLEM", 19, 34], ["C=C double bonds in the polymers", "TREATMENT", 122, 154], ["cracking orthogonal to the strain", "PROBLEM", 172, 205], ["strained rubber", "OBSERVATION", 19, 34]]], ["We found that even a short exposure of strained elastics to 20 ppm O3 (15 minutes, less than generally required for viral inactivation) often resulted in compromised headband integrity or complete failure.(which was not certified by peer review)A subset of NIOSH-approved N95 respirators cleared by the Food and Drug Administration (FDA) are referred to as Surgical N95 Respirators.", [["O3", "CHEMICAL", 67, 69], ["O3", "CHEMICAL", 67, 69], ["N95", "ORGANISM", 272, 275], ["strained elastics", "TREATMENT", 39, 56], ["viral inactivation", "TREATMENT", 116, 134], ["compromised headband integrity", "PROBLEM", 154, 184], ["complete failure", "PROBLEM", 188, 204], ["N95 respirators", "TREATMENT", 272, 287], ["compromised", "OBSERVATION_MODIFIER", 154, 165], ["headband integrity", "OBSERVATION", 166, 184], ["complete", "OBSERVATION_MODIFIER", 188, 196], ["failure", "OBSERVATION", 197, 204]]], ["29 While we were unable to obtain samples of these FDA-approved respirators, many are manufactured with stapled headband attachments.", [["stapled headband attachments", "TREATMENT", 104, 132], ["stapled", "OBSERVATION", 104, 111]]], ["This presents a significant practical barrier to the use of ozone to disinfect N95 respirators.", [["ozone", "CHEMICAL", 60, 65], ["ozone", "CHEMICAL", 60, 65], ["ozone", "SIMPLE_CHEMICAL", 60, 65], ["N95 respirators", "TREATMENT", 79, 94], ["significant", "OBSERVATION_MODIFIER", 16, 27]]], ["However, headbands made of thermoplastic elastomer or polyisoprene with polypropylene overbraid can be attached by ultrasonic welding (such as the 3M 8210 and ZKG9501 KN95 respirators that we were able to obtain for this study).", [["polyisoprene", "CHEMICAL", 54, 66], ["polypropylene overbraid", "CHEMICAL", 72, 95], ["polyisoprene", "CHEMICAL", 54, 66], ["polypropylene", "CHEMICAL", 72, 85], ["polyisoprene", "SIMPLE_CHEMICAL", 54, 66], ["polypropylene overbraid", "SIMPLE_CHEMICAL", 72, 95], ["thermoplastic elastomer", "TREATMENT", 27, 50], ["polyisoprene", "TREATMENT", 54, 66], ["polypropylene overbraid", "TREATMENT", 72, 95], ["ZKG9501 KN95 respirators", "TREATMENT", 159, 183], ["this study", "TEST", 216, 226]]], ["These headbands showed no degradation upon several hours of repeated ozone treatments (Figure S4) , and so we surmise that welded attachments do not induce significant elastomer strain at the point of attachment.N95 particle filtration efficiencyFull-thickness sections of N95 respirator material before and after extensive ozone exposure were tested for filtration ability using sodium chloride aerosols in a manner closely analogous to the NIOSH N95 respirator penetration testing guidelines.", [["sections", "ANATOMY", 261, 269], ["ozone", "CHEMICAL", 69, 74], ["ozone", "CHEMICAL", 324, 329], ["sodium chloride", "CHEMICAL", 380, 395], ["ozone", "CHEMICAL", 69, 74], ["ozone", "CHEMICAL", 324, 329], ["sodium chloride", "CHEMICAL", 380, 395], ["sections", "MULTI-TISSUE_STRUCTURE", 261, 269], ["sodium chloride aerosols", "SIMPLE_CHEMICAL", 380, 404], ["These headbands", "TEST", 0, 15], ["degradation", "PROBLEM", 26, 37], ["repeated ozone treatments", "TREATMENT", 60, 85], ["significant elastomer strain", "PROBLEM", 156, 184], ["N95 particle filtration efficiency", "TREATMENT", 212, 246], ["N95 respirator material", "TREATMENT", 273, 296], ["extensive ozone exposure", "TREATMENT", 314, 338], ["sodium chloride aerosols", "TREATMENT", 380, 404], ["no", "UNCERTAINTY", 23, 25], ["degradation", "OBSERVATION_MODIFIER", 26, 37], ["significant", "OBSERVATION_MODIFIER", 156, 167], ["elastomer strain", "OBSERVATION", 168, 184], ["filtration efficiency", "OBSERVATION", 225, 246]]], ["30 No substantial loss of filtration performance was found for these ozone-treated materials ( Figure S5 , Table S5 ).Additional experiments and conclusionsOzone is readily and inexpensively generated and has a long history of disinfection use against bacteria, fungi, and other viruses.", [["ozone", "CHEMICAL", 69, 74], ["Ozone", "CHEMICAL", 156, 161], ["ozone", "CHEMICAL", 69, 74], ["Ozone", "CHEMICAL", 156, 161], ["ozone", "SIMPLE_CHEMICAL", 69, 74], ["Ozone", "SIMPLE_CHEMICAL", 156, 161], ["substantial loss of filtration performance", "PROBLEM", 6, 48], ["disinfection", "PROBLEM", 227, 239], ["bacteria", "PROBLEM", 252, 260], ["fungi", "PROBLEM", 262, 267], ["other viruses", "PROBLEM", 273, 286], ["substantial", "OBSERVATION_MODIFIER", 6, 17], ["loss", "OBSERVATION", 18, 22], ["viruses", "OBSERVATION", 279, 286]]], ["As a highly oxidizing and diffusible species, it causes damage to lipid membranes, 31 amino acids, 32,33 and polynucleotides; 20,34-40 an early report on a nonenveloped virus (poliovirus) identified genomic damage as the most likely mechanism of viral inactivation.", [["lipid membranes", "ANATOMY", 66, 81], ["amino acids", "CHEMICAL", 86, 97], ["genomic damage", "DISEASE", 199, 213], ["amino acids", "CHEMICAL", 86, 97], ["lipid membranes", "CELLULAR_COMPONENT", 66, 81], ["amino acids", "AMINO_ACID", 86, 97], ["a highly oxidizing and diffusible species", "PROBLEM", 3, 44], ["damage to lipid membranes", "PROBLEM", 56, 81], ["amino acids", "TEST", 86, 97], ["polynucleotides", "TEST", 109, 124], ["a nonenveloped virus (poliovirus)", "PROBLEM", 154, 187], ["genomic damage", "PROBLEM", 199, 213], ["viral inactivation", "PROBLEM", 246, 264], ["diffusible species", "OBSERVATION", 26, 44], ["genomic damage", "OBSERVATION", 199, 213], ["most likely", "UNCERTAINTY", 221, 232], ["viral inactivation", "OBSERVATION", 246, 264]]], ["41 We established here that ozone is highly effective in the inactivation of enveloped respiratory viruses that serve as surrogates for coronaviruses, as long as the relative humidity during ozone exposure is approximately 50% or greater at room temperature.", [["ozone", "CHEMICAL", 28, 33], ["ozone", "CHEMICAL", 191, 196], ["ozone", "CHEMICAL", 28, 33], ["ozone", "CHEMICAL", 191, 196], ["ozone", "SIMPLE_CHEMICAL", 28, 33], ["coronaviruses", "ORGANISM", 136, 149], ["ozone", "SIMPLE_CHEMICAL", 191, 196], ["enveloped respiratory viruses", "PROBLEM", 77, 106], ["coronaviruses", "PROBLEM", 136, 149], ["ozone exposure", "TEST", 191, 205], ["ozone", "OBSERVATION_MODIFIER", 28, 33], ["highly", "OBSERVATION_MODIFIER", 37, 43], ["effective", "OBSERVATION_MODIFIER", 44, 53], ["respiratory viruses", "OBSERVATION", 87, 106]]], ["Although not presented above because of inadequate numbers of replicates or controls, we made several additional observations that may be useful to others. (i) We found that the deactivation of viruses could be enhanced by the simple expedient of including water-saturated paper towels in the sample space of the personal PAP cleaning device and the larger Global Ozone Innovations (GOI) cabinet. (ii) A brief test of plastic tubing used in a standard hospital ventilator showed highly effective virus deactivation under the same conditions found effective for Tyvek, but care must be taken to make sure that ozone can reach throughout the interior of the ventilator tube.", [["Ozone", "CHEMICAL", 364, 369], ["ozone", "CHEMICAL", 609, 614], ["Ozone", "CHEMICAL", 364, 369], ["ozone", "CHEMICAL", 609, 614], ["ozone", "SIMPLE_CHEMICAL", 609, 614], ["ventilator tube", "TISSUE", 656, 671], ["the deactivation of viruses", "PROBLEM", 174, 201], ["water-saturated paper towels", "TREATMENT", 257, 285], ["the personal PAP cleaning device", "TREATMENT", 309, 341], ["plastic tubing", "TREATMENT", 418, 432], ["a standard hospital ventilator", "TREATMENT", 441, 471], ["highly effective virus deactivation", "PROBLEM", 479, 514], ["the ventilator tube", "TREATMENT", 652, 671], ["viruses", "OBSERVATION", 194, 201], ["simple", "OBSERVATION_MODIFIER", 227, 233], ["expedient", "OBSERVATION_MODIFIER", 234, 243], ["larger", "OBSERVATION_MODIFIER", 350, 356], ["Global", "OBSERVATION_MODIFIER", 357, 363], ["Ozone Innovations", "OBSERVATION", 364, 381], ["plastic tubing", "OBSERVATION", 418, 432], ["effective", "OBSERVATION_MODIFIER", 486, 495], ["virus", "OBSERVATION", 496, 501], ["ventilator tube", "OBSERVATION", 656, 671]]], ["Just placing a coiled length of ventilator tubing inside an ozone cabinet may not ensure adequate air flow for this purpose.Additional experiments and conclusions.", [["ozone", "CHEMICAL", 60, 65], ["ozone", "CHEMICAL", 60, 65], ["a coiled length of ventilator tubing", "TREATMENT", 13, 49], ["an ozone cabinet", "TREATMENT", 57, 73], ["coiled", "OBSERVATION", 15, 21], ["length", "OBSERVATION_MODIFIER", 22, 28], ["ventilator tubing", "OBSERVATION", 32, 49], ["ozone", "OBSERVATION", 60, 65], ["may not ensure", "UNCERTAINTY", 74, 88], ["adequate", "OBSERVATION_MODIFIER", 89, 97], ["air flow", "OBSERVATION", 98, 106]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint (iii) We also had the opportunity to test the performance of a trailer equipped by GOI to disinfect a large number of garments or other pieces of equipment in a single run.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["large", "OBSERVATION_MODIFIER", 444, 449]]], ["This unit used 16 corona discharge generators to disinfect a volume of 30 cubic meters, probably reaching ozone concentrations of hundreds of ppm.", [["ozone", "CHEMICAL", 106, 111], ["ozone", "CHEMICAL", 106, 111], ["ozone", "SIMPLE_CHEMICAL", 106, 111], ["16 corona discharge generators", "TREATMENT", 15, 45], ["a volume of 30 cubic meters", "TREATMENT", 59, 86]]], ["Our results were highly variable due to variations in ambient relative humidity, following closely on the trends described above for more highly controlled devices.(which was not certified by peer review)In addition to the aforementioned studies of nonenveloped 21 and enveloped 24 viruses, the key role of relative humidity in ozone reactivity has additional precedent in the literature.", [["ozone", "CHEMICAL", 328, 333], ["ozone", "CHEMICAL", 328, 333], ["ozone", "SIMPLE_CHEMICAL", 328, 333], ["ambient relative humidity", "TREATMENT", 54, 79], ["the aforementioned studies", "TEST", 219, 245], ["ozone reactivity", "OBSERVATION", 328, 344]]], ["Humidity has been found to be an important accelerant of ozone reactivity with small organic molecules in aerosol particles, for reasons having to do with substrate solubility at the particle-gas interface 42 and other surface properties and chemistries.", [["surface", "ANATOMY", 219, 226], ["ozone", "CHEMICAL", 57, 62], ["ozone", "CHEMICAL", 57, 62], ["ozone", "SIMPLE_CHEMICAL", 57, 62], ["Humidity", "TREATMENT", 0, 8], ["small organic molecules in aerosol particles", "TREATMENT", 79, 123], ["substrate solubility", "TREATMENT", 155, 175], ["chemistries", "TEST", 242, 253], ["small", "OBSERVATION_MODIFIER", 79, 84], ["organic molecules", "OBSERVATION", 85, 102], ["aerosol particles", "OBSERVATION", 106, 123]]], ["43, 44 Similarly, lignin degradation by ozone is sensitive to moisture for complex reasons, 45 On the other hand, relative humidity was not found to be a strong contributing factor to the reactivity of ozone with other kinds of surfaces, such as inorganic oxides.", [["lignin", "CHEMICAL", 18, 24], ["ozone", "CHEMICAL", 40, 45], ["ozone", "CHEMICAL", 202, 207], ["inorganic oxides", "CHEMICAL", 246, 262], ["ozone", "CHEMICAL", 40, 45], ["ozone", "CHEMICAL", 202, 207], ["oxides", "CHEMICAL", 256, 262], ["lignin", "SIMPLE_CHEMICAL", 18, 24], ["ozone", "SIMPLE_CHEMICAL", 40, 45], ["ozone", "SIMPLE_CHEMICAL", 202, 207], ["inorganic oxides", "SIMPLE_CHEMICAL", 246, 262], ["inorganic oxides", "TREATMENT", 246, 262]]], ["46, 47 We suggest that humidity may play at least two potential roles in rendering ozone more damaging to enveloped viruses: (a) water may promote the generation of highly reactive hydroxyl radicals from ozone, 48, 49 and (b) more humidity may plasticize surfaces or otherwise make it easier for ozone to interact with surface-bound species, such as by diffusion to reach the viruses.(which was not certified by peer review)As noted above, the major impediment to the use of ozone for the decontamination of large numbers of N95 respirators is damage caused to elastic headbands when secured by staples.", [["surface", "ANATOMY", 319, 326], ["ozone", "CHEMICAL", 83, 88], ["hydroxyl", "CHEMICAL", 181, 189], ["ozone", "CHEMICAL", 204, 209], ["ozone", "CHEMICAL", 296, 301], ["ozone", "CHEMICAL", 475, 480], ["ozone", "CHEMICAL", 83, 88], ["hydroxyl", "CHEMICAL", 181, 189], ["ozone", "CHEMICAL", 204, 209], ["ozone", "CHEMICAL", 296, 301], ["ozone", "CHEMICAL", 475, 480], ["ozone", "SIMPLE_CHEMICAL", 83, 88], ["reactive hydroxyl radicals", "SIMPLE_CHEMICAL", 172, 198], ["ozone", "SIMPLE_CHEMICAL", 204, 209], ["ozone", "SIMPLE_CHEMICAL", 296, 301], ["ozone", "SIMPLE_CHEMICAL", 475, 480], ["humidity", "TREATMENT", 23, 31], ["surface-bound species", "PROBLEM", 319, 340], ["ozone", "TREATMENT", 475, 480], ["the decontamination", "TREATMENT", 485, 504], ["N95 respirators", "TREATMENT", 525, 540], ["damage", "PROBLEM", 544, 550], ["elastic headbands", "TREATMENT", 561, 578], ["staples", "TREATMENT", 595, 602], ["reactive", "OBSERVATION_MODIFIER", 172, 180], ["hydroxyl radicals", "OBSERVATION", 181, 198], ["viruses", "OBSERVATION", 376, 383], ["large", "OBSERVATION_MODIFIER", 508, 513], ["elastic headbands", "OBSERVATION", 561, 578], ["staples", "OBSERVATION", 595, 602]]], ["This would seem to require detachment and reattachment of the elastic before and after ozone treatment (the elastic can be treated with ozone as long as it isn't stretched), or by re-engineering of the attachment method such as by replacing the bands with cloth ties.", [["ozone", "CHEMICAL", 87, 92], ["ozone", "CHEMICAL", 136, 141], ["ozone", "CHEMICAL", 87, 92], ["ozone", "CHEMICAL", 136, 141], ["ozone", "SIMPLE_CHEMICAL", 87, 92], ["detachment", "PROBLEM", 27, 37], ["reattachment", "TREATMENT", 42, 54], ["ozone treatment", "TREATMENT", 87, 102], ["ozone", "TREATMENT", 136, 141], ["the bands with cloth ties", "TREATMENT", 241, 266], ["detachment", "OBSERVATION", 27, 37], ["reattachment", "OBSERVATION_MODIFIER", 42, 54], ["elastic", "OBSERVATION_MODIFIER", 62, 69]]], ["However, scalable humid ozone treatment does seem to be a robust potential solution for many other materials, in addition to airborne viruses.", [["ozone", "CHEMICAL", 24, 29], ["ozone", "CHEMICAL", 24, 29], ["scalable humid ozone treatment", "TREATMENT", 9, 39], ["airborne viruses", "PROBLEM", 125, 141], ["airborne viruses", "OBSERVATION", 125, 141]]], ["21MethodsDescription of fabric sample swatches: Fabric samples for viral inoculation were prepared by cutting 1 cm x 1 cm sample swatches from four different materials: surgical face masks, Tyvek (disposable gown), N95 respirators, bunny suits, and PAPR hoods (both the fabric and plastic face shield).MethodsCell lines and Viruses MDCK (ATCC) and HEp-2 (ATCC) cells were maintained in DMEM + 10% fetal bovine serum and 1% pen-strep at 5% CO2 and 37\u00b0C. H1N1 Influenza A WSN/33-PA-2A-NLuc (BEI) and RSV-luc5 (Viratree) reporter strains were obtained from the indicated suppliers, and designated here as \"IAV\" and \"RSV,\" respectively.", [["Fabric samples", "ANATOMY", 48, 62], ["face", "ANATOMY", 178, 182], ["Cell lines", "ANATOMY", 309, 319], ["MDCK", "ANATOMY", 332, 336], ["ATCC", "ANATOMY", 338, 342], ["HEp-2 (ATCC) cells", "ANATOMY", 348, 366], ["fetal bovine serum", "ANATOMY", 397, 415], ["CO2", "CHEMICAL", 439, 442], ["WSN/33-PA-2A-NLuc", "CHEMICAL", 470, 487], ["CO2", "CHEMICAL", 439, 442], ["Fabric samples", "CANCER", 48, 62], ["Cell lines", "CELL", 309, 319], ["Viruses MDCK", "CELL", 324, 336], ["ATCC", "CELL", 338, 342], ["HEp-2 (ATCC) cells", "CELL", 348, 366], ["bovine", "ORGANISM", 403, 409], ["serum", "ORGANISM_SUBSTANCE", 410, 415], ["CO2", "SIMPLE_CHEMICAL", 439, 442], ["H1N1", "ORGANISM", 453, 457], ["Influenza A WSN", "ORGANISM", 458, 473], ["33-PA-2A", "ORGANISM", 474, 482], ["NLuc", "GENE_OR_GENE_PRODUCT", 483, 487], ["BEI", "GENE_OR_GENE_PRODUCT", 489, 492], ["RSV-luc5", "ORGANISM", 498, 506], ["Viratree", "GENE_OR_GENE_PRODUCT", 508, 516], ["RSV", "ORGANISM", 613, 616], ["Cell lines", "CELL_LINE", 309, 319], ["Viruses MDCK", "CELL_LINE", 324, 336], ["ATCC", "CELL_LINE", 338, 342], ["HEp-2 (ATCC) cells", "CELL_LINE", 348, 366], ["NLuc (BEI) and RSV-luc5 (Viratree) reporter strains", "DNA", 483, 534], ["bovine", "SPECIES", 403, 409], ["H1N1 Influenza", "SPECIES", 453, 467], ["RSV", "SPECIES", 498, 501], ["bovine", "SPECIES", 403, 409], ["RSV-luc5", "SPECIES", 498, 506], ["RSV", "SPECIES", 613, 616], ["Fabric samples", "TREATMENT", 48, 62], ["viral inoculation", "PROBLEM", 67, 84], ["sample swatches", "TEST", 122, 137], ["surgical face masks", "TREATMENT", 169, 188], ["Tyvek (disposable gown", "TREATMENT", 190, 212], ["N95 respirators", "TREATMENT", 215, 230], ["bunny suits", "TREATMENT", 232, 243], ["PAPR hoods", "TREATMENT", 249, 259], ["the fabric and plastic face shield", "TREATMENT", 266, 300], ["MethodsCell lines", "TREATMENT", 302, 319], ["Viruses MDCK (ATCC)", "TEST", 324, 343], ["HEp-2 (ATCC) cells", "TREATMENT", 348, 366], ["DMEM", "TEST", 386, 390], ["fetal bovine serum", "TEST", 397, 415], ["CO2", "TEST", 439, 442], ["H1N1 Influenza", "TEST", 453, 467], ["A WSN", "TEST", 468, 473], ["PA", "TEST", 477, 479], ["NLuc", "TEST", 483, 487], ["BEI", "TEST", 489, 492], ["RSV", "TEST", 498, 501], ["reporter strains", "TEST", 518, 534], ["Cell lines", "OBSERVATION", 309, 319], ["RSV", "ANATOMY", 498, 501]]], ["Viral stocks were prepared as follows.", [["Viral", "ORGANISM", 0, 5], ["Viral stocks", "PROBLEM", 0, 12]]], ["IAV was propagated in MDCK cells, where virus was added to cells at a multiplicity of infection (MOI) of 0.01 for 45 minutes before being removed and replaced with virus growth medium (DMEM with 1% pen-strep, 2 mM L-glutamine, 0.2% bovine serum albumin, and 25 mM HEPES buffer).", [["MDCK cells", "ANATOMY", 22, 32], ["cells", "ANATOMY", 59, 64], ["serum", "ANATOMY", 239, 244], ["infection", "DISEASE", 86, 95], ["L-glutamine", "CHEMICAL", 214, 225], ["L-glutamine", "CHEMICAL", 214, 225], ["HEPES", "CHEMICAL", 264, 269], ["IAV", "ORGANISM", 0, 3], ["MDCK cells", "CELL", 22, 32], ["cells", "CELL", 59, 64], ["L-glutamine", "SIMPLE_CHEMICAL", 214, 225], ["bovine", "ORGANISM", 232, 238], ["serum", "ORGANISM_SUBSTANCE", 239, 244], ["albumin", "SIMPLE_CHEMICAL", 245, 252], ["MDCK cells", "CELL_LINE", 22, 32], ["bovine", "SPECIES", 232, 238], ["IAV", "SPECIES", 0, 3], ["IAV", "PROBLEM", 0, 3], ["virus", "PROBLEM", 40, 45], ["infection", "PROBLEM", 86, 95], ["virus growth medium", "TREATMENT", 164, 183], ["1% pen-strep", "TREATMENT", 195, 207], ["2 mM L-glutamine", "TREATMENT", 209, 225], ["0.2% bovine serum albumin", "TREATMENT", 227, 252], ["25 mM HEPES buffer", "TREATMENT", 258, 276], ["MDCK cells", "OBSERVATION", 22, 32], ["infection", "OBSERVATION", 86, 95]]], ["Virus was harvested when 90% of the cytopathic effects were visualized.", [["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5], ["the cytopathic effects", "PROBLEM", 32, 54], ["cytopathic", "OBSERVATION_MODIFIER", 36, 46]]], ["Media was collected, spun down at 300xg for 15 minutes to remove cell .", [["cell", "ANATOMY", 65, 69], ["cell", "CELL", 65, 69]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint debris and supernatant was aliquoted.", [["supernatant", "ANATOMY", 353, 364], ["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint debris", "TREATMENT", 325, 348], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["debris", "OBSERVATION", 342, 348]]], ["RSV was propagated in HEp-2 cells, where virus was added to cells at a MOI of 0.1 for 1 h before adding virus growth medium (DMEM with 10% fetal bovine serum and 1% pen-strep) to the inoculum.", [["HEp-2 cells", "ANATOMY", 22, 33], ["cells", "ANATOMY", 60, 65], ["fetal bovine serum", "ANATOMY", 139, 157], ["pen-strep", "ANATOMY", 165, 174], ["RSV", "ORGANISM", 0, 3], ["HEp-2 cells", "CELL", 22, 33], ["cells", "CELL", 60, 65], ["bovine", "ORGANISM", 145, 151], ["serum", "ORGANISM_SUBSTANCE", 152, 157], ["HEp-2 cells", "CELL_LINE", 22, 33], ["bovine", "SPECIES", 145, 151], ["RSV", "SPECIES", 0, 3], ["bovine", "SPECIES", 145, 151], ["RSV", "PROBLEM", 0, 3], ["HEp-2 cells", "TREATMENT", 22, 33], ["virus", "PROBLEM", 41, 46], ["virus growth medium", "PROBLEM", 104, 123], ["DMEM", "TEST", 125, 129], ["fetal bovine serum", "TEST", 139, 157], ["inoculum", "OBSERVATION", 183, 191]]], ["Cell-associated virus was harvested by scraping the cells when 90% of cytopathic effects were visualized.", [["Cell", "ANATOMY", 0, 4], ["cells", "ANATOMY", 52, 57], ["Cell", "CELL", 0, 4], ["cells", "CELL", 52, 57], ["Cell-associated virus", "PROBLEM", 0, 21], ["cytopathic effects", "PROBLEM", 70, 88], ["virus", "OBSERVATION", 16, 21], ["cytopathic", "OBSERVATION_MODIFIER", 70, 80]]], ["Virus-containing media was then vortexed and aliquoted for use.Sample preparation and disinfectionVirus solutions (50 \u00b5L) in growth media at ~10 5 PFU/ml were deposited by pipette onto 1 cm x 1 cm pieces of each candidate material, as evenly as possible over at least half of the surface area.", [["surface area", "ANATOMY", 280, 292], ["Virus", "ORGANISM", 0, 5], ["Virus-containing media", "TREATMENT", 0, 22], ["Sample preparation", "TREATMENT", 63, 81], ["disinfectionVirus solutions", "TREATMENT", 86, 113], ["growth media", "TREATMENT", 125, 137], ["surface", "OBSERVATION_MODIFIER", 280, 287]]], ["The samples were allowed to dry in air at room temperature for 30 minutes and were transported to the disinfection unit in plastic cases.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["air", "OBSERVATION", 35, 38]]], ["For initial treatment experiments, samples were left inside open cases during ozone exposure.", [["samples", "ANATOMY", 35, 42], ["ozone", "CHEMICAL", 78, 83], ["ozone", "CHEMICAL", 78, 83], ["ozone", "SIMPLE_CHEMICAL", 78, 83], ["initial treatment experiments", "TREATMENT", 4, 33], ["samples", "TEST", 35, 42]]], ["To better approximate the treatment of actual intact PPE garments and materials, most subsequent samples were pinned to cotton shirts and hung in the ozone cabinets so as to allow air/ozone access to both sides of the sample swatch.", [["samples", "ANATOMY", 97, 104], ["sample", "ANATOMY", 218, 224], ["ozone", "CHEMICAL", 150, 155], ["ozone", "CHEMICAL", 184, 189], ["ozone", "CHEMICAL", 150, 155], ["ozone", "CHEMICAL", 184, 189], ["actual intact PPE garments", "TREATMENT", 39, 65], ["air/ozone access", "TREATMENT", 180, 196], ["the sample swatch", "TEST", 214, 231], ["PPE garments", "OBSERVATION", 53, 65]]], ["For the small zippered pouch of the VirtuCLEAN PAP cleaning device, the samples were pinned to an N95 respirator placed inside the pouch.Sample preparation and disinfectionNo-disinfection control samples remained at room temperature dry and untreated, while ethanol controls were sprayed with 70% ethanol and then allowed to dry and remain at room temperature for the duration of the disinfection procedure.", [["samples", "ANATOMY", 72, 79], ["pouch", "ANATOMY", 131, 136], ["samples", "ANATOMY", 196, 203], ["ethanol", "CHEMICAL", 258, 265], ["ethanol", "CHEMICAL", 297, 304], ["ethanol", "CHEMICAL", 258, 265], ["ethanol", "CHEMICAL", 297, 304], ["pouch", "TISSUE", 131, 136], ["ethanol", "SIMPLE_CHEMICAL", 258, 265], ["ethanol", "SIMPLE_CHEMICAL", 297, 304], ["the small zippered pouch", "TREATMENT", 4, 28], ["the VirtuCLEAN PAP cleaning device", "TREATMENT", 32, 66], ["an N95 respirator", "TREATMENT", 95, 112], ["Sample preparation", "TREATMENT", 137, 155], ["disinfectionNo-disinfection control", "TREATMENT", 160, 195], ["ethanol controls", "TREATMENT", 258, 274], ["70% ethanol", "TREATMENT", 293, 304], ["the disinfection procedure", "TREATMENT", 380, 406], ["small", "OBSERVATION_MODIFIER", 8, 13], ["zippered pouch", "OBSERVATION", 14, 28], ["cleaning device", "OBSERVATION", 51, 66], ["pouch", "ANATOMY", 131, 136]]], ["After treatment (or control non-treatment), fabric samples were immersed in 300 \u03bcL of virus growth media (for IAV, DMEM with 1% pen-strep, 2 mM L-glutamine, 0.2% bovine serum albumin, and 25 mM HEPES buffer; for RSV, DMEM with 10% fetal bovine serum and 1% pen-strep) for 30 minutes at room temperature in the top of a 0.65 \u03bcm filter.", [["samples", "ANATOMY", 51, 58], ["serum", "ANATOMY", 169, 174], ["fetal bovine serum", "ANATOMY", 231, 249], ["pen-strep", "ANATOMY", 257, 266], ["L-glutamine", "CHEMICAL", 144, 155], ["L-glutamine", "CHEMICAL", 144, 155], ["L-glutamine", "SIMPLE_CHEMICAL", 144, 155], ["bovine", "ORGANISM", 162, 168], ["serum", "ORGANISM_SUBSTANCE", 169, 174], ["albumin", "SIMPLE_CHEMICAL", 175, 182], ["RSV", "ORGANISM", 212, 215], ["bovine", "ORGANISM", 237, 243], ["serum", "ORGANISM_SUBSTANCE", 244, 249], ["bovine", "SPECIES", 162, 168], ["bovine", "SPECIES", 237, 243], ["IAV", "SPECIES", 110, 113], ["RSV", "SPECIES", 212, 215], ["bovine", "SPECIES", 237, 243], ["treatment", "TREATMENT", 6, 15], ["fabric samples", "TEST", 44, 58], ["virus growth media", "PROBLEM", 86, 104], ["IAV", "PROBLEM", 110, 113], ["1% pen-strep", "TREATMENT", 125, 137], ["2 mM L-glutamine", "TREATMENT", 139, 155], ["0.2% bovine serum albumin", "TREATMENT", 157, 182], ["25 mM HEPES buffer", "TREATMENT", 188, 206], ["RSV", "PROBLEM", 212, 215], ["DMEM", "TEST", 217, 221], ["fetal bovine serum", "TEST", 231, 249], ["a 0.65 \u03bcm filter", "TREATMENT", 317, 333], ["\u03bcm filter", "OBSERVATION", 324, 333]]], ["Each sample was then spun at 12000xg for 2 minutes to extract virus/media, designated as \"virus inoculum.\"", [["sample", "ANATOMY", 5, 11]]], ["For virus applied to hard plastic surfaces, the surface was swabbed with a sterile cotton swab dipped in virus growth media.", [["surface", "ANATOMY", 48, 55], ["surface", "CELLULAR_COMPONENT", 48, 55], ["cotton", "SPECIES", 83, 89], ["virus", "PROBLEM", 4, 9], ["a sterile cotton swab", "TREATMENT", 73, 94], ["virus growth media", "PROBLEM", 105, 123], ["hard plastic", "OBSERVATION_MODIFIER", 21, 33], ["surfaces", "OBSERVATION_MODIFIER", 34, 42], ["surface", "OBSERVATION_MODIFIER", 48, 55], ["virus growth", "OBSERVATION", 105, 117]]], ["The cotton swab was then incubated in 300 \u03bcL of virus growth media for 30 minutes at room temperature, followed by removal of the swab and centrifugation at 12000xg for 2 minutes.", [["cotton swab", "ANATOMY", 4, 15], ["cotton swab", "ORGANISM_SUBSTANCE", 4, 15], ["cotton", "SPECIES", 4, 10], ["The cotton swab", "TEST", 0, 15], ["virus growth media", "TREATMENT", 48, 66], ["the swab", "TREATMENT", 126, 134], ["centrifugation", "TREATMENT", 139, 153]]], ["MDCK cells (IAV) or HEp-2 cells (RSV) plated in a 24 well plate at confluency were washed once with 1xPBS and then incubated with 100 \u03bcL of virus inoculum for 1 hour at 37\u00b0C, being rocked every 15 minutes.", [["MDCK cells", "ANATOMY", 0, 10], ["HEp-2 cells", "ANATOMY", 20, 31], ["MDCK cells", "CELL", 0, 10], ["IAV", "CELL", 12, 15], ["HEp-2 cells", "CELL", 20, 31], ["RSV", "ORGANISM", 33, 36], ["MDCK cells", "CELL_LINE", 0, 10], ["IAV", "CELL_LINE", 12, 15], ["HEp-2 cells", "CELL_LINE", 20, 31], ["IAV", "SPECIES", 12, 15], ["RSV", "SPECIES", 33, 36], ["MDCK cells", "TEST", 0, 10], ["IAV", "TEST", 12, 15], ["HEp-2 cells", "TREATMENT", 20, 31], ["1xPBS", "TREATMENT", 100, 105], ["virus inoculum", "TREATMENT", 140, 154], ["HEp", "ANATOMY", 20, 23]]], ["After 1 hour, the inoculum was removed and the cells were washed once with 1xPBS.", [["cells", "ANATOMY", 47, 52], ["cells", "CELL", 47, 52], ["the inoculum", "TREATMENT", 14, 26], ["the cells", "TREATMENT", 43, 52], ["1xPBS", "TREATMENT", 75, 80]]], ["500 \u03bcL of virus growth media was added to cells, which were then incubated at 37\u00b0C overnight before analysis.Sample preparation and disinfectionPlaque Assay MDCK cells were plated in 6-well plates until confluent.", [["cells", "ANATOMY", 42, 47], ["Plaque", "ANATOMY", 144, 150], ["MDCK cells", "ANATOMY", 157, 167], ["cells", "CELL", 42, 47], ["MDCK cells", "CELL", 157, 167], ["MDCK cells", "CELL_LINE", 157, 167], ["virus growth media", "TREATMENT", 10, 28], ["analysis", "TEST", 100, 108], ["Sample preparation", "TREATMENT", 109, 127], ["disinfection", "TREATMENT", 132, 144], ["Plaque Assay MDCK cells", "TEST", 144, 167], ["MDCK cells", "OBSERVATION", 157, 167], ["confluent", "OBSERVATION_MODIFIER", 203, 212]]], ["Cells were washed twice and incubated with 200 \u03bcL of virus inoculum, diluted in DMEM + 0.1% trypsin-TPCK, for 1 h at 37\u00b0C, being rocked every 15 minutes.", [["Cells", "ANATOMY", 0, 5], ["trypsin-TPCK", "CHEMICAL", 92, 104], ["TPCK", "CHEMICAL", 100, 104], ["Cells", "CELL", 0, 5], ["trypsin-TPCK", "SIMPLE_CHEMICAL", 92, 104], ["virus inoculum", "TREATMENT", 53, 67]]], ["The inoculum solution was then removed, the cells were washed once, and then were incubated at 37\u00b0C with an Avicel-DMEM overlay media containing a 1:1 ratio of 2.4% Avicel (FMC Biopolymer RC-481) and DMEM, supplemented with 0.2% BSA, 1% pen-strep, 2 mM L-glutamine, 0.1% trypsin-TPCK, and 25 mM HEPES buffer.", [["cells", "ANATOMY", 44, 49], ["Avicel", "CHEMICAL", 165, 171], ["FMC Biopolymer RC-481", "CHEMICAL", 173, 194], ["BSA", "CHEMICAL", 229, 232], ["L-glutamine", "CHEMICAL", 253, 264], ["trypsin-TPCK", "CHEMICAL", 271, 283], ["L-glutamine", "CHEMICAL", 253, 264], ["TPCK", "CHEMICAL", 279, 283], ["HEPES", "CHEMICAL", 295, 300], ["cells", "CELL", 44, 49], ["Avicel", "SIMPLE_CHEMICAL", 165, 171], ["BSA", "SIMPLE_CHEMICAL", 229, 232], ["pen-strep", "SIMPLE_CHEMICAL", 237, 246], ["L-glutamine", "SIMPLE_CHEMICAL", 253, 264], ["trypsin-TPCK", "SIMPLE_CHEMICAL", 271, 283], ["The inoculum solution", "TREATMENT", 0, 21], ["a 1:1 ratio", "TEST", 145, 156], ["Avicel", "TEST", 165, 171], ["DMEM", "TEST", 200, 204], ["2 mM L-glutamine", "TREATMENT", 248, 264], ["trypsin-TPCK", "TREATMENT", 271, 283], ["25 mM HEPES buffer", "TREATMENT", 289, 307], ["inoculum", "OBSERVATION_MODIFIER", 4, 12]]], ["After 3 days, the overlay was removed and cells were fixed in 4% paraformaldehyde for 30 minutes, before being stained with crystal violet (0.1% in 20% ethanol) for 30 minutes.", [["cells", "ANATOMY", 42, 47], ["crystal violet", "CHEMICAL", 124, 138], ["ethanol", "CHEMICAL", 152, 159], ["paraformaldehyde", "CHEMICAL", 65, 81], ["ethanol", "CHEMICAL", 152, 159], ["cells", "CELL", 42, 47], ["paraformaldehyde", "SIMPLE_CHEMICAL", 65, 81], ["violet", "SIMPLE_CHEMICAL", 132, 138], ["ethanol", "SIMPLE_CHEMICAL", 152, 159], ["cells", "TREATMENT", 42, 47], ["crystal violet", "TREATMENT", 124, 138]]], ["After the crystal violet was removed, the monolayer was air dried and plaques were counted.Sample preparation and disinfection.", [["monolayer", "ANATOMY", 42, 51], ["plaques", "ANATOMY", 70, 77], ["monolayer", "CELL", 42, 51], ["plaques", "ORGANISM_SUBSTANCE", 70, 77], ["the crystal violet", "TREATMENT", 6, 24], ["plaques", "PROBLEM", 70, 77], ["Sample preparation", "TREATMENT", 91, 109], ["disinfection", "TREATMENT", 114, 126], ["monolayer", "OBSERVATION_MODIFIER", 42, 51], ["air dried", "OBSERVATION", 56, 65], ["plaques", "OBSERVATION", 70, 77], ["disinfection", "OBSERVATION", 114, 126]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint RT-qPCR The supernatant was removed and the cells were washed and then processed with an RNAeasy PLUS RNA extraction kit (Qiagen) to extract RNA. cDNA was then generated from isolated RNA with a High-Capacity cDNA Reverse Transcription Kit (ThermoFisher).", [["supernatant", "ANATOMY", 354, 365], ["cells", "ANATOMY", 386, 391], ["CC", "CHEMICAL", 0, 2], ["cells", "CELL", 386, 391], ["cDNA", "DNA", 488, 492], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint RT", "TREATMENT", 325, 344], ["The supernatant", "TREATMENT", 350, 365], ["the cells", "TREATMENT", 382, 391], ["an RNAeasy PLUS RNA extraction kit", "TREATMENT", 428, 462], ["isolated RNA", "PROBLEM", 517, 529], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["RT-qPCR was then performed for IAV PB1, with Taqman probe (ACACGAGTGGACAAGCTGACACAA) and primers (ATCTTTGAGACCTCGTGTCTTG and CAGCAGGCTGGTTCCTATTTA) or for RSV F, with Taqman probe (TGCCATAGCATGACACAATGGCTCCT) and primers (AACAGATGTAAGCAGCTCCGTTATC and CGATTTTTATTGGATGCTGTACATTT) (ThermoFisher).NLuc Reporter AssayThe cell media was removed and the cells were washed once with 1xPBS.", [["cell", "ANATOMY", 318, 322], ["cells", "ANATOMY", 349, 354], ["IAV PB1", "ORGANISM", 31, 38], ["cell", "CELL", 318, 322], ["cells", "CELL", 349, 354], ["IAV PB1", "DNA", 31, 38], ["Taqman probe", "DNA", 45, 57], ["Taqman probe", "DNA", 167, 179], ["IAV PB1", "SPECIES", 31, 38], ["RSV", "SPECIES", 155, 158], ["RT-qPCR", "TEST", 0, 7], ["IAV PB1", "TREATMENT", 31, 38], ["Taqman probe (ACACGAGTGGACAAGCTGACACAA)", "TREATMENT", 45, 84], ["primers (ATCTTTGAGACCTCGTGTCTTG and CAGCAGGCTGGTTCCTATTTA)", "TREATMENT", 89, 147], ["RSV F", "PROBLEM", 155, 160], ["Taqman probe (TGCCATAGCATGACACAATGGCTCCT)", "TREATMENT", 167, 208], ["primers (AACAGATGTAAGCAGCTCCGTTATC and CGATTTTTATTGGATGCTGTACATTT)", "TREATMENT", 213, 279], ["The cell media", "TREATMENT", 314, 328], ["the cells", "TREATMENT", 345, 354], ["1xPBS", "TREATMENT", 377, 382], ["cell media", "OBSERVATION", 318, 328]]], ["250 uL of Nano-Glo Luciferase Assay Reagent (Promega) (1:100 ratio of Nano-Glo Luciferase Assay Substrate:Nano-Glo Luciferase Assay Buffer) was added per well and incubated for 3 minutes at room temperature.", [["Nano-Glo Luciferase Assay Reagent (Promega)", "TREATMENT", 10, 53], ["Nano-Glo Luciferase Assay Substrate", "TREATMENT", 70, 105], ["Nano-Glo Luciferase Assay Buffer)", "TREATMENT", 106, 139]]], ["100 uL of Nano-Glo Luciferase Assay Reagent was pipetted from each well as technical duplicates into a white 96 well plate and luminescence was quantified.NLuc Reporter AssayLuciferase Reporter Assay Supernatants were removed and cells were washed once with 1xPBS.", [["Supernatants", "ANATOMY", 200, 212], ["cells", "ANATOMY", 230, 235], ["NLuc", "GENE_OR_GENE_PRODUCT", 155, 159], ["AssayLuciferase", "GENE_OR_GENE_PRODUCT", 169, 184], ["cells", "CELL", 230, 235], ["Nano-Glo Luciferase Assay Reagent", "TREATMENT", 10, 43], ["NLuc Reporter AssayLuciferase Reporter Assay Supernatants", "TREATMENT", 155, 212], ["1xPBS", "TREATMENT", 258, 263]]], ["250 ul of Bright-Glo Luciferase Assay Reagent (Promega) was added per well and incubated for 3 minutes at room temperature.", [["Promega", "ORGANISM", 47, 54], ["Bright-Glo Luciferase Assay Reagent (Promega)", "TREATMENT", 10, 55]]], ["100 ul of Bright-Glo Luciferase Assay Reagent was pipetted from each well as technical duplicates into a white 96 well plate and luminescence was quantified.Mechanical test methods:We treated various pieces of equipment for multiple cycles to assess mechanical tolerance of PPE to ozone treatment compared to control items.", [["ozone", "CHEMICAL", 281, 286], ["ozone", "CHEMICAL", 281, 286], ["ozone", "SIMPLE_CHEMICAL", 281, 286], ["Bright-Glo Luciferase Assay", "TEST", 10, 37], ["various pieces of equipment", "TREATMENT", 192, 219], ["multiple cycles", "TREATMENT", 224, 239], ["mechanical tolerance of PPE", "TREATMENT", 250, 277], ["ozone treatment", "TREATMENT", 281, 296]]], ["Items tested are listed in Table S4 .Mechanical test methods:Particle filtration efficiency testing methods Seven different respirators were assessed at 20 ppm ozone, with minimum treatment durations ranging from 160 to 320 min.", [["ozone", "CHEMICAL", 160, 165], ["ozone", "CHEMICAL", 160, 165], ["Particle filtration efficiency", "TREATMENT", 61, 91], ["minimum treatment durations", "TREATMENT", 172, 199]]], ["Sample material from each of the respirators that underwent mechanical tests were used to assess post-treatment particle filtration efficiency.", [["the respirators", "TREATMENT", 29, 44], ["mechanical tests", "TEST", 60, 76], ["post-treatment particle filtration efficiency", "PROBLEM", 97, 142]]], ["Circular samples of 2.5 cm diameter were punched from each respirator and placed into a filter holder.", [["samples", "ANATOMY", 9, 16], ["Circular samples", "TEST", 0, 16], ["a filter holder", "TREATMENT", 86, 101], ["2.5 cm", "OBSERVATION_MODIFIER", 20, 26], ["diameter", "OBSERVATION_MODIFIER", 27, 35], ["filter holder", "OBSERVATION", 88, 101]]], ["Aerosol size distribution and number concentration with and without the sample were measured by a Scanning Mobility Particle Sizer (SMPS) system 50 to determine particle filtration efficiency.", [["sample", "ANATOMY", 72, 78], ["a Scanning Mobility Particle Sizer (SMPS) system", "TREATMENT", 96, 144], ["particle filtration efficiency", "PROBLEM", 161, 191], ["size", "OBSERVATION_MODIFIER", 8, 12], ["distribution", "OBSERVATION_MODIFIER", 13, 25], ["number", "OBSERVATION_MODIFIER", 30, 36], ["concentration", "OBSERVATION_MODIFIER", 37, 50], ["filtration efficiency", "OBSERVATION", 170, 191]]], ["The SMPS system consists of a Differential Mobility Analyzer (TSI 3080) and a Condensation Particle Counter (TSI 3775).", [["TSI", "TEST", 62, 65], ["a Condensation Particle Counter", "TREATMENT", 76, 107]]], ["Polydispersed aerosols were generated via atomization of 0.05 M sodium chloride solution.", [["sodium chloride", "CHEMICAL", 64, 79], ["sodium chloride", "CHEMICAL", 64, 79], ["sodium chloride solution", "SIMPLE_CHEMICAL", 64, 88], ["Polydispersed aerosols", "TREATMENT", 0, 22], ["0.05 M sodium chloride solution", "TREATMENT", 57, 88]]], ["Two sets of testing were performed per each sample and averaged.", [["testing", "TEST", 12, 19]]], ["We note that these tests were not completely equivalent to the NIOSH standard, and differences include but not limited to the following:Mechanical test methods:\u2022 Tested respirators were not pre-conditioned at 38\u00b0C and 85% relative humidity \u2022 Aerosol mass concentration was substantially lower in this test \u2022 Aerosol size distribution was skewed toward smaller size compared to NIOSH standard.Mechanical test methods:.", [["these tests", "TEST", 13, 24], ["Aerosol mass concentration", "TREATMENT", 242, 268], ["size", "OBSERVATION_MODIFIER", 316, 320], ["smaller", "OBSERVATION_MODIFIER", 352, 359], ["size", "OBSERVATION_MODIFIER", 360, 364]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint Ozone treatment methods From April 2 to April 24, 2020, we assessed four different ozone treatment devices from three manufactures, Global Ozone Innovations (GOI), Zono Technologies (ZT), and VirtuCLEAN (VC) ( Table S2) .", [["CC", "CHEMICAL", 0, 2], ["Ozone", "CHEMICAL", 342, 347], ["ozone", "CHEMICAL", 425, 430], ["Ozone", "CHEMICAL", 481, 486], ["Ozone", "CHEMICAL", 342, 347], ["ozone", "CHEMICAL", 425, 430], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint Ozone treatment", "TREATMENT", 325, 357], ["different ozone treatment devices", "TREATMENT", 415, 448], ["Global Ozone Innovations", "PROBLEM", 474, 498], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["Global Ozone", "OBSERVATION", 474, 486]]], ["These devices are designed to disinfect recreational or medical equipment, and have been largely evaluated against bacterial pathogens, 51 but few studies have assessed the efficacy of these technologies against encapsulated viruses.", [["These devices", "TREATMENT", 0, 13], ["bacterial pathogens", "PROBLEM", 115, 134], ["few studies", "TEST", 143, 154], ["encapsulated viruses", "PROBLEM", 212, 232], ["viruses", "OBSERVATION", 225, 232]]], ["The GOI and VC units rely on ozone alone, whereas the ZT cabinet also treats with elevated (80%) humidity via a water reservoir and ultrasonic humidifier.", [["ozone", "CHEMICAL", 29, 34], ["ozone", "CHEMICAL", 29, 34], ["GOI", "SIMPLE_CHEMICAL", 4, 7], ["ozone", "SIMPLE_CHEMICAL", 29, 34], ["The GOI and VC units", "TREATMENT", 0, 20], ["the ZT cabinet", "TREATMENT", 50, 64], ["a water reservoir", "TREATMENT", 110, 127], ["ultrasonic humidifier", "TREATMENT", 132, 153], ["elevated", "OBSERVATION_MODIFIER", 82, 90]]], ["The GOI and VC devices generate ozone via corona discharge and the ZT cabinet, which additionally uses elevated humidity, uses 184 nm photolytic UV ozone generators because humidity reduces corona plate generation efficiency.", [["ozone", "CHEMICAL", 32, 37], ["UV ozone", "CHEMICAL", 145, 153], ["ozone", "CHEMICAL", 32, 37], ["ozone", "CHEMICAL", 148, 153], ["GOI", "SIMPLE_CHEMICAL", 4, 7], ["ozone", "SIMPLE_CHEMICAL", 32, 37], ["The GOI and VC devices", "TREATMENT", 0, 22], ["the ZT cabinet", "TREATMENT", 63, 77], ["elevated humidity", "PROBLEM", 103, 120], ["184 nm photolytic UV ozone generators", "TREATMENT", 127, 164], ["corona plate generation efficiency", "PROBLEM", 190, 224], ["corona plate", "OBSERVATION", 190, 202], ["generation efficiency", "OBSERVATION", 203, 224]]], ["When not otherwise noted, all experimental runs were performed at ambient temperature (ca.", [["all experimental runs", "PROBLEM", 26, 47]]], ["24-25\u00b0C) and pressure.(which was not certified by peer review)All the devices tested use atmospheric oxygen to generate a nominal ozone concentration of approximately 20 ppm.", [["oxygen", "CHEMICAL", 101, 107], ["ozone", "CHEMICAL", 130, 135], ["oxygen", "CHEMICAL", 101, 107], ["ozone", "CHEMICAL", 130, 135], ["oxygen", "SIMPLE_CHEMICAL", 101, 107], ["ozone", "SIMPLE_CHEMICAL", 130, 135], ["pressure", "TEST", 13, 21], ["All the devices", "TREATMENT", 62, 77], ["atmospheric oxygen", "TREATMENT", 89, 107], ["a nominal ozone concentration", "TREATMENT", 120, 149], ["pressure", "OBSERVATION_MODIFIER", 13, 21]]], ["Whereas the GOI and ZT cabinets control this by virtue of internal sensing and real-time regulation, the less expensive VC cleaner turns ozone generation on and off to give rise to cycles of ozone concentrations ranging from 10-30 ppm, averaging 17-20 ppm ( Figure S1 ).", [["ozone", "CHEMICAL", 137, 142], ["ozone", "CHEMICAL", 191, 196], ["ozone", "CHEMICAL", 137, 142], ["ozone", "CHEMICAL", 191, 196], ["ozone", "SIMPLE_CHEMICAL", 137, 142], ["ozone", "SIMPLE_CHEMICAL", 191, 196], ["ZT cabinets", "TREATMENT", 20, 31], ["internal sensing", "TREATMENT", 58, 74], ["the less expensive VC cleaner", "TREATMENT", 101, 130], ["ozone concentrations", "TEST", 191, 211]]], ["To extend runs beyond the time limits imposed by the manufacturer's hard-coded time limits, the VC device was simply restarted immediately at the end of each treatment cycle.", [["the VC device", "TREATMENT", 92, 105]]], ["Both GOI and ZT provided extensive remote or on-site engineering support to permit modification of time and concentration set points in support of these experiments.(which was not certified by peer review)The Zono Technologies cabinet and VirtuCLEAN device do not offer data logging and export, so a SPEC Sensors Digital O3 Sensor was placed inside the devices and used to log ozone concentration, temperature, and relative humidity levels during runs (see Figure S1 ).", [["O3", "CHEMICAL", 321, 323], ["ozone", "CHEMICAL", 377, 382], ["O3", "CHEMICAL", 321, 323], ["ozone", "CHEMICAL", 377, 382], ["ozone", "SIMPLE_CHEMICAL", 377, 382], ["site engineering support", "TREATMENT", 48, 72], ["The Zono Technologies cabinet", "TREATMENT", 205, 234], ["VirtuCLEAN device", "TREATMENT", 239, 256], ["a SPEC Sensors Digital O3 Sensor", "TREATMENT", 298, 330], ["the devices", "TREATMENT", 349, 360], ["log ozone concentration", "TEST", 373, 396], ["temperature", "TEST", 398, 409], ["relative humidity levels", "TEST", 415, 439]]], ["While these sensors are rated from 0-5 ppm O3, we observed they matched the readings from an EcoSensor SM-7 0-50 ppm range sensor in the ZT cabinet up to at least 45 ppm.", [["O3", "CHEMICAL", 43, 45], ["O3", "SIMPLE_CHEMICAL", 43, 45], ["an EcoSensor SM", "TEST", 90, 105]]], ["These sensors, as well as the EcoSensor SM-7, required a warm up period for reliable operation.(which was not certified by peer review)Each instrument device uses a ventilation or ozone destruction cycle (reversing airflow through a catalyst) following treatment to return ozone concentrations back to safe levels.", [["ozone", "CHEMICAL", 180, 185], ["ozone", "CHEMICAL", 273, 278], ["ozone", "CHEMICAL", 180, 185], ["ozone", "CHEMICAL", 273, 278], ["ozone", "SIMPLE_CHEMICAL", 273, 278], ["the EcoSensor SM", "TEST", 26, 42], ["a warm up period", "TREATMENT", 55, 71], ["reliable operation", "TREATMENT", 76, 94], ["instrument device", "TREATMENT", 140, 157], ["a ventilation", "TREATMENT", 163, 176], ["ozone destruction cycle", "TREATMENT", 180, 203], ["a catalyst", "TREATMENT", 231, 241], ["treatment", "TREATMENT", 253, 262], ["return ozone concentrations", "TREATMENT", 266, 293], ["operation", "OBSERVATION", 85, 94]]], ["The ZT instrument passes the internal atmosphere continuously over a catalyst until ozone levels are reduced, and the VC unit completes a 5 minute vent through a catalyst (which worked well in our hands).", [["ozone", "CHEMICAL", 84, 89], ["ozone", "CHEMICAL", 84, 89], ["ozone", "SIMPLE_CHEMICAL", 84, 89], ["The ZT instrument", "TREATMENT", 0, 17], ["a catalyst", "TREATMENT", 67, 77], ["ozone levels", "TEST", 84, 96], ["a 5 minute vent", "TREATMENT", 136, 151], ["a catalyst", "TREATMENT", 160, 170], ["reduced", "OBSERVATION_MODIFIER", 101, 108]]], ["All devices tolerated back-to-back runs over multiple hours with no change in ozone generation, and require no consumables chemicals or reagents, other than water.(which was not certified by peer review)(5T32EB021962-02) and the NSF Graduate Research Fellowship program (DGE-1650044).", [["ozone", "CHEMICAL", 78, 83], ["DGE-1650044", "CHEMICAL", 271, 282], ["ozone", "CHEMICAL", 78, 83], ["ozone", "SIMPLE_CHEMICAL", 78, 83], ["All devices", "TREATMENT", 0, 11], ["change in ozone generation", "PROBLEM", 68, 94], ["ozone generation", "OBSERVATION", 78, 94]]], ["T.J. and N.L.N. acknowledge support from the Center for the Science and Technology of Advanced Materials and Interfaces (STAMI) at Georgia Tech.(which was not certified by peer review)Disclaimer: No financial support was received from any commercial entity and the findings reported here have not been reviewed or endorsed by any company.", [["financial support", "TREATMENT", 199, 216], ["No", "UNCERTAINTY", 196, 198]]], ["While our observations do not suggest the presence of hidden effects, there may be negative consequences to material integrity or performance resulting from ozone treatment that we have not identified. .", [["ozone", "CHEMICAL", 157, 162], ["ozone", "CHEMICAL", 157, 162], ["ozone", "SIMPLE_CHEMICAL", 157, 162], ["ozone treatment", "TREATMENT", 157, 172]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint Figure S1 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Comparison of ozone concentration, temperature, and humidity during a standard run cycle for each device.", [["ozone", "CHEMICAL", 14, 19], ["ozone", "CHEMICAL", 14, 19], ["ozone", "SIMPLE_CHEMICAL", 14, 19], ["ozone concentration", "TEST", 14, 33], ["temperature", "TEST", 35, 46], ["a standard run cycle", "TREATMENT", 68, 88], ["each device", "TREATMENT", 93, 104]]], ["Line style convention for bottom plot follows from first plot.", [["bottom plot", "TEST", 26, 37]]], ["Also demonstrates these treatment devices do not exceed commonly recommended N95 respirator storage temperatures of < 30\u00b0C. GO = Global Ozone cabinet, ZT = Zono Technologies cabinet, VC = VirtuCLEAN portable PAP disinfection zippered pouch.", [["Ozone", "CHEMICAL", 136, 141], ["Ozone", "CHEMICAL", 136, 141], ["these treatment devices", "TREATMENT", 18, 41], ["respirator storage temperatures", "TEST", 81, 112], ["Global Ozone cabinet", "TREATMENT", 129, 149], ["VirtuCLEAN portable PAP disinfection zippered pouch", "TREATMENT", 188, 239], ["zippered pouch", "OBSERVATION", 225, 239]]], ["Inactivation of influenza A virus by ozone as a function of temperature, holding atmospheric moisture roughly constant.", [["influenza A virus", "DISEASE", 16, 33], ["ozone", "CHEMICAL", 37, 42], ["ozone", "CHEMICAL", 37, 42], ["influenza A virus", "ORGANISM", 16, 33], ["ozone", "SIMPLE_CHEMICAL", 37, 42], ["influenza A virus", "SPECIES", 16, 33], ["influenza A virus", "SPECIES", 16, 33], ["influenza A virus", "PROBLEM", 16, 33], ["atmospheric moisture", "TREATMENT", 81, 101], ["influenza", "OBSERVATION", 16, 25]]], ["Here the data are displayed for illustrative purposes in terms of (a) observed luminescence from the NanoLuc assay and (b) reduction of viral infectivity derived from the data in panel (a) .", [["the NanoLuc assay", "TEST", 97, 114], ["viral infectivity", "PROBLEM", 136, 153], ["viral infectivity", "OBSERVATION", 136, 153]]], ["Approximate water vapor concentrations: ambient (25 \u00b0C), 14.3 g/m 3 = 62% RH; 37 \u00b0C, 14.5 g/m 3 = 33% RH; 45 \u00b0C, 17.7 g/m 3 = 27% RH.(which was not certified by peer review).", [["Approximate water vapor concentrations", "TREATMENT", 0, 38]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint a) Filtration efficiency was not measured for the corresponding untreated sample. b) \"Pass\" denotes similar filtration efficiency compared to a corresponding control measurement, or filtration efficiency >95% for respirators lacking a control measurement. c) Filtration efficiency >89%; without comparison to a control sample, change due to ozone treatment could not be assessed. d) Filtration efficiency >92%; without comparison to a control sample, change due to ozone treatment could not be assessed. e) Filtration efficiency appears to be higher for the treated sample (reason unknown), but both untreated and treated samples have low overall filtration efficiency. .", [["sample", "ANATOMY", 457, 463], ["samples", "ANATOMY", 1005, 1012], ["CC", "CHEMICAL", 0, 2], ["ozone", "CHEMICAL", 724, 729], ["ozone", "CHEMICAL", 848, 853], ["ozone", "CHEMICAL", 724, 729], ["ozone", "CHEMICAL", 848, 853], ["ozone", "SIMPLE_CHEMICAL", 724, 729], ["ozone", "SIMPLE_CHEMICAL", 848, 853], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv preprint a) Filtration efficiency", "TREATMENT", 366, 407], ["similar filtration efficiency", "PROBLEM", 483, 512], ["a corresponding control measurement", "TEST", 525, 560], ["filtration efficiency", "TEST", 565, 586], ["respirators", "TREATMENT", 596, 607], ["Filtration efficiency", "TEST", 642, 663], ["a control sample", "TEST", 692, 708], ["ozone treatment", "TREATMENT", 724, 739], ["Filtration efficiency", "TEST", 766, 787], ["a control sample", "TEST", 816, 832], ["ozone treatment", "TREATMENT", 848, 863], ["Filtration efficiency", "PROBLEM", 890, 911], ["low overall filtration efficiency", "PROBLEM", 1018, 1051], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["Filtration efficiency", "OBSERVATION", 890, 911], ["higher", "OBSERVATION_MODIFIER", 926, 932], ["low overall", "OBSERVATION_MODIFIER", 1018, 1029], ["filtration efficiency", "OBSERVATION", 1030, 1051]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint Figure S4 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Respirators assessed for headband compatibility with ozone disinfection.", [["ozone", "CHEMICAL", 53, 58], ["ozone", "CHEMICAL", 53, 58], ["ozone", "SIMPLE_CHEMICAL", 53, 58], ["ozone disinfection", "TREATMENT", 53, 71], ["ozone disinfection", "OBSERVATION", 53, 71]]], ["All of the respirators with failed bands feature stapled attachments.(which was not certified by peer review).", [["failed bands feature stapled attachments", "TREATMENT", 28, 68], ["stapled attachments", "OBSERVATION", 49, 68]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint Figure S5 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Particle filtration efficiency of untreated (control) and ozone-treated N95 respirators.", [["ozone", "CHEMICAL", 58, 63], ["ozone", "CHEMICAL", 58, 63], ["ozone", "SIMPLE_CHEMICAL", 58, 63], ["Particle filtration efficiency", "TREATMENT", 0, 30], ["N95 respirators", "TREATMENT", 72, 87], ["efficiency", "OBSERVATION_MODIFIER", 20, 30]]], ["Uncertainties are calculated from one standard deviation of aerosol volume concentration measured by the SMPS instrument. a) 3M 8210 and 8515 respirators. b) Sperian N1115 XL and N1125 S respirators.(which was not certified by peer review).", [["aerosol volume concentration", "TREATMENT", 60, 88], ["the SMPS instrument", "TEST", 101, 120], ["Sperian", "TEST", 158, 165], ["aerosol volume", "OBSERVATION", 60, 74], ["SMPS instrument", "OBSERVATION", 105, 120]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.23.20111435 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv", "TREATMENT", 366, 373], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "PMC5708621": [["IntroductionSevere Acute Respiratory Syndrome (SARS) is a severe emerging viral disease with high fatality characterized by fever, headache and severe respiratory symptoms including cough, dyspnea and pneumonia [1].", [["respiratory", "ANATOMY", 151, 162], ["Acute Respiratory Syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["viral disease", "DISEASE", 74, 87], ["fever", "DISEASE", 124, 129], ["headache", "DISEASE", 131, 139], ["respiratory symptoms", "DISEASE", 151, 171], ["cough", "DISEASE", 182, 187], ["dyspnea", "DISEASE", 189, 196], ["pneumonia", "DISEASE", 201, 210], ["Acute Respiratory Syndrome", "PROBLEM", 19, 45], ["a severe emerging viral disease", "PROBLEM", 56, 87], ["high fatality", "PROBLEM", 93, 106], ["fever", "PROBLEM", 124, 129], ["headache", "PROBLEM", 131, 139], ["severe respiratory symptoms", "PROBLEM", 144, 171], ["cough", "PROBLEM", 182, 187], ["dyspnea", "PROBLEM", 189, 196], ["pneumonia", "PROBLEM", 201, 210], ["Acute", "OBSERVATION_MODIFIER", 19, 24], ["Respiratory Syndrome", "OBSERVATION", 25, 45], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["viral disease", "OBSERVATION", 74, 87], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["respiratory", "ANATOMY", 151, 162], ["pneumonia", "OBSERVATION", 201, 210]]], ["Due to its high transmissibility among humans, after its first emergence in southern China in late 2002, it rapidly led to a global pandemic in 2003 and was marked as one of the most significant public health threats in the 21st century [2,3].", [["humans", "ORGANISM", 39, 45], ["humans", "SPECIES", 39, 45], ["humans", "SPECIES", 39, 45], ["a global pandemic", "PROBLEM", 123, 140], ["high", "OBSERVATION_MODIFIER", 11, 15], ["transmissibility", "OBSERVATION", 16, 32], ["marked", "OBSERVATION_MODIFIER", 157, 163]]], ["The causative agent, SARS coronavirus (SARS-CoV), has been previously assigned to group 2b CoV and is now a member of the lineage B of genus Betacoronavirus in the family Coronaviridae [4].", [["SARS coronavirus", "DISEASE", 21, 37], ["SARS-CoV)", "DISEASE", 39, 48], ["SARS coronavirus", "ORGANISM", 21, 37], ["SARS-CoV", "ORGANISM", 39, 47], ["2b CoV", "ORGANISM", 88, 94], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 141, 156], ["SARS coronavirus", "SPECIES", 21, 37], ["SARS coronavirus", "SPECIES", 21, 37], ["SARS-CoV", "SPECIES", 39, 47], ["The causative agent", "PROBLEM", 0, 19], ["SARS coronavirus", "PROBLEM", 21, 37]]], ["It shares similar genome organization with other coronaviruses, but exhibits a unique genomic structure which includes a number of specific accessory genes, including ORF3a, 3b, ORF6, ORF7a, 7b, ORF8a, 8b and 9b [5,6].IntroductionMasked palm civets (Paguma larvata) were initially hypothesized to be the animal origin of SARS-CoV [7,8].", [["SARS", "DISEASE", 321, 325], ["ORF3a", "GENE_OR_GENE_PRODUCT", 167, 172], ["3", "GENE_OR_GENE_PRODUCT", 174, 175], ["b", "GENE_OR_GENE_PRODUCT", 175, 176], ["ORF6", "GENE_OR_GENE_PRODUCT", 178, 182], ["ORF7a", "GENE_OR_GENE_PRODUCT", 184, 189], ["7b", "GENE_OR_GENE_PRODUCT", 191, 193], ["ORF8a", "GENE_OR_GENE_PRODUCT", 195, 200], ["8b", "GENE_OR_GENE_PRODUCT", 202, 204], ["palm civets", "ORGANISM", 237, 248], ["Paguma larvata", "ORGANISM", 250, 264], ["SARS-CoV", "ORGANISM", 321, 329], ["accessory genes", "DNA", 140, 155], ["ORF3a", "DNA", 167, 172], ["ORF6", "DNA", 178, 182], ["ORF7a", "DNA", 184, 189], ["7b", "DNA", 191, 193], ["ORF8a", "DNA", 195, 200], ["Paguma larvata", "SPECIES", 250, 264], ["Paguma larvata", "SPECIES", 250, 264], ["SARS-CoV", "SPECIES", 321, 329], ["other coronaviruses", "PROBLEM", 43, 62], ["a unique genomic structure", "PROBLEM", 77, 103], ["ORF3a", "TEST", 167, 172], ["ORF6", "TEST", 178, 182], ["ORF7a", "TEST", 184, 189], ["ORF8a", "TEST", 195, 200], ["genome organization", "OBSERVATION", 18, 37], ["coronaviruses", "OBSERVATION", 49, 62], ["genomic structure", "OBSERVATION", 86, 103], ["accessory genes", "OBSERVATION", 140, 155]]], ["However, since a large number of genetically diverse SARS-related coronaviruses (SARSr-CoV) have been detected in multiple species of horseshoe bats (genus Rhinolophus) from different areas of China and Europe in the aftermath of SARS, it is prevailingly considered that SARS-CoV originated in horseshoe bats with civets acting as the intermediate amplifying and transmitting host [9\u201316].", [["SARS", "DISEASE", 53, 57], ["SARS", "DISEASE", 230, 234], ["SARS", "DISEASE", 271, 275], ["SARS-related coronaviruses", "ORGANISM", 53, 79], ["SARSr-CoV", "ORGANISM", 81, 90], ["horseshoe bats", "ORGANISM", 134, 148], ["SARS-CoV", "ORGANISM", 271, 279], ["horseshoe bats", "ORGANISM", 294, 308], ["SARSr-CoV", "SPECIES", 81, 90], ["horseshoe bats", "SPECIES", 134, 148], ["SARS-CoV", "SPECIES", 271, 279], ["genetically diverse SARS", "PROBLEM", 33, 57], ["coronaviruses (SARSr-CoV", "PROBLEM", 66, 90], ["horseshoe bats", "PROBLEM", 134, 148], ["genus Rhinolophus", "PROBLEM", 150, 167], ["SARS", "PROBLEM", 230, 234], ["SARS", "PROBLEM", 271, 275], ["large", "OBSERVATION_MODIFIER", 17, 22], ["number", "OBSERVATION_MODIFIER", 23, 29], ["genetically", "OBSERVATION_MODIFIER", 33, 44], ["diverse", "OBSERVATION_MODIFIER", 45, 52], ["SARS", "OBSERVATION", 53, 57], ["multiple", "OBSERVATION_MODIFIER", 114, 122], ["species", "OBSERVATION_MODIFIER", 123, 130], ["horseshoe bats", "OBSERVATION", 134, 148], ["different", "OBSERVATION_MODIFIER", 174, 183], ["areas", "OBSERVATION_MODIFIER", 184, 189]]], ["Recently we have reported four novel SARSr-CoVs from Chinese horseshoe bats that shared much higher genomic sequence similarity to the epidemic strains, particularly in their S gene, of which two strains (termed WIV1 and WIV16) have been successfully cultured in vitro [17,18].", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 37, 47], ["horseshoe bats", "ORGANISM", 61, 75], ["WIV1", "GENE_OR_GENE_PRODUCT", 212, 216], ["WIV16", "GENE_OR_GENE_PRODUCT", 221, 226], ["SARSr-CoVs", "DNA", 37, 47], ["S gene", "DNA", 175, 181], ["WIV16", "DNA", 221, 226], ["Chinese horseshoe bats", "SPECIES", 53, 75], ["Chinese horseshoe bats", "PROBLEM", 53, 75], ["the epidemic strains", "PROBLEM", 131, 151], ["horseshoe bats", "OBSERVATION", 61, 75]]], ["These newly identified SARSr-CoVs have been demonstrated to use the same cellular receptor (angiotensin converting enzyme-2 [ACE-2]) as SARS-CoV does and replicate efficiently in primary human airway cells [17\u201319].IntroductionDespite the cumulative evidence for the emergence of SARS-CoV from bats, all bat SARSr-CoVs described so far are clearly distinct from SARS-CoV in the S gene and/or one or more accessory genes such as ORF3 and ORF8, suggesting they are likely not the direct ancestor of SARS-CoV.", [["cellular", "ANATOMY", 73, 81], ["airway cells", "ANATOMY", 193, 205], ["angiotensin", "CHEMICAL", 92, 103], ["SARS", "DISEASE", 279, 283], ["SARS", "DISEASE", 496, 500], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 23, 33], ["cellular", "CELL", 73, 81], ["angiotensin converting enzyme-2", "GENE_OR_GENE_PRODUCT", 92, 123], ["ACE-2", "GENE_OR_GENE_PRODUCT", 125, 130], ["SARS-CoV", "ORGANISM", 136, 144], ["human", "ORGANISM", 187, 192], ["airway cells", "CELL", 193, 205], ["SARS-CoV", "ORGANISM", 279, 287], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 307, 317], ["SARS-CoV", "ORGANISM", 361, 369], ["ORF3", "GENE_OR_GENE_PRODUCT", 427, 431], ["ORF8", "GENE_OR_GENE_PRODUCT", 436, 440], ["SARS-CoV", "ORGANISM", 496, 504], ["SARSr", "PROTEIN", 23, 28], ["CoVs", "PROTEIN", 29, 33], ["cellular receptor", "PROTEIN", 73, 90], ["ACE", "PROTEIN", 125, 128], ["primary human airway cells", "CELL_TYPE", 179, 205], ["bat SARSr-CoVs", "DNA", 303, 317], ["S gene", "DNA", 377, 383], ["accessory genes", "DNA", 403, 418], ["ORF3", "DNA", 427, 431], ["ORF8", "DNA", 436, 440], ["human", "SPECIES", 187, 192], ["SARS-CoV", "SPECIES", 136, 144], ["human", "SPECIES", 187, 192], ["SARS-CoV", "SPECIES", 279, 287], ["SARS-CoV", "SPECIES", 361, 369], ["SARS-CoV", "SPECIES", 496, 504], ["angiotensin converting enzyme-", "TREATMENT", 92, 122], ["ACE", "TEST", 125, 128], ["SARS", "PROBLEM", 136, 140], ["SARS", "PROBLEM", 279, 283], ["CoVs", "PROBLEM", 313, 317], ["SARS", "PROBLEM", 361, 365], ["airway", "ANATOMY", 193, 199]]], ["Thus a critical gap remains in our understanding of how and where SARS-CoV originated from bat reservoirs.", [["SARS", "DISEASE", 66, 70], ["SARS-CoV", "ORGANISM", 66, 74], ["bat", "ORGANISM", 91, 94], ["SARS-CoV", "SPECIES", 66, 74], ["a critical gap", "PROBLEM", 5, 19], ["SARS", "PROBLEM", 66, 70], ["CoV", "PROBLEM", 71, 74]]], ["Previously, we reported a number of bat SARSr-CoVs with diverse S protein sequences from a single cave in Yunnan Province, including the four strains mentioned above most closely related to SARS-CoV [17,18].", [["SARS", "DISEASE", 190, 194], ["bat", "ORGANISM", 36, 39], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 40, 50], ["SARS-CoV", "ORGANISM", 190, 198], ["SARSr", "PROTEIN", 40, 45], ["CoVs", "PROTEIN", 46, 50], ["S protein sequences", "DNA", 64, 83], ["SARS-CoV", "SPECIES", 190, 198], ["diverse S protein sequences", "TREATMENT", 56, 83], ["the four strains", "TREATMENT", 133, 149]]], ["Here we report the latest results of our 5-year longitudinal surveillance of bat SARSr-CoVs in this single location and systematic evolutionary analysis using full-length genome sequences of 15 SARSr-CoV strains (11 novel ones and 4 from previous studies).", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 81, 91], ["SARSr-CoV", "ORGANISM", 194, 203], ["bat SARSr-CoVs", "DNA", 77, 91], ["full-length genome sequences", "DNA", 159, 187], ["SARSr-CoV", "SPECIES", 194, 203], ["bat SARSr", "TEST", 77, 86], ["CoVs", "PROBLEM", 87, 91], ["systematic evolutionary analysis", "TEST", 120, 152], ["full-length genome sequences", "TEST", 159, 187], ["SARSr", "TEST", 194, 199], ["CoV strains", "TEST", 200, 211], ["previous studies", "TEST", 238, 254]]], ["Efficiency of human ACE2 usage and the functions of accessory genes ORF8 and 8a were also evaluated for some of the newly identified strains.Continued circulation of diverse SARSr-CoVs in bats from a single location ::: ResultsWe have carried out a five-year longitudinal surveillance (April 2011 to October 2015) on SARSr-CoVs in bats from a single habitat in proximity to Kunming city, Yunnan province, China, which was mainly inhabited by horseshoe bats.", [["human", "ORGANISM", 14, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["ORF8", "GENE_OR_GENE_PRODUCT", 68, 72], ["8a", "GENE_OR_GENE_PRODUCT", 77, 79], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 174, 184], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 317, 327], ["bats", "ORGANISM", 331, 335], ["ACE2", "PROTEIN", 20, 24], ["accessory genes", "DNA", 52, 67], ["ORF8", "DNA", 68, 72], ["8a", "DNA", 77, 79], ["SARSr-CoVs", "DNA", 174, 184], ["SARSr-CoVs", "DNA", 317, 327], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["human ACE2 usage", "TREATMENT", 14, 30], ["the newly identified strains", "PROBLEM", 112, 140], ["human ACE2", "OBSERVATION", 14, 24], ["diverse", "OBSERVATION_MODIFIER", 166, 173], ["SARSr", "OBSERVATION", 174, 179], ["horseshoe bats", "OBSERVATION", 442, 456]]], ["A total of 602 alimentary specimens (anal swabs or feces) were collected and tested for the presence of CoVs by a Pan-CoV RT-PCR targeting the 440-nt RdRp fragment that is conserved among all known \u03b1- and \u03b2-CoVs [20].", [["alimentary specimens", "ANATOMY", 15, 35], ["anal swabs", "ANATOMY", 37, 47], ["feces", "ANATOMY", 51, 56], ["alimentary specimens", "CANCER", 15, 35], ["anal swabs", "MULTI-TISSUE_STRUCTURE", 37, 47], ["feces", "ORGANISM_SUBDIVISION", 51, 56], ["CoVs", "GENE_OR_GENE_PRODUCT", 104, 108], ["CoVs", "DNA", 104, 108], ["440-nt RdRp fragment", "DNA", 143, 163], ["Pan-CoV", "SPECIES", 114, 121], ["alimentary specimens", "TEST", 15, 35], ["anal swabs or feces", "TEST", 37, 56], ["CoVs", "PROBLEM", 104, 108], ["a Pan-CoV RT", "TREATMENT", 112, 124], ["PCR", "TEST", 125, 128], ["nt RdRp fragment", "PROBLEM", 147, 163], ["RdRp fragment", "OBSERVATION", 150, 163]]], ["In total, 84 samples tested positive for CoVs.", [["samples", "ANATOMY", 13, 20], ["samples", "CANCER", 13, 20], ["CoVs", "GENE_OR_GENE_PRODUCT", 41, 45], ["CoVs", "PROTEIN", 41, 45], ["84 samples", "TEST", 10, 20], ["CoVs", "PROBLEM", 41, 45]]], ["Sequencing of the PCR amplicons revealed the presence of SARSr-CoVs in the majority (64/84) of the CoV-positive samples (Table 1).", [["samples", "ANATOMY", 112, 119], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 57, 67], ["CoV", "ORGANISM", 99, 102], ["PCR amplicons", "DNA", 18, 31], ["SARSr-CoVs", "DNA", 57, 67], ["the PCR amplicons", "TEST", 14, 31], ["SARSr-CoVs", "PROBLEM", 57, 67], ["the CoV", "TEST", 95, 102], ["CoV", "ANATOMY", 99, 102]]], ["Host species identification by amplification of either Cytb or ND1 gene suggested that most (57/64) of the SARSr-CoV positive samples were from Rhinolophus sinicus, while the remaining 7 samples were from Rhinolophus ferrumequinum, Rhinolophus affinis and from Aselliscus stoliczkanus which belongs to the family Hipposideridae.Continued circulation of diverse SARSr-CoVs in bats from a single location ::: ResultsBased on the preliminary analysis of the partial RdRp sequences, all of the 64 bat SARSr-CoV sequences showed high similarity among themselves and with other reported bat SARSr-CoVs and SARS-CoVs from humans and civets.", [["samples", "ANATOMY", 126, 133], ["samples", "ANATOMY", 187, 194], ["Cytb", "GENE_OR_GENE_PRODUCT", 55, 59], ["ND1", "GENE_OR_GENE_PRODUCT", 63, 66], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 107, 116], ["Rhinolophus sinicus", "ORGANISM", 144, 163], ["Rhinolophus ferrumequinum", "ORGANISM", 205, 230], ["Rhinolophus affinis", "ORGANISM", 232, 251], ["Aselliscus stoliczkanus", "ORGANISM", 261, 284], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 361, 371], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 497, 506], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 585, 595], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 600, 609], ["humans", "ORGANISM", 615, 621], ["Cytb or ND1 gene", "DNA", 55, 71], ["SARSr-CoVs", "DNA", 361, 371], ["RdRp sequences", "DNA", 463, 477], ["64 bat SARSr-CoV sequences", "DNA", 490, 516], ["bat SARSr-CoVs and SARS-CoVs", "DNA", 581, 609], ["Rhinolophus sinicus", "SPECIES", 144, 163], ["Rhinolophus ferrumequinum", "SPECIES", 205, 230], ["Rhinolophus affinis", "SPECIES", 232, 251], ["Aselliscus stoliczkanus", "SPECIES", 261, 284], ["humans", "SPECIES", 615, 621], ["SARSr-CoV", "SPECIES", 107, 116], ["Rhinolophus sinicus", "SPECIES", 144, 163], ["Rhinolophus ferrumequinum", "SPECIES", 205, 230], ["Rhinolophus affinis", "SPECIES", 232, 251], ["Aselliscus stoliczkanus", "SPECIES", 261, 284], ["humans", "SPECIES", 615, 621], ["Cytb or ND1 gene", "TEST", 55, 71], ["the SARSr", "TEST", 103, 112], ["CoV positive samples", "PROBLEM", 113, 133], ["the preliminary analysis", "TEST", 423, 447], ["the partial RdRp sequences", "TEST", 451, 477], ["bat SARSr", "TEST", 493, 502], ["CoV sequences", "TEST", 503, 516], ["high similarity among themselves", "PROBLEM", 524, 556], ["bat SARSr", "TEST", 581, 590], ["SARS", "PROBLEM", 600, 604], ["diverse", "OBSERVATION_MODIFIER", 353, 360], ["SARSr", "OBSERVATION", 361, 366]]], ["To understand the genetic diversity of these bat SARSr-CoVs, the most variable region of the SARSr-CoV S gene, corresponding to the receptor-binding domain (RBD) of SARS-CoV, were amplified and sequenced.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 49, 59], ["SARSr-CoV S", "GENE_OR_GENE_PRODUCT", 93, 104], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 165, 173], ["bat SARSr-CoVs", "DNA", 45, 59], ["SARSr-CoV S gene", "DNA", 93, 109], ["receptor-binding domain", "PROTEIN", 132, 155], ["RBD", "PROTEIN", 157, 160], ["SARSr-CoV", "SPECIES", 93, 102], ["SARS-CoV", "SPECIES", 165, 173], ["CoVs", "PROBLEM", 55, 59], ["SARS", "PROBLEM", 165, 169]]], ["Due to low viral load in some samples, RBD sequences were successfully amplified only from 49 samples.", [["samples", "ANATOMY", 30, 37], ["samples", "ANATOMY", 94, 101], ["samples", "CANCER", 30, 37], ["RBD sequences", "DNA", 39, 52], ["low viral load", "PROBLEM", 7, 21], ["RBD sequences", "TEST", 39, 52], ["low", "OBSERVATION_MODIFIER", 7, 10], ["viral load", "OBSERVATION", 11, 21]]], ["These RBD sequences displayed high genetic diversity and could be divided into two large clades, both of which included multiple genotypes.", [["RBD sequences", "DNA", 6, 19], ["These RBD sequences", "TEST", 0, 19], ["high genetic diversity", "PROBLEM", 30, 52], ["multiple genotypes", "PROBLEM", 120, 138], ["high genetic diversity", "OBSERVATION", 30, 52], ["large", "OBSERVATION_MODIFIER", 83, 88], ["clades", "OBSERVATION", 89, 95]]], ["Clade 1 strains shared an identical size and higher amino acid (aa) sequence identity with SARS-CoV RBD, while clade 2 had a shorter size than SARS-CoV S due to two deletions (5 and 12\u201313 aa, respectively) (S1 Fig).", [["amino acid", "CHEMICAL", 52, 62], ["SARS-CoV RBD", "DISEASE", 91, 103], ["amino acid", "CHEMICAL", 52, 62], ["amino acid", "AMINO_ACID", 52, 62], ["SARS-CoV", "ORGANISM", 91, 99], ["SARS-CoV RBD", "PROTEIN", 91, 103], ["SARS-CoV", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 143, 151], ["higher amino acid (aa) sequence identity", "PROBLEM", 45, 85], ["SARS", "PROBLEM", 91, 95], ["CoV RBD", "PROBLEM", 96, 103], ["a shorter size than SARS", "PROBLEM", 123, 147], ["CoV S", "TEST", 148, 153], ["two deletions", "PROBLEM", 161, 174], ["size", "OBSERVATION_MODIFIER", 36, 40]]], ["Co-infections by two strains of different clades were detected in two samples, Rs3262 and Rs4087 (S1 Fig).Genomic characterization of the novel SARSr-CoVs ::: ResultsBased on the diversity of RBD sequences, 11 novel SARSr-CoV strains named by abbreviation of bat species and sample ID (Rs4081, Rs4084, Rs4231, Rs4237, Rs4247, Rs4255, Rs4874, Rs7327, Rs9401, Rf4092 and As6526) were selected for full-length genomic sequencing based on sample abundance, genotype of RBD as well as sampling time.", [["samples", "ANATOMY", 70, 77], ["sample", "ANATOMY", 435, 441], ["Co-infections", "DISEASE", 0, 13], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 144, 154], ["SARSr-CoV", "ORGANISM", 216, 225], ["bat", "ORGANISM", 259, 262], ["SARSr-CoVs", "DNA", 144, 154], ["RBD sequences", "DNA", 192, 205], ["RBD", "PROTEIN", 465, 468], ["Co-infections", "PROBLEM", 0, 13], ["different clades", "PROBLEM", 32, 48], ["Rs", "TEST", 79, 81], ["Rs", "TEST", 90, 92], ["Genomic characterization", "TEST", 106, 130], ["RBD sequences", "TEST", 192, 205], ["novel SARSr", "TEST", 210, 221], ["CoV strains", "PROBLEM", 222, 233], ["Rs", "TEST", 286, 288], ["Rs", "TEST", 294, 296], ["Rs", "TEST", 302, 304], ["Rs", "TEST", 310, 312], ["Rs", "TEST", 318, 320], ["Rs", "TEST", 326, 328], ["Rs", "TEST", 334, 336], ["Rs", "TEST", 342, 344], ["Rs", "TEST", 350, 352], ["Rf", "TEST", 358, 360], ["full-length genomic sequencing", "TREATMENT", 395, 425], ["sample abundance", "TEST", 435, 451], ["genotype of RBD", "PROBLEM", 453, 468], ["RBD", "OBSERVATION", 465, 468]]], ["For each RBD genotype and each time of sampling, at least one representative strain was selected.", [["RBD", "PROTEIN", 9, 12], ["each RBD genotype", "PROBLEM", 4, 21], ["sampling", "TEST", 39, 47]]], ["The genome size of these novel SARSr-CoVs ranged from 29694 to 30291 nucleotides (nt).", [["nucleotides", "CHEMICAL", 69, 80], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 31, 41], ["SARSr-CoVs", "DNA", 31, 41], ["these novel SARSr", "TEST", 19, 36], ["CoVs", "TEST", 37, 41], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["This gave a total of 15 full-length genomes of bat SARSr-CoVs from this single location (13 from R.sinicus, and one each from R. ferrumequinum and A. stoliczkanus), including our previously reported strains, Rs3367, RsSHC014, WIV1 and WIV16 [17,18].", [["bat", "ORGANISM", 47, 50], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 51, 61], ["R. ferrumequinum", "ORGANISM", 126, 142], ["A. stoliczkanus", "ORGANISM", 147, 162], ["Rs3367", "CELL", 208, 214], ["full-length genomes", "DNA", 24, 43], ["bat SARSr-CoVs", "DNA", 47, 61], ["R. ferrumequinum", "SPECIES", 126, 142], ["A. stoliczkanus", "SPECIES", 147, 162], ["R. ferrumequinum", "SPECIES", 126, 142], ["A. stoliczkanus", "SPECIES", 147, 162], ["Rs", "TEST", 208, 210]]], ["The genomes of all 15 SARSr-CoVs circulating in this single cave shared 92.0% to 99.9% nt sequence identity.", [["SARSr", "GENE_OR_GENE_PRODUCT", 22, 27], ["CoVs", "GENE_OR_GENE_PRODUCT", 28, 32], ["SARSr", "DNA", 22, 27], ["CoVs", "DNA", 28, 32], ["nt sequence identity", "TEST", 87, 107]]], ["The overall nt sequence identity between these SARSr-CoVs and human and civet SARS-CoVs is 93.2% to 96%, significantly higher than that observed for bat SARSr-CoVs reported from other locations in China (88\u201393%) [9,10,12,14,21,22].", [["SARS", "DISEASE", 78, 82], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 47, 57], ["human", "ORGANISM", 62, 67], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 153, 163], ["SARSr-CoVs and human and civet SARS-CoVs", "DNA", 47, 87], ["bat SARSr-CoVs", "DNA", 149, 163], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["these SARSr", "TEST", 41, 52], ["civet SARS", "TEST", 72, 82], ["CoVs", "TEST", 83, 87], ["bat SARSr", "TEST", 149, 158], ["CoVs", "PROBLEM", 159, 163]]], ["The genome sequence similarity among the 15 SARSr-CoVs and SARS-CoV SZ3 strain was examined by Simplot analysis (Fig 1).", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 44, 54], ["SARS-CoV SZ3", "ORGANISM", 59, 71], ["SARSr-CoVs and SARS-CoV SZ3 strain", "DNA", 44, 78], ["SARS-CoV", "SPECIES", 59, 67], ["The genome sequence similarity", "TEST", 0, 30], ["SARSr", "TEST", 44, 49], ["SARS", "PROBLEM", 59, 63], ["CoV SZ3 strain", "PROBLEM", 64, 78]]], ["The 15 SARSr-CoVs are highly conserved and share a uniformly high sequence similarity to SARS-CoV in the non-structural gene ORF1a (96.6% to 97.1% nt sequence identity, 98.0% to 98.3% aa sequence identity) and ORF1b (96.1% to 96.6% nt sequence identity, 99.0% to 99.4% aa sequence identity).", [["SARS", "DISEASE", 89, 93], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 7, 17], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 89, 97], ["ORF1a", "GENE_OR_GENE_PRODUCT", 125, 130], ["ORF1b", "GENE_OR_GENE_PRODUCT", 210, 215], ["15 SARSr-CoVs", "DNA", 4, 17], ["SARS-CoV", "DNA", 89, 97], ["non-structural gene ORF1a", "DNA", 105, 130], ["ORF1b", "DNA", 210, 215], ["SARS-CoV", "SPECIES", 89, 97], ["a uniformly high sequence", "PROBLEM", 49, 74], ["SARS", "TEST", 89, 93], ["nt sequence identity", "TEST", 147, 167], ["aa sequence identity", "TEST", 184, 204], ["ORF1b", "TEST", 210, 215], ["nt sequence identity", "TEST", 232, 252]]], ["In contrast, a considerable genetic diversity is shown in the S gene (corresponding to SZ3 genome position 21477 to 25244) and ORF8 (corresponding to SZ3 genome position 27764 to 28132) (Fig 1).Genomic characterization of the novel SARSr-CoVs ::: ResultsThe 11 novel SARSr-CoVs identified from this single location generally shared similar genome organization with SARS-CoV and other bat SARSr-CoVs.", [["ORF8", "GENE_OR_GENE_PRODUCT", 127, 131], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 267, 277], ["SARS-CoV", "ORGANISM", 365, 373], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 388, 398], ["S gene", "DNA", 62, 68], ["SZ3 genome", "DNA", 87, 97], ["ORF8", "DNA", 127, 131], ["SZ3 genome", "DNA", 150, 160], ["SARSr-CoVs", "DNA", 232, 242], ["SARSr", "PROTEIN", 267, 272], ["CoVs", "DNA", 273, 277], ["SARS-CoV and other bat SARSr-CoVs", "DNA", 365, 398], ["SARS-CoV", "SPECIES", 365, 373], ["a considerable genetic diversity", "PROBLEM", 13, 45], ["Genomic characterization", "TEST", 194, 218], ["novel SARSr", "TEST", 261, 272], ["CoVs", "PROBLEM", 273, 277], ["SARS", "PROBLEM", 365, 369], ["CoVs", "PROBLEM", 394, 398], ["diversity", "OBSERVATION", 36, 45], ["genome organization", "OBSERVATION", 340, 359], ["CoVs", "OBSERVATION", 394, 398]]], ["In our previous study, we identified an additional ORF termed ORFx present between ORF6 and ORF7 in strain WIV1 and WIV16 [18,23].", [["ORFx", "GENE_OR_GENE_PRODUCT", 62, 66], ["ORF6", "GENE_OR_GENE_PRODUCT", 83, 87], ["ORF7", "GENE_OR_GENE_PRODUCT", 92, 96], ["ORF", "DNA", 51, 54], ["ORFx", "DNA", 62, 66], ["ORF6", "DNA", 83, 87], ["ORF7", "DNA", 92, 96], ["our previous study", "TEST", 3, 21], ["an additional ORF termed ORFx", "PROBLEM", 37, 66], ["ORF6", "TREATMENT", 83, 87]]], ["In this study, ORFx was also found in the genomes of Rs7327 and Rs4874.", [["ORFx", "GENE_OR_GENE_PRODUCT", 15, 19], ["Rs4874", "CELL", 64, 70], ["ORFx", "PROTEIN", 15, 19], ["this study", "TEST", 3, 13]]], ["Compared with that of WIV1 and WIV16, the length of ORFx in Rs7327 and Rs4874 was extended to 510 nt due to a deletion of 2 nt in a poly-T sequence that resulted in a shift of reading frame (Fig 2 and S2 Fig).Co-circulation of different bat SARSr-CoVs with S, ORF8 and ORF3 sequences similar to those in SARS-CoV at a single location ::: ResultsThe primary difference between SARS-CoV and most bat SARSr-CoVs is located in S gene.", [["Rs4874", "CHEMICAL", 71, 77], ["poly-T", "CHEMICAL", 132, 138], ["SARS", "DISEASE", 304, 308], ["SARS", "DISEASE", 376, 380], ["ORFx", "GENE_OR_GENE_PRODUCT", 52, 56], ["Rs4874", "GENE_OR_GENE_PRODUCT", 71, 77], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 241, 251], ["ORF8", "GENE_OR_GENE_PRODUCT", 260, 264], ["ORF3", "GENE_OR_GENE_PRODUCT", 269, 273], ["SARS-CoV", "ORGANISM", 304, 312], ["SARS-CoV", "ORGANISM", 376, 384], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 398, 408], ["WIV1", "DNA", 22, 26], ["WIV16", "DNA", 31, 36], ["ORFx", "DNA", 52, 56], ["Rs7327", "DNA", 60, 66], ["poly-T sequence", "DNA", 132, 147], ["reading frame", "DNA", 176, 189], ["bat SARSr-CoVs with S, ORF8 and ORF3 sequences", "DNA", 237, 283], ["SARS-CoV and most bat SARSr-CoVs", "DNA", 376, 408], ["S gene", "DNA", 423, 429], ["SARS-CoV", "SPECIES", 304, 312], ["SARS-CoV", "SPECIES", 376, 384], ["ORFx", "TEST", 52, 56], ["a deletion of 2 nt", "PROBLEM", 108, 126], ["a poly-T sequence", "TREATMENT", 130, 147], ["Fig", "TEST", 191, 194], ["ORF8", "TEST", 260, 264], ["ORF3 sequences", "TEST", 269, 283], ["SARS", "TEST", 376, 380], ["CoVs", "PROBLEM", 404, 408], ["length", "OBSERVATION_MODIFIER", 42, 48], ["CoVs", "OBSERVATION", 404, 408]]], ["The S protein is functionally divided into two subunits, denoted S1 and S2, which is responsible for receptor binding and cellular membrane fusion, respectively.", [["cellular membrane", "ANATOMY", 122, 139], ["S1", "GENE_OR_GENE_PRODUCT", 65, 67], ["S2", "GENE_OR_GENE_PRODUCT", 72, 74], ["cellular membrane", "CELLULAR_COMPONENT", 122, 139], ["S protein", "PROTEIN", 4, 13], ["S1", "PROTEIN", 65, 67], ["S2", "PROTEIN", 72, 74], ["The S protein", "TEST", 0, 13], ["receptor binding", "PROBLEM", 101, 117], ["cellular membrane fusion", "TREATMENT", 122, 146], ["S1", "ANATOMY", 65, 67], ["S2", "ANATOMY", 72, 74], ["responsible for", "UNCERTAINTY", 85, 100], ["receptor binding", "OBSERVATION", 101, 117], ["cellular membrane fusion", "OBSERVATION", 122, 146]]], ["S1 consists of two domains, the N-terminal domain (NTD) and C-terminal domain (CTD) which is also known as the RBD in SARS-CoV [24].", [["SARS", "DISEASE", 118, 122], ["C", "CHEMICAL", 60, 61], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 118, 126], ["S1", "PROTEIN", 0, 2], ["N-terminal domain", "PROTEIN", 32, 49], ["NTD", "PROTEIN", 51, 54], ["C-terminal domain", "PROTEIN", 60, 77], ["CTD", "PROTEIN", 79, 82], ["RBD", "PROTEIN", 111, 114], ["SARS-CoV", "SPECIES", 118, 126], ["the N-terminal domain (NTD)", "PROBLEM", 28, 55], ["C-terminal domain (CTD)", "PROBLEM", 60, 83]]], ["SARS-CoV and bat SARSr-CoVs share high sequence identity in the S2 region in contrast to the S1 region.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["bat", "ORGANISM", 13, 16], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 17, 27], ["SARS-CoV and bat SARSr-CoVs", "DNA", 0, 27], ["S2 region", "DNA", 64, 73], ["S1 region", "DNA", 93, 102], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["bat SARSr", "TEST", 13, 22], ["S2", "ANATOMY", 64, 66], ["region", "ANATOMY_MODIFIER", 67, 73], ["S1", "ANATOMY", 93, 95], ["region", "ANATOMY_MODIFIER", 96, 102]]], ["Among the 15 SARSr-CoVs identified from bats in the surveyed cave, six strains with deletions in their RBD regions (Rs4081, Rs4237, Rs4247, Rs4255, Rf4092 and As6526) showed 78.2% to 80.2% aa sequence identity to SARS-CoV in the S protein, while the other nine strains without deletions were much more closely related to SARS-CoV, with 90.0% (Rs4084) to 97.2% (Rs4874) aa sequence identity.", [["SARS", "DISEASE", 213, 217], ["SARS", "DISEASE", 321, 325], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 13, 23], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 213, 221], ["SARS-CoV", "ORGANISM", 321, 329], ["SARSr-CoVs", "DNA", 13, 23], ["RBD regions", "DNA", 103, 114], ["Rs4081", "DNA", 116, 122], ["Rs4237", "DNA", 124, 130], ["Rs4247", "DNA", 132, 138], ["Rf4092", "DNA", 148, 154], ["SARS-CoV", "DNA", 213, 221], ["S protein", "PROTEIN", 229, 238], ["SARS-CoV", "SPECIES", 213, 221], ["SARS-CoV", "SPECIES", 321, 329], ["deletions in their RBD regions", "PROBLEM", 84, 114], ["Rs", "TEST", 124, 126], ["Rs", "TEST", 132, 134], ["Rs", "TEST", 140, 142], ["Rf", "TEST", 148, 150], ["aa sequence identity", "TEST", 189, 209], ["SARS", "TEST", 213, 217], ["CoV", "TEST", 218, 221], ["the S protein", "TEST", 225, 238], ["deletions", "PROBLEM", 277, 286], ["SARS", "TEST", 321, 325], ["CoV", "TEST", 326, 329], ["Rs", "TEST", 343, 345], ["aa sequence identity", "TEST", 369, 389], ["RBD", "ANATOMY", 103, 106], ["regions", "ANATOMY_MODIFIER", 107, 114]]], ["These nine SARSr-CoVs can be further divided into four genotypes according to their S1 sequences (Fig 2): RsSHC014/Rs4084 showed more genetic differences from SARS-CoV in both NTD and RBD regions; The RBD sequences of SARSr-CoV Rs7327, Rs9401 and previously reported WIV1/Rs3367 closely resembled that of SARS-CoV.", [["SARS", "DISEASE", 159, 163], ["SARS", "DISEASE", 305, 309], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 11, 21], ["RsSHC014", "GENE_OR_GENE_PRODUCT", 106, 114], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 159, 167], ["SARSr-CoV Rs7327", "GENE_OR_GENE_PRODUCT", 218, 234], ["Rs9401", "GENE_OR_GENE_PRODUCT", 236, 242], ["SARS-CoV", "ORGANISM", 305, 313], ["SARSr", "PROTEIN", 11, 16], ["CoVs", "DNA", 17, 21], ["S1 sequences", "DNA", 84, 96], ["NTD and RBD regions", "DNA", 176, 195], ["RBD sequences", "DNA", 201, 214], ["Rs9401", "DNA", 236, 242], ["WIV1", "DNA", 267, 271], ["Rs3367", "DNA", 272, 278], ["SARS-CoV", "SPECIES", 159, 167], ["SARSr-CoV Rs7327", "SPECIES", 218, 234], ["SARS-CoV", "SPECIES", 305, 313], ["SARS", "PROBLEM", 159, 163], ["CoV in both NTD and RBD regions", "PROBLEM", 164, 195], ["The RBD sequences", "TEST", 197, 214], ["SARSr", "TEST", 218, 223], ["CoV Rs", "TEST", 224, 230], ["Rs", "TEST", 236, 238], ["WIV1", "TEST", 267, 271], ["SARS", "PROBLEM", 305, 309], ["CoV", "PROBLEM", 310, 313], ["both", "ANATOMY_MODIFIER", 171, 175], ["NTD", "ANATOMY", 176, 179], ["RBD", "OBSERVATION", 184, 187]]], ["However, they were distinct from SARS-CoV but similar to RsSHC014 in NTD.", [["SARS", "DISEASE", 33, 37], ["RsSHC014", "CHEMICAL", 57, 65], ["SARS-CoV", "ORGANISM", 33, 41], ["RsSHC014", "GENE_OR_GENE_PRODUCT", 57, 65], ["RsSHC014", "DNA", 57, 65], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["CoV", "PROBLEM", 38, 41], ["NTD", "PROBLEM", 69, 72], ["distinct", "OBSERVATION_MODIFIER", 19, 27], ["SARS", "OBSERVATION", 33, 37]]], ["In contrast, we found a novel SARSr-CoV, termed Rs4231, which shared highly similar NTD, but not RBD sequence with SARS-CoV (Figs 2 and 3).", [["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 30, 39], ["Rs4231", "GENE_OR_GENE_PRODUCT", 48, 54], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 115, 123], ["SARSr-CoV", "DNA", 30, 39], ["Rs4231", "DNA", 48, 54], ["NTD", "PROTEIN", 84, 87], ["RBD sequence", "PROTEIN", 97, 109], ["SARSr-CoV", "SPECIES", 30, 39], ["SARS-CoV", "SPECIES", 115, 123], ["RBD sequence", "TEST", 97, 109], ["SARS", "TEST", 115, 119], ["CoV (Figs", "TEST", 120, 129]]], ["Its S protein showed 94.6% to 95% aa sequence identity to those of human and civet SARS-CoVs (S1 Table).", [["human", "ORGANISM", 67, 72], ["S protein", "PROTEIN", 4, 13], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["Its S protein", "TEST", 0, 13], ["aa sequence identity", "TEST", 34, 54], ["human", "TEST", 67, 72]]], ["Strains with both NTD and RBD highly homologous to those of SARS-CoV were also present in this cave.", [["SARS", "DISEASE", 60, 64], ["SARS-CoV", "ORGANISM", 60, 68], ["NTD", "PROTEIN", 18, 21], ["RBD", "PROTEIN", 26, 29], ["SARS-CoV", "SPECIES", 60, 68], ["Strains", "PROBLEM", 0, 7], ["both NTD", "PROBLEM", 13, 21], ["RBD", "PROBLEM", 26, 29], ["SARS", "PROBLEM", 60, 64], ["CoV", "PROBLEM", 65, 68], ["RBD", "OBSERVATION", 26, 29]]], ["In addition to WIV16 which we described previously [18], Rs4874 was also found to have the S protein closest to SARS-CoV S (> 97% aa sequence identity) of all the bat SARSr-CoVs reported to date (Figs 2 and 3).", [["SARS", "DISEASE", 112, 116], ["Rs4874", "GENE_OR_GENE_PRODUCT", 57, 63], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 167, 177], ["WIV16", "DNA", 15, 20], ["S protein", "PROTEIN", 91, 100], ["SARS-CoV S", "DNA", 112, 122], ["SARSr", "PROTEIN", 167, 172], ["CoVs", "PROTEIN", 173, 177], ["SARS-CoV", "SPECIES", 112, 120], ["the S protein", "TEST", 87, 100], ["SARS", "TEST", 112, 116], ["CoV S", "TEST", 117, 122], ["aa sequence identity", "TEST", 130, 150], ["the bat SARSr", "TEST", 159, 172], ["CoVs", "PROBLEM", 173, 177], ["Figs", "TEST", 196, 200], ["bat", "ANATOMY", 163, 166]]], ["In addition to the SARSr-CoVs subjected to full-length genome sequencing, we also obtained the RBD and NTD sequences from other samples collected in this cave.", [["samples", "ANATOMY", 128, 135], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 19, 29], ["SARSr-CoVs", "DNA", 19, 29], ["RBD and NTD sequences", "DNA", 95, 116], ["the SARSr-CoVs", "PROBLEM", 15, 29], ["the RBD and NTD sequences", "TEST", 91, 116], ["other samples", "TEST", 122, 135]]], ["The sequences with high identity to SARS-CoV RBD were amplified from 10 more R. sinicus samples.", [["samples", "ANATOMY", 88, 95], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 36, 44], ["sinicus samples", "CANCER", 80, 95], ["SARS-CoV RBD", "DNA", 36, 48], ["R. sinicus", "SPECIES", 77, 87], ["SARS-CoV", "SPECIES", 36, 44], ["R. sinicus", "SPECIES", 77, 87], ["The sequences", "TEST", 0, 13], ["CoV RBD", "PROBLEM", 41, 48]]], ["SARSr-CoVs with this genotype of RBD were detected in different seasons throughout the five years.", [["RBD", "DISEASE", 33, 36], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 0, 10], ["RBD", "GENE_OR_GENE_PRODUCT", 33, 36], ["SARSr-CoVs", "DNA", 0, 10], ["RBD", "PROTEIN", 33, 36], ["SARSr", "TEST", 0, 5], ["this genotype of RBD", "PROBLEM", 16, 36], ["CoVs", "OBSERVATION_MODIFIER", 6, 10], ["RBD", "OBSERVATION", 33, 36]]], ["Strains containing the NTD similar to SARS-CoV were only found in 2013 (S2 Table).Co-circulation of different bat SARSr-CoVs with S, ORF8 and ORF3 sequences similar to those in SARS-CoV at a single location ::: ResultsORF8 is another highly variable gene among different SARS-CoV and SARSr-CoV strains [25,26].", [["SARS", "DISEASE", 38, 42], ["SARS", "DISEASE", 177, 181], ["SARS-CoV", "ORGANISM", 38, 46], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 114, 124], ["ORF8", "GENE_OR_GENE_PRODUCT", 133, 137], ["ORF3", "GENE_OR_GENE_PRODUCT", 142, 146], ["SARS-CoV", "ORGANISM", 177, 185], ["ResultsORF8", "GENE_OR_GENE_PRODUCT", 211, 222], ["SARS-CoV", "ORGANISM", 271, 279], ["SARSr-CoV", "ORGANISM", 284, 293], ["bat SARSr-CoVs with S, ORF8 and ORF3 sequences", "DNA", 110, 156], ["ResultsORF8", "DNA", 211, 222], ["SARS-CoV", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 177, 185], ["SARS-CoV", "SPECIES", 271, 279], ["SARSr-CoV", "SPECIES", 284, 293], ["Strains", "PROBLEM", 0, 7], ["the NTD", "PROBLEM", 19, 26], ["SARS", "PROBLEM", 38, 42], ["CoV", "TEST", 43, 46], ["ORF8", "TEST", 133, 137], ["ORF3 sequences", "TEST", 142, 156], ["different SARS", "TEST", 261, 275], ["CoV", "TEST", 276, 279], ["SARSr", "TEST", 284, 289], ["CoV strains", "PROBLEM", 290, 301]]], ["We aligned the ORF8 nt sequences of the representative SARSr-CoVs discovered in this surveillance with those of other SARSr-CoVs and SARS-CoVs (Fig 4).", [["SARS", "DISEASE", 133, 137], ["ORF8", "GENE_OR_GENE_PRODUCT", 15, 19], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 55, 65], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 118, 128], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 133, 142], ["ORF8 nt sequences", "DNA", 15, 32], ["SARSr-CoVs", "DNA", 55, 65], ["SARSr-CoVs and SARS-CoVs", "DNA", 118, 142], ["the ORF8 nt sequences", "TEST", 11, 32], ["this surveillance", "TEST", 80, 97], ["other SARSr", "TEST", 112, 123], ["SARS", "PROBLEM", 133, 137]]], ["Though WIV16, WIV1, Rs4231 and RsSHC014 were genetically closer to SARS-CoV in S gene, they contained a single 366-nt ORF8 without the 29-nt deletion present in most human SARS-CoVs and showed only 47.1% to 51.0% nt sequence identity to human and civet SARS-CoVs.", [["SARS", "DISEASE", 172, 176], ["SARS", "DISEASE", 253, 257], ["WIV16", "GENE_OR_GENE_PRODUCT", 7, 12], ["WIV1", "GENE_OR_GENE_PRODUCT", 14, 18], ["Rs4231", "GENE_OR_GENE_PRODUCT", 20, 26], ["RsSHC014", "GENE_OR_GENE_PRODUCT", 31, 39], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 67, 75], ["ORF8", "GENE_OR_GENE_PRODUCT", 118, 122], ["human", "ORGANISM", 166, 171], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 172, 181], ["human", "ORGANISM", 237, 242], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 253, 262], ["WIV16", "DNA", 7, 12], ["WIV1", "DNA", 14, 18], ["Rs4231", "DNA", 20, 26], ["RsSHC014", "DNA", 31, 39], ["SARS-CoV", "DNA", 67, 75], ["S gene", "DNA", 79, 85], ["366-nt ORF8", "DNA", 111, 122], ["29-nt deletion", "DNA", 135, 149], ["human SARS-CoVs", "DNA", 166, 181], ["human and civet SARS-CoVs", "DNA", 237, 262], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 237, 242], ["SARS-CoV", "SPECIES", 67, 75], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 237, 242], ["WIV1", "TEST", 14, 18], ["Rs", "TEST", 20, 22], ["RsSHC014", "TEST", 31, 39], ["SARS", "TEST", 67, 71], ["nt ORF8", "TEST", 115, 122], ["nt deletion", "PROBLEM", 138, 149], ["CoVs", "TEST", 177, 181], ["CoVs", "PROBLEM", 258, 262]]], ["However, the ORF8 of strain Rf4092 from R. ferrumequinum exhibited high similarity to that of civet SARS-CoV.", [["Rf4092", "CHEMICAL", 28, 34], ["ORF8", "GENE_OR_GENE_PRODUCT", 13, 17], ["strain Rf4092", "ORGANISM", 21, 34], ["R. ferrumequinum", "ORGANISM", 40, 56], ["SARS-CoV", "ORGANISM", 100, 108], ["ORF8", "DNA", 13, 17], ["R. ferrumequinum", "SPECIES", 40, 56], ["Rf4092", "SPECIES", 28, 34], ["R. ferrumequinum", "SPECIES", 40, 56], ["SARS-CoV", "SPECIES", 100, 108], ["strain Rf", "TEST", 21, 30]]], ["It possessed a single long ORF8 of the same length (369 nt) as that of civet SARS-CoV strain SZ3, with only 10 nt mutations and 3 aa mutations detected (Fig 4).", [["SARS-CoV", "ORGANISM", 77, 85], ["ORF8", "DNA", 27, 31], ["SARS-CoV", "SPECIES", 77, 85], ["civet SARS", "PROBLEM", 71, 81], ["CoV strain SZ3", "PROBLEM", 82, 96], ["10 nt mutations", "PROBLEM", 108, 123], ["3 aa mutations", "PROBLEM", 128, 142]]], ["Similar ORF8 sequences were also amplified from other 7 samples collected in the cave during 2011 to 2013, from both R. ferrumequinum and R. sinicus (S2 Table).", [["samples", "ANATOMY", 56, 63], ["ORF8", "GENE_OR_GENE_PRODUCT", 8, 12], ["R. ferrumequinum", "ORGANISM", 117, 133], ["R. sinicus", "ORGANISM", 138, 148], ["ORF8 sequences", "DNA", 8, 22], ["R. ferrumequinum", "SPECIES", 117, 133], ["R. sinicus", "SPECIES", 138, 148], ["R. ferrumequinum", "SPECIES", 117, 133], ["R. sinicus", "SPECIES", 138, 148], ["Similar ORF8 sequences", "TEST", 0, 22], ["cave", "ANATOMY", 81, 85]]], ["The ORF8 of Rs4084 was highly similar to Rf4092\u2019s but was split into two overlapping ORFs, ORF8a and ORF8b, due to a short 5-nt deletion (Figs 2 and 4).", [["Rs4084", "CHEMICAL", 12, 18], ["ORF8", "GENE_OR_GENE_PRODUCT", 4, 8], ["Rs4084", "GENE_OR_GENE_PRODUCT", 12, 18], ["ORF8a", "GENE_OR_GENE_PRODUCT", 91, 96], ["ORF8b", "GENE_OR_GENE_PRODUCT", 101, 106], ["ORF8", "DNA", 4, 8], ["Rs4084", "DNA", 12, 18], ["Rf4092", "DNA", 41, 47], ["ORFs", "DNA", 85, 89], ["ORF8a", "DNA", 91, 96], ["ORF8b", "DNA", 101, 106], ["short 5-nt deletion", "DNA", 117, 136], ["Rf4092", "SPECIES", 41, 47], ["The ORF8 of Rs", "TEST", 0, 14], ["Rf", "TEST", 41, 43], ["ORF8b", "TEST", 101, 106], ["a short 5-nt deletion", "PROBLEM", 115, 136], ["Figs", "TEST", 138, 142]]], ["The position of start codons and stop codons of the two ORFs were consistent with those in most human SARS-CoV strains.", [["SARS", "DISEASE", 102, 106], ["human", "ORGANISM", 96, 101], ["SARS-CoV strains", "ORGANISM", 102, 118], ["start codons", "DNA", 16, 28], ["ORFs", "DNA", 56, 60], ["human", "SPECIES", 96, 101], ["human SARS-CoV", "SPECIES", 96, 110], ["start codons", "TREATMENT", 16, 28], ["stop codons", "TREATMENT", 33, 44], ["the two ORFs", "PROBLEM", 48, 60], ["CoV strains", "PROBLEM", 107, 118], ["consistent with", "UNCERTAINTY", 66, 81]]], ["Excluding the 8-aa insertion, Rs4084 and SARS-CoV strain BJ01 displayed identical aa sequence of ORF8a, and only three different aa residues were observed between their ORF8b (Fig 4).", [["SARS-CoV", "ORGANISM", 41, 49], ["ORF8a", "GENE_OR_GENE_PRODUCT", 97, 102], ["ORF8a", "PROTEIN", 97, 102], ["ORF8b", "PROTEIN", 169, 174], ["SARS-CoV", "SPECIES", 41, 49], ["Rs", "TEST", 30, 32], ["SARS", "TEST", 41, 45], ["CoV strain BJ01", "TEST", 46, 61], ["ORF8a", "TEST", 97, 102], ["three different aa residues", "PROBLEM", 113, 140], ["aa residues", "OBSERVATION", 129, 140]]], ["To our knowledge, Rs4084 was the first bat SARSr-CoV reported that resembled the late human SARS-CoVs in both ORF8 gene organization and sequence.Co-circulation of different bat SARSr-CoVs with S, ORF8 and ORF3 sequences similar to those in SARS-CoV at a single location ::: ResultsAnother key difference between SARS-CoV and bat SARSr-CoV genomes is the ORF3 coding region [10,17,21].", [["Rs4084", "CHEMICAL", 18, 24], ["SARS", "DISEASE", 92, 96], ["SARS", "DISEASE", 241, 245], ["SARS", "DISEASE", 313, 317], ["SARSr-CoV", "ORGANISM", 43, 52], ["human", "ORGANISM", 86, 91], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 92, 101], ["ORF8", "GENE_OR_GENE_PRODUCT", 110, 114], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 178, 188], ["ORF8", "GENE_OR_GENE_PRODUCT", 197, 201], ["ORF3", "GENE_OR_GENE_PRODUCT", 206, 210], ["SARS-CoV", "ORGANISM", 241, 249], ["SARS-CoV", "ORGANISM", 313, 321], ["bat SARSr-CoV", "ORGANISM", 326, 339], ["human SARS-CoVs", "DNA", 86, 101], ["ORF8 gene organization", "DNA", 110, 132], ["bat SARSr-CoVs with S, ORF8 and ORF3 sequences", "DNA", 174, 220], ["SARS-CoV and bat SARSr-CoV genomes", "DNA", 313, 347], ["ORF3 coding region", "DNA", 355, 373], ["human", "SPECIES", 86, 91], ["SARSr-CoV", "SPECIES", 43, 52], ["human", "SPECIES", 86, 91], ["SARS-CoV", "SPECIES", 241, 249], ["SARS-CoV", "SPECIES", 313, 321], ["bat SARSr-CoV", "SPECIES", 326, 339], ["the late human SARS", "PROBLEM", 77, 96], ["CoVs", "PROBLEM", 97, 101], ["ORF8", "TEST", 197, 201], ["ORF3 sequences", "TEST", 206, 220], ["SARS", "TEST", 313, 317], ["CoV", "TEST", 318, 321], ["bat SARSr", "TEST", 326, 335]]], ["We analyzed the ORF3a sequences amplified from 42 samples and found that most of the SARSr-CoVs closely related to SARS-CoV in the S gene shared higher ORF3a sequence similarity (96.4% to 98.9% aa identity) with SARS-CoV (S3 Fig and S2 Table).", [["samples", "ANATOMY", 50, 57], ["SARS", "DISEASE", 115, 119], ["ORF3a", "GENE_OR_GENE_PRODUCT", 16, 21], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 85, 95], ["SARS-CoV", "ORGANISM", 115, 123], ["ORF3a", "GENE_OR_GENE_PRODUCT", 152, 157], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 212, 220], ["ORF3a sequences", "DNA", 16, 31], ["SARSr-CoVs", "DNA", 85, 95], ["SARS-CoV", "DNA", 115, 123], ["S gene", "DNA", 131, 137], ["ORF3a sequence", "DNA", 152, 166], ["SARS-CoV", "SPECIES", 115, 123], ["SARS-CoV", "SPECIES", 212, 220], ["the ORF3a sequences", "TEST", 12, 31], ["the SARSr", "TEST", 81, 90], ["CoVs", "PROBLEM", 91, 95], ["SARS", "PROBLEM", 115, 119], ["aa identity", "TEST", 194, 205], ["SARS", "TEST", 212, 216]]], ["The ORF3b of SARS CoV, sharing a large part of its coding sequence with the ORF3a, encodes a 154-aa protein [27], but it is truncated to different extents at the C-terminal in previously described bat SARSr-CoVs including WIV1 and WIV16 (S4 Fig).", [["SARS", "DISEASE", 13, 17], ["C", "CHEMICAL", 162, 163], ["ORF3b", "GENE_OR_GENE_PRODUCT", 4, 9], ["SARS CoV", "ORGANISM", 13, 21], ["ORF3a", "GENE_OR_GENE_PRODUCT", 76, 81], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 201, 211], ["WIV1", "GENE_OR_GENE_PRODUCT", 222, 226], ["ORF3b", "PROTEIN", 4, 9], ["SARS CoV", "PROTEIN", 13, 21], ["ORF3a", "DNA", 76, 81], ["C-terminal", "PROTEIN", 162, 172], ["SARSr", "PROTEIN", 201, 206], ["CoVs", "PROTEIN", 207, 211], ["WIV1", "PROTEIN", 222, 226], ["WIV16", "PROTEIN", 231, 236], ["S4 Fig", "PROTEIN", 238, 244], ["SARS CoV", "SPECIES", 13, 21], ["SARS CoV", "PROBLEM", 13, 21], ["aa protein", "TEST", 97, 107], ["WIV1", "TEST", 222, 226], ["large", "OBSERVATION_MODIFIER", 33, 38], ["different", "OBSERVATION_MODIFIER", 137, 146], ["extents", "OBSERVATION_MODIFIER", 147, 154], ["terminal", "ANATOMY_MODIFIER", 164, 172]]], ["In the current study, we identified a non-truncated ORF3b for the first time (Rs7327), which maintained the nuclear localization signal at its C-terminal.", [["nuclear", "ANATOMY", 108, 115], ["ORF3b", "GENE_OR_GENE_PRODUCT", 52, 57], ["nuclear", "CELLULAR_COMPONENT", 108, 115], ["ORF3b", "PROTEIN", 52, 57], ["the current study", "TEST", 3, 20]]], ["Moreover, it shared 98.1% aa sequence identity with SARS-CoV strain Tor2 with only three aa substitutions (S4 Fig).", [["SARS-CoV", "ORGANISM", 52, 60], ["SARS-CoV", "SPECIES", 52, 60], ["aa sequence identity", "TEST", 26, 46], ["SARS", "PROBLEM", 52, 56], ["CoV strain Tor2", "TREATMENT", 57, 72]]], ["Thus, Rs7327 is the bat SARSr-CoV most similar to SARS-CoV in the ORF3 region known to date.Recombination analysis ::: ResultsThe full-length genome sequences of all 15 SARSr-CoVs from the surveyed cave were screened for evidence of potential recombination events.", [["SARS", "DISEASE", 50, 54], ["Rs7327", "GENE_OR_GENE_PRODUCT", 6, 12], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 24, 33], ["SARS-CoV", "ORGANISM", 50, 58], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 169, 179], ["ORF3 region", "DNA", 66, 77], ["full-length genome sequences", "DNA", 130, 158], ["SARSr-CoVs", "DNA", 169, 179], ["SARSr-CoV", "SPECIES", 24, 33], ["SARS-CoV", "SPECIES", 50, 58], ["the bat SARSr", "TEST", 16, 29], ["CoV", "PROBLEM", 30, 33], ["SARS", "PROBLEM", 50, 54], ["CoV in the ORF3 region", "PROBLEM", 55, 77], ["potential recombination events", "PROBLEM", 233, 263], ["SARS", "OBSERVATION", 50, 54]]], ["Both similarity plot and bootscan analyses revealed frequent recombination events among these SARSr-CoV strains.", [["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 94, 103], ["SARSr-CoV", "SPECIES", 94, 103], ["Both similarity plot", "TEST", 0, 20], ["bootscan analyses", "TEST", 25, 42], ["frequent recombination events", "PROBLEM", 52, 81], ["frequent recombination", "OBSERVATION", 52, 74]]], ["It was suggested that WIV16, the closest progenitor of human SARS-CoV known to date [18], was likely to be a recombinant strain from three SARSr-CoVs harbored by bats in the same cave, namely WIV1, Rs4231 and Rs4081, with strong P value (<10\u221230).", [["WIV16", "GENE_OR_GENE_PRODUCT", 22, 27], ["human", "ORGANISM", 55, 60], ["SARS-CoV", "ORGANISM", 61, 69], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 139, 149], ["bats", "ORGANISM", 162, 166], ["WIV16", "PROTEIN", 22, 27], ["human", "SPECIES", 55, 60], ["human SARS-CoV", "SPECIES", 55, 69], ["human SARS", "PROBLEM", 55, 65], ["a recombinant strain", "PROBLEM", 107, 127], ["Rs", "TEST", 209, 211], ["strong P value", "TEST", 222, 236]]], ["In the genomic region between nt 22615 and 28160, which contained the region encoding the RBD and the S2 subunit of the S protein, WIV16 was highly similar to WIV1, sharing 99% sequence identity.", [["RBD", "GENE_OR_GENE_PRODUCT", 90, 93], ["WIV16", "GENE_OR_GENE_PRODUCT", 131, 136], ["genomic region", "DNA", 7, 21], ["nt 22615 and 28160", "DNA", 30, 48], ["RBD", "PROTEIN", 90, 93], ["S2 subunit", "PROTEIN", 102, 112], ["S protein", "PROTEIN", 120, 129], ["WIV16", "PROTEIN", 131, 136], ["WIV1", "DNA", 159, 163], ["nt", "TEST", 30, 32], ["the S protein", "TEST", 116, 129], ["WIV1", "TEST", 159, 163], ["genomic", "ANATOMY_MODIFIER", 7, 14], ["region", "ANATOMY_MODIFIER", 15, 21], ["region", "ANATOMY_MODIFIER", 70, 76], ["RBD", "ANATOMY", 90, 93], ["S2", "ANATOMY_MODIFIER", 102, 104]]], ["In contrast, in the region between nt 18391 and 22615, which covered a part of ORF1b and the region encoding the NTD of the S gene, WIV16 showed substantially closer relationship to Rs4231.", [["Rs4231", "CHEMICAL", 182, 188], ["ORF1b", "GENE_OR_GENE_PRODUCT", 79, 84], ["WIV16", "GENE_OR_GENE_PRODUCT", 132, 137], ["nt 18391 and 22615", "DNA", 35, 53], ["ORF1b", "DNA", 79, 84], ["NTD", "DNA", 113, 116], ["S gene", "DNA", 124, 130], ["WIV16", "DNA", 132, 137], ["Rs4231", "DNA", 182, 188], ["nt", "TEST", 35, 37], ["region", "ANATOMY_MODIFIER", 20, 26]]], ["Meanwhile, the ORF1ab sequences upstream from nt 18391 of WIV16 displayed the highest genetic similarity (99.8% nt sequence identity) to that of Rs4081.Recombination analysis ::: ResultsEvidence of recombination event was also detected in the genome of the novel SARSr-CoV Rs4084, which had a unique genome organization with split ORF8a and 8b.", [["Rs4081", "CHEMICAL", 145, 151], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 15, 21], ["SARSr-CoV R", "GENE_OR_GENE_PRODUCT", 263, 274], ["ORF1ab sequences", "DNA", 15, 31], ["nt 18391", "DNA", 46, 54], ["WIV16", "DNA", 58, 63], ["Rs4081", "DNA", 145, 151], ["SARSr-CoV Rs4084", "DNA", 263, 279], ["ORF8a", "DNA", 331, 336], ["SARSr-CoV Rs4084", "SPECIES", 263, 279], ["the ORF1ab sequences upstream", "TEST", 11, 40], ["nt", "TEST", 46, 48], ["recombination event", "PROBLEM", 198, 217], ["CoV Rs", "TEST", 269, 275], ["genome organization", "OBSERVATION", 300, 319]]], ["The previously reported strain RsSHC014 and the newly identified strain Rf4092 were suggested to be the major and minor parent of Rs4084, respectively (P value < 10\u221280).", [["RsSHC014", "CHEMICAL", 31, 39], ["Rf4092", "CHEMICAL", 72, 78], ["Rf4092", "CELL", 72, 78], ["P value", "TEST", 152, 159]]], ["The breakpoint was located at nt 26796 (S5 Fig).", [["nt 26796", "DNA", 30, 38]]], ["In the region downstream of the breakpoint including ORF8, Rs4084 showed closet genetic relationship with Rf4092, sharing 98.9% nt sequence identity, while it shared the highest nt sequence identity (99.4%) with RsSHC014 in the majority of its genome upstream from the breakpoint.Recombination analysis ::: ResultsWhen civet SARS-CoV SZ3 was used as the query sequence in similarity plot and bootscan analysis, evidence for recombination events was also detected (Fig 5B).", [["Rf4092", "CHEMICAL", 106, 112], ["ORF8", "GENE_OR_GENE_PRODUCT", 53, 57], ["Rs4084", "GENE_OR_GENE_PRODUCT", 59, 65], ["SARS-CoV", "ORGANISM", 325, 333], ["ORF8", "DNA", 53, 57], ["Rs4084", "DNA", 59, 65], ["Rf4092", "DNA", 106, 112], ["RsSHC014", "DNA", 212, 220], ["genome upstream", "DNA", 244, 259], ["civet SARS-CoV SZ3", "DNA", 319, 337], ["Rf4092", "SPECIES", 106, 112], ["SARS-CoV", "SPECIES", 325, 333], ["Rs", "TEST", 59, 61], ["the highest nt sequence identity", "PROBLEM", 166, 198], ["RsSHC014", "TREATMENT", 212, 220], ["CoV SZ3", "TEST", 330, 337], ["the query sequence", "TEST", 350, 368], ["similarity plot", "TEST", 372, 387], ["bootscan analysis", "TEST", 392, 409], ["recombination events", "PROBLEM", 424, 444]]], ["In the region between the two breakpoints at the genome positions nt 21161 and nt 27766, including the S gene, closer genetic relationship between SZ3 and WIV16 was observed.", [["SZ3", "GENE_OR_GENE_PRODUCT", 147, 150], ["WIV16", "GENE_OR_GENE_PRODUCT", 155, 160], ["genome positions nt 21161", "DNA", 49, 74], ["nt 27766", "DNA", 79, 87], ["S gene", "DNA", 103, 109], ["SZ3", "DNA", 147, 150], ["WIV16", "DNA", 155, 160], ["nt", "TEST", 79, 81], ["region", "ANATOMY_MODIFIER", 7, 13], ["two", "OBSERVATION_MODIFIER", 26, 29], ["breakpoints", "OBSERVATION", 30, 41]]], ["However, from position nt 27766 towards the 3\u2019 end of its genome, a notably close genetic relationship was observed between SZ3 and Rf4092 instead.", [["SZ3", "CHEMICAL", 124, 127], ["Rf4092", "CHEMICAL", 132, 138], ["3\u2019 end", "CELLULAR_COMPONENT", 44, 50], ["genome", "CELLULAR_COMPONENT", 58, 64], ["position nt 27766", "DNA", 14, 31], ["3\u2019 end", "DNA", 44, 50], ["SZ3", "DNA", 124, 127], ["position nt", "TEST", 14, 25]]], ["Throughout the non-structural gene, moreover, SZ3 shared a similarly high sequence identity with WIV16 and Rf4092.", [["Rf4092", "CHEMICAL", 107, 113], ["SZ3", "GENE_OR_GENE_PRODUCT", 46, 49], ["non-structural gene", "DNA", 15, 34], ["SZ3", "PROTEIN", 46, 49], ["a similarly high sequence identity", "PROBLEM", 57, 91], ["Rf", "TEST", 107, 109]]], ["It indicates that civet SARS-CoV was likely to be the descendent from a recombinant of the precursors of WIV16 and Rf4092, or that the SARSr-CoVs found in this cave, like WIV16 or Rf4092, may have been the descendants of the SARS-CoV lineage.Phylogenetic analysis ::: ResultsPhylogenetic trees were constructed using the nt sequences of nonstructural protein gene ORF1a and ORF1b.", [["SARS", "DISEASE", 24, 28], ["Rf4092", "CHEMICAL", 115, 121], ["SARS", "DISEASE", 225, 229], ["SARS-CoV", "ORGANISM", 24, 32], ["WIV16", "GENE_OR_GENE_PRODUCT", 105, 110], ["Rf4092", "GENE_OR_GENE_PRODUCT", 115, 121], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 135, 145], ["WIV16", "GENE_OR_GENE_PRODUCT", 171, 176], ["Rf4092", "GENE_OR_GENE_PRODUCT", 180, 186], ["SARS-CoV", "ORGANISM", 225, 233], ["ORF1a", "GENE_OR_GENE_PRODUCT", 364, 369], ["ORF1b", "GENE_OR_GENE_PRODUCT", 374, 379], ["SARSr", "PROTEIN", 135, 140], ["CoVs", "DNA", 141, 145], ["WIV16", "DNA", 171, 176], ["Rf4092", "DNA", 180, 186], ["nt sequences", "DNA", 321, 333], ["nonstructural protein gene", "DNA", 337, 363], ["ORF1a", "DNA", 364, 369], ["ORF1b", "DNA", 374, 379], ["SARS-CoV", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 225, 233], ["civet SARS-CoV", "PROBLEM", 18, 32], ["the SARSr", "TEST", 131, 140], ["CoVs", "PROBLEM", 141, 145], ["Phylogenetic analysis", "TEST", 242, 263], ["the nt sequences", "TREATMENT", 317, 333], ["nonstructural protein gene ORF1a", "TREATMENT", 337, 369], ["ORF1b", "TREATMENT", 374, 379]]], ["Unlike the high genetic diversity in the S gene, nearly all SARSr-CoVs from the bat cave we surveyed were closely clustered, and showed closer phylogenetic relationship to SARS-CoV than the majority of currently known bat SARSr-CoVs discovered from other locations, except YNLF_31C and 34C which were recently reported in greater horseshoe bats from another location in Yunnan [22] (Fig 6).", [["SARS", "DISEASE", 172, 176], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 60, 70], ["bat cave", "ORGANISM", 80, 88], ["SARS-CoV", "ORGANISM", 172, 180], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 222, 232], ["YNLF_31C", "GENE_OR_GENE_PRODUCT", 273, 281], ["34C", "GENE_OR_GENE_PRODUCT", 286, 289], ["S gene", "DNA", 41, 47], ["SARSr-CoVs", "DNA", 60, 70], ["SARSr", "DNA", 222, 227], ["CoVs", "DNA", 228, 232], ["YNLF_31C", "DNA", 273, 281], ["34C", "DNA", 286, 289], ["SARS-CoV", "SPECIES", 172, 180], ["SARS", "PROBLEM", 172, 176], ["CoVs", "PROBLEM", 228, 232], ["high", "OBSERVATION_MODIFIER", 11, 15], ["genetic diversity", "OBSERVATION", 16, 33]]], ["The phylogeny of SARSr-CoVs in ORF1a and ORF1b appeared to be associated with their geographical distribution rather than with host species.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 17, 27], ["ORF1a", "GENE_OR_GENE_PRODUCT", 31, 36], ["ORF1b", "GENE_OR_GENE_PRODUCT", 41, 46], ["SARSr", "DNA", 17, 22], ["CoVs", "DNA", 23, 27], ["ORF1a", "DNA", 31, 36], ["ORF1b", "DNA", 41, 46], ["SARSr", "TEST", 17, 22], ["CoVs", "PROBLEM", 23, 27], ["host species", "PROBLEM", 127, 139]]], ["Regardless of different host bat species, SARS-CoV and SARSr-CoVs detected in bats from southwestern China (Yunnan, Guizhou and Guangxi province) formed one clade, in which SARSr-CoV strains showing closer relationship to SARS-CoV were all from Yunnan.", [["SARS", "DISEASE", 222, 226], ["SARS-CoV", "ORGANISM", 42, 50], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 55, 65], ["SARSr-CoV", "ORGANISM", 173, 182], ["SARS-CoV", "ORGANISM", 222, 230], ["SARS-CoV and SARSr-CoVs", "DNA", 42, 65], ["SARS-CoV", "SPECIES", 42, 50], ["SARSr-CoV", "SPECIES", 173, 182], ["SARS-CoV", "SPECIES", 222, 230], ["different host bat species", "PROBLEM", 14, 40], ["SARS", "PROBLEM", 42, 46], ["SARSr", "TEST", 55, 60], ["CoVs", "PROBLEM", 61, 65], ["CoV strains", "PROBLEM", 179, 190], ["SARS", "PROBLEM", 222, 226], ["CoV", "PROBLEM", 227, 230], ["host bat species", "OBSERVATION", 24, 40]]], ["SARSr-CoVs detected in southeastern, central and northern provinces, such as Hong Kong, Hubei and Shaanxi, formed the other clade which was phylogenetically distant to human and civet SARS-CoVs (Fig 6 and S6 Fig).Rescue of bat SARSr-CoVs and virus infectivity experiments ::: ResultsIn the current study, we successfully cultured an additional novel SARSr-CoV Rs4874 from a single fecal sample using an optimized protocol and Vero E6 cells [17].", [["fecal sample", "ANATOMY", 381, 393], ["Vero E6 cells", "ANATOMY", 426, 439], ["SARSr-CoVs", "CHEMICAL", 0, 10], ["SARS", "DISEASE", 184, 188], ["Rs4874", "CHEMICAL", 360, 366], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 0, 10], ["human", "ORGANISM", 168, 173], ["bat", "ORGANISM", 223, 226], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 227, 237], ["SARSr-CoV Rs4874", "CELL", 350, 366], ["Vero E6 cells", "CELL", 426, 439], ["SARSr-CoVs", "DNA", 0, 10], ["Vero E6 cells", "CELL_LINE", 426, 439], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["SARSr-CoV Rs4874", "SPECIES", 350, 366], ["Vero E6", "SPECIES", 426, 433], ["CoVs (Fig", "TREATMENT", 189, 198], ["the current study", "TEST", 286, 303], ["CoV Rs", "TEST", 356, 362], ["a single fecal sample", "TEST", 372, 393], ["an optimized protocol", "TREATMENT", 400, 421], ["Vero E6 cells", "TEST", 426, 439], ["CoVs", "OBSERVATION", 6, 10], ["central", "ANATOMY_MODIFIER", 37, 44], ["bat", "ANATOMY", 223, 226]]], ["Its S protein shared 99.9% aa sequence identity with that of previously isolated WIV16 and it was identical to WIV16 in RBD.", [["RBD", "DISEASE", 120, 123], ["WIV16", "CANCER", 81, 86], ["S protein", "PROTEIN", 4, 13], ["WIV16", "PROTEIN", 81, 86], ["WIV16", "PROTEIN", 111, 116], ["RBD", "PROTEIN", 120, 123], ["Its S protein", "TEST", 0, 13], ["aa sequence identity", "TEST", 27, 47], ["RBD", "OBSERVATION", 120, 123]]], ["Using the reverse genetics technique we previously developed for WIV1 [23], we constructed a group of infectious bacterial artificial chromosome (BAC) clones with the backbone of WIV1 and variants of S genes from 8 different bat SARSr-CoVs.", [["WIV1", "GENE_OR_GENE_PRODUCT", 179, 183], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 229, 239], ["infectious bacterial artificial chromosome (BAC) clones", "DNA", 102, 157], ["WIV1", "DNA", 179, 183], ["S genes", "DNA", 200, 207], ["bat SARSr-CoVs", "DNA", 225, 239], ["infectious bacterial artificial chromosome (BAC) clones", "PROBLEM", 102, 157], ["variants of S genes", "PROBLEM", 188, 207], ["infectious", "OBSERVATION_MODIFIER", 102, 112]]], ["Only the infectious clones for Rs4231 and Rs7327 led to cytopathic effects in Vero E6 cells after transfection (S7 Fig).", [["clones", "ANATOMY", 20, 26], ["Vero E6 cells", "ANATOMY", 78, 91], ["Rs7327", "CHEMICAL", 42, 48], ["clones", "CELL", 20, 26], ["Vero E6 cells", "CELL", 78, 91], ["Vero E6 cells", "CELL_LINE", 78, 91], ["Rs4231", "SPECIES", 31, 37], ["Vero E6", "SPECIES", 78, 85], ["the infectious clones", "PROBLEM", 5, 26], ["Rs", "TEST", 31, 33], ["Rs", "TEST", 42, 44], ["cytopathic effects", "PROBLEM", 56, 74], ["Vero E6 cells", "TREATMENT", 78, 91], ["infectious", "OBSERVATION", 9, 19], ["cytopathic", "OBSERVATION_MODIFIER", 56, 66], ["E6 cells", "OBSERVATION", 83, 91]]], ["The other six strains with deletions in the RBD region, Rf4075, Rs4081, Rs4085, Rs4235, As6526 and Rp3 (S1 Fig) failed to be rescued, as no cytopathic effects was observed and viral replication cannot be detected by immunofluorescence assay in Vero E6 cells (S7 Fig).", [["Vero E6 cells", "ANATOMY", 244, 257], ["Vero E6 cells", "CELL", 244, 257], ["RBD region", "DNA", 44, 54], ["Rf4075", "DNA", 56, 62], ["Rs4081", "DNA", 64, 70], ["Rp3", "DNA", 99, 102], ["Vero E6 cells", "CELL_LINE", 244, 257], ["Vero E6", "SPECIES", 244, 251], ["deletions in the RBD region", "PROBLEM", 27, 54], ["Rf", "TEST", 56, 58], ["Rs", "TEST", 64, 66], ["Rs", "TEST", 72, 74], ["Rs", "TEST", 80, 82], ["As", "TEST", 88, 90], ["Rp3", "TEST", 99, 102], ["cytopathic effects", "PROBLEM", 140, 158], ["viral replication", "PROBLEM", 176, 193], ["immunofluorescence assay", "TEST", 216, 240], ["RBD", "ANATOMY", 44, 47], ["region", "ANATOMY_MODIFIER", 48, 54]]], ["In contrast, when Vero E6 cells were respectively infected with the two successfully rescued chimeric SARSr-CoVs, WIV1-Rs4231S and WIV1-Rs7327S, and the newly isolated Rs4874, efficient virus replication was detected in all infections (Fig 7).", [["Vero E6 cells", "ANATOMY", 18, 31], ["Rs4874", "CHEMICAL", 168, 174], ["infections", "DISEASE", 224, 234], ["Vero E6 cells", "CELL", 18, 31], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 102, 112], ["WIV1-Rs4231S", "GENE_OR_GENE_PRODUCT", 114, 126], ["WIV1-Rs7327S", "GENE_OR_GENE_PRODUCT", 131, 143], ["Rs4874", "CELL", 168, 174], ["Vero E6 cells", "CELL_LINE", 18, 31], ["SARSr", "PROTEIN", 102, 107], ["CoVs", "PROTEIN", 108, 112], ["WIV1", "PROTEIN", 114, 118], ["Rs4231S", "PROTEIN", 119, 126], ["WIV1", "DNA", 131, 135], ["Rs7327S", "DNA", 136, 143], ["Rs4874", "DNA", 168, 174], ["Vero E6", "SPECIES", 18, 25], ["WIV1-Rs7327S", "SPECIES", 131, 143], ["Vero E6 cells", "PROBLEM", 18, 31], ["WIV1", "TEST", 114, 118], ["WIV1", "TEST", 131, 135], ["efficient virus replication", "PROBLEM", 176, 203], ["virus replication", "OBSERVATION", 186, 203]]], ["To assess whether the three novel SARSr-CoVs can use human ACE2 as a cellular entry receptor, we conducted virus infectivity studies using HeLa cells with or without the expression of human ACE2.", [["cellular", "ANATOMY", 69, 77], ["HeLa cells", "ANATOMY", 139, 149], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 34, 44], ["human", "ORGANISM", 53, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["cellular", "CELL", 69, 77], ["HeLa cells", "CELL", 139, 149], ["human", "ORGANISM", 184, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 190, 194], ["SARSr", "PROTEIN", 34, 39], ["CoVs", "PROTEIN", 40, 44], ["human ACE2", "PROTEIN", 53, 63], ["cellular entry receptor", "PROTEIN", 69, 92], ["HeLa cells", "CELL_LINE", 139, 149], ["human ACE2", "PROTEIN", 184, 194], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 184, 189], ["human ACE2", "TREATMENT", 53, 63], ["a cellular entry receptor", "TREATMENT", 67, 92], ["HeLa cells", "TREATMENT", 139, 149], ["human ACE2", "TREATMENT", 184, 194]]], ["All viruses replicated efficiently in the human ACE2-expressing cells.", [["cells", "ANATOMY", 64, 69], ["human", "ORGANISM", 42, 47], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["cells", "CELL", 64, 69], ["human ACE2-expressing cells", "CELL_LINE", 42, 69], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["All viruses", "PROBLEM", 0, 11], ["viruses", "OBSERVATION", 4, 11], ["expressing cells", "OBSERVATION", 53, 69]]], ["The results were further confirmed by quantification of viral RNA using real-time RT-PCR (Fig 8).Activation of activating transcription factor 6 (ATF6) by the ORF8 proteins of different bat SARSr-CoVs ::: ResultsThe induction of the ATF6-dependent transcription by the ORF8s of SARS-CoV and bat SARSr-CoVs were investigated using a luciferase reporter, 5\u00d7ATF6-GL3.", [["SARS", "DISEASE", 278, 282], ["activating transcription factor 6", "GENE_OR_GENE_PRODUCT", 111, 144], ["ATF6", "GENE_OR_GENE_PRODUCT", 146, 150], ["ORF8", "GENE_OR_GENE_PRODUCT", 159, 163], ["ATF6", "GENE_OR_GENE_PRODUCT", 233, 237], ["ORF8s", "GENE_OR_GENE_PRODUCT", 269, 274], ["SARS-CoV", "ORGANISM", 278, 286], ["bat", "ORGANISM", 291, 294], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 295, 305], ["luciferase", "GENE_OR_GENE_PRODUCT", 332, 342], ["ATF6", "GENE_OR_GENE_PRODUCT", 355, 359], ["GL3", "GENE_OR_GENE_PRODUCT", 360, 363], ["viral RNA", "RNA", 56, 65], ["activating transcription factor 6", "PROTEIN", 111, 144], ["ATF6", "PROTEIN", 146, 150], ["ORF8 proteins", "PROTEIN", 159, 172], ["bat SARSr-CoVs", "PROTEIN", 186, 200], ["ATF6", "PROTEIN", 233, 237], ["ORF8s", "DNA", 269, 274], ["SARS-CoV and bat SARSr-CoVs", "DNA", 278, 305], ["luciferase reporter", "DNA", 332, 351], ["ATF6", "PROTEIN", 355, 359], ["GL3", "PROTEIN", 360, 363], ["SARS-CoV", "SPECIES", 278, 286], ["viral RNA", "PROBLEM", 56, 65], ["activating transcription factor", "TREATMENT", 111, 142], ["the ATF6-dependent transcription", "TREATMENT", 229, 261], ["SARS", "TEST", 278, 282], ["CoV", "TEST", 283, 286], ["a luciferase reporter", "TEST", 330, 351], ["viral RNA", "OBSERVATION", 56, 65]]], ["In HeLa cells transiently transfected with the expression plasmids of the ORF8s of bat SARSr-CoV Rf1, Rf4092 and WIV1, the relative luciferase activities of the 5\u00d7ATF6-GL3 reporter was enhanced by 5.56 to 9.26 folds compared with cells transfected with the pCAGGS empty vector, while it was increased by 4.42 fold by the SARS-CoV GZ02 ORF8.", [["HeLa cells", "ANATOMY", 3, 13], ["cells", "ANATOMY", 230, 235], ["HeLa cells", "CELL", 3, 13], ["ORF8s", "GENE_OR_GENE_PRODUCT", 74, 79], ["bat SARSr-CoV Rf1", "ORGANISM", 83, 100], ["Rf4092", "GENE_OR_GENE_PRODUCT", 102, 108], ["WIV1", "GENE_OR_GENE_PRODUCT", 113, 117], ["luciferase", "GENE_OR_GENE_PRODUCT", 132, 142], ["ATF6", "GENE_OR_GENE_PRODUCT", 163, 167], ["GL3", "GENE_OR_GENE_PRODUCT", 168, 171], ["cells", "CELL", 230, 235], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 257, 263], ["HeLa cells", "CELL_LINE", 3, 13], ["expression plasmids", "DNA", 47, 66], ["ORF8s", "DNA", 74, 79], ["bat SARSr-CoV Rf1", "DNA", 83, 100], ["Rf4092", "DNA", 102, 108], ["WIV1", "DNA", 113, 117], ["luciferase", "PROTEIN", 132, 142], ["5\u00d7ATF6-GL3 reporter", "DNA", 161, 180], ["pCAGGS empty vector", "DNA", 257, 276], ["SARS-CoV GZ02 ORF8", "DNA", 321, 339], ["SARSr-CoV", "SPECIES", 87, 96], ["SARS-CoV", "SPECIES", 321, 329], ["WIV1", "TEST", 113, 117], ["the pCAGGS empty vector", "TREATMENT", 253, 276], ["HeLa cells", "OBSERVATION", 3, 13]]], ["As a control, the treatment with tunicamyxin (TM) stimulated the transcription by about 11 folds (Fig 9A).", [["tunicamyxin", "CHEMICAL", 33, 44], ["tunicamyxin", "CHEMICAL", 33, 44], ["tunicamyxin", "SIMPLE_CHEMICAL", 33, 44], ["tunicamyxin (TM)", "TREATMENT", 33, 49], ["the transcription", "TREATMENT", 61, 78]]], ["The results suggests that various ORF8 proteins of bat SARSr-CoVs can activate ATF6, and those of some strains have a stronger effect than the SARS-CoV ORF8.Induction of apoptosis by the ORF8a of the newly identified bat SARSr-CoV ::: ResultsWe conducted transient transfection to examine whether the ORF8a of SARSr-CoV Rs4084 triggered apoptosis.", [["Rs4084", "CHEMICAL", 320, 326], ["ORF8", "GENE_OR_GENE_PRODUCT", 34, 38], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 55, 65], ["ATF6", "GENE_OR_GENE_PRODUCT", 79, 83], ["SARS-CoV ORF8", "ORGANISM", 143, 156], ["ORF8a", "GENE_OR_GENE_PRODUCT", 187, 192], ["ORF8a", "GENE_OR_GENE_PRODUCT", 301, 306], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 310, 319], ["ORF8 proteins", "PROTEIN", 34, 47], ["SARSr", "PROTEIN", 55, 60], ["CoVs", "PROTEIN", 61, 65], ["ATF6", "PROTEIN", 79, 83], ["SARS-CoV ORF8", "PROTEIN", 143, 156], ["ORF8a", "PROTEIN", 187, 192], ["SARSr-CoV", "PROTEIN", 221, 230], ["ORF8a", "PROTEIN", 301, 306], ["SARSr", "PROTEIN", 310, 315], ["SARS-CoV", "SPECIES", 143, 151], ["SARSr-CoV Rs4084", "SPECIES", 310, 326], ["CoVs", "PROBLEM", 61, 65], ["ATF6", "TEST", 79, 83], ["some strains", "PROBLEM", 98, 110], ["apoptosis", "PROBLEM", 170, 179], ["SARSr", "TEST", 310, 315], ["CoV Rs", "TEST", 316, 322], ["apoptosis", "PROBLEM", 337, 346], ["apoptosis", "OBSERVATION", 337, 346]]], ["As shown in Fig 9B, 11.76% and 9.40% of the 293T cells transfected with the SARSr-CoV Rs4084-ORF8a and SARS-CoV Tor2-ORF8a expression plasmid underwent apoptosis, respectively.", [["293T cells", "ANATOMY", 44, 54], ["293T cells", "CELL", 44, 54], ["SARSr-CoV Rs4084-ORF8a", "GENE_OR_GENE_PRODUCT", 76, 98], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["ORF8a", "GENE_OR_GENE_PRODUCT", 117, 122], ["293T cells", "CELL_LINE", 44, 54], ["SARSr-CoV Rs4084-ORF8a and SARS-CoV Tor2-ORF8a expression plasmid", "DNA", 76, 141], ["SARS-CoV", "SPECIES", 103, 111], ["the SARSr", "TEST", 72, 81], ["CoV Rs", "TEST", 82, 88], ["ORF8a", "TEST", 93, 98], ["SARS", "TEST", 103, 107], ["CoV Tor2", "TEST", 108, 116], ["apoptosis", "PROBLEM", 152, 161], ["apoptosis", "OBSERVATION", 152, 161]]], ["In contrast, transfection with the empty vector resulted in apoptosis in only 2.79% of the cells.", [["cells", "ANATOMY", 91, 96], ["cells", "CELL", 91, 96], ["transfection", "TREATMENT", 13, 25], ["the empty vector", "TREATMENT", 31, 47], ["apoptosis", "PROBLEM", 60, 69], ["apoptosis", "OBSERVATION_MODIFIER", 60, 69]]], ["The results indicate that Rs4084 ORF8a has an apoptosis induction activity similar to that of SARS-CoV [28].DiscussionGenetically diverse SARSr-CoVs have been detected in various horseshoe bat species across a wide geographic range in China in the past decade [9\u201312,14,29].", [["Rs4084", "CHEMICAL", 26, 32], ["SARS", "DISEASE", 94, 98], ["Rs4084 ORF8a", "GENE_OR_GENE_PRODUCT", 26, 38], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 94, 102], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 138, 148], ["SARSr-CoVs", "DNA", 138, 148], ["SARS-CoV", "SPECIES", 94, 102], ["an apoptosis induction activity", "TREATMENT", 43, 74], ["CoVs", "PROBLEM", 144, 148], ["wide", "OBSERVATION_MODIFIER", 210, 214]]], ["However, most bat SARSr-CoVs show considerable genetic distance to SARS-CoV, particularly in the highly variable S1, ORF8 and ORF3 regions [10,25].", [["SARS", "DISEASE", 67, 71], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 18, 28], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 67, 75], ["ORF8", "GENE_OR_GENE_PRODUCT", 117, 121], ["ORF3", "GENE_OR_GENE_PRODUCT", 126, 130], ["SARSr", "PROTEIN", 18, 23], ["CoVs", "PROTEIN", 24, 28], ["highly variable S1, ORF8 and ORF3 regions", "DNA", 97, 138], ["SARS-CoV", "SPECIES", 67, 75], ["SARS", "PROBLEM", 67, 71], ["CoV", "PROBLEM", 72, 75], ["S1", "ANATOMY_MODIFIER", 113, 115]]], ["Recently, several novel SARSr-CoVs have been described to be more closely related to SARS-CoV, either in the S gene or in ORF8.", [["SARS", "DISEASE", 85, 89], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 24, 34], ["SARS-CoV", "ORGANISM", 85, 93], ["ORF8", "GENE_OR_GENE_PRODUCT", 122, 126], ["SARSr", "PROTEIN", 24, 29], ["CoVs", "DNA", 30, 34], ["S gene", "DNA", 109, 115], ["ORF8", "DNA", 122, 126], ["SARS-CoV", "SPECIES", 85, 93], ["several novel SARSr-CoVs", "PROBLEM", 10, 34]]], ["The S proteins of RsSHC014, Rs3367, WIV1 and WIV16, which were reported in our previous studies, shared 90% to 97% aa sequence identities to those of human/civet SARS-CoVs [17,18].", [["RsSHC014", "GENE_OR_GENE_PRODUCT", 18, 26], ["Rs3367", "GENE_OR_GENE_PRODUCT", 28, 34], ["WIV1", "GENE_OR_GENE_PRODUCT", 36, 40], ["WIV16", "GENE_OR_GENE_PRODUCT", 45, 50], ["human", "ORGANISM", 150, 155], ["S proteins", "PROTEIN", 4, 14], ["RsSHC014", "PROTEIN", 18, 26], ["Rs3367", "PROTEIN", 28, 34], ["WIV1", "PROTEIN", 36, 40], ["WIV16", "PROTEIN", 45, 50], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 150, 155], ["The S proteins", "TEST", 0, 14], ["RsSHC014", "TEST", 18, 26], ["Rs", "TEST", 28, 30], ["WIV1", "TEST", 36, 40]]], ["Another strain from Rhinolophus affinis in Yunnan termed LYRa11 showed 90% aa sequence identity to SARS-CoV in the S gene [13].", [["SARS", "DISEASE", 99, 103], ["Rhinolophus affinis", "ORGANISM", 20, 39], ["LYRa11", "GENE_OR_GENE_PRODUCT", 57, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 99, 107], ["LYRa11", "DNA", 57, 63], ["SARS-CoV", "DNA", 99, 107], ["S gene", "DNA", 115, 121], ["Rhinolophus affinis", "SPECIES", 20, 39], ["Rhinolophus affinis", "SPECIES", 20, 39], ["SARS-CoV", "SPECIES", 99, 107], ["Another strain from Rhinolophus affinis", "PROBLEM", 0, 39], ["SARS", "TEST", 99, 103]]], ["In addition, two studies have described 4 novel SARSr-CoVs (YNLF_31C/34C and GX2013/YN2013) which possessed a full-length ORF8 with substantially higher similarity to that of SARS-CoV [22,30].", [["SARS", "DISEASE", 175, 179], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 48, 58], ["ORF8", "GENE_OR_GENE_PRODUCT", 122, 126], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 175, 183], ["SARSr", "PROTEIN", 48, 53], ["CoVs", "DNA", 54, 58], ["YNLF_31C", "PROTEIN", 60, 68], ["34C", "PROTEIN", 69, 72], ["GX2013", "PROTEIN", 77, 83], ["YN2013", "DNA", 84, 90], ["full-length ORF8", "DNA", 110, 126], ["SARS-CoV", "SPECIES", 175, 183], ["two studies", "TEST", 13, 24], ["CoV", "TEST", 180, 183]]], ["These findings provide strong genetic evidence for the bat origin of SARS-CoV with regard to the S gene or ORF8.", [["SARS", "DISEASE", 69, 73], ["SARS-CoV", "ORGANISM", 69, 77], ["ORF8", "GENE_OR_GENE_PRODUCT", 107, 111], ["S gene", "DNA", 97, 103], ["ORF8", "DNA", 107, 111], ["SARS-CoV", "SPECIES", 69, 77], ["SARS", "PROBLEM", 69, 73]]], ["However, all of these SARSr-CoVs were distinct from SARS-CoV in at least one other gene, suggesting that none of them was the immediate progenitor of SARS-CoV.", [["SARS", "DISEASE", 150, 154], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 22, 32], ["SARS-CoV", "ORGANISM", 52, 60], ["progenitor", "CELL", 136, 146], ["SARS-CoV", "ORGANISM", 150, 158], ["SARSr-CoVs", "DNA", 22, 32], ["SARS-CoV", "SPECIES", 52, 60], ["SARS-CoV", "SPECIES", 150, 158], ["these SARSr", "TEST", 16, 27], ["CoVs", "PROBLEM", 28, 32], ["SARS", "PROBLEM", 52, 56], ["CoV", "PROBLEM", 155, 158]]], ["Moreover, these SARSr-CoVs were discovered in bat populations from physically distinct locations.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 16, 26], ["bat populations", "CELL", 46, 61], ["SARSr-CoVs", "DNA", 16, 26], ["these SARSr", "TEST", 10, 21], ["CoVs", "PROBLEM", 22, 26], ["physically distinct", "OBSERVATION_MODIFIER", 67, 86]]], ["The site of origin of the true progenitor of SARS-CoV and the evolutionary origin of SARS-CoV have until now remained elusive.", [["progenitor", "ANATOMY", 31, 41], ["SARS", "DISEASE", 45, 49], ["SARS", "DISEASE", 85, 89], ["progenitor", "CELL", 31, 41], ["SARS-CoV", "ORGANISM", 45, 53], ["SARS-CoV", "ORGANISM", 85, 93], ["SARS-CoV", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 85, 93], ["SARS", "PROBLEM", 45, 49], ["CoV", "PROBLEM", 50, 53], ["SARS", "PROBLEM", 85, 89], ["CoV", "PROBLEM", 90, 93], ["true progenitor", "OBSERVATION", 26, 41], ["SARS", "OBSERVATION", 45, 49], ["origin", "OBSERVATION_MODIFIER", 75, 81], ["SARS", "OBSERVATION", 85, 89]]], ["In the current study, we have identified a bat habitat potentially important for SARSr-CoV evolution where a series of recombination events have likely occurred among different SARSr-CoV strains, which provides new insights into the origin of SARS-CoV.DiscussionSARS first emerged in Guangdong province in late 2002 [7].", [["SARS", "DISEASE", 243, 247], ["SARSr-CoV", "ORGANISM", 81, 90], ["SARSr-CoV", "ORGANISM", 177, 186], ["SARS-CoV", "ORGANISM", 243, 251], ["SARSr-CoV", "SPECIES", 81, 90], ["SARSr-CoV", "SPECIES", 177, 186], ["SARS-CoV", "SPECIES", 243, 251], ["the current study", "TEST", 3, 20], ["a bat habitat", "TREATMENT", 41, 54], ["recombination events", "PROBLEM", 119, 139], ["CoV strains", "PROBLEM", 183, 194], ["SARS", "OBSERVATION", 243, 247]]], ["However, SARSr-CoVs discovered in bats from neighboring areas of Guangdong to date have shown phylogenetic disparity from SARS-CoV especially in the S gene [9,10,14], suggesting SARS-CoV may have originated from another region.", [["SARSr-CoVs", "CHEMICAL", 9, 19], ["SARS", "DISEASE", 122, 126], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 9, 19], ["SARS-CoV", "ORGANISM", 122, 130], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 178, 186], ["SARSr", "PROTEIN", 9, 14], ["CoVs", "DNA", 15, 19], ["S gene", "DNA", 149, 155], ["SARS-CoV", "SPECIES", 122, 130], ["SARS-CoV", "SPECIES", 178, 186], ["SARSr", "TEST", 9, 14], ["CoVs", "PROBLEM", 15, 19], ["phylogenetic disparity", "PROBLEM", 94, 116], ["SARS", "PROBLEM", 122, 126], ["CoV", "PROBLEM", 127, 130], ["SARS-CoV", "PROBLEM", 178, 186]]], ["Our analysis of the phylogeny of SARS-CoVs and all known bat SARSr-CoVs using the nt sequence of their non-structural ORF1a and ORF1b genes, which constitute the majority of the genome, shows that SARSr-CoV evolution is strongly correlated with their geographical origin, but not host species.", [["SARS", "DISEASE", 33, 37], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 33, 42], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 61, 71], ["ORF1a", "GENE_OR_GENE_PRODUCT", 118, 123], ["ORF1b", "GENE_OR_GENE_PRODUCT", 128, 133], ["SARSr-CoV", "ORGANISM", 197, 206], ["SARS-CoVs", "DNA", 33, 42], ["bat SARSr-CoVs", "DNA", 57, 71], ["nt sequence", "DNA", 82, 93], ["non-structural ORF1a and ORF1b genes", "DNA", 103, 139], ["SARSr", "DNA", 197, 202], ["SARS-CoVs", "SPECIES", 33, 42], ["Our analysis", "TEST", 0, 12], ["SARS", "PROBLEM", 33, 37], ["CoVs", "PROBLEM", 38, 42], ["CoVs", "PROBLEM", 67, 71], ["the nt sequence", "TEST", 78, 93], ["SARSr", "TEST", 197, 202], ["host species", "PROBLEM", 280, 292]]], ["It is noteworthy that SARSr-CoVs detected in Yunnan are more closely related to SARS-CoV than strains from other regions in China.", [["SARS", "DISEASE", 80, 84], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 22, 32], ["SARS-CoV", "ORGANISM", 80, 88], ["SARSr", "PROTEIN", 22, 27], ["CoVs", "PROTEIN", 28, 32], ["SARS-CoV", "SPECIES", 80, 88], ["SARSr-CoVs", "PROBLEM", 22, 32], ["SARS", "PROBLEM", 80, 84], ["strains", "PROBLEM", 94, 101], ["CoVs", "OBSERVATION", 28, 32], ["China", "ANATOMY", 124, 129]]], ["This finding implies that Yunnan, or southwestern China, is more likely to be the geographical source of SARS-CoV than other regions in China, but data from more extensive surveillance are yet needed to support this inference.DiscussionIn our longitudinal surveillance of SARSr-CoVs in a single cave in Yunnan where we discovered Rs3367, RsSHC014, WIV1 and WIV16, the CoV prevalence in fecal samples varied among different sampling time.", [["fecal samples", "ANATOMY", 386, 399], ["SARS", "DISEASE", 105, 109], ["SARSr-CoVs", "CHEMICAL", 272, 282], ["SARS-CoV", "ORGANISM", 105, 113], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 272, 282], ["Rs3367", "GENE_OR_GENE_PRODUCT", 330, 336], ["RsSHC014", "GENE_OR_GENE_PRODUCT", 338, 346], ["WIV1", "GENE_OR_GENE_PRODUCT", 348, 352], ["WIV16", "GENE_OR_GENE_PRODUCT", 357, 362], ["CoV", "ORGANISM", 368, 371], ["fecal samples", "CANCER", 386, 399], ["SARSr-CoVs", "DNA", 272, 282], ["WIV1", "DNA", 348, 352], ["WIV16", "DNA", 357, 362], ["SARS-CoV", "SPECIES", 105, 113], ["SARS", "PROBLEM", 105, 109], ["extensive surveillance", "TEST", 162, 184], ["CoVs", "PROBLEM", 278, 282], ["Rs", "TEST", 330, 332], ["RsSHC014", "TEST", 338, 346], ["WIV1", "TEST", 348, 352], ["the CoV prevalence", "TEST", 364, 382], ["fecal samples", "TEST", 386, 399], ["more likely to be", "UNCERTAINTY", 60, 77], ["SARS", "OBSERVATION", 105, 109], ["fecal", "ANATOMY", 386, 391]]], ["This may be due to the establishment of a susceptible subpopulation of newborn bats which had not developed their own immunity after the parturition period [31].", [["bats", "ORGANISM", 79, 83], ["may be due to", "UNCERTAINTY", 5, 18], ["susceptible", "OBSERVATION_MODIFIER", 42, 53], ["subpopulation", "OBSERVATION_MODIFIER", 54, 67], ["newborn bats", "OBSERVATION", 71, 83]]], ["Another factor may be the changes in the composition of bat species in the cave at different sampling dates.", [["bat species", "PROBLEM", 56, 67], ["factor may be", "UNCERTAINTY", 8, 21]]], ["For example, in September 2012 when the CoV prevalence reached 51.3%, the majority of samples were from R. sinicus, but in May 2015 when only 3 out of the 145 samples tested positive, Aselliscus stoliczkanus was the predominant bat species in the cave.", [["samples", "ANATOMY", 86, 93], ["samples", "ANATOMY", 159, 166], ["samples", "CANCER", 86, 93], ["R. sinicus", "ORGANISM", 104, 114], ["samples", "CANCER", 159, 166], ["Aselliscus stoliczkanus", "ORGANISM", 184, 207], ["bat", "ORGANISM", 228, 231], ["R. sinicus", "SPECIES", 104, 114], ["Aselliscus stoliczkanus", "SPECIES", 184, 207], ["R. sinicus", "SPECIES", 104, 114], ["Aselliscus stoliczkanus", "SPECIES", 184, 207], ["the CoV prevalence", "TEST", 36, 54], ["the 145 samples", "TEST", 151, 166], ["Aselliscus stoliczkanus", "TEST", 184, 207], ["predominant bat species", "OBSERVATION", 216, 239], ["cave", "ANATOMY", 247, 251]]], ["We failed to amplify the RBD sequences from 15 of the 64 SARSr-CoV positive samples.", [["samples", "ANATOMY", 76, 83], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 57, 66], ["RBD sequences", "DNA", 25, 38], ["SARSr-CoV", "SPECIES", 57, 66], ["the RBD sequences", "TEST", 21, 38]]], ["Most of these samples had comparatively low viral concentration (< 107 copies/g) (S8 Fig), as revealed by our previous quantitative studies [32].", [["samples", "ANATOMY", 14, 21], ["samples", "CANCER", 14, 21], ["these samples", "TEST", 8, 21], ["comparatively low viral concentration", "PROBLEM", 26, 63]]], ["The unsuccessful amplification of RBD in some samples with high viral concentration was probably because of the more divergent sequences in this region of these SARSr-CoV genomes.DiscussionIn this cave, we have now obtained full-length genome sequences of additional 11 novel SARSr-CoVs from bats.", [["samples", "ANATOMY", 46, 53], ["RBD", "DISEASE", 34, 37], ["RBD", "GENE_OR_GENE_PRODUCT", 34, 37], ["samples", "CANCER", 46, 53], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 161, 170], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 276, 286], ["bats", "ORGANISM", 292, 296], ["RBD", "PROTEIN", 34, 37], ["SARSr-CoV genomes", "DNA", 161, 178], ["full-length genome sequences", "DNA", 224, 252], ["SARSr-CoVs", "DNA", 276, 286], ["SARSr-CoV", "SPECIES", 161, 170], ["The unsuccessful amplification of RBD", "PROBLEM", 0, 37], ["some samples", "TEST", 41, 53], ["high viral concentration", "PROBLEM", 59, 83], ["RBD", "OBSERVATION", 34, 37], ["CoV genomes", "OBSERVATION", 167, 178]]], ["Our findings suggest the co-circulation of different bat SARSr-CoVs highly similar to SARS-CoV in the most variable S1 (NTD and RBD), ORF8 and ORF3 regions, respectively, in this single location.", [["SARS", "DISEASE", 86, 90], ["SARSr", "GENE_OR_GENE_PRODUCT", 57, 62], ["CoVs", "GENE_OR_GENE_PRODUCT", 63, 67], ["SARS-CoV", "ORGANISM", 86, 94], ["ORF8", "GENE_OR_GENE_PRODUCT", 134, 138], ["ORF3", "GENE_OR_GENE_PRODUCT", 143, 147], ["bat SARSr-CoVs", "DNA", 53, 67], ["SARS-CoV", "DNA", 86, 94], ["S1 (NTD and RBD), ORF8 and ORF3 regions", "DNA", 116, 155], ["SARS-CoV", "SPECIES", 86, 94], ["different bat SARSr", "TEST", 43, 62], ["CoVs", "PROBLEM", 63, 67], ["SARS", "TEST", 86, 90], ["CoV", "TEST", 91, 94], ["S1", "ANATOMY_MODIFIER", 116, 118], ["RBD", "ANATOMY", 128, 131]]], ["In the ORF1a, ORF1b, E, M and N genes, the SARSr-CoVs circulating in this cave also shared > 98% aa sequence identities with human/civet SARS-CoVs.", [["SARS", "DISEASE", 137, 141], ["ORF1a", "GENE_OR_GENE_PRODUCT", 7, 12], ["ORF1b", "GENE_OR_GENE_PRODUCT", 14, 19], ["E", "GENE_OR_GENE_PRODUCT", 21, 22], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 43, 53], ["human", "ORGANISM", 125, 130], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 137, 146], ["ORF1a, ORF1b, E, M and N genes", "DNA", 7, 37], ["SARSr", "DNA", 43, 48], ["CoVs", "DNA", 49, 53], ["human/civet SARS-CoVs", "DNA", 125, 146], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["ORF1b", "TEST", 14, 19], ["the SARSr", "TEST", 39, 48], ["CoVs", "PROBLEM", 142, 146]]], ["Thus, all of the building blocks of the SARS-CoV genome were present in SARSr-CoVs from this single location in Yunnan during our sampling period.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV", "ORGANISM", 40, 48], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 72, 82], ["SARS-CoV genome", "DNA", 40, 55], ["SARSr-CoVs", "DNA", 72, 82], ["SARS-CoV", "SPECIES", 40, 48], ["the SARS", "PROBLEM", 36, 44], ["CoV genome", "PROBLEM", 45, 55], ["CoV genome", "OBSERVATION", 45, 55]]], ["Furthermore, strains closely related to different representative bat SARSr-CoVs from other provinces (e.g. Rs672, HKU3 and Rf1) in the RBD region were also detected there.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 69, 79], ["HKU3", "GENE_OR_GENE_PRODUCT", 114, 118], ["Rf1", "GENE_OR_GENE_PRODUCT", 123, 126], ["bat SARSr-CoVs", "DNA", 65, 79], ["HKU3", "DNA", 114, 118], ["Rf1", "DNA", 123, 126], ["RBD region", "DNA", 135, 145], ["strains", "PROBLEM", 13, 20], ["CoVs", "PROBLEM", 75, 79], ["Rs", "TEST", 107, 109], ["HKU3", "TEST", 114, 118], ["RBD", "ANATOMY", 135, 138], ["region", "ANATOMY_MODIFIER", 139, 145]]], ["Therefore, this cave could be regarded as a rich gene pool of bat SARSr-CoVs, wherein concurrent circulation of a high diversity of SARSr-CoV strains has led to an unusually diverse assemblage of SARSr-CoVs.DiscussionDuring our 5-year surveillance in this single cave, we first reported Rs3367 and WIV1 in 2013, with RBD sequence closely resembling that of SARS-CoV [17].", [["SARS", "DISEASE", 357, 361], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 66, 76], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 132, 141], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 196, 206], ["CoVs", "PROTEIN", 72, 76], ["SARSr-CoVs", "DNA", 196, 206], ["WIV1", "DNA", 298, 302], ["RBD sequence", "DNA", 317, 329], ["SARSr-CoV", "SPECIES", 132, 141], ["SARS-CoV", "SPECIES", 357, 365], ["CoVs", "PROBLEM", 72, 76], ["a high diversity of SARSr", "PROBLEM", 112, 137], ["CoV strains", "PROBLEM", 138, 149], ["Rs", "TEST", 287, 289], ["WIV1", "TEST", 298, 302], ["RBD sequence", "TEST", 317, 329], ["SARS", "TEST", 357, 361], ["high diversity", "OBSERVATION_MODIFIER", 114, 128], ["diverse", "OBSERVATION_MODIFIER", 174, 181], ["assemblage", "OBSERVATION_MODIFIER", 182, 192]]], ["More recently, we discovered WIV16 which had an RBD almost identical to WIV1\u2019s but shared much higher similarity with SARS-CoV than WIV1 in the NTD region of S1, making it the closest SARSr-CoV to the epidemic strains identified to date [18].", [["SARS", "DISEASE", 118, 122], ["WIV16", "GENE_OR_GENE_PRODUCT", 29, 34], ["SARS-CoV", "ORGANISM", 118, 126], ["SARSr-CoV", "ORGANISM", 184, 193], ["WIV16", "PROTEIN", 29, 34], ["RBD", "PROTEIN", 48, 51], ["WIV1", "DNA", 72, 76], ["WIV1", "DNA", 132, 136], ["NTD region", "DNA", 144, 154], ["SARS-CoV", "SPECIES", 118, 126], ["SARSr-CoV", "SPECIES", 184, 193], ["an RBD", "PROBLEM", 45, 51], ["SARS", "PROBLEM", 118, 122], ["the epidemic strains", "PROBLEM", 197, 217], ["RBD", "OBSERVATION", 48, 51], ["SARS", "OBSERVATION", 118, 122], ["NTD", "ANATOMY", 144, 147], ["region", "ANATOMY_MODIFIER", 148, 154], ["S1", "ANATOMY", 158, 160]]], ["In this study, we found a novel strain Rs4231 from the same location sharing almost identical NTD sequence with WIV16 but distinct from it in the RBD, with evidence of a recombination event.", [["RBD", "DISEASE", 146, 149], ["Rs4231", "CELL", 39, 45], ["NTD sequence", "DNA", 94, 106], ["WIV16", "PROTEIN", 112, 117], ["RBD", "PROTEIN", 146, 149], ["this study", "TEST", 3, 13], ["a novel strain Rs", "PROBLEM", 24, 41], ["a recombination event", "PROBLEM", 168, 189], ["NTD", "OBSERVATION", 94, 97], ["RBD", "ANATOMY", 146, 149], ["with evidence of", "UNCERTAINTY", 151, 167], ["recombination event", "OBSERVATION", 170, 189]]], ["Our recombination analysis indicated that a recombination event may have taken place at the junction between the coding region of NTD and RBD in the Rs4231 and WIV1 genomes and resulted in WIV16.", [["NTD", "GENE_OR_GENE_PRODUCT", 130, 133], ["RBD", "GENE_OR_GENE_PRODUCT", 138, 141], ["Rs4231", "GENE_OR_GENE_PRODUCT", 149, 155], ["NTD", "DNA", 130, 133], ["RBD", "DNA", 138, 141], ["Rs4231 and WIV1 genomes", "DNA", 149, 172], ["WIV16", "DNA", 189, 194], ["Our recombination analysis", "TEST", 0, 26], ["a recombination event", "PROBLEM", 42, 63], ["NTD", "PROBLEM", 130, 133], ["RBD in the Rs", "TEST", 138, 151], ["NTD", "OBSERVATION", 130, 133], ["RBD", "OBSERVATION", 138, 141]]], ["Recombination at this genomic position also happened among other SARSr-CoVs relatively distant to SARS-CoV found in this location (e.g. Rs4081 and Rs4247, S5 Fig).", [["SARS", "DISEASE", 98, 102], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 65, 75], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 98, 106], ["SARSr-CoVs", "DNA", 65, 75], ["Rs4247", "DNA", 147, 153], ["SARS-CoV", "SPECIES", 98, 106], ["SARS", "PROBLEM", 98, 102], ["CoV", "PROBLEM", 103, 106], ["Rs", "TEST", 136, 138], ["Rs", "TEST", 147, 149]]], ["The frequent recombination at this hotspot in the S gene increased the genetic diversity of SARSr-CoVs harbored in these bat populations and might have been responsible for the generation of the S gene of the direct progenitor strain of SARS-CoV.DiscussionThe genomes of SARS-CoVs from patients during the early epidemic phase and civet SARS-CoVs all contained a single full-length ORF8 [3,7].", [["progenitor strain", "ANATOMY", 216, 233], ["SARS", "DISEASE", 237, 241], ["SARS", "DISEASE", 337, 341], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 92, 102], ["bat populations", "CELL", 121, 136], ["SARS-CoV", "ORGANISM", 237, 245], ["SARS-CoVs", "ORGANISM", 271, 280], ["patients", "ORGANISM", 286, 294], ["S gene", "DNA", 50, 56], ["SARSr", "DNA", 92, 97], ["CoVs", "DNA", 98, 102], ["S gene", "DNA", 195, 201], ["civet SARS-CoVs", "DNA", 331, 346], ["ORF8", "DNA", 382, 386], ["patients", "SPECIES", 286, 294], ["SARS-CoV", "SPECIES", 237, 245], ["SARS-CoVs", "SPECIES", 337, 346], ["The frequent recombination", "TREATMENT", 0, 26], ["SARS", "PROBLEM", 271, 275], ["CoVs", "PROBLEM", 276, 280]]], ["We have found that a number of bat SARSr-CoVs from this cave possessed a complete ORF8 highly similar to that of early human/civet SARS-CoV (>97% nt sequence identity), represented by strain Rf4092 (S3C Fig).", [["SARSr", "GENE_OR_GENE_PRODUCT", 35, 40], ["CoVs", "GENE_OR_GENE_PRODUCT", 41, 45], ["ORF8", "GENE_OR_GENE_PRODUCT", 82, 86], ["human", "ORGANISM", 119, 124], ["civet SARS-CoV", "ORGANISM", 125, 139], ["SARSr", "PROTEIN", 35, 40], ["CoVs", "PROTEIN", 41, 45], ["ORF8", "DNA", 82, 86], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["SARS-CoV", "SPECIES", 131, 139], ["CoVs", "PROBLEM", 41, 45], ["early human/civet SARS", "TEST", 113, 135], ["CoV", "TEST", 136, 139]]], ["This provided further evidence for the source of human SARS-CoV ORF8 in bats [22,30].", [["SARS", "DISEASE", 55, 59], ["human", "ORGANISM", 49, 54], ["SARS-CoV ORF8", "ORGANISM", 55, 68], ["bats", "ORGANISM", 72, 76], ["human SARS-CoV ORF8", "PROTEIN", 49, 68], ["human", "SPECIES", 49, 54], ["human SARS-CoV", "SPECIES", 49, 63], ["human SARS", "PROBLEM", 49, 59]]], ["In contrast, the ORF8 was split into overlapping ORF8a and ORF8b in most human SARS-CoV strains from later-phase patients due to the acquisition of a 29-nt deletion [8,26].", [["SARS", "DISEASE", 79, 83], ["ORF8", "GENE_OR_GENE_PRODUCT", 17, 21], ["ORF8a", "GENE_OR_GENE_PRODUCT", 49, 54], ["ORF8b", "GENE_OR_GENE_PRODUCT", 59, 64], ["human", "ORGANISM", 73, 78], ["SARS-CoV strains", "ORGANISM", 79, 95], ["patients", "ORGANISM", 113, 121], ["ORF8", "PROTEIN", 17, 21], ["ORF8a", "DNA", 49, 54], ["ORF8b", "DNA", 59, 64], ["29-nt deletion", "DNA", 150, 164], ["human", "SPECIES", 73, 78], ["patients", "SPECIES", 113, 121], ["human SARS-CoV", "SPECIES", 73, 87], ["ORF8b", "TREATMENT", 59, 64], ["CoV strains", "PROBLEM", 84, 95], ["a 29-nt deletion", "TREATMENT", 148, 164]]], ["In this study, we have discovered for the first time a bat SARSr-CoV with ORF8a and ORF8b highly similar to the later-phase human SARS-CoVs, though the split of ORF8 in the bat SARSr-CoV and that in human SARS-CoV were two independent events.", [["SARS", "DISEASE", 130, 134], ["SARS", "DISEASE", 205, 209], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 59, 68], ["ORF8a", "GENE_OR_GENE_PRODUCT", 74, 79], ["ORF8b", "GENE_OR_GENE_PRODUCT", 84, 89], ["human", "ORGANISM", 124, 129], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 130, 139], ["ORF8", "GENE_OR_GENE_PRODUCT", 161, 165], ["bat SARSr-CoV", "ORGANISM", 173, 186], ["human", "ORGANISM", 199, 204], ["SARS-CoV", "ORGANISM", 205, 213], ["SARSr", "PROTEIN", 59, 64], ["ORF8a", "PROTEIN", 74, 79], ["ORF8b", "PROTEIN", 84, 89], ["later-phase human SARS-CoVs", "DNA", 112, 139], ["ORF8", "DNA", 161, 165], ["bat SARSr-CoV", "DNA", 173, 186], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 199, 204], ["bat SARSr-CoV", "SPECIES", 55, 68], ["human", "SPECIES", 124, 129], ["bat SARSr-CoV", "SPECIES", 173, 186], ["human SARS-CoV", "SPECIES", 199, 213], ["this study", "TEST", 3, 13], ["ORF8a", "TREATMENT", 74, 79], ["ORF8b", "TREATMENT", 84, 89], ["CoVs", "PROBLEM", 135, 139], ["ORF8", "TEST", 161, 165]]], ["Our recombination analysis suggests that this strain, Rs4084, likely acquired its ORF8 from Rf4092 through recombination, followed by the development of the 5-nt deletion which led to the splitting.", [["ORF8", "GENE_OR_GENE_PRODUCT", 82, 86], ["Rf4092", "GENE_OR_GENE_PRODUCT", 92, 98], ["ORF8", "DNA", 82, 86], ["Rf4092", "DNA", 92, 98], ["5-nt deletion", "DNA", 157, 170], ["Our recombination analysis", "TEST", 0, 26], ["this strain", "PROBLEM", 41, 52], ["the 5-nt deletion", "PROBLEM", 153, 170]]], ["It suggests that ORF8 region in bat SARSr-CoV genomes is prone to deletions as in human SARS-CoV [3,25].", [["SARS", "DISEASE", 88, 92], ["ORF8", "GENE_OR_GENE_PRODUCT", 17, 21], ["bat", "ORGANISM", 32, 35], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 36, 45], ["human", "ORGANISM", 82, 87], ["SARS-CoV", "ORGANISM", 88, 96], ["ORF8 region", "DNA", 17, 28], ["bat SARSr-CoV genomes", "DNA", 32, 53], ["human", "SPECIES", 82, 87], ["bat SARSr-CoV", "SPECIES", 32, 45], ["human SARS-CoV", "SPECIES", 82, 96], ["ORF8 region", "PROBLEM", 17, 28]]], ["Finally, the recombination analysis suggests that an ancestral strain of SARS-CoV SZ3 would have been generated if the recombination around ORF8 had occurred between the lineages that led to WIV16 and Rf4092.", [["SARS", "DISEASE", 73, 77], ["Rf4092", "CHEMICAL", 201, 207], ["SARS-CoV SZ3", "ORGANISM", 73, 85], ["ORF8", "GENE_OR_GENE_PRODUCT", 140, 144], ["SARS-CoV SZ3", "DNA", 73, 85], ["ORF8", "DNA", 140, 144], ["WIV16", "DNA", 191, 196], ["SARS-CoV", "SPECIES", 73, 81], ["the recombination analysis", "TEST", 9, 35], ["an ancestral strain of SARS", "PROBLEM", 50, 77], ["CoV SZ3", "PROBLEM", 78, 85]]], ["Taken together, the evidence of recombination events among SARSr-CoVs harbored by bats in this single location suggests that the direct progenitor of SARS-CoV may have originated as a result of a series of recombination within the S gene and around ORF8.", [["SARS", "DISEASE", 150, 154], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 59, 69], ["SARS-CoV", "ORGANISM", 150, 158], ["ORF8", "GENE_OR_GENE_PRODUCT", 249, 253], ["SARSr-CoVs", "DNA", 59, 69], ["S gene", "DNA", 231, 237], ["ORF8", "DNA", 249, 253], ["SARS-CoV", "SPECIES", 150, 158], ["recombination events", "PROBLEM", 32, 52], ["CoVs", "PROBLEM", 65, 69], ["SARS", "PROBLEM", 150, 154], ["CoV", "PROBLEM", 155, 158]]], ["This could have been followed by the spillover from bats to civets and people either in the region, or during movement of infected animals through the wildlife trade.", [["people", "SPECIES", 71, 77], ["infected", "OBSERVATION", 122, 130]]], ["However, given the paucity of data on animal trade prior to the SARS outbreak, the likely high geographical sampling bias in bat surveillance for SARSr-CoVs in southern China, and the possibility that other caves harbor similar bat species assemblages and a rich diversity of SARSr-CoVs, a definite conclusion about the geographical origin of SARS-CoV cannot be drawn at this point.DiscussionR. sinicus are regarded as the primary natural host of SARS-CoV, as all SARSr-CoVs highly homologous to SARS-CoV in the S gene were predominantly found in this species.", [["SARS", "DISEASE", 64, 68], ["SARSr-CoVs", "CHEMICAL", 146, 156], ["SARS", "DISEASE", 343, 347], ["SARS", "DISEASE", 447, 451], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 146, 156], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 276, 286], ["SARS-CoV", "ORGANISM", 343, 351], ["DiscussionR. sinicus", "ORGANISM", 382, 402], ["SARS-CoV", "ORGANISM", 447, 455], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 464, 474], ["SARS-CoV", "ORGANISM", 496, 504], ["SARSr-CoVs", "DNA", 464, 474], ["SARS-CoV", "DNA", 496, 504], ["S gene", "DNA", 512, 518], ["SARS-CoV", "SPECIES", 343, 351], ["DiscussionR. sinicus", "SPECIES", 382, 402], ["SARS-CoV", "SPECIES", 447, 455], ["SARS-CoV", "SPECIES", 496, 504], ["the SARS outbreak", "PROBLEM", 60, 77], ["bat surveillance", "TEST", 125, 141], ["SARSr", "PROBLEM", 146, 151], ["CoVs", "PROBLEM", 152, 156], ["CoVs", "PROBLEM", 282, 286], ["SARS", "PROBLEM", 343, 347], ["CoV", "PROBLEM", 348, 351], ["SARS", "PROBLEM", 447, 451], ["CoV", "PROBLEM", 452, 455], ["all SARSr", "TEST", 460, 469], ["CoVs", "PROBLEM", 470, 474], ["SARS", "PROBLEM", 496, 500], ["CoV", "PROBLEM", 501, 504]]], ["However, it is noted that two SARSr-CoVs previously reported from R. ferrumequinum showed the closest phylogenetic position to SARS-CoV in the ORF1a/1b trees.", [["SARS", "DISEASE", 127, 131], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 30, 40], ["R. ferrumequinum", "ORGANISM", 66, 82], ["SARS-CoV", "ORGANISM", 127, 135], ["ORF1a/1b", "ORGANISM", 143, 151], ["SARSr", "PROTEIN", 30, 35], ["CoVs", "DNA", 36, 40], ["ORF1a", "DNA", 143, 148], ["R. ferrumequinum", "SPECIES", 66, 82], ["R. ferrumequinum", "SPECIES", 66, 82], ["SARS-CoV", "SPECIES", 127, 135], ["two SARSr-CoVs", "PROBLEM", 26, 40], ["SARS", "PROBLEM", 127, 131]]], ["These strains were discovered in another location in Yunnan 80 km from the cave surveyed in the current study [22].", [["These strains", "PROBLEM", 0, 13], ["the current study", "TEST", 92, 109]]], ["This information also supports the speculation that SARS-CoV may have originated from this region.", [["SARS", "DISEASE", 52, 56], ["SARS-CoV", "ORGANISM", 52, 60], ["SARS-CoV", "SPECIES", 52, 60], ["SARS-CoV", "PROBLEM", 52, 60]]], ["Nonetheless, since the correlation between the host species and the phylogeny of SARSr-CoV ORF1ab seems limited, more SARSr-CoV sequences need to be obtained from different Rhinolophus bat species in both locations in Yunnan, and from other locations in southern China.", [["SARSr-CoV ORF1ab", "ORGANISM", 81, 97], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 118, 127], ["Rhinolophus bat", "ORGANISM", 173, 188], ["SARSr-CoV ORF1ab", "DNA", 81, 97], ["SARSr-CoV sequences", "DNA", 118, 137], ["SARSr-CoV", "SPECIES", 81, 90], ["SARSr-CoV", "SPECIES", 118, 127], ["Rhinolophus bat", "SPECIES", 173, 188], ["SARSr", "TEST", 81, 86], ["CoV ORF1ab", "TEST", 87, 97], ["CoV sequences", "TEST", 124, 137], ["different Rhinolophus bat species", "PROBLEM", 163, 196]]], ["In particular, it will be important to assess whether R. ferrumequinum played a more important role in the evolution of SARS-CoV ORF1ab.DiscussionThe cave we studied is located approximately 60 km from the city of Kunming.", [["ferrumequinum", "CHEMICAL", 57, 70], ["SARS", "DISEASE", 120, 124], ["R. ferrumequinum", "ORGANISM", 54, 70], ["SARS-CoV ORF1ab", "GENE_OR_GENE_PRODUCT", 120, 135], ["SARS-CoV ORF1ab", "PROTEIN", 120, 135], ["R. ferrumequinum", "SPECIES", 54, 70], ["R. ferrumequinum", "SPECIES", 54, 70], ["SARS-CoV", "SPECIES", 120, 128], ["SARS", "PROBLEM", 120, 124], ["CoV ORF1ab", "TREATMENT", 125, 135]]], ["Beside a number of rhinolophid and hipposiderid species from which SARSr-CoVs have been detected, other bats like myotis were also present there.", [["rhinolophid", "CANCER", 19, 30], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 67, 77], ["bats", "ORGANISM", 104, 108], ["myotis", "CANCER", 114, 120], ["SARSr", "PROTEIN", 67, 72], ["CoVs", "PROTEIN", 73, 77], ["rhinolophid and hipposiderid species", "PROBLEM", 19, 55], ["hipposiderid species", "OBSERVATION", 35, 55]]], ["The temperature in the cave is around 22\u201325\u00b0C and the humidity around 85%-90%.", [["The temperature", "TEST", 0, 15], ["the humidity", "TEST", 50, 62], ["humidity", "OBSERVATION_MODIFIER", 54, 62]]], ["The physical nature of the cave is not unique, but it does appear to host a particularly dense population of bats in the reproductive season.", [["bats", "ORGANISM", 109, 113], ["cave", "OBSERVATION", 27, 31], ["particularly", "OBSERVATION_MODIFIER", 76, 88], ["dense", "OBSERVATION_MODIFIER", 89, 94], ["population", "OBSERVATION", 95, 105]]], ["Similar caves co-inhabited by bat populations of different species are not rare in other areas in Yunnan.", [["different species", "PROBLEM", 49, 66], ["caves", "OBSERVATION", 8, 13], ["bat", "OBSERVATION_MODIFIER", 30, 33], ["populations", "OBSERVATION_MODIFIER", 34, 45], ["different species", "OBSERVATION", 49, 66], ["not", "UNCERTAINTY", 71, 74], ["rare", "OBSERVATION_MODIFIER", 75, 79]]], ["We propose that efforts to study the ecology, host species diversity, and viral strain populations of these caves may provide critical information on what drives SARSr-CoV evolution.DiscussionOur previous studies demonstrated the capacity of both WIV1 and WIV16 to use ACE2 orthologs for cell entry and to efficiently replicate in human cells [17,18].", [["cell", "ANATOMY", 288, 292], ["cells", "ANATOMY", 337, 342], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 162, 171], ["WIV1", "GENE_OR_GENE_PRODUCT", 247, 251], ["WIV16", "GENE_OR_GENE_PRODUCT", 256, 261], ["ACE2", "GENE_OR_GENE_PRODUCT", 269, 273], ["cell", "CELL", 288, 292], ["human", "ORGANISM", 331, 336], ["cells", "CELL", 337, 342], ["WIV1", "PROTEIN", 247, 251], ["WIV16", "PROTEIN", 256, 261], ["ACE2", "PROTEIN", 269, 273], ["human cells", "CELL_TYPE", 331, 342], ["human", "SPECIES", 331, 336], ["SARSr-CoV", "SPECIES", 162, 171], ["human", "SPECIES", 331, 336], ["host species diversity", "PROBLEM", 46, 68], ["viral strain populations", "TREATMENT", 74, 98], ["previous studies", "TEST", 196, 212], ["ACE2 orthologs", "TREATMENT", 269, 283], ["cell entry", "TEST", 288, 298]]], ["In this study, we confirmed the use of human ACE2 as receptor of two novel SARSr-CoVs by using chimeric viruses with the WIV1 backbone replaced with the S gene of the newly identified SARSr-CoVs.", [["human", "ORGANISM", 39, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 75, 85], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 184, 194], ["human ACE2", "PROTEIN", 39, 49], ["SARSr", "PROTEIN", 75, 80], ["CoVs", "PROTEIN", 81, 85], ["WIV1 backbone", "DNA", 121, 134], ["S gene", "DNA", 153, 159], ["SARSr-CoVs", "DNA", 184, 194], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["this study", "TEST", 3, 13], ["human ACE2", "TREATMENT", 39, 49], ["two novel SARSr-CoVs", "TREATMENT", 65, 85], ["chimeric viruses", "TREATMENT", 95, 111], ["the WIV1 backbone", "TREATMENT", 117, 134]]], ["Rs7327\u2019s S protein varied from that of WIV1 and WIV16 at three aa residues in the receptor-binding motif, including one contact residue (aa 484) with human ACE2.", [["Rs7327\u2019s S protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["WIV1", "GENE_OR_GENE_PRODUCT", 39, 43], ["human", "ORGANISM", 150, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["Rs7327", "PROTEIN", 0, 6], ["S protein", "PROTEIN", 9, 18], ["WIV1", "PROTEIN", 39, 43], ["WIV16", "PROTEIN", 48, 53], ["receptor-binding motif", "PROTEIN", 82, 104], ["human ACE2", "PROTEIN", 150, 160], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 150, 155], ["S protein", "TEST", 9, 18], ["WIV1", "TEST", 39, 43], ["human ACE2", "TREATMENT", 150, 160]]], ["This difference did not seem to affect its entry and replication efficiency in human ACE2-expressing cells.", [["cells", "ANATOMY", 101, 106], ["human", "ORGANISM", 79, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["cells", "CELL", 101, 106], ["human ACE2-expressing cells", "CELL_LINE", 79, 106], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["replication efficiency", "OBSERVATION", 53, 75]]], ["A previous study using the SARS-CoV infectious clone showed that the RsSHC014 S protein could efficiently utilize human ACE2 [33], despite being distinct from SARS-CoV and WIV1 in the RBD (S1 Fig).", [["SARS-CoV", "ORGANISM", 27, 35], ["RsSHC014 S", "GENE_OR_GENE_PRODUCT", 69, 79], ["human", "ORGANISM", 114, 119], ["ACE2", "GENE_OR_GENE_PRODUCT", 120, 124], ["SARS-CoV", "ORGANISM", 159, 167], ["WIV1", "ORGANISM", 172, 176], ["RsSHC014 S protein", "PROTEIN", 69, 87], ["ACE2", "PROTEIN", 120, 124], ["RBD", "PROTEIN", 184, 187], ["human", "SPECIES", 114, 119], ["SARS-CoV", "SPECIES", 27, 35], ["human", "SPECIES", 114, 119], ["SARS-CoV", "SPECIES", 159, 167], ["A previous study", "TEST", 0, 16], ["the SARS", "TEST", 23, 31], ["CoV infectious clone", "TEST", 32, 52], ["the RsSHC014 S protein", "TEST", 65, 87], ["human ACE2", "TEST", 114, 124], ["SARS", "PROBLEM", 159, 163], ["CoV and WIV1 in the RBD", "PROBLEM", 164, 187], ["SARS", "OBSERVATION", 159, 163], ["RBD", "ANATOMY", 184, 187]]], ["We examined the infectivity of Rs4231, which shared similar RBD sequence with RsSHC014 but had a distinct NTD sequence, and found the chimeric virus WIV1-Rs4231S also readily replicated in HeLa cells expressing human ACE2 molecule.", [["HeLa cells", "ANATOMY", 189, 199], ["Rs4231", "GENE_OR_GENE_PRODUCT", 31, 37], ["RsSHC014", "GENE_OR_GENE_PRODUCT", 78, 86], ["WIV1", "GENE_OR_GENE_PRODUCT", 149, 153], ["Rs4231S", "GENE_OR_GENE_PRODUCT", 154, 161], ["HeLa cells", "CELL", 189, 199], ["human", "ORGANISM", 211, 216], ["ACE2", "GENE_OR_GENE_PRODUCT", 217, 221], ["Rs4231", "PROTEIN", 31, 37], ["RBD sequence", "DNA", 60, 72], ["RsSHC014", "PROTEIN", 78, 86], ["NTD sequence", "DNA", 106, 118], ["WIV1", "PROTEIN", 149, 153], ["Rs4231S", "PROTEIN", 154, 161], ["HeLa cells", "CELL_LINE", 189, 199], ["human ACE2 molecule", "PROTEIN", 211, 230], ["human", "SPECIES", 211, 216], ["human", "SPECIES", 211, 216], ["a distinct NTD sequence", "PROBLEM", 95, 118], ["the chimeric virus WIV1", "TEST", 130, 153], ["HeLa cells", "OBSERVATION", 189, 199]]], ["The novel live SARSr-CoV we isolated in the current study (Rs4874) has an S gene almost identical to that of WIV16.", [["SARSr-CoV", "ORGANISM", 15, 24], ["S gene", "DNA", 74, 80], ["WIV16", "DNA", 109, 114], ["SARSr-CoV", "SPECIES", 15, 24], ["the current study", "TEST", 40, 57]]], ["As expected, it is also capable of utilizing human ACE2.", [["human", "ORGANISM", 45, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["human ACE2", "PROTEIN", 45, 55], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["human ACE2", "TREATMENT", 45, 55]]], ["These results indicate that diverse variants of SARSr-CoV S protein without deletions in their RBD are able to use human ACE2.", [["SARSr-CoV S", "GENE_OR_GENE_PRODUCT", 48, 59], ["human", "ORGANISM", 115, 120], ["ACE2", "GENE_OR_GENE_PRODUCT", 121, 125], ["SARSr-CoV S protein", "PROTEIN", 48, 67], ["RBD", "PROTEIN", 95, 98], ["human ACE2", "PROTEIN", 115, 125], ["human", "SPECIES", 115, 120], ["SARSr-CoV", "SPECIES", 48, 57], ["human", "SPECIES", 115, 120], ["diverse variants", "PROBLEM", 28, 44], ["SARSr-CoV S protein", "TREATMENT", 48, 67], ["deletions in their RBD", "PROBLEM", 76, 98], ["human ACE2", "TREATMENT", 115, 125]]], ["In contrast, our previous study revealed that the S protein of a R. sinicus SARSr-CoV with deletions (Rp3) failed to use human, civet and bat ACE2 for cell entry [34].", [["cell", "ANATOMY", 151, 155], ["R. sinicus", "ORGANISM", 65, 75], ["SARSr-CoV", "ORGANISM", 76, 85], ["human", "ORGANISM", 121, 126], ["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["cell", "CELL", 151, 155], ["S protein", "PROTEIN", 50, 59], ["Rp3", "DNA", 102, 105], ["human, civet and bat ACE2", "PROTEIN", 121, 146], ["R. sinicus", "SPECIES", 65, 75], ["human", "SPECIES", 121, 126], ["R. sinicus SARSr-CoV", "SPECIES", 65, 85], ["human", "SPECIES", 121, 126], ["our previous study", "TEST", 13, 31], ["the S protein", "TEST", 46, 59], ["deletions (Rp3)", "TREATMENT", 91, 106]]], ["In this study, in addition to Rs4231 and Rs7327, we also constructed infectious clones with the S gene of Rs4081, Rf4075, Rs4085, Rs4235 and As6526, which all contained the deletions in their RBD.", [["RBD", "DISEASE", 192, 195], ["Rs4231", "GENE_OR_GENE_PRODUCT", 30, 36], ["Rs7327", "GENE_OR_GENE_PRODUCT", 41, 47], ["Rs4231", "DNA", 30, 36], ["S gene", "DNA", 96, 102], ["Rs4081", "DNA", 106, 112], ["Rf4075", "DNA", 114, 120], ["Rs4085", "DNA", 122, 128], ["Rs4235", "DNA", 130, 136], ["RBD", "DNA", 192, 195], ["this study", "TEST", 3, 13], ["Rs", "TEST", 30, 32], ["constructed infectious clones", "PROBLEM", 57, 86], ["Rf", "TEST", 114, 116], ["Rs", "TEST", 122, 124], ["Rs", "TEST", 130, 132], ["the deletions in their RBD", "PROBLEM", 169, 195], ["infectious", "OBSERVATION", 69, 79]]], ["These 7 strains, plus Rs4874 and the previously studied WIV1 and RsSHC014, could represent all types of S variants of SARSr-CoVs in this location (S3A Fig).", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 118, 128], ["WIV1", "DNA", 56, 60], ["RsSHC014", "PROTEIN", 65, 73], ["SARSr-CoVs", "DNA", 118, 128], ["S variants", "PROBLEM", 104, 114], ["SARSr-CoVs", "PROBLEM", 118, 128], ["could represent", "UNCERTAINTY", 75, 90], ["S variants", "OBSERVATION", 104, 114], ["CoVs", "OBSERVATION", 124, 128]]], ["However, none of the strains with deletions in the RBD could be rescued from Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 77, 90], ["RBD", "GENE_OR_GENE_PRODUCT", 51, 54], ["Vero E6 cells", "CELL", 77, 90], ["RBD", "PROTEIN", 51, 54], ["Vero E6 cells", "CELL_LINE", 77, 90], ["Vero E6", "SPECIES", 77, 84], ["the strains", "PROBLEM", 17, 28], ["deletions in the RBD", "PROBLEM", 34, 54], ["Vero E6 cells", "PROBLEM", 77, 90], ["Vero E6 cells", "OBSERVATION", 77, 90]]], ["Therefore, the two distinct clades of SARSr-CoV S gene may represent the usage of different receptors in their bat hosts.DiscussionThe full-length ORF8 protein of SARS-CoV is a luminal endoplasmic reticulum (ER) membrane-associated protein that induces the activation of ATF6, an ER stress-regulated transcription factor that activates the transcription of ER chaperones involved in protein folding [35].", [["luminal endoplasmic reticulum", "ANATOMY", 177, 206], ["ER", "ANATOMY", 208, 210], ["membrane", "ANATOMY", 212, 220], ["SARS", "DISEASE", 163, 167], ["SARSr-CoV S", "GENE_OR_GENE_PRODUCT", 38, 49], ["bat hosts", "ORGANISM", 111, 120], ["ORF8", "GENE_OR_GENE_PRODUCT", 147, 151], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 163, 171], ["luminal", "CELLULAR_COMPONENT", 177, 184], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 185, 206], ["ER", "GENE_OR_GENE_PRODUCT", 208, 210], ["membrane", "CELLULAR_COMPONENT", 212, 220], ["ATF6", "GENE_OR_GENE_PRODUCT", 271, 275], ["ER", "GENE_OR_GENE_PRODUCT", 280, 282], ["ER", "GENE_OR_GENE_PRODUCT", 357, 359], ["SARSr-CoV S gene", "DNA", 38, 54], ["ORF8 protein", "PROTEIN", 147, 159], ["SARS-CoV", "PROTEIN", 163, 171], ["luminal endoplasmic reticulum (ER) membrane-associated protein", "PROTEIN", 177, 239], ["ATF6", "PROTEIN", 271, 275], ["ER stress-regulated transcription factor", "PROTEIN", 280, 320], ["ER chaperones", "PROTEIN", 357, 370], ["SARS-CoV", "SPECIES", 163, 171], ["SARSr-CoV S gene", "TREATMENT", 38, 54], ["SARS", "PROBLEM", 163, 167], ["a luminal endoplasmic reticulum", "PROBLEM", 175, 206], ["associated protein", "PROBLEM", 221, 239], ["an ER stress", "TEST", 277, 289], ["ER chaperones", "TREATMENT", 357, 370], ["distinct", "OBSERVATION_MODIFIER", 19, 27], ["clades", "OBSERVATION_MODIFIER", 28, 34], ["may represent", "UNCERTAINTY", 55, 68], ["luminal", "ANATOMY_MODIFIER", 177, 184], ["endoplasmic reticulum", "ANATOMY", 185, 206]]], ["We amplified the ORF8 genes of Rf1, Rf4092 and WIV1, which represent three different genotypes of bat SARSr-CoV ORF8 (S3C Fig), and constructed the expression plasmids.", [["plasmids", "ANATOMY", 159, 167], ["ORF8", "GENE_OR_GENE_PRODUCT", 17, 21], ["Rf1", "GENE_OR_GENE_PRODUCT", 31, 34], ["Rf4092", "GENE_OR_GENE_PRODUCT", 36, 42], ["WIV1", "GENE_OR_GENE_PRODUCT", 47, 51], ["SARSr-CoV ORF8", "GENE_OR_GENE_PRODUCT", 102, 116], ["ORF8 genes", "DNA", 17, 27], ["Rf1", "DNA", 31, 34], ["Rf4092", "DNA", 36, 42], ["WIV1", "DNA", 47, 51], ["SARSr", "DNA", 102, 107], ["CoV ORF8", "DNA", 108, 116], ["S3C Fig", "DNA", 118, 125], ["expression plasmids", "DNA", 148, 167], ["Rf4092", "SPECIES", 36, 42], ["bat SARSr-CoV", "SPECIES", 98, 111], ["WIV1", "TEST", 47, 51], ["bat SARSr", "TEST", 98, 107], ["the expression plasmids", "TREATMENT", 144, 167]]], ["All of the three ORF8 proteins transiently expressed in HeLa cells can stimulate the ATF6-dependent transcription.", [["HeLa cells", "ANATOMY", 56, 66], ["ORF8", "GENE_OR_GENE_PRODUCT", 17, 21], ["HeLa cells", "CELL", 56, 66], ["ATF6", "GENE_OR_GENE_PRODUCT", 85, 89], ["ORF8 proteins", "PROTEIN", 17, 30], ["HeLa cells", "CELL_LINE", 56, 66], ["ATF6", "PROTEIN", 85, 89], ["HeLa cells", "TREATMENT", 56, 66], ["HeLa cells", "OBSERVATION", 56, 66]]], ["Among them, the WIV1 ORF8, which is highly divergent from the SARS-CoV ORF8, exhibited the strongest activation.", [["WIV1", "GENE_OR_GENE_PRODUCT", 16, 20], ["ORF8", "GENE_OR_GENE_PRODUCT", 21, 25], ["SARS-CoV ORF8", "GENE_OR_GENE_PRODUCT", 62, 75], ["WIV1 ORF8", "DNA", 16, 25], ["SARS-CoV ORF8", "DNA", 62, 75], ["SARS-CoV", "SPECIES", 62, 70], ["the WIV1 ORF8", "TEST", 12, 25], ["the SARS", "TEST", 58, 66], ["CoV ORF8", "TEST", 67, 75]]], ["The results indicate that the variants of bat SARSr-CoV ORF8 proteins may play a role in modulating ER stress by activating the ATF6 pathway.", [["SARSr-CoV ORF8", "GENE_OR_GENE_PRODUCT", 46, 60], ["ER", "GENE_OR_GENE_PRODUCT", 100, 102], ["ATF6", "GENE_OR_GENE_PRODUCT", 128, 132], ["bat SARSr-CoV ORF8 proteins", "PROTEIN", 42, 69], ["ER", "PROTEIN", 100, 102], ["ATF6", "PROTEIN", 128, 132], ["SARSr-CoV", "SPECIES", 46, 55], ["bat SARSr", "TEST", 42, 51]]], ["In addition, the ORF8a protein of SARS-CoV from the later phase has been demonstrated to induce apoptosis [28].", [["SARS", "DISEASE", 34, 38], ["ORF8a", "GENE_OR_GENE_PRODUCT", 17, 22], ["SARS-CoV", "ORGANISM", 34, 42], ["ORF8a protein", "PROTEIN", 17, 30], ["SARS-CoV", "SPECIES", 34, 42], ["the ORF8a protein", "TEST", 13, 30], ["SARS", "TEST", 34, 38], ["apoptosis", "TEST", 96, 105]]], ["In this study, we have found that the ORF8a protein of the newly identified SARSr-CoV Rs4084, which contained an 8-aa insertion compared with the SARS-CoV ORF8a, significantly triggered apoptosis in 293T cells as well.DiscussionCompared with the 154-aa ORF3b of SARS-CoV, the ORF3b proteins of all previously identified bat SARSr-CoVs were smaller in size due to the early translation termination.", [["293T cells", "ANATOMY", 199, 209], ["SARS", "DISEASE", 262, 266], ["ORF8a", "GENE_OR_GENE_PRODUCT", 38, 43], ["SARSr-CoV Rs4084", "GENE_OR_GENE_PRODUCT", 76, 92], ["SARS-CoV ORF8a", "GENE_OR_GENE_PRODUCT", 146, 160], ["293T cells", "CELL", 199, 209], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 262, 270], ["ORF3b", "GENE_OR_GENE_PRODUCT", 276, 281], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 324, 334], ["ORF8a protein", "PROTEIN", 38, 51], ["SARSr-CoV Rs4084", "DNA", 76, 92], ["8-aa insertion", "DNA", 113, 127], ["SARS-CoV ORF8a", "DNA", 146, 160], ["293T cells", "CELL_LINE", 199, 209], ["154-aa ORF3b", "DNA", 246, 258], ["ORF3b proteins", "PROTEIN", 276, 290], ["SARSr", "PROTEIN", 324, 329], ["CoVs", "PROTEIN", 330, 334], ["SARSr-CoV Rs4084", "SPECIES", 76, 92], ["SARS-CoV", "SPECIES", 146, 154], ["SARS-CoV", "SPECIES", 262, 270], ["this study", "TEST", 3, 13], ["the ORF8a protein", "TEST", 34, 51], ["CoV Rs", "TEST", 82, 88], ["an 8-aa insertion", "TREATMENT", 110, 127], ["the SARS", "TEST", 142, 150], ["CoV ORF8a", "TEST", 151, 160], ["significantly triggered apoptosis in 293T cells", "PROBLEM", 162, 209], ["the ORF3b proteins", "TEST", 272, 290], ["bat SARSr", "TEST", 320, 329], ["CoVs", "PROBLEM", 330, 334], ["apoptosis", "OBSERVATION", 186, 195], ["293T cells", "OBSERVATION", 199, 209], ["smaller", "OBSERVATION_MODIFIER", 340, 347], ["size", "OBSERVATION_MODIFIER", 351, 355], ["early", "OBSERVATION_MODIFIER", 367, 372], ["translation", "OBSERVATION", 373, 384]]], ["However, for the first time, we discovered an ORF3b without the C-terminal truncation in a bat SARSr-CoV, Rs7327, which differed from the ORF 3b of SARS-CoV GZ02 strain at only one aa residue.", [["C", "CHEMICAL", 64, 65], ["ORF3b", "GENE_OR_GENE_PRODUCT", 46, 51], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 95, 104], ["SARS-CoV GZ02", "ORGANISM", 148, 161], ["ORF3b", "PROTEIN", 46, 51], ["C-terminal truncation", "DNA", 64, 85], ["SARSr", "PROTEIN", 95, 100], ["CoV", "PROTEIN", 101, 104], ["Rs7327", "PROTEIN", 106, 112], ["SARS-CoV", "SPECIES", 148, 156], ["the C-terminal truncation", "PROBLEM", 60, 85], ["the ORF", "TEST", 134, 141], ["SARS", "PROBLEM", 148, 152], ["CoV GZ02 strain", "PROBLEM", 153, 168], ["truncation", "OBSERVATION", 75, 85]]], ["The SARS-CoV ORF3b antagonizes interferon function by modulating the activity of IFN regulatory factor 3 (IRF3) [27].", [["SARS", "DISEASE", 4, 8], ["SARS-CoV ORF3b", "GENE_OR_GENE_PRODUCT", 4, 18], ["interferon", "GENE_OR_GENE_PRODUCT", 31, 41], ["IFN regulatory factor 3", "GENE_OR_GENE_PRODUCT", 81, 104], ["IRF3", "GENE_OR_GENE_PRODUCT", 106, 110], ["SARS-CoV ORF3b", "PROTEIN", 4, 18], ["interferon", "PROTEIN", 31, 41], ["IFN regulatory factor 3", "PROTEIN", 81, 104], ["IRF3", "PROTEIN", 106, 110], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV ORF3b antagonizes interferon function", "TREATMENT", 9, 50], ["IFN regulatory factor", "TEST", 81, 102]]], ["As previous studies suggested, the nuclear localization signal-containing C-terminal may not be required for the IFN antagonist activity of ORF3b [36].", [["nuclear", "ANATOMY", 35, 42], ["C", "CHEMICAL", 74, 75], ["nuclear", "CELLULAR_COMPONENT", 35, 42], ["C-terminal", "PROTEIN", 74, 84], ["IFN", "PROTEIN", 113, 116], ["ORF3b", "PROTEIN", 140, 145], ["previous studies", "TEST", 3, 19], ["the nuclear localization signal", "TEST", 31, 62], ["the IFN antagonist activity", "TREATMENT", 109, 136]]], ["Our previous studies also demonstrated that the ORF3b protein of a bat SARSr-CoV, termed Rm1, which was C-terminally truncated to 56 aa and shared 62% aa sequence identity with SARS-CoV, still displayed the IFN antagonist activity [37].", [["ORF3b", "GENE_OR_GENE_PRODUCT", 48, 53], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 71, 80], ["Rm1", "GENE_OR_GENE_PRODUCT", 89, 92], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 177, 185], ["ORF3b protein", "PROTEIN", 48, 61], ["SARSr", "PROTEIN", 71, 76], ["CoV", "PROTEIN", 77, 80], ["Rm1", "PROTEIN", 89, 92], ["IFN", "PROTEIN", 207, 210], ["bat SARSr-CoV", "SPECIES", 67, 80], ["SARS-CoV", "SPECIES", 177, 185], ["Our previous studies", "TEST", 0, 20], ["the ORF3b protein", "TEST", 44, 61], ["a bat SARSr", "TEST", 65, 76], ["aa sequence identity", "TEST", 151, 171], ["SARS", "TEST", 177, 181], ["CoV", "TEST", 182, 185]]], ["It is very interesting to investigate in further studies whether Rs7327\u2019s ORF3b and other versions of truncated ORF3b such as WIV1 and WIV16 also show IFN antagonism profiles.DiscussionAs a whole, our findings from a 5-year longitudinal study conclusively demonstrate that all building blocks of the pandemic SARS-CoV genome are present in bat SARSr-CoVs from a single location in Yunnan.", [["SARS", "DISEASE", 309, 313], ["Rs7327", "GENE_OR_GENE_PRODUCT", 65, 71], ["ORF3b", "GENE_OR_GENE_PRODUCT", 74, 79], ["ORF3b", "GENE_OR_GENE_PRODUCT", 112, 117], ["WIV1", "GENE_OR_GENE_PRODUCT", 126, 130], ["WIV16", "GENE_OR_GENE_PRODUCT", 135, 140], ["IFN", "GENE_OR_GENE_PRODUCT", 151, 154], ["SARS-CoV", "ORGANISM", 309, 317], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 344, 354], ["Rs7327", "PROTEIN", 65, 71], ["ORF3b", "PROTEIN", 74, 79], ["truncated ORF3b", "PROTEIN", 102, 117], ["WIV1", "PROTEIN", 126, 130], ["WIV16", "PROTEIN", 135, 140], ["IFN", "PROTEIN", 151, 154], ["pandemic SARS-CoV genome", "DNA", 300, 324], ["bat SARSr-CoVs", "DNA", 340, 354], ["SARS-CoV", "SPECIES", 309, 317], ["further studies", "TEST", 41, 56], ["Rs", "TEST", 65, 67], ["WIV1", "TEST", 126, 130], ["IFN antagonism profiles", "PROBLEM", 151, 174], ["longitudinal study", "TEST", 224, 242], ["the pandemic SARS", "PROBLEM", 296, 313], ["CoV genome", "PROBLEM", 314, 324], ["CoVs", "PROBLEM", 350, 354], ["CoV genome", "OBSERVATION", 314, 324]]], ["The data show that frequent recombination events have happened among those SARSr-CoVs in the same cave.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 75, 85], ["SARSr-CoVs", "DNA", 75, 85], ["The data", "TEST", 0, 8], ["frequent recombination events", "PROBLEM", 19, 48]]], ["While we cannot rule out the possibility that similar gene pools of SARSr-CoVs exist elsewhere, we have provided sufficient evidence to conclude that SARS-CoV most likely originated from horseshoe bats via recombination events among existing SARSr-CoVs.", [["SARS", "DISEASE", 150, 154], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 68, 78], ["SARS-CoV", "ORGANISM", 150, 158], ["horseshoe bats", "ORGANISM", 187, 201], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 242, 252], ["SARSr", "PROTEIN", 68, 73], ["CoVs", "DNA", 74, 78], ["SARSr-CoVs", "DNA", 242, 252], ["SARS-CoV", "SPECIES", 150, 158], ["SARS-CoV", "PROBLEM", 150, 158]]], ["In addition, we have also revealed that various SARSr-CoVs capable of using human ACE2 are still circulating among bats in this region.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 48, 58], ["human", "ORGANISM", 76, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["SARSr", "PROTEIN", 48, 53], ["CoVs", "PROTEIN", 54, 58], ["human ACE2", "PROTEIN", 76, 86], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["human ACE2", "TREATMENT", 76, 86]]], ["Thus, the risk of spillover into people and emergence of a disease similar to SARS is possible.", [["SARS", "DISEASE", 78, 82], ["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39], ["a disease", "PROBLEM", 57, 66], ["SARS", "PROBLEM", 78, 82]]], ["Thus, we propose that monitoring of SARSr-CoV evolution at this and other sites should continue, as well as examination of human behavioral risk for infection and serological surveys of people, to determine if spillover is already occurring at these sites and to design intervention strategies to avoid future disease emergence.Ethics statement ::: Materials and methodsAll sampling procedures were performed by veterinarians with approval from Animal Ethics Committee of the Wuhan Institute of Virology (WIVH05210201).", [["infection", "DISEASE", 149, 158], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 36, 45], ["human", "ORGANISM", 123, 128], ["people", "ORGANISM", 186, 192], ["human", "SPECIES", 123, 128], ["people", "SPECIES", 186, 192], ["human", "SPECIES", 123, 128], ["SARSr", "TEST", 36, 41], ["CoV evolution", "PROBLEM", 42, 55], ["examination", "TEST", 108, 119], ["infection", "PROBLEM", 149, 158], ["serological surveys", "TEST", 163, 182], ["spillover", "PROBLEM", 210, 219], ["intervention strategies", "TREATMENT", 270, 293], ["future disease emergence", "PROBLEM", 303, 327], ["All sampling procedures", "TEST", 370, 393]]], ["The study was conducted in accordance with the Guide for the Care and Use of Wild Mammals in Research of the People\u2019s Republic of China.Sampling ::: Materials and methodsBat samplings were conducted ten times from April 2011 to October 2015 at different seasons in their natural habitat at a single location (cave) in Kunming, Yunnan Province, China.", [["The study", "TEST", 0, 9]]], ["All members of field teams wore appropriate personal protective equipment, including N95 masks, tear-resistant gloves, disposable outerwear, and safety glasses.", [["personal protective equipment", "TREATMENT", 44, 73], ["N95 masks", "TREATMENT", 85, 94], ["tear-resistant gloves", "TREATMENT", 96, 117], ["safety glasses", "TREATMENT", 145, 159]]], ["Bats were trapped and fecal swab samples were collected as described previously [9].", [["fecal swab samples", "ANATOMY", 22, 40], ["Bats", "CELL", 0, 4], ["fecal swab samples", "ORGANISM_SUBSTANCE", 22, 40], ["fecal swab samples", "TEST", 22, 40], ["fecal", "ANATOMY", 22, 27]]], ["Clean plastic sheets measuring 2.0 by 2.0 m were placed under known bat roosting sites at about 18:00 h each evening for collection of fecal samples.", [["fecal samples", "ANATOMY", 135, 148], ["fecal samples", "ORGANISM_SUBSTANCE", 135, 148], ["Clean plastic sheets", "TREATMENT", 0, 20], ["collection of fecal samples", "TEST", 121, 148], ["plastic", "OBSERVATION_MODIFIER", 6, 13], ["sheets", "OBSERVATION_MODIFIER", 14, 20], ["bat", "ANATOMY", 68, 71], ["fecal", "ANATOMY", 135, 140]]], ["Fresh fecal pellets were collected from sheets early in the next morning.", [["fecal pellets", "ANATOMY", 6, 19], ["fecal pellets", "ORGANISM_SUBSTANCE", 6, 19], ["Fresh fecal pellets", "PROBLEM", 0, 19], ["fecal pellets", "OBSERVATION", 6, 19]]], ["Each sample (approximately 1 gram of fecal pellet) was collected in 1ml of viral transport medium composed of Hank's balanced salt solution at pH7.4 containing BSA (1%), amphotericin (15 \u03bcg/ml), penicillin G (100 units/ml), and streptomycin (50 \u03bcg/ml), and were stored at -80\u00b0C until processing.", [["sample", "ANATOMY", 5, 11], ["fecal pellet", "ANATOMY", 37, 49], ["pH7.", "CHEMICAL", 143, 147], ["BSA", "CHEMICAL", 160, 163], ["amphotericin", "CHEMICAL", 170, 182], ["penicillin", "CHEMICAL", 195, 205], ["streptomycin", "CHEMICAL", 228, 240], ["amphotericin", "CHEMICAL", 170, 182], ["penicillin G", "CHEMICAL", 195, 207], ["streptomycin", "CHEMICAL", 228, 240], ["BSA", "SIMPLE_CHEMICAL", 160, 163], ["amphotericin", "SIMPLE_CHEMICAL", 170, 182], ["penicillin G", "SIMPLE_CHEMICAL", 195, 207], ["streptomycin", "SIMPLE_CHEMICAL", 228, 240], ["C", "GENE_OR_GENE_PRODUCT", 276, 277], ["Each sample", "TEST", 0, 11], ["fecal pellet", "TREATMENT", 37, 49], ["viral transport medium", "TREATMENT", 75, 97], ["Hank's balanced salt solution", "TREATMENT", 110, 139], ["amphotericin", "TREATMENT", 170, 182], ["penicillin G", "TREATMENT", 195, 207], ["streptomycin", "TREATMENT", 228, 240]]], ["Bats trapped for this study were released back into their habitat.RNA extraction, PCR screening and sequencing ::: Materials and methodsFecal swab or pellet samples were vortexed for 1 min, and 140 \u03bcl of supernatant was collected from each sample after centrifuge at 3000 rpm under 4\u00b0C for 1min.", [["Fecal swab", "ANATOMY", 136, 146], ["pellet samples", "ANATOMY", 150, 164], ["supernatant", "ANATOMY", 204, 215], ["sample", "ANATOMY", 240, 246], ["Bats", "CELL", 0, 4], ["Fecal swab", "ORGANISM_SUBSTANCE", 136, 146], ["pellet samples", "ORGANISM_SUBSTANCE", 150, 164], ["this study", "TEST", 17, 27], ["RNA extraction", "TEST", 66, 80], ["PCR screening", "TEST", 82, 95], ["methods", "TEST", 129, 136], ["Fecal swab", "TEST", 136, 146], ["pellet samples", "TEST", 150, 164]]], ["Viral RNA was extracted with Viral RNA Mini Kit (Qiagen) following the manufacturer\u2019s instructions.", [["Viral", "ORGANISM", 0, 5], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["RNA", "OBSERVATION", 6, 9]]], ["RNA was eluted in 60 \u03bcl of buffer AVE (RNase-free water with 0.04% sodium azide, Qiagen), aliquoted, and stored at -80\u00b0C. One-step hemi-nested RT-PCR (Invitrogen) was employed to detect the presence of coronavirus sequences as described previously using a set of primers that target a 440-nt fragment in the RNA-dependent RNA polymerase gene (RdRp) of all known alpha- and betacoronaviruses [20].", [["sodium azide", "CHEMICAL", 67, 79], ["sodium azide", "CHEMICAL", 67, 79], ["RNase", "SIMPLE_CHEMICAL", 39, 44], ["sodium azide", "SIMPLE_CHEMICAL", 67, 79], ["Qiagen", "SIMPLE_CHEMICAL", 81, 87], ["coronavirus", "ORGANISM", 202, 213], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 308, 336], ["alpha", "GENE_OR_GENE_PRODUCT", 362, 367], ["RNA", "RNA", 0, 3], ["RNase", "PROTEIN", 39, 44], ["coronavirus sequences", "DNA", 202, 223], ["440-nt fragment", "DNA", 285, 300], ["RNA-dependent RNA polymerase gene", "DNA", 308, 341], ["RdRp", "DNA", 343, 347], ["alpha", "PROTEIN", 362, 367], ["RNA", "TEST", 0, 3], ["RNase-free water", "TREATMENT", 39, 55], ["0.04% sodium azide", "TREATMENT", 61, 79], ["One-step hemi-nested RT-PCR", "TREATMENT", 122, 149], ["coronavirus sequences", "PROBLEM", 202, 223], ["a set of primers", "TREATMENT", 254, 270], ["a 440-nt fragment", "TREATMENT", 283, 300], ["the RNA", "TEST", 304, 311], ["all known alpha", "TREATMENT", 352, 367], ["betacoronaviruses", "TREATMENT", 373, 390], ["coronavirus", "OBSERVATION", 202, 213]]], ["For the first round PCR, the 25 \u03bcl reaction mix contained 12.5 \u03bcl PCR 2 \u00d7 reaction mix buffer, 10 pmol of each primer, 2.5 mM MgSO4, 20 U RNase inhibitor, 1 \u03bcl SuperScript III/Platinum Taq Enzyme Mix and 5 \u03bcl RNA template.", [["MgSO4", "CHEMICAL", 126, 131], ["MgSO4", "CHEMICAL", 126, 131], ["MgSO4", "SIMPLE_CHEMICAL", 126, 131], ["RNase", "GENE_OR_GENE_PRODUCT", 138, 143], ["Platinum Taq Enzyme Mix and 5 \u03bcl RNA template", "DNA", 176, 221], ["PCR", "TEST", 20, 23], ["the 25 \u03bcl reaction mix", "TREATMENT", 25, 47], ["PCR", "TEST", 66, 69], ["each primer", "TREATMENT", 106, 117], ["2.5 mM MgSO4", "TREATMENT", 119, 131], ["20 U RNase inhibitor", "TREATMENT", 133, 153], ["III/Platinum Taq Enzyme Mix", "TREATMENT", 172, 199], ["5 \u03bcl RNA template", "TREATMENT", 204, 221]]], ["The amplification was performed as follows: 50\u00b0C for 30 min, 94\u00b0C for 2 min, followed by 40 cycles consisting of 94\u00b0C for 15 sec, 52\u00b0C for 30 sec, 68\u00b0C for 40 sec, and a final extension of 68\u00b0C for 5 min.", [["The amplification", "TEST", 0, 17]]], ["For the second round PCR, the 25 \u03bcl reaction mix contained 2.5 \u03bcl PCR reaction buffer, 5 pmol of each primer, 50 mM MgCl2, 0.5mM dNTP, 0.1 \u03bcl Platinum Taq Enzyme (Invitrogen) and 1 \u03bcl product of the first round PCR.", [["MgCl2", "CHEMICAL", 116, 121], ["NTP", "CHEMICAL", 130, 133], ["MgCl2", "CHEMICAL", 116, 121], ["NTP", "CHEMICAL", 130, 133], ["MgCl2", "SIMPLE_CHEMICAL", 116, 121], ["NTP", "SIMPLE_CHEMICAL", 130, 133], ["the second round PCR", "TEST", 4, 24], ["the 25 \u03bcl reaction mix", "TREATMENT", 26, 48], ["2.5 \u03bcl PCR reaction buffer", "TREATMENT", 59, 85], ["50 mM MgCl2", "TREATMENT", 110, 121], ["0.5mM dNTP", "TREATMENT", 123, 133], ["0.1 \u03bcl Platinum Taq Enzyme (Invitrogen)", "TREATMENT", 135, 174]]], ["The amplification was performed as follows: 94\u00b0C for 3 min followed by 35 cycles consisting of 94\u00b0C for 30 sec, 52\u00b0C for 30 sec, 72\u00b0C for 40 sec, and a final extension of 72\u00b0C for 7 min.", [["The amplification", "TEST", 0, 17]]], ["The RBD region was amplified using the one-step nested RT-PCR method previously described [17].RNA extraction, PCR screening and sequencing ::: Materials and methodsPCR products were gel purified and sequenced with an ABI Prism 3730 DNA analyzer (Applied Biosystems, USA).", [["DNA", "CELLULAR_COMPONENT", 233, 236], ["RBD region", "DNA", 4, 14], ["the one-step nested RT-PCR method", "TREATMENT", 35, 68], ["RNA extraction", "TEST", 95, 109], ["PCR screening", "TEST", 111, 124], ["methodsPCR products", "TREATMENT", 158, 177], ["an ABI Prism", "TEST", 215, 227], ["DNA analyzer", "TEST", 233, 245], ["RBD", "ANATOMY", 4, 7], ["region", "ANATOMY_MODIFIER", 8, 14]]], ["PCR products with low concentration or generating heterogeneity in the sequencing chromatograms were cloned into pGEM-T Easy Vector (Promega) for sequencing.", [["pGEM", "PROTEIN", 113, 117], ["PCR products", "TREATMENT", 0, 12], ["low concentration", "PROBLEM", 18, 35], ["the sequencing chromatograms", "TEST", 67, 95], ["T Easy Vector (Promega)", "TREATMENT", 118, 141], ["low concentration", "OBSERVATION_MODIFIER", 18, 35], ["heterogeneity", "OBSERVATION_MODIFIER", 50, 63]]], ["The positive samples in this study were termed using the abbreviated name of bat species plus the sample ID number (e.g. Rs4081).", [["samples", "ANATOMY", 13, 20], ["bat", "ORGANISM", 77, 80], ["this study", "TEST", 24, 34], ["positive", "OBSERVATION_MODIFIER", 4, 12]]], ["To confirm the bat species of individual sample, PCR amplification of cytochrome b (Cytob) or NADH dehydrogenase subunit 1 (ND1) gene was performed using DNA extracted from the feces or swabs [38,39].Sequencing of full-length genomes ::: Materials and methodsFull genomic sequences of 11 SARSr-CoVs were determined by One-step PCR (Invitrogen) amplification of overlapping genomic fragments with degenerate primers designed by multiple alignment of available SARS-CoV and bat SARSr- CoV sequences deposited in GenBank, and additional specific primers designed from the results of previous rounds of sequencing in this study.", [["sample", "ANATOMY", 41, 47], ["feces", "ANATOMY", 177, 182], ["swabs", "ANATOMY", 186, 191], ["fragments", "ANATOMY", 381, 390], ["NADH", "CHEMICAL", 94, 98], ["NADH", "CHEMICAL", 94, 98], ["cytochrome b", "GENE_OR_GENE_PRODUCT", 70, 82], ["Cytob", "GENE_OR_GENE_PRODUCT", 84, 89], ["NADH dehydrogenase subunit 1", "GENE_OR_GENE_PRODUCT", 94, 122], ["ND1", "GENE_OR_GENE_PRODUCT", 124, 127], ["DNA", "CELLULAR_COMPONENT", 154, 157], ["feces", "ORGANISM_SUBSTANCE", 177, 182], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 288, 298], ["cytochrome b", "PROTEIN", 70, 82], ["Cytob", "PROTEIN", 84, 89], ["NADH dehydrogenase subunit 1 (ND1) gene", "DNA", 94, 133], ["full-length genomes", "DNA", 214, 233], ["SARSr-CoVs", "DNA", 288, 298], ["overlapping genomic fragments", "DNA", 361, 390], ["SARS-CoV and bat SARSr- CoV sequences", "DNA", 459, 496], ["SARS-CoV", "SPECIES", 459, 467], ["individual sample", "TEST", 30, 47], ["PCR amplification", "TEST", 49, 66], ["cytochrome b (Cytob)", "TREATMENT", 70, 90], ["NADH dehydrogenase subunit", "TREATMENT", 94, 120], ["DNA", "PROBLEM", 154, 157], ["swabs", "TEST", 186, 191], ["Full genomic sequences", "TEST", 259, 281], ["SARSr", "TEST", 288, 293], ["One-step PCR", "TEST", 318, 330], ["overlapping genomic fragments", "PROBLEM", 361, 390], ["degenerate primers", "PROBLEM", 396, 414], ["available SARS", "TEST", 449, 463], ["CoV", "TEST", 464, 467], ["bat SARSr", "TEST", 472, 481], ["CoV sequences", "TEST", 483, 496], ["this study", "TEST", 613, 623], ["genomic fragments", "OBSERVATION", 373, 390]]], ["Primer sequences are available upon request.", [["Primer sequences", "DNA", 0, 16], ["Primer sequences", "TEST", 0, 16]]], ["Sequences of the 5\u2019 and 3\u2019 genomic ends were obtained by 5\u2019 and 3\u2019 RACE (Roche), respectively.", [["5\u2019 and 3\u2019 genomic ends", "DNA", 17, 39], ["5\u2019 and 3\u2019 RACE", "DNA", 57, 71], ["Sequences", "TEST", 0, 9]]], ["PCR products with expected size were gel-purified and subjected directly to sequencing.", [["PCR products", "TREATMENT", 0, 12], ["size", "OBSERVATION_MODIFIER", 27, 31]]], ["Each fragment was sequenced at least twice.", [["Each fragment", "PROBLEM", 0, 13], ["fragment", "OBSERVATION", 5, 13]]], ["The sequencing chromatogram of each product was thoroughly examined and sequence heterogeneity was not observed.", [["The sequencing chromatogram", "TEST", 0, 27]]], ["For some fragments with low concentration of amplicons, the PCR products were cloned into pGEM-T Easy Vector (Promega) for sequencing.", [["fragments", "ANATOMY", 9, 18], ["PCR products", "DNA", 60, 72], ["pGEM", "PROTEIN", 90, 94], ["some fragments", "PROBLEM", 4, 18], ["low concentration of amplicons", "TREATMENT", 24, 54], ["the PCR products", "TREATMENT", 56, 72], ["fragments", "OBSERVATION", 9, 18], ["low concentration", "OBSERVATION_MODIFIER", 24, 41]]], ["At least five independent clones were sequenced to obtain a consensus sequence.", [["clones", "CELL", 26, 32], ["consensus sequence", "DNA", 60, 78], ["a consensus sequence", "TEST", 58, 78]]], ["Co-presence of sequences of distinct SARSr-CoVs was not found in any of the amplicons.", [["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 37, 47], ["SARSr", "DNA", 37, 42], ["CoVs", "DNA", 43, 47], ["distinct SARSr-CoVs", "PROBLEM", 28, 47], ["amplicons", "OBSERVATION", 76, 85]]], ["The sequences of overlapping genomic fragments were assembled to obtain the full-length genome sequences, with each overlapping sequence longer than 100 bp.Evolution analysis ::: Materials and methodsFull-length genome sequences of the 15 SARSr-CoVs detected from bats in the cave surveyed in this study were aligned with those of selected SARS-CoVs using MUSCLE [40].", [["fragments", "ANATOMY", 37, 46], ["SARS", "DISEASE", 340, 344], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 239, 249], ["overlapping genomic fragments", "DNA", 17, 46], ["full-length genome sequences", "DNA", 76, 104], ["SARSr-CoVs", "DNA", 239, 249], ["SARS-CoVs", "DNA", 340, 349], ["overlapping genomic fragments", "PROBLEM", 17, 46], ["bp", "TEST", 153, 155], ["this study", "TEST", 293, 303], ["genomic fragments", "OBSERVATION", 29, 46], ["MUSCLE", "ANATOMY", 356, 362]]], ["The potential recombination events suggested by strong P values (<10\u221220) were further confirmed using similarity plot and bootscan analyses implemented in Simplot 3.5.1 [42].", [["P", "DNA", 55, 56], ["strong P values", "TEST", 48, 63], ["similarity plot", "TEST", 102, 117], ["bootscan analyses", "TEST", 122, 139], ["Simplot", "TEST", 155, 162]]], ["Phylogenetic trees based on nucleotide sequences were constructed using the Maximum Likelihood algorithm under the LG model with bootstrap values determined by 1000 replicates in the PhyML (version 3.0) software package [43].Virus isolation ::: Materials and methodsThe Vero E6 cell line was kindly provided by Australian Animal Health Laboratory, CSIRO (Geelong, Australia).", [["Vero E6 cell line", "ANATOMY", 270, 287], ["nucleotide", "CHEMICAL", 28, 38], ["Virus", "ORGANISM", 225, 230], ["Vero E6 cell line", "CELL", 270, 287], ["Vero E6 cell line", "CELL_LINE", 270, 287], ["Phylogenetic trees", "PROBLEM", 0, 18], ["nucleotide sequences", "TEST", 28, 48], ["bootstrap values", "TEST", 129, 145], ["Materials", "TREATMENT", 245, 254], ["The Vero E6 cell line", "TREATMENT", 266, 287], ["E6 cell line", "OBSERVATION", 275, 287]]], ["Vero E6 monolayer was maintained in DMEM medium supplemented with 10% fetal calf serum (FCS).", [["monolayer", "ANATOMY", 8, 17], ["fetal calf serum", "ANATOMY", 70, 86], ["Vero E6 monolayer", "CELL", 0, 17], ["fetal calf", "ORGANISM_SUBSTANCE", 70, 80], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["FCS", "ORGANISM_SUBSTANCE", 88, 91], ["Vero E6 monolayer", "CELL_LINE", 0, 17], ["calf", "SPECIES", 76, 80], ["Vero E6 monolayer", "TREATMENT", 0, 17], ["E6 monolayer", "OBSERVATION", 5, 17], ["calf", "ANATOMY", 76, 80]]], ["Fecal samples (in 200 \u03bcl buffer) were gradient centrifuged at 3,000\u201312,000 g, and the supernatant was diluted 1:10 in DMEM before being added to Vero E6 cells.", [["Fecal samples", "ANATOMY", 0, 13], ["supernatant", "ANATOMY", 86, 97], ["cells", "ANATOMY", 153, 158], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["Vero E6 cells", "CELL", 145, 158], ["Vero E6 cells", "CELL_LINE", 145, 158], ["Vero E6", "SPECIES", 145, 152], ["Fecal samples", "TEST", 0, 13], ["Vero E6 cells", "TREATMENT", 145, 158], ["E6 cells", "OBSERVATION", 150, 158]]], ["After incubation at 37\u00b0C for 1 h, the inoculum was removed and replaced with fresh DMEM medium with 2% FCS.", [["the inoculum", "TREATMENT", 34, 46], ["fresh DMEM medium", "TREATMENT", 77, 94], ["2% FCS", "TREATMENT", 100, 106]]], ["The cells were incubated at 37\u00b0C and checked daily for cytopathic effect.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["C", "GENE_OR_GENE_PRODUCT", 31, 32], ["C", "TEST", 31, 32], ["cytopathic effect", "PROBLEM", 55, 72]]], ["All tissue culture media were supplemented with triple antibiotics penicillin/ streptomycin/amphotericin (Gibco) (penicillin 200 IU/ml, streptomycin 0.2 mg/ml, amphotericin 0.5 \u03bcg/ml).", [["tissue", "ANATOMY", 4, 10], ["penicillin", "CHEMICAL", 67, 77], ["streptomycin", "CHEMICAL", 79, 91], ["amphotericin", "CHEMICAL", 92, 104], ["Gibco", "CHEMICAL", 106, 111], ["penicillin", "CHEMICAL", 114, 124], ["streptomycin", "CHEMICAL", 136, 148], ["amphotericin", "CHEMICAL", 160, 172], ["penicillin", "CHEMICAL", 67, 77], ["streptomycin", "CHEMICAL", 79, 91], ["amphotericin", "CHEMICAL", 92, 104], ["penicillin", "CHEMICAL", 114, 124], ["streptomycin", "CHEMICAL", 136, 148], ["amphotericin", "CHEMICAL", 160, 172], ["tissue", "TISSUE", 4, 10], ["penicillin", "SIMPLE_CHEMICAL", 67, 77], ["streptomycin", "SIMPLE_CHEMICAL", 79, 91], ["amphotericin", "SIMPLE_CHEMICAL", 92, 104], ["Gibco", "SIMPLE_CHEMICAL", 106, 111], ["penicillin", "SIMPLE_CHEMICAL", 114, 124], ["streptomycin", "SIMPLE_CHEMICAL", 136, 148], ["amphotericin", "SIMPLE_CHEMICAL", 160, 172], ["All tissue culture media", "TEST", 0, 24], ["triple antibiotics penicillin", "TREATMENT", 48, 77], ["streptomycin", "TREATMENT", 79, 91], ["amphotericin (Gibco)", "TREATMENT", 92, 112], ["penicillin", "TREATMENT", 114, 124], ["streptomycin", "TREATMENT", 136, 148], ["amphotericin", "TREATMENT", 160, 172]]], ["Three blind passages were carried out for each sample.", [["Three blind passages", "PROBLEM", 0, 20], ["each sample", "TEST", 42, 53]]], ["After each passage, both the culture supernatant and cell pellet were examined for presence of SARSr-CoV by RT-PCR using specific primers targeting the RdRp or S gene.", [["supernatant", "ANATOMY", 37, 48], ["cell pellet", "ANATOMY", 53, 64], ["cell pellet", "CELL", 53, 64], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 95, 104], ["SARSr", "PROTEIN", 95, 100], ["RdRp or S gene", "DNA", 152, 166], ["SARSr-CoV", "SPECIES", 95, 104], ["the culture supernatant", "TEST", 25, 48], ["cell pellet", "TEST", 53, 64], ["SARSr", "TEST", 95, 100], ["PCR", "TEST", 111, 114], ["specific primers", "TREATMENT", 121, 137], ["the RdRp", "TREATMENT", 148, 156]]], ["The viruses which caused obvious cytopathic effect and could be detected in three blind passages by RT-PCR were further confirmed by electron microscopy.Construction of recombinant viruses ::: Materials and methodsRecombinant viruses with the S gene of the novel bat SARSr-CoVs and the backbone of the infectious clone of SARSr-CoV WIV1 were constructed using the reverse genetic system described previously [23] (S9 Fig).", [["bat", "ORGANISM", 263, 266], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 267, 277], ["SARSr-CoV WIV1", "ORGANISM", 322, 336], ["S gene", "DNA", 243, 249], ["SARSr", "PROTEIN", 267, 272], ["CoVs", "DNA", 273, 277], ["SARSr-CoV WIV1", "DNA", 322, 336], ["SARSr-CoV WIV1", "SPECIES", 322, 336], ["The viruses", "PROBLEM", 0, 11], ["obvious cytopathic effect", "PROBLEM", 25, 50], ["RT-PCR", "TEST", 100, 106], ["electron microscopy", "TEST", 133, 152], ["Materials", "TREATMENT", 193, 202], ["methodsRecombinant viruses", "PROBLEM", 207, 233], ["CoV WIV1", "TREATMENT", 328, 336], ["viruses", "OBSERVATION", 4, 11], ["caused obvious", "UNCERTAINTY", 18, 32], ["cytopathic effect", "OBSERVATION", 33, 50], ["recombinant viruses", "OBSERVATION", 169, 188], ["infectious", "OBSERVATION", 302, 312]]], ["The fragments E and F were re-amplified with primer pairs (FE, 5\u2019-AGGGCCCACCTGGCACTGGTAAGAGTCATTTTGC-3\u2019, R-EsBsaI, 5\u2019-ACTGGTCTCTTCGTTTAGTTATTAACTAAAATATCACTAGACACC-3\u2019) and (F-FsBsaI, 5\u2019-TGAGGTCTCCGAACTTATGGATTTGTTTATGAG-3\u2019, RF, 5\u2019-AGGTAGGCCTCTAGGGCAGCTAAC-3\u2019), respectively.", [["fragments", "ANATOMY", 4, 13], ["E", "DNA", 14, 15], ["F", "DNA", 20, 21], ["primer pairs", "DNA", 45, 57], ["FE", "TEST", 59, 61], ["AGGGCCCACCTGGCACTGGTAAGAGTCATTTTGC", "TEST", 66, 100], ["EsBsaI", "TEST", 107, 113], ["ACTGGTCTCTTCGTTTAGTTATTAACTAAAATATCACTAGACACC", "TEST", 118, 163], ["FsBsaI", "TEST", 175, 181], ["TGAGGTCTCCGAACTTATGGATTTGTTTATGAG", "TEST", 186, 219], ["RF", "TEST", 224, 226], ["AGGTAGGCCTCTAGGGCAGCTAAC", "TEST", 231, 255]]], ["The products were named as fragment Es and Fs, which leave the spike gene coding region as an independent fragment.", [["fragment Es and Fs", "DNA", 27, 45], ["spike gene coding region", "DNA", 63, 87], ["Fs", "TEST", 43, 45], ["an independent fragment", "PROBLEM", 91, 114], ["independent", "OBSERVATION_MODIFIER", 94, 105], ["fragment", "OBSERVATION", 106, 114]]], ["BsaI sites (5\u2019-GGTCTCN|NNNN-3\u2019) were introduced into the 3\u2019 terminal of the Es fragment and the 5\u2019 terminal of the Fs fragment, respectively.", [["BsaI", "GENE_OR_GENE_PRODUCT", 0, 4], ["BsaI sites", "DNA", 0, 10], ["3\u2019 terminal", "DNA", 57, 68], ["Es fragment", "DNA", 76, 87], ["5\u2019 terminal", "DNA", 96, 107], ["Fs fragment", "DNA", 115, 126], ["BsaI sites", "TEST", 0, 10], ["3\u2019", "ANATOMY_MODIFIER", 57, 59], ["terminal", "ANATOMY_MODIFIER", 60, 68], ["Es fragment", "OBSERVATION", 76, 87], ["5\u2019", "ANATOMY_MODIFIER", 96, 98], ["terminal", "ANATOMY_MODIFIER", 99, 107], ["Fs fragment", "OBSERVATION", 115, 126]]], ["The spike sequence of Rs4231 was amplified with the primer pair (F-Rs4231-BsmBI, 5\u2019-AGTCGTCTCAACGAACATGTTTATTTTCTTATTCTTTCTCACTCTCAC-3\u2019 and R-Rs4231-BsmBI, 5\u2019-TCACGTCTCAGTTCGTTTATGTGTAATGTAATTTGACACCCTTG-3\u2019).", [["Rs4231", "GENE_OR_GENE_PRODUCT", 22, 28], ["Rs4231", "DNA", 22, 28], ["primer pair", "DNA", 52, 63], ["The spike sequence", "TEST", 0, 18], ["BsmBI", "TEST", 74, 79], ["AGTCGTCTCAACGAACATGTTTATTTTCTTATTCTTTCTCACTCTCAC", "TEST", 84, 132], ["R", "TEST", 140, 141], ["BsmBI", "TEST", 149, 154], ["TCACGTCTCAGTTCGTTTATGTGTAATGTAATTTGACACCCTTG", "TEST", 159, 203]]], ["The S gene sequence of Rs7327 was amplified with primer pair (F-Rs7327-BsaI, 5\u2019-AGTGGTCTCAACGAACATGAAATTGTTAGTTTTAGTTTTTGCTAC-3\u2019 and R-Rs7327-BsaI, 5\u2019- TCAGGTCTCAGTTCGTTTATGTGTAATGTAATTTAACACCCTTG-3\u2019).", [["Rs7327", "GENE_OR_GENE_PRODUCT", 23, 29], ["S gene sequence", "DNA", 4, 19], ["Rs7327", "DNA", 23, 29], ["primer pair", "DNA", 49, 60], ["Rs7327", "DNA", 135, 141], ["primer pair", "TEST", 49, 60], ["BsaI", "TEST", 71, 75], ["AGTGGTCTCAACGAACATGAAATTGTTAGTTTTAGTTTTTGCTAC", "TEST", 80, 125], ["R", "TEST", 133, 134], ["BsaI", "TEST", 142, 146], ["TCAGGTCTCAGTTCGTTTATGTGTAATGTAATTTAACACCCTTG", "TEST", 152, 196]]], ["The fragment Es and Fs were both digested with BglI (NEB) and BsaI (NEB).", [["BglI", "GENE_OR_GENE_PRODUCT", 47, 51], ["NEB", "GENE_OR_GENE_PRODUCT", 53, 56], ["BsaI", "GENE_OR_GENE_PRODUCT", 62, 66], ["NEB", "GENE_OR_GENE_PRODUCT", 68, 71], ["fragment Es and Fs", "DNA", 4, 22], ["BglI", "PROTEIN", 47, 51], ["NEB", "PROTEIN", 53, 56], ["BsaI", "PROTEIN", 62, 66], ["NEB", "PROTEIN", 68, 71], ["Fs", "TEST", 20, 22], ["BglI (NEB", "TREATMENT", 47, 56], ["BsaI (NEB", "TREATMENT", 62, 71], ["fragment", "OBSERVATION_MODIFIER", 4, 12]]], ["The Rs4231 S gene was digested with BsmBI.", [["Rs4231 S", "GENE_OR_GENE_PRODUCT", 4, 12], ["Rs4231 S gene", "DNA", 4, 17], ["BsmBI", "PROTEIN", 36, 41], ["BsmBI", "TEST", 36, 41]]], ["The Rs7327 S gene was digested with BsaI.", [["Rs7327 S", "GENE_OR_GENE_PRODUCT", 4, 12], ["BsaI", "GENE_OR_GENE_PRODUCT", 36, 40], ["Rs7327 S gene", "DNA", 4, 17], ["BsaI", "PROTEIN", 36, 40]]], ["The other fragments and bacterial artificial chromosome (BAC) were prepared as described previously.", [["fragments", "ANATOMY", 10, 19], ["chromosome", "ANATOMY", 45, 55], ["BAC", "ANATOMY", 57, 60], ["chromosome", "CELLULAR_COMPONENT", 45, 55], ["BAC", "CELLULAR_COMPONENT", 57, 60], ["bacterial artificial chromosome", "DNA", 24, 55], ["BAC", "DNA", 57, 60], ["The other fragments and bacterial artificial chromosome (BAC)", "PROBLEM", 0, 61], ["fragments", "OBSERVATION_MODIFIER", 10, 19], ["bacterial", "OBSERVATION_MODIFIER", 24, 33], ["artificial chromosome", "OBSERVATION", 34, 55]]], ["Then the two prepared spike DNA fragments were separately inserted into BAC with Es, Fs and other fragments.", [["DNA", "CELLULAR_COMPONENT", 28, 31], ["spike DNA fragments", "DNA", 22, 41], ["Es, Fs and other fragments", "DNA", 81, 107], ["the two prepared spike DNA fragments", "PROBLEM", 5, 41], ["other fragments", "PROBLEM", 92, 107], ["spike", "OBSERVATION_MODIFIER", 22, 27], ["DNA fragments", "OBSERVATION", 28, 41], ["fragments", "OBSERVATION", 98, 107]]], ["The correct infectious BAC clones were screened.", [["BAC clones", "CELL", 23, 33], ["infectious BAC clones", "CELL_LINE", 12, 33], ["The correct infectious BAC clones", "PROBLEM", 0, 33], ["infectious", "OBSERVATION_MODIFIER", 12, 22]]], ["The chimeric viruses were rescued as described previously [23].Determination of virus infectivity by immunofluorescence assay ::: Materials and methodsThe HeLa cell line was kindly provided by Australian Animal Health Laboratory, CSIRO (Geelong, Australia).", [["HeLa cell line", "ANATOMY", 155, 169], ["HeLa cell line", "CELL", 155, 169], ["HeLa cell line", "CELL_LINE", 155, 169], ["The chimeric viruses", "PROBLEM", 0, 20], ["virus infectivity", "PROBLEM", 80, 97], ["The HeLa cell line", "TREATMENT", 151, 169], ["viruses", "OBSERVATION", 13, 20], ["virus infectivity", "OBSERVATION", 80, 97], ["HeLa cell line", "OBSERVATION", 155, 169]]], ["HeLa cells expressing human ACE2 were constructed as described previously [17].", [["HeLa cells", "ANATOMY", 0, 10], ["HeLa cells", "CELL", 0, 10], ["human", "ORGANISM", 22, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["HeLa cells", "CELL_LINE", 0, 10], ["human ACE2", "PROTEIN", 22, 32], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27]]], ["HeLa cells expressing human ACE2 and Vero E6 cells were cultured on coverslips in 24-well plates (Corning) incubated with the newly isolated or recombinant bat SARSr-CoVs at a multiplicity of infection (MOI) = 1.0 for 1h.", [["HeLa cells", "ANATOMY", 0, 10], ["Vero E6 cells", "ANATOMY", 37, 50], ["infection", "DISEASE", 192, 201], ["HeLa cells", "CELL", 0, 10], ["human", "ORGANISM", 22, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["Vero E6 cells", "CELL", 37, 50], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 160, 170], ["HeLa cells", "CELL_LINE", 0, 10], ["human ACE2", "PROTEIN", 22, 32], ["Vero E6 cells", "CELL_LINE", 37, 50], ["recombinant bat SARSr-CoVs", "PROTEIN", 144, 170], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["Vero E6", "SPECIES", 37, 44], ["HeLa cells", "TREATMENT", 0, 10], ["human ACE2", "TREATMENT", 22, 32], ["Vero E6 cells", "TREATMENT", 37, 50], ["coverslips", "TEST", 68, 78], ["the newly isolated or recombinant bat SARSr", "PROBLEM", 122, 165], ["CoVs", "PROBLEM", 166, 170], ["infection", "PROBLEM", 192, 201], ["infection", "OBSERVATION", 192, 201]]], ["The inoculum was removed and the cells were washed twice with PBS and supplemented with medium.", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["The inoculum", "TREATMENT", 0, 12], ["the cells", "TREATMENT", 29, 38], ["PBS", "TREATMENT", 62, 65], ["inoculum", "OBSERVATION", 4, 12]]], ["Vero E6 cells without virus inoculation and HeLa cells without ACE2 were used as negative control.", [["cells", "ANATOMY", 8, 13], ["HeLa cells", "ANATOMY", 44, 54], ["Vero E6 cells", "CELL", 0, 13], ["HeLa cells", "CELL", 44, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["Vero E6 cells", "CELL_LINE", 0, 13], ["HeLa cells", "CELL_LINE", 44, 54], ["ACE2", "PROTEIN", 63, 67], ["Vero E6 cells", "PROBLEM", 0, 13], ["virus inoculation", "PROBLEM", 22, 39], ["HeLa cells", "TEST", 44, 54], ["ACE2", "TEST", 63, 67], ["E6 cells", "OBSERVATION", 5, 13], ["without", "UNCERTAINTY", 14, 21], ["virus inoculation", "OBSERVATION", 22, 39], ["HeLa cells", "OBSERVATION", 44, 54]]], ["Twenty-four hours after infection, cells were rinsed with PBS and fixed with 4% formaldehyde in PBS (pH7.4) at 4\u00b0C for 20 min.", [["cells", "ANATOMY", 35, 40], ["infection", "DISEASE", 24, 33], ["formaldehyde", "CHEMICAL", 80, 92], ["formaldehyde", "CHEMICAL", 80, 92], ["cells", "CELL", 35, 40], ["formaldehyde", "SIMPLE_CHEMICAL", 80, 92], ["infection", "PROBLEM", 24, 33], ["PBS", "TREATMENT", 58, 61], ["4% formaldehyde in PBS", "TREATMENT", 77, 99], ["infection", "OBSERVATION", 24, 33]]], ["ACE2 expression was detected by using goat anti-human ACE2 immunoglobulin followed by FITC-labelled donkey anti-goat immunoglobulin (PTGLab).", [["FITC", "CHEMICAL", 86, 90], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 59, 73], ["FITC", "SIMPLE_CHEMICAL", 86, 90], ["donkey", "ORGANISM", 100, 106], ["anti-goat immunoglobulin", "SIMPLE_CHEMICAL", 107, 131], ["PTGLab", "GENE_OR_GENE_PRODUCT", 133, 139], ["ACE2", "PROTEIN", 0, 4], ["goat anti-human ACE2 immunoglobulin", "PROTEIN", 38, 73], ["FITC-labelled donkey anti-goat immunoglobulin", "PROTEIN", 86, 131], ["PTGLab", "PROTEIN", 133, 139], ["goat", "SPECIES", 38, 42], ["donkey", "SPECIES", 100, 106], ["goat", "SPECIES", 38, 42], ["ACE2 expression", "PROBLEM", 0, 15], ["goat anti-human ACE2 immunoglobulin", "TREATMENT", 38, 73], ["FITC", "TEST", 86, 90]]], ["Virus replication was detected by using rabbit antibody against the nucleocapsid protein of bat SARSr-CoV Rp3 followed by Cy3-conjugated mouse anti-rabbit IgG.", [["Virus", "ORGANISM", 0, 5], ["rabbit", "ORGANISM", 40, 46], ["SARSr-CoV Rp3", "GENE_OR_GENE_PRODUCT", 96, 109], ["Cy3", "SIMPLE_CHEMICAL", 122, 125], ["mouse", "ORGANISM", 137, 142], ["rabbit antibody", "PROTEIN", 40, 55], ["nucleocapsid protein", "PROTEIN", 68, 88], ["bat SARSr", "PROTEIN", 92, 101], ["CoV Rp3", "PROTEIN", 102, 109], ["Cy3-conjugated mouse anti-rabbit IgG", "PROTEIN", 122, 158], ["rabbit", "SPECIES", 40, 46], ["mouse", "SPECIES", 137, 142], ["anti-rabbit", "SPECIES", 143, 154], ["rabbit", "SPECIES", 40, 46], ["bat SARSr-CoV", "SPECIES", 92, 105], ["mouse", "SPECIES", 137, 142], ["anti-rabbit", "SPECIES", 143, 154], ["Virus replication", "TREATMENT", 0, 17], ["rabbit antibody", "TEST", 40, 55], ["the nucleocapsid protein", "TEST", 64, 88], ["bat SARSr", "TEST", 92, 101], ["CoV Rp3", "TEST", 102, 109], ["Cy3-conjugated mouse anti-rabbit IgG", "TREATMENT", 122, 158]]], ["Nuclei were stained with DAPI.", [["Nuclei", "ANATOMY", 0, 6], ["DAPI", "CHEMICAL", 25, 29], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["DAPI", "SIMPLE_CHEMICAL", 25, 29], ["DAPI", "TEST", 25, 29], ["DAPI", "OBSERVATION", 25, 29]]], ["Staining patterns were observed under an FV1200 confocal microscope (Olympus).Determination of virus replication in Vero E6 cells by plaque assay ::: Materials and methodsVero E6 cells were infected with WIV1, Rs4874, WIV1-Rs4231S, and WIV1-Rs7327S at an MOI of 1.0 and 0.01.", [["Vero E6 cells", "ANATOMY", 116, 129], ["plaque", "ANATOMY", 133, 139], ["Vero E6 cells", "ANATOMY", 171, 184], ["Vero E6 cells", "CELL", 116, 129], ["Vero E6 cells", "CELL", 171, 184], ["WIV1-Rs4231S", "CELL", 218, 230], ["Vero E6 cells", "CELL_LINE", 116, 129], ["Vero E6 cells", "CELL_LINE", 171, 184], ["WIV1", "DNA", 236, 240], ["Vero E6", "SPECIES", 116, 123], ["Vero E6", "SPECIES", 171, 178], ["WIV1-Rs4231S", "SPECIES", 218, 230], ["Staining patterns", "TEST", 0, 17], ["virus replication", "PROBLEM", 95, 112], ["Rs", "TEST", 210, 212], ["WIV1", "TEST", 218, 222], ["Rs", "TEST", 223, 225], ["WIV1", "TEST", 236, 240], ["an MOI", "TEST", 252, 258], ["virus replication", "OBSERVATION", 95, 112], ["Vero E6 cells", "OBSERVATION", 116, 129], ["plaque", "OBSERVATION", 133, 139]]], ["After incubation for an hour, the cells were washed with DHanks for three times and supplied with DMEM containing 2% FCS.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39], ["the cells", "TREATMENT", 30, 39], ["DHanks", "TREATMENT", 57, 63], ["DMEM", "TREATMENT", 98, 102], ["2% FCS", "TREATMENT", 114, 120]]], ["Samples were collected at 0, 10, 27, and 48 h post infection.", [["Samples", "ANATOMY", 0, 7], ["infection", "DISEASE", 51, 60], ["Samples", "TEST", 0, 7], ["infection", "PROBLEM", 51, 60], ["infection", "OBSERVATION", 51, 60]]], ["The viral titers were determined by plaque assay.Determination of virus replication in HeLa cells expressing human ACE2 by quantitative RT-PCR ::: Materials and methodsHeLa cells expressing human ACE2 were inoculated with WIV1, Rs4874, WIV1-Rs4231S, and WIV1-Rs7327S at an MOI of 1.0, and were incubated for 1h at 37\u00b0C. After the inoculum was removed, the cells were supplemented with medium containing 1% FBS.", [["plaque", "ANATOMY", 36, 42], ["HeLa cells", "ANATOMY", 87, 97], ["HeLa cells", "ANATOMY", 168, 178], ["cells", "ANATOMY", 356, 361], ["FBS", "ANATOMY", 406, 409], ["HeLa cells", "CELL", 87, 97], ["human", "ORGANISM", 109, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["HeLa cells", "CELL", 168, 178], ["human", "ORGANISM", 190, 195], ["ACE2", "GENE_OR_GENE_PRODUCT", 196, 200], ["WIV1-Rs4231S", "CELL", 236, 248], ["WIV1-Rs7327S", "CELL", 254, 266], ["cells", "CELL", 356, 361], ["FBS", "ORGANISM_SUBSTANCE", 406, 409], ["HeLa cells", "CELL_LINE", 87, 97], ["human ACE2", "PROTEIN", 109, 119], ["HeLa cells", "CELL_LINE", 168, 178], ["human ACE2", "PROTEIN", 190, 200], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 190, 195], ["The viral titers", "TEST", 0, 16], ["plaque assay", "TEST", 36, 48], ["virus replication", "TREATMENT", 66, 83], ["human ACE2", "TEST", 190, 200], ["Rs", "TEST", 228, 230], ["WIV1", "TEST", 236, 240], ["Rs", "TEST", 241, 243], ["WIV1", "TEST", 254, 258], ["an MOI", "TEST", 270, 276], ["the inoculum", "TREATMENT", 326, 338], ["the cells", "TREATMENT", 352, 361], ["1% FBS", "TREATMENT", 403, 409], ["viral titers", "OBSERVATION", 4, 16], ["plaque", "OBSERVATION", 36, 42], ["virus replication", "OBSERVATION", 66, 83], ["inoculum", "OBSERVATION", 330, 338]]], ["Supernatants were collected at 0, 12, 24 and 48h.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12]]], ["Virus titers were determined using quantitative RT-PCR targeting the partial N gene with a standard curve which expresses the correlation between Ct value and virus titer (shown as TCID50/ml).", [["Virus", "ORGANISM", 0, 5], ["N gene", "DNA", 77, 83], ["Virus titers", "TEST", 0, 12], ["quantitative RT-PCR", "TEST", 35, 54], ["a standard curve", "TEST", 89, 105], ["Ct value", "TEST", 146, 154], ["virus titer", "TEST", 159, 170]]], ["The standard curve was made using RNA dilutions from the purified Rs4874 virus stock (with a titer of 2.15 \u00d7 106 TCID50/ml).", [["Rs4874 virus", "ORGANISM", 66, 78], ["Rs4874 virus", "SPECIES", 66, 78], ["RNA dilutions", "TREATMENT", 34, 47]]], ["For qPCR, RNA was extracted from 140 \u03bcl of each supernatant with Viral RNA Mini Kit (Qiagen) following manufacturer\u2019s instructions and eluted in 60 \u03bcl AVE buffer.", [["supernatant", "ANATOMY", 48, 59], ["qPCR", "TEST", 4, 8], ["RNA", "TEST", 10, 13], ["Viral RNA Mini Kit (Qiagen)", "TREATMENT", 65, 92]]], ["The PCR was performed with the TaqMan AgPath-ID One-Step RT\u2013PCR Kit (Applied Biosystems) in a 25 \u03bcl reaction mix containing 4 \u03bcl RNA, 1 \u00d7 RT\u2013PCR enzyme mix, 1 \u00d7 RT\u2013PCR buffer, 40 pmol forward primer (5\u2019-GTGGTGGTGACGGCA AAATG-3\u2019), 40 pmol reverse primer (5\u2019-AAGTGAAGCTTCTGGGCCAG-3\u2019) and 12 pmol probe (5\u2019-FAM-AAAGAGCTCAGCCCCAGATG-BHQ1-3\u2019).", [["TaqMan AgPath", "DNA", 31, 44], ["40 pmol reverse primer", "DNA", 230, 252], ["BHQ1", "DNA", 329, 333], ["The PCR", "TEST", 0, 7], ["the TaqMan AgPath", "TREATMENT", 27, 44], ["Step RT\u2013PCR Kit (Applied Biosystems)", "TREATMENT", 52, 88], ["a 25 \u03bcl reaction mix", "TREATMENT", 92, 112], ["RT", "TEST", 138, 140], ["enzyme mix", "TEST", 145, 155], ["RT", "TEST", 161, 163], ["forward primer", "TEST", 184, 198], ["GTGGTGGTGACGGCA", "TEST", 203, 218], ["AAATG", "TEST", 219, 224], ["AAGTGAAGCTTCTGGGCCAG", "TEST", 257, 277], ["pmol probe", "TEST", 289, 299], ["FAM", "TEST", 304, 307], ["AAAGAGCTCAGCCCCAGATG", "TEST", 308, 328]]], ["The amplification was performed as follows: 50\u00b0C for 10 min, 95\u00b0C for 10 min followed by 50 cycles consisting of 95\u00b0C for 15 sec and 60\u00b0C for 20 sec.Plasmids ::: Materials and methodsThe ORF8 genes of bat SARSr-CoV WIV1 and Rf4092 and the ORF8a gene of bat SARSr-CoV Rs4084 were amplified by PCR from the viral RNA extracted from the isolated virus or fecal samples.", [["fecal samples", "ANATOMY", 352, 365], ["ORF8", "GENE_OR_GENE_PRODUCT", 187, 191], ["bat SARSr-CoV WIV1", "ORGANISM", 201, 219], ["Rf4092", "GENE_OR_GENE_PRODUCT", 224, 230], ["ORF8a", "GENE_OR_GENE_PRODUCT", 239, 244], ["SARSr-CoV Rs4084", "GENE_OR_GENE_PRODUCT", 257, 273], ["fecal samples", "ORGANISM_SUBSTANCE", 352, 365], ["ORF8 genes", "DNA", 187, 197], ["bat SARSr-CoV WIV1", "DNA", 201, 219], ["Rf4092", "DNA", 224, 230], ["ORF8a gene", "DNA", 239, 249], ["bat SARSr-CoV Rs4084", "DNA", 253, 273], ["viral RNA", "RNA", 305, 314], ["bat SARSr-CoV", "SPECIES", 201, 214], ["SARSr-CoV Rs4084", "SPECIES", 257, 273], ["The ORF8 genes", "TEST", 183, 197], ["bat SARSr", "TEST", 201, 210], ["CoV WIV1", "TEST", 211, 219], ["Rf4092", "TEST", 224, 230], ["bat SARSr", "TEST", 253, 262], ["CoV Rs", "TEST", 263, 269], ["PCR", "TEST", 292, 295], ["the viral RNA", "PROBLEM", 301, 314], ["the isolated virus", "PROBLEM", 330, 348], ["fecal samples", "TEST", 352, 365], ["bat", "ANATOMY", 201, 204], ["viral RNA", "OBSERVATION", 305, 314], ["virus", "OBSERVATION", 343, 348]]], ["The ORF8 gene of SARS-CoV GZ02 and bat SARSr-CoV Rf1, and the ORF8a gene of SARS-CoV Tor2 were synthesized by Tsingke Biological Technology Co., Ltd (Wuhan, China).", [["ORF8", "GENE_OR_GENE_PRODUCT", 4, 8], ["SARS-CoV GZ02", "ORGANISM", 17, 30], ["bat SARSr-CoV Rf1", "ORGANISM", 35, 52], ["ORF8a", "GENE_OR_GENE_PRODUCT", 62, 67], ["SARS-CoV Tor2", "GENE_OR_GENE_PRODUCT", 76, 89], ["ORF8 gene", "DNA", 4, 13], ["SARS-CoV GZ02", "DNA", 17, 30], ["bat SARSr-CoV Rf1", "DNA", 35, 52], ["ORF8a gene", "DNA", 62, 72], ["SARS-CoV Tor2", "DNA", 76, 89], ["SARS-CoV", "SPECIES", 17, 25], ["bat SARSr-CoV", "SPECIES", 35, 48], ["SARS-CoV", "SPECIES", 76, 84], ["SARS", "TEST", 17, 21], ["CoV GZ02", "TEST", 22, 30], ["bat SARSr", "TEST", 35, 44], ["CoV Rf1", "TEST", 45, 52], ["SARS", "PROBLEM", 76, 80]]], ["All genes were cloned into the pCAGGS vector constructed with a C-terminal HA tag.", [["C", "CHEMICAL", 64, 65], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 31, 37], ["pCAGGS vector", "DNA", 31, 44], ["C-terminal HA tag", "DNA", 64, 81], ["a C-terminal HA tag", "TREATMENT", 62, 81]]], ["Expression of the proteins was confirmed by Western blotting using a mAb against the HA tag.", [["mAb", "PROTEIN", 69, 72], ["HA tag", "PROTEIN", 85, 91], ["the proteins", "PROBLEM", 14, 26], ["a mAb", "TREATMENT", 67, 72], ["the HA tag", "PROBLEM", 81, 91]]], ["Five tandem copies of the ATF6 consensus binding sites were synthesized and inserted into the pGL3-Basic vector to construct the luciferase reporter plasmid 5\u00d7ATF6-GL3, in which the luciferase gene is under the control of the c-fos minimal promoter and the ATF6 consensus binding sites.Luciferase reporter assay ::: Materials and methodsHeLa cells in 24-well plates were transfected using Lipofectamine 3000 reagent (Life Technologies) following the manufacturer\u2019s instruction.", [["HeLa cells", "ANATOMY", 337, 347], ["ATF6", "GENE_OR_GENE_PRODUCT", 26, 30], ["pGL3", "GENE_OR_GENE_PRODUCT", 94, 98], ["luciferase", "GENE_OR_GENE_PRODUCT", 129, 139], ["ATF6", "GENE_OR_GENE_PRODUCT", 159, 163], ["GL3", "GENE_OR_GENE_PRODUCT", 164, 167], ["luciferase", "GENE_OR_GENE_PRODUCT", 182, 192], ["c-fos", "GENE_OR_GENE_PRODUCT", 226, 231], ["ATF6", "GENE_OR_GENE_PRODUCT", 257, 261], ["HeLa cells", "CELL", 337, 347], ["ATF6 consensus binding sites", "DNA", 26, 54], ["pGL3-Basic vector", "DNA", 94, 111], ["luciferase reporter plasmid 5", "DNA", 129, 158], ["ATF6", "PROTEIN", 159, 163], ["GL3", "DNA", 164, 167], ["luciferase gene", "DNA", 182, 197], ["c-fos minimal promoter", "DNA", 226, 248], ["ATF6 consensus binding sites", "DNA", 257, 285], ["HeLa cells", "CELL_LINE", 337, 347], ["the c-fos minimal promoter", "TREATMENT", 222, 248], ["methodsHeLa cells", "TEST", 330, 347], ["Lipofectamine", "TREATMENT", 389, 402], ["binding sites", "OBSERVATION", 272, 285]]], ["Cells per well were co-transfected with 600ng of the 5\u00d7ATF6-GL3 reporter plasmid, with 300ng of each expression plasmid of SARS-CoV and SARSr-CoV ORF8 or empty vector and 20ng of pRL-TK (Promega) which served as an internal control.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ATF6", "GENE_OR_GENE_PRODUCT", 55, 59], ["GL3", "GENE_OR_GENE_PRODUCT", 60, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 123, 131], ["SARSr-CoV ORF8", "GENE_OR_GENE_PRODUCT", 136, 150], ["Promega", "ORGANISM", 187, 194], ["5\u00d7ATF6-GL3 reporter plasmid", "DNA", 53, 80], ["expression plasmid", "DNA", 101, 119], ["SARS-CoV and SARSr-CoV ORF8", "DNA", 123, 150], ["empty vector", "DNA", 154, 166], ["pRL", "DNA", 179, 182], ["SARS-CoV", "SPECIES", 123, 131], ["SARSr-CoV", "SPECIES", 136, 145], ["ATF6-GL3 reporter plasmid", "TREATMENT", 55, 80], ["SARS", "TEST", 123, 127], ["CoV", "TEST", 128, 131], ["SARSr", "TEST", 136, 141], ["CoV ORF8", "TREATMENT", 142, 150], ["empty vector", "TREATMENT", 154, 166], ["pRL", "TEST", 179, 182], ["TK (Promega)", "TREATMENT", 183, 195], ["an internal control", "TREATMENT", 212, 231]]], ["The cells were incubated for 24h, and were treated with or without 2\u03bcg/ml tunicamycin for 16h.", [["cells", "ANATOMY", 4, 9], ["tunicamycin", "CHEMICAL", 74, 85], ["tunicamycin", "CHEMICAL", 74, 85], ["cells", "CELL", 4, 9], ["tunicamycin", "SIMPLE_CHEMICAL", 74, 85], ["tunicamycin", "TREATMENT", 74, 85]]], ["Cells were harvested and lysed.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Luciferase activity was determined using a dual-luciferase assay system (Promega).", [["luciferase", "GENE_OR_GENE_PRODUCT", 48, 58], ["a dual-luciferase assay system", "TREATMENT", 41, 71]]], ["The experiment was performed in triplicate wells.Quantification of apoptotic cells ::: Materials and methods293T cells in 12-well plates were transfected using Lipofectamine 3000 reagent (Life Technologies) following the manufacturer\u2019s instruction.", [["cells", "ANATOMY", 77, 82], ["293T cells", "ANATOMY", 108, 118], ["cells", "CELL", 77, 82], ["293T cells", "CELL", 108, 118], ["apoptotic cells", "CELL_TYPE", 67, 82], ["293T cells", "CELL_LINE", 108, 118], ["methods293T cells", "TREATMENT", 101, 118], ["Lipofectamine", "TREATMENT", 160, 173], ["apoptotic cells", "OBSERVATION", 67, 82]]], ["Cells per well were transfected with 3\u03bcg of the expression plasmid of SARS-CoV Tor2 or SARSr-CoV Rs4084 ORF8a, or the empty vector.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["SARS-CoV Tor2", "GENE_OR_GENE_PRODUCT", 70, 83], ["SARSr-CoV", "GENE_OR_GENE_PRODUCT", 87, 96], ["expression plasmid", "DNA", 48, 66], ["SARS-CoV Tor2", "DNA", 70, 83], ["SARSr-CoV Rs4084 ORF8a", "DNA", 87, 109], ["empty vector", "DNA", 118, 130], ["SARS-CoV", "SPECIES", 70, 78], ["SARSr-CoV Rs4084", "SPECIES", 87, 103], ["SARS", "TEST", 70, 74], ["CoV Tor2", "TEST", 75, 83], ["SARSr", "TEST", 87, 92], ["empty vector", "OBSERVATION", 118, 130]]], ["24h post transfection, apoptotic cells were quantified by using the Annexin V-fluorescein isothiocyanate (FITC)/PI Apoptosis Detection Kit (Yeasen Biotech, Shanghai) in accordance with the manufacturer\u2019s instruction.", [["cells", "ANATOMY", 33, 38], ["Annexin V-fluorescein isothiocyanate", "CHEMICAL", 68, 104], ["fluorescein isothiocyanate", "CHEMICAL", 78, 104], ["FITC", "CHEMICAL", 106, 110], ["cells", "CELL", 33, 38], ["Annexin V-fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 68, 104], ["FITC", "SIMPLE_CHEMICAL", 106, 110], ["apoptotic cells", "CELL_TYPE", 23, 38], ["apoptotic cells", "PROBLEM", 23, 38], ["the Annexin V", "TEST", 64, 77], ["fluorescein isothiocyanate", "TREATMENT", 78, 104], ["apoptotic cells", "OBSERVATION", 23, 38]]], ["Apoptosis was analyzed by flow cytometry.", [["Apoptosis", "TEST", 0, 9], ["flow cytometry", "TEST", 26, 40]]], ["The experiment was performed in triplicate wells.Accession numbers ::: Materials and methodsThe complete genome sequences of bat SARS-related coronavirus strains As6526, Rs4081, Rs4084, Rf4092, Rs4231, Rs4237, Rs4247, Rs4255, Rs4874, Rs7327 and Rs9401 have been deposited in the GenBank database with the accession numbers from KY417142 to KY417152, respectively.", [["SARS", "DISEASE", 129, 133], ["bat SARS-related coronavirus", "ORGANISM", 125, 153], ["Rs9401", "DNA", 245, 251], ["coronavirus", "SPECIES", 142, 153], ["bat SARS", "TEST", 125, 133], ["coronavirus strains", "TEST", 142, 161], ["Rs", "TEST", 170, 172], ["Rs", "TEST", 178, 180], ["Rf", "TEST", 186, 188], ["Rs", "TEST", 194, 196], ["Rs", "TEST", 202, 204], ["Rs", "TEST", 210, 212], ["Rs", "TEST", 218, 220], ["Rs", "TEST", 226, 228]]]], "3658d8c263801692ecbb137c285e8b3119626471": [["IntroductionIn viral infections, both adaptive and innate immune reactions cooperate to protect the host and, whenever it is possible, to eradicate or control the infection.", [["viral infections", "DISEASE", 15, 31], ["infection", "DISEASE", 163, 172], ["IntroductionIn viral infections", "PROBLEM", 0, 31], ["innate immune reactions", "TREATMENT", 51, 74], ["the infection", "PROBLEM", 159, 172], ["viral infections", "OBSERVATION", 15, 31], ["infection", "OBSERVATION", 163, 172]]], ["The early synthesis of soluble factors (cytokines, chemokines) influences substantially the subsequent immune response and may, therefore, affect the course of infection.", [["infection", "DISEASE", 160, 169], ["soluble factors", "PROTEIN", 23, 38], ["cytokines", "PROTEIN", 40, 49], ["chemokines", "PROTEIN", 51, 61], ["The early synthesis of soluble factors", "TREATMENT", 0, 38], ["cytokines, chemokines)", "TREATMENT", 40, 62], ["infection", "PROBLEM", 160, 169], ["infection", "OBSERVATION", 160, 169]]], ["One of the important effectors of natural immunity are \u2425\u2426 T lymphocytes, which display a broad antiviral activity against different viruses such as retroviruses, flaviviruses, paramyxoviruses, orthomyxoviruses, picornaviruses, coronaviruses, rhabdoviruses, arenaviruses, herpesviruses, hepadnaviruses, and orthopoxviruses (reviewed in [1] ).", [["\u2425\u2426 T lymphocytes", "ANATOMY", 55, 71], ["picornaviruses, coronaviruses", "DISEASE", 211, 240], ["rhabdoviruses", "DISEASE", 242, 255], ["arenaviruses", "DISEASE", 257, 269], ["herpesviruses", "DISEASE", 271, 284], ["hepadnaviruses", "DISEASE", 286, 300], ["orthopoxviruses", "DISEASE", 306, 321], ["\u2425\u2426 T lymphocytes", "CELL", 55, 71], ["retroviruses", "ORGANISM", 148, 160], ["rhabdoviruses", "GENE_OR_GENE_PRODUCT", 242, 255], ["\u2425\u2426 T lymphocytes", "CELL_TYPE", 55, 71], ["a broad antiviral activity", "PROBLEM", 87, 113], ["different viruses", "PROBLEM", 122, 139], ["retroviruses", "PROBLEM", 148, 160], ["flaviviruses", "PROBLEM", 162, 174], ["paramyxoviruses", "PROBLEM", 176, 191], ["orthomyxoviruses", "PROBLEM", 193, 209], ["picornaviruses", "PROBLEM", 211, 225], ["coronaviruses", "PROBLEM", 227, 240], ["rhabdoviruses", "PROBLEM", 242, 255], ["arenaviruses", "PROBLEM", 257, 269], ["herpesviruses", "PROBLEM", 271, 284], ["hepadnaviruses", "PROBLEM", 286, 300], ["orthopoxviruses", "PROBLEM", 306, 321], ["broad", "OBSERVATION_MODIFIER", 89, 94], ["antiviral activity", "OBSERVATION", 95, 113], ["viruses", "OBSERVATION", 132, 139]]], ["This broad antiviral activity of \u2425\u2426 T cells is likely to play a crucial defensive role, especially considering that their relatively large numbers (e.g., approximately one out of every 30 adult human peripheral blood lymphocytes is a V\u24259V\u24262 T lymphocyte) can respond very quickly (typically, no antigen processing 0165 is required for the potent major histocompatibility complex (MHC)-unrestricted activities of V\u24259V\u24262 T cells) and release soluble antiviral factors.Pharmacological stimulation of \u2425\u2426 T cellsMany natural ligands recognized by human V\u24259V\u24262 T cells are known.", [["\u2425\u2426 T cells", "ANATOMY", 33, 43], ["peripheral blood lymphocytes", "ANATOMY", 200, 228], ["V\u24259V\u24262 T lymphocyte", "ANATOMY", 234, 253], ["V\u24259V\u24262 T cells", "ANATOMY", 412, 426], ["\u2425\u2426 T cells", "ANATOMY", 497, 507], ["V\u24259V\u24262 T cells", "ANATOMY", 548, 562], ["\u2425\u2426 T cells", "CELL", 33, 43], ["human", "ORGANISM", 194, 199], ["peripheral blood lymphocytes", "CELL", 200, 228], ["V\u24259V\u24262 T cells", "CELL", 412, 426], ["\u2425\u2426 T cells", "CELL", 497, 507], ["human", "ORGANISM", 542, 547], ["V\u24259V\u24262 T cells", "CELL", 548, 562], ["\u2425\u2426 T cells", "CELL_TYPE", 33, 43], ["human peripheral blood lymphocytes", "CELL_TYPE", 194, 228], ["T lymphocyte", "CELL_TYPE", 241, 253], ["antigen processing 0165", "PROTEIN", 295, 318], ["major histocompatibility complex", "PROTEIN", 346, 378], ["MHC", "PROTEIN", 380, 383], ["V\u24259V\u24262 T cells", "CELL_LINE", 412, 426], ["antiviral factors", "PROTEIN", 448, 465], ["\u2425\u2426 T cells", "CELL_TYPE", 497, 507], ["human V\u24259V\u24262 T cells", "CELL_LINE", 542, 562], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 542, 547], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 542, 547], ["\u2425\u2426 T cells", "PROBLEM", 33, 43], ["blood lymphocytes", "TEST", 211, 228], ["a V", "TEST", 232, 235], ["release soluble antiviral factors", "TREATMENT", 432, 465], ["Pharmacological stimulation of \u2425\u2426 T cells", "TREATMENT", 466, 507], ["antiviral activity", "OBSERVATION", 11, 29]]], ["Probably the most important representatives of this group are intermediates of isoprenoid biosynthesis [2] (e.g., 3-formyl-1-butyl-pyrophosphate and isopentenylpyrophosphate) and were first isolated from mycobacteria [3] [4] [5] .", [["isoprenoid", "CHEMICAL", 79, 89], ["3-formyl-1-butyl-pyrophosphate", "CHEMICAL", 114, 144], ["isopentenylpyrophosphate", "CHEMICAL", 149, 173], ["isoprenoid", "CHEMICAL", 79, 89], ["3-formyl-1-butyl-pyrophosphate", "CHEMICAL", 114, 144], ["isopentenylpyrophosphate", "CHEMICAL", 149, 173], ["isoprenoid", "SIMPLE_CHEMICAL", 79, 89], ["[2]", "SIMPLE_CHEMICAL", 103, 106], ["3-formyl-1-butyl-pyrophosphate", "SIMPLE_CHEMICAL", 114, 144], ["isopentenylpyrophosphate", "SIMPLE_CHEMICAL", 149, 173], ["mycobacteria [3] [4] [5]", "SIMPLE_CHEMICAL", 204, 228], ["isoprenoid biosynthesis", "TEST", 79, 102], ["formyl", "TEST", 116, 122], ["butyl-pyrophosphate", "TREATMENT", 125, 144], ["isopentenylpyrophosphate", "TREATMENT", 149, 173]]], ["Other natural and synthetic phospho-ligands [6, 7] , alkylamines [8] and aminobiphosphonates [9] also stimulate V\u24259V\u24262 T cells.", [["V\u24259V\u24262 T cells", "ANATOMY", 112, 126], ["[6, 7] , alkylamines [8] and aminobiphosphonates", "CHEMICAL", 44, 92], ["phospho-", "CHEMICAL", 28, 36], ["alkylamines", "CHEMICAL", 53, 64], ["aminobiphosphonates", "CHEMICAL", 73, 92], ["phospho-ligands [6, 7]", "SIMPLE_CHEMICAL", 28, 50], ["alkylamines [8]", "SIMPLE_CHEMICAL", 53, 68], ["aminobiphosphonates [9]", "SIMPLE_CHEMICAL", 73, 96], ["V\u24259V\u24262 T cells", "CELL_LINE", 112, 126], ["Other natural and synthetic phospho-ligands", "TREATMENT", 0, 43], ["alkylamines", "TEST", 53, 64], ["aminobiphosphonates", "TEST", 73, 92], ["stimulate V", "TEST", 102, 113]]], ["Structure-function studies of V\u24259V\u24262specific ligands suggest that some of these molecules could be readily docked into a putative binding site of the V\u24259V\u24262 TCR [10, 11] .", [["V\u24259V\u24262specific ligands", "GENE_OR_GENE_PRODUCT", 30, 52], ["V\u24259V", "PROTEIN", 150, 154], ["TCR", "PROTEIN", 157, 160], ["V\u24259V\u24262specific ligands", "PROBLEM", 30, 52]]], ["Functionally, mature V\u24259V\u24262 T cells express cell-surface inhibitory receptors for MHC class I molecules (INMRs) that may control TCR-mediated reactivities in the antiviral response [12, 13] .Pharmacological stimulation of \u2425\u2426 T cellsPhosphostim (phosphobromohydrin) is the first drug that was designed to stimulate selectively V\u24259V\u24262 T cells.", [["V\u24259V\u24262 T cells", "ANATOMY", 21, 35], ["cell", "ANATOMY", 44, 48], ["surface", "ANATOMY", 49, 56], ["\u2425\u2426 T cells", "ANATOMY", 222, 232], ["V\u24259V\u24262 T cells", "ANATOMY", 326, 340], ["TCR", "CHEMICAL", 129, 132], ["Phosphostim", "CHEMICAL", 232, 243], ["phosphobromohydrin", "CHEMICAL", 245, 263], ["Phosphostim", "CHEMICAL", 232, 243], ["phosphobromohydrin", "CHEMICAL", 245, 263], ["cell", "CELL", 44, 48], ["INMRs", "GENE_OR_GENE_PRODUCT", 105, 110], ["TCR", "GENE_OR_GENE_PRODUCT", 129, 132], ["\u2425\u2426 T cells", "CELL", 222, 232], ["Phosphostim", "SIMPLE_CHEMICAL", 232, 243], ["phosphobromohydrin", "SIMPLE_CHEMICAL", 245, 263], ["mature V\u24259V\u24262 T cells", "CELL_LINE", 14, 35], ["cell-surface inhibitory receptors", "PROTEIN", 44, 77], ["MHC class I molecules", "PROTEIN", 82, 103], ["INMRs", "PROTEIN", 105, 110], ["TCR", "PROTEIN", 129, 132], ["\u2425\u2426 T cells", "CELL_TYPE", 222, 232], ["V\u24259V\u24262 T cells", "CELL_LINE", 326, 340], ["Pharmacological stimulation", "TREATMENT", 191, 218], ["\u2425\u2426 T cellsPhosphostim (phosphobromohydrin", "TREATMENT", 222, 263]]], ["Currently, this new drug is in Phase I/Phase II clinical trials in cancer patients.", [["cancer", "ANATOMY", 67, 73], ["cancer", "DISEASE", 67, 73], ["cancer", "CANCER", 67, 73], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82]]], ["Nitrogen-containing bisphosphonates (N-BPs) have been used to prevent bone demineralization in patients with osteoporosis, multiple myeloma, and certain metastatic cancers (e.g., breast and prostate).", [["bone", "ANATOMY", 70, 74], ["myeloma", "ANATOMY", 132, 139], ["metastatic cancers", "ANATOMY", 153, 171], ["breast", "ANATOMY", 179, 185], ["prostate", "ANATOMY", 190, 198], ["Nitrogen", "CHEMICAL", 0, 8], ["bisphosphonates", "CHEMICAL", 20, 35], ["N-BPs", "CHEMICAL", 37, 42], ["bone demineralization", "DISEASE", 70, 91], ["osteoporosis", "DISEASE", 109, 121], ["multiple myeloma", "DISEASE", 123, 139], ["cancers", "DISEASE", 164, 171], ["breast and prostate)", "DISEASE", 179, 199], ["Nitrogen", "CHEMICAL", 0, 8], ["bisphosphonates", "CHEMICAL", 20, 35], ["N-BPs", "CHEMICAL", 37, 42], ["Nitrogen", "SIMPLE_CHEMICAL", 0, 8], ["bisphosphonates", "SIMPLE_CHEMICAL", 20, 35], ["N-BPs", "SIMPLE_CHEMICAL", 37, 42], ["bone", "TISSUE", 70, 74], ["patients", "ORGANISM", 95, 103], ["myeloma", "CANCER", 132, 139], ["metastatic cancers", "CANCER", 153, 171], ["breast", "CANCER", 179, 185], ["prostate", "ORGAN", 190, 198], ["patients", "SPECIES", 95, 103], ["Nitrogen", "TREATMENT", 0, 8], ["bisphosphonates (N-BPs)", "TREATMENT", 20, 43], ["bone demineralization", "PROBLEM", 70, 91], ["osteoporosis", "PROBLEM", 109, 121], ["multiple myeloma", "PROBLEM", 123, 139], ["certain metastatic cancers (e.g., breast and prostate)", "PROBLEM", 145, 199], ["bone", "ANATOMY", 70, 74], ["demineralization", "OBSERVATION", 75, 91], ["osteoporosis", "OBSERVATION", 109, 121], ["multiple", "OBSERVATION_MODIFIER", 123, 131], ["myeloma", "OBSERVATION", 132, 139], ["metastatic", "OBSERVATION_MODIFIER", 153, 163], ["cancers", "OBSERVATION", 164, 171], ["breast", "ANATOMY", 179, 185], ["prostate", "ANATOMY", 190, 198]]], ["Recently, N-BPs have been shown to induce activation of V\u24259V\u24262 T cells accompanied by augmented: (a) cytotoxic activities; (b) cytokine/\u2424-chemokine production; and (c) DNA synthetic responses in V\u24259V\u24262 T cells.", [["V\u24259V\u24262 T cells", "ANATOMY", 56, 70], ["V\u24259V\u24262 T cells", "ANATOMY", 195, 209], ["N-BPs", "CHEMICAL", 10, 15], ["N-BPs", "CHEMICAL", 10, 15], ["N-BPs", "SIMPLE_CHEMICAL", 10, 15], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["V\u24259V\u24262 T cells", "CELL", 195, 209], ["V\u24259V\u24262 T cells", "CELL_LINE", 56, 70], ["cytokine", "PROTEIN", 127, 135], ["chemokine", "PROTEIN", 138, 147], ["V\u24259V\u24262 T cells", "CELL_LINE", 195, 209], ["cytotoxic activities", "TEST", 101, 121], ["cytokine/\u2424", "TEST", 127, 137], ["chemokine production", "TEST", 138, 158], ["DNA synthetic responses", "TEST", 168, 191]]], ["These unexpected activities of N-BPs have opened new possibilities of therapeutic usage for these drugs.Pharmacological stimulation of \u2425\u2426 T cellsThe mechanism of N-BP action appears to include the inhibition of farnesyl pyrophosphate synthase activity (as one of the key enzymes in the mevalonate pathway, farnesyl pyrophosphate synthase catalyzes the sequential head-to-tail condensation of two molecules of isopentenyl pyrophosphate with dimethylallyl pyrophosphate).", [["\u2425\u2426 T cells", "ANATOMY", 135, 145], ["head", "ANATOMY", 363, 367], ["N-BPs", "CHEMICAL", 31, 36], ["N-BP", "CHEMICAL", 162, 166], ["farnesyl pyrophosphate", "CHEMICAL", 211, 233], ["mevalonate", "CHEMICAL", 286, 296], ["farnesyl pyrophosphate", "CHEMICAL", 306, 328], ["isopentenyl pyrophosphate", "CHEMICAL", 409, 434], ["dimethylallyl pyrophosphate", "CHEMICAL", 440, 467], ["N-BPs", "CHEMICAL", 31, 36], ["N-BP", "CHEMICAL", 162, 166], ["farnesyl pyrophosphate", "CHEMICAL", 211, 233], ["mevalonate", "CHEMICAL", 286, 296], ["farnesyl pyrophosphate", "CHEMICAL", 306, 328], ["isopentenyl pyrophosphate", "CHEMICAL", 409, 434], ["dimethylallyl pyrophosphate", "CHEMICAL", 440, 467], ["N-BPs", "SIMPLE_CHEMICAL", 31, 36], ["\u2425\u2426 T cells", "CELL", 135, 145], ["N-BP", "SIMPLE_CHEMICAL", 162, 166], ["farnesyl pyrophosphate synthase", "GENE_OR_GENE_PRODUCT", 211, 242], ["mevalonate", "SIMPLE_CHEMICAL", 286, 296], ["farnesyl pyrophosphate synthase", "GENE_OR_GENE_PRODUCT", 306, 337], ["isopentenyl pyrophosphate", "SIMPLE_CHEMICAL", 409, 434], ["dimethylallyl pyrophosphate", "SIMPLE_CHEMICAL", 440, 467], ["\u2425\u2426 T cells", "CELL_TYPE", 135, 145], ["farnesyl pyrophosphate synthase", "PROTEIN", 211, 242], ["farnesyl pyrophosphate synthase", "PROTEIN", 306, 337], ["these drugs", "TREATMENT", 92, 103], ["Pharmacological stimulation of \u2425\u2426 T cells", "TREATMENT", 104, 145], ["N-BP action", "TREATMENT", 162, 173], ["farnesyl pyrophosphate synthase activity", "TREATMENT", 211, 251], ["the key enzymes", "TEST", 263, 278], ["the mevalonate pathway", "TEST", 282, 304], ["farnesyl pyrophosphate synthase", "TEST", 306, 337], ["the sequential head", "TEST", 348, 367], ["isopentenyl pyrophosphate", "TREATMENT", 409, 434], ["dimethylallyl pyrophosphate", "TREATMENT", 440, 467]]], ["This leads to an accumulation of isopentenyl pyrophosphate, an essential metabolite that is directly recognized by V\u24259V\u24262 T cells [14] .", [["V\u24259V\u24262 T cells", "ANATOMY", 115, 129], ["isopentenyl pyrophosphate", "CHEMICAL", 33, 58], ["isopentenyl pyrophosphate", "CHEMICAL", 33, 58], ["isopentenyl pyrophosphate", "SIMPLE_CHEMICAL", 33, 58], ["V\u24259V\u24262 T cells", "CELL_LINE", 115, 129], ["isopentenyl pyrophosphate", "TREATMENT", 33, 58], ["accumulation", "OBSERVATION_MODIFIER", 17, 29], ["isopentenyl pyrophosphate", "OBSERVATION", 33, 58], ["essential", "OBSERVATION_MODIFIER", 63, 72], ["metabolite", "OBSERVATION", 73, 83]]], ["Interestingly, the mevalonate pathway is critical for protein prenylation, which may be important for viral assembly (Fig. 1) .", [["mevalonate", "CHEMICAL", 19, 29], ["mevalonate", "CHEMICAL", 19, 29], ["mevalonate", "SIMPLE_CHEMICAL", 19, 29], ["the mevalonate pathway", "TEST", 15, 37], ["protein prenylation", "TREATMENT", 54, 73], ["viral assembly (Fig", "PROBLEM", 102, 121]]], ["In hepatoma cells exposed to lovastatin (an inhibitor of 3hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate), hepatitic C virus (HCV) RNA replication is impaired due to the dissolution of the HCV replication complex [15] .", [["hepatoma cells", "ANATOMY", 3, 17], ["hepatoma", "DISEASE", 3, 11], ["lovastatin", "CHEMICAL", 29, 39], ["3hydroxy-3-methylglutaryl-coenzyme A", "CHEMICAL", 57, 93], ["mevalonate", "CHEMICAL", 170, 180], ["lovastatin", "CHEMICAL", 29, 39], ["3hydroxy-3-methylglutaryl-coenzyme A", "CHEMICAL", 57, 93], ["HMG-CoA", "CHEMICAL", 95, 102], ["HMG-CoA", "CHEMICAL", 159, 166], ["mevalonate", "CHEMICAL", 170, 180], ["hepatoma cells", "CELL", 3, 17], ["lovastatin", "SIMPLE_CHEMICAL", 29, 39], ["3hydroxy-3-methylglutaryl-coenzyme A", "SIMPLE_CHEMICAL", 57, 93], ["HMG-CoA) reductase", "GENE_OR_GENE_PRODUCT", 95, 113], ["HMG-CoA", "GENE_OR_GENE_PRODUCT", 159, 166], ["mevalonate", "SIMPLE_CHEMICAL", 170, 180], ["hepatitic C virus", "ORGANISM", 183, 200], ["HCV", "ORGANISM", 202, 205], ["hepatoma cells", "CELL_TYPE", 3, 17], ["3hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase", "PROTEIN", 57, 113], ["HMG", "PROTEIN", 159, 162], ["HCV replication complex", "PROTEIN", 265, 288], ["C virus", "SPECIES", 193, 200], ["HCV", "SPECIES", 202, 205], ["HCV", "SPECIES", 265, 268], ["hepatoma cells", "PROBLEM", 3, 17], ["lovastatin", "TREATMENT", 29, 39], ["an inhibitor", "TREATMENT", 41, 53], ["3hydroxy", "TEST", 57, 65], ["methylglutaryl", "TREATMENT", 68, 82], ["coenzyme A (HMG-CoA) reductase", "TREATMENT", 83, 113], ["the enzyme", "TEST", 115, 125], ["HMG", "TEST", 159, 162], ["mevalonate", "TREATMENT", 170, 180], ["hepatitic C virus", "PROBLEM", 183, 200], ["HCV) RNA replication", "TREATMENT", 202, 222], ["hepatoma cells", "OBSERVATION", 3, 17], ["HCV", "OBSERVATION", 265, 268]]], ["The lovastatin treatment can also block respiratory syncytial virus (RSV) replication and cell-to-cell fusion in vivo and in vitro by inhibiting the isoprenylation of the cellular protein RhoA [16] .Pharmacological stimulation of \u2425\u2426 T cellsSimilarly, BZA-5B (an inhibitor of protein prenylation) blocks the production of hepatitis delta virus (HDV) particles in vitro in a dose dependent manner [17] .", [["cell", "ANATOMY", 90, 94], ["cell", "ANATOMY", 98, 102], ["cellular", "ANATOMY", 171, 179], ["lovastatin", "CHEMICAL", 4, 14], ["respiratory syncytial virus", "DISEASE", 40, 67], ["BZA-5B", "CHEMICAL", 251, 257], ["hepatitis delta", "DISEASE", 321, 336], ["lovastatin", "CHEMICAL", 4, 14], ["BZA-5B", "CHEMICAL", 251, 257], ["lovastatin", "SIMPLE_CHEMICAL", 4, 14], ["respiratory syncytial virus", "ORGANISM", 40, 67], ["RSV", "ORGANISM", 69, 72], ["cell", "CELL", 90, 94], ["cell", "CELL", 98, 102], ["cellular", "CELL", 171, 179], ["RhoA", "GENE_OR_GENE_PRODUCT", 188, 192], ["BZA-5B", "GENE_OR_GENE_PRODUCT", 251, 257], ["hepatitis delta virus", "ORGANISM", 321, 342], ["HDV", "ORGANISM", 344, 347], ["cellular protein", "PROTEIN", 171, 187], ["RhoA [16]", "PROTEIN", 188, 197], ["hepatitis delta virus", "SPECIES", 321, 342], ["respiratory syncytial virus", "SPECIES", 40, 67], ["RSV", "SPECIES", 69, 72], ["hepatitis delta virus", "SPECIES", 321, 342], ["HDV", "SPECIES", 344, 347], ["The lovastatin treatment", "TREATMENT", 0, 24], ["block respiratory syncytial virus", "PROBLEM", 34, 67], ["RSV) replication", "TREATMENT", 69, 85], ["cell-to-cell fusion", "TREATMENT", 90, 109], ["the cellular protein RhoA", "TEST", 167, 192], ["Pharmacological stimulation", "TREATMENT", 199, 226], ["\u2425\u2426 T cellsSimilarly", "TREATMENT", 230, 249], ["BZA", "TEST", 251, 254], ["an inhibitor of protein prenylation", "TREATMENT", 259, 294], ["hepatitis delta virus (HDV) particles", "TREATMENT", 321, 358], ["syncytial virus", "OBSERVATION", 52, 67]]], ["In particular, the inhibition of large delta antigen prenylation mediated by BZA-5B interferes with the assembly of HDV virions.", [["BZA-5B", "CHEMICAL", 77, 83], ["large delta antigen", "GENE_OR_GENE_PRODUCT", 33, 52], ["BZA-5B", "GENE_OR_GENE_PRODUCT", 77, 83], ["HDV", "ORGANISM", 116, 119], ["BZA", "PROTEIN", 77, 80], ["HDV", "SPECIES", 116, 119], ["large delta antigen prenylation", "TREATMENT", 33, 64], ["HDV virions", "PROBLEM", 116, 127], ["large", "OBSERVATION_MODIFIER", 33, 38], ["HDV virions", "OBSERVATION", 116, 127]]], ["In addition, the increased concentration of large delta antigen within infected cells may act as a potent trans dominant inhibitor of HDV replication [18] .Pharmacological stimulation of \u2425\u2426 T cellsThe block of mevalonate pathway by N-BPs also results in a decreased synthesis of cholesterol.", [["cells", "ANATOMY", 80, 85], ["\u2425\u2426 T cells", "ANATOMY", 187, 197], ["mevalonate", "CHEMICAL", 210, 220], ["N-BPs", "CHEMICAL", 232, 237], ["cholesterol", "CHEMICAL", 279, 290], ["mevalonate", "CHEMICAL", 210, 220], ["N-BPs", "CHEMICAL", 232, 237], ["cholesterol", "CHEMICAL", 279, 290], ["large delta antigen", "GENE_OR_GENE_PRODUCT", 44, 63], ["cells", "CELL", 80, 85], ["HDV", "ORGANISM", 134, 137], ["\u2425\u2426 T cells", "CELL", 187, 197], ["mevalonate", "SIMPLE_CHEMICAL", 210, 220], ["N-BPs", "SIMPLE_CHEMICAL", 232, 237], ["cholesterol", "SIMPLE_CHEMICAL", 279, 290], ["large delta antigen", "PROTEIN", 44, 63], ["infected cells", "CELL_TYPE", 71, 85], ["\u2425\u2426 T cells", "CELL_TYPE", 187, 197], ["HDV", "SPECIES", 134, 137], ["the increased concentration", "PROBLEM", 13, 40], ["large delta antigen within infected cells", "PROBLEM", 44, 85], ["a potent trans dominant inhibitor", "TREATMENT", 97, 130], ["HDV replication", "TREATMENT", 134, 149], ["Pharmacological stimulation of \u2425\u2426 T cells", "TREATMENT", 156, 197], ["mevalonate pathway", "TREATMENT", 210, 228], ["a decreased synthesis of cholesterol", "PROBLEM", 254, 290], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["concentration", "OBSERVATION_MODIFIER", 27, 40], ["large", "OBSERVATION_MODIFIER", 44, 49], ["delta", "OBSERVATION_MODIFIER", 50, 55], ["infected cells", "OBSERVATION", 71, 85], ["decreased", "OBSERVATION", 256, 265]]], ["It has been reported that cholesterol is critical for HIV passage through cell membranes and that the ability of Nef protein to increase viral infectivity depends on cholesterol [19] .", [["cell membranes", "ANATOMY", 74, 88], ["cholesterol", "CHEMICAL", 26, 37], ["cholesterol", "CHEMICAL", 166, 177], ["cholesterol", "CHEMICAL", 26, 37], ["cholesterol", "CHEMICAL", 166, 177], ["cholesterol", "SIMPLE_CHEMICAL", 26, 37], ["HIV", "ORGANISM", 54, 57], ["cell membranes", "CELLULAR_COMPONENT", 74, 88], ["Nef", "GENE_OR_GENE_PRODUCT", 113, 116], ["cholesterol", "SIMPLE_CHEMICAL", 166, 177], ["Nef protein", "PROTEIN", 113, 124], ["HIV", "SPECIES", 54, 57], ["HIV passage through cell membranes", "PROBLEM", 54, 88], ["Nef protein", "TREATMENT", 113, 124], ["viral infectivity", "PROBLEM", 137, 154], ["cholesterol", "TEST", 166, 177], ["cell membranes", "OBSERVATION", 74, 88], ["viral infectivity", "OBSERVATION", 137, 154]]], ["Specifically, Nef is involved in transporting newly synthesized cholesterol to the site of viral budding and promotes the incorporation of cholesterol into viral particles.", [["cholesterol", "CHEMICAL", 64, 75], ["cholesterol", "CHEMICAL", 139, 150], ["cholesterol", "CHEMICAL", 64, 75], ["cholesterol", "CHEMICAL", 139, 150], ["Nef", "GENE_OR_GENE_PRODUCT", 14, 17], ["cholesterol", "SIMPLE_CHEMICAL", 64, 75], ["cholesterol", "SIMPLE_CHEMICAL", 139, 150], ["Nef", "PROTEIN", 14, 17], ["viral budding", "PROBLEM", 91, 104], ["the incorporation of cholesterol into viral particles", "TREATMENT", 118, 171], ["viral budding", "OBSERVATION", 91, 104], ["viral particles", "OBSERVATION", 156, 171]]], ["These data suggest that an efficient cholesterol synthesis in HIV-infected cells is important for the production of infectious virions [20] .", [["cells", "ANATOMY", 75, 80], ["cholesterol", "CHEMICAL", 37, 48], ["HIV-infected", "DISEASE", 62, 74], ["cholesterol", "CHEMICAL", 37, 48], ["cholesterol", "SIMPLE_CHEMICAL", 37, 48], ["HIV", "ORGANISM", 62, 65], ["cells", "CELL", 75, 80], ["HIV-infected cells", "CELL_TYPE", 62, 80], ["HIV", "SPECIES", 62, 65], ["HIV", "SPECIES", 62, 65], ["These data", "TEST", 0, 10], ["an efficient cholesterol synthesis", "PROBLEM", 24, 58], ["HIV-infected cells", "PROBLEM", 62, 80], ["infectious virions", "PROBLEM", 116, 134], ["infected cells", "OBSERVATION", 66, 80]]], ["Altogether, these results open a new possibility of using the inhibitors of mevalonate pathway as double-edge swords-that is as antivirals interfering with virion production as well as stimulators of V\u24259V\u24262 T cell cytotoxic and other antiviral effects.Non-cytolytic antiviral immunity mediated by V\u24259V\u24262 T cellsImmune responses to viral infections comprise both cytolytic (i.e., cytotoxicity against virus-infected cells) and non-cytolytic activities of V\u24259V\u24262 T cells.", [["T cell", "ANATOMY", 207, 213], ["cells", "ANATOMY", 415, 420], ["V\u24259V\u24262 T cells", "ANATOMY", 454, 468], ["mevalonate", "CHEMICAL", 76, 86], ["viral infections", "DISEASE", 331, 347], ["mevalonate", "CHEMICAL", 76, 86], ["mevalonate", "SIMPLE_CHEMICAL", 76, 86], ["T cell", "CELL", 207, 213], ["cells", "CELL", 415, 420], ["virus-infected cells", "CELL_TYPE", 400, 420], ["V\u24259V\u24262 T cells", "CELL_LINE", 454, 468], ["V\u24259V", "SPECIES", 297, 301], ["the inhibitors", "TREATMENT", 58, 72], ["mevalonate pathway", "TREATMENT", 76, 94], ["antivirals", "TREATMENT", 128, 138], ["virion production", "TREATMENT", 156, 173], ["2 T cell cytotoxic", "TREATMENT", 205, 223], ["other antiviral effects", "TREATMENT", 228, 251], ["viral infections", "PROBLEM", 331, 347], ["both cytolytic", "PROBLEM", 357, 371], ["cytotoxicity", "TEST", 379, 391], ["virus", "PROBLEM", 400, 405], ["infected cells", "PROBLEM", 406, 420], ["non-cytolytic activities", "TEST", 426, 450], ["V", "TEST", 454, 455]]], ["The innate noncytolytic activity encompasses the production and release of several soluble molecules.", [["soluble molecules", "PROTEIN", 83, 100], ["noncytolytic activity", "OBSERVATION", 11, 32]]], ["As shown in Fig. 2 , peripheral blood mononuclear cells (PBMCs) stimulated with isopentenyl pyrophosphate (IPP, a classical non-peptidic antigen for V\u24259V\u24262 T cells) release an array of cytokines (e.g., IFN-\u2425, TNF-\u2423, IL-1\u2423, IL-6, GM-CSF, TPO, OSM) and chemokines (e.g., MIP-1\u2423/\u2424, RANTES, SDF-1, MCP-2 MDC, ENA-78 and GRO) with known antiviral and/or immunomodulatory properties.", [["peripheral blood mononuclear cells", "ANATOMY", 21, 55], ["PBMCs", "ANATOMY", 57, 62], ["V\u24259V\u24262 T cells", "ANATOMY", 149, 163], ["isopentenyl pyrophosphate", "CHEMICAL", 80, 105], ["IPP", "CHEMICAL", 107, 110], ["isopentenyl pyrophosphate", "CHEMICAL", 80, 105], ["IPP", "CHEMICAL", 107, 110], ["peripheral blood mononuclear cells", "CELL", 21, 55], ["PBMCs", "CELL", 57, 62], ["isopentenyl pyrophosphate", "SIMPLE_CHEMICAL", 80, 105], ["IPP", "SIMPLE_CHEMICAL", 107, 110], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 202, 207], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 209, 214], ["IL-1\u2423", "GENE_OR_GENE_PRODUCT", 216, 221], ["IL-6", "GENE_OR_GENE_PRODUCT", 223, 227], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 229, 235], ["TPO", "GENE_OR_GENE_PRODUCT", 237, 240], ["OSM", "GENE_OR_GENE_PRODUCT", 242, 245], ["MIP-1\u2423", "GENE_OR_GENE_PRODUCT", 269, 275], ["\u2424", "GENE_OR_GENE_PRODUCT", 276, 277], ["RANTES", "GENE_OR_GENE_PRODUCT", 279, 285], ["SDF-1", "GENE_OR_GENE_PRODUCT", 287, 292], ["MCP-2", "GENE_OR_GENE_PRODUCT", 294, 299], ["ENA-78", "GENE_OR_GENE_PRODUCT", 305, 311], ["GRO", "GENE_OR_GENE_PRODUCT", 316, 319], ["peripheral blood mononuclear cells", "CELL_TYPE", 21, 55], ["PBMCs", "CELL_TYPE", 57, 62], ["V\u24259V\u24262 T cells", "CELL_TYPE", 149, 163], ["cytokines", "PROTEIN", 185, 194], ["IFN", "PROTEIN", 202, 205], ["TNF", "PROTEIN", 209, 212], ["IL", "PROTEIN", 216, 218], ["IL-6", "PROTEIN", 223, 227], ["GM", "PROTEIN", 229, 231], ["CSF", "PROTEIN", 232, 235], ["TPO", "PROTEIN", 237, 240], ["OSM", "PROTEIN", 242, 245], ["chemokines", "PROTEIN", 251, 261], ["MIP", "PROTEIN", 269, 272], ["1\u2423", "PROTEIN", 273, 275], ["\u2424", "PROTEIN", 276, 277], ["RANTES", "PROTEIN", 279, 285], ["SDF", "PROTEIN", 287, 290], ["MCP", "PROTEIN", 294, 297], ["MDC", "PROTEIN", 300, 303], ["ENA", "PROTEIN", 305, 308], ["GRO", "PROTEIN", 316, 319], ["peripheral blood mononuclear cells", "TEST", 21, 55], ["PBMCs", "TEST", 57, 62], ["isopentenyl pyrophosphate", "TEST", 80, 105], ["IPP", "TEST", 107, 110], ["a classical non-peptidic antigen", "TEST", 112, 144], ["V", "TEST", 149, 150], ["cytokines", "TEST", 185, 194], ["e.g.", "TEST", 196, 200], ["IFN", "TEST", 202, 205], ["\u2425", "TEST", 206, 207], ["TNF", "TEST", 209, 212], ["IL", "TEST", 216, 218], ["IL", "TEST", 223, 225], ["GM", "TEST", 229, 231], ["CSF", "TEST", 232, 235], ["TPO", "TEST", 237, 240], ["OSM", "TEST", 242, 245], ["chemokines", "TEST", 251, 261], ["MIP", "TEST", 269, 272], ["RANTES", "TEST", 279, 285], ["SDF", "TEST", 287, 290], ["MCP", "TEST", 294, 297], ["ENA", "TEST", 305, 308], ["known antiviral and/or immunomodulatory properties", "PROBLEM", 326, 376], ["peripheral", "ANATOMY_MODIFIER", 21, 31], ["blood", "ANATOMY", 32, 37], ["mononuclear cells", "OBSERVATION", 38, 55], ["antiviral", "OBSERVATION", 332, 341]]], ["After stimulation and in sharp contrast to many non-\u2425\u2426 TCR-expressing lymphoid cells, single V\u24259V\u24262 T lymphocytes produce more than one of these soluble antiviral/immunoregulatory factors (Fig. 3) .", [["lymphoid cells", "ANATOMY", 70, 84], ["V\u24259V\u24262 T lymphocytes", "ANATOMY", 93, 113], ["TCR", "GENE_OR_GENE_PRODUCT", 55, 58], ["lymphoid cells", "CELL", 70, 84], ["T lymphocytes", "CELL", 100, 113], ["non-\u2425\u2426 TCR-expressing lymphoid cells", "CELL_LINE", 48, 84], ["V\u24259V\u24262 T lymphocytes", "CELL_LINE", 93, 113], ["immunoregulatory factors", "PROTEIN", 163, 187], ["stimulation", "TREATMENT", 6, 17], ["single V\u24259V", "TEST", 86, 97], ["these soluble antiviral/immunoregulatory factors", "TREATMENT", 139, 187], ["lymphoid cells", "OBSERVATION", 70, 84]]], ["The innate response is followed by humoral and cellular adaptive immune responses influenced by many of these soluble molecules.", [["cellular", "ANATOMY", 47, 55], ["cellular", "CELL", 47, 55], ["soluble molecules", "PROTEIN", 110, 127]]], ["In addition, the non-cytolytic antiviral molecules continue to suppress the infectious process in vital organs without destroying important cells and also can boost the antiviral potency of classical \u2423\u2424 cytotoxic T lymphocytes (CTLs) [21] .Non-cytolytic antiviral immunity mediated by V\u24259V\u24262 T cellsThe main factor with known antiviral activities released by \u2425\u2426 T cells is IFN-\u2425-a key molecule in recruiting and activat-ing killer T cells, NK cells and macrophages, and triggering intracellular pathways that suppress viral replication without direct cytolytic effects on host cells [22, 23] .", [["organs", "ANATOMY", 104, 110], ["cells", "ANATOMY", 140, 145], ["\u2423\u2424 cytotoxic T lymphocytes", "ANATOMY", 200, 226], ["CTLs", "ANATOMY", 228, 232], ["V\u24259V\u24262 T cells", "ANATOMY", 285, 299], ["\u2425\u2426 T cells", "ANATOMY", 359, 369], ["activat-ing killer T cells", "ANATOMY", 412, 438], ["NK cells", "ANATOMY", 440, 448], ["macrophages", "ANATOMY", 453, 464], ["intracellular", "ANATOMY", 481, 494], ["cells", "ANATOMY", 577, 582], ["organs", "ORGAN", 104, 110], ["cells", "CELL", 140, 145], ["\u2423\u2424 cytotoxic T lymphocytes", "CELL", 200, 226], ["CTLs", "CELL", 228, 232], ["V\u24259V\u24262 T cells", "CELL", 285, 299], ["\u2425\u2426 T cells", "CELL", 359, 369], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 373, 378], ["ing killer T cells", "CELL", 420, 438], ["NK cells", "CELL", 440, 448], ["macrophages", "CELL", 453, 464], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 481, 494], ["host cells", "CELL", 572, 582], ["non-cytolytic antiviral molecules", "PROTEIN", 17, 50], ["classical \u2423\u2424 cytotoxic T lymphocytes", "CELL_TYPE", 190, 226], ["CTLs", "CELL_TYPE", 228, 232], ["V\u24259V\u24262 T cells", "CELL_LINE", 285, 299], ["\u2425\u2426 T cells", "CELL_TYPE", 359, 369], ["IFN", "PROTEIN", 373, 376], ["\u2425", "PROTEIN", 377, 378], ["ing killer T cells", "CELL_TYPE", 420, 438], ["NK cells", "CELL_TYPE", 440, 448], ["macrophages", "CELL_TYPE", 453, 464], ["host cells", "CELL_TYPE", 572, 582], ["V\u24259V", "SPECIES", 285, 289], ["the non-cytolytic antiviral molecules", "TREATMENT", 13, 50], ["the infectious process", "PROBLEM", 72, 94], ["Non-cytolytic antiviral immunity", "PROBLEM", 240, 272], ["known antiviral activities", "PROBLEM", 320, 346], ["IFN", "TEST", 373, 376], ["a key molecule", "PROBLEM", 379, 393], ["activat", "TEST", 412, 419], ["macrophages", "PROBLEM", 453, 464], ["intracellular pathways", "TREATMENT", 481, 503], ["viral replication", "TREATMENT", 518, 535], ["direct cytolytic effects", "PROBLEM", 544, 568], ["infectious", "OBSERVATION", 76, 86], ["main", "OBSERVATION_MODIFIER", 303, 307], ["antiviral activities", "OBSERVATION", 326, 346]]], ["In vitro, the noncytolytic antiviral activity of interferons has been demonstrated in infections with HCV, hepatitis B virus (HBV), herpesviruses, orthopoxviruses, picornaviruses, retroviruses, influenza and other type of viruses (reviewed in [21, 24] ).", [["infections", "DISEASE", 86, 96], ["HCV, hepatitis B", "DISEASE", 102, 118], ["picornaviruses, retroviruses", "DISEASE", 164, 192], ["influenza", "DISEASE", 194, 203], ["interferons", "GENE_OR_GENE_PRODUCT", 49, 60], ["HCV", "ORGANISM", 102, 105], ["hepatitis B virus", "ORGANISM", 107, 124], ["HBV", "ORGANISM", 126, 129], ["herpesviruses", "ORGANISM", 132, 145], ["orthopoxviruses", "GENE_OR_GENE_PRODUCT", 147, 162], ["retroviruses", "ORGANISM", 180, 192], ["interferons", "PROTEIN", 49, 60], ["hepatitis B virus", "SPECIES", 107, 124], ["HCV", "SPECIES", 102, 105], ["hepatitis B virus", "SPECIES", 107, 124], ["HBV", "SPECIES", 126, 129], ["the noncytolytic antiviral activity of interferons", "TREATMENT", 10, 60], ["infections", "PROBLEM", 86, 96], ["HCV", "PROBLEM", 102, 105], ["hepatitis B virus", "PROBLEM", 107, 124], ["HBV", "PROBLEM", 126, 129], ["herpesviruses", "PROBLEM", 132, 145], ["orthopoxviruses", "PROBLEM", 147, 162], ["picornaviruses", "PROBLEM", 164, 178], ["retroviruses", "PROBLEM", 180, 192], ["influenza", "PROBLEM", 194, 203], ["viruses", "PROBLEM", 222, 229], ["infections", "OBSERVATION", 86, 96]]], ["In hepatitis B-transgenic mice, IFN-\u2425 released by CD8 T cells is able to diminish the HBV gene expression and replication and activates hepatocytes to clear the virus through a non-cytolytic pathway [25] .", [["CD8 T cells", "ANATOMY", 50, 61], ["hepatocytes", "ANATOMY", 136, 147], ["hepatitis B", "DISEASE", 3, 14], ["hepatitis B-transgenic mice", "ORGANISM", 3, 30], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 32, 37], ["CD8 T cells", "CELL", 50, 61], ["HBV", "ORGANISM", 86, 89], ["hepatocytes", "CELL", 136, 147], ["IFN", "PROTEIN", 32, 35], ["\u2425", "PROTEIN", 36, 37], ["CD8 T cells", "CELL_TYPE", 50, 61], ["hepatocytes", "CELL_TYPE", 136, 147], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["HBV", "SPECIES", 86, 89], ["hepatitis B", "TEST", 3, 14], ["IFN", "TEST", 32, 35], ["the HBV gene expression", "TREATMENT", 82, 105], ["hepatitis", "OBSERVATION", 3, 12]]], ["In the acute phase of HCV infection, the ability of T cells to produce IFN-\u2425 is associated with virus clearance [26] .", [["T cells", "ANATOMY", 52, 59], ["HCV infection", "DISEASE", 22, 35], ["HCV", "ORGANISM", 22, 25], ["T cells", "CELL", 52, 59], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 71, 76], ["T cells", "CELL_TYPE", 52, 59], ["IFN", "PROTEIN", 71, 74], ["HCV", "SPECIES", 22, 25], ["HCV infection", "PROBLEM", 22, 35], ["T cells", "PROBLEM", 52, 59], ["IFN", "TEST", 71, 74], ["virus clearance", "PROBLEM", 96, 111], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["phase", "OBSERVATION_MODIFIER", 13, 18], ["HCV", "OBSERVATION_MODIFIER", 22, 25], ["infection", "OBSERVATION", 26, 35]]], ["Recently, it has been shown that NS3 peptide-stimulated CD8 T cells release IFN-\u2425 and reduce HCV RNA replication activity [27] .", [["CD8 T cells", "ANATOMY", 56, 67], ["NS3 peptide", "GENE_OR_GENE_PRODUCT", 33, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 56, 59], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 76, 81], ["HCV", "ORGANISM", 93, 96], ["CD8 T cells", "CELL_TYPE", 56, 67], ["IFN", "PROTEIN", 76, 79], ["HCV", "SPECIES", 93, 96], ["NS3 peptide", "TREATMENT", 33, 44], ["stimulated CD8 T cells", "TREATMENT", 45, 67], ["IFN", "TEST", 76, 79]]], ["Generally, in chimpanzees (Pan troglodytes), the appearance of CD8positive CTLs is better correlated with protection against HCV than the antibody response [28] .", [["chimpanzees", "ORGANISM", 14, 25], ["Pan troglodytes", "ORGANISM", 27, 42], ["HCV", "ORGANISM", 125, 128], ["CD8positive CTLs", "CELL_TYPE", 63, 79], ["Pan troglodytes", "SPECIES", 27, 42], ["Pan troglodytes", "SPECIES", 27, 42], ["HCV", "SPECIES", 125, 128], ["CD8positive CTLs", "PROBLEM", 63, 79], ["HCV", "PROBLEM", 125, 128], ["the antibody response", "TEST", 134, 155]]], ["This is compatible with the idea that the production of IFN-\u2425 by CD8-positive T-lymphocytes may contribute to the resolution of the infection [28] .", [["CD8-positive T-lymphocytes", "ANATOMY", 65, 91], ["infection", "DISEASE", 132, 141], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 56, 61], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["IFN", "PROTEIN", 56, 59], ["CD8-positive T-lymphocytes", "CELL_TYPE", 65, 91], ["IFN", "TEST", 56, 59], ["CD8", "TEST", 65, 68], ["the infection", "PROBLEM", 128, 141], ["compatible with", "UNCERTAINTY", 8, 23], ["infection", "OBSERVATION", 132, 141]]], ["Despite the potent interferon effects, the majority of Fig. 3 .", [["interferon", "PROTEIN", 19, 29], ["the potent interferon effects", "TREATMENT", 8, 37], ["potent", "OBSERVATION_MODIFIER", 12, 18], ["interferon", "OBSERVATION", 19, 29]]], ["In contrast to \u2423\u2424 T lymphocytes or CD3-negative cells, a substantial proportion of activated V\u24262 T lymphocytes produce multiple cytokines.", [["\u2423\u2424 T lymphocytes", "ANATOMY", 15, 31], ["CD3-negative cells", "ANATOMY", 35, 53], ["V\u24262 T lymphocytes", "ANATOMY", 93, 110], ["\u2423\u2424 T lymphocytes", "CELL", 15, 31], ["CD3", "GENE_OR_GENE_PRODUCT", 35, 38], ["V\u24262 T lymphocytes", "CELL", 93, 110], ["\u2423\u2424 T lymphocytes", "CELL_TYPE", 15, 31], ["CD3-negative cells", "CELL_TYPE", 35, 53], ["activated V\u24262 T lymphocytes", "CELL_TYPE", 83, 110], ["cytokines", "PROTEIN", 128, 137], ["CD3", "TEST", 35, 38], ["activated V", "PROBLEM", 83, 94], ["multiple cytokines", "PROBLEM", 119, 137], ["lymphocytes", "ANATOMY", 20, 31], ["CD3", "ANATOMY", 35, 38], ["negative cells", "OBSERVATION", 39, 53], ["multiple", "OBSERVATION_MODIFIER", 119, 127], ["cytokines", "OBSERVATION", 128, 137]]], ["Human PBMCs were incubated (24 h) in culture medium with of 128 M sodium pamidronate and the IFN-\u2425 and TNF-\u2423 intracellular presence was assessed by flow cytometry.", [["PBMCs", "ANATOMY", 6, 11], ["intracellular", "ANATOMY", 109, 122], ["sodium pamidronate", "CHEMICAL", 66, 84], ["sodium pamidronate", "CHEMICAL", 66, 84], ["Human", "ORGANISM", 0, 5], ["PBMCs", "CELL", 6, 11], ["sodium pamidronate", "SIMPLE_CHEMICAL", 66, 84], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 93, 98], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 103, 108], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 109, 122], ["Human PBMCs", "CELL_TYPE", 0, 11], ["IFN", "PROTEIN", 93, 96], ["TNF", "PROTEIN", 103, 106], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human PBMCs", "TEST", 0, 11], ["culture medium", "TEST", 37, 51], ["128 M sodium pamidronate", "TREATMENT", 60, 84], ["the IFN", "TEST", 89, 96], ["TNF", "TEST", 103, 106], ["intracellular presence", "PROBLEM", 109, 131], ["flow cytometry", "TEST", 148, 162]]], ["During the last 4 h of incubation, brefeldin A (10 g/ml) was present to block the cytokine release from cells.", [["cells", "ANATOMY", 104, 109], ["brefeldin A", "CHEMICAL", 35, 46], ["brefeldin A", "CHEMICAL", 35, 46], ["brefeldin A", "SIMPLE_CHEMICAL", 35, 46], ["cells", "CELL", 104, 109], ["cytokine", "PROTEIN", 82, 90], ["incubation", "TREATMENT", 23, 33]]], ["Polyclonal stimulation with concanavalin A (not shown) generated a very similar pattern-that is large numbers of V\u24262+ CD3+ double producers (in contrast to predominant single producers in the \u2423\u2424 + CD3+ and V\u24262-CD3-pools) with the exception of substantially larger amounts of single-TNF-\u2423-positive \u2423\u2424 T cells.", [["\u2423\u2424 + CD3+", "ANATOMY", 192, 201], ["V\u24262-CD3-pools", "ANATOMY", 206, 219], ["\u2423\u2424 T cells", "ANATOMY", 297, 307], ["concanavalin A", "CHEMICAL", 28, 42], ["concanavalin A", "SIMPLE_CHEMICAL", 28, 42], ["V\u24262", "GENE_OR_GENE_PRODUCT", 113, 116], ["CD3", "GENE_OR_GENE_PRODUCT", 118, 121], ["CD3", "GENE_OR_GENE_PRODUCT", 197, 200], ["V\u24262", "GENE_OR_GENE_PRODUCT", 206, 209], ["CD3", "GENE_OR_GENE_PRODUCT", 210, 213], ["TNF", "GENE_OR_GENE_PRODUCT", 282, 285], ["\u2423-", "GENE_OR_GENE_PRODUCT", 286, 288], ["V\u24262", "PROTEIN", 113, 116], ["CD3", "PROTEIN", 118, 121], ["CD3", "PROTEIN", 197, 200], ["V\u24262", "PROTEIN", 206, 209], ["CD3", "PROTEIN", 210, 213], ["single-TNF-\u2423-positive \u2423\u2424 T cells", "CELL_LINE", 275, 307], ["Polyclonal stimulation with concanavalin A", "TREATMENT", 0, 42], ["double producers", "PROBLEM", 123, 139], ["CD3", "TEST", 197, 200], ["V\u24262", "TEST", 206, 209], ["TNF", "TEST", 282, 285], ["large", "OBSERVATION_MODIFIER", 96, 101], ["substantially", "OBSERVATION_MODIFIER", 243, 256], ["larger", "OBSERVATION_MODIFIER", 257, 263], ["amounts", "OBSERVATION_MODIFIER", 264, 271]]], ["The cytokine production by the \u2423\u2424+ CD3+ or V\u24262-CD3-cells in pamidronate-stimulated cultures was inhibited by anti-IFN-\u2425 mAbs suggesting that IFN-\u2425 released by pamidronate-stimulated V\u24259V\u24262 T cells may be an important factor in the induction of cytokine synthesis by the tested non-V\u24259V\u24262 T cell pools.Non-cytolytic antiviral immunity mediated by V\u24259V\u24262 T cellspatients become persistently infected with HCV.", [["\u2423\u2424+ CD3+ or V\u24262-CD3-cells", "ANATOMY", 31, 56], ["cultures", "ANATOMY", 83, 91], ["V\u24259V\u24262 T cells", "ANATOMY", 182, 196], ["non-V\u24259V\u24262 T cell", "ANATOMY", 277, 294], ["T cellspatients", "ANATOMY", 353, 368], ["pamidronate", "CHEMICAL", 60, 71], ["pamidronate", "CHEMICAL", 159, 170], ["pamidronate", "CHEMICAL", 60, 71], ["pamidronate", "CHEMICAL", 159, 170], ["\u2423\u2424", "GENE_OR_GENE_PRODUCT", 31, 33], ["CD3", "GENE_OR_GENE_PRODUCT", 35, 38], ["V\u24262", "GENE_OR_GENE_PRODUCT", 43, 46], ["CD3", "GENE_OR_GENE_PRODUCT", 47, 50], ["pamidronate", "SIMPLE_CHEMICAL", 60, 71], ["anti-IFN-\u2425 mAbs", "GENE_OR_GENE_PRODUCT", 109, 124], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 141, 146], ["pamidronate", "SIMPLE_CHEMICAL", 159, 170], ["V\u24259V\u24262 T cells", "CELL", 182, 196], ["T cell", "CELL", 288, 294], ["HCV", "ORGANISM", 403, 406], ["cytokine", "PROTEIN", 4, 12], ["\u2423\u2424+ CD3+ or V\u24262-CD3-cells", "CELL_LINE", 31, 56], ["pamidronate-stimulated cultures", "CELL_LINE", 60, 91], ["anti-IFN", "PROTEIN", 109, 117], ["IFN", "PROTEIN", 141, 144], ["V\u24259V\u24262 T cells", "CELL_LINE", 182, 196], ["cytokine", "PROTEIN", 244, 252], ["V\u24259V", "SPECIES", 346, 350], ["HCV", "SPECIES", 403, 406], ["The cytokine production", "TEST", 0, 23], ["the \u2423\u2424", "TEST", 27, 33], ["CD3", "TEST", 35, 38], ["V\u24262", "TEST", 43, 46], ["pamidronate", "TEST", 60, 71], ["stimulated cultures", "TEST", 72, 91], ["anti-IFN-\u2425 mAbs", "TEST", 109, 124], ["IFN", "TEST", 141, 144], ["pamidronate", "TEST", 159, 170], ["cytokine synthesis", "TREATMENT", 244, 262], ["HCV", "PROBLEM", 403, 406], ["persistently", "OBSERVATION_MODIFIER", 376, 388], ["infected", "OBSERVATION", 389, 397], ["HCV", "OBSERVATION", 403, 406]]], ["This chronic infection is associated with a drastic impairment of IFN-\u2425 production by T cells [29] and a hepatic expansion of HCV-specific CD8-positive T lymphocytes with a regulatory phenotype [30] .", [["T cells", "ANATOMY", 86, 93], ["hepatic", "ANATOMY", 105, 112], ["CD8-positive T lymphocytes", "ANATOMY", 139, 165], ["chronic infection", "DISEASE", 5, 22], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 66, 71], ["T cells", "CELL", 86, 93], ["hepatic", "ORGAN", 105, 112], ["HCV", "ORGANISM", 126, 129], ["CD8", "GENE_OR_GENE_PRODUCT", 139, 142], ["IFN", "PROTEIN", 66, 69], ["T cells", "CELL_TYPE", 86, 93], ["HCV-specific CD8-positive T lymphocytes", "CELL_TYPE", 126, 165], ["HCV", "SPECIES", 126, 129], ["This chronic infection", "PROBLEM", 0, 22], ["a drastic impairment of IFN", "PROBLEM", 42, 69], ["T cells", "PROBLEM", 86, 93], ["a hepatic expansion", "TEST", 103, 122], ["HCV", "TEST", 126, 129], ["specific CD8", "TEST", 130, 142], ["positive T lymphocytes", "PROBLEM", 143, 165], ["chronic", "OBSERVATION_MODIFIER", 5, 12], ["infection", "OBSERVATION", 13, 22], ["drastic", "OBSERVATION_MODIFIER", 44, 51], ["impairment", "OBSERVATION", 52, 62], ["hepatic", "ANATOMY", 105, 112], ["HCV", "OBSERVATION", 126, 129]]], ["Thus, the induction of IFN-\u2425 production by V\u24259V\u24262 T lymphocytes could represent a new strategy to inhibit viral replication and to support the Th1-type immune response.Non-cytolytic antiviral immunity mediated by V\u24259V\u24262 T cellsInterleukin-1\u2423 (IL-1\u2423) produced by activated \u2425\u2426 T cells can have either stimulatory or inhibitory effects on HIV infection [31, 32] .", [["V\u24259V\u24262 T lymphocytes", "ANATOMY", 43, 63], ["\u2425\u2426 T cells", "ANATOMY", 272, 282], ["HIV infection", "DISEASE", 336, 349], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 23, 28], ["V\u24259V\u24262 T lymphocytes", "CELL", 43, 63], ["Interleukin-1\u2423", "GENE_OR_GENE_PRODUCT", 227, 241], ["IL-1\u2423", "GENE_OR_GENE_PRODUCT", 243, 248], ["\u2425\u2426 T cells", "CELL", 272, 282], ["HIV", "ORGANISM", 336, 339], ["IFN", "PROTEIN", 23, 26], ["V\u24259V\u24262 T lymphocytes", "CELL_LINE", 43, 63], ["V\u24259V\u24262 T cells", "CELL_LINE", 213, 227], ["Interleukin-1\u2423 (IL-1\u2423", "PROTEIN", 227, 248], ["\u2425\u2426 T cells", "CELL_TYPE", 272, 282], ["HIV", "SPECIES", 336, 339], ["IFN", "TEST", 23, 26], ["V", "TEST", 43, 44], ["T lymphocytes", "PROBLEM", 50, 63], ["viral replication", "TREATMENT", 106, 123], ["Non-cytolytic antiviral immunity", "PROBLEM", 168, 200], ["Interleukin", "TEST", 227, 238], ["IL", "TEST", 243, 245], ["activated \u2425\u2426 T cells", "PROBLEM", 262, 282], ["HIV infection", "PROBLEM", 336, 349]]], ["Also, it has been shown that the cytomegalovirus (CMV) infection is reduced in marrow stromal cells that either secrete IL-1 or are treated with exogenous IL-1 [33] .", [["marrow stromal cells", "ANATOMY", 79, 99], ["cytomegalovirus (CMV) infection", "DISEASE", 33, 64], ["cytomegalovirus", "ORGANISM", 33, 48], ["CMV", "ORGANISM", 50, 53], ["marrow stromal cells", "CELL", 79, 99], ["IL-1", "GENE_OR_GENE_PRODUCT", 120, 124], ["IL-1", "GENE_OR_GENE_PRODUCT", 155, 159], ["marrow stromal cells", "CELL_TYPE", 79, 99], ["IL-1", "PROTEIN", 120, 124], ["CMV", "SPECIES", 50, 53], ["the cytomegalovirus (CMV) infection", "PROBLEM", 29, 64], ["marrow stromal cells", "PROBLEM", 79, 99], ["exogenous IL", "TREATMENT", 145, 157], ["cytomegalovirus", "OBSERVATION", 33, 48], ["reduced", "OBSERVATION_MODIFIER", 68, 75], ["marrow stromal cells", "OBSERVATION", 79, 99]]], ["Stimulated \u2425\u2426 T cells also produce interleukin-6 (IL-6), a potent lymphoid cell growth factor, which affects Blymphocytes, T-lymphocytes or hybridoma cells, and may influence cytotoxic T cells in combination with other factors such as IL-2 and IFN-\u2425.", [["\u2425\u2426 T cells", "ANATOMY", 11, 21], ["lymphoid cell", "ANATOMY", 66, 79], ["Blymphocytes", "ANATOMY", 109, 121], ["T-lymphocytes", "ANATOMY", 123, 136], ["hybridoma cells", "ANATOMY", 140, 155], ["cytotoxic T cells", "ANATOMY", 175, 192], ["\u2425\u2426 T cells", "CELL", 11, 21], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 35, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 50, 54], ["lymphoid cell", "CELL", 66, 79], ["Blymphocytes", "CELL", 109, 121], ["T-lymphocytes", "CELL", 123, 136], ["hybridoma cells", "CELL", 140, 155], ["cytotoxic T cells", "CELL", 175, 192], ["IL-2", "GENE_OR_GENE_PRODUCT", 235, 239], ["IFN", "GENE_OR_GENE_PRODUCT", 244, 247], ["\u2425\u2426 T cells", "CELL_TYPE", 11, 21], ["interleukin-6 (IL-6", "PROTEIN", 35, 54], ["lymphoid cell growth factor", "PROTEIN", 66, 93], ["Blymphocytes", "CELL_TYPE", 109, 121], ["T-lymphocytes", "CELL_TYPE", 123, 136], ["hybridoma cells", "CELL_LINE", 140, 155], ["cytotoxic T cells", "CELL_TYPE", 175, 192], ["IL", "PROTEIN", 235, 237], ["IFN", "PROTEIN", 244, 247], ["interleukin", "TEST", 35, 46], ["IL", "TEST", 50, 52], ["a potent lymphoid cell growth factor", "PROBLEM", 57, 93], ["Blymphocytes", "TEST", 109, 121], ["hybridoma cells", "PROBLEM", 140, 155], ["cytotoxic T cells", "PROBLEM", 175, 192], ["IL", "TEST", 235, 237], ["potent", "OBSERVATION_MODIFIER", 59, 65], ["lymphoid cell", "OBSERVATION", 66, 79], ["lymphocytes", "ANATOMY", 125, 136], ["hybridoma cells", "OBSERVATION", 140, 155], ["cytotoxic T cells", "OBSERVATION", 175, 192]]], ["IL-6 production by skin fibroblasts that support the replication of dengue virus and other flaviviruses in vivo may be an important factor in controlling flavivirus infections [34] .", [["skin fibroblasts", "ANATOMY", 19, 35], ["dengue", "DISEASE", 68, 74], ["flaviviruses", "DISEASE", 91, 103], ["flavivirus infections", "DISEASE", 154, 175], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["skin fibroblasts", "CELL", 19, 35], ["dengue virus", "ORGANISM", 68, 80], ["flavivirus", "ORGANISM", 154, 164], ["IL-6", "PROTEIN", 0, 4], ["skin fibroblasts", "CELL_TYPE", 19, 35], ["dengue virus", "SPECIES", 68, 80], ["dengue virus", "SPECIES", 68, 80], ["IL", "TREATMENT", 0, 2], ["skin fibroblasts", "PROBLEM", 19, 35], ["dengue virus", "PROBLEM", 68, 80], ["other flaviviruses", "PROBLEM", 85, 103], ["flavivirus infections", "PROBLEM", 154, 175], ["skin", "ANATOMY", 19, 23], ["fibroblasts", "OBSERVATION", 24, 35]]], ["Moreover, IL-6 was shown to strengthen the retinoic acid-mediated suppression of HIV-1 replication in macrophages [32] .Non-cytolytic antiviral immunity mediated by V\u24259V\u24262 T cellsThe granulocyte-macrophage colony-stimulating factor (GM-CSF) produced by activated \u2425\u2426 T cells is a potent species-specific stimulator of precursors of granulocytes, macrophages and eosinophils.", [["macrophages", "ANATOMY", 102, 113], ["V\u24259V\u24262 T cells", "ANATOMY", 165, 179], ["\u2425\u2426 T cells", "ANATOMY", 263, 273], ["granulocytes", "ANATOMY", 331, 343], ["macrophages", "ANATOMY", 345, 356], ["eosinophils", "ANATOMY", 361, 372], ["retinoic acid-mediated", "CHEMICAL", 43, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 10, 14], ["retinoic acid-mediated", "SIMPLE_CHEMICAL", 43, 65], ["HIV-1", "ORGANISM", 81, 86], ["macrophages", "CELL", 102, 113], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 183, 231], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 233, 239], ["\u2425\u2426 T cells", "CELL", 263, 273], ["granulocytes", "CELL", 331, 343], ["macrophages", "CELL", 345, 356], ["eosinophils", "CELL", 361, 372], ["IL-6", "PROTEIN", 10, 14], ["macrophages", "CELL_TYPE", 102, 113], ["V\u24259V\u24262 T cells", "CELL_LINE", 165, 179], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 183, 231], ["GM", "PROTEIN", 233, 235], ["CSF", "PROTEIN", 236, 239], ["activated \u2425\u2426 T cells", "CELL_TYPE", 253, 273], ["granulocytes", "CELL_TYPE", 331, 343], ["macrophages", "CELL_TYPE", 345, 356], ["eosinophils", "CELL_TYPE", 361, 372], ["HIV-1", "SPECIES", 81, 86], ["HIV-1", "SPECIES", 81, 86], ["V\u24259V", "SPECIES", 165, 169], ["HIV", "PROBLEM", 81, 84], ["Non-cytolytic antiviral immunity", "TEST", 120, 152], ["T cells", "TEST", 172, 179], ["The granulocyte", "TEST", 179, 194], ["macrophage colony", "TEST", 195, 212], ["stimulating factor", "TEST", 213, 231], ["GM-CSF", "TEST", 233, 239], ["activated \u2425\u2426 T cells", "PROBLEM", 253, 273], ["a potent species", "PROBLEM", 277, 293], ["granulocytes", "TEST", 331, 343], ["macrophages", "TEST", 345, 356], ["eosinophils", "TEST", 361, 372], ["granulocyte", "ANATOMY", 183, 194], ["macrophage colony", "OBSERVATION", 195, 212]]], ["Antiviral effects of GM-CSF have been reported in dengue infections [34] .", [["GM", "CHEMICAL", 21, 23], ["dengue infections", "DISEASE", 50, 67], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 21, 27], ["CSF", "PROTEIN", 24, 27], ["dengue", "SPECIES", 50, 56], ["Antiviral effects", "TREATMENT", 0, 17], ["GM-CSF", "TEST", 21, 27], ["dengue infections", "PROBLEM", 50, 67]]], ["GM-CSF can boost antiviral humoral immunity to influenza and simian immunodeficiency virus (SIV) [35] , increase humoral and cellular immune responses against herpes simplex virus-2 (HSV-2) [36] and improve protection against Epstein-Barr virus (EBV)-induced lymphoproliferative disorders [37] .", [["cellular", "ANATOMY", 125, 133], ["GM", "CHEMICAL", 0, 2], ["influenza and simian immunodeficiency virus", "DISEASE", 47, 90], ["herpes simplex virus", "DISEASE", 159, 179], ["Epstein-Barr virus (EBV)", "DISEASE", 226, 250], ["lymphoproliferative disorders", "DISEASE", 259, 288], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["simian immunodeficiency virus", "ORGANISM", 61, 90], ["SIV", "ORGANISM", 92, 95], ["cellular", "CELL", 125, 133], ["herpes simplex virus-2", "ORGANISM", 159, 181], ["HSV-2", "ORGANISM", 183, 188], ["Epstein-Barr virus", "ORGANISM", 226, 244], ["EBV", "ORGANISM", 246, 249], ["simian immunodeficiency virus", "SPECIES", 61, 90], ["herpes simplex virus-2", "SPECIES", 159, 181], ["HSV-2", "SPECIES", 183, 188], ["simian immunodeficiency virus", "SPECIES", 61, 90], ["SIV", "SPECIES", 92, 95], ["herpes simplex virus-2", "SPECIES", 159, 181], ["HSV", "SPECIES", 183, 186], ["Epstein-Barr virus", "SPECIES", 226, 244], ["EBV", "SPECIES", 246, 249], ["GM", "TEST", 0, 2], ["CSF", "PROBLEM", 3, 6], ["antiviral humoral immunity", "TREATMENT", 17, 43], ["influenza", "PROBLEM", 47, 56], ["simian immunodeficiency virus", "PROBLEM", 61, 90], ["cellular immune responses", "TEST", 125, 150], ["herpes simplex virus", "PROBLEM", 159, 179], ["HSV", "TEST", 183, 186], ["Epstein-Barr virus", "PROBLEM", 226, 244], ["lymphoproliferative disorders", "PROBLEM", 259, 288], ["Barr virus", "OBSERVATION", 234, 244]]], ["Also thrombopoietin (stimulates the proliferation and maturation of megakaryocytes) and oncostatin M (growth regulating cytokine) are secreted by activated \u2425\u2426 T cells, but their effect on viral replication remains unclear.Non-cytolytic antiviral immunity mediated by V\u24259V\u24262 T cellsChemokines, a superfamily of proinflammatory cytokines, are released by many activated \u2425\u2426 T cells.", [["megakaryocytes", "ANATOMY", 68, 82], ["\u2425\u2426 T cells", "ANATOMY", 156, 166], ["V\u24259V\u24262 T cells", "ANATOMY", 267, 281], ["\u2425\u2426 T cells", "ANATOMY", 368, 378], ["thrombopoietin", "GENE_OR_GENE_PRODUCT", 5, 19], ["megakaryocytes", "CELL", 68, 82], ["oncostatin M", "GENE_OR_GENE_PRODUCT", 88, 100], ["\u2425\u2426 T cells", "CELL", 156, 166], ["\u2425\u2426 T cells", "CELL", 368, 378], ["thrombopoietin", "PROTEIN", 5, 19], ["megakaryocytes", "CELL_TYPE", 68, 82], ["oncostatin M", "PROTEIN", 88, 100], ["growth regulating cytokine", "PROTEIN", 102, 128], ["\u2425\u2426 T cells", "CELL_TYPE", 156, 166], ["V\u24259V\u24262 T cells", "CELL_LINE", 267, 281], ["Chemokines", "PROTEIN", 281, 291], ["proinflammatory cytokines", "PROTEIN", 310, 335], ["activated \u2425\u2426 T cells", "CELL_TYPE", 358, 378], ["V\u24259V", "SPECIES", 267, 271], ["thrombopoietin", "TREATMENT", 5, 19], ["the proliferation", "PROBLEM", 32, 49], ["megakaryocytes)", "PROBLEM", 68, 83], ["oncostatin M (growth regulating cytokine", "TREATMENT", 88, 128], ["activated \u2425\u2426 T cells", "TREATMENT", 146, 166], ["viral replication", "TREATMENT", 188, 205], ["Non-cytolytic antiviral immunity", "TREATMENT", 222, 254], ["proinflammatory cytokines", "PROBLEM", 310, 335], ["thrombopoietin", "OBSERVATION", 5, 19], ["megakaryocytes", "ANATOMY", 68, 82], ["viral replication", "OBSERVATION", 188, 205], ["proinflammatory cytokines", "OBSERVATION", 310, 335]]], ["Chemokines act primarily as chemoattractants and activators of specific types of leukocytes.", [["leukocytes", "ANATOMY", 81, 91], ["leukocytes", "CELL", 81, 91], ["Chemokines", "PROTEIN", 0, 10], ["chemoattractants", "PROTEIN", 28, 44], ["leukocytes", "CELL_TYPE", 81, 91], ["leukocytes", "PROBLEM", 81, 91], ["leukocytes", "OBSERVATION", 81, 91]]], ["Some chemokines (such as the \u2424-chemokines MIP-1\u2423, MIP-1\u2424 and RANTES) influence directly the rate of HIV replication [38] .", [["MIP-1\u2423", "GENE_OR_GENE_PRODUCT", 42, 48], ["MIP-1", "GENE_OR_GENE_PRODUCT", 50, 55], ["RANTES", "GENE_OR_GENE_PRODUCT", 61, 67], ["HIV", "ORGANISM", 100, 103], ["chemokines", "PROTEIN", 5, 15], ["\u2424-chemokines MIP-1\u2423", "PROTEIN", 29, 48], ["MIP", "PROTEIN", 50, 53], ["RANTES", "PROTEIN", 61, 67], ["HIV", "SPECIES", 100, 103], ["Some chemokines", "PROBLEM", 0, 15], ["the \u2424-chemokines MIP", "TEST", 25, 45], ["MIP", "TEST", 50, 53], ["HIV replication", "TREATMENT", 100, 115], ["chemokines", "OBSERVATION", 5, 15]]], ["The stromal-derived factor (SDF-1) that blocks the entry of CXCR4-dependent (T cell-tropic) HIV-1 isolates [39] has been identified as a ligand for LESTR/fusin [40] .", [["T cell", "ANATOMY", 77, 83], ["stromal-derived factor", "GENE_OR_GENE_PRODUCT", 4, 26], ["SDF-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["CXCR4", "GENE_OR_GENE_PRODUCT", 60, 65], ["HIV-1", "ORGANISM", 92, 97], ["LESTR", "GENE_OR_GENE_PRODUCT", 148, 153], ["fusin", "GENE_OR_GENE_PRODUCT", 154, 159], ["stromal-derived factor", "PROTEIN", 4, 26], ["SDF", "PROTEIN", 28, 31], ["CXCR4", "PROTEIN", 60, 65], ["LESTR", "PROTEIN", 148, 153], ["HIV-1", "SPECIES", 92, 97], ["HIV-1", "SPECIES", 92, 97], ["CXCR4", "TEST", 60, 65], ["HIV", "TEST", 92, 95], ["LESTR/fusin", "TREATMENT", 148, 159], ["stromal", "ANATOMY", 4, 11]]], ["RANTES and MCP-3 inhibit T cell-tropic HIV-1 isolates [41] and the macrophage chemotactic protein (MDC, macrophage-derived chemokine) can also block HIV-1 entry [42] .", [["T cell", "ANATOMY", 25, 31], ["RANTES", "GENE_OR_GENE_PRODUCT", 0, 6], ["MCP-3", "GENE_OR_GENE_PRODUCT", 11, 16], ["T cell", "CELL", 25, 31], ["HIV-1", "ORGANISM", 39, 44], ["macrophage chemotactic protein", "GENE_OR_GENE_PRODUCT", 67, 97], ["MDC", "GENE_OR_GENE_PRODUCT", 99, 102], ["macrophage", "CELL", 104, 114], ["HIV-1", "ORGANISM", 149, 154], ["RANTES", "PROTEIN", 0, 6], ["MCP-3", "PROTEIN", 11, 16], ["macrophage chemotactic protein", "PROTEIN", 67, 97], ["MDC", "PROTEIN", 99, 102], ["macrophage-derived chemokine", "PROTEIN", 104, 132], ["HIV-1", "SPECIES", 39, 44], ["HIV-1", "SPECIES", 149, 154], ["HIV-1", "SPECIES", 39, 44], ["HIV-1", "SPECIES", 149, 154], ["RANTES", "TEST", 0, 6], ["MCP", "TEST", 11, 14], ["T cell", "TEST", 25, 31], ["tropic HIV", "TEST", 32, 42], ["the macrophage chemotactic protein", "TEST", 63, 97], ["MDC", "TEST", 99, 102], ["macrophage-derived chemokine)", "TREATMENT", 104, 133]]], ["Other CD8 antiviral factors (e.g., CAF) inhibit HIV-1 transcription [43] .", [["CD8", "GENE_OR_GENE_PRODUCT", 6, 9], ["HIV-1", "GENE_OR_GENE_PRODUCT", 48, 53], ["CD8 antiviral factors", "PROTEIN", 6, 27], ["CAF", "PROTEIN", 35, 38], ["HIV-1", "SPECIES", 48, 53], ["HIV-1", "SPECIES", 48, 53], ["Other CD8 antiviral factors", "PROBLEM", 0, 27], ["CD8 antiviral", "OBSERVATION", 6, 19]]], ["The post-integration mode of action makes CAF distinct from \u2424-chemokines and similar to IL-16 [44] .", [["CAF", "CHEMICAL", 42, 45], ["CAF", "CANCER", 42, 45], ["IL-16", "GENE_OR_GENE_PRODUCT", 88, 93], ["\u2424-chemokines", "PROTEIN", 60, 72], ["IL", "PROTEIN", 88, 90], ["CAF distinct from \u2424-chemokines", "PROBLEM", 42, 72], ["IL", "TEST", 88, 90]]], ["Importantly, antigen-stimulated V\u24259V\u24262 T cells produce the HIV-inhibitory \u2424-chemokines (MIP-1\u2423, MIP-1\u2424, and RANTES) [45, 46] that block both CCR5 co-receptor-dependent (e.g., HIV-1 BAL ) and CXCR4 co-receptor-dependent (e.g., HIV-1 LAI ) viral isolates [45] .", [["V\u24259V\u24262 T cells", "ANATOMY", 32, 46], ["antigen", "GENE_OR_GENE_PRODUCT", 13, 20], ["HIV", "ORGANISM", 59, 62], ["MIP-1\u2423", "GENE_OR_GENE_PRODUCT", 88, 94], ["MIP-1\u2424", "GENE_OR_GENE_PRODUCT", 96, 102], ["RANTES", "GENE_OR_GENE_PRODUCT", 108, 114], ["CCR5", "GENE_OR_GENE_PRODUCT", 141, 145], ["HIV-1", "ORGANISM", 175, 180], ["BAL", "GENE_OR_GENE_PRODUCT", 181, 184], ["CXCR4", "GENE_OR_GENE_PRODUCT", 191, 196], ["HIV-1 LAI", "ORGANISM", 226, 235], ["V\u24259V\u24262 T cells", "CELL_LINE", 32, 46], ["HIV-inhibitory \u2424-chemokines", "PROTEIN", 59, 86], ["MIP", "PROTEIN", 88, 91], ["1\u2423", "PROTEIN", 92, 94], ["MIP", "PROTEIN", 96, 99], ["1\u2424", "PROTEIN", 100, 102], ["RANTES", "PROTEIN", 108, 114], ["CCR5 co-receptor", "PROTEIN", 141, 157], ["CXCR4 co-receptor", "PROTEIN", 191, 208], ["HIV-1", "SPECIES", 175, 180], ["HIV-1", "SPECIES", 226, 231], ["HIV", "SPECIES", 59, 62], ["HIV-1", "SPECIES", 175, 180], ["HIV-1", "SPECIES", 226, 231], ["antigen", "TEST", 13, 20], ["the HIV", "TEST", 55, 62], ["chemokines", "TEST", 76, 86], ["MIP", "TEST", 88, 91], ["MIP", "TEST", 96, 99], ["RANTES", "TEST", 108, 114], ["CCR5 co-receptor", "TEST", 141, 157], ["HIV", "TEST", 175, 178], ["BAL", "TEST", 181, 184], ["CXCR4 co-receptor", "TEST", 191, 208], ["HIV", "TEST", 226, 229], ["viral isolates", "TEST", 238, 252]]], ["However, it is likely that additional, not molecularly defined antiviral activities of \u2425\u2426 T cells contribute to the observed antiviral effects.Non-cytolytic antiviral immunity mediated by V\u24259V\u24262 T cellsAntigen-stimulated V\u24259V\u24262 T cells rapidly establish chemotactic gradients that may shape the host inflammatory response against various pathogens including HIV.", [["\u2425\u2426 T cells", "ANATOMY", 87, 97], ["V\u24259V\u24262 T cells", "ANATOMY", 188, 202], ["V\u24259V\u24262 T cells", "ANATOMY", 221, 235], ["\u2425\u2426 T cells", "CELL", 87, 97], ["HIV", "ORGANISM", 358, 361], ["\u2425\u2426 T cells", "CELL_TYPE", 87, 97], ["V\u24259V\u24262 T cells", "CELL_LINE", 188, 202], ["Antigen-stimulated V\u24259V\u24262 T cells", "CELL_LINE", 202, 235], ["HIV", "SPECIES", 358, 361], ["V\u24259V", "SPECIES", 188, 192], ["HIV", "SPECIES", 358, 361], ["\u2425\u2426 T cells", "PROBLEM", 87, 97], ["the observed antiviral effects", "PROBLEM", 112, 142], ["Non-cytolytic antiviral immunity", "PROBLEM", 143, 175], ["T cells", "TEST", 195, 202], ["Antigen", "TEST", 202, 209], ["stimulated V", "TEST", 210, 222], ["T cells", "PROBLEM", 228, 235], ["chemotactic gradients", "PROBLEM", 254, 275], ["various pathogens", "PROBLEM", 330, 347], ["HIV", "PROBLEM", 358, 361], ["is likely", "UNCERTAINTY", 12, 21], ["antiviral", "OBSERVATION", 63, 72], ["antiviral effects", "OBSERVATION", 125, 142], ["chemotactic gradients", "OBSERVATION", 254, 275], ["host", "OBSERVATION_MODIFIER", 295, 299], ["inflammatory", "OBSERVATION_MODIFIER", 300, 312]]], ["The activation of V\u24259V\u24262 T cells with IPP induces (within 4-12 h) the production of MIP-1\u2423, MIP-1\u2424, and lymphotactin, but not macrophage chemoattractant protein-1 (MCP-1) [46] .", [["V\u24259V\u24262 T cells", "ANATOMY", 18, 32], ["IPP", "CHEMICAL", 38, 41], ["IPP", "CHEMICAL", 38, 41], ["IPP", "SIMPLE_CHEMICAL", 38, 41], ["MIP-1", "GENE_OR_GENE_PRODUCT", 84, 89], ["MIP-1", "GENE_OR_GENE_PRODUCT", 92, 97], ["lymphotactin", "GENE_OR_GENE_PRODUCT", 104, 116], ["macrophage chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 126, 162], ["MCP-1", "GENE_OR_GENE_PRODUCT", 164, 169], ["V\u24259V\u24262 T cells", "CELL_LINE", 18, 32], ["MIP", "PROTEIN", 84, 87], ["MIP-1\u2424", "PROTEIN", 92, 98], ["lymphotactin", "PROTEIN", 104, 116], ["macrophage chemoattractant protein-1 (MCP-1", "PROTEIN", 126, 169], ["IPP induces", "PROBLEM", 38, 49], ["MIP", "TEST", 84, 87], ["MIP", "TEST", 92, 95], ["lymphotactin", "TEST", 104, 116], ["macrophage chemoattractant protein-", "TEST", 126, 161], ["MCP", "TEST", 164, 167]]], ["The induction of MIP-1\u2423 and MIP-1\u2424 is unaffected by IL-4, IL-10, or INF-\u2425, but IPP plus IL-12-induced release of MIP-1\u2423, but not MIP-1\u2424, is blocked by TGF-\u2424.", [["IPP", "CHEMICAL", 79, 82], ["IPP", "CHEMICAL", 79, 82], ["MIP-1", "GENE_OR_GENE_PRODUCT", 17, 22], ["MIP-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["IL-4", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-10", "GENE_OR_GENE_PRODUCT", 58, 63], ["INF-\u2425", "GENE_OR_GENE_PRODUCT", 68, 73], ["IPP", "SIMPLE_CHEMICAL", 79, 82], ["IL-12", "GENE_OR_GENE_PRODUCT", 88, 93], ["MIP-1", "GENE_OR_GENE_PRODUCT", 113, 118], ["MIP-1\u2424", "GENE_OR_GENE_PRODUCT", 129, 135], ["TGF-\u2424.", "GENE_OR_GENE_PRODUCT", 151, 157], ["MIP-1", "PROTEIN", 17, 22], ["MIP-1", "PROTEIN", 28, 33], ["INF", "PROTEIN", 68, 71], ["MIP", "PROTEIN", 113, 116], ["MIP-1\u2424", "PROTEIN", 129, 135], ["TGF", "PROTEIN", 151, 154], ["MIP", "TEST", 17, 20], ["MIP", "TEST", 28, 31], ["IL", "TEST", 52, 54], ["IL", "TEST", 58, 60], ["IPP", "TEST", 79, 82], ["IL", "TEST", 88, 90], ["MIP", "TEST", 113, 116], ["MIP", "TEST", 129, 132], ["TGF", "TEST", 151, 154]]], ["V\u24259V\u24262 T cells also express many \u2424-chemokine receptors including CCR1, CCR5, and CCR8 that can be downregulated by activation stimuli.", [["9V\u24262 T cells", "ANATOMY", 2, 14], ["CCR1", "GENE_OR_GENE_PRODUCT", 65, 69], ["CCR5", "GENE_OR_GENE_PRODUCT", 71, 75], ["CCR8", "GENE_OR_GENE_PRODUCT", 81, 85], ["V\u24259V\u24262 T cells", "CELL_LINE", 0, 14], ["\u2424-chemokine receptors", "PROTEIN", 33, 54], ["CCR1", "PROTEIN", 65, 69], ["CCR5", "PROTEIN", 71, 75], ["CCR8", "PROTEIN", 81, 85], ["V", "TEST", 0, 1], ["CCR1", "TEST", 65, 69], ["CCR5", "TEST", 71, 75], ["CCR8", "TREATMENT", 81, 85], ["activation stimuli", "TEST", 115, 133]]], ["Activating signals for \u2425\u2426 T cells also induce the production of macrophage chemoattractant protein-2 (MCP-2) and MDC.", [["\u2425\u2426 T cells", "ANATOMY", 23, 33], ["\u2425\u2426 T cells", "CELL", 23, 33], ["macrophage chemoattractant protein-2", "GENE_OR_GENE_PRODUCT", 64, 100], ["MCP-2", "GENE_OR_GENE_PRODUCT", 102, 107], ["MDC", "GENE_OR_GENE_PRODUCT", 113, 116], ["\u2425\u2426 T cells", "CELL_TYPE", 23, 33], ["macrophage chemoattractant protein-2", "PROTEIN", 64, 100], ["MCP", "PROTEIN", 102, 105], ["MDC", "PROTEIN", 113, 116], ["\u2425\u2426 T cells", "TREATMENT", 23, 33], ["macrophage chemoattractant protein", "TEST", 64, 98], ["MCP", "TEST", 102, 105]]], ["MCP-2 plays an important role in the inflammatory response of blood monocytes and tissue macrophages and inhibits the replication of HIV-1 via CCR5 [47] .", [["blood monocytes", "ANATOMY", 62, 77], ["tissue macrophages", "ANATOMY", 82, 100], ["MCP-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["blood monocytes", "CELL", 62, 77], ["tissue macrophages", "CELL", 82, 100], ["HIV-1", "ORGANISM", 133, 138], ["CCR5", "GENE_OR_GENE_PRODUCT", 143, 147], ["MCP-2", "PROTEIN", 0, 5], ["blood monocytes", "CELL_TYPE", 62, 77], ["tissue macrophages", "CELL_TYPE", 82, 100], ["CCR5", "PROTEIN", 143, 147], ["HIV-1", "SPECIES", 133, 138], ["HIV-1", "SPECIES", 133, 138], ["MCP", "TEST", 0, 3], ["blood monocytes", "TEST", 62, 77], ["tissue macrophages", "PROBLEM", 82, 100], ["HIV", "TEST", 133, 136], ["inflammatory", "OBSERVATION_MODIFIER", 37, 49], ["blood monocytes", "OBSERVATION", 62, 77], ["tissue macrophages", "OBSERVATION", 82, 100]]], ["MDC is chemotactic for monocytes, dendritic cells, activated lymphocytes, and NK cells and exhibits anti-HIV-1 activity [48] .", [["monocytes", "ANATOMY", 23, 32], ["dendritic cells", "ANATOMY", 34, 49], ["lymphocytes", "ANATOMY", 61, 72], ["NK cells", "ANATOMY", 78, 86], ["MDC", "GENE_OR_GENE_PRODUCT", 0, 3], ["monocytes", "CELL", 23, 32], ["dendritic cells", "CELL", 34, 49], ["lymphocytes", "CELL", 61, 72], ["NK cells", "CELL", 78, 86], ["anti-HIV-1", "GENE_OR_GENE_PRODUCT", 100, 110], ["MDC", "CELL_TYPE", 0, 3], ["monocytes", "CELL_TYPE", 23, 32], ["dendritic cells", "CELL_TYPE", 34, 49], ["activated lymphocytes", "CELL_TYPE", 51, 72], ["NK cells", "CELL_TYPE", 78, 86], ["monocytes", "PROBLEM", 23, 32], ["dendritic cells", "PROBLEM", 34, 49], ["activated lymphocytes", "PROBLEM", 51, 72], ["NK cells", "TEST", 78, 86], ["anti-HIV", "TEST", 100, 108], ["chemotactic for", "UNCERTAINTY", 7, 22], ["dendritic cells", "OBSERVATION", 34, 49], ["lymphocytes", "OBSERVATION", 61, 72], ["NK cells", "OBSERVATION", 78, 86]]], ["Cumulatively, the high levels of proinflammatory cytokines and chemokines with antiviral properties produced by activated V\u24259V\u24262 T cells may influence the progression of HIV disease.Non-cytolytic antiviral immunity mediated by V\u24259V\u24262 T cellsOther interesting IPP-induced molecules include the epithelial neutrophil activating peptide-78 (ENA-78) that is a chemotactic and activating factor for neutrophils, and human GRO (MGSA) that promotes neutrophil chemotaxis and degranulation.", [["V\u24259V\u24262 T cells", "ANATOMY", 122, 136], ["V\u24259V\u24262 T cells", "ANATOMY", 227, 241], ["epithelial", "ANATOMY", 293, 303], ["neutrophils", "ANATOMY", 394, 405], ["neutrophil", "ANATOMY", 442, 452], ["HIV disease", "DISEASE", 170, 181], ["IPP", "CHEMICAL", 259, 262], ["IPP", "CHEMICAL", 259, 262], ["HIV", "ORGANISM", 170, 173], ["IPP", "SIMPLE_CHEMICAL", 259, 262], ["epithelial neutrophil activating peptide-78", "GENE_OR_GENE_PRODUCT", 293, 336], ["ENA-78", "GENE_OR_GENE_PRODUCT", 338, 344], ["neutrophils", "CELL", 394, 405], ["human", "ORGANISM", 411, 416], ["GRO", "GENE_OR_GENE_PRODUCT", 417, 420], ["MGSA", "GENE_OR_GENE_PRODUCT", 422, 426], ["neutrophil", "CELL", 442, 452], ["proinflammatory cytokines", "PROTEIN", 33, 58], ["chemokines", "PROTEIN", 63, 73], ["activated V\u24259V\u24262 T cells", "CELL_LINE", 112, 136], ["V\u24259V\u24262 T cells", "CELL_LINE", 227, 241], ["IPP-induced molecules", "PROTEIN", 259, 280], ["epithelial neutrophil", "CELL_TYPE", 293, 314], ["chemotactic and activating factor", "PROTEIN", 356, 389], ["neutrophils", "CELL_TYPE", 394, 405], ["human GRO", "PROTEIN", 411, 420], ["MGSA", "PROTEIN", 422, 426], ["human", "SPECIES", 411, 416], ["HIV", "SPECIES", 170, 173], ["V\u24259V", "SPECIES", 227, 231], ["human", "SPECIES", 411, 416], ["proinflammatory cytokines", "TREATMENT", 33, 58], ["antiviral properties", "TREATMENT", 79, 99], ["HIV disease", "PROBLEM", 170, 181], ["Non-cytolytic antiviral immunity", "PROBLEM", 182, 214], ["induced molecules", "PROBLEM", 263, 280], ["the epithelial neutrophil activating peptide", "TEST", 289, 333], ["ENA", "TEST", 338, 341], ["a chemotactic and activating factor", "PROBLEM", 354, 389], ["neutrophils", "TEST", 394, 405], ["human GRO (MGSA", "TEST", 411, 426], ["neutrophil chemotaxis", "PROBLEM", 442, 463], ["degranulation", "PROBLEM", 468, 481], ["proinflammatory cytokines", "OBSERVATION", 33, 58], ["progression", "OBSERVATION_MODIFIER", 155, 166], ["HIV disease", "OBSERVATION", 170, 181], ["epithelial neutrophil", "ANATOMY", 293, 314], ["neutrophil chemotaxis", "OBSERVATION", 442, 463]]], ["Through these molecules, \u2425\u2426 T cells may influence the behavior of granulocytes-that is the cells that are likely to release of \u2423-defensins and other non-cytolytic antiviral factors. \u2423-defensins are a family of antimicrobial peptides that have been identified in animals (including human and non-human primates) and plants.", [["\u2425\u2426 T cells", "ANATOMY", 25, 35], ["granulocytes", "ANATOMY", 66, 78], ["cells", "ANATOMY", 91, 96], ["\u2423-defensins", "CHEMICAL", 182, 193], ["\u2425\u2426 T cells", "CELL", 25, 35], ["granulocytes", "CELL", 66, 78], ["cells", "CELL", 91, 96], ["\u2423-defensins", "GENE_OR_GENE_PRODUCT", 127, 138], ["\u2423-defensins", "SIMPLE_CHEMICAL", 182, 193], ["human", "ORGANISM", 281, 286], ["non-human primates", "ORGANISM", 291, 309], ["\u2425\u2426 T cells", "CELL_TYPE", 25, 35], ["granulocytes", "CELL_TYPE", 66, 78], ["\u2423-defensins", "PROTEIN", 127, 138], ["non-cytolytic antiviral factors", "PROTEIN", 149, 180], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 281, 286], ["\u2425\u2426 T cells", "PROBLEM", 25, 35], ["granulocytes", "PROBLEM", 66, 78], ["\u2423-defensins", "PROBLEM", 127, 138], ["other non-cytolytic antiviral factors", "PROBLEM", 143, 180], ["antimicrobial peptides", "TREATMENT", 210, 232], ["granulocytes", "OBSERVATION", 66, 78], ["likely to", "UNCERTAINTY", 106, 115], ["antiviral factors", "OBSERVATION", 163, 180]]], ["They play an important role in infections, inflammation, wound repair, and acquired immunity.", [["wound", "ANATOMY", 57, 62], ["infections", "DISEASE", 31, 41], ["inflammation", "DISEASE", 43, 55], ["wound", "PATHOLOGICAL_FORMATION", 57, 62], ["infections", "PROBLEM", 31, 41], ["inflammation", "PROBLEM", 43, 55], ["wound repair", "TREATMENT", 57, 69], ["infections", "OBSERVATION", 31, 41], ["inflammation", "OBSERVATION", 43, 55], ["wound repair", "OBSERVATION", 57, 69]]], ["Based on the disulfide pairing of their characteristic six cysteine residues, they are divided into \u2423defensins and \u2424-defensins. \u2423-defensins are mainly released by granulocytes and can inhibit HIV infection in vitro [49] .", [["granulocytes", "ANATOMY", 163, 175], ["HIV infection", "DISEASE", 192, 205], ["disulfide", "CHEMICAL", 13, 22], ["cysteine", "CHEMICAL", 59, 67], ["cysteine", "AMINO_ACID", 59, 67], ["\u2423defensins", "GENE_OR_GENE_PRODUCT", 100, 110], ["\u2424-defensins", "GENE_OR_GENE_PRODUCT", 115, 126], ["\u2423-defensins", "GENE_OR_GENE_PRODUCT", 128, 139], ["granulocytes", "CELL", 163, 175], ["HIV", "ORGANISM", 192, 195], ["\u2423defensins", "PROTEIN", 100, 110], ["\u2424-defensins", "PROTEIN", 115, 126], ["granulocytes", "CELL_TYPE", 163, 175], ["HIV", "SPECIES", 192, 195], ["HIV", "SPECIES", 192, 195], ["their characteristic six cysteine residues", "PROBLEM", 34, 76], ["defensins", "PROBLEM", 130, 139], ["granulocytes", "PROBLEM", 163, 175], ["HIV infection", "PROBLEM", 192, 205], ["cysteine residues", "OBSERVATION", 59, 76], ["defensins", "OBSERVATION", 130, 139], ["granulocytes", "OBSERVATION", 163, 175]]], ["In addition to their anti-HIV activities, \u2423-defensins interfere with the replication of HSV-1 and HSV-2, CMV, vesicular stomatitis virus (VSV), and influenza virus [50] .", [["vesicular stomatitis", "DISEASE", 110, 130], ["influenza virus", "DISEASE", 148, 163], ["\u2423-defensins", "CHEMICAL", 42, 53], ["\u2423-defensins", "SIMPLE_CHEMICAL", 42, 53], ["HSV-1", "ORGANISM", 88, 93], ["HSV-2", "ORGANISM", 98, 103], ["CMV", "ORGANISM", 105, 108], ["vesicular stomatitis virus", "ORGANISM", 110, 136], ["VSV", "ORGANISM", 138, 141], ["influenza virus", "ORGANISM", 148, 163], ["HSV-1", "SPECIES", 88, 93], ["HSV-2", "SPECIES", 98, 103], ["vesicular stomatitis virus", "SPECIES", 110, 136], ["influenza virus", "SPECIES", 148, 163], ["HSV-1", "SPECIES", 88, 93], ["HSV-2", "SPECIES", 98, 103], ["CMV", "SPECIES", 105, 108], ["vesicular stomatitis virus", "SPECIES", 110, 136], ["VSV", "SPECIES", 138, 141], ["\u2423-defensins", "TREATMENT", 42, 53], ["HSV", "TEST", 88, 91], ["HSV", "TEST", 98, 101], ["CMV", "PROBLEM", 105, 108], ["vesicular stomatitis virus (VSV)", "PROBLEM", 110, 142], ["influenza virus", "PROBLEM", 148, 163], ["vesicular stomatitis", "ANATOMY", 110, 130]]], ["The expression of \u2423-defensins in \u2425\u2426 T cells has been described [51] , but further studies are required to explore the contribution of \u2425\u2426 T cells to the production and action of defensins during viral infections.Non-cytolytic antiviral immunity mediated by V\u24259V\u24262 T cellsAnother proinflammatory factor released by activated \u2425\u2426 T cells is TNF-\u2423, a potent lymphoid factor with (unlike the molecules described above) cytotoxic effects on a wide range of target cells.", [["\u2425\u2426 T cells", "ANATOMY", 33, 43], ["\u2425\u2426 T cells", "ANATOMY", 134, 144], ["V\u24259V\u24262 T cells", "ANATOMY", 256, 270], ["\u2425\u2426 T cells", "ANATOMY", 323, 333], ["cells", "ANATOMY", 457, 462], ["viral infections", "DISEASE", 194, 210], ["\u2423-defensins", "GENE_OR_GENE_PRODUCT", 18, 29], ["\u2425\u2426 T cells", "CELL", 33, 43], ["\u2425\u2426 T cells", "CELL", 134, 144], ["defensins", "GENE_OR_GENE_PRODUCT", 177, 186], ["\u2425\u2426 T cells", "CELL", 323, 333], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 337, 342], ["lymphoid factor", "GENE_OR_GENE_PRODUCT", 353, 368], ["cells", "CELL", 457, 462], ["\u2423-defensins", "PROTEIN", 18, 29], ["\u2425\u2426 T cells", "CELL_TYPE", 33, 43], ["\u2425\u2426 T cells", "CELL_TYPE", 134, 144], ["defensins", "PROTEIN", 177, 186], ["V\u24259V\u24262 T cells", "CELL_LINE", 256, 270], ["proinflammatory factor", "PROTEIN", 278, 300], ["activated \u2425\u2426 T cells", "CELL_TYPE", 313, 333], ["TNF", "PROTEIN", 337, 340], ["lymphoid factor", "PROTEIN", 353, 368], ["target cells", "CELL_TYPE", 450, 462], ["\u2423-defensins in \u2425\u2426 T cells", "PROBLEM", 18, 43], ["further studies", "TEST", 74, 89], ["\u2425\u2426 T cells", "PROBLEM", 134, 144], ["defensins", "PROBLEM", 177, 186], ["viral infections", "PROBLEM", 194, 210], ["Non-cytolytic antiviral immunity", "PROBLEM", 211, 243], ["Another proinflammatory factor", "PROBLEM", 270, 300], ["activated \u2425\u2426 T cells", "TEST", 313, 333], ["TNF", "TEST", 337, 340], ["a potent lymphoid factor", "PROBLEM", 344, 368], ["cytotoxic effects", "PROBLEM", 413, 430], ["target cells", "OBSERVATION", 450, 462]]], ["Beneficial effects of TNF-\u2423 in cellular immunity to VSV [52] , CMV [53] , HSV-1 [54] , and vaccinia virus [55] have been noted.", [["cellular", "ANATOMY", 31, 39], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 22, 27], ["cellular", "CELL", 31, 39], ["VSV [52]", "ORGANISM", 52, 60], ["CMV [53]", "ORGANISM", 63, 71], ["HSV-1 [54", "ORGANISM", 74, 83], ["vaccinia virus", "ORGANISM", 91, 105], ["TNF", "PROTEIN", 22, 25], ["HSV-1", "SPECIES", 74, 79], ["vaccinia virus", "SPECIES", 91, 105], ["VSV", "SPECIES", 52, 55], ["HSV-1", "SPECIES", 74, 79], ["vaccinia virus", "SPECIES", 91, 105], ["TNF", "TEST", 22, 25], ["VSV", "TEST", 52, 55], ["CMV", "TEST", 63, 66], ["HSV", "TEST", 74, 77], ["vaccinia virus", "PROBLEM", 91, 105]]], ["TNF-\u2423 was shown to enhance HIV-1 replication in chronically infected promonocytic and T-lymphoid cell lines by activation of the nuclear factor NF-B, which stimulates the long terminal repeat (LTR) of the provirus [31] .", [["promonocytic", "ANATOMY", 69, 81], ["T-lymphoid cell lines", "ANATOMY", 86, 107], ["long terminal repeat", "ANATOMY", 171, 191], ["LTR", "ANATOMY", 193, 196], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 0, 5], ["HIV-1", "ORGANISM", 27, 32], ["promonocytic", "CELL", 69, 81], ["T-lymphoid cell lines", "CELL", 86, 107], ["NF-B", "GENE_OR_GENE_PRODUCT", 144, 148], ["long terminal repeat", "CELLULAR_COMPONENT", 171, 191], ["LTR", "CELLULAR_COMPONENT", 193, 196], ["TNF", "PROTEIN", 0, 3], ["chronically infected promonocytic and T-lymphoid cell lines", "CELL_LINE", 48, 107], ["nuclear factor NF-B", "PROTEIN", 129, 148], ["long terminal repeat", "DNA", 171, 191], ["LTR", "DNA", 193, 196], ["HIV-1", "SPECIES", 27, 32], ["HIV-1", "SPECIES", 27, 32], ["TNF", "TEST", 0, 3], ["HIV", "TEST", 27, 30], ["chronically infected promonocytic", "PROBLEM", 48, 81], ["T-lymphoid cell lines", "TREATMENT", 86, 107], ["the nuclear factor NF", "TEST", 125, 146], ["chronically", "OBSERVATION_MODIFIER", 48, 59], ["infected promonocytic", "OBSERVATION", 60, 81], ["lymphoid cell lines", "OBSERVATION", 88, 107]]], ["In contrast, IFN-\u2425 (an important enhancer of TNF-\u2423 production by macrophages) inhibits the HIV-1 growth in primary macrophages [56] .", [["macrophages", "ANATOMY", 65, 76], ["primary macrophages", "ANATOMY", 107, 126], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 13, 18], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 45, 50], ["macrophages", "CELL", 65, 76], ["HIV-1", "ORGANISM", 91, 96], ["macrophages", "CELL", 115, 126], ["IFN", "PROTEIN", 13, 16], ["TNF", "PROTEIN", 45, 48], ["macrophages", "CELL_TYPE", 65, 76], ["primary macrophages", "CELL_TYPE", 107, 126], ["HIV-1", "SPECIES", 91, 96], ["HIV-1", "SPECIES", 91, 96], ["IFN", "TEST", 13, 16], ["TNF", "TEST", 45, 48], ["the HIV", "PROBLEM", 87, 94]]], ["While TNF-\u2423 has a protective role in activated CD4+ T cells against R5-tropic viruses, it enhances CXCR4 expression of CD4+ T cells and mediates an increased susceptibility to infection with X4tropic HIV and SIV strains.", [["CD4+ T cells", "ANATOMY", 47, 59], ["CD4+ T cells", "ANATOMY", 119, 131], ["infection", "DISEASE", 176, 185], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 6, 11], ["CD4", "GENE_OR_GENE_PRODUCT", 47, 50], ["R5-tropic viruses", "ORGANISM", 68, 85], ["CXCR4", "GENE_OR_GENE_PRODUCT", 99, 104], ["CD4", "GENE_OR_GENE_PRODUCT", 119, 122], ["X4tropic HIV", "ORGANISM", 191, 203], ["SIV", "ORGANISM", 208, 211], ["TNF", "PROTEIN", 6, 9], ["\u2423", "PROTEIN", 10, 11], ["activated CD4+ T cells", "CELL_TYPE", 37, 59], ["CXCR4", "PROTEIN", 99, 104], ["CD4", "PROTEIN", 119, 122], ["T cells", "CELL_TYPE", 124, 131], ["HIV", "SPECIES", 200, 203], ["HIV", "SPECIES", 200, 203], ["SIV", "SPECIES", 208, 211], ["TNF", "TEST", 6, 9], ["R5-tropic viruses", "PROBLEM", 68, 85], ["CD4+ T cells", "PROBLEM", 119, 131], ["an increased susceptibility to infection", "PROBLEM", 145, 185], ["X4tropic HIV", "PROBLEM", 191, 203], ["SIV strains", "PROBLEM", 208, 219], ["tropic viruses", "OBSERVATION", 71, 85], ["increased", "OBSERVATION_MODIFIER", 148, 157], ["infection", "OBSERVATION", 176, 185], ["SIV strains", "OBSERVATION", 208, 219]]], ["Therefore, the role of TNF-\u2423 in HIV infections is somewhat intricate, and further studies are needed to clarify its effects.ConclusionsNovel synthetic drugs, N-BPs and Phosphostim that can activate V\u24259V\u24262 T cells have been developed recently as well as effective in vivo \u2425\u2426-stimulatory protocols [57] .", [["V\u24259V\u24262 T cells", "ANATOMY", 198, 212], ["HIV infections", "DISEASE", 32, 46], ["N-BPs", "CHEMICAL", 158, 163], ["Phosphostim", "CHEMICAL", 168, 179], ["N-BPs", "CHEMICAL", 158, 163], ["Phosphostim", "CHEMICAL", 168, 179], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 23, 28], ["HIV", "ORGANISM", 32, 35], ["N-BPs", "SIMPLE_CHEMICAL", 158, 163], ["Phosphostim", "SIMPLE_CHEMICAL", 168, 179], ["TNF", "PROTEIN", 23, 26], ["V\u24259V\u24262 T cells", "CELL_LINE", 198, 212], ["HIV", "SPECIES", 32, 35], ["HIV", "SPECIES", 32, 35], ["TNF", "TEST", 23, 26], ["HIV infections", "PROBLEM", 32, 46], ["further studies", "TEST", 74, 89], ["Novel synthetic drugs", "TREATMENT", 135, 156], ["BPs", "TEST", 160, 163], ["Phosphostim", "TREATMENT", 168, 179], ["V", "TEST", 198, 199], ["T cells", "PROBLEM", 205, 212], ["vivo \u2425\u2426-stimulatory protocols", "TREATMENT", 266, 295]]], ["Some of these molecules are able not only to activate V\u24259V\u24262 T cells, but also can inhibit protein prenylation or cholesterol biosynthesis that may be required for viral assembly.", [["V\u24259V\u24262 T cells", "ANATOMY", 54, 68], ["cholesterol", "CHEMICAL", 114, 125], ["cholesterol", "CHEMICAL", 114, 125], ["cholesterol", "SIMPLE_CHEMICAL", 114, 125], ["V\u24259V\u24262 T cells", "CELL_LINE", 54, 68], ["protein prenylation", "PROBLEM", 91, 110], ["cholesterol biosynthesis", "PROBLEM", 114, 138], ["viral assembly", "PROBLEM", 164, 178]]], ["Thus, N-BPs/Phosphostim-based therapeutic strategies should be considered to enhance the current inadequate armaments for fighting emerging and re-emerging viruses.", [["N-BPs", "CHEMICAL", 6, 11], ["Phosphostim", "CHEMICAL", 12, 23], ["BPs", "CHEMICAL", 8, 11], ["Phosphostim", "CHEMICAL", 12, 23], ["N-BPs", "SIMPLE_CHEMICAL", 6, 11], ["Phosphostim", "SIMPLE_CHEMICAL", 12, 23], ["N-BPs", "TEST", 6, 11], ["Phosphostim", "TEST", 12, 23], ["therapeutic strategies", "TREATMENT", 30, 52]]]], "f114b50d9c6927b687919b004d82317fd4def6cc": [["IntroductionSchiff base is known in the name of Hugo Schiff who first reported the reversible acid-catalyzed condensation reaction between primary amine with carbonyl compounds [1, 2] .", [["amine", "CHEMICAL", 147, 152], ["carbonyl", "CHEMICAL", 158, 166], ["primary amine", "CHEMICAL", 139, 152], ["carbonyl", "CHEMICAL", 158, 166], ["amine", "SIMPLE_CHEMICAL", 147, 152], ["carbonyl compounds [1, 2]", "SIMPLE_CHEMICAL", 158, 183], ["the reversible acid-catalyzed condensation reaction", "PROBLEM", 79, 130], ["carbonyl compounds", "TREATMENT", 158, 176], ["reversible", "OBSERVATION_MODIFIER", 83, 93], ["acid-catalyzed condensation", "OBSERVATION", 94, 121]]], ["They are also known as imines with general structure ReCH\u00bcNeR 0 , where R and R 0 is linear or cyclic alkyl and/or aryl group which may be differently substituted [3] .", [["alkyl", "CHEMICAL", 102, 107], ["aryl", "CHEMICAL", 115, 119], ["imines", "CHEMICAL", 23, 29], ["ReCH\u00bcNeR 0", "CHEMICAL", 53, 63], ["aryl", "CHEMICAL", 115, 119], ["R 0", "SIMPLE_CHEMICAL", 78, 81], ["cyclic alkyl", "SIMPLE_CHEMICAL", 95, 107], ["aryl", "SIMPLE_CHEMICAL", 115, 119], ["linear or cyclic alkyl and/or aryl group", "PROBLEM", 85, 125]]], ["Schiff bases are an important class of ligands for co-ordination chemistry, and they coordinate to metal ions via azomethine nitrogen [4] .", [["azomethine nitrogen", "CHEMICAL", 114, 133], ["Schiff bases", "CHEMICAL", 0, 12], ["azomethine nitrogen", "CHEMICAL", 114, 133], ["metal ions", "SIMPLE_CHEMICAL", 99, 109], ["azomethine", "SIMPLE_CHEMICAL", 114, 124], ["Schiff bases", "PROBLEM", 0, 12], ["co-ordination chemistry", "TEST", 51, 74], ["metal ions via azomethine nitrogen", "TREATMENT", 99, 133], ["bases", "ANATOMY_MODIFIER", 7, 12]]], ["Schiff base ligands have been extensively studied in the field of coordination chemistry mainly because of their facile syntheses, easy availability, and electronic properties.", [["Schiff base", "CHEMICAL", 0, 11], ["Schiff base ligands", "PROBLEM", 0, 19], ["coordination chemistry", "TEST", 66, 88]]], ["In recent times, Schiff base coordination chemistry has attracted much attention because of their significance in organic synthesis, analytical chemistry, refining of metals, metallurgy, electroplating, and photography [5e7].", [["Schiff base", "CHEMICAL", 17, 28], ["Schiff", "SIMPLE_CHEMICAL", 17, 23], ["metals", "SIMPLE_CHEMICAL", 167, 173], ["Schiff base coordination chemistry", "TEST", 17, 51], ["analytical chemistry", "TEST", 133, 153], ["photography", "TEST", 207, 218]]], ["Schiffbases have wide applications in dyeAbbreviations: CT DNA, Calf thymus deoxyribonucleic acid; DTBP, 2,6-di-tert-butylphenol; 35-DTBP, 3,5-di-tert-butylphenol; scCO 2 , Super-critical carbon dioxide; DTBQ, 2,6-di-tert-butyl-4,4 0 -benzoquinone; TTBDQ, 3,5,3 0 ,5 0 -tetra-tert-butyl-4,4 0 -diphenoquinone; OLED, Organic light emitting diode; Phen, 1,10-phenanthroline; Bipy, 2,2bipyridine; BBPT, Biacetyl bis(4-phenyl-3-thiosemicarbazone); BGPT, Bipyridyl glyoxal bis(4-phenyl-3-thiosemicarbazone); BMTS, Biacetyl monothiosemicarbazone; PPTS, Picolinealdehyde-4-phenyl-3-thiosemicarbazone; NQTS, ortho-Naphthoquinone thiosemicarbazone; NQSC, Naphthoquinone semicarbazone; MCF-7, Michigan Cancer industry, catalysis, fungicidal, and agrochemical [8, 9] .", [["deoxyribonucleic acid", "CHEMICAL", 76, 97], ["DTBP", "CHEMICAL", 99, 103], ["2,6-di-tert-butylphenol", "CHEMICAL", 105, 128], ["35-DTBP", "CHEMICAL", 130, 137], ["3,5-di-tert-butylphenol", "CHEMICAL", 139, 162], ["carbon dioxide", "CHEMICAL", 188, 202], ["DTBQ", "CHEMICAL", 204, 208], ["2,6-di-tert-butyl-4,4 0 -benzoquinone", "CHEMICAL", 210, 247], ["TTBDQ", "CHEMICAL", 249, 254], ["3,5,3 0 ,5 0 -tetra-tert-butyl-4,4 0 -diphenoquinone", "CHEMICAL", 256, 308], ["OLED", "CHEMICAL", 310, 314], ["Phen", "CHEMICAL", 346, 350], ["1,10-phenanthroline", "CHEMICAL", 352, 371], ["Bipy, 2,2bipyridine", "CHEMICAL", 373, 392], ["BBPT", "CHEMICAL", 394, 398], ["Biacetyl bis(4-phenyl-3-thiosemicarbazone", "CHEMICAL", 400, 441], ["BGPT", "CHEMICAL", 444, 448], ["Bipyridyl glyoxal bis", "CHEMICAL", 450, 471], ["4-phenyl-3-thiosemicarbazone", "CHEMICAL", 472, 500], ["BMTS", "CHEMICAL", 503, 507], ["Biacetyl monothiosemicarbazone", "CHEMICAL", 509, 539], ["PPTS", "CHEMICAL", 541, 545], ["Picolinealdehyde-4-phenyl-3-thiosemicarbazone", "CHEMICAL", 547, 592], ["NQTS", "CHEMICAL", 594, 598], ["ortho-Naphthoquinone thiosemicarbazone", "CHEMICAL", 600, 638], ["NQSC", "CHEMICAL", 640, 644], ["Naphthoquinone semicarbazone", "CHEMICAL", 646, 674], ["MCF-7", "CHEMICAL", 676, 681], ["Cancer", "DISEASE", 692, 698], ["DTBP", "CHEMICAL", 99, 103], ["2,6-di-tert-butylphenol", "CHEMICAL", 105, 128], ["35-DTBP", "CHEMICAL", 130, 137], ["3,5-di-tert-butylphenol", "CHEMICAL", 139, 162], ["scCO 2", "CHEMICAL", 164, 170], ["carbon dioxide", "CHEMICAL", 188, 202], ["DTBQ", "CHEMICAL", 204, 208], ["2,6-di-tert-butyl-4,4 0 -benzoquinone", "CHEMICAL", 210, 247], ["TTBDQ", "CHEMICAL", 249, 254], ["3,5,3 0 ,5 0 -tetra-tert-butyl-4,4 0 -diphenoquinone", "CHEMICAL", 256, 308], ["OLED", "CHEMICAL", 310, 314], ["Phen", "CHEMICAL", 346, 350], ["1,10-phenanthroline", "CHEMICAL", 352, 371], ["Bipy", "CHEMICAL", 373, 377], ["2,2bipyridine", "CHEMICAL", 379, 392], ["BBPT", "CHEMICAL", 394, 398], ["Biacetyl bis(4-phenyl-3-thiosemicarbazone)", "CHEMICAL", 400, 442], ["BGPT", "CHEMICAL", 444, 448], ["Bipyridyl glyoxal bis(4-phenyl-3-thiosemicarbazone)", "CHEMICAL", 450, 501], ["BMTS", "CHEMICAL", 503, 507], ["Biacetyl monothiosemicarbazone", "CHEMICAL", 509, 539], ["PPTS", "CHEMICAL", 541, 545], ["Picolinealdehyde-4-phenyl-3-thiosemicarbazone", "CHEMICAL", 547, 592], ["NQTS", "CHEMICAL", 594, 598], ["ortho-Naphthoquinone thiosemicarbazone", "CHEMICAL", 600, 638], ["NQSC", "CHEMICAL", 640, 644], ["Naphthoquinone semicarbazone", "CHEMICAL", 646, 674], ["MCF-7", "CHEMICAL", 676, 681], ["Schiffbases", "SIMPLE_CHEMICAL", 0, 11], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["Calf thymus deoxyribonucleic acid", "SIMPLE_CHEMICAL", 64, 97], ["DTBP", "SIMPLE_CHEMICAL", 99, 103], ["2,6-di-tert-butylphenol", "SIMPLE_CHEMICAL", 105, 128], ["35-DTBP", "SIMPLE_CHEMICAL", 130, 137], ["3,5-di-tert-butylphenol", "SIMPLE_CHEMICAL", 139, 162], ["scCO 2", "SIMPLE_CHEMICAL", 164, 170], ["Super-critical carbon dioxide", "SIMPLE_CHEMICAL", 173, 202], ["DTBQ", "SIMPLE_CHEMICAL", 204, 208], ["2,6-di-tert-butyl-4,4 0 -benzoquinone", "SIMPLE_CHEMICAL", 210, 247], ["TTBDQ", "SIMPLE_CHEMICAL", 249, 254], ["3,5,3 0 ,5 0 -tetra-tert-butyl-4,4 0 -diphenoquinone", "SIMPLE_CHEMICAL", 256, 308], ["OLED", "SIMPLE_CHEMICAL", 310, 314], ["Phen, 1,10-phenanthroline", "SIMPLE_CHEMICAL", 346, 371], ["Bipy, 2,2bipyridine", "SIMPLE_CHEMICAL", 373, 392], ["BBPT", "SIMPLE_CHEMICAL", 394, 398], ["Biacetyl bis(4-phenyl-3-thiosemicarbazone", "SIMPLE_CHEMICAL", 400, 441], ["BGPT", "SIMPLE_CHEMICAL", 444, 448], ["Bipyridyl glyoxal bis(4-phenyl-3-thiosemicarbazone", "SIMPLE_CHEMICAL", 450, 500], ["BMTS", "SIMPLE_CHEMICAL", 503, 507], ["Biacetyl monothiosemicarbazone", "SIMPLE_CHEMICAL", 509, 539], ["PPTS", "SIMPLE_CHEMICAL", 541, 545], ["Picolinealdehyde-4-phenyl-3-thiosemicarbazone", "SIMPLE_CHEMICAL", 547, 592], ["NQTS", "SIMPLE_CHEMICAL", 594, 598], ["ortho-Naphthoquinone thiosemicarbazone", "SIMPLE_CHEMICAL", 600, 638], ["NQSC", "SIMPLE_CHEMICAL", 640, 644], ["Naphthoquinone semicarbazone", "SIMPLE_CHEMICAL", 646, 674], ["MCF-7", "SIMPLE_CHEMICAL", 676, 681], ["CT DNA", "TEST", 56, 62], ["Calf thymus deoxyribonucleic acid", "TEST", 64, 97], ["DTBP", "TEST", 99, 103], ["butylphenol", "TREATMENT", 117, 128], ["butylphenol", "TREATMENT", 151, 162], ["critical carbon dioxide", "TREATMENT", 179, 202], ["DTBQ", "TEST", 204, 208], ["di-tert-butyl", "TREATMENT", 214, 227], ["benzoquinone", "TREATMENT", 235, 247], ["TTBDQ", "TEST", 249, 254], ["tetra-tert-butyl", "TREATMENT", 270, 286], ["diphenoquinone", "TREATMENT", 294, 308], ["Organic light emitting diode", "TREATMENT", 316, 344], ["Phen", "TREATMENT", 346, 350], ["phenanthroline", "TREATMENT", 357, 371], ["Bipy", "TREATMENT", 373, 377], ["bipyridine", "TREATMENT", 382, 392], ["BBPT", "TREATMENT", 394, 398], ["Biacetyl bis", "TREATMENT", 400, 412], ["phenyl", "TREATMENT", 415, 421], ["thiosemicarbazone", "TREATMENT", 424, 441], ["BGPT", "TREATMENT", 444, 448], ["Bipyridyl glyoxal bis", "TREATMENT", 450, 471], ["phenyl", "TREATMENT", 474, 480], ["thiosemicarbazone)", "TREATMENT", 483, 501], ["BMTS", "TREATMENT", 503, 507], ["Biacetyl monothiosemicarbazone", "TREATMENT", 509, 539], ["Picolinealdehyde", "TREATMENT", 547, 563], ["phenyl", "TREATMENT", 566, 572], ["thiosemicarbazone", "TREATMENT", 575, 592], ["NQTS", "TREATMENT", 594, 598], ["ortho", "TREATMENT", 600, 605], ["Naphthoquinone thiosemicarbazone", "TREATMENT", 606, 638], ["NQSC", "TREATMENT", 640, 644], ["Naphthoquinone semicarbazone", "TREATMENT", 646, 674], ["MCF", "TREATMENT", 676, 679], ["wide", "OBSERVATION_MODIFIER", 17, 21], ["Calf thymus", "ANATOMY", 64, 75]]], ["Several Schiff bases are reported to possess remarkable antibacterial, antifungal, and anticancer activities [10] .", [["anticancer", "ANATOMY", 87, 97], ["Schiff bases", "CHEMICAL", 8, 20], ["anticancer", "CANCER", 87, 97], ["Several Schiff bases", "PROBLEM", 0, 20], ["remarkable antibacterial", "TREATMENT", 45, 69], ["antifungal", "TREATMENT", 71, 81], ["Schiff bases", "OBSERVATION", 8, 20], ["remarkable", "OBSERVATION_MODIFIER", 45, 55], ["antibacterial", "OBSERVATION_MODIFIER", 56, 69]]], ["In such class of compounds, the C\u00bcN moiety is important for biological activity.", [["C\u00bcN", "CHEMICAL", 32, 35], ["C\u00bcN", "SIMPLE_CHEMICAL", 32, 35], ["the C\u00bcN moiety", "TREATMENT", 28, 42]]], ["Abdel-Rahman et al. [10] have reported number of transition metal complexes by using variety of Schiff base ligands and have studied their different biological activities such as antimicrobial, anticancer, antifungal, etc. For example, a number of Fe (II) complexes have designed and synthesized by using variety of Schiff bases ligands derived from 5bromosalicylaldehyde (bs) and various a-amino acids such as Lalanine (ala), L-phenylalanine (phala), L-aspartic acid (aspa), Lhistidine (his), and L-arginine (arg).", [["anticancer", "ANATOMY", 194, 204], ["Fe", "CHEMICAL", 248, 250], ["5bromosalicylaldehyde", "CHEMICAL", 350, 371], ["Lalanine", "CHEMICAL", 411, 419], ["L-phenylalanine", "CHEMICAL", 427, 442], ["L-aspartic acid", "CHEMICAL", 452, 467], ["aspa", "CHEMICAL", 469, 473], ["Lhistidine", "CHEMICAL", 476, 486], ["L-arginine", "CHEMICAL", 498, 508], ["transition metal", "CHEMICAL", 49, 65], ["Schiff base", "CHEMICAL", 96, 107], ["Fe (II)", "CHEMICAL", 248, 255], ["Schiff bases", "CHEMICAL", 316, 328], ["5bromosalicylaldehyde", "CHEMICAL", 350, 371], ["a-amino acids", "CHEMICAL", 389, 402], ["Lalanine", "CHEMICAL", 411, 419], ["L-phenylalanine", "CHEMICAL", 427, 442], ["L-aspartic acid", "CHEMICAL", 452, 467], ["aspa", "CHEMICAL", 469, 473], ["Lhistidine", "CHEMICAL", 476, 486], ["L-arginine", "CHEMICAL", 498, 508], ["arg", "CHEMICAL", 510, 513], ["anticancer", "CANCER", 194, 204], ["Fe (II)", "SIMPLE_CHEMICAL", 248, 255], ["Schiff bases ligands", "SIMPLE_CHEMICAL", 316, 336], ["5bromosalicylaldehyde", "SIMPLE_CHEMICAL", 350, 371], ["bs", "SIMPLE_CHEMICAL", 373, 375], ["a-amino acids", "SIMPLE_CHEMICAL", 389, 402], ["Lalanine", "SIMPLE_CHEMICAL", 411, 419], ["ala", "SIMPLE_CHEMICAL", 421, 424], ["L-phenylalanine", "SIMPLE_CHEMICAL", 427, 442], ["phala), L-aspartic acid", "SIMPLE_CHEMICAL", 444, 467], ["aspa", "SIMPLE_CHEMICAL", 469, 473], ["Lhistidine", "SIMPLE_CHEMICAL", 476, 486], ["L-arginine", "SIMPLE_CHEMICAL", 498, 508], ["arg", "SIMPLE_CHEMICAL", 510, 513], ["Fe (II) complexes", "PROTEIN", 248, 265], ["Schiff base ligands", "TREATMENT", 96, 115], ["antimicrobial, anticancer", "TREATMENT", 179, 204], ["antifungal", "TREATMENT", 206, 216], ["Schiff bases ligands", "TREATMENT", 316, 336], ["5bromosalicylaldehyde (bs", "TREATMENT", 350, 375], ["various a-amino acids", "TREATMENT", 381, 402], ["Lalanine (ala)", "TREATMENT", 411, 425], ["L-phenylalanine (phala)", "TREATMENT", 427, 450], ["L-aspartic acid (aspa)", "TREATMENT", 452, 474], ["Lhistidine", "TREATMENT", 476, 486], ["L-arginine (arg)", "TREATMENT", 498, 514], ["Schiff bases", "OBSERVATION", 316, 328]]], ["These complexes were screened for their antibacterial and antifungal activity against Escherichia coli, Pseudomonasaeruginosa, and Bacillus cereus and different antifungal cultures such as Penicillium purpurogenium, Aspergillus flavus, and Trichothecium rosium.", [["cultures", "ANATOMY", 172, 180], ["Escherichia coli", "ORGANISM", 86, 102], ["Pseudomonasaeruginosa", "SIMPLE_CHEMICAL", 104, 125], ["Bacillus cereus", "ORGANISM", 131, 146], ["Penicillium purpurogenium", "ORGANISM", 189, 214], ["Aspergillus flavus", "ORGANISM", 216, 234], ["Trichothecium rosium", "ORGANISM", 240, 260], ["antifungal cultures", "CELL_LINE", 161, 180], ["Escherichia coli", "SPECIES", 86, 102], ["Bacillus cereus", "SPECIES", 131, 146], ["Penicillium purpurogenium", "SPECIES", 189, 214], ["Aspergillus flavus", "SPECIES", 216, 234], ["Trichothecium rosium", "SPECIES", 240, 260], ["Escherichia coli", "SPECIES", 86, 102], ["Bacillus cereus", "SPECIES", 131, 146], ["Penicillium purpurogenium", "SPECIES", 189, 214], ["Aspergillus flavus", "SPECIES", 216, 234], ["Trichothecium rosium", "SPECIES", 240, 260], ["their antibacterial", "TREATMENT", 34, 53], ["antifungal activity", "TREATMENT", 58, 77], ["Escherichia coli", "PROBLEM", 86, 102], ["Pseudomonasaeruginosa", "PROBLEM", 104, 125], ["Bacillus cereus", "PROBLEM", 131, 146], ["different antifungal cultures", "TEST", 151, 180], ["Penicillium purpurogenium", "PROBLEM", 189, 214], ["Aspergillus flavus", "PROBLEM", 216, 234], ["Bacillus cereus", "OBSERVATION", 131, 146], ["Aspergillus flavus", "OBSERVATION", 216, 234]]], ["It is found that Fe (II) complexes exhibited strong antibacterial and antifungal activity compared with the amino acids Schiff base ligands.", [["Fe", "CHEMICAL", 17, 19], ["amino acids", "CHEMICAL", 108, 119], ["Fe (II)", "CHEMICAL", 17, 24], ["amino acids", "CHEMICAL", 108, 119], ["Schiff base", "CHEMICAL", 120, 131], ["Fe (II)", "SIMPLE_CHEMICAL", 17, 24], ["amino acids", "AMINO_ACID", 108, 119], ["Fe (II) complexes", "PROTEIN", 17, 34], ["Fe (II) complexes", "PROBLEM", 17, 34], ["strong antibacterial", "TREATMENT", 45, 65], ["antifungal activity", "TREATMENT", 70, 89], ["the amino acids Schiff base ligands", "TREATMENT", 104, 139], ["strong", "OBSERVATION_MODIFIER", 45, 51], ["antibacterial", "OBSERVATION_MODIFIER", 52, 65], ["antifungal activity", "OBSERVATION", 70, 89]]], ["Also, this complexes were tested for their interaction with calf thymus (CT) DNA by utilizing viscosity, UV-visible spectroscopy, and agarose gel electrophoresis measurements at pH \u00bc 7.2.", [["calf thymus", "ANATOMY", 60, 71], ["thymus", "ORGAN", 65, 71], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["agarose", "SIMPLE_CHEMICAL", 134, 141], ["calf thymus (CT) DNA", "DNA", 60, 80], ["calf", "SPECIES", 60, 64], ["UV", "TEST", 105, 107], ["visible spectroscopy", "TEST", 108, 128], ["agarose gel electrophoresis measurements", "TEST", 134, 174], ["pH", "TEST", 178, 180], ["calf thymus", "ANATOMY", 60, 71]]], ["The results revealed that the studied complexes showed different DNA binding constants that depend on the Schiff base ligands, and they strongly bind to CT DNA through intercalative mode [10b] .bases have wide applications in dyeSeveral nanosized Fe(II), Cd(II), and Zn(II) complexes with Schiff base ligand 2-[(2-Hydroxy-3-methoxy-benzylidene)-amino]pyridin-3-ol obtained from 2-amino-3-hydroxy-pyridine and 3methoxysalicylaldehyde have been prepared sonochemically, and all the compounds were investigated for their antimicrobial activity against some pathogens [10d] .", [["Fe", "CHEMICAL", 247, 249], ["Cd", "CHEMICAL", 255, 257], ["Zn", "CHEMICAL", 267, 269], ["2-[(2-Hydroxy-3-methoxy-benzylidene)-amino]pyridin-3-ol", "CHEMICAL", 308, 363], ["2-amino-3-hydroxy-pyridine", "CHEMICAL", 378, 404], ["3methoxysalicylaldehyde", "CHEMICAL", 409, 432], ["Schiff base", "CHEMICAL", 106, 117], ["Fe(II)", "CHEMICAL", 247, 253], ["Cd(II)", "CHEMICAL", 255, 261], ["Zn(II)", "CHEMICAL", 267, 273], ["Schiff base", "CHEMICAL", 289, 300], ["2-[(2-Hydroxy-3-methoxy-benzylidene)-amino]pyridin-3-ol", "CHEMICAL", 308, 363], ["2-amino-3-hydroxy-pyridine", "CHEMICAL", 378, 404], ["3methoxysalicylaldehyde", "CHEMICAL", 409, 432], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["Fe(II)", "SIMPLE_CHEMICAL", 247, 253], ["Cd(II)", "SIMPLE_CHEMICAL", 255, 261], ["Zn(II)", "SIMPLE_CHEMICAL", 267, 273], ["Schiff base ligand 2-[(2-Hydroxy-3-methoxy-benzylidene)-amino]pyridin-3-ol", "SIMPLE_CHEMICAL", 289, 363], ["2-amino-3-hydroxy-pyridine", "SIMPLE_CHEMICAL", 378, 404], ["3methoxysalicylaldehyde", "SIMPLE_CHEMICAL", 409, 432], ["CT DNA", "DNA", 153, 159], ["Zn(II) complexes", "PROTEIN", 267, 283], ["the studied complexes", "TEST", 26, 47], ["different DNA binding constants", "PROBLEM", 55, 86], ["the Schiff base ligands", "TEST", 102, 125], ["CT DNA", "TEST", 153, 159], ["wide applications", "TREATMENT", 205, 222], ["dyeSeveral nanosized Fe(II)", "TREATMENT", 226, 253], ["Zn(II) complexes", "TREATMENT", 267, 283], ["Schiff base ligand", "TEST", 289, 307], ["Hydroxy", "TEST", 314, 321], ["methoxy", "TREATMENT", 324, 331], ["benzylidene", "TREATMENT", 332, 343], ["amino]pyridin", "TREATMENT", 345, 358], ["hydroxy-pyridine", "TREATMENT", 388, 404], ["3methoxysalicylaldehyde", "TREATMENT", 409, 432], ["some pathogens", "PROBLEM", 549, 563], ["binding constants", "OBSERVATION", 69, 86], ["wide", "OBSERVATION_MODIFIER", 205, 209]]], ["It is found that ligand showed the less antimicrobial activity against the fungi and bacteria, whereas all the complexes exhibited more activity toward same fungi and bacteria.", [["the fungi", "PROBLEM", 71, 80], ["bacteria", "PROBLEM", 85, 93], ["bacteria", "PROBLEM", 167, 175], ["less", "OBSERVATION_MODIFIER", 35, 39], ["antimicrobial activity", "OBSERVATION_MODIFIER", 40, 62]]], ["Some complexes showed great cytotoxic activity against colon carcinoma cells (HCT-116 cell line) and hepatic cellular carcinoma cells, (HepG-2).", [["colon carcinoma cells", "ANATOMY", 55, 76], ["HCT-116 cell line", "ANATOMY", 78, 95], ["hepatic cellular carcinoma cells", "ANATOMY", 101, 133], ["HepG-2", "ANATOMY", 136, 142], ["colon carcinoma", "DISEASE", 55, 70], ["hepatic cellular carcinoma", "DISEASE", 101, 127], ["colon carcinoma cells", "CELL", 55, 76], ["HCT-116 cell line", "CELL", 78, 95], ["hepatic cellular carcinoma cells", "CELL", 101, 133], ["HepG-2", "CELL", 136, 142], ["colon carcinoma cells", "CELL_LINE", 55, 76], ["HCT-116 cell line", "CELL_LINE", 78, 95], ["hepatic cellular carcinoma cells", "CELL_TYPE", 101, 133], ["HepG-2", "CELL_LINE", 136, 142], ["Some complexes", "PROBLEM", 0, 14], ["great cytotoxic activity", "PROBLEM", 22, 46], ["colon carcinoma cells", "PROBLEM", 55, 76], ["HCT", "TEST", 78, 81], ["cell line", "TEST", 86, 95], ["hepatic cellular carcinoma cells", "PROBLEM", 101, 133], ["HepG", "TEST", 136, 140], ["great", "OBSERVATION_MODIFIER", 22, 27], ["cytotoxic activity", "OBSERVATION", 28, 46], ["colon", "ANATOMY", 55, 60], ["carcinoma", "OBSERVATION", 61, 70], ["cell line", "OBSERVATION", 86, 95], ["hepatic", "ANATOMY", 101, 108], ["cellular carcinoma cells", "OBSERVATION", 109, 133]]], ["Metal Schiff base complexes are known since the mid-19th century.", [["Schiff base", "CHEMICAL", 6, 17], ["Metal Schiff base complexes", "PROBLEM", 0, 27], ["Schiff", "OBSERVATION", 6, 12], ["base complexes", "OBSERVATION", 13, 27]]], ["A large number of literature has highlighted their use as Schiff base ligands which are generally monodentate, bidentate, tridentate, tetradentate, etc. and depends on the presence of donor atoms.", [["tetradentate", "CHEMICAL", 134, 146], ["Schiff base", "CHEMICAL", 58, 69], ["tetradentate", "CHEMICAL", 134, 146], ["tetradentate", "SIMPLE_CHEMICAL", 134, 146], ["Schiff base ligands", "TEST", 58, 77], ["tetradentate", "TREATMENT", 134, 146], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["They have wide application in coordination chemistry as they are capable to form stable complexes with transition metals [11] .", [["coordination chemistry", "TEST", 30, 52], ["wide", "OBSERVATION_MODIFIER", 10, 14]]], ["Owing to stability of Schiff base metal complexes as well as biological activity [12] , electrochemistry [13] and potential applications in oxidation catalysis [14] , researchers have focused significant attention to the chemistry of metal Schiff base complexes having nitrogen and other donor atoms [15] because of their vast applications in dyes, polymers, enzyme preparation as well as used as catalyst in different biological systems.", [["nitrogen", "CHEMICAL", 269, 277], ["Schiff base", "CHEMICAL", 22, 33], ["Schiff base", "CHEMICAL", 240, 251], ["nitrogen", "CHEMICAL", 269, 277], ["Schiff", "SIMPLE_CHEMICAL", 22, 28], ["metal Schiff base complexes", "SIMPLE_CHEMICAL", 234, 261], ["nitrogen", "SIMPLE_CHEMICAL", 269, 277], ["dyes", "SIMPLE_CHEMICAL", 343, 347], ["Schiff base metal complexes", "PROTEIN", 22, 49], ["Schiff base metal complexes", "TREATMENT", 22, 49], ["potential applications in oxidation catalysis", "TREATMENT", 114, 159], ["metal Schiff base complexes", "TREATMENT", 234, 261], ["nitrogen and other donor atoms", "TREATMENT", 269, 299], ["polymers", "TREATMENT", 349, 357], ["enzyme preparation", "TREATMENT", 359, 377], ["stability", "OBSERVATION_MODIFIER", 9, 18], ["Schiff base", "OBSERVATION", 22, 33], ["metal complexes", "OBSERVATION", 34, 49]]], ["Schiff bases are widely investigated owing to their selectivity, sensitivity, and synthetic flexibility to the central metal atom and the presence of azomethine group which brings in revealing the mechanism of transformation reaction biologically [16] .bases have wide applications in dyeSome Cu (II), Co (II), and Ni (II) complexes have been reported by using Schiff base ligand derived from 2-amino-3-hydroxypyridine and 3-methoxysalicylaldehyde and were investigated for their in vitro antimicrobial activities against the numerous bacteria and fungi.", [["azomethine", "CHEMICAL", 150, 160], ["Cu", "CHEMICAL", 293, 295], ["Co (II", "CHEMICAL", 302, 308], ["Ni", "CHEMICAL", 315, 317], ["2-amino-3-hydroxypyridine", "CHEMICAL", 393, 418], ["3-methoxysalicylaldehyde", "CHEMICAL", 423, 447], ["Schiff bases", "CHEMICAL", 0, 12], ["azomethine", "CHEMICAL", 150, 160], ["Cu (II)", "CHEMICAL", 293, 300], ["Co (II)", "CHEMICAL", 302, 309], ["Ni (II)", "CHEMICAL", 315, 322], ["Schiff base", "CHEMICAL", 361, 372], ["2-amino-3-hydroxypyridine", "CHEMICAL", 393, 418], ["3-methoxysalicylaldehyde", "CHEMICAL", 423, 447], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["azomethine", "SIMPLE_CHEMICAL", 150, 160], ["Cu (II)", "SIMPLE_CHEMICAL", 293, 300], ["Co (II)", "SIMPLE_CHEMICAL", 302, 309], ["Ni (II)", "SIMPLE_CHEMICAL", 315, 322], ["Schiff base ligand", "SIMPLE_CHEMICAL", 361, 379], ["2-amino-3-hydroxypyridine", "SIMPLE_CHEMICAL", 393, 418], ["3-methoxysalicylaldehyde", "SIMPLE_CHEMICAL", 423, 447], ["Ni (II) complexes", "PROTEIN", 315, 332], ["sensitivity", "TEST", 65, 76], ["azomethine group", "TREATMENT", 150, 166], ["transformation reaction", "PROBLEM", 210, 233], ["Co (II), and Ni (II) complexes", "PROBLEM", 302, 332], ["Schiff base ligand", "TEST", 361, 379], ["hydroxypyridine", "TREATMENT", 403, 418], ["methoxysalicylaldehyde", "TREATMENT", 425, 447], ["vitro antimicrobial activities", "TREATMENT", 483, 513], ["the numerous bacteria", "PROBLEM", 522, 543], ["bases", "ANATOMY_MODIFIER", 7, 12], ["central", "ANATOMY_MODIFIER", 111, 118], ["wide", "OBSERVATION_MODIFIER", 264, 268], ["numerous", "OBSERVATION_MODIFIER", 526, 534], ["bacteria", "OBSERVATION", 535, 543]]], ["Also, these complexes were tested for DNA binding, and it was found that these compounds could bind to DNA through intercalative mode.", [["DNA", "CELLULAR_COMPONENT", 38, 41], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["DNA binding", "PROBLEM", 38, 49]]], ["However, the cytotoxicity of these metal Schiff base complexes on different cell line such as human colon carcinoma cells, (HCT-116 cell line), as well as breast carcinoma cells, (MCF-7 cell line), illustrated effective cytotoxicity effect against the growth of carcinoma cells as compared with the clinically used vinblastine standard [16c].", [["cell line", "ANATOMY", 76, 85], ["colon carcinoma cells", "ANATOMY", 100, 121], ["HCT-116 cell line", "ANATOMY", 124, 141], ["breast carcinoma cells", "ANATOMY", 155, 177], ["MCF-7 cell line", "ANATOMY", 180, 195], ["carcinoma cells", "ANATOMY", 262, 277], ["colon carcinoma", "DISEASE", 100, 115], ["breast carcinoma", "DISEASE", 155, 171], ["carcinoma", "DISEASE", 262, 271], ["vinblastine", "CHEMICAL", 315, 326], ["Schiff base", "CHEMICAL", 41, 52], ["vinblastine", "CHEMICAL", 315, 326], ["metal Schiff base", "SIMPLE_CHEMICAL", 35, 52], ["cell line", "CELL", 76, 85], ["human", "ORGANISM", 94, 99], ["colon carcinoma cells", "CELL", 100, 121], ["HCT-116 cell line", "CELL", 124, 141], ["breast carcinoma cells", "CELL", 155, 177], ["MCF-7 cell line", "CELL", 180, 195], ["carcinoma cells", "CELL", 262, 277], ["vinblastine", "SIMPLE_CHEMICAL", 315, 326], ["cell line", "CELL_LINE", 76, 85], ["human colon carcinoma cells", "CELL_LINE", 94, 121], ["HCT-116 cell line", "CELL_LINE", 124, 141], ["breast carcinoma cells", "CELL_LINE", 155, 177], ["MCF-7 cell line", "CELL_LINE", 180, 195], ["carcinoma cells", "CELL_TYPE", 262, 277], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["these metal Schiff base complexes", "PROBLEM", 29, 62], ["different cell line", "TREATMENT", 66, 85], ["human colon carcinoma cells", "PROBLEM", 94, 121], ["HCT", "TEST", 124, 127], ["breast carcinoma cells", "PROBLEM", 155, 177], ["MCF", "TEST", 180, 183], ["cell line", "TREATMENT", 186, 195], ["illustrated effective cytotoxicity effect", "PROBLEM", 198, 239], ["carcinoma cells", "PROBLEM", 262, 277], ["vinblastine standard", "TREATMENT", 315, 335], ["metal Schiff", "OBSERVATION", 35, 47], ["base", "OBSERVATION_MODIFIER", 48, 52], ["complexes", "OBSERVATION_MODIFIER", 53, 62], ["different cell line", "OBSERVATION", 66, 85], ["colon", "ANATOMY", 100, 105], ["carcinoma cells", "OBSERVATION", 106, 121], ["breast", "ANATOMY", 155, 161], ["carcinoma", "OBSERVATION", 162, 171], ["effective", "OBSERVATION_MODIFIER", 210, 219], ["cytotoxicity effect", "OBSERVATION", 220, 239], ["growth", "OBSERVATION_MODIFIER", 252, 258], ["carcinoma cells", "OBSERVATION", 262, 277]]], ["Among most popular ones, the salen/ salophen-based metal coordination complexes have found immense applications in sensors, catalysis, biology, and material science.", [["salen", "CHEMICAL", 29, 34], ["salophen", "CHEMICAL", 36, 44], ["salen", "CHEMICAL", 29, 34], ["salophen", "CHEMICAL", 36, 44], ["salen", "SIMPLE_CHEMICAL", 29, 34], ["salophen", "SIMPLE_CHEMICAL", 36, 44], ["the salen/ salophen", "TREATMENT", 25, 44]]], ["Many researchers have investigated a large number of Schiff base ligands as chelating compounds, e.g. metal chelates of copper, cobalt, etc. for a variety of interesting catalytic application.", [["copper", "CHEMICAL", 120, 126], ["cobalt", "CHEMICAL", 128, 134], ["Schiff base", "CHEMICAL", 53, 64], ["copper", "CHEMICAL", 120, 126], ["cobalt", "CHEMICAL", 128, 134], ["chelating compounds", "SIMPLE_CHEMICAL", 76, 95], ["metal chelates", "SIMPLE_CHEMICAL", 102, 116], ["copper", "SIMPLE_CHEMICAL", 120, 126], ["cobalt", "SIMPLE_CHEMICAL", 128, 134], ["Schiff base ligands", "TREATMENT", 53, 72], ["chelating compounds", "TREATMENT", 76, 95], ["interesting catalytic application", "TREATMENT", 158, 191], ["large", "OBSERVATION_MODIFIER", 37, 42]]], ["Co (II) salen complex of N,N-bis(3,5-di-tert-butyl-salicylidene-1,2cyclohexane diaminato) was used as catalyst in oxidation of 2,6di-tert-butylphenol (DTBP) and 3,5-di-tert-butylphenol in super-critical carbon dioxide (scCO 2 ) [17] .bases have wide applications in dyeThe oxidation of DTBP resulted into 2,6-di-tert-butyl-4,4 0benzoquinone(DTBQ) along with the side product of radical coupling, i.e. 3,5,3 0 ,5 0 -tetra-tert-butyl-4,4 0 -diphenoquinone (TTBDQ) (Scheme 1).", [["Co", "CHEMICAL", 0, 2], ["salen", "CHEMICAL", 8, 13], ["N,N-bis", "CHEMICAL", 25, 32], ["3,5-di-tert-butyl-salicylidene-1,2cyclohexane diaminato", "CHEMICAL", 33, 88], ["2,6di-tert-butylphenol", "CHEMICAL", 127, 149], ["DTBP", "CHEMICAL", 151, 155], ["3,5-di-tert-butylphenol", "CHEMICAL", 161, 184], ["carbon dioxide", "CHEMICAL", 203, 217], ["scCO 2", "CHEMICAL", 219, 225], ["DTBP", "CHEMICAL", 286, 290], ["2,6-di-tert-butyl-4,4 0benzoquinone", "CHEMICAL", 305, 340], ["DTBQ", "CHEMICAL", 341, 345], ["3,5,3 0 ,5 0 -tetra-tert-butyl-4,4 0 -diphenoquinone", "CHEMICAL", 401, 453], ["Co (II) salen", "CHEMICAL", 0, 13], ["N,N-bis(3,5-di-tert-butyl-salicylidene-1,2cyclohexane diaminato", "CHEMICAL", 25, 88], ["2,6di-tert-butylphenol", "CHEMICAL", 127, 149], ["DTBP", "CHEMICAL", 151, 155], ["3,5-di-tert-butylphenol", "CHEMICAL", 161, 184], ["carbon dioxide", "CHEMICAL", 203, 217], ["scCO 2", "CHEMICAL", 219, 225], ["DTBP", "CHEMICAL", 286, 290], ["2,6-di-tert-butyl-4,4 0benzoquinone", "CHEMICAL", 305, 340], ["DTBQ", "CHEMICAL", 341, 345], ["3,5,3 0 ,5 0 -tetra-tert-butyl-4,4 0 -diphenoquinone", "CHEMICAL", 401, 453], ["TTBDQ", "CHEMICAL", 455, 460], ["Co (II) salen", "SIMPLE_CHEMICAL", 0, 13], ["N,N-bis(3,5-di-tert-butyl-salicylidene-1,2cyclohexane diaminato", "SIMPLE_CHEMICAL", 25, 88], ["2,6di-tert-butylphenol", "SIMPLE_CHEMICAL", 127, 149], ["DTBP", "SIMPLE_CHEMICAL", 151, 155], ["3,5-di-tert-butylphenol", "SIMPLE_CHEMICAL", 161, 184], ["super-critical carbon dioxide", "SIMPLE_CHEMICAL", 188, 217], ["scCO 2 ) [17]", "SIMPLE_CHEMICAL", 219, 232], ["DTBP", "SIMPLE_CHEMICAL", 286, 290], ["2,6-di-tert-butyl-4,4 0benzoquinone", "SIMPLE_CHEMICAL", 305, 340], ["DTBQ", "SIMPLE_CHEMICAL", 341, 345], ["radical", "SIMPLE_CHEMICAL", 378, 385], ["3,5,3 0 ,5 0 -tetra-tert-butyl-4,4 0 -diphenoquinone", "SIMPLE_CHEMICAL", 401, 453], ["TTBDQ", "SIMPLE_CHEMICAL", 455, 460], ["Co (II) salen complex", "PROTEIN", 0, 21], ["bis", "TEST", 29, 32], ["di", "TEST", 37, 39], ["tert", "TEST", 40, 44], ["butyl", "TREATMENT", 45, 50], ["salicylidene", "TREATMENT", 51, 63], ["cyclohexane diaminato)", "TREATMENT", 67, 89], ["tert-butylphenol (DTBP", "TREATMENT", 133, 155], ["tert", "TREATMENT", 168, 172], ["butylphenol", "TREATMENT", 173, 184], ["critical carbon dioxide (scCO", "TREATMENT", 194, 223], ["wide applications", "TREATMENT", 245, 262], ["DTBP", "TEST", 286, 290], ["benzoquinone(DTBQ)", "TREATMENT", 328, 346], ["radical coupling", "TREATMENT", 378, 394], ["diphenoquinone (TTBDQ)", "TREATMENT", 439, 461], ["wide", "OBSERVATION_MODIFIER", 245, 249], ["radical", "OBSERVATION", 378, 385]]], ["The conversion and selectivity of catalyst were examined as a function of pressure, temperature, and concentration of catalyst.bases have wide applications in dyeNumber of transition and heavy metal ions complexes were synthesized by using novel salen-based Schiff base ligands (3e6) which were obtained from respective diamines (1 and 2) [18] .", [["salen", "CHEMICAL", 246, 251], ["3e6", "CHEMICAL", 279, 282], ["salen", "CHEMICAL", 246, 251], ["Schiff base", "CHEMICAL", 258, 269], ["diamines", "CHEMICAL", 320, 328], ["heavy metal ions complexes", "SIMPLE_CHEMICAL", 187, 213], ["salen", "SIMPLE_CHEMICAL", 246, 251], ["Schiff base ligands", "SIMPLE_CHEMICAL", 258, 277], ["3e6", "SIMPLE_CHEMICAL", 279, 282], ["selectivity of catalyst", "TREATMENT", 19, 42], ["concentration of catalyst", "TREATMENT", 101, 126], ["wide applications", "TREATMENT", 138, 155], ["heavy metal ions complexes", "TREATMENT", 187, 213], ["novel salen-based Schiff base ligands", "TREATMENT", 240, 277], ["wide", "OBSERVATION_MODIFIER", 138, 142]]], ["The Mn (III) complexes (7e10) (Scheme 2A) of these Schiff base ligands were chiral catalysts and are reported to be useful for asymmetric epoxidation of indene (Scheme 2B).", [["Mn", "CHEMICAL", 4, 6], ["indene", "CHEMICAL", 153, 159], ["Mn (III)", "CHEMICAL", 4, 12], ["Schiff base", "CHEMICAL", 51, 62], ["indene", "CHEMICAL", 153, 159], ["Mn (III)", "SIMPLE_CHEMICAL", 4, 12], ["Schiff base ligands", "SIMPLE_CHEMICAL", 51, 70], ["indene", "SIMPLE_CHEMICAL", 153, 159], ["Mn (III) complexes", "PROTEIN", 4, 22], ["these Schiff base ligands", "TEST", 45, 70], ["asymmetric epoxidation of indene", "PROBLEM", 127, 159]]], ["Also some of the Mn (III) salen complexes were used to catalyze the asymmetric epoxidation of conjugated olefins, e.g. the Mn (II) complexes of bis(2pyridinaldehyde)-ethylenediamine, bis(2-pyridin-aldehyde)propylenediamine ligands were used in epoxidation of olefins however reasonable epoxide selectivity was possible only in the presence of iodosobenzene (PhIO) as oxidant [19] .bases have wide applications in dyeRecently, Che et al. [20] reported Pt (II) complexes with Schiff base ligands N,N 0 -bis(salicylidene)-1,2-ethylenediamine (L1), N,N 0bis(salicylidene)-1,3-propanediamine (L2), and N,N 0 -bis(salicylidene)-1,1,2,2-tetramethylethylenediamine (L3) and explained the utilization of vapor deposited Pt (II)-salen (11) triplet emitters as efficient electrophosphorescent dyes in multilayer organic light emitting diode (OLED) devices with a maximum luminous efficiency of 31 Cd A \u00c01 .", [["Mn", "CHEMICAL", 17, 19], ["Mn", "CHEMICAL", 123, 125], ["bis(2pyridinaldehyde)-ethylenediamine", "CHEMICAL", 144, 181], ["bis(2-pyridin-aldehyde", "CHEMICAL", 183, 205], ["propylenediamine", "CHEMICAL", 206, 222], ["iodosobenzene", "CHEMICAL", 343, 356], ["PhIO", "CHEMICAL", 358, 362], ["Pt", "CHEMICAL", 451, 453], ["N,N 0 -bis(salicylidene)-1,2-ethylenediamine", "CHEMICAL", 494, 538], ["N,N 0bis(salicylidene)-1,3-propanediamine", "CHEMICAL", 545, 586], ["N,N 0 -bis(salicylidene)-1,1,2,2-tetramethylethylenediamine", "CHEMICAL", 597, 656], ["Pt (II)-salen", "CHEMICAL", 711, 724], ["Cd", "CHEMICAL", 886, 888], ["Mn (III)", "CHEMICAL", 17, 25], ["olefins", "CHEMICAL", 105, 112], ["Mn (II)", "CHEMICAL", 123, 130], ["bis(2pyridinaldehyde)-ethylenediamine", "CHEMICAL", 144, 181], ["bis(2-pyridin-aldehyde)propylenediamine", "CHEMICAL", 183, 222], ["olefins", "CHEMICAL", 259, 266], ["epoxide", "CHEMICAL", 286, 293], ["iodosobenzene", "CHEMICAL", 343, 356], ["PhIO", "CHEMICAL", 358, 362], ["Pt (II)", "CHEMICAL", 451, 458], ["Schiff base", "CHEMICAL", 474, 485], ["N,N 0 -bis(salicylidene)-1,2-ethylenediamine", "CHEMICAL", 494, 538], ["N,N 0bis(salicylidene)-1,3-propanediamine", "CHEMICAL", 545, 586], ["N,N 0 -bis(salicylidene)-1,1,2,2-tetramethylethylenediamine", "CHEMICAL", 597, 656], ["Pt (II)", "CHEMICAL", 711, 718], ["salen", "CHEMICAL", 719, 724], ["Cd A \u00c01", "CHEMICAL", 886, 893], ["Mn (III) salen", "SIMPLE_CHEMICAL", 17, 31], ["conjugated olefins", "SIMPLE_CHEMICAL", 94, 112], ["Mn (II)", "SIMPLE_CHEMICAL", 123, 130], ["bis(2pyridinaldehyde)-ethylenediamine", "SIMPLE_CHEMICAL", 144, 181], ["bis(2-pyridin-aldehyde)propylenediamine ligands", "SIMPLE_CHEMICAL", 183, 230], ["olefins", "SIMPLE_CHEMICAL", 259, 266], ["epoxide", "SIMPLE_CHEMICAL", 286, 293], ["iodosobenzene", "SIMPLE_CHEMICAL", 343, 356], ["PhIO", "SIMPLE_CHEMICAL", 358, 362], ["Pt (II)", "SIMPLE_CHEMICAL", 451, 458], ["Schiff base ligands N,N 0 -bis(salicylidene)-1,2-ethylenediamine (L1), N,N 0bis(salicylidene)-1,3-propanediamine (L2)", "SIMPLE_CHEMICAL", 474, 591], ["N,N 0 -bis(salicylidene)-1,1,2,2-tetramethylethylenediamine", "SIMPLE_CHEMICAL", 597, 656], ["Pt (II)-salen (11) triplet emitters", "SIMPLE_CHEMICAL", 711, 746], ["electrophosphorescent dyes", "SIMPLE_CHEMICAL", 760, 786], ["Mn (III) salen complexes", "PROTEIN", 17, 41], ["Mn (II) complexes", "PROTEIN", 123, 140], ["the Mn (III) salen complexes", "PROBLEM", 13, 41], ["conjugated olefins", "TREATMENT", 94, 112], ["bis(2pyridinaldehyde)", "TREATMENT", 144, 165], ["ethylenediamine", "TREATMENT", 166, 181], ["bis(2-pyridin-aldehyde)propylenediamine ligands", "TREATMENT", 183, 230], ["epoxidation of olefins", "TREATMENT", 244, 266], ["iodosobenzene (PhIO", "TREATMENT", 343, 362], ["wide applications", "TREATMENT", 392, 409], ["Che et al.", "TEST", 426, 436], ["Schiff base ligands", "TEST", 474, 493], ["N", "TEST", 496, 497], ["bis", "TEST", 501, 504], ["salicylidene", "TEST", 505, 517], ["ethylenediamine (L1)", "TREATMENT", 523, 543], ["propanediamine", "TREATMENT", 572, 586], ["bis(salicylidene)", "TREATMENT", 604, 621], ["tetramethylethylenediamine (L3)", "TREATMENT", 630, 661], ["vapor deposited Pt (II)-salen (11) triplet emitters", "TREATMENT", 695, 746], ["efficient electrophosphorescent dyes", "TREATMENT", 750, 786], ["multilayer organic light emitting diode (OLED) devices", "TREATMENT", 790, 844], ["a maximum luminous efficiency", "TREATMENT", 850, 879], ["asymmetric", "OBSERVATION_MODIFIER", 68, 78], ["epoxidation", "OBSERVATION", 79, 90], ["conjugated olefins", "OBSERVATION", 94, 112], ["wide", "OBSERVATION_MODIFIER", 392, 396], ["L3", "ANATOMY", 658, 660], ["luminous efficiency", "OBSERVATION", 860, 879]]], ["They observed that the performance of the OLEDs using the Schiff base dopant L3 is significantly superior to the previously reported Pt (II) emitters.bases have wide applications in dyeMost of the Schiff bases are synthesized by condensation of salicylaldehyde with aromatic amines as well as aliphatic amines.", [["Schiff base dopant", "CHEMICAL", 58, 76], ["Pt", "CHEMICAL", 133, 135], ["salicylaldehyde", "CHEMICAL", 245, 260], ["aromatic amines", "CHEMICAL", 266, 281], ["aliphatic amines", "CHEMICAL", 293, 309], ["Schiff base", "CHEMICAL", 58, 69], ["Pt (II)", "CHEMICAL", 133, 140], ["Schiff bases", "CHEMICAL", 197, 209], ["salicylaldehyde", "CHEMICAL", 245, 260], ["aromatic amines", "CHEMICAL", 266, 281], ["aliphatic amines", "CHEMICAL", 293, 309], ["Pt (II)", "SIMPLE_CHEMICAL", 133, 140], ["Schiff bases", "SIMPLE_CHEMICAL", 197, 209], ["salicylaldehyde", "SIMPLE_CHEMICAL", 245, 260], ["aromatic amines", "SIMPLE_CHEMICAL", 266, 281], ["aliphatic amines", "SIMPLE_CHEMICAL", 293, 309], ["the OLEDs", "TREATMENT", 38, 47], ["the Schiff base dopant L3", "TREATMENT", 54, 79], ["Pt (II) emitters", "TREATMENT", 133, 149], ["wide applications", "TREATMENT", 161, 178], ["dye", "TREATMENT", 182, 185], ["aromatic amines", "TREATMENT", 266, 281], ["aliphatic amines", "TREATMENT", 293, 309], ["L3", "ANATOMY", 77, 79], ["wide", "OBSERVATION_MODIFIER", 161, 165], ["applications", "OBSERVATION", 166, 178], ["Schiff", "OBSERVATION", 197, 203], ["bases", "ANATOMY_MODIFIER", 204, 209]]], ["Several imines have been reported by Calvin and Bailes [21] by practicing condensation reaction of salicylaldehyde and substituted anilines and other aromatic amines.", [["salicylaldehyde", "CHEMICAL", 99, 114], ["substituted anilines", "CHEMICAL", 119, 139], ["aromatic amines", "CHEMICAL", 150, 165], ["imines", "CHEMICAL", 8, 14], ["salicylaldehyde", "CHEMICAL", 99, 114], ["anilines", "CHEMICAL", 131, 139], ["aromatic amines", "CHEMICAL", 150, 165], ["Calvin", "SIMPLE_CHEMICAL", 37, 43], ["Bailes [21]", "SIMPLE_CHEMICAL", 48, 59], ["salicylaldehyde", "SIMPLE_CHEMICAL", 99, 114], ["substituted anilines", "SIMPLE_CHEMICAL", 119, 139], ["aromatic amines", "SIMPLE_CHEMICAL", 150, 165], ["salicylaldehyde", "TREATMENT", 99, 114], ["substituted anilines", "TREATMENT", 119, 139], ["other aromatic amines", "TREATMENT", 144, 165]]], ["The spectroscopic analysis of such nitrogencontaining molecules revealed interesting electronic properties.", [["nitrogencontaining molecules", "PROTEIN", 35, 63], ["The spectroscopic analysis", "TEST", 0, 26], ["such nitrogencontaining molecules", "TEST", 30, 63], ["electronic properties", "OBSERVATION", 85, 106]]], ["It is reported that greater ligation with metal ions could be because of presence of a loan pair of electrons in these compounds.", [["metal ions", "SIMPLE_CHEMICAL", 42, 52], ["greater ligation with metal ions", "TREATMENT", 20, 52], ["greater", "OBSERVATION_MODIFIER", 20, 27], ["ligation", "OBSERVATION", 28, 36]]], ["Large number of such azomethines and their complexes with a variety of transition metals has been documented as review articles in the recent past years [22, 23] Similarly, Gao and Zheung [24] have synthesized some Schiff base ligands 16, 17, and 18 by condensation of 2hydroxyacetophenone with different chiral diamines such as 1,2diamino-cyclohexane, 1,2-diphenylethylenediamine, and 2,2 0 -diamino-1,1 0 -binaphthalene, respectively (Scheme 4), to study the steric, electronic, and geometric effect of a methyl (-CH 3 ) group on an azomethine carbon in asymmetric catalytic reaction.bases have wide applications in dyeRecently, More et al. [25] have described alkynyl functionalized salicylaldiminebases have wide applications in dyeimino]methyl}-4-(4-nitrophenylethynyl)phenol (19) and its Zn (II) and Ni (II) complexes.", [["azomethines", "CHEMICAL", 21, 32], ["2hydroxyacetophenone", "CHEMICAL", 269, 289], ["1,2diamino-cyclohexane", "CHEMICAL", 329, 351], ["1,2-diphenylethylenediamine", "CHEMICAL", 353, 380], ["2,2 0 -diamino-1,1 0 -binaphthalene", "CHEMICAL", 386, 421], ["methyl", "CHEMICAL", 507, 513], ["azomethine carbon", "CHEMICAL", 535, 552], ["salicylaldiminebases", "CHEMICAL", 686, 706], ["dyeimino]methyl}-4-(4-nitrophenylethynyl)phenol", "CHEMICAL", 733, 780], ["Zn", "CHEMICAL", 794, 796], ["Ni", "CHEMICAL", 806, 808], ["azomethines", "CHEMICAL", 21, 32], ["Schiff base", "CHEMICAL", 215, 226], ["2hydroxyacetophenone", "CHEMICAL", 269, 289], ["diamines", "CHEMICAL", 312, 320], ["1,2diamino-cyclohexane", "CHEMICAL", 329, 351], ["1,2-diphenylethylenediamine", "CHEMICAL", 353, 380], ["2,2 0 -diamino-1,1 0 -binaphthalene", "CHEMICAL", 386, 421], ["methyl (-CH 3 )", "CHEMICAL", 507, 522], ["azomethine carbon", "CHEMICAL", 535, 552], ["alkynyl", "CHEMICAL", 663, 670], ["salicylaldiminebases", "CHEMICAL", 686, 706], ["dyeimino]methyl}-4-(4-nitrophenylethynyl)phenol", "CHEMICAL", 733, 780], ["Zn (II)", "CHEMICAL", 794, 801], ["Ni (II)", "CHEMICAL", 806, 813], ["azomethines", "SIMPLE_CHEMICAL", 21, 32], ["Gao", "SIMPLE_CHEMICAL", 173, 176], ["Zheung [24]", "SIMPLE_CHEMICAL", 181, 192], ["2hydroxyacetophenone", "SIMPLE_CHEMICAL", 269, 289], ["chiral diamines", "SIMPLE_CHEMICAL", 305, 320], ["1,2diamino-cyclohexane, 1,2-diphenylethylenediamine", "SIMPLE_CHEMICAL", 329, 380], ["2,2 0 -diamino-1,1 0 -binaphthalene", "SIMPLE_CHEMICAL", 386, 421], ["methyl (-CH 3 )", "SIMPLE_CHEMICAL", 507, 522], ["azomethine carbon", "SIMPLE_CHEMICAL", 535, 552], ["alkynyl functionalized salicylaldiminebases", "SIMPLE_CHEMICAL", 663, 706], ["dyeimino]methyl}-4-(4-nitrophenylethynyl)phenol (19)", "SIMPLE_CHEMICAL", 733, 785], ["Zn (II)", "SIMPLE_CHEMICAL", 794, 801], ["Ni (II)", "SIMPLE_CHEMICAL", 806, 813], ["Zn (II) and Ni (II) complexes", "PROTEIN", 794, 823], ["such azomethines", "PROBLEM", 16, 32], ["transition metals", "TREATMENT", 71, 88], ["some Schiff base ligands", "TEST", 210, 234], ["2hydroxyacetophenone", "TREATMENT", 269, 289], ["different chiral diamines", "TREATMENT", 295, 320], ["1,2diamino-cyclohexane", "TREATMENT", 329, 351], ["diphenylethylenediamine", "TREATMENT", 357, 380], ["a methyl (-CH", "TREATMENT", 505, 518], ["an azomethine carbon", "TREATMENT", 532, 552], ["asymmetric catalytic reaction", "PROBLEM", 556, 585], ["wide applications", "TREATMENT", 597, 614], ["alkynyl functionalized salicylaldiminebases", "TREATMENT", 663, 706], ["dyeimino", "TEST", 733, 741], ["methyl}", "TEST", 742, 749], ["nitrophenylethynyl)phenol", "TREATMENT", 755, 780], ["its Zn (II)", "TREATMENT", 790, 801], ["Ni (II) complexes", "TREATMENT", 806, 823], ["number", "OBSERVATION_MODIFIER", 6, 12], ["such azomethines", "OBSERVATION", 16, 32], ["catalytic reaction", "OBSERVATION", 567, 585], ["wide", "OBSERVATION_MODIFIER", 597, 601]]], ["It was reported that the emission properties of the complexes can be influenced by the p-conjugation, coligands (phen, bipy), and size of the counter anion (ClO 4 \u00c0 , BF 4 \u00c0 , and PF 6 \u00c0 ).bases have wide applications in dyeMore et al. [26] also reported Ni (II) and Zn (II) salophen complexes as promising non-linear optical material because of the effect of p-conjugation is such luminescent complexes.", [["Ni (II", "CHEMICAL", 255, 261], ["Zn", "CHEMICAL", 267, 269], ["salophen", "CHEMICAL", 275, 283], ["phen", "CHEMICAL", 113, 117], ["ClO 4 \u00c0", "CHEMICAL", 157, 164], ["Ni (II)", "CHEMICAL", 255, 262], ["Zn (II)", "CHEMICAL", 267, 274], ["salophen", "CHEMICAL", 275, 283], ["phen", "SIMPLE_CHEMICAL", 113, 117], ["bipy", "SIMPLE_CHEMICAL", 119, 123], ["anion", "SIMPLE_CHEMICAL", 150, 155], ["ClO 4 \u00c0", "SIMPLE_CHEMICAL", 157, 164], ["Ni (II)", "SIMPLE_CHEMICAL", 255, 262], ["Zn (II) salophen complexes", "SIMPLE_CHEMICAL", 267, 293], ["Zn (II) salophen complexes", "PROTEIN", 267, 293], ["luminescent complexes", "PROTEIN", 382, 403], ["BF", "TEST", 167, 169], ["PF", "TEST", 180, 182], ["wide applications", "TREATMENT", 200, 217], ["Zn (II) salophen complexes", "TREATMENT", 267, 293], ["non-linear optical material", "PROBLEM", 307, 334], ["such luminescent complexes", "PROBLEM", 377, 403], ["size", "OBSERVATION_MODIFIER", 130, 134], ["wide", "OBSERVATION_MODIFIER", 200, 204]]], ["A significant number of Schiff base metal complexes are reported as reasonably successful models of biological compounds [27] .bases have wide applications in dyeThey have played vital role in the progress of modern coordination chemistry, and also in the improvement of inorganic biochemistry, catalysis as well as in useful materials due to optical and magnetic properties [28e30].", [["Schiff base", "CHEMICAL", 24, 35], ["Schiff base metal complexes", "SIMPLE_CHEMICAL", 24, 51], ["inorganic", "SIMPLE_CHEMICAL", 271, 280], ["Schiff base metal complexes", "PROBLEM", 24, 51], ["wide applications", "TREATMENT", 138, 155], ["modern coordination chemistry", "TEST", 209, 238], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["Schiff base", "OBSERVATION", 24, 35], ["metal complexes", "OBSERVATION", 36, 51], ["wide", "OBSERVATION_MODIFIER", 138, 142], ["dye", "OBSERVATION", 159, 162]]], ["In recent years, the technology based on light emission or charge transport capacity is of specific interest for electronic devices such as solar cells and active components for image and data treatment storage [31] .", [["solar cells", "ANATOMY", 140, 151], ["solar cells", "CELL", 140, 151], ["solar cells", "CELL_TYPE", 140, 151], ["light emission", "TEST", 41, 55], ["charge transport capacity", "PROBLEM", 59, 84], ["electronic devices", "TREATMENT", 113, 131], ["solar cells", "TREATMENT", 140, 151], ["image", "TEST", 178, 183], ["solar cells", "OBSERVATION", 140, 151]]], ["Since the Schiff base and their metal complexes have different functional groups, they also plays important role in the areas of stereochemistry, spectroscopy, and magnetic fields [32] .bases have wide applications in dyeSimilarly, Semicarbazone is an imine derivative, usually obtained by condensation of semicarbazide with suitable aldehyde or ketone.", [["Semicarbazone", "CHEMICAL", 232, 245], ["semicarbazide", "CHEMICAL", 306, 319], ["aldehyde", "CHEMICAL", 334, 342], ["ketone", "CHEMICAL", 346, 352], ["Schiff base", "CHEMICAL", 10, 21], ["Semicarbazone", "CHEMICAL", 232, 245], ["imine", "CHEMICAL", 252, 257], ["semicarbazide", "CHEMICAL", 306, 319], ["aldehyde", "CHEMICAL", 334, 342], ["ketone", "CHEMICAL", 346, 352], ["dyeSimilarly", "SIMPLE_CHEMICAL", 218, 230], ["Semicarbazone", "SIMPLE_CHEMICAL", 232, 245], ["imine derivative", "SIMPLE_CHEMICAL", 252, 268], ["semicarbazide", "SIMPLE_CHEMICAL", 306, 319], ["aldehyde", "SIMPLE_CHEMICAL", 334, 342], ["ketone", "SIMPLE_CHEMICAL", 346, 352], ["the Schiff base", "PROBLEM", 6, 21], ["spectroscopy", "TEST", 146, 158], ["wide applications in dyeSimilarly", "PROBLEM", 197, 230], ["Semicarbazone", "TREATMENT", 232, 245], ["an imine derivative", "TREATMENT", 249, 268], ["semicarbazide", "TREATMENT", 306, 319], ["Schiff", "OBSERVATION", 10, 16], ["base", "ANATOMY_MODIFIER", 17, 21], ["wide", "OBSERVATION_MODIFIER", 197, 201]]], ["Semicarbazones have potentially wide range of biological applications, such as anticancer, antioxidant, antifungal, anticonvulsant, antiinflammatory, analgesic, and antibacterial agents [33] .", [["anticancer", "ANATOMY", 79, 89], ["Semicarbazones", "CHEMICAL", 0, 14], ["Semicarbazones", "CHEMICAL", 0, 14], ["Semicarbazones", "SIMPLE_CHEMICAL", 0, 14], ["anticancer", "CANCER", 79, 89], ["Semicarbazones", "TREATMENT", 0, 14], ["biological applications", "TREATMENT", 46, 69], ["anticancer", "TREATMENT", 79, 89], ["antioxidant", "TREATMENT", 91, 102], ["antifungal", "TREATMENT", 104, 114], ["anticonvulsant", "TREATMENT", 116, 130], ["antiinflammatory", "TREATMENT", 132, 148], ["analgesic", "TREATMENT", 150, 159], ["antibacterial agents", "TREATMENT", 165, 185]]], ["Semicarbazone and its metal complexes play the significant role in an industrial, pharmaceutical, and agricultural chemistry.", [["Semicarbazone", "CHEMICAL", 0, 13], ["Semicarbazone", "CHEMICAL", 0, 13], ["Semicarbazone", "SIMPLE_CHEMICAL", 0, 13], ["Semicarbazone", "TREATMENT", 0, 13], ["its metal complexes", "TREATMENT", 18, 37], ["agricultural chemistry", "TEST", 102, 124], ["significant", "OBSERVATION_MODIFIER", 47, 58]]], ["They are also used as polymers, dyes, and as catalysts in different biological systems, like Schiff base ligands.", [["Schiff base", "CHEMICAL", 93, 104], ["dyes", "SIMPLE_CHEMICAL", 32, 36], ["Schiff base ligands", "SIMPLE_CHEMICAL", 93, 112], ["polymers, dyes", "TREATMENT", 22, 36], ["Schiff", "OBSERVATION", 93, 99], ["base ligands", "OBSERVATION", 100, 112]]], ["Typical aerobic oxidation of DTBP by Co(salen).", [["DTBP", "CHEMICAL", 29, 33], ["Co", "CHEMICAL", 37, 39], ["salen", "CHEMICAL", 40, 45], ["DTBP", "CHEMICAL", 29, 33], ["Co(salen)", "CHEMICAL", 37, 46], ["DTBP", "SIMPLE_CHEMICAL", 29, 33], ["Co(salen", "SIMPLE_CHEMICAL", 37, 45], ["aerobic oxidation", "OBSERVATION", 8, 25]]], ["DTBP, 2,6-di-tert-butylphenol. that the metal complex can be more active than the free ligand.", [["DTBP", "CHEMICAL", 0, 4], ["2,6-di-tert-butylphenol", "CHEMICAL", 6, 29], ["DTBP", "CHEMICAL", 0, 4], ["2,6-di-tert-butylphenol", "CHEMICAL", 6, 29], ["DTBP", "SIMPLE_CHEMICAL", 0, 4], ["2,6-di-tert-butylphenol", "SIMPLE_CHEMICAL", 6, 29], ["metal complex", "PROTEIN", 40, 53], ["DTBP", "TEST", 0, 4], ["butylphenol", "TREATMENT", 18, 29], ["metal complex", "OBSERVATION_MODIFIER", 40, 53], ["active", "OBSERVATION_MODIFIER", 66, 72]]], ["Transition metal complexes of semicarbazone have been widely studied because of their coordinating ability and analytical application [34] .bases have wide applications in dyeA variety of structural and coordination aspects of semicarbazones and thiosemicarbazone metal complexes of different group element have been discussed by Casas et al. [35] .", [["semicarbazone", "CHEMICAL", 30, 43], ["semicarbazones", "CHEMICAL", 227, 241], ["thiosemicarbazone", "CHEMICAL", 246, 263], ["semicarbazone", "CHEMICAL", 30, 43], ["semicarbazones", "CHEMICAL", 227, 241], ["thiosemicarbazone", "CHEMICAL", 246, 263], ["semicarbazone", "SIMPLE_CHEMICAL", 30, 43], ["semicarbazones", "SIMPLE_CHEMICAL", 227, 241], ["thiosemicarbazone metal complexes", "SIMPLE_CHEMICAL", 246, 279], ["Transition metal complexes of semicarbazone", "TREATMENT", 0, 43], ["wide applications", "TREATMENT", 151, 168], ["semicarbazones", "TREATMENT", 227, 241], ["thiosemicarbazone metal complexes", "TREATMENT", 246, 279], ["wide", "OBSERVATION_MODIFIER", 151, 155], ["applications", "OBSERVATION", 156, 168]]], ["Large number of thiosemicabazones is used for the detection and determination of different cations and anions.", [["thiosemicabazones", "CHEMICAL", 16, 33], ["thiosemicabazones", "CHEMICAL", 16, 33], ["thiosemicabazones", "SIMPLE_CHEMICAL", 16, 33], ["cations", "SIMPLE_CHEMICAL", 91, 98], ["anions", "SIMPLE_CHEMICAL", 103, 109], ["thiosemicabazones", "TREATMENT", 16, 33], ["the detection", "TEST", 46, 59], ["different cations", "TREATMENT", 81, 98], ["number", "OBSERVATION_MODIFIER", 6, 12], ["thiosemicabazones", "OBSERVATION", 16, 33]]], ["Spectrophotometry or extractive spectrophotometry are often employed for the quantitative determination of ions; in addition to these, some other techniques are also used such as gravimetry, titrimetry, and fluorimetry by Suvarapu et al. [36] .", [["Spectrophotometry", "TEST", 0, 17], ["extractive spectrophotometry", "TEST", 21, 49]]], ["Asuero et al. [37] and Singh et al. [38] described application of thiosemicarbazone in inorganic analysis where they showed that biacetyl bis(4-phenyl-3-thiosemicarbazone) (BBPT) as well as bipyridyl glyoxal bis(4phenyl-3-thiosemicarbazone) (BGPT) can be employed in the spectrophotometric determination of copper, zinc, mercury, and palladium.", [["thiosemicarbazone", "CHEMICAL", 66, 83], ["biacetyl bis", "CHEMICAL", 129, 141], ["4-phenyl-3-thiosemicarbazone", "CHEMICAL", 142, 170], ["BBPT", "CHEMICAL", 173, 177], ["bipyridyl", "CHEMICAL", 190, 199], ["glyoxal bis", "CHEMICAL", 200, 211], ["4phenyl-3-thiosemicarbazone", "CHEMICAL", 212, 239], ["BGPT", "CHEMICAL", 242, 246], ["copper", "CHEMICAL", 307, 313], ["zinc", "CHEMICAL", 315, 319], ["mercury", "CHEMICAL", 321, 328], ["palladium", "CHEMICAL", 334, 343], ["thiosemicarbazone", "CHEMICAL", 66, 83], ["biacetyl bis(4-phenyl-3-thiosemicarbazone)", "CHEMICAL", 129, 171], ["BBPT", "CHEMICAL", 173, 177], ["bipyridyl glyoxal bis(4phenyl-3-thiosemicarbazone)", "CHEMICAL", 190, 240], ["BGPT", "CHEMICAL", 242, 246], ["copper", "CHEMICAL", 307, 313], ["zinc", "CHEMICAL", 315, 319], ["mercury", "CHEMICAL", 321, 328], ["palladium", "CHEMICAL", 334, 343], ["thiosemicarbazone", "SIMPLE_CHEMICAL", 66, 83], ["biacetyl bis(4-phenyl-3-thiosemicarbazone", "SIMPLE_CHEMICAL", 129, 170], ["BBPT", "SIMPLE_CHEMICAL", 173, 177], ["bipyridyl glyoxal bis(4phenyl-3-thiosemicarbazone", "SIMPLE_CHEMICAL", 190, 239], ["BGPT", "SIMPLE_CHEMICAL", 242, 246], ["copper", "SIMPLE_CHEMICAL", 307, 313], ["zinc", "SIMPLE_CHEMICAL", 315, 319], ["mercury", "SIMPLE_CHEMICAL", 321, 328], ["palladium", "SIMPLE_CHEMICAL", 334, 343], ["thiosemicarbazone in inorganic analysis", "TEST", 66, 105], ["biacetyl bis", "TEST", 129, 141], ["phenyl-3-thiosemicarbazone) (BBPT)", "TREATMENT", 144, 178], ["bipyridyl glyoxal bis", "TREATMENT", 190, 211], ["4phenyl-3-thiosemicarbazone)", "TREATMENT", 212, 240], ["the spectrophotometric determination", "TEST", 267, 303], ["palladium", "ANATOMY", 334, 343]]], ["Such studies explained that the complexing properties of BBPT and BGPT are much better than those exhibited by biacetyl monothiosemicarbazone (BMTS) and picolinealdehyde-4-phenyl-3-thiosemicarbazone (PPTS).", [["BBPT", "CHEMICAL", 57, 61], ["BGPT", "CHEMICAL", 66, 70], ["biacetyl monothiosemicarbazone", "CHEMICAL", 111, 141], ["BMTS", "CHEMICAL", 143, 147], ["picolinealdehyde-4-phenyl-3-thiosemicarbazone", "CHEMICAL", 153, 198], ["PPTS", "CHEMICAL", 200, 204], ["BBPT", "CHEMICAL", 57, 61], ["BGPT", "CHEMICAL", 66, 70], ["biacetyl monothiosemicarbazone", "CHEMICAL", 111, 141], ["BMTS", "CHEMICAL", 143, 147], ["picolinealdehyde-4-phenyl-3-thiosemicarbazone", "CHEMICAL", 153, 198], ["PPTS", "CHEMICAL", 200, 204], ["BBPT", "SIMPLE_CHEMICAL", 57, 61], ["BGPT", "SIMPLE_CHEMICAL", 66, 70], ["biacetyl monothiosemicarbazone", "SIMPLE_CHEMICAL", 111, 141], ["BMTS", "SIMPLE_CHEMICAL", 143, 147], ["picolinealdehyde-4-phenyl-3-thiosemicarbazone", "SIMPLE_CHEMICAL", 153, 198], ["PPTS", "SIMPLE_CHEMICAL", 200, 204], ["Such studies", "TEST", 0, 12], ["BBPT and BGPT", "PROBLEM", 57, 70], ["biacetyl monothiosemicarbazone (BMTS)", "TREATMENT", 111, 148], ["picolinealdehyde", "TREATMENT", 153, 169], ["phenyl", "TREATMENT", 172, 178]]], ["Also, BBPT is recommended as a reagent for the extractive spectrophotometric determination of cadmium and bismuth.", [["BBPT", "CHEMICAL", 6, 10], ["cadmium", "CHEMICAL", 94, 101], ["bismuth", "CHEMICAL", 106, 113], ["cadmium", "CHEMICAL", 94, 101], ["bismuth", "CHEMICAL", 106, 113], ["BBPT", "SIMPLE_CHEMICAL", 6, 10], ["cadmium", "SIMPLE_CHEMICAL", 94, 101], ["bismuth", "SIMPLE_CHEMICAL", 106, 113], ["the extractive spectrophotometric determination", "TEST", 43, 90]]], ["In addition to their interesting coordination chemistry, semicarbazone and thiosemicabazones have attracted enormous attention because of their potentially useful biological activities [39] .", [["semicarbazone", "CHEMICAL", 57, 70], ["thiosemicabazones", "CHEMICAL", 75, 92], ["semicarbazone", "CHEMICAL", 57, 70], ["thiosemicabazones", "CHEMICAL", 75, 92], ["semicarbazone", "SIMPLE_CHEMICAL", 57, 70], ["thiosemicabazones", "SIMPLE_CHEMICAL", 75, 92], ["semicarbazone", "TREATMENT", 57, 70], ["thiosemicabazones", "TREATMENT", 75, 92]]], ["There are several reports existing on biological activity of thiosemicabazones and their transition metal complexes [40] .", [["thiosemicabazones", "CHEMICAL", 61, 78], ["thiosemicabazones", "CHEMICAL", 61, 78], ["transition metal", "CHEMICAL", 89, 105], ["thiosemicabazones", "SIMPLE_CHEMICAL", 61, 78], ["thiosemicabazones", "TREATMENT", 61, 78], ["biological activity", "OBSERVATION_MODIFIER", 38, 57]]], ["The mechanism of biological activity of thiosemicarbazones are because of their ability to inhibit the biosynthesis of DNA, probably by blocking the enzyme ribonucleotide diphosphate reductase; binding to the nitrogen bases of DNA, by hindering base replication; and by creating the lesions in DNA strands by oxidative rupture [41, 42] .", [["lesions", "ANATOMY", 283, 290], ["thiosemicarbazones", "CHEMICAL", 40, 58], ["diphosphate", "CHEMICAL", 171, 182], ["thiosemicarbazones", "CHEMICAL", 40, 58], ["ribonucleotide diphosphate", "CHEMICAL", 156, 182], ["nitrogen", "CHEMICAL", 209, 217], ["thiosemicarbazones", "SIMPLE_CHEMICAL", 40, 58], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["ribonucleotide diphosphate reductase", "GENE_OR_GENE_PRODUCT", 156, 192], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["lesions", "PATHOLOGICAL_FORMATION", 283, 290], ["DNA", "CELLULAR_COMPONENT", 294, 297], ["enzyme ribonucleotide diphosphate reductase", "PROTEIN", 149, 192], ["thiosemicarbazones", "TREATMENT", 40, 58], ["the biosynthesis of DNA", "PROBLEM", 99, 122], ["the enzyme ribonucleotide diphosphate reductase", "PROBLEM", 145, 192], ["the nitrogen bases of DNA", "TREATMENT", 205, 230], ["the lesions", "PROBLEM", 279, 290], ["oxidative rupture", "PROBLEM", 309, 326], ["diphosphate reductase", "OBSERVATION", 171, 192], ["lesions", "OBSERVATION", 283, 290], ["oxidative rupture", "OBSERVATION", 309, 326]]], ["Zn (II) complexes of 2-acetylpyridine-4-phenyl semicarbazone have also been reported for their antimicrobial activity against various bacteria and fungi [43] .", [["Zn", "CHEMICAL", 0, 2], ["2-acetylpyridine-4-phenyl semicarbazone", "CHEMICAL", 21, 60], ["Zn (II)", "CHEMICAL", 0, 7], ["2-acetylpyridine-4-phenyl semicarbazone", "CHEMICAL", 21, 60], ["Zn (II)", "SIMPLE_CHEMICAL", 0, 7], ["2-acetylpyridine-4-phenyl semicarbazone", "SIMPLE_CHEMICAL", 21, 60], ["Zn (II) complexes", "PROTEIN", 0, 17], ["Zn (II) complexes", "TREATMENT", 0, 17], ["acetylpyridine", "TREATMENT", 23, 37], ["phenyl semicarbazone", "TREATMENT", 40, 60], ["various bacteria", "PROBLEM", 126, 142], ["fungi", "PROBLEM", 147, 152]]], ["The synthesis of metal complexes of 1-vinyl-pyrrole-2-carbaldehyde semicarbazone and thiosemicarbazone and their importance in pharmaceutical as well as in medicinal field have been reported by Milkhaleva et al. [44] . ortho-Naphthoquinone thiosemicarbazone (NQTS) as well as naphthoquinone semicarbazone (NQSC) and their different Ni (II) complexes [45] were investigated for their in vitro anticancer activity in MCF-7 human breast cancer cells.", [["anticancer", "ANATOMY", 392, 402], ["MCF-7", "ANATOMY", 415, 420], ["breast cancer cells", "ANATOMY", 427, 446], ["1-vinyl-pyrrole-2-carbaldehyde semicarbazone", "CHEMICAL", 36, 80], ["thiosemicarbazone", "CHEMICAL", 85, 102], ["ortho-Naphthoquinone thiosemicarbazone", "CHEMICAL", 219, 257], ["NQTS", "CHEMICAL", 259, 263], ["naphthoquinone semicarbazone", "CHEMICAL", 276, 304], ["NQSC", "CHEMICAL", 306, 310], ["Ni", "CHEMICAL", 332, 334], ["breast cancer", "DISEASE", 427, 440], ["1-vinyl-pyrrole-2-carbaldehyde semicarbazone", "CHEMICAL", 36, 80], ["thiosemicarbazone", "CHEMICAL", 85, 102], ["ortho-Naphthoquinone thiosemicarbazone", "CHEMICAL", 219, 257], ["NQTS", "CHEMICAL", 259, 263], ["naphthoquinone semicarbazone", "CHEMICAL", 276, 304], ["NQSC", "CHEMICAL", 306, 310], ["Ni (II)", "CHEMICAL", 332, 339], ["1-vinyl-pyrrole-2-carbaldehyde semicarbazone", "SIMPLE_CHEMICAL", 36, 80], ["thiosemicarbazone", "SIMPLE_CHEMICAL", 85, 102], ["ortho-Naphthoquinone thiosemicarbazone", "SIMPLE_CHEMICAL", 219, 257], ["NQTS", "SIMPLE_CHEMICAL", 259, 263], ["naphthoquinone semicarbazone", "SIMPLE_CHEMICAL", 276, 304], ["NQSC", "SIMPLE_CHEMICAL", 306, 310], ["Ni (II) complexes [45]", "SIMPLE_CHEMICAL", 332, 354], ["anticancer", "CANCER", 392, 402], ["MCF-7", "CELL", 415, 420], ["human", "ORGANISM", 421, 426], ["breast cancer cells", "CELL", 427, 446], ["Ni (II) complexes", "PROTEIN", 332, 349], ["MCF-7 human breast cancer cells", "CELL_LINE", 415, 446], ["human", "SPECIES", 421, 426], ["MCF-7", "SPECIES", 415, 420], ["human", "SPECIES", 421, 426], ["vinyl-pyrrole", "TREATMENT", 38, 51], ["carbaldehyde semicarbazone", "TREATMENT", 54, 80], ["thiosemicarbazone", "TREATMENT", 85, 102], ["ortho-Naphthoquinone thiosemicarbazone (NQTS)", "TREATMENT", 219, 264], ["naphthoquinone semicarbazone (NQSC)", "TREATMENT", 276, 311], ["human breast cancer cells", "PROBLEM", 421, 446], ["breast", "ANATOMY", 427, 433], ["cancer cells", "OBSERVATION", 434, 446]]], ["It is observed that nickel complex with NQTS and NQSC is more active in the inhibitory action of MCF-7 cell proliferation than the free ligands.", [["MCF-7 cell", "ANATOMY", 97, 107], ["nickel", "CHEMICAL", 20, 26], ["NQTS", "CHEMICAL", 40, 44], ["NQSC", "CHEMICAL", 49, 53], ["nickel", "CHEMICAL", 20, 26], ["NQTS", "CHEMICAL", 40, 44], ["NQSC", "CHEMICAL", 49, 53], ["nickel", "SIMPLE_CHEMICAL", 20, 26], ["NQTS", "SIMPLE_CHEMICAL", 40, 44], ["NQSC", "SIMPLE_CHEMICAL", 49, 53], ["MCF-7 cell", "CELL", 97, 107], ["nickel complex", "PROTEIN", 20, 34], ["nickel complex with NQTS", "PROBLEM", 20, 44], ["MCF", "TEST", 97, 100], ["nickel", "OBSERVATION_MODIFIER", 20, 26], ["complex", "OBSERVATION_MODIFIER", 27, 34], ["more", "OBSERVATION_MODIFIER", 57, 61], ["active", "OBSERVATION_MODIFIER", 62, 68], ["7 cell proliferation", "OBSERVATION", 101, 121], ["free ligands", "OBSERVATION", 131, 143]]], ["This exposed the remarkable anticancer properties of these compounds.", [["anticancer", "ANATOMY", 28, 38], ["anticancer", "CANCER", 28, 38], ["remarkable", "OBSERVATION_MODIFIER", 17, 27], ["anticancer properties", "OBSERVATION", 28, 49], ["compounds", "OBSERVATION_MODIFIER", 59, 68]]], ["Chandra and Tyagi [46] have reported the synthesis, electron paramagnetic resonance (EPR), and electronic spectral studies of Mn (II) and Cr (III) complexes of vanillin thiosemicarbazone and semicarbazone, and they observed octahedral geometry for these complexes.", [["Mn", "CHEMICAL", 126, 128], ["Cr", "CHEMICAL", 138, 140], ["vanillin thiosemicarbazone", "CHEMICAL", 160, 186], ["semicarbazone", "CHEMICAL", 191, 204], ["Mn (II)", "CHEMICAL", 126, 133], ["Cr (III)", "CHEMICAL", 138, 146], ["vanillin thiosemicarbazone", "CHEMICAL", 160, 186], ["semicarbazone", "CHEMICAL", 191, 204], ["electron", "SIMPLE_CHEMICAL", 52, 60], ["Mn (II)", "SIMPLE_CHEMICAL", 126, 133], ["Cr (III)", "SIMPLE_CHEMICAL", 138, 146], ["vanillin thiosemicarbazone", "SIMPLE_CHEMICAL", 160, 186], ["semicarbazone", "SIMPLE_CHEMICAL", 191, 204], ["Cr (III) complexes", "PROTEIN", 138, 156], ["electronic spectral studies", "TEST", 95, 122], ["Cr", "TEST", 138, 140], ["vanillin thiosemicarbazone", "TREATMENT", 160, 186], ["semicarbazone", "TREATMENT", 191, 204], ["octahedral geometry", "OBSERVATION", 224, 243]]], ["Several novel semicarbazones and their Zn (II) and Cd (II) complexes (Scheme 6) were reported by Jadhav et al. [47] for their use as precursor for the synthesis of nanostructured metal selenides with particle diameter typically below 5e10 nm.", [["semicarbazones", "CHEMICAL", 14, 28], ["Zn", "CHEMICAL", 39, 41], ["Cd", "CHEMICAL", 51, 53], ["semicarbazones", "CHEMICAL", 14, 28], ["Zn (II)", "CHEMICAL", 39, 46], ["Cd (II)", "CHEMICAL", 51, 58], ["metal selenides", "CHEMICAL", 179, 194], ["semicarbazones", "SIMPLE_CHEMICAL", 14, 28], ["Zn (II)", "SIMPLE_CHEMICAL", 39, 46], ["Cd (II)", "SIMPLE_CHEMICAL", 51, 58], ["nanostructured metal selenides", "SIMPLE_CHEMICAL", 164, 194], ["Zn (II) and Cd (II) complexes", "PROTEIN", 39, 68], ["Several novel semicarbazones", "TREATMENT", 0, 28], ["their Zn (II) and Cd (II) complexes (Scheme", "TREATMENT", 33, 76], ["the synthesis of nanostructured metal selenides", "TREATMENT", 147, 194], ["particle diameter", "OBSERVATION_MODIFIER", 200, 217]]], ["Such precursors gave new dimension to their utility and possibly allowed their entry in the field of nanotechnology.bases have wide applications in dyeIn recent years, sulfur-containing ligands such as thiosemicabazones and dithiocarbamates and their transition metal complexes have attracted enormous attention because of their pharmacological properties such as antibacterial, antifungal, antiviral, and antitumor activities [48,49] e.g. Cory et al. [50] have studied and reported that 3-aminopyridine-2carboxaldehyde thiosemicarbazone and 3-amino-4methylpyridine-2-carboxaldehyde thiosemicarbazone were most active with respect to inhibition of cell growth and ribonucleotide reductase activity as compared with 5-aminopyridine-2-carboxaldehyde thiosemicarbazone and 4-methyl-5aminopyridine-2-carboxaldehyde thiosemicarbazone.bases have wide applications in dyeLiberta and West [51] have described that the heterocyclic thiosemicarbazones containing hydrogen and either an alkyl or aryl group attached at 4 N are moderately inactive antifungal agents.", [["antitumor", "ANATOMY", 406, 415], ["cell", "ANATOMY", 648, 652], ["sulfur", "CHEMICAL", 168, 174], ["thiosemicabazones", "CHEMICAL", 202, 219], ["dithiocarbamates", "CHEMICAL", 224, 240], ["3-aminopyridine-2carboxaldehyde thiosemicarbazone", "CHEMICAL", 488, 537], ["3-amino-4methylpyridine-2-carboxaldehyde thiosemicarbazone", "CHEMICAL", 542, 600], ["5-aminopyridine-2-carboxaldehyde thiosemicarbazone", "CHEMICAL", 715, 765], ["4-methyl-5aminopyridine-2-carboxaldehyde thiosemicarbazone", "CHEMICAL", 770, 828], ["thiosemicarbazones", "CHEMICAL", 923, 941], ["hydrogen", "CHEMICAL", 953, 961], ["alkyl", "CHEMICAL", 976, 981], ["aryl", "CHEMICAL", 985, 989], ["sulfur", "CHEMICAL", 168, 174], ["thiosemicabazones", "CHEMICAL", 202, 219], ["dithiocarbamates", "CHEMICAL", 224, 240], ["transition metal", "CHEMICAL", 251, 267], ["3-aminopyridine-2carboxaldehyde thiosemicarbazone", "CHEMICAL", 488, 537], ["3-amino-4methylpyridine-2-carboxaldehyde thiosemicarbazone", "CHEMICAL", 542, 600], ["ribonucleotide", "CHEMICAL", 664, 678], ["5-aminopyridine-2-carboxaldehyde thiosemicarbazone", "CHEMICAL", 715, 765], ["4-methyl-5aminopyridine-2-carboxaldehyde thiosemicarbazone", "CHEMICAL", 770, 828], ["thiosemicarbazones", "CHEMICAL", 923, 941], ["hydrogen", "CHEMICAL", 953, 961], ["aryl", "CHEMICAL", 985, 989], ["sulfur", "SIMPLE_CHEMICAL", 168, 174], ["thiosemicabazones", "SIMPLE_CHEMICAL", 202, 219], ["dithiocarbamates", "SIMPLE_CHEMICAL", 224, 240], ["antitumor", "CANCER", 406, 415], ["3-aminopyridine-2carboxaldehyde thiosemicarbazone", "SIMPLE_CHEMICAL", 488, 537], ["3-amino-4methylpyridine-2-carboxaldehyde thiosemicarbazone", "SIMPLE_CHEMICAL", 542, 600], ["cell", "CELL", 648, 652], ["ribonucleotide reductase", "GENE_OR_GENE_PRODUCT", 664, 688], ["5-aminopyridine-2-carboxaldehyde thiosemicarbazone", "SIMPLE_CHEMICAL", 715, 765], ["4-methyl-5aminopyridine-2-carboxaldehyde thiosemicarbazone", "SIMPLE_CHEMICAL", 770, 828], ["heterocyclic thiosemicarbazones", "SIMPLE_CHEMICAL", 910, 941], ["hydrogen", "SIMPLE_CHEMICAL", 953, 961], ["alkyl", "SIMPLE_CHEMICAL", 976, 981], ["aryl", "SIMPLE_CHEMICAL", 985, 989], ["4 N", "SIMPLE_CHEMICAL", 1008, 1011], ["antifungal agents", "SIMPLE_CHEMICAL", 1036, 1053], ["ribonucleotide reductase", "PROTEIN", 664, 688], ["wide applications", "TREATMENT", 127, 144], ["sulfur-containing ligands", "TREATMENT", 168, 193], ["thiosemicabazones", "TREATMENT", 202, 219], ["dithiocarbamates", "TREATMENT", 224, 240], ["their transition metal complexes", "TREATMENT", 245, 277], ["antibacterial", "TREATMENT", 364, 377], ["antifungal", "TREATMENT", 379, 389], ["antiviral", "TREATMENT", 391, 400], ["antitumor activities", "TREATMENT", 406, 426], ["aminopyridine", "TREATMENT", 490, 503], ["2carboxaldehyde thiosemicarbazone", "TREATMENT", 504, 537], ["amino", "TREATMENT", 544, 549], ["4methylpyridine", "TREATMENT", 550, 565], ["carboxaldehyde thiosemicarbazone", "TREATMENT", 568, 600], ["cell growth", "TREATMENT", 648, 659], ["ribonucleotide reductase activity", "TREATMENT", 664, 697], ["aminopyridine", "TREATMENT", 717, 730], ["carboxaldehyde thiosemicarbazone", "TREATMENT", 733, 765], ["methyl", "TREATMENT", 772, 778], ["5aminopyridine", "TREATMENT", 779, 793], ["carboxaldehyde thiosemicarbazone", "TREATMENT", 796, 828], ["the heterocyclic thiosemicarbazones containing hydrogen", "TREATMENT", 906, 961], ["an alkyl or aryl group attached", "TREATMENT", 973, 1004], ["moderately inactive antifungal agents", "TREATMENT", 1016, 1053], ["wide", "OBSERVATION_MODIFIER", 127, 131], ["wide", "OBSERVATION_MODIFIER", 840, 844], ["moderately", "OBSERVATION_MODIFIER", 1016, 1026], ["inactive", "OBSERVATION_MODIFIER", 1027, 1035], ["antifungal agents", "OBSERVATION", 1036, 1053]]], ["Fungal growth inhibition resulted for the uncomplexed thiosemicabazones and its Cu (II) and Ni (II) complexes against Aspergillus niger showed that the thiosemicarbazones exhibit higher antifungal activity against A. niger as compared with their Cu (II) and Ni (II) complexes, which showed less or no activity toward A. niger.", [["thiosemicabazones", "CHEMICAL", 54, 71], ["Cu", "CHEMICAL", 80, 82], ["Ni", "CHEMICAL", 92, 94], ["thiosemicarbazones", "CHEMICAL", 152, 170], ["Cu", "CHEMICAL", 246, 248], ["Ni", "CHEMICAL", 258, 260], ["thiosemicabazones", "CHEMICAL", 54, 71], ["Cu (II)", "CHEMICAL", 80, 87], ["Ni (II)", "CHEMICAL", 92, 99], ["thiosemicarbazones", "CHEMICAL", 152, 170], ["Cu (II)", "CHEMICAL", 246, 253], ["Ni (II)", "CHEMICAL", 258, 265], ["thiosemicabazones", "SIMPLE_CHEMICAL", 54, 71], ["Cu (II)", "SIMPLE_CHEMICAL", 80, 87], ["Ni (II)", "SIMPLE_CHEMICAL", 92, 99], ["Aspergillus niger", "ORGANISM", 118, 135], ["thiosemicarbazones", "SIMPLE_CHEMICAL", 152, 170], ["A. niger", "ORGANISM", 214, 222], ["Cu (II)", "SIMPLE_CHEMICAL", 246, 253], ["Ni (II)", "SIMPLE_CHEMICAL", 258, 265], ["A. niger", "ORGANISM", 317, 325], ["Ni (II) complexes", "PROTEIN", 92, 109], ["Ni (II) complexes", "PROTEIN", 258, 275], ["Aspergillus niger", "SPECIES", 118, 135], ["A. niger", "SPECIES", 214, 222], ["A. niger", "SPECIES", 317, 325], ["Aspergillus niger", "SPECIES", 118, 135], ["A. niger", "SPECIES", 214, 222], ["A. niger", "SPECIES", 317, 325], ["Fungal growth inhibition", "PROBLEM", 0, 24], ["the uncomplexed thiosemicabazones", "PROBLEM", 38, 71], ["Ni (II) complexes against Aspergillus niger", "PROBLEM", 92, 135], ["the thiosemicarbazones", "PROBLEM", 148, 170], ["Ni (II) complexes", "TEST", 258, 275], ["higher", "OBSERVATION_MODIFIER", 179, 185], ["antifungal activity", "OBSERVATION", 186, 205]]], ["Each compound showed activity above the minimal concentration, i.e. 200 mg ml \u00c01 .Preparation of Schiff baseThere are various reaction pathways to synthesize Schiff base(s).", [["Schiff base", "CHEMICAL", 97, 108], ["Schiff base", "CHEMICAL", 97, 108], ["Schiff base", "CHEMICAL", 158, 169], ["Schiff base", "SIMPLE_CHEMICAL", 158, 169], ["Schiff base", "TREATMENT", 97, 108], ["various reaction pathways", "PROBLEM", 118, 143], ["activity", "OBSERVATION_MODIFIER", 21, 29], ["Schiff base", "OBSERVATION", 97, 108], ["various", "OBSERVATION_MODIFIER", 118, 125], ["reaction pathways", "OBSERVATION", 126, 143], ["Schiff base", "OBSERVATION", 158, 169]]], ["An acid catalyzed condensation reaction of primary amine with an aldehyde or ketone under refluxing condition is the most commonly used method, e.g. mineral acids are often employed as catalysts (Scheme 7).", [["amine", "CHEMICAL", 51, 56], ["aldehyde", "CHEMICAL", 65, 73], ["ketone", "CHEMICAL", 77, 83], ["primary amine", "CHEMICAL", 43, 56], ["aldehyde", "CHEMICAL", 65, 73], ["ketone", "CHEMICAL", 77, 83], ["primary amine", "SIMPLE_CHEMICAL", 43, 56], ["aldehyde", "SIMPLE_CHEMICAL", 65, 73], ["ketone", "SIMPLE_CHEMICAL", 77, 83], ["mineral acids", "SIMPLE_CHEMICAL", 149, 162], ["An acid catalyzed condensation reaction", "PROBLEM", 0, 39], ["an aldehyde or ketone under refluxing condition", "TREATMENT", 62, 109], ["mineral acids", "TREATMENT", 149, 162], ["acid catalyzed", "OBSERVATION", 3, 17], ["refluxing", "OBSERVATION", 90, 99]]], ["In this reaction, the nucleophilic nitrogen atom of amine attacks on the carbonyl carbon results into an unstable intermediate, i.e. carbinolamine.", [["amine", "CHEMICAL", 52, 57], ["carbonyl carbon", "CHEMICAL", 73, 88], ["carbinolamine", "CHEMICAL", 133, 146], ["nitrogen", "CHEMICAL", 35, 43], ["amine", "CHEMICAL", 52, 57], ["carbonyl carbon", "CHEMICAL", 73, 88], ["carbinolamine", "CHEMICAL", 133, 146], ["amine", "SIMPLE_CHEMICAL", 52, 57], ["carbonyl carbon", "SIMPLE_CHEMICAL", 73, 88], ["carbinolamine", "SIMPLE_CHEMICAL", 133, 146], ["this reaction", "PROBLEM", 3, 16], ["the nucleophilic nitrogen atom", "TREATMENT", 18, 48], ["the carbonyl carbon", "TEST", 69, 88], ["carbinolamine", "TREATMENT", 133, 146]]], ["Owing to the elimination of one molecule of water, a C\u00bcN bond is formed, and the product is known as imine.", [["imine", "CHEMICAL", 101, 106], ["C\u00bcN", "CHEMICAL", 53, 56], ["imine", "CHEMICAL", 101, 106], ["water", "SIMPLE_CHEMICAL", 44, 49], ["C\u00bcN", "SIMPLE_CHEMICAL", 53, 56], ["imine", "SIMPLE_CHEMICAL", 101, 106], ["a C\u00bcN bond", "TREATMENT", 51, 61]]], ["In general, reactivity of aldehyde is more than ketone in the formation of Schiff base as the reaction center of aldehyde is sterically less hindered as compared with the ketone.", [["aldehyde", "CHEMICAL", 26, 34], ["ketone", "CHEMICAL", 48, 54], ["Schiff", "CHEMICAL", 75, 81], ["aldehyde", "CHEMICAL", 113, 121], ["ketone", "CHEMICAL", 171, 177], ["aldehyde", "CHEMICAL", 26, 34], ["ketone", "CHEMICAL", 48, 54], ["Schiff base", "CHEMICAL", 75, 86], ["aldehyde", "CHEMICAL", 113, 121], ["ketone", "CHEMICAL", 171, 177], ["aldehyde", "SIMPLE_CHEMICAL", 26, 34], ["ketone", "SIMPLE_CHEMICAL", 48, 54], ["Schiff base", "SIMPLE_CHEMICAL", 75, 86], ["aldehyde", "SIMPLE_CHEMICAL", 113, 121], ["ketone", "SIMPLE_CHEMICAL", 171, 177], ["the ketone", "TEST", 167, 177], ["aldehyde", "OBSERVATION_MODIFIER", 26, 34], ["Schiff base", "OBSERVATION", 75, 86], ["aldehyde", "OBSERVATION_MODIFIER", 113, 121], ["sterically less", "OBSERVATION_MODIFIER", 125, 140]]], ["The condensation reaction is affected by the pH of the solution and the steric as well as electronic effect of an amine and carbonyl compounds.", [["amine", "CHEMICAL", 114, 119], ["carbonyl", "CHEMICAL", 124, 132], ["amine", "CHEMICAL", 114, 119], ["carbonyl", "CHEMICAL", 124, 132], ["amine", "SIMPLE_CHEMICAL", 114, 119], ["carbonyl compounds", "SIMPLE_CHEMICAL", 124, 142], ["The condensation reaction", "PROBLEM", 0, 25], ["an amine and carbonyl compounds", "TREATMENT", 111, 142], ["condensation reaction", "OBSERVATION", 4, 25], ["steric", "ANATOMY_MODIFIER", 72, 78], ["carbonyl compounds", "OBSERVATION", 124, 142]]], ["Because the dehydration of the carbinolamine is the rate-determining step of Schiff base formation, such reactions are catalyzed by acids.", [["dehydration", "DISEASE", 12, 23], ["carbinolamine", "CHEMICAL", 31, 44], ["carbinolamine", "CHEMICAL", 31, 44], ["Schiff base", "CHEMICAL", 77, 88], ["carbinolamine", "SIMPLE_CHEMICAL", 31, 44], ["Schiff base", "SIMPLE_CHEMICAL", 77, 88], ["the dehydration", "PROBLEM", 8, 23], ["the carbinolamine", "TREATMENT", 27, 44], ["the rate", "TEST", 48, 56], ["Schiff base formation", "PROBLEM", 77, 98], ["dehydration", "OBSERVATION", 12, 23], ["Schiff base", "OBSERVATION", 77, 88]]], ["One should also note that the higher concentration of acid will protonate the amine and restricting its functionality as a nucleophile, thus suppressing formation carbinolamine.", [["amine", "CHEMICAL", 78, 83], ["carbinolamine", "CHEMICAL", 163, 176], ["amine", "CHEMICAL", 78, 83], ["carbinolamine", "CHEMICAL", 163, 176], ["amine", "SIMPLE_CHEMICAL", 78, 83], ["carbinolamine", "SIMPLE_CHEMICAL", 163, 176], ["acid will protonate the amine", "TREATMENT", 54, 83], ["a nucleophile", "TREATMENT", 121, 134], ["suppressing formation carbinolamine", "TREATMENT", 141, 176]]], ["Therefore, syntheses of many Schiff bases are carried out at mild acidic pH.", [["Schiff bases", "CHEMICAL", 29, 41], ["many Schiff bases", "PROBLEM", 24, 41], ["mild acidic pH", "PROBLEM", 61, 75], ["Schiff bases", "OBSERVATION", 29, 41], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["acidic pH", "OBSERVATION", 66, 75]]], ["Similarly, in basic conditions, the reaction is hindered because of non-availability of protons to catalyze the elimination of the carbinolamine hydroxyl group.Preparation of semicarbazoneDifferent types of semicarbazone (Scheme 8) derivatives could be synthesized by adding stoichiometric quantity of suitable aldehyde or ketone with respective semicarbazide in presence of sodium acetate [52] .", [["carbinolamine hydroxyl", "CHEMICAL", 131, 153], ["semicarbazoneDifferent", "CHEMICAL", 175, 197], ["semicarbazone", "CHEMICAL", 207, 220], ["aldehyde", "CHEMICAL", 311, 319], ["ketone", "CHEMICAL", 323, 329], ["semicarbazide", "CHEMICAL", 346, 359], ["sodium acetate", "CHEMICAL", 375, 389], ["carbinolamine hydroxyl", "CHEMICAL", 131, 153], ["semicarbazoneDifferent", "CHEMICAL", 175, 197], ["semicarbazone", "CHEMICAL", 207, 220], ["aldehyde", "CHEMICAL", 311, 319], ["ketone", "CHEMICAL", 323, 329], ["semicarbazide", "CHEMICAL", 346, 359], ["sodium acetate", "CHEMICAL", 375, 389], ["protons", "SIMPLE_CHEMICAL", 88, 95], ["carbinolamine hydroxyl", "SIMPLE_CHEMICAL", 131, 153], ["semicarbazone", "SIMPLE_CHEMICAL", 207, 220], ["Scheme 8) derivatives", "SIMPLE_CHEMICAL", 222, 243], ["aldehyde", "SIMPLE_CHEMICAL", 311, 319], ["ketone", "SIMPLE_CHEMICAL", 323, 329], ["semicarbazide", "SIMPLE_CHEMICAL", 346, 359], ["sodium acetate [52]", "SIMPLE_CHEMICAL", 375, 394], ["the reaction", "PROBLEM", 32, 44], ["the carbinolamine hydroxyl group", "TREATMENT", 127, 159], ["semicarbazoneDifferent types", "TREATMENT", 175, 203], ["semicarbazone (Scheme 8) derivatives", "TREATMENT", 207, 243], ["ketone", "TREATMENT", 323, 329], ["respective semicarbazide", "TREATMENT", 335, 359], ["sodium acetate", "TREATMENT", 375, 389]]], ["Sometimes hydrochloric acid must be added in the reaction mixture.", [["hydrochloric acid", "CHEMICAL", 10, 27], ["hydrochloric acid", "CHEMICAL", 10, 27], ["hydrochloric acid", "SIMPLE_CHEMICAL", 10, 27], ["Sometimes hydrochloric acid", "TREATMENT", 0, 27]]], ["Usually ketones require the elevated temperature than aldehydes for reaction completion.", [["aldehydes", "CHEMICAL", 54, 63], ["ketones", "CHEMICAL", 8, 15], ["aldehydes", "CHEMICAL", 54, 63], ["ketones", "SIMPLE_CHEMICAL", 8, 15], ["aldehydes", "SIMPLE_CHEMICAL", 54, 63], ["the elevated temperature", "PROBLEM", 24, 48], ["elevated temperature", "OBSERVATION_MODIFIER", 28, 48]]], ["The ammoniarelated compounds such as semicarbazide is added to the carbonyl group, and it results into the formation of semicarbazone.", [["semicarbazide", "CHEMICAL", 37, 50], ["semicarbazone", "CHEMICAL", 120, 133], ["semicarbazide", "CHEMICAL", 37, 50], ["carbonyl", "CHEMICAL", 67, 75], ["semicarbazone", "CHEMICAL", 120, 133], ["semicarbazide", "SIMPLE_CHEMICAL", 37, 50], ["carbonyl", "SIMPLE_CHEMICAL", 67, 75], ["semicarbazone", "SIMPLE_CHEMICAL", 120, 133], ["The ammoniarelated compounds", "TREATMENT", 0, 28], ["semicarbazide", "TREATMENT", 37, 50], ["semicarbazone", "TREATMENT", 120, 133]]], ["Such transformation of carbonyl compounds such as aldehydes and ketones into imine derivatives is an exothermic and pH dependent reaction.Preparation of semicarbazoneThere is possibility that they exist in tautomeric keto (20) and enol (21) forms in metal complexes.", [["carbonyl", "CHEMICAL", 23, 31], ["aldehydes", "CHEMICAL", 50, 59], ["ketones", "CHEMICAL", 64, 71], ["imine", "CHEMICAL", 77, 82], ["semicarbazone", "CHEMICAL", 153, 166], ["keto (20) and enol", "CHEMICAL", 217, 235], ["carbonyl", "CHEMICAL", 23, 31], ["aldehydes", "CHEMICAL", 50, 59], ["ketones", "CHEMICAL", 64, 71], ["imine", "CHEMICAL", 77, 82], ["semicarbazone", "CHEMICAL", 153, 166], ["keto", "CHEMICAL", 217, 221], ["enol", "CHEMICAL", 231, 235], ["carbonyl compounds", "SIMPLE_CHEMICAL", 23, 41], ["aldehydes", "SIMPLE_CHEMICAL", 50, 59], ["ketones", "SIMPLE_CHEMICAL", 64, 71], ["imine derivatives", "SIMPLE_CHEMICAL", 77, 94], ["semicarbazone", "SIMPLE_CHEMICAL", 153, 166], ["tautomeric keto (20)", "SIMPLE_CHEMICAL", 206, 226], ["enol (21)", "SIMPLE_CHEMICAL", 231, 240], ["metal complexes", "SIMPLE_CHEMICAL", 250, 265], ["metal complexes", "PROTEIN", 250, 265], ["carbonyl compounds", "PROBLEM", 23, 41], ["ketones into imine derivatives", "TREATMENT", 64, 94], ["an exothermic and pH dependent reaction", "PROBLEM", 98, 137], ["semicarbazone", "TREATMENT", 153, 166], ["tautomeric keto", "TEST", 206, 221], ["carbonyl compounds", "OBSERVATION", 23, 41], ["exothermic", "OBSERVATION_MODIFIER", 101, 111], ["pH dependent", "OBSERVATION_MODIFIER", 116, 128]]], ["In keto form, semicarbazone acts as neutral bidentate ligand as they coordinate to metal ion through imine nitrogen and carbonyl oxygen; while in enol form, it can deprotonate and emerges to serve as a mono anionic bidentate ligand in metal complexes.Preparation of semicarbazoneThe ligand may coordinate through N (NH) and O (C\u00bcO) groups as bidentate.", [["semicarbazone", "CHEMICAL", 14, 27], ["imine nitrogen", "CHEMICAL", 101, 115], ["oxygen", "CHEMICAL", 129, 135], ["deprotonate", "CHEMICAL", 164, 175], ["semicarbazone", "CHEMICAL", 266, 279], ["semicarbazone", "CHEMICAL", 14, 27], ["imine", "CHEMICAL", 101, 106], ["nitrogen", "CHEMICAL", 107, 115], ["carbonyl", "CHEMICAL", 120, 128], ["oxygen", "CHEMICAL", 129, 135], ["enol", "CHEMICAL", 146, 150], ["semicarbazone", "CHEMICAL", 266, 279], ["N (NH)", "CHEMICAL", 313, 319], ["O (C\u00bcO)", "CHEMICAL", 324, 331], ["keto", "SIMPLE_CHEMICAL", 3, 7], ["semicarbazone", "SIMPLE_CHEMICAL", 14, 27], ["metal ion", "SIMPLE_CHEMICAL", 83, 92], ["imine nitrogen", "SIMPLE_CHEMICAL", 101, 115], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 120, 135], ["enol", "SIMPLE_CHEMICAL", 146, 150], ["deprotonate", "SIMPLE_CHEMICAL", 164, 175], ["metal complexes", "SIMPLE_CHEMICAL", 235, 250], ["semicarbazone", "SIMPLE_CHEMICAL", 266, 279], ["N (NH)", "SIMPLE_CHEMICAL", 313, 319], ["O (C\u00bcO)", "SIMPLE_CHEMICAL", 324, 331], ["metal complexes", "PROTEIN", 235, 250], ["semicarbazone acts", "TREATMENT", 14, 32], ["neutral bidentate ligand", "TREATMENT", 36, 60], ["metal ion through imine nitrogen", "TREATMENT", 83, 115], ["carbonyl oxygen", "TREATMENT", 120, 135], ["a mono anionic bidentate ligand in metal complexes", "TREATMENT", 200, 250], ["semicarbazone", "TREATMENT", 266, 279], ["carbonyl oxygen", "OBSERVATION", 120, 135]]], ["Though if there could be some additional coordination position in the semicarbazone, it may acts as tridentate ligand, i.e. NNO type.", [["semicarbazone", "CHEMICAL", 70, 83], ["semicarbazone", "CHEMICAL", 70, 83], ["NNO", "CHEMICAL", 124, 127], ["semicarbazone", "SIMPLE_CHEMICAL", 70, 83], ["the semicarbazone", "TREATMENT", 66, 83], ["coordination", "OBSERVATION_MODIFIER", 41, 53], ["position", "OBSERVATION_MODIFIER", 54, 62]]], ["Thus, there are high coordination probabilities that the ligand may show through the keto-enol transformation.ApplicationsSchiff bases, semicarbazones, thiosemicabazones, and their metal complexes are extensively studied owing to their wide range of applications in biological activity such as antifungal, antitumor, antibacterial, anticancer, etc.; in pharmaceuticals; and as catalyst [53] They are also used in dyes [54] , polymers, [54] as well as they are applied in nanotechnology [55] , laser [56] , transistor [57] , in defense as gas generating agents [58] , and pyrotechnic mixtures [59] .", [["antitumor", "ANATOMY", 306, 315], ["anticancer", "ANATOMY", 332, 342], ["keto-enol", "CHEMICAL", 85, 94], ["semicarbazones", "CHEMICAL", 136, 150], ["thiosemicabazones", "CHEMICAL", 152, 169], ["keto-enol", "CHEMICAL", 85, 94], ["Schiff bases", "CHEMICAL", 122, 134], ["semicarbazones", "CHEMICAL", 136, 150], ["thiosemicabazones", "CHEMICAL", 152, 169], ["keto-enol", "SIMPLE_CHEMICAL", 85, 94], ["Schiff bases", "SIMPLE_CHEMICAL", 122, 134], ["semicarbazones", "SIMPLE_CHEMICAL", 136, 150], ["thiosemicabazones", "SIMPLE_CHEMICAL", 152, 169], ["antitumor", "CANCER", 306, 315], ["anticancer", "CANCER", 332, 342], ["[53] They", "SIMPLE_CHEMICAL", 386, 395], ["dyes [54]", "SIMPLE_CHEMICAL", 413, 422], ["[58]", "SIMPLE_CHEMICAL", 560, 564], ["high coordination probabilities", "PROBLEM", 16, 47], ["Schiff bases", "TREATMENT", 122, 134], ["semicarbazones", "TREATMENT", 136, 150], ["thiosemicabazones", "TREATMENT", 152, 169], ["their metal complexes", "TREATMENT", 175, 196], ["antifungal, antitumor", "TREATMENT", 294, 315], ["antibacterial", "TREATMENT", 317, 330], ["anticancer", "TREATMENT", 332, 342], ["high", "OBSERVATION_MODIFIER", 16, 20], ["coordination probabilities", "OBSERVATION", 21, 47], ["enol transformation", "OBSERVATION", 90, 109]]], ["Imine derivatives are employed in optical computers, to measure and to control the intensity of the radiation, in molecular memory storage, and in imaging systems, as organic material in reversible optical memories also in biological systems used as photo-detectors ( Fig. 1 ).Biological activity for biomedical fieldMajority of Schiff bases are useful as antibacterial and antifungal agents.", [["Imine", "CHEMICAL", 0, 5], ["Imine", "CHEMICAL", 0, 5], ["Schiff bases", "CHEMICAL", 329, 341], ["Imine derivatives", "SIMPLE_CHEMICAL", 0, 17], ["Schiff bases", "SIMPLE_CHEMICAL", 329, 341], ["Imine derivatives", "TREATMENT", 0, 17], ["the radiation", "TREATMENT", 96, 109], ["imaging systems", "TEST", 147, 162], ["organic material in reversible optical memories", "PROBLEM", 167, 214], ["antibacterial", "TREATMENT", 356, 369], ["antifungal agents", "TREATMENT", 374, 391], ["radiation", "OBSERVATION", 100, 109], ["reversible", "OBSERVATION_MODIFIER", 187, 197], ["optical memories", "OBSERVATION", 198, 214]]], ["An azomethine (imine) group eN\u00bcCH-, in Schiff base helps to explain the mechanism of trans-amination as well as racemization reaction in biological system.", [["azomethine", "CHEMICAL", 3, 13], ["imine", "CHEMICAL", 15, 20], ["eN\u00bcCH", "CHEMICAL", 28, 33], ["azomethine", "CHEMICAL", 3, 13], ["imine", "CHEMICAL", 15, 20], ["eN\u00bcCH", "CHEMICAL", 28, 33], ["Schiff base", "CHEMICAL", 39, 50], ["azomethine (imine)", "SIMPLE_CHEMICAL", 3, 21], ["eN\u00bcCH", "SIMPLE_CHEMICAL", 28, 33], ["Schiff base", "SIMPLE_CHEMICAL", 39, 50], ["An azomethine (imine) group eN\u00bcCH", "TREATMENT", 0, 33], ["Schiff base", "TREATMENT", 39, 50], ["trans-amination", "TREATMENT", 85, 100], ["racemization reaction in biological system", "PROBLEM", 112, 154]]], ["MetaleSchiff base complexes have been widely studied for their application as antitumor, antibacterial, antifungal, and herbicidal agents [60, 61] as is depicted in Fig. 2 below.Biological activity for biomedical fieldSchiff base ligands, 4-[(4-bromo-phenylimino)-methyl]-benzene-1,2,3-triol (22), 4-[(3,5-di-tert-butyl-4-hydroxy-phenylimino)-methyl]-benzene-1,2,3-triol (23), 3-(p-tolylimino-methyl)benzene-1,2-diol (24), 3-[(4-bromo-phenylimino)-methyl]-benzene-1,2-diol (25) , and 4-[(3,5-di-tert-butyl-4-hydroxy-phenylimino)-methyl]-benzene-1,3-diol (26) , and their Cd (II) and Cu (II) complexes have been reported by Golcu et al. [62] where, ligands and their metal complexes were studied for in vitro antibacterial and antifungal activities against Bacillus megaterium and Candida tropicalis.", [["antitumor", "ANATOMY", 78, 87], ["4-[(4-bromo-phenylimino)-methyl]-benzene-1,2,3-triol", "CHEMICAL", 239, 291], ["4-[(3,5-di-tert-butyl-4-hydroxy-phenylimino)-methyl]-benzene-1,2,3-triol", "CHEMICAL", 298, 370], ["3-(p-tolylimino-methyl)benzene-1,2-diol", "CHEMICAL", 377, 416], ["3-[(4-bromo-phenylimino)-methyl]-benzene-1,2-diol", "CHEMICAL", 423, 472], ["4-[(3,5-di-tert-butyl-4-hydroxy-phenylimino)-methyl]-benzene-1,3-diol", "CHEMICAL", 484, 553], ["Cd", "CHEMICAL", 571, 573], ["Cu", "CHEMICAL", 583, 585], ["Schiff base", "CHEMICAL", 218, 229], ["4-[(4-bromo-phenylimino)-methyl]-benzene-1,2,3-triol", "CHEMICAL", 239, 291], ["4-[(3,5-di-tert-butyl-4-hydroxy-phenylimino)-methyl]-benzene-1,2,3-triol", "CHEMICAL", 298, 370], ["3-(p-tolylimino-methyl)benzene-1,2-diol", "CHEMICAL", 377, 416], ["3-[(4-bromo-phenylimino)-methyl]-benzene-1,2-diol", "CHEMICAL", 423, 472], ["4-[(3,5-di-tert-butyl-4-hydroxy-phenylimino)-methyl]-benzene-1,3-diol", "CHEMICAL", 484, 553], ["Cd (II)", "CHEMICAL", 571, 578], ["Cu (II)", "CHEMICAL", 583, 590], ["antitumor", "CANCER", 78, 87], ["herbicidal agents", "SIMPLE_CHEMICAL", 120, 137], ["Schiff base ligands", "SIMPLE_CHEMICAL", 218, 237], ["4-[(4-bromo-phenylimino)-methyl]-benzene-1,2,3-triol (22), 4-[(3,5-di-tert-butyl-4-hydroxy-phenylimino)-methyl]-benzene-1,2,3-triol (23), 3-(p-tolylimino-methyl)benzene-1,2-diol (24), 3-[(4-bromo-phenylimino)-methyl]-benzene-1,2-diol (25)", "SIMPLE_CHEMICAL", 239, 477], ["4-[(3,5-di-tert-butyl-4-hydroxy-phenylimino)-methyl]-benzene-1,3-diol (26)", "SIMPLE_CHEMICAL", 484, 558], ["Cd (II)", "SIMPLE_CHEMICAL", 571, 578], ["Cu (II)", "SIMPLE_CHEMICAL", 583, 590], ["metal complexes", "SIMPLE_CHEMICAL", 666, 681], ["Bacillus megaterium", "ORGANISM", 756, 775], ["Candida tropicalis", "ORGANISM", 780, 798], ["Cu (II) complexes", "PROTEIN", 583, 600], ["Bacillus megaterium", "SPECIES", 756, 775], ["Candida tropicalis", "SPECIES", 780, 798], ["Bacillus megaterium", "SPECIES", 756, 775], ["Candida tropicalis", "SPECIES", 780, 798], ["MetaleSchiff base complexes", "TREATMENT", 0, 27], ["antitumor", "TREATMENT", 78, 87], ["antibacterial", "TREATMENT", 89, 102], ["antifungal", "TREATMENT", 104, 114], ["herbicidal agents", "TREATMENT", 120, 137], ["biomedical fieldSchiff base ligands", "TEST", 202, 237], ["bromo", "TEST", 245, 250], ["methyl]-benzene", "TREATMENT", 264, 279], ["di-tert-butyl", "TREATMENT", 306, 319], ["hydroxy", "TREATMENT", 322, 329], ["phenylimino", "TREATMENT", 330, 341], ["methyl]-benzene", "TREATMENT", 343, 358], ["p-tolylimino-methyl)benzene", "TREATMENT", 380, 407], ["bromo-phenylimino)", "TREATMENT", 429, 447], ["methyl]-benzene", "TREATMENT", 448, 463], ["tert-butyl", "TREATMENT", 495, 505], ["hydroxy", "TREATMENT", 508, 515], ["phenylimino", "TREATMENT", 516, 527], ["methyl]-benzene", "TREATMENT", 529, 544], ["Cu (II) complexes", "TREATMENT", 583, 600], ["vitro antibacterial", "TREATMENT", 702, 721], ["antifungal activities", "TREATMENT", 726, 747], ["Bacillus megaterium", "PROBLEM", 756, 775], ["Candida tropicalis", "PROBLEM", 780, 798], ["Candida tropicalis", "OBSERVATION", 780, 798]]], ["All the ligands and their Cu (II) and Cd (II) complexes were found to be highly active against the bacterium B. megaterium.", [["Cu (II", "CHEMICAL", 26, 32], ["Cd", "CHEMICAL", 38, 40], ["Cu (II)", "CHEMICAL", 26, 33], ["Cd (II)", "CHEMICAL", 38, 45], ["Cu (II)", "SIMPLE_CHEMICAL", 26, 33], ["Cd (II)", "SIMPLE_CHEMICAL", 38, 45], ["B. megaterium", "ORGANISM", 109, 122], ["Cd (II) complexes", "PROTEIN", 38, 55], ["B. megaterium", "SPECIES", 109, 122], ["B. megaterium", "SPECIES", 109, 122], ["the bacterium B. megaterium", "PROBLEM", 95, 122]]], ["Authors reported that Cu (II) complex with ligand (23) showed higher activity against C. tropicalis than the complex with ligand (22).Antimicrobial activityIspir et al. [63] described the Schiff bases of 2,6diacetylpyridine and 2-pyridine carboxaldehyde with 4-amino-2,3-dimethyl-1-phenyl-3-pyrozolin-5-one[4,4'-(1E,1 0 E)-(1,1'-(pyridine-2,6-diyl)bis(ethan-1-yl-1-ylidene))bis(azan-1-yl-1-ylidene) bis(1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H) one) (27) , and (E)-1,5-dimethyl-2-phenyl-4-(1-(pyridin-2-yl)ethylideneamino)-1Hpyrazol-3(2H)-one (28) ] and their Co (II), Cu (II), Ni (II), Mn (II) and Cr (III) complexes (29e38) (Scheme 9) exhibit antibacterial and antifungal activities against E. coli, Staphylococcus aureus, Klebsiella pneumoniae, Mycobacterium smegmatis, P. aeruginosa, Enterobacter cloacae, and Micrococcus leteus.Antimicrobial activityThe Schiff base 4-chloro-2-(2-morphiolinoethylimino)methylphenolatomethanolchloro (39) and its Zn (II) complex also was reported to be antibacterial in nature against Gram \u00feve bacterial strains (Bacillus subtilis and S. aureus) and Gram -ve bacterial strains (E. coli and Pseudomonas fluorescence) [64] .", [["Cu", "CHEMICAL", 22, 24], ["2,6diacetylpyridine", "CHEMICAL", 204, 223], ["2-pyridine carboxaldehyde", "CHEMICAL", 228, 253], ["4-amino-2,3-dimethyl-1-phenyl-3-pyrozolin-5-one", "CHEMICAL", 259, 306], ["4,4'-(1E,1 0 E)-(1,1'-(pyridine-2,6-diyl)bis(ethan-1-yl-1-ylidene))bis(azan-1-yl-1-ylidene) bis", "CHEMICAL", 307, 402], ["1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H) one", "CHEMICAL", 403, 445], ["1,5-dimethyl-2-phenyl-4-(1-(pyridin-2-yl)ethylideneamino)-1Hpyrazol-3(2H)-one", "CHEMICAL", 462, 539], ["Co", "CHEMICAL", 557, 559], ["Cu", "CHEMICAL", 566, 568], ["Ni", "CHEMICAL", 575, 577], ["Mn", "CHEMICAL", 584, 586], ["Cr", "CHEMICAL", 596, 598], ["Staphylococcus aureus", "DISEASE", 699, 720], ["Schiff base", "CHEMICAL", 856, 867], ["4-chloro-2-(2-morphiolinoethylimino)methylphenolatomethanolchloro (39)", "CHEMICAL", 868, 938], ["Zn", "CHEMICAL", 947, 949], ["Cu (II)", "CHEMICAL", 22, 29], ["Schiff bases", "CHEMICAL", 188, 200], ["2,6diacetylpyridine", "CHEMICAL", 204, 223], ["2-pyridine carboxaldehyde", "CHEMICAL", 228, 253], ["4-amino-2,3-dimethyl-1-phenyl-3-pyrozolin-5-one[4,4'-(1E,1 0 E)-(1,1'-(pyridine-2,6-diyl)bis(ethan-1-yl-1-ylidene))bis(azan-1-yl-1-ylidene) bis(1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H) one", "CHEMICAL", 259, 445], ["(E)-1,5-dimethyl-2-phenyl-4-(1-(pyridin-2-yl)ethylideneamino)-1Hpyrazol-3(2H)-one", "CHEMICAL", 458, 539], ["Co (II)", "CHEMICAL", 557, 564], ["Cu (II)", "CHEMICAL", 566, 573], ["Ni (II)", "CHEMICAL", 575, 582], ["Mn (II)", "CHEMICAL", 584, 591], ["Cr (III)", "CHEMICAL", 596, 604], ["Schiff base", "CHEMICAL", 856, 867], ["4-chloro-2-(2-morphiolinoethylimino)methylphenolatomethanolchloro", "CHEMICAL", 868, 933], ["Zn (II)", "CHEMICAL", 947, 954], ["Cu (II) complex", "GENE_OR_GENE_PRODUCT", 22, 37], ["ligand (23)", "SIMPLE_CHEMICAL", 43, 54], ["C. tropicalis", "ORGANISM", 86, 99], ["2,6diacetylpyridine", "SIMPLE_CHEMICAL", 204, 223], ["2-pyridine carboxaldehyde", "SIMPLE_CHEMICAL", 228, 253], ["4-amino-2,3-dimethyl-1-phenyl-3-pyrozolin-5-one[4,4'-(1E,1 0 E)-(1,1'-(pyridine-2,6-diyl)bis(ethan-1-yl-1-ylidene))bis(azan-1-yl-1-ylidene) bis(1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H) one) (27)", "SIMPLE_CHEMICAL", 259, 451], ["(E)-1,5-dimethyl-2-phenyl-4-(1-(pyridin-2-yl)ethylideneamino)-1Hpyrazol-3(2H)-one (28)", "SIMPLE_CHEMICAL", 458, 544], ["Co (II)", "SIMPLE_CHEMICAL", 557, 564], ["Cu (II)", "SIMPLE_CHEMICAL", 566, 573], ["Ni (II)", "SIMPLE_CHEMICAL", 575, 582], ["Mn (II)", "SIMPLE_CHEMICAL", 584, 591], ["Cr (III) complexes", "SIMPLE_CHEMICAL", 596, 614], ["29e38", "SIMPLE_CHEMICAL", 616, 621], ["Scheme 9)", "SIMPLE_CHEMICAL", 624, 633], ["E. coli", "ORGANISM", 690, 697], ["Staphylococcus aureus", "ORGANISM", 699, 720], ["Klebsiella pneumoniae", "ORGANISM", 722, 743], ["Mycobacterium smegmatis", "ORGANISM", 745, 768], ["P. aeruginosa", "ORGANISM", 770, 783], ["Enterobacter cloacae", "ORGANISM", 785, 805], ["Micrococcus leteus", "ORGANISM", 811, 829], ["Schiff base 4-chloro-2-(2-morphiolinoethylimino)methylphenolatomethanolchloro (39)", "SIMPLE_CHEMICAL", 856, 938], ["Zn (II)", "SIMPLE_CHEMICAL", 947, 954], ["Gram \u00feve bacterial strains", "ORGANISM", 1019, 1045], ["Bacillus subtilis", "ORGANISM", 1047, 1064], ["S. aureus", "ORGANISM", 1069, 1078], ["E. coli", "ORGANISM", 1112, 1119], ["Cu (II) complex", "PROTEIN", 22, 37], ["C. tropicalis", "SPECIES", 86, 99], ["E. coli", "SPECIES", 690, 697], ["Staphylococcus aureus", "SPECIES", 699, 720], ["Klebsiella pneumoniae", "SPECIES", 722, 743], ["Mycobacterium smegmatis", "SPECIES", 745, 768], ["P. aeruginosa", "SPECIES", 770, 783], ["Enterobacter cloacae", "SPECIES", 785, 805], ["Micrococcus leteus", "SPECIES", 811, 829], ["Bacillus subtilis", "SPECIES", 1047, 1064], ["S. aureus", "SPECIES", 1069, 1078], ["E. coli", "SPECIES", 1112, 1119], ["C. tropicalis", "SPECIES", 86, 99], ["E. coli", "SPECIES", 690, 697], ["Staphylococcus aureus", "SPECIES", 699, 720], ["Klebsiella pneumoniae", "SPECIES", 722, 743], ["Mycobacterium smegmatis", "SPECIES", 745, 768], ["P. aeruginosa", "SPECIES", 770, 783], ["Enterobacter cloacae", "SPECIES", 785, 805], ["Micrococcus leteus", "SPECIES", 811, 829], ["Bacillus subtilis", "SPECIES", 1047, 1064], ["S. aureus", "SPECIES", 1069, 1078], ["E. coli", "SPECIES", 1112, 1119], ["C. tropicalis", "PROBLEM", 86, 99], ["the Schiff bases", "TREATMENT", 184, 200], ["diacetylpyridine", "TREATMENT", 207, 223], ["pyridine carboxaldehyde", "TREATMENT", 230, 253], ["amino", "TREATMENT", 261, 266], ["dimethyl", "TREATMENT", 271, 279], ["phenyl", "TREATMENT", 282, 288], ["(pyridine", "TREATMENT", 329, 338], ["bis(ethan-1-yl-1-ylidene)", "TREATMENT", 348, 373], ["bis(azan-1-yl-1-ylidene) bis", "TREATMENT", 374, 402], ["dimethyl", "TREATMENT", 407, 415], ["phenyl-1H-pyrazol", "TREATMENT", 418, 435], ["dimethyl", "TREATMENT", 466, 474], ["phenyl-4-(1", "TREATMENT", 477, 488], ["pyridin", "TREATMENT", 490, 497], ["ethylideneamino", "TREATMENT", 503, 518], ["1Hpyrazol", "TREATMENT", 520, 529], ["Cr (III) complexes", "TREATMENT", 596, 614], ["antibacterial", "TREATMENT", 642, 655], ["antifungal activities", "TREATMENT", 660, 681], ["E. coli", "PROBLEM", 690, 697], ["Staphylococcus aureus", "PROBLEM", 699, 720], ["Klebsiella pneumoniae", "PROBLEM", 722, 743], ["Mycobacterium smegmatis", "PROBLEM", 745, 768], ["P. aeruginosa", "PROBLEM", 770, 783], ["Enterobacter cloacae", "PROBLEM", 785, 805], ["Micrococcus leteus", "PROBLEM", 811, 829], ["Antimicrobial activity", "TEST", 830, 852], ["The Schiff base", "TEST", 852, 867], ["chloro", "TREATMENT", 870, 876], ["2-morphiolinoethylimino)methylphenolatomethanolchloro", "TREATMENT", 880, 933], ["its Zn (II) complex", "TREATMENT", 943, 962], ["Gram", "TEST", 1019, 1023], ["bacterial strains (Bacillus subtilis", "PROBLEM", 1028, 1064], ["S. aureus", "TEST", 1069, 1078], ["Gram", "TEST", 1084, 1088], ["bacterial strains", "PROBLEM", 1093, 1110], ["E. coli and Pseudomonas fluorescence", "PROBLEM", 1112, 1148], ["Staphylococcus aureus", "OBSERVATION", 699, 720], ["Klebsiella pneumoniae", "OBSERVATION", 722, 743], ["Mycobacterium smegmatis", "OBSERVATION", 745, 768], ["Micrococcus leteus", "OBSERVATION", 811, 829]]], ["It was stated that the ligands showed greater activity against some of the Gram-Scheme 8.", [["the Gram", "TEST", 71, 79], ["greater", "OBSERVATION_MODIFIER", 38, 45], ["activity", "OBSERVATION_MODIFIER", 46, 54]]], ["General reaction mechanism of semicarbazone synthesis. negative bacterial strains.", [["semicarbazone", "CHEMICAL", 30, 43], ["semicarbazone", "CHEMICAL", 30, 43], ["semicarbazone", "SIMPLE_CHEMICAL", 30, 43], ["semicarbazone synthesis", "PROBLEM", 30, 53], ["bacterial strains", "PROBLEM", 64, 81], ["semicarbazone synthesis", "OBSERVATION", 30, 53], ["bacterial strains", "OBSERVATION", 64, 81]]], ["Cu (II), Co (II), and Mn (II) salicylidene complexes were reported for good antimicrobial activity toward all the gram \u00feve and gram eve bacteria, and it was reported that metaleligand complexes have higher antibacterial activity than the free ligands [65] .", [["Cu (II", "CHEMICAL", 0, 6], ["Co (II", "CHEMICAL", 9, 15], ["Mn", "CHEMICAL", 22, 24], ["salicylidene", "CHEMICAL", 30, 42], ["metaleligand", "CHEMICAL", 171, 183], ["Cu (II)", "CHEMICAL", 0, 7], ["Co (II)", "CHEMICAL", 9, 16], ["Mn (II)", "CHEMICAL", 22, 29], ["salicylidene", "CHEMICAL", 30, 42], ["metaleligand", "CHEMICAL", 171, 183], ["Cu (II)", "SIMPLE_CHEMICAL", 0, 7], ["Co (II)", "SIMPLE_CHEMICAL", 9, 16], ["Mn (II) salicylidene complexes", "SIMPLE_CHEMICAL", 22, 52], ["metaleligand", "SIMPLE_CHEMICAL", 171, 183], ["metaleligand complexes", "PROTEIN", 171, 193], ["Co (II)", "TEST", 9, 16], ["Mn (II) salicylidene complexes", "PROBLEM", 22, 52], ["the gram", "TEST", 110, 118], ["bacteria", "PROBLEM", 136, 144], ["metaleligand complexes", "PROBLEM", 171, 193], ["higher antibacterial activity", "PROBLEM", 199, 228], ["antibacterial activity", "OBSERVATION", 206, 228]]], ["It is also highlighted that the complexes containing nitro group showed better activity than the complexes with chloro and bromo group [66] .", [["nitro", "CHEMICAL", 53, 58], ["chloro", "CHEMICAL", 112, 118], ["bromo", "CHEMICAL", 123, 128], ["nitro", "CHEMICAL", 53, 58], ["chloro", "CHEMICAL", 112, 118], ["bromo", "CHEMICAL", 123, 128], ["nitro", "SIMPLE_CHEMICAL", 53, 58], ["chloro", "SIMPLE_CHEMICAL", 112, 118], ["bromo", "SIMPLE_CHEMICAL", 123, 128], ["nitro group", "TREATMENT", 53, 64], ["chloro and bromo group", "TREATMENT", 112, 134]]], ["Pandeya et al. [67] have reported the Schiff base of substituted Isatin with 4-(4 0 -chlorophenyl)-6-(4 00methylphenyl)-2-aminopyrimidine (e.g. 3-[4 0 (4 00 -chloro phenyl)-6'-(4 000 -methylphenyl)pyrimidin-2 0 -yl]iminoisatin) and its Mannich base derivatives (Scheme 10).", [["Isatin", "CHEMICAL", 65, 71], ["4-(4 0 -chlorophenyl)-6-(4 00methylphenyl)-2-aminopyrimidine", "CHEMICAL", 77, 137], ["3-[4 0 (4 00 -chloro phenyl)-6'-(4 000 -methylphenyl)pyrimidin-2 0 -yl]iminoisatin", "CHEMICAL", 144, 226], ["Schiff base", "CHEMICAL", 38, 49], ["Isatin", "CHEMICAL", 65, 71], ["4-(4 0 -chlorophenyl)-6-(4 00methylphenyl)-2-aminopyrimidine", "CHEMICAL", 77, 137], ["3-[4 0 (4 00 -chloro phenyl)-6'-(4 000 -methylphenyl)pyrimidin-2 0 -yl]iminoisatin", "CHEMICAL", 144, 226], ["Mannich base", "CHEMICAL", 236, 248], ["Isatin", "SIMPLE_CHEMICAL", 65, 71], ["4-(4 0 -chlorophenyl)-6-(4 00methylphenyl)-2-aminopyrimidine", "SIMPLE_CHEMICAL", 77, 137], ["e.g. 3-[4 0 (4 00 -chloro phenyl)-6'-(4 000 -methylphenyl)pyrimidin-2 0 -yl]iminoisatin", "SIMPLE_CHEMICAL", 139, 226], ["Mannich base derivatives", "SIMPLE_CHEMICAL", 236, 260], ["the Schiff base of substituted Isatin", "TREATMENT", 34, 71], ["chlorophenyl)", "TREATMENT", 85, 98], ["-aminopyrimidine", "TREATMENT", 121, 137], ["chloro phenyl)", "TREATMENT", 158, 172], ["methylphenyl", "TREATMENT", 184, 196], ["pyrimidin", "TREATMENT", 197, 206], ["its Mannich base derivatives", "TREATMENT", 232, 260]]], ["These compounds were tested for in vitro antibacterial activity and observed that all compounds are more active against Salmonella typhimurium, S. aureus, Enterococcus faecalis, P. aeruginosa, K. pneumoniae, Staphylococcus albus, Aeromonas hydrophila, Vibrio cholerae-01, B. subtilis, and Providencia rettgeri.", [["Aeromonas hydrophila", "DISEASE", 230, 250], ["Salmonella typhimurium", "ORGANISM", 120, 142], ["S. aureus", "ORGANISM", 144, 153], ["Enterococcus faecalis", "ORGANISM", 155, 176], ["P. aeruginosa", "ORGANISM", 178, 191], ["K. pneumoniae", "ORGANISM", 193, 206], ["Staphylococcus albus", "ORGANISM", 208, 228], ["Aeromonas hydrophila", "ORGANISM", 230, 250], ["Vibrio cholerae-01", "ORGANISM", 252, 270], ["B. subtilis", "ORGANISM", 272, 283], ["Providencia rettgeri", "ORGANISM", 289, 309], ["Salmonella typhimurium", "SPECIES", 120, 142], ["S. aureus", "SPECIES", 144, 153], ["Enterococcus faecalis", "SPECIES", 155, 176], ["P. aeruginosa", "SPECIES", 178, 191], ["K. pneumoniae", "SPECIES", 193, 206], ["Staphylococcus albus", "SPECIES", 208, 228], ["Aeromonas hydrophila", "SPECIES", 230, 250], ["Vibrio cholerae", "SPECIES", 252, 267], ["B. subtilis", "SPECIES", 272, 283], ["Providencia rettgeri", "SPECIES", 289, 309], ["Salmonella typhimurium", "SPECIES", 120, 142], ["S. aureus", "SPECIES", 144, 153], ["Enterococcus faecalis", "SPECIES", 155, 176], ["P. aeruginosa", "SPECIES", 178, 191], ["K. pneumoniae", "SPECIES", 193, 206], ["Staphylococcus albus", "SPECIES", 208, 228], ["Aeromonas hydrophila", "SPECIES", 230, 250], ["Vibrio cholerae-01", "SPECIES", 252, 270], ["B. subtilis", "SPECIES", 272, 283], ["Providencia rettgeri", "SPECIES", 289, 309], ["Salmonella typhimurium", "PROBLEM", 120, 142], ["S. aureus", "PROBLEM", 144, 153], ["Enterococcus faecalis", "PROBLEM", 155, 176], ["P. aeruginosa", "PROBLEM", 178, 191], ["K. pneumoniae", "PROBLEM", 193, 206], ["Staphylococcus albus", "PROBLEM", 208, 228], ["Aeromonas hydrophila", "PROBLEM", 230, 250], ["Vibrio cholerae", "TEST", 252, 267], ["Providencia rettgeri", "TREATMENT", 289, 309], ["aureus", "OBSERVATION", 147, 153], ["Enterococcus faecalis", "OBSERVATION", 155, 176], ["Staphylococcus albus", "OBSERVATION", 208, 228], ["Providencia rettgeri", "OBSERVATION", 289, 309]]], ["All compounds were tested for their inhibitory effect of the replication of HIV-1 in human MT-4 cells.Antimicrobial activitySchiff base obtained from 2-aminophenol or 2-aminothiophenol with 1-phenyl-2,3-dimehyl-4(4-iminopentan-2-one)-pyrazol-5one, [l-phenyl-2,3-dimethyl-4(4-iminopentan-2-one) pyrazol-5iminophenol (40), and 1-pheny-l-2,3-dimethyl-4(4-iminopentan-2-one)pyrazol-5-imino thiophenol (41) ] and their neutral tetradentate transition metal [Cu (II), Ni (II), Zn (II), Co (II) and VO (II)] complexes showed antimicrobial activity against Bacillus subtilis, Salmonella typhi, S. aureus, Pseudomonous aeruginosa, Aspergillus niger, etc. It is observed that compared with free ligands, metal complexes have higher antimicrobial activity [68] .Antimicrobial activitySchiff bases derived from thiophene carboxaldehyde and aminobenzoic acid [69], furaldehyde [70] , benzimidazole [71] , thiazole [72, 73] , furfuraldiamine [74] , pyridine and benzyldithiocarbazate [75] , pyrazolone [76, 77] , glucosamine [78] , hydrazide [79] , p-fluoro benzaldehyde [80] , p-anisidiene [81] , thiosemicabazones [82] , and imidazolinones [83] show antibacterial activity.Antimicrobial activityDesai et al. [82] have been reported some oxime, semicarbazone, and thiosemicarbazones by using 2,4-dihydroxyacetophenone, 2,4dihydroxy-5-nitroacetophenone, and 2,4-dihydroxy-5-bromo-acetophenone and were evaluated for their inhibitory effect against S. aureus and E. coli by agar diffusion technique.", [["MT-4 cells", "ANATOMY", 91, 101], ["2-aminophenol", "CHEMICAL", 150, 163], ["2-aminothiophenol", "CHEMICAL", 167, 184], ["1-phenyl-2,3-dimehyl-4(4-iminopentan-2-one)-pyrazol-5one", "CHEMICAL", 190, 246], ["[l-phenyl-2,3-dimethyl-4(4-iminopentan-2-one) pyrazol-5iminophenol (40), and 1-pheny-l-2,3-dimethyl-4(4-iminopentan-2-one", "CHEMICAL", 248, 369], ["pyrazol-5-imino thiophenol", "CHEMICAL", 370, 396], ["tetradentate", "CHEMICAL", 422, 434], ["Cu", "CHEMICAL", 453, 455], ["Ni", "CHEMICAL", 462, 464], ["Zn", "CHEMICAL", 471, 473], ["Co", "CHEMICAL", 480, 482], ["thiophene carboxaldehyde", "CHEMICAL", 799, 823], ["aminobenzoic acid [69], furaldehyde [70] , benzimidazole [71] , thiazole [72, 73] , furfuraldiamine [74] , pyridine", "CHEMICAL", 828, 943], ["benzyldithiocarbazate [75] , pyrazolone [76, 77] , glucosamine [78] , hydrazide [79] , p-fluoro benzaldehyde [80] , p-anisidiene [81] , thiosemicabazones [82]", "CHEMICAL", 948, 1106], ["imidazolinones", "CHEMICAL", 1113, 1127], ["semicarbazone", "CHEMICAL", 1232, 1245], ["thiosemicarbazones", "CHEMICAL", 1251, 1269], ["2,4-dihydroxyacetophenone", "CHEMICAL", 1279, 1304], ["2,4dihydroxy-5-nitroacetophenone", "CHEMICAL", 1306, 1338], ["2,4-dihydroxy-5-bromo-acetophenone", "CHEMICAL", 1344, 1378], ["2-aminophenol", "CHEMICAL", 150, 163], ["2-aminothiophenol", "CHEMICAL", 167, 184], ["1-phenyl-2,3-dimehyl-4(4-iminopentan-2-one)-pyrazol-5one", "CHEMICAL", 190, 246], ["[l-phenyl-2,3-dimethyl-4(4-iminopentan-2-one) pyrazol-5iminophenol", "CHEMICAL", 248, 314], ["1-pheny-l-2,3-dimethyl-4(4-iminopentan-2-one)pyrazol-5-imino thiophenol", "CHEMICAL", 325, 396], ["transition metal", "CHEMICAL", 435, 451], ["Cu (II)", "CHEMICAL", 453, 460], ["Ni (II)", "CHEMICAL", 462, 469], ["Zn (II)", "CHEMICAL", 471, 478], ["Co (II)", "CHEMICAL", 480, 487], ["VO (II)", "CHEMICAL", 492, 499], ["thiophene carboxaldehyde", "CHEMICAL", 799, 823], ["aminobenzoic acid", "CHEMICAL", 828, 845], ["furaldehyde", "CHEMICAL", 852, 863], ["benzimidazole", "CHEMICAL", 871, 884], ["thiazole", "CHEMICAL", 892, 900], ["furfuraldiamine", "CHEMICAL", 912, 927], ["pyridine", "CHEMICAL", 935, 943], ["benzyldithiocarbazate", "CHEMICAL", 948, 969], ["pyrazolone", "CHEMICAL", 977, 987], ["glucosamine", "CHEMICAL", 999, 1010], ["hydrazide", "CHEMICAL", 1018, 1027], ["p-fluoro benzaldehyde", "CHEMICAL", 1035, 1056], ["p-anisidiene", "CHEMICAL", 1064, 1076], ["thiosemicabazones", "CHEMICAL", 1084, 1101], ["imidazolinones", "CHEMICAL", 1113, 1127], ["oxime", "CHEMICAL", 1225, 1230], ["semicarbazone", "CHEMICAL", 1232, 1245], ["thiosemicarbazones", "CHEMICAL", 1251, 1269], ["2,4-dihydroxyacetophenone", "CHEMICAL", 1279, 1304], ["2,4dihydroxy-5-nitroacetophenone", "CHEMICAL", 1306, 1338], ["2,4-dihydroxy-5-bromo-acetophenone", "CHEMICAL", 1344, 1378], ["HIV-1", "ORGANISM", 76, 81], ["human", "ORGANISM", 85, 90], ["MT-4 cells", "CELL", 91, 101], ["2-aminophenol", "SIMPLE_CHEMICAL", 150, 163], ["2-aminothiophenol", "SIMPLE_CHEMICAL", 167, 184], ["1-phenyl-2,3-dimehyl-4(4-iminopentan-2-one)-pyrazol-5one", "SIMPLE_CHEMICAL", 190, 246], ["[l-phenyl-2,3-dimethyl-4(4-iminopentan-2-one) pyrazol-5iminophenol (40)", "SIMPLE_CHEMICAL", 248, 319], ["1-pheny-l-2,3-dimethyl-4(4-iminopentan-2-one)pyrazol-5-imino thiophenol (41)", "SIMPLE_CHEMICAL", 325, 401], ["tetradentate transition metal [Cu (II)", "SIMPLE_CHEMICAL", 422, 460], ["Ni (II)", "SIMPLE_CHEMICAL", 462, 469], ["Zn (II)", "SIMPLE_CHEMICAL", 471, 478], ["Co (II)", "SIMPLE_CHEMICAL", 480, 487], ["VO (II)] complexes", "SIMPLE_CHEMICAL", 492, 510], ["Bacillus subtilis", "ORGANISM", 549, 566], ["Salmonella typhi", "ORGANISM", 568, 584], ["S. aureus", "ORGANISM", 586, 595], ["Pseudomonous aeruginosa", "ORGANISM", 597, 620], ["Aspergillus niger", "ORGANISM", 622, 639], ["metal complexes", "SIMPLE_CHEMICAL", 694, 709], ["thiophene carboxaldehyde", "SIMPLE_CHEMICAL", 799, 823], ["aminobenzoic acid [69]", "SIMPLE_CHEMICAL", 828, 850], ["furaldehyde [70]", "SIMPLE_CHEMICAL", 852, 868], ["benzimidazole [71] , thiazole [72, 73] , furfuraldiamine [74] , pyridine", "SIMPLE_CHEMICAL", 871, 943], ["benzyldithiocarbazate [75]", "SIMPLE_CHEMICAL", 948, 974], ["pyrazolone [76, 77] , glucosamine [78]", "SIMPLE_CHEMICAL", 977, 1015], ["hydrazide [79] , p-fluoro benzaldehyde [80] , p-anisidiene [81]", "SIMPLE_CHEMICAL", 1018, 1081], ["thiosemicabazones [82]", "SIMPLE_CHEMICAL", 1084, 1106], ["imidazolinones [83]", "SIMPLE_CHEMICAL", 1113, 1132], ["oxime", "SIMPLE_CHEMICAL", 1225, 1230], ["semicarbazone", "SIMPLE_CHEMICAL", 1232, 1245], ["thiosemicarbazones", "SIMPLE_CHEMICAL", 1251, 1269], ["2,4-dihydroxyacetophenone", "SIMPLE_CHEMICAL", 1279, 1304], ["2,4dihydroxy-5-nitroacetophenone", "SIMPLE_CHEMICAL", 1306, 1338], ["2,4-dihydroxy-5-bromo-acetophenone", "SIMPLE_CHEMICAL", 1344, 1378], ["S. aureus", "ORGANISM", 1434, 1443], ["E. coli", "ORGANISM", 1448, 1455], ["human MT-4 cells", "CELL_LINE", 85, 101], ["HIV-1", "SPECIES", 76, 81], ["human", "SPECIES", 85, 90], ["Bacillus subtilis", "SPECIES", 549, 566], ["Salmonella typhi", "SPECIES", 568, 584], ["S. aureus", "SPECIES", 586, 595], ["Pseudomonous aeruginosa", "SPECIES", 597, 620], ["Aspergillus niger", "SPECIES", 622, 639], ["S. aureus", "SPECIES", 1434, 1443], ["E. coli", "SPECIES", 1448, 1455], ["HIV-1", "SPECIES", 76, 81], ["human", "SPECIES", 85, 90], ["Bacillus subtilis", "SPECIES", 549, 566], ["Salmonella typhi", "SPECIES", 568, 584], ["S. aureus", "SPECIES", 586, 595], ["Pseudomonous aeruginosa", "SPECIES", 597, 620], ["Aspergillus niger", "SPECIES", 622, 639], ["S. aureus", "SPECIES", 1434, 1443], ["E. coli", "SPECIES", 1448, 1455], ["HIV", "TEST", 76, 79], ["Antimicrobial activitySchiff base", "TREATMENT", 102, 135], ["aminophenol", "TREATMENT", 152, 163], ["aminothiophenol", "TREATMENT", 169, 184], ["phenyl", "TEST", 192, 198], ["dimehyl", "TEST", 203, 210], ["pyrazol", "TREATMENT", 234, 241], ["phenyl", "TREATMENT", 251, 257], ["dimethyl", "TREATMENT", 262, 270], ["iminopentan", "TREATMENT", 275, 286], ["pyrazol", "TREATMENT", 294, 301], ["5iminophenol", "TREATMENT", 302, 314], ["dimethyl", "TREATMENT", 339, 347], ["iminopentan", "TREATMENT", 352, 363], ["pyrazol", "TREATMENT", 370, 377], ["their neutral tetradentate transition metal [Cu (II), Ni (II)", "TREATMENT", 408, 469], ["Zn (II)", "TREATMENT", 471, 478], ["antimicrobial activity", "TEST", 518, 540], ["Bacillus subtilis", "PROBLEM", 549, 566], ["Salmonella typhi", "PROBLEM", 568, 584], ["S. aureus", "PROBLEM", 586, 595], ["Pseudomonous aeruginosa", "PROBLEM", 597, 620], ["Aspergillus niger", "PROBLEM", 622, 639], ["higher antimicrobial activity", "PROBLEM", 715, 744], ["Antimicrobial activitySchiff bases", "TREATMENT", 751, 785], ["thiophene carboxaldehyde", "TREATMENT", 799, 823], ["aminobenzoic acid", "TREATMENT", 828, 845], ["furaldehyde", "TREATMENT", 852, 863], ["benzimidazole", "TREATMENT", 871, 884], ["thiazole", "TREATMENT", 892, 900], ["furfuraldiamine", "TREATMENT", 912, 927], ["pyridine", "TREATMENT", 935, 943], ["benzyldithiocarbazate", "TREATMENT", 948, 969], ["pyrazolone", "TREATMENT", 977, 987], ["glucosamine", "TREATMENT", 999, 1010], ["hydrazide", "TREATMENT", 1018, 1027], ["p-fluoro benzaldehyde", "TREATMENT", 1035, 1056], ["p-anisidiene", "TREATMENT", 1064, 1076], ["thiosemicabazones", "TREATMENT", 1084, 1101], ["imidazolinones", "TREATMENT", 1113, 1127], ["antibacterial activity", "TREATMENT", 1138, 1160], ["some oxime", "TREATMENT", 1220, 1230], ["semicarbazone", "TREATMENT", 1232, 1245], ["thiosemicarbazones", "TREATMENT", 1251, 1269], ["dihydroxyacetophenone", "TREATMENT", 1283, 1304], ["2,4dihydroxy", "TREATMENT", 1306, 1318], ["nitroacetophenone", "TREATMENT", 1321, 1338], ["dihydroxy", "TREATMENT", 1348, 1357], ["bromo", "TREATMENT", 1360, 1365], ["acetophenone", "TREATMENT", 1366, 1378], ["S. aureus", "PROBLEM", 1434, 1443], ["E. coli", "PROBLEM", 1448, 1455], ["agar diffusion technique", "TEST", 1459, 1483], ["aureus", "OBSERVATION", 589, 595], ["higher", "OBSERVATION_MODIFIER", 715, 721], ["antimicrobial activity", "OBSERVATION", 722, 744], ["aureus", "OBSERVATION", 1437, 1443], ["E. coli", "OBSERVATION", 1448, 1455]]], ["All the compounds exhibited great activity against Gram -ve bacteria, i.e. E. coli and poor activity against Gram \u00feve bacteria, i.e. S. aureus.Antimicrobial activityMohmed et al. [84] have reported some Fe (III), Cu (II), Zn (II), and UO2 (II) complexes of Schiff base obtained from 2-thiophene carboxaldehyde and 2-aminobenzoic acid and were tested for their antibacterial activity against bacterial species, E. coli, P. aeruginosa, Streptococcus pyogenes, and fungi (Candida).", [["Fe", "CHEMICAL", 203, 205], ["Cu", "CHEMICAL", 213, 215], ["Zn", "CHEMICAL", 222, 224], ["UO2 (II", "CHEMICAL", 235, 242], ["Schiff", "CHEMICAL", 257, 263], ["2-thiophene carboxaldehyde", "CHEMICAL", 283, 309], ["2-aminobenzoic acid", "CHEMICAL", 314, 333], ["Fe (III)", "CHEMICAL", 203, 211], ["Cu (II)", "CHEMICAL", 213, 220], ["Zn (II)", "CHEMICAL", 222, 229], ["UO2 (II)", "CHEMICAL", 235, 243], ["Schiff base", "CHEMICAL", 257, 268], ["2-thiophene carboxaldehyde", "CHEMICAL", 283, 309], ["2-aminobenzoic acid", "CHEMICAL", 314, 333], ["Gram -ve bacteria", "SIMPLE_CHEMICAL", 51, 68], ["E. coli", "ORGANISM", 75, 82], ["S. aureus", "ORGANISM", 133, 142], ["Fe (III)", "SIMPLE_CHEMICAL", 203, 211], ["Cu (II)", "SIMPLE_CHEMICAL", 213, 220], ["Zn (II)", "SIMPLE_CHEMICAL", 222, 229], ["UO2 (II)", "SIMPLE_CHEMICAL", 235, 243], ["Schiff base", "SIMPLE_CHEMICAL", 257, 268], ["2-thiophene carboxaldehyde", "SIMPLE_CHEMICAL", 283, 309], ["2-aminobenzoic acid", "SIMPLE_CHEMICAL", 314, 333], ["E. coli", "ORGANISM", 410, 417], ["P. aeruginosa", "ORGANISM", 419, 432], ["Streptococcus pyogenes", "ORGANISM", 434, 456], ["Candida)", "ORGANISM", 469, 477], ["UO2 (II) complexes", "PROTEIN", 235, 253], ["E. coli", "SPECIES", 75, 82], ["S. aureus", "SPECIES", 133, 142], ["E. coli", "SPECIES", 410, 417], ["P. aeruginosa", "SPECIES", 419, 432], ["Streptococcus pyogenes", "SPECIES", 434, 456], ["E. coli", "SPECIES", 75, 82], ["S. aureus", "SPECIES", 133, 142], ["E. coli", "SPECIES", 410, 417], ["P. aeruginosa", "SPECIES", 419, 432], ["Streptococcus pyogenes", "SPECIES", 434, 456], ["Gram -ve bacteria", "PROBLEM", 51, 68], ["E. coli", "PROBLEM", 75, 82], ["poor activity", "PROBLEM", 87, 100], ["Gram \u00feve bacteria", "PROBLEM", 109, 126], ["S. aureus", "PROBLEM", 133, 142], ["Antimicrobial activity", "TREATMENT", 143, 165], ["some Fe (III)", "PROBLEM", 198, 211], ["Zn (II)", "TEST", 222, 229], ["UO2 (II) complexes of Schiff base", "PROBLEM", 235, 268], ["2-thiophene carboxaldehyde", "TREATMENT", 283, 309], ["aminobenzoic acid", "TREATMENT", 316, 333], ["bacterial species", "PROBLEM", 391, 408], ["E. coli", "PROBLEM", 410, 417], ["P. aeruginosa", "PROBLEM", 419, 432], ["Streptococcus pyogenes", "PROBLEM", 434, 456], ["fungi", "PROBLEM", 462, 467], ["E. coli", "OBSERVATION", 75, 82], ["poor activity", "OBSERVATION_MODIFIER", 87, 100], ["aureus", "OBSERVATION", 136, 142], ["Streptococcus pyogenes", "OBSERVATION", 434, 456]]], ["It is found that metal complexes are more effective against some bacterial species (Gram-positive and Gram-negative bacteria) as compared with the parent Schiff base ligand.", [["Schiff base", "CHEMICAL", 154, 165], ["metal complexes", "SIMPLE_CHEMICAL", 17, 32], ["Gram-positive", "GENE_OR_GENE_PRODUCT", 84, 97], ["Gram", "GENE_OR_GENE_PRODUCT", 102, 106], ["metal complexes", "PROBLEM", 17, 32], ["some bacterial species", "PROBLEM", 60, 82], ["Gram-positive and Gram-negative bacteria", "PROBLEM", 84, 124], ["metal complexes", "OBSERVATION", 17, 32], ["bacterial species", "OBSERVATION", 65, 82], ["negative bacteria", "OBSERVATION_MODIFIER", 107, 124], ["Schiff", "OBSERVATION", 154, 160], ["base ligand", "OBSERVATION", 161, 172]]], ["It is also reported that Fe (III), Cu (II), Zn (II), and UO2 (II) complexes inhibited the growth of E. coli and could be employed in the treatment of common diseases such as septicemia, gastroenteritis, and urinary tract infections caused by E. coli.", [["urinary tract", "ANATOMY", 207, 220], ["Fe", "CHEMICAL", 25, 27], ["Cu", "CHEMICAL", 35, 37], ["Zn", "CHEMICAL", 44, 46], ["UO2 (II", "CHEMICAL", 57, 64], ["septicemia", "DISEASE", 174, 184], ["gastroenteritis", "DISEASE", 186, 201], ["urinary tract infections", "DISEASE", 207, 231], ["Fe (III)", "CHEMICAL", 25, 33], ["Cu (II)", "CHEMICAL", 35, 42], ["Zn (II)", "CHEMICAL", 44, 51], ["UO2 (II)", "CHEMICAL", 57, 65], ["Fe (III)", "SIMPLE_CHEMICAL", 25, 33], ["Cu (II)", "SIMPLE_CHEMICAL", 35, 42], ["Zn (II)", "SIMPLE_CHEMICAL", 44, 51], ["UO2 (II)", "SIMPLE_CHEMICAL", 57, 65], ["E. coli", "ORGANISM", 100, 107], ["urinary tract", "ORGANISM_SUBDIVISION", 207, 220], ["E. coli", "ORGANISM", 242, 249], ["UO2 (II) complexes", "PROTEIN", 57, 75], ["E. coli", "SPECIES", 100, 107], ["E. coli", "SPECIES", 242, 249], ["E. coli", "SPECIES", 100, 107], ["E. coli", "SPECIES", 242, 249], ["Zn (II)", "TEST", 44, 51], ["UO2 (II) complexes", "PROBLEM", 57, 75], ["E. coli", "PROBLEM", 100, 107], ["common diseases", "PROBLEM", 150, 165], ["septicemia", "PROBLEM", 174, 184], ["gastroenteritis", "PROBLEM", 186, 201], ["urinary tract infections", "PROBLEM", 207, 231], ["E. coli", "PROBLEM", 242, 249], ["E. coli", "OBSERVATION", 100, 107], ["septicemia", "OBSERVATION", 174, 184], ["gastroenteritis", "OBSERVATION", 186, 201], ["urinary tract", "ANATOMY", 207, 220], ["E. coli", "OBSERVATION", 242, 249]]], ["Khanna et al. [86] have synthesized a number semicarbazone and their corresponding heterocyclic organoselenium compounds such as cycloalkeno-1,2,3-selenadiazoles (cyclopenteno, cyclohexeno, cyclohepteno, and cycloocteno-1,2,3-selenadiazoles), at room temperature by applying solventless conditions.", [["semicarbazone", "CHEMICAL", 45, 58], ["organoselenium", "CHEMICAL", 96, 110], ["cycloalkeno-1,2,3-selenadiazoles", "CHEMICAL", 129, 161], ["cyclopenteno, cyclohexeno, cyclohepteno, and cycloocteno-1,2,3-selenadiazoles", "CHEMICAL", 163, 240], ["semicarbazone", "CHEMICAL", 45, 58], ["organoselenium", "CHEMICAL", 96, 110], ["cycloalkeno-1,2,3-selenadiazoles", "CHEMICAL", 129, 161], ["cyclopenteno", "CHEMICAL", 163, 175], ["cyclohexeno", "CHEMICAL", 177, 188], ["cyclohepteno", "CHEMICAL", 190, 202], ["cycloocteno-1,2,3-selenadiazoles", "CHEMICAL", 208, 240], ["semicarbazone", "SIMPLE_CHEMICAL", 45, 58], ["heterocyclic organoselenium compounds", "SIMPLE_CHEMICAL", 83, 120], ["cycloalkeno-1,2,3-selenadiazoles", "SIMPLE_CHEMICAL", 129, 161], ["cyclopenteno, cyclohexeno, cyclohepteno, and cycloocteno-1,2,3-selenadiazoles", "SIMPLE_CHEMICAL", 163, 240], ["a number semicarbazone", "TREATMENT", 36, 58], ["their corresponding heterocyclic organoselenium compounds", "PROBLEM", 63, 120], ["cycloalkeno", "TEST", 129, 140], ["selenadiazoles", "TREATMENT", 147, 161], ["cyclopenteno", "TREATMENT", 163, 175], ["cyclohexeno", "TREATMENT", 177, 188], ["cyclohepteno", "TREATMENT", 190, 202], ["cycloocteno", "TREATMENT", 208, 219], ["selenadiazoles", "TREATMENT", 226, 240], ["heterocyclic organoselenium", "OBSERVATION", 83, 110]]], ["The synthesized semicarbazones and their 1,2,3-selenadiazoles were tested for their antimicrobial activity against different pathogenic bacteria.", [["semicarbazones", "CHEMICAL", 16, 30], ["1,2,3-selenadiazoles", "CHEMICAL", 41, 61], ["semicarbazones", "CHEMICAL", 16, 30], ["1,2,3-selenadiazoles", "CHEMICAL", 41, 61], ["semicarbazones", "SIMPLE_CHEMICAL", 16, 30], ["1,2,3-selenadiazoles", "SIMPLE_CHEMICAL", 41, 61], ["The synthesized semicarbazones", "TREATMENT", 0, 30], ["selenadiazoles", "TREATMENT", 47, 61], ["different pathogenic bacteria", "PROBLEM", 115, 144], ["pathogenic bacteria", "OBSERVATION", 125, 144]]], ["It was observed that selenadiazoles exhibited enhanced antimicrobial activity against E. coli, S. aureus, S. typhi, and P. aeruginosa as compared with their respective semicarbazones.", [["selenadiazoles", "CHEMICAL", 21, 35], ["selenadiazoles", "CHEMICAL", 21, 35], ["semicarbazones", "CHEMICAL", 168, 182], ["selenadiazoles", "SIMPLE_CHEMICAL", 21, 35], ["E. coli", "ORGANISM", 86, 93], ["S. aureus", "ORGANISM", 95, 104], ["S. typhi", "ORGANISM", 106, 114], ["P. aeruginosa", "ORGANISM", 120, 133], ["semicarbazones", "SIMPLE_CHEMICAL", 168, 182], ["E. coli", "SPECIES", 86, 93], ["S. aureus", "SPECIES", 95, 104], ["S. typhi", "SPECIES", 106, 114], ["P. aeruginosa", "SPECIES", 120, 133], ["E. coli", "SPECIES", 86, 93], ["S. aureus", "SPECIES", 95, 104], ["S. typhi", "SPECIES", 106, 114], ["P. aeruginosa", "SPECIES", 120, 133], ["selenadiazoles", "TREATMENT", 21, 35], ["E. coli", "PROBLEM", 86, 93], ["S. aureus", "PROBLEM", 95, 104], ["S. typhi", "PROBLEM", 106, 114], ["P. aeruginosa", "PROBLEM", 120, 133], ["aureus", "OBSERVATION", 98, 104]]], ["Among these all selenadiazoles, cyclopenteno-1,2,3-selenadiazole exhibited very good inhibition against highly resistant P. aeruginosa.Antimicrobial activitySchiff base ligands containing p-amino salicylic acid improve the antimycobacterial activity against Mycobacterium and M. Lovis BCG.", [["selenadiazoles", "CHEMICAL", 16, 30], ["cyclopenteno-1,2,3-selenadiazole", "CHEMICAL", 32, 64], ["p-amino salicylic acid", "CHEMICAL", 188, 210], ["selenadiazoles", "CHEMICAL", 16, 30], ["cyclopenteno-1,2,3-selenadiazole", "CHEMICAL", 32, 64], ["p-amino salicylic acid", "CHEMICAL", 188, 210], ["selenadiazoles", "SIMPLE_CHEMICAL", 16, 30], ["cyclopenteno-1,2,3-selenadiazole", "SIMPLE_CHEMICAL", 32, 64], ["P. aeruginosa", "ORGANISM", 121, 134], ["p-amino salicylic acid", "SIMPLE_CHEMICAL", 188, 210], ["M. Lovis BCG", "ORGANISM", 276, 288], ["P. aeruginosa", "SPECIES", 121, 134], ["M. Lovis BCG", "SPECIES", 276, 288], ["P. aeruginosa", "SPECIES", 121, 134], ["M. Lovis", "SPECIES", 276, 284], ["these all selenadiazoles", "TREATMENT", 6, 30], ["cyclopenteno", "TREATMENT", 32, 44], ["selenadiazole", "TREATMENT", 51, 64], ["highly resistant P. aeruginosa", "PROBLEM", 104, 134], ["Antimicrobial activitySchiff base ligands", "TREATMENT", 135, 176], ["p-amino salicylic acid", "TREATMENT", 188, 210], ["the antimycobacterial activity", "TREATMENT", 219, 249], ["Mycobacterium", "PROBLEM", 258, 271], ["antimycobacterial activity", "OBSERVATION", 223, 249]]], ["Patole et al. [87] have been described some new multifunctional conjugates (46e51) of p-amino salicylic acid (PAS) (Scheme 12) capable of metal chelation along with the results on the evaluation of their antimycobacterial activity against M. smegmatis and Mycobacterium bovis (BCG).", [["p-amino salicylic acid", "CHEMICAL", 86, 108], ["p-amino salicylic acid", "CHEMICAL", 86, 108], ["PAS", "CHEMICAL", 110, 113], ["46e51", "SIMPLE_CHEMICAL", 76, 81], ["p-amino salicylic acid", "SIMPLE_CHEMICAL", 86, 108], ["PAS", "SIMPLE_CHEMICAL", 110, 113], ["metal", "SIMPLE_CHEMICAL", 138, 143], ["M. smegmatis", "ORGANISM", 239, 251], ["Mycobacterium bovis", "ORGANISM", 256, 275], ["BCG", "ORGANISM", 277, 280], ["M. smegmatis", "SPECIES", 239, 251], ["Mycobacterium bovis", "SPECIES", 256, 275], ["M. smegmatis", "SPECIES", 239, 251], ["Mycobacterium bovis", "SPECIES", 256, 275], ["p-amino salicylic acid", "TREATMENT", 86, 108], ["metal chelation", "TREATMENT", 138, 153], ["the evaluation", "TEST", 180, 194], ["their antimycobacterial activity", "TEST", 198, 230], ["M. smegmatis", "PROBLEM", 239, 251], ["Mycobacterium bovis", "PROBLEM", 256, 275]]], ["Hydroxyl-rich side chains in ligands exhibit increased antimycobacterial activity against M. smegmatis and M. bovis BCG.", [["Hydroxyl", "CHEMICAL", 0, 8], ["Hydroxyl", "CHEMICAL", 0, 8], ["Hydroxyl-rich side chains", "SIMPLE_CHEMICAL", 0, 25], ["M. smegmatis", "ORGANISM", 90, 102], ["M. bovis", "ORGANISM", 107, 115], ["BCG", "ORGANISM", 116, 119], ["M. smegmatis", "SPECIES", 90, 102], ["M. bovis", "SPECIES", 107, 115], ["BCG", "SPECIES", 116, 119], ["M. smegmatis", "SPECIES", 90, 102], ["M. bovis", "SPECIES", 107, 115], ["Hydroxyl-rich side chains", "TREATMENT", 0, 25], ["increased antimycobacterial activity", "PROBLEM", 45, 81], ["M. smegmatis", "PROBLEM", 90, 102], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["antimycobacterial activity", "OBSERVATION", 55, 81]]], ["Schiff base of cyclobutane and thiozole ring show antimicrobial activity.", [["cyclobutane", "CHEMICAL", 15, 26], ["thiozole", "CHEMICAL", 31, 39], ["Schiff base", "CHEMICAL", 0, 11], ["cyclobutane", "CHEMICAL", 15, 26], ["thiozole", "CHEMICAL", 31, 39], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["cyclobutane", "SIMPLE_CHEMICAL", 15, 26], ["thiozole ring", "SIMPLE_CHEMICAL", 31, 44], ["cyclobutane", "TREATMENT", 15, 26], ["thiozole ring", "TREATMENT", 31, 44], ["antimicrobial activity", "TREATMENT", 50, 72], ["antimicrobial activity", "OBSERVATION", 50, 72]]], ["Some Cu (II), Ni (II)dSchiff base complexes exhibit antibacterial activity against Colibacillus and P. aeruginosa [88] .Antimicrobial activitySchiff base (Scheme 13) derived from glycylglycine respectively with imidazole-2-carboxaldehyde (52) and indole-3carboxaldehyde (53) and their Zn (II) complexes were biologically tested against S. aureus, E. coli, K. pneumoniae, Proteus vulgaris, and P. aeruginosa by the disc-diffusion method.", [["Cu (II", "CHEMICAL", 5, 11], ["Ni", "CHEMICAL", 14, 16], ["Schiff", "CHEMICAL", 22, 28], ["Colibacillus", "CHEMICAL", 83, 95], ["glycylglycine", "CHEMICAL", 179, 192], ["imidazole-2-carboxaldehyde", "CHEMICAL", 211, 237], ["indole-3carboxaldehyde", "CHEMICAL", 247, 269], ["Zn", "CHEMICAL", 285, 287], ["Proteus vulgaris", "DISEASE", 371, 387], ["Cu (II)", "CHEMICAL", 5, 12], ["Ni (II)", "CHEMICAL", 14, 21], ["Schiff base", "CHEMICAL", 22, 33], ["glycylglycine", "CHEMICAL", 179, 192], ["imidazole-2-carboxaldehyde", "CHEMICAL", 211, 237], ["indole-3carboxaldehyde", "CHEMICAL", 247, 269], ["Zn (II)", "CHEMICAL", 285, 292], ["Cu (II", "SIMPLE_CHEMICAL", 5, 11], ["Ni (II)dSchiff base complexes", "SIMPLE_CHEMICAL", 14, 43], ["Colibacillus", "ORGANISM", 83, 95], ["P. aeruginosa", "ORGANISM", 100, 113], ["glycylglycine", "SIMPLE_CHEMICAL", 179, 192], ["imidazole-2-carboxaldehyde (52)", "SIMPLE_CHEMICAL", 211, 242], ["indole-3carboxaldehyde (53)", "SIMPLE_CHEMICAL", 247, 274], ["Zn (II)", "SIMPLE_CHEMICAL", 285, 292], ["S. aureus", "ORGANISM", 336, 345], ["E. coli", "ORGANISM", 347, 354], ["K. pneumoniae", "ORGANISM", 356, 369], ["Proteus vulgaris", "ORGANISM", 371, 387], ["P. aeruginosa", "ORGANISM", 393, 406], ["Zn (II) complexes", "PROTEIN", 285, 302], ["P. aeruginosa", "SPECIES", 100, 113], ["S. aureus", "SPECIES", 336, 345], ["E. coli", "SPECIES", 347, 354], ["K. pneumoniae", "SPECIES", 356, 369], ["Proteus vulgaris", "SPECIES", 371, 387], ["P. aeruginosa", "SPECIES", 393, 406], ["P. aeruginosa", "SPECIES", 100, 113], ["S. aureus", "SPECIES", 336, 345], ["E. coli", "SPECIES", 347, 354], ["K. pneumoniae", "SPECIES", 356, 369], ["Proteus vulgaris", "SPECIES", 371, 387], ["P. aeruginosa", "SPECIES", 393, 406], ["Ni (II)dSchiff base complexes", "TEST", 14, 43], ["antibacterial activity", "TEST", 52, 74], ["Colibacillus and P. aeruginosa", "PROBLEM", 83, 113], ["Antimicrobial activitySchiff base (Scheme", "TREATMENT", 120, 161], ["glycylglycine", "TEST", 179, 192], ["imidazole", "TREATMENT", 211, 220], ["indole-3carboxaldehyde", "TREATMENT", 247, 269], ["their Zn (II) complexes", "TREATMENT", 279, 302], ["S. aureus", "PROBLEM", 336, 345], ["E. coli", "PROBLEM", 347, 354], ["K. pneumoniae", "PROBLEM", 356, 369], ["Proteus vulgaris", "PROBLEM", 371, 387], ["P. aeruginosa", "PROBLEM", 393, 406], ["the disc-diffusion method", "TEST", 410, 435], ["antibacterial activity", "OBSERVATION", 52, 74], ["aureus", "OBSERVATION", 339, 345], ["E. coli", "OBSERVATION", 347, 354], ["disc", "ANATOMY", 414, 418]]], ["As comparative study of inhibition value, the complexes show higher antimicrobial activity than the free ligands [89] .Antimicrobial activityWadher et al. [90] have substituted aldehydes (59e72) and the Cu (II), Co (II), Ni (II) complexes (Scheme 15B) of 2-(2 0 -hydroxy)benzylidene-amino-naphthathiazole (64) .Antimicrobial activityAll ligands and these metal complexes were investigated for their antimicrobial activity against Gram \u00feve and Gram eve bacteria by measuring the zone of inhibition in mm.", [["aldehydes", "CHEMICAL", 177, 186], ["59e72", "CHEMICAL", 188, 193], ["Cu", "CHEMICAL", 203, 205], ["Co", "CHEMICAL", 212, 214], ["Ni", "CHEMICAL", 221, 223], ["2-(2 0 -hydroxy)benzylidene-amino-naphthathiazole", "CHEMICAL", 255, 304], ["aldehydes", "CHEMICAL", 177, 186], ["Cu (II)", "CHEMICAL", 203, 210], ["Co (II)", "CHEMICAL", 212, 219], ["Ni (II)", "CHEMICAL", 221, 228], ["2-(2 0 -hydroxy)benzylidene-amino-naphthathiazole", "CHEMICAL", 255, 304], ["aldehydes", "SIMPLE_CHEMICAL", 177, 186], ["59e72", "SIMPLE_CHEMICAL", 188, 193], ["Cu (II)", "SIMPLE_CHEMICAL", 203, 210], ["Co (II)", "SIMPLE_CHEMICAL", 212, 219], ["Ni (II) complexes", "SIMPLE_CHEMICAL", 221, 238], ["Scheme 15B", "SIMPLE_CHEMICAL", 240, 250], ["2-(2 0 -hydroxy)benzylidene-amino-naphthathiazole", "SIMPLE_CHEMICAL", 255, 304], ["Ni (II) complexes", "PROTEIN", 221, 238], ["comparative study", "TEST", 3, 20], ["inhibition value", "TEST", 24, 40], ["substituted aldehydes", "TEST", 165, 186], ["Scheme", "TEST", 240, 246], ["benzylidene", "TREATMENT", 271, 282], ["amino-naphthathiazole", "TREATMENT", 283, 304], ["Antimicrobial activity", "TREATMENT", 311, 333], ["these metal complexes", "TREATMENT", 349, 370], ["their antimicrobial activity", "TEST", 393, 421], ["Gram", "TEST", 430, 434], ["Gram eve bacteria", "TEST", 443, 460], ["higher", "OBSERVATION_MODIFIER", 61, 67], ["antimicrobial activity", "OBSERVATION", 68, 90], ["metal complexes", "OBSERVATION", 355, 370]]], ["It is observed that the Cu (II) complex with 2-(2 0 -hydroxy)benzylidene-amino-naphthathiazole acts as potential antimicrobial agent as well as the ligands containing nitro, halogen, hydroxyl, methoxy, etc. exhibited good inhibitory activity.Antimicrobial activityThe antimicrobial activity of Schiff base methyl-2-pyridyl ketone semicarbazone (73) and its Cu (II) complexes have been synthesized by Shaabani et al. [93] and have been investigated against the bacteria B. subtilis, S. aureus, E. coli, and Erwinia carotovora and fungals Candida kefyr, Candida krusei, and A. niger.", [["Cu", "CHEMICAL", 24, 26], ["2-(2 0 -hydroxy)benzylidene-amino-naphthathiazole", "CHEMICAL", 45, 94], ["nitro", "CHEMICAL", 167, 172], ["hydroxyl", "CHEMICAL", 183, 191], ["Schiff base methyl-2-pyridyl ketone semicarbazone", "CHEMICAL", 294, 343], ["Cu", "CHEMICAL", 357, 359], ["Cu (II)", "CHEMICAL", 24, 31], ["2-(2 0 -hydroxy)benzylidene-amino-naphthathiazole", "CHEMICAL", 45, 94], ["nitro", "CHEMICAL", 167, 172], ["halogen", "CHEMICAL", 174, 181], ["hydroxyl", "CHEMICAL", 183, 191], ["methoxy", "CHEMICAL", 193, 200], ["Schiff base methyl-2-pyridyl ketone semicarbazone", "CHEMICAL", 294, 343], ["Cu (II)", "CHEMICAL", 357, 364], ["Cu (II)", "SIMPLE_CHEMICAL", 24, 31], ["2-(2 0 -hydroxy)benzylidene-amino-naphthathiazole", "SIMPLE_CHEMICAL", 45, 94], ["nitro", "SIMPLE_CHEMICAL", 167, 172], ["halogen", "SIMPLE_CHEMICAL", 174, 181], ["hydroxyl", "SIMPLE_CHEMICAL", 183, 191], ["methoxy", "SIMPLE_CHEMICAL", 193, 200], ["Schiff base methyl-2-pyridyl ketone semicarbazone (73)", "SIMPLE_CHEMICAL", 294, 348], ["Cu (II) complexes", "SIMPLE_CHEMICAL", 357, 374], ["B. subtilis", "ORGANISM", 469, 480], ["S. aureus", "ORGANISM", 482, 491], ["E. coli", "ORGANISM", 493, 500], ["Erwinia carotovora", "ORGANISM", 506, 524], ["fungals Candida kefyr", "ORGANISM", 529, 550], ["Candida krusei", "ORGANISM", 552, 566], ["A. niger", "ORGANISM", 572, 580], ["Cu (II) complex", "PROTEIN", 24, 39], ["Cu (II) complexes", "PROTEIN", 357, 374], ["B. subtilis", "SPECIES", 469, 480], ["S. aureus", "SPECIES", 482, 491], ["E. coli", "SPECIES", 493, 500], ["Erwinia carotovora", "SPECIES", 506, 524], ["Candida kefyr", "SPECIES", 537, 550], ["Candida krusei", "SPECIES", 552, 566], ["A. niger", "SPECIES", 572, 580], ["B. subtilis", "SPECIES", 469, 480], ["S. aureus", "SPECIES", 482, 491], ["E. coli", "SPECIES", 493, 500], ["Erwinia carotovora", "SPECIES", 506, 524], ["Candida kefyr", "SPECIES", 537, 550], ["Candida krusei", "SPECIES", 552, 566], ["A. niger", "SPECIES", 572, 580], ["the Cu (II) complex", "TREATMENT", 20, 39], ["benzylidene", "TREATMENT", 61, 72], ["amino-naphthathiazole acts", "TREATMENT", 73, 99], ["potential antimicrobial agent", "TREATMENT", 103, 132], ["the ligands", "TREATMENT", 144, 155], ["nitro", "TREATMENT", 167, 172], ["halogen", "TREATMENT", 174, 181], ["hydroxyl", "TREATMENT", 183, 191], ["methoxy", "TREATMENT", 193, 200], ["etc", "TREATMENT", 202, 205], ["Antimicrobial activity", "TREATMENT", 242, 264], ["Schiff base methyl-2-pyridyl ketone semicarbazone", "TREATMENT", 294, 343], ["its Cu (II) complexes", "TREATMENT", 353, 374], ["the bacteria B. subtilis", "PROBLEM", 456, 480], ["S. aureus", "PROBLEM", 482, 491], ["E. coli", "PROBLEM", 493, 500], ["Erwinia carotovora", "TREATMENT", 506, 524], ["Candida krusei", "PROBLEM", 552, 566], ["good", "OBSERVATION_MODIFIER", 217, 221], ["inhibitory activity", "OBSERVATION", 222, 241], ["aureus", "OBSERVATION", 485, 491], ["E. coli", "OBSERVATION", 493, 500], ["Erwinia carotovora", "OBSERVATION", 506, 524], ["Candida krusei", "OBSERVATION", 552, 566]]], ["The ligand 73 shows poor biological activity as compared with the thiosemicarbazone which contains sulfur instead of oxygen atom.", [["thiosemicarbazone", "CHEMICAL", 66, 83], ["sulfur", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 117, 123], ["thiosemicarbazone", "CHEMICAL", 66, 83], ["sulfur", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 117, 123], ["thiosemicarbazone", "SIMPLE_CHEMICAL", 66, 83], ["sulfur", "SIMPLE_CHEMICAL", 99, 105], ["oxygen atom", "SIMPLE_CHEMICAL", 117, 128], ["The ligand", "TEST", 0, 10], ["poor biological activity", "PROBLEM", 20, 44], ["the thiosemicarbazone", "TREATMENT", 62, 83], ["sulfur instead of oxygen atom", "TREATMENT", 99, 128], ["poor", "OBSERVATION_MODIFIER", 20, 24], ["biological activity", "OBSERVATION_MODIFIER", 25, 44], ["oxygen atom", "OBSERVATION", 117, 128]]], ["Cu (II) complexes showed enhanced antimicrobial activity than the parent ligand.Antimicrobial activityChohan and Sumrra [94] have reported a new series of biologically active thienyl-derived triazole Schiff bases and their VO (IV) (74e78) complexes (Scheme 16).", [["Cu", "CHEMICAL", 0, 2], ["thienyl", "CHEMICAL", 175, 182], ["Cu (II)", "CHEMICAL", 0, 7], ["thienyl", "CHEMICAL", 175, 182], ["triazole", "CHEMICAL", 191, 199], ["Schiff bases", "CHEMICAL", 200, 212], ["VO (IV)", "CHEMICAL", 223, 230], ["Cu (II)", "SIMPLE_CHEMICAL", 0, 7], ["thienyl-derived triazole Schiff bases", "SIMPLE_CHEMICAL", 175, 212], ["VO (IV)", "SIMPLE_CHEMICAL", 223, 230], ["Cu (II) complexes", "PROTEIN", 0, 17], ["enhanced antimicrobial activity", "PROBLEM", 25, 56], ["Antimicrobial activityChohan", "TREATMENT", 80, 108], ["biologically active thienyl", "TREATMENT", 155, 182], ["triazole Schiff bases", "TREATMENT", 191, 212], ["their VO (IV)", "TREATMENT", 217, 230], ["antimicrobial activity", "OBSERVATION", 34, 56]]], ["All the ligands and their VO (IV) complexes were tested in vitro antimicrobial activity against Gramnegative bacterial strains (E. coli, Shigella flexneri, P. aeruginosa, Salmonella enterica serover typhi) as well as Gram-positive bacterial strains (S. aureus and B. subtilis).", [["VO (IV)", "CHEMICAL", 26, 33], ["Gramnegative bacterial strains", "ORGANISM", 96, 126], ["E. coli", "ORGANISM", 128, 135], ["Shigella flexneri", "ORGANISM", 137, 154], ["P. aeruginosa", "ORGANISM", 156, 169], ["Salmonella enterica serover typhi", "ORGANISM", 171, 204], ["Gram-", "GENE_OR_GENE_PRODUCT", 217, 222], ["S. aureus", "ORGANISM", 250, 259], ["B. subtilis", "ORGANISM", 264, 275], ["VO (IV) complexes", "PROTEIN", 26, 43], ["E. coli", "SPECIES", 128, 135], ["Shigella flexneri", "SPECIES", 137, 154], ["P. aeruginosa", "SPECIES", 156, 169], ["Salmonella enterica", "SPECIES", 171, 190], ["serover typhi", "SPECIES", 191, 204], ["S. aureus", "SPECIES", 250, 259], ["B. subtilis", "SPECIES", 264, 275], ["E. coli", "SPECIES", 128, 135], ["Shigella flexneri", "SPECIES", 137, 154], ["P. aeruginosa", "SPECIES", 156, 169], ["Salmonella enterica serover typhi", "SPECIES", 171, 204], ["S. aureus", "SPECIES", 250, 259], ["B. subtilis", "SPECIES", 264, 275], ["their VO (IV) complexes", "TREATMENT", 20, 43], ["vitro antimicrobial activity", "TREATMENT", 59, 87], ["Gramnegative bacterial strains", "PROBLEM", 96, 126], ["E. coli", "PROBLEM", 128, 135], ["Shigella flexneri", "PROBLEM", 137, 154], ["P. aeruginosa", "PROBLEM", 156, 169], ["Salmonella enterica serover typhi", "PROBLEM", 171, 204], ["Gram-positive bacterial strains", "PROBLEM", 217, 248], ["S. aureus", "PROBLEM", 250, 259], ["B. subtilis", "PROBLEM", 264, 275], ["positive bacterial strains", "OBSERVATION", 222, 248], ["aureus", "OBSERVATION", 253, 259]]], ["It was reported that because of the presence of chloro and nitro group in the VO (IV) complexes, (77) and (78) were found to be the most active antimicrobial agent against Gram-positive and Gram-negative bacterial strains.", [["chloro", "CHEMICAL", 48, 54], ["nitro", "CHEMICAL", 59, 64], ["chloro", "CHEMICAL", 48, 54], ["nitro", "CHEMICAL", 59, 64], ["VO (IV)", "CHEMICAL", 78, 85], ["chloro", "SIMPLE_CHEMICAL", 48, 54], ["nitro", "SIMPLE_CHEMICAL", 59, 64], ["(77)", "SIMPLE_CHEMICAL", 97, 101], ["(78)", "SIMPLE_CHEMICAL", 106, 110], ["Gram-", "GENE_OR_GENE_PRODUCT", 172, 177], ["Gram-", "GENE_OR_GENE_PRODUCT", 190, 195], ["chloro", "TREATMENT", 48, 54], ["nitro group in the VO (IV) complexes", "TREATMENT", 59, 95], ["Gram-positive and Gram-negative bacterial strains", "PROBLEM", 172, 221], ["bacterial strains", "OBSERVATION", 204, 221]]], ["Among these compounds, the compound (78) showed highest inhibition against B. subtilis bacterial strain (3.891 \u00c2 10 \u00c08 M).Antifungal activityFungi are the heterotrophic eukaryotic organisms which can grow on any surface.", [["surface", "ANATOMY", 212, 219], ["B. subtilis bacterial strain", "ORGANISM", 75, 103], ["surface", "CELLULAR_COMPONENT", 212, 219], ["B. subtilis", "SPECIES", 75, 86], ["B. subtilis", "SPECIES", 75, 86], ["highest inhibition against B. subtilis bacterial strain", "PROBLEM", 48, 103], ["Antifungal activityFungi", "PROBLEM", 122, 146], ["the heterotrophic eukaryotic organisms", "PROBLEM", 151, 189], ["heterotrophic eukaryotic organisms", "OBSERVATION", 155, 189], ["surface", "OBSERVATION_MODIFIER", 212, 219]]], ["In recent years, there was a significant increase in the occurrence of general fungal infections [95] .", [["fungal infections", "DISEASE", 79, 96], ["general fungal infections", "PROBLEM", 71, 96], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["fungal", "OBSERVATION_MODIFIER", 79, 85], ["infections", "OBSERVATION", 86, 96]]], ["Generally fungal infections are bounded to the surface tissues and moderately easy to cure.", [["surface tissues", "ANATOMY", 47, 62], ["fungal infections", "DISEASE", 10, 27], ["surface tissues", "TISSUE", 47, 62], ["Generally fungal infections", "PROBLEM", 0, 27], ["fungal", "OBSERVATION_MODIFIER", 10, 16], ["infections", "OBSERVATION", 17, 27], ["surface", "OBSERVATION_MODIFIER", 47, 54], ["moderately", "OBSERVATION_MODIFIER", 67, 77]]], ["So it is necessary to explore and develop more effective antifungal agents.", [["antifungal agents", "TREATMENT", 57, 74]]], ["The fungicidal activity toward Curvularia enhanced with the presence of methoxy, halogen, and naphthyl groups in the ligands.", [["Curvularia", "CHEMICAL", 31, 41], ["methoxy", "CHEMICAL", 72, 79], ["naphthyl", "CHEMICAL", 94, 102], ["methoxy", "CHEMICAL", 72, 79], ["halogen", "CHEMICAL", 81, 88], ["naphthyl", "CHEMICAL", 94, 102], ["Curvularia", "SIMPLE_CHEMICAL", 31, 41], ["methoxy", "SIMPLE_CHEMICAL", 72, 79], ["halogen", "SIMPLE_CHEMICAL", 81, 88], ["naphthyl groups", "SIMPLE_CHEMICAL", 94, 109], ["methoxy, halogen", "TREATMENT", 72, 88], ["fungicidal activity", "OBSERVATION", 4, 23]]], ["Sulfur-containing Schiff bases derived from thiazole and benzothiazole derivatives possess effectual antifungal activity [96, 97] .Antifungal activityPahontu et al. [96] have reported the 1-phenyl-3-methyl-4benzoyl-5-pyrazolone-4-ethyl-thiosemicarbazone (79) complexes.", [["Sulfur", "CHEMICAL", 0, 6], ["thiazole", "CHEMICAL", 44, 52], ["benzothiazole", "CHEMICAL", 57, 70], ["1-phenyl-3-methyl-4benzoyl-5-pyrazolone-4-ethyl-thiosemicarbazone", "CHEMICAL", 188, 253], ["Sulfur", "CHEMICAL", 0, 6], ["Schiff bases", "CHEMICAL", 18, 30], ["thiazole", "CHEMICAL", 44, 52], ["benzothiazole", "CHEMICAL", 57, 70], ["1-phenyl-3-methyl-4benzoyl-5-pyrazolone-4-ethyl-thiosemicarbazone", "CHEMICAL", 188, 253], ["Sulfur", "SIMPLE_CHEMICAL", 0, 6], ["Schiff bases", "SIMPLE_CHEMICAL", 18, 30], ["thiazole", "SIMPLE_CHEMICAL", 44, 52], ["benzothiazole derivatives", "SIMPLE_CHEMICAL", 57, 82], ["1-phenyl-3-methyl-4benzoyl-5-pyrazolone-4-ethyl-thiosemicarbazone (79) complexes", "SIMPLE_CHEMICAL", 188, 268], ["Sulfur", "TREATMENT", 0, 6], ["Schiff bases", "TREATMENT", 18, 30], ["thiazole", "TREATMENT", 44, 52], ["benzothiazole derivatives", "TREATMENT", 57, 82], ["antifungal activity", "TEST", 101, 120], ["Antifungal", "TREATMENT", 131, 141], ["phenyl", "TEST", 190, 196], ["methyl", "TREATMENT", 199, 205], ["benzoyl", "TREATMENT", 207, 214], ["-ethyl-thiosemicarbazone", "TREATMENT", 229, 253]]], ["The antimycotic property of the copper complexes 80, 81, 82, and 83 was studied, and they showed that bacteriostatic and bactericidal activity toward Candida fungi in a concentration range of 1.5e4.0 lg/ml.", [["copper", "CHEMICAL", 32, 38], ["copper", "CHEMICAL", 32, 38], ["copper", "SIMPLE_CHEMICAL", 32, 38], ["Candida fungi", "ORGANISM", 150, 163], ["the copper complexes", "TEST", 28, 48], ["bacteriostatic and bactericidal activity", "PROBLEM", 102, 142], ["Candida fungi", "TEST", 150, 163], ["antimycotic", "OBSERVATION_MODIFIER", 4, 15], ["bacteriostatic", "OBSERVATION_MODIFIER", 102, 116], ["bactericidal activity", "OBSERVATION", 121, 142], ["Candida fungi", "OBSERVATION", 150, 163]]], ["Copper complexes were compared with the nystatin, a compound employed in medicine for mycoses treatment and found that copper complexes have 20e25 times higher antimycotic activity against Candida fungi than nystatin.", [["Copper", "CHEMICAL", 0, 6], ["nystatin", "CHEMICAL", 40, 48], ["mycoses", "DISEASE", 86, 93], ["copper", "CHEMICAL", 119, 125], ["nystatin", "CHEMICAL", 208, 216], ["Copper", "CHEMICAL", 0, 6], ["nystatin", "CHEMICAL", 40, 48], ["copper", "CHEMICAL", 119, 125], ["nystatin", "CHEMICAL", 208, 216], ["Copper", "SIMPLE_CHEMICAL", 0, 6], ["nystatin", "SIMPLE_CHEMICAL", 40, 48], ["copper complexes", "SIMPLE_CHEMICAL", 119, 135], ["Candida fungi", "ORGANISM", 189, 202], ["nystatin", "SIMPLE_CHEMICAL", 208, 216], ["Copper complexes", "PROBLEM", 0, 16], ["the nystatin", "TREATMENT", 36, 48], ["mycoses treatment", "TREATMENT", 86, 103], ["copper complexes", "PROBLEM", 119, 135], ["Candida fungi", "PROBLEM", 189, 202], ["nystatin", "TREATMENT", 208, 216]]], ["Semicarbazones (86, 88) and thiosemicarbazones (87, 89) and its Ni (II) complexes exhibited antifungal activities toward many pathogenic fungi.", [["Semicarbazones", "CHEMICAL", 0, 14], ["86, 88) and thiosemicarbazones (87, 89)", "CHEMICAL", 16, 55], ["Ni", "CHEMICAL", 64, 66], ["Semicarbazones", "CHEMICAL", 0, 14], ["thiosemicarbazones", "CHEMICAL", 28, 46], ["Ni (II)", "CHEMICAL", 64, 71], ["Semicarbazones", "SIMPLE_CHEMICAL", 0, 14], ["thiosemicarbazones", "SIMPLE_CHEMICAL", 28, 46], ["Ni (II)", "SIMPLE_CHEMICAL", 64, 71], ["Ni (II) complexes", "PROTEIN", 64, 81], ["Semicarbazones", "TREATMENT", 0, 14], ["thiosemicarbazones", "TREATMENT", 28, 46], ["its Ni (II) complexes", "TREATMENT", 60, 81], ["antifungal activities", "TREATMENT", 92, 113], ["many pathogenic fungi", "PROBLEM", 121, 142], ["pathogenic fungi", "OBSERVATION", 126, 142]]], ["Some of the Ni (II) complexes show reasonable activity against the pathogenic fungi, but they were found to be much lower than those of standard fungicide Nistatin [98] (Scheme 18).Antifungal activityThe synthesis and antifungal activity of some Schiff base ligands and its Sn (IV) complexes against some plant pathogenic fungi has been investigated and reported by Rehman et al. [99] .", [["Ni", "CHEMICAL", 12, 14], ["Nistatin", "CHEMICAL", 155, 163], ["Sn", "CHEMICAL", 274, 276], ["Ni (II)", "CHEMICAL", 12, 19], ["Nistatin", "CHEMICAL", 155, 163], ["Schiff base", "CHEMICAL", 246, 257], ["Sn (IV)", "CHEMICAL", 274, 281], ["Ni (II)", "SIMPLE_CHEMICAL", 12, 19], ["Sn (IV)", "GENE_OR_GENE_PRODUCT", 274, 281], ["Ni (II) complexes", "PROTEIN", 12, 29], ["Sn (IV) complexes", "PROTEIN", 274, 291], ["the pathogenic fungi", "PROBLEM", 63, 83], ["standard fungicide Nistatin", "TREATMENT", 136, 163], ["Antifungal activity", "TREATMENT", 181, 200], ["The synthesis", "TREATMENT", 200, 213], ["antifungal activity", "TREATMENT", 218, 237], ["some Schiff base ligands", "PROBLEM", 241, 265], ["Sn (IV) complexes", "TREATMENT", 274, 291], ["some plant pathogenic fungi", "PROBLEM", 300, 327], ["reasonable activity", "OBSERVATION", 35, 54], ["pathogenic fungi", "OBSERVATION", 67, 83], ["antifungal activity", "OBSERVATION", 218, 237], ["Schiff base ligands", "OBSERVATION", 246, 265], ["pathogenic fungi", "OBSERVATION", 311, 327]]], ["The various concentrations (50, 100, 250, and 500 ppm) of the ligands and its Sn (IV) complexes were employed to investigate the germination effect of Colletotrichum glocosporiodes, Alternaria brassicicola, Alternaria brassicae, C. capsici, and Helminthosporium graminium by using the hanging drop method.", [["Sn", "CHEMICAL", 78, 80], ["Sn (IV)", "CHEMICAL", 78, 85], ["Sn (IV)", "GENE_OR_GENE_PRODUCT", 78, 85], ["Colletotrichum glocosporiodes", "ORGANISM", 151, 180], ["Alternaria brassicicola", "ORGANISM", 182, 205], ["Alternaria brassicae", "ORGANISM", 207, 227], ["C. capsici", "ORGANISM", 229, 239], ["Helminthosporium graminium", "ORGANISM", 245, 271], ["Sn (IV) complexes", "PROTEIN", 78, 95], ["Colletotrichum glocosporiodes", "SPECIES", 151, 180], ["Alternaria brassicicola", "SPECIES", 182, 205], ["Alternaria brassicae", "SPECIES", 207, 227], ["C. capsici", "SPECIES", 229, 239], ["Helminthosporium graminium", "SPECIES", 245, 271], ["Colletotrichum glocosporiodes", "SPECIES", 151, 180], ["Alternaria brassicicola", "SPECIES", 182, 205], ["Alternaria brassicae", "SPECIES", 207, 227], ["C. capsici", "SPECIES", 229, 239], ["Helminthosporium graminium", "SPECIES", 245, 271], ["Sn (IV) complexes", "TREATMENT", 78, 95], ["Colletotrichum glocosporiodes", "TREATMENT", 151, 180], ["Alternaria brassicicola", "TREATMENT", 182, 205], ["Alternaria brassicae", "TREATMENT", 207, 227], ["Helminthosporium graminium", "TREATMENT", 245, 271], ["the hanging drop method", "TREATMENT", 281, 304], ["Colletotrichum glocosporiodes", "OBSERVATION", 151, 180]]], ["It is observed that all the compounds have outstanding fungicidal activity.", [["fungicidal activity", "OBSERVATION", 55, 74]]], ["The toxicity is enhanced with the increase in concentration of compounds.Antifungal activityChandra et al. [100] have reported the synthesis and characterization of Schiff base ligand 3,3 0 -thiodipropionic acid-bis(4amino-5-ethylimino-2,3-dimethyl-1-phenyl-3-pyrazoline (90) and its Co (II), Ni (II) and Cu (II) complexes (a and b) (Scheme 19).", [["toxicity", "DISEASE", 4, 12], ["3,3 0 -thiodipropionic acid-bis", "CHEMICAL", 184, 215], ["4amino-5-ethylimino-2,3-dimethyl-1-phenyl-3-pyrazoline", "CHEMICAL", 216, 270], ["Ni", "CHEMICAL", 293, 295], ["Cu", "CHEMICAL", 305, 307], ["Schiff base", "CHEMICAL", 165, 176], ["3,3 0 -thiodipropionic acid-bis(4amino-5-ethylimino-2,3-dimethyl-1-phenyl-3-pyrazoline", "CHEMICAL", 184, 270], ["Co (II)", "CHEMICAL", 284, 291], ["Ni (II)", "CHEMICAL", 293, 300], ["Cu (II)", "CHEMICAL", 305, 312], ["Schiff base ligand 3,3 0 -thiodipropionic acid-bis(4amino-5-ethylimino-2,3-dimethyl-1-phenyl-3-pyrazoline (90)", "SIMPLE_CHEMICAL", 165, 275], ["Co (II)", "SIMPLE_CHEMICAL", 284, 291], ["Ni (II)", "SIMPLE_CHEMICAL", 293, 300], ["Cu (II) complexes", "SIMPLE_CHEMICAL", 305, 322], ["The toxicity", "PROBLEM", 0, 12], ["the synthesis", "TEST", 127, 140], ["Schiff base ligand", "TEST", 165, 183], ["thiodipropionic acid", "TEST", 191, 211], ["bis", "TEST", 212, 215], ["4amino", "TEST", 216, 222], ["ethylimino", "TREATMENT", 225, 235], ["dimethyl", "TREATMENT", 240, 248], ["phenyl-3-pyrazoline", "TREATMENT", 251, 270], ["Ni (II) and Cu (II) complexes (a and b) (Scheme", "TREATMENT", 293, 340], ["toxicity", "OBSERVATION", 4, 12], ["enhanced", "OBSERVATION_MODIFIER", 16, 24], ["increase", "OBSERVATION_MODIFIER", 34, 42]]], ["All the compounds were screened for their antifungal activity against A. brassicae, A. niger and Fusarium oxysporum, and it is found that all the synthesized complexes exhibit enhanced activity as compared with that of free ligands.", [["A. brassicae", "ORGANISM", 70, 82], ["A. niger", "ORGANISM", 84, 92], ["Fusarium oxysporum", "ORGANISM", 97, 115], ["A. brassicae", "SPECIES", 70, 82], ["A. niger", "SPECIES", 84, 92], ["Fusarium oxysporum", "SPECIES", 97, 115], ["A. brassicae", "SPECIES", 70, 82], ["A. niger", "SPECIES", 84, 92], ["Fusarium oxysporum", "SPECIES", 97, 115], ["their antifungal activity", "TREATMENT", 36, 61], ["Fusarium oxysporum", "PROBLEM", 97, 115], ["enhanced activity", "OBSERVATION", 176, 193]]], ["Schiff base synthesized from furan or furylglycoxal with different amines exhibit antifungal activity against H. gramineum, Syncephalostrum racemosus, and Collectotrichum capsici [101] .Antifungal activityRaman et al. [102] have been synthesized macrocyclic ligands by the condensation reaction of diethyl phthalate with Schiff bases obtained from o-phenylenediamine and Knoevenagel condensed bketoanilides and its Cu (II) complexes.", [["Schiff base", "CHEMICAL", 0, 11], ["furan", "CHEMICAL", 29, 34], ["furylglycoxal", "CHEMICAL", 38, 51], ["amines", "CHEMICAL", 67, 73], ["diethyl phthalate", "CHEMICAL", 298, 315], ["o-phenylenediamine", "CHEMICAL", 348, 366], ["Knoevenagel", "CHEMICAL", 371, 382], ["bketoanilides", "CHEMICAL", 393, 406], ["Cu", "CHEMICAL", 415, 417], ["Schiff base", "CHEMICAL", 0, 11], ["furan", "CHEMICAL", 29, 34], ["furylglycoxal", "CHEMICAL", 38, 51], ["amines", "CHEMICAL", 67, 73], ["diethyl phthalate", "CHEMICAL", 298, 315], ["Schiff bases", "CHEMICAL", 321, 333], ["o-phenylenediamine", "CHEMICAL", 348, 366], ["Knoevenagel", "CHEMICAL", 371, 382], ["bketoanilides", "CHEMICAL", 393, 406], ["Cu (II)", "CHEMICAL", 415, 422], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["furan", "SIMPLE_CHEMICAL", 29, 34], ["furylglycoxal", "SIMPLE_CHEMICAL", 38, 51], ["amines", "SIMPLE_CHEMICAL", 67, 73], ["H. gramineum", "ORGANISM", 110, 122], ["Syncephalostrum racemosus", "ORGANISM", 124, 149], ["Collectotrichum capsici", "ORGANISM", 155, 178], ["diethyl phthalate", "SIMPLE_CHEMICAL", 298, 315], ["Schiff bases", "SIMPLE_CHEMICAL", 321, 333], ["o-phenylenediamine", "SIMPLE_CHEMICAL", 348, 366], ["Knoevenagel condensed bketoanilides", "SIMPLE_CHEMICAL", 371, 406], ["Cu (II)", "SIMPLE_CHEMICAL", 415, 422], ["Cu (II) complexes", "PROTEIN", 415, 432], ["H. gramineum", "SPECIES", 110, 122], ["Syncephalostrum racemosus", "SPECIES", 124, 149], ["Collectotrichum capsici", "SPECIES", 155, 178], ["H. gramineum", "SPECIES", 110, 122], ["Syncephalostrum racemosus", "SPECIES", 124, 149], ["Collectotrichum capsici", "SPECIES", 155, 178], ["Schiff base synthesized", "PROBLEM", 0, 23], ["furan", "TREATMENT", 29, 34], ["furylglycoxal", "TREATMENT", 38, 51], ["different amines", "TREATMENT", 57, 73], ["antifungal activity", "TREATMENT", 82, 101], ["H. gramineum", "PROBLEM", 110, 122], ["synthesized macrocyclic ligands", "TREATMENT", 234, 265], ["the condensation reaction of diethyl phthalate", "TREATMENT", 269, 315], ["Schiff bases", "TREATMENT", 321, 333], ["o-phenylenediamine", "TREATMENT", 348, 366], ["Knoevenagel condensed bketoanilides", "TREATMENT", 371, 406], ["its Cu (II) complexes", "TREATMENT", 411, 432]]], ["These complexes were investigated the in vitro antifungal activities against fungi such as Rhizopus stolonifer, Rhizoctonia bataicola, A. niger, A. flavus, and C. albicans.Antifungal activityIt is observed that all the Cu (II) complexes exhibited stronger antifungal activities than free ligands.", [["Cu", "CHEMICAL", 219, 221], ["Cu (II)", "CHEMICAL", 219, 226], ["Rhizopus stolonifer", "ORGANISM", 91, 110], ["Rhizoctonia bataicola", "ORGANISM", 112, 133], ["A. niger", "ORGANISM", 135, 143], ["A. flavus", "ORGANISM", 145, 154], ["C. albicans", "ORGANISM", 160, 171], ["Cu (II) complexes", "PROTEIN", 219, 236], ["Rhizopus stolonifer", "SPECIES", 91, 110], ["Rhizoctonia bataicola", "SPECIES", 112, 133], ["A. niger", "SPECIES", 135, 143], ["A. flavus", "SPECIES", 145, 154], ["C. albicans", "SPECIES", 160, 171], ["Rhizopus stolonifer", "SPECIES", 91, 110], ["Rhizoctonia bataicola", "SPECIES", 112, 133], ["A. niger", "SPECIES", 135, 143], ["A. flavus", "SPECIES", 145, 154], ["C. albicans", "SPECIES", 160, 171], ["fungi", "PROBLEM", 77, 82], ["C. albicans", "PROBLEM", 160, 171], ["Antifungal activity", "TREATMENT", 172, 191], ["flavus", "OBSERVATION", 148, 154], ["stronger", "OBSERVATION_MODIFIER", 247, 255], ["antifungal activities", "OBSERVATION", 256, 277]]], ["Some Schiff bases of furfurglidene nictoinamide [103] exhibits antifungal activity against A. niger, Alternaria solani, and C. capsici whereas Schiff base of quinazolinones [104] exhibit antifungal activity against C. albicans, Trichophyton rubrum, mentagrophytes, A. niger, and Micosporum gypseum.", [["furfurglidene nictoinamide [103]", "CHEMICAL", 21, 53], ["quinazolinones", "CHEMICAL", 158, 172], ["Schiff bases", "CHEMICAL", 5, 17], ["furfurglidene nictoinamide", "CHEMICAL", 21, 47], ["Schiff base", "CHEMICAL", 143, 154], ["quinazolinones", "CHEMICAL", 158, 172], ["furfurglidene nictoinamide [103]", "SIMPLE_CHEMICAL", 21, 53], ["A. niger", "ORGANISM", 91, 99], ["Alternaria solani", "ORGANISM", 101, 118], ["C. capsici", "ORGANISM", 124, 134], ["Schiff", "SIMPLE_CHEMICAL", 143, 149], ["quinazolinones [104]", "SIMPLE_CHEMICAL", 158, 178], ["C. albicans", "ORGANISM", 215, 226], ["Trichophyton rubrum", "ORGANISM", 228, 247], ["mentagrophytes", "ORGANISM", 249, 263], ["A. niger", "ORGANISM", 265, 273], ["Micosporum gypseum", "ORGANISM", 279, 297], ["A. niger", "SPECIES", 91, 99], ["Alternaria solani", "SPECIES", 101, 118], ["C. capsici", "SPECIES", 124, 134], ["C. albicans", "SPECIES", 215, 226], ["Trichophyton rubrum", "SPECIES", 228, 247], ["A. niger", "SPECIES", 265, 273], ["Micosporum gypseum", "SPECIES", 279, 297], ["A. niger", "SPECIES", 91, 99], ["Alternaria solani", "SPECIES", 101, 118], ["C. capsici", "SPECIES", 124, 134], ["C. albicans", "SPECIES", 215, 226], ["Trichophyton rubrum", "SPECIES", 228, 247], ["A. niger", "SPECIES", 265, 273], ["Micosporum gypseum", "SPECIES", 279, 297], ["furfurglidene nictoinamide", "TREATMENT", 21, 47], ["antifungal activity", "TREATMENT", 63, 82], ["Alternaria solani", "TREATMENT", 101, 118], ["Schiff base of quinazolinones", "TREATMENT", 143, 172], ["antifungal activity", "TREATMENT", 187, 206], ["C. albicans", "PROBLEM", 215, 226], ["Trichophyton rubrum", "PROBLEM", 228, 247], ["Micosporum gypseum", "PROBLEM", 279, 297], ["Schiff bases", "OBSERVATION", 5, 17]]], ["Schiff base derived from 3-substituted phenyl-4-amino-5-hydrazino-1,2,4-triazole with benzaldehyde, 2hydroxyacetophenone or indoline-2,3-dione and its Zn (II) complexes have been reported by Singh et al. [105] .", [["3-substituted phenyl-4-amino-5-hydrazino-1,2,4-triazole", "CHEMICAL", 25, 80], ["benzaldehyde", "CHEMICAL", 86, 98], ["2hydroxyacetophenone", "CHEMICAL", 100, 120], ["indoline-2,3-dione", "CHEMICAL", 124, 142], ["Zn", "CHEMICAL", 151, 153], ["Schiff base", "CHEMICAL", 0, 11], ["3-substituted phenyl-4-amino-5-hydrazino-1,2,4-triazole", "CHEMICAL", 25, 80], ["benzaldehyde", "CHEMICAL", 86, 98], ["2hydroxyacetophenone", "CHEMICAL", 100, 120], ["indoline-2,3-dione", "CHEMICAL", 124, 142], ["Zn (II)", "CHEMICAL", 151, 158], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["3-substituted phenyl-4-amino-5-hydrazino-1,2,4-triazole", "SIMPLE_CHEMICAL", 25, 80], ["benzaldehyde", "SIMPLE_CHEMICAL", 86, 98], ["2hydroxyacetophenone", "SIMPLE_CHEMICAL", 100, 120], ["indoline-2,3-dione", "SIMPLE_CHEMICAL", 124, 142], ["Zn (II)", "SIMPLE_CHEMICAL", 151, 158], ["Zn (II) complexes", "PROTEIN", 151, 168], ["Schiff base", "TEST", 0, 11], ["substituted phenyl", "TREATMENT", 27, 45], ["amino", "TREATMENT", 48, 53], ["hydrazino", "TREATMENT", 56, 65], ["triazole", "TREATMENT", 72, 80], ["benzaldehyde", "TREATMENT", 86, 98], ["2hydroxyacetophenone", "TREATMENT", 100, 120], ["indoline", "TREATMENT", 124, 132], ["its Zn (II) complexes", "TREATMENT", 147, 168]]], ["All the Schiff base ligands and their Zn (II) complexes were studied for their antifungal activities against Colletotrichum falcatum, Aspergillus niger, F. oxysporum, and Carvularia pallescence.", [["Zn", "CHEMICAL", 38, 40], ["Schiff base", "CHEMICAL", 8, 19], ["Zn (II)", "CHEMICAL", 38, 45], ["Zn (II)", "SIMPLE_CHEMICAL", 38, 45], ["Colletotrichum falcatum", "ORGANISM", 109, 132], ["Aspergillus niger", "ORGANISM", 134, 151], ["F. oxysporum", "ORGANISM", 153, 165], ["Zn (II) complexes", "PROTEIN", 38, 55], ["Colletotrichum falcatum", "SPECIES", 109, 132], ["Aspergillus niger", "SPECIES", 134, 151], ["F. oxysporum", "SPECIES", 153, 165], ["Colletotrichum falcatum", "SPECIES", 109, 132], ["Aspergillus niger", "SPECIES", 134, 151], ["F. oxysporum", "SPECIES", 153, 165], ["Carvularia pallescence", "SPECIES", 171, 193], ["their Zn (II) complexes", "TREATMENT", 32, 55], ["their antifungal activities", "TREATMENT", 73, 100], ["Colletotrichum falcatum", "PROBLEM", 109, 132], ["Aspergillus niger", "PROBLEM", 134, 151]]], ["To evaluate their antifungal activity against A. flavus, these ligands and their ruthenium complexes were tested in vitro at four different concentrations.", [["ruthenium", "CHEMICAL", 81, 90], ["ruthenium", "CHEMICAL", 81, 90], ["A. flavus", "ORGANISM", 46, 55], ["ruthenium complexes", "SIMPLE_CHEMICAL", 81, 100], ["A. flavus", "SPECIES", 46, 55], ["A. flavus", "SPECIES", 46, 55], ["A. flavus", "PROBLEM", 46, 55], ["their ruthenium complexes", "TREATMENT", 75, 100]]], ["It is observed that the ruthenium complexes were more toxic against the A. flavus as compared with their parent ligands.", [["ruthenium", "CHEMICAL", 24, 33], ["ruthenium", "CHEMICAL", 24, 33], ["ruthenium complexes", "SIMPLE_CHEMICAL", 24, 43], ["A. flavus", "ORGANISM", 72, 81], ["A. flavus", "SPECIES", 72, 81], ["A. flavus", "SPECIES", 72, 81], ["the ruthenium complexes", "PROBLEM", 20, 43], ["the A. flavus", "PROBLEM", 68, 81], ["toxic", "OBSERVATION_MODIFIER", 54, 59], ["flavus", "OBSERVATION", 75, 81]]], ["The toxicity of these complexes increased on increasing the concentration.Antiviral activityNowadays, our society is facing one of the main health disorder apoptosis obstructions, i.e. cancer [109] .", [["cancer", "ANATOMY", 185, 191], ["toxicity", "DISEASE", 4, 12], ["disorder apoptosis obstructions", "DISEASE", 147, 178], ["cancer", "DISEASE", 185, 191], ["obstructions", "PATHOLOGICAL_FORMATION", 166, 178], ["cancer", "CANCER", 185, 191], ["The toxicity of these complexes", "PROBLEM", 0, 31], ["apoptosis obstructions", "PROBLEM", 156, 178], ["cancer", "PROBLEM", 185, 191], ["toxicity", "OBSERVATION_MODIFIER", 4, 12], ["complexes", "OBSERVATION_MODIFIER", 22, 31], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["obstructions", "OBSERVATION", 166, 178], ["cancer", "OBSERVATION", 185, 191]]], ["For the treatment of cancer, chemotherapy is not effective.", [["cancer", "ANATOMY", 21, 27], ["cancer", "DISEASE", 21, 27], ["cancer", "CANCER", 21, 27], ["cancer", "PROBLEM", 21, 27], ["chemotherapy", "TREATMENT", 29, 41], ["cancer", "OBSERVATION", 21, 27]]], ["Hence, it has great importance to discover some novel and effective anticancer medicine [110] .", [["anticancer", "ANATOMY", 68, 78], ["anticancer", "CANCER", 68, 78], ["effective anticancer medicine", "TREATMENT", 58, 87]]], ["Platinum-based complexes like cis-platin have been used as anticancer agent in chemotherapy [111, 112] .", [["anticancer", "ANATOMY", 59, 69], ["Platinum", "CHEMICAL", 0, 8], ["cis-platin", "CHEMICAL", 30, 40], ["Platinum", "CHEMICAL", 0, 8], ["cis-platin", "CHEMICAL", 30, 40], ["Platinum-based complexes", "SIMPLE_CHEMICAL", 0, 24], ["cis-platin", "SIMPLE_CHEMICAL", 30, 40], ["anticancer", "CANCER", 59, 69], ["Platinum-based complexes", "TREATMENT", 0, 24], ["cis-platin", "TREATMENT", 30, 40], ["anticancer agent", "TREATMENT", 59, 75], ["chemotherapy", "TREATMENT", 79, 91], ["cis-platin", "OBSERVATION", 30, 40]]], ["In recent years, researchers have attracted enormous attention to develop non-platinum metalbased complexes as anticancer agents.", [["anticancer", "ANATOMY", 111, 121], ["non-platinum metalbased complexes", "SIMPLE_CHEMICAL", 74, 107], ["anticancer", "CANCER", 111, 121], ["non-platinum metalbased complexes", "PROTEIN", 74, 107], ["non-platinum metalbased complexes", "TREATMENT", 74, 107], ["anticancer agents", "TREATMENT", 111, 128]]], ["Isatin derivatives show noticeable antiviral activity in the treatment of HIV.", [["Isatin", "CHEMICAL", 0, 6], ["HIV", "DISEASE", 74, 77], ["Isatin", "CHEMICAL", 0, 6], ["Isatin derivatives", "SIMPLE_CHEMICAL", 0, 18], ["HIV", "ORGANISM", 74, 77], ["HIV", "SPECIES", 74, 77], ["HIV", "SPECIES", 74, 77], ["Isatin derivatives", "TREATMENT", 0, 18], ["HIV", "PROBLEM", 74, 77], ["noticeable", "OBSERVATION_MODIFIER", 24, 34], ["antiviral activity", "OBSERVATION", 35, 53]]], ["Either HIV-1 infected or mock-infected MT-4 cells in human were incubated with different concentration of Isatin derivates (shown in Scheme 10), and the number of viable cells was determined by 3-(4,5dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method after virus infection.", [["MT-4 cells", "ANATOMY", 39, 49], ["cells", "ANATOMY", 170, 175], ["Isatin", "CHEMICAL", 106, 112], ["3-(4,5dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 194, 255], ["infection", "DISEASE", 281, 290], ["Isatin", "CHEMICAL", 106, 112], ["3-(4,5dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 194, 255], ["MTT", "CHEMICAL", 257, 260], ["HIV-1", "ORGANISM", 7, 12], ["MT-4 cells", "CELL", 39, 49], ["human", "ORGANISM", 53, 58], ["Isatin derivates", "SIMPLE_CHEMICAL", 106, 122], ["cells", "CELL", 170, 175], ["3-(4,5dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "SIMPLE_CHEMICAL", 194, 255], ["MTT", "SIMPLE_CHEMICAL", 257, 260], ["mock-infected MT-4 cells", "CELL_LINE", 25, 49], ["HIV-1", "SPECIES", 7, 12], ["human", "SPECIES", 53, 58], ["HIV-1", "SPECIES", 7, 12], ["human", "SPECIES", 53, 58], ["Isatin derivates", "TREATMENT", 106, 122], ["4,5dimethyl thiazol", "TREATMENT", 197, 216], ["diphenyl tetrazolium bromide", "TREATMENT", 227, 255], ["virus infection", "PROBLEM", 275, 290], ["infection", "OBSERVATION", 281, 290]]], ["At the concentration below its threshold toxicity, none of the Isatin derivatives displayed noticeable anti-HIV activity [113] .", [["toxicity", "DISEASE", 41, 49], ["Isatin", "CHEMICAL", 63, 69], ["Isatin", "CHEMICAL", 63, 69], ["Isatin derivatives", "SIMPLE_CHEMICAL", 63, 81], ["anti-HIV", "CANCER", 103, 111], ["its threshold toxicity", "PROBLEM", 27, 49], ["the Isatin derivatives", "TREATMENT", 59, 81]]], ["In addition to this, Isatin Schiff base ligands have been widely reported antiviral activities against Moloney leukemia virus [114] , vaccinia [115] , rhino virus [116] , and SARS virus [117] .", [["Moloney leukemia virus", "DISEASE", 103, 125], ["SARS", "DISEASE", 175, 179], ["Isatin Schiff base", "CHEMICAL", 21, 39], ["Isatin", "SIMPLE_CHEMICAL", 21, 27], ["Moloney leukemia virus", "ORGANISM", 103, 125], ["114]", "ORGANISM", 127, 131], ["vaccinia [115]", "ORGANISM", 134, 148], ["rhino virus", "ORGANISM", 151, 162], ["SARS virus", "ORGANISM", 175, 185], ["Moloney leukemia virus", "SPECIES", 103, 125], ["rhino virus", "SPECIES", 151, 162], ["Moloney leukemia virus", "SPECIES", 103, 125], ["rhino virus", "SPECIES", 151, 162], ["SARS virus", "SPECIES", 175, 185], ["this, Isatin Schiff base ligands", "TREATMENT", 15, 47], ["antiviral activities", "TREATMENT", 74, 94], ["Moloney leukemia virus", "PROBLEM", 103, 125], ["vaccinia", "TEST", 134, 142], ["rhino virus", "PROBLEM", 151, 162], ["SARS virus", "PROBLEM", 175, 185]]], ["Similarly, inhibition activities of Isatin derivatives derived from Isatin, sodium hydride, and different bromide compounds against a new viral uncharacteristic pneumonia, i.e. severe acute respiratory syndrome coronavirus (SARS CoV) were also studied by Chen et al. [117] .", [["Isatin", "CHEMICAL", 36, 42], ["Isatin", "CHEMICAL", 68, 74], ["sodium hydride", "CHEMICAL", 76, 90], ["bromide", "CHEMICAL", 106, 113], ["pneumonia", "DISEASE", 161, 170], ["acute respiratory syndrome coronavirus", "DISEASE", 184, 222], ["SARS", "DISEASE", 224, 228], ["Isatin", "CHEMICAL", 36, 42], ["Isatin", "CHEMICAL", 68, 74], ["sodium hydride", "CHEMICAL", 76, 90], ["bromide", "CHEMICAL", 106, 113], ["Isatin derivatives", "SIMPLE_CHEMICAL", 36, 54], ["Isatin", "SIMPLE_CHEMICAL", 68, 74], ["sodium hydride", "SIMPLE_CHEMICAL", 76, 90], ["bromide compounds", "SIMPLE_CHEMICAL", 106, 123], ["severe acute respiratory syndrome coronavirus", "SPECIES", 177, 222], ["SARS CoV", "SPECIES", 224, 232], ["Isatin derivatives", "TREATMENT", 36, 54], ["Isatin", "TREATMENT", 68, 74], ["sodium hydride", "TREATMENT", 76, 90], ["different bromide compounds", "TREATMENT", 96, 123], ["a new viral uncharacteristic pneumonia", "PROBLEM", 132, 170], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 177, 222], ["new", "OBSERVATION_MODIFIER", 134, 137], ["viral", "OBSERVATION_MODIFIER", 138, 143], ["uncharacteristic", "OBSERVATION_MODIFIER", 144, 160], ["pneumonia", "OBSERVATION", 161, 170], ["severe", "OBSERVATION_MODIFIER", 177, 183], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["respiratory syndrome coronavirus", "OBSERVATION", 190, 222]]], ["They concluded that the Nsubstituted Isatin derivatives showed the inhibition activity against SARS CoV 3C-like protease (3CL pro ) in minimum micromolar range such as 0.95e17.50 mM.", [["Isatin", "CHEMICAL", 37, 43], ["Isatin", "CHEMICAL", 37, 43], ["Nsubstituted Isatin derivatives", "SIMPLE_CHEMICAL", 24, 55], ["SARS CoV 3C", "ORGANISM", 95, 106], ["SARS CoV 3C-like protease", "PROTEIN", 95, 120], ["3CL pro", "PROTEIN", 122, 129], ["SARS CoV", "SPECIES", 95, 103], ["the Nsubstituted Isatin derivatives", "TREATMENT", 20, 55], ["the inhibition activity", "PROBLEM", 63, 86], ["SARS CoV 3C", "TREATMENT", 95, 106], ["protease (3CL pro", "TREATMENT", 112, 129]]], ["The inhibition properties were evaluated by fluorescence resonance energy transfer (FRET) as well as confirmed through high performance liquid chromatography (HPLC) analysis.", [["The inhibition properties", "TREATMENT", 0, 25], ["high performance liquid chromatography", "TEST", 119, 157], ["HPLC) analysis", "TEST", 159, 173]]], ["Among these all derivatives, compound 94 (Scheme 21A) was found the more potent and selective inhibitor for the SARS CoV 3CL pro .Antiviral activityAn Isatin-thiosemicarbazone (methisazone) plays a vital role as a prophylactic agent against several viral diseases [118] .", [["compound 94", "CHEMICAL", 29, 40], ["Isatin-thiosemicarbazone", "CHEMICAL", 151, 175], ["methisazone", "CHEMICAL", 177, 188], ["viral diseases", "DISEASE", 249, 263], ["Isatin-thiosemicarbazone", "CHEMICAL", 151, 175], ["methisazone", "CHEMICAL", 177, 188], ["compound 94", "SIMPLE_CHEMICAL", 29, 40], ["Scheme 21A", "SIMPLE_CHEMICAL", 42, 52], ["Isatin-thiosemicarbazone", "SIMPLE_CHEMICAL", 151, 175], ["methisazone", "SIMPLE_CHEMICAL", 177, 188], ["SARS CoV 3CL pro", "PROTEIN", 112, 128], ["SARS CoV", "SPECIES", 112, 120], ["selective inhibitor", "TREATMENT", 84, 103], ["Antiviral activityAn Isatin", "TREATMENT", 130, 157], ["thiosemicarbazone (methisazone)", "TREATMENT", 158, 189], ["a vital role", "TREATMENT", 196, 208], ["a prophylactic agent", "TREATMENT", 212, 232], ["several viral diseases", "PROBLEM", 241, 263]]], ["Some 5fluoroisatin derivatives have been prepared and screened for antiviral activity, the replication of vesicular stomatitis virus (VSV), as well as cytotoxicity evaluation in Vero clone CCL-81 cell lines by Abbas et al. [119] .", [["CCL-81 cell lines", "ANATOMY", 189, 206], ["5fluoroisatin", "CHEMICAL", 5, 18], ["vesicular stomatitis", "DISEASE", 106, 126], ["5fluoroisatin", "CHEMICAL", 5, 18], ["5fluoroisatin derivatives", "SIMPLE_CHEMICAL", 5, 30], ["vesicular stomatitis virus", "ORGANISM", 106, 132], ["VSV", "ORGANISM", 134, 137], ["Vero clone CCL-81 cell lines", "CELL", 178, 206], ["Vero clone CCL-81 cell lines", "CELL_LINE", 178, 206], ["vesicular stomatitis virus", "SPECIES", 106, 132], ["stomatitis virus", "SPECIES", 116, 132], ["VSV", "SPECIES", 134, 137], ["Vero clone CCL-81", "SPECIES", 178, 195], ["Some 5fluoroisatin derivatives", "TREATMENT", 0, 30], ["antiviral activity", "TREATMENT", 67, 85], ["vesicular stomatitis virus", "PROBLEM", 106, 132], ["cytotoxicity evaluation", "TEST", 151, 174], ["Vero clone CCL", "TREATMENT", 178, 192], ["vesicular stomatitis", "ANATOMY", 106, 126], ["cell lines", "OBSERVATION", 196, 206]]], ["Among these all compounds, N1-(5-fluoro-2oxoindolin-3-ylidene)-N4-(p-fluoro-(or p-dimethylamino) benzylidene) thiocarbo hydrazone and N-allyl (or n-butyl)-2-(5-fluoro-2oxoindolin-3-ylidene)hydrazine carbo-thioamide as well as 95a-f (Scheme 21B) showed good inhibitory activity as antiviral agents.", [["N1-(5-fluoro-2oxoindolin-3-ylidene)-N4-(p-fluoro-(or p-dimethylamino) benzylidene) thiocarbo hydrazone", "CHEMICAL", 27, 129], ["N-allyl (or n-butyl)-2-(5-fluoro-2oxoindolin-3-ylidene)hydrazine carbo-thioamide", "CHEMICAL", 134, 214], ["N1-(5-fluoro-2oxoindolin-3-ylidene)-N4-(p-fluoro-(or p-dimethylamino) benzylidene) thiocarbo hydrazone", "CHEMICAL", 27, 129], ["N-allyl", "CHEMICAL", 134, 141], ["n-butyl)-2-(5-fluoro-2oxoindolin-3-ylidene)hydrazine carbo-thioamide", "CHEMICAL", 146, 214], ["N1-(5-fluoro-2oxoindolin-3-ylidene)-N4-(p-fluoro-(or p-dimethylamino) benzylidene) thiocarbo hydrazone", "SIMPLE_CHEMICAL", 27, 129], ["N-allyl (or n-butyl)-2-(5-fluoro-2oxoindolin-3-ylidene)hydrazine carbo-thioamide", "SIMPLE_CHEMICAL", 134, 214], ["95a-f (Scheme 21B", "SIMPLE_CHEMICAL", 226, 243], ["N1", "TEST", 27, 29], ["2oxoindolin", "TREATMENT", 40, 51], ["N4-(p-fluoro-(or p-dimethylamino) benzylidene", "TREATMENT", 63, 108], ["thiocarbo hydrazone", "TREATMENT", 110, 129], ["N-allyl (or n-butyl)", "TREATMENT", 134, 154], ["fluoro", "TREATMENT", 160, 166], ["2oxoindolin", "TREATMENT", 167, 178], ["hydrazine carbo-thioamide", "TREATMENT", 189, 214], ["antiviral agents", "TREATMENT", 280, 296]]], ["Schiff bases of oximes, hydrazone, semicarbazones, and thiosemicarbazones derived from 5-acyl-1,2,4-triazines (96a-c) have been reported by Mojzych et al. [120] to investigate their biological activities.", [["hydrazone", "CHEMICAL", 24, 33], ["semicarbazones", "CHEMICAL", 35, 49], ["thiosemicarbazones", "CHEMICAL", 55, 73], ["5-acyl-1,2,4-triazines", "CHEMICAL", 87, 109], ["Schiff bases", "CHEMICAL", 0, 12], ["oximes", "CHEMICAL", 16, 22], ["hydrazone", "CHEMICAL", 24, 33], ["semicarbazones", "CHEMICAL", 35, 49], ["thiosemicarbazones", "CHEMICAL", 55, 73], ["5-acyl-1,2,4-triazines", "CHEMICAL", 87, 109], ["oximes", "SIMPLE_CHEMICAL", 16, 22], ["hydrazone", "SIMPLE_CHEMICAL", 24, 33], ["semicarbazones", "SIMPLE_CHEMICAL", 35, 49], ["thiosemicarbazones", "SIMPLE_CHEMICAL", 55, 73], ["5-acyl-1,2,4-triazines", "SIMPLE_CHEMICAL", 87, 109], ["96a-c", "SIMPLE_CHEMICAL", 111, 116], ["Schiff bases of oximes", "TREATMENT", 0, 22], ["hydrazone", "TREATMENT", 24, 33], ["semicarbazones", "TREATMENT", 35, 49], ["thiosemicarbazones", "TREATMENT", 55, 73], ["triazines", "TREATMENT", 100, 109]]], ["Among those, few compounds showed considerable antiviral activities.", [["considerable", "OBSERVATION_MODIFIER", 34, 46], ["antiviral activities", "OBSERVATION", 47, 67]]], ["It is observed that 5-acyl-3methylsulfamyl-1,2,4-triazine 96a and its derivatives (97a-b) (Scheme 22) showed potential antiviral activity against Coxsackie Virus B4 in Vero cell culture as well as in HeLa cell culture with the EC 50 value of 20 and 45 mg/mL, respectively.Antiviral activityMany traditional as well as novel Pt (II) (98e102) and Pd (II) (103e107) complexes (Scheme 23) of thiosemicarbazones derived from 5-substitutedthiophene-2-carboxal-dehydes have been documented along with their antiviral and cytotoxic activities by researchers where they reported that the platinum complexes or free ligands were more cytostatic than the corresponding palladium complexes [121] .Antiviral activityVariety of polyphenol derivatives are biologically important Schiff bases, and they offer great scope in pharmaceutical chemistry, e.g. Gossypol derivatives exhibit high antiviral activities.", [["cell culture", "ANATOMY", 173, 185], ["HeLa cell culture", "ANATOMY", 200, 217], ["EC", "ANATOMY", 227, 229], ["5-acyl-3methylsulfamyl-1,2,4-triazine 96a", "CHEMICAL", 20, 61], ["Pt (II", "CHEMICAL", 324, 330], ["98e102", "CHEMICAL", 333, 339], ["Pd", "CHEMICAL", 345, 347], ["thiosemicarbazones", "CHEMICAL", 388, 406], ["5-substitutedthiophene-2-carboxal-dehydes", "CHEMICAL", 420, 461], ["platinum", "CHEMICAL", 579, 587], ["palladium", "CHEMICAL", 658, 667], ["polyphenol", "CHEMICAL", 714, 724], ["Gossypol", "CHEMICAL", 839, 847], ["5-acyl-3methylsulfamyl-1,2,4-triazine 96a", "CHEMICAL", 20, 61], ["Pt (II)", "CHEMICAL", 324, 331], ["Pd (II)", "CHEMICAL", 345, 352], ["thiosemicarbazones", "CHEMICAL", 388, 406], ["5-substitutedthiophene-2-carboxal-dehydes", "CHEMICAL", 420, 461], ["platinum", "CHEMICAL", 579, 587], ["palladium", "CHEMICAL", 658, 667], ["polyphenol", "CHEMICAL", 714, 724], ["Schiff bases", "CHEMICAL", 764, 776], ["Gossypol", "CHEMICAL", 839, 847], ["5-acyl-3methylsulfamyl-1,2,4-triazine 96a", "SIMPLE_CHEMICAL", 20, 61], ["97a-b", "SIMPLE_CHEMICAL", 83, 88], ["Coxsackie Virus B4", "ORGANISM", 146, 164], ["Vero cell", "CELL", 168, 177], ["HeLa cell", "CELL", 200, 209], ["EC", "CELL", 227, 229], ["Pt (II) (98e102)", "SIMPLE_CHEMICAL", 324, 340], ["Pd (II) (103e107)", "SIMPLE_CHEMICAL", 345, 362], ["thiosemicarbazones", "SIMPLE_CHEMICAL", 388, 406], ["5-substitutedthiophene-2-carboxal-dehydes", "SIMPLE_CHEMICAL", 420, 461], ["platinum complexes", "SIMPLE_CHEMICAL", 579, 597], ["palladium complexes [121]", "SIMPLE_CHEMICAL", 658, 683], ["polyphenol derivatives", "SIMPLE_CHEMICAL", 714, 736], ["Schiff", "SIMPLE_CHEMICAL", 764, 770], ["Gossypol derivatives", "SIMPLE_CHEMICAL", 839, 859], ["Vero cell culture", "CELL_LINE", 168, 185], ["HeLa cell culture", "CELL_LINE", 200, 217], ["Coxsackie Virus", "SPECIES", 146, 161], ["Coxsackie Virus B4", "SPECIES", 146, 164], ["5-acyl-3methylsulfamyl", "TREATMENT", 20, 42], ["triazine", "TREATMENT", 49, 57], ["its derivatives", "TREATMENT", 66, 81], ["potential antiviral activity", "PROBLEM", 109, 137], ["Coxsackie Virus B4", "PROBLEM", 146, 164], ["Vero cell culture", "TEST", 168, 185], ["HeLa cell culture", "TEST", 200, 217], ["the EC", "TEST", 223, 229], ["Antiviral activity", "TREATMENT", 272, 290], ["thiosemicarbazones", "TREATMENT", 388, 406], ["substitutedthiophene", "TREATMENT", 422, 442], ["carboxal", "TREATMENT", 445, 453], ["dehydes", "PROBLEM", 454, 461], ["the platinum complexes or free ligands", "PROBLEM", 575, 613], ["Antiviral activity", "TREATMENT", 685, 703], ["polyphenol derivatives", "TREATMENT", 714, 736], ["pharmaceutical chemistry", "TEST", 808, 832], ["Gossypol derivatives", "TREATMENT", 839, 859], ["high antiviral activities", "TREATMENT", 868, 893], ["antiviral activity", "OBSERVATION", 119, 137], ["polyphenol derivatives", "OBSERVATION", 714, 736], ["Schiff bases", "OBSERVATION", 764, 776], ["antiviral activities", "OBSERVATION", 873, 893]]], ["Owing to its much lower toxicity, Gossypol derivatives often used in medical therapy [122, 123] .", [["toxicity", "DISEASE", 24, 32], ["Gossypol", "CHEMICAL", 34, 42], ["Gossypol", "CHEMICAL", 34, 42], ["Gossypol derivatives", "SIMPLE_CHEMICAL", 34, 54], ["its much lower toxicity", "PROBLEM", 9, 32], ["Gossypol derivatives", "TREATMENT", 34, 54]]], ["Schiff base Ag (I) complexes with glycine salicylaldehyde showed effective results against Cucumber mosaic virus [124] .", [["Ag", "CHEMICAL", 12, 14], ["glycine", "CHEMICAL", 34, 41], ["salicylaldehyde", "CHEMICAL", 42, 57], ["Cucumber mosaic virus", "DISEASE", 91, 112], ["Schiff base Ag (I)", "CHEMICAL", 0, 18], ["glycine salicylaldehyde", "CHEMICAL", 34, 57], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["glycine salicylaldehyde", "SIMPLE_CHEMICAL", 34, 57], ["Cucumber mosaic virus", "ORGANISM", 91, 112], ["Schiff base Ag (I) complexes", "PROTEIN", 0, 28], ["Cucumber mosaic virus", "SPECIES", 91, 112], ["Cucumber mosaic virus", "SPECIES", 91, 112], ["Schiff base Ag", "TEST", 0, 14], ["glycine salicylaldehyde", "TEST", 34, 57], ["Cucumber mosaic virus", "PROBLEM", 91, 112]]], ["Ni (II), Pd (II), and Pt (II) complexes with semicarbazone (108) and thiosemicarbazone (109) of p-tolu-aldehyde have been reported by Chandra and Tyagi [125] .", [["Ni", "CHEMICAL", 0, 2], ["Pd (II", "CHEMICAL", 9, 15], ["Pt", "CHEMICAL", 22, 24], ["semicarbazone", "CHEMICAL", 45, 58], ["thiosemicarbazone", "CHEMICAL", 69, 86], ["p-tolu-aldehyde", "CHEMICAL", 96, 111], ["Ni (II)", "CHEMICAL", 0, 7], ["Pd (II)", "CHEMICAL", 9, 16], ["Pt (II)", "CHEMICAL", 22, 29], ["semicarbazone", "CHEMICAL", 45, 58], ["thiosemicarbazone", "CHEMICAL", 69, 86], ["p-tolu-aldehyde", "CHEMICAL", 96, 111], ["Ni (II)", "SIMPLE_CHEMICAL", 0, 7], ["Pd (II)", "SIMPLE_CHEMICAL", 9, 16], ["Pt (II)", "SIMPLE_CHEMICAL", 22, 29], ["semicarbazone (108)", "SIMPLE_CHEMICAL", 45, 64], ["thiosemicarbazone (109)", "SIMPLE_CHEMICAL", 69, 92], ["p-tolu-aldehyde", "SIMPLE_CHEMICAL", 96, 111], ["Pt (II) complexes", "PROTEIN", 22, 39], ["semicarbazone", "TREATMENT", 45, 58], ["thiosemicarbazone", "TREATMENT", 69, 86], ["p-tolu-aldehyde", "TREATMENT", 96, 111]]], ["They have investigated their antifungal activities against the fungal species Alternaria alternata, A. niger, and Fusarium odum by using food poison technique on potato dextrose agar medium.", [["potato dextrose agar", "CHEMICAL", 162, 182], ["Alternaria alternata", "ORGANISM", 78, 98], ["A. niger", "ORGANISM", 100, 108], ["Fusarium odum", "ORGANISM", 114, 127], ["Alternaria alternata", "SPECIES", 78, 98], ["A. niger", "SPECIES", 100, 108], ["Fusarium odum", "SPECIES", 114, 127], ["potato", "SPECIES", 162, 168], ["Alternaria alternata", "SPECIES", 78, 98], ["A. niger", "SPECIES", 100, 108], ["Fusarium odum", "SPECIES", 114, 127], ["potato", "SPECIES", 162, 168], ["their antifungal activities", "TREATMENT", 23, 50], ["the fungal species", "PROBLEM", 59, 77], ["potato dextrose agar medium", "TREATMENT", 162, 189]]], ["The fungicidal screening of these compounds showed that the metal chelates possess a great antifungal activity compared with the parent ligands.", [["metal chelates", "SIMPLE_CHEMICAL", 60, 74], ["The fungicidal screening", "TEST", 0, 24], ["these compounds", "TEST", 28, 43], ["the metal chelates", "TREATMENT", 56, 74], ["fungicidal", "OBSERVATION_MODIFIER", 4, 14], ["great", "OBSERVATION_MODIFIER", 85, 90], ["antifungal activity", "OBSERVATION", 91, 110]]], ["This result is attributed because of the increase in delocalization of p-electrons upon chelation which improved the penetration of the metal complexes to the lipid membrane, and the metal binding sites are blocked in the enzymes of microorganisms.Antiviral activitySchiff base derived from salicylaldehyde and 1-amino-3hydroxyguanidine tosylate is good compound for planning the new antiviral agents.", [["lipid membrane", "ANATOMY", 159, 173], ["salicylaldehyde", "CHEMICAL", 291, 306], ["1-amino-3hydroxyguanidine tosylate", "CHEMICAL", 311, 345], ["salicylaldehyde", "CHEMICAL", 291, 306], ["1-amino-3hydroxyguanidine tosylate", "CHEMICAL", 311, 345], ["lipid membrane", "CELLULAR_COMPONENT", 159, 173], ["salicylaldehyde", "SIMPLE_CHEMICAL", 291, 306], ["1-amino-3hydroxyguanidine tosylate", "SIMPLE_CHEMICAL", 311, 345], ["metal complexes", "PROTEIN", 136, 151], ["metal binding sites", "PROTEIN", 183, 202], ["the increase in delocalization of p-electrons", "PROBLEM", 37, 82], ["chelation", "TREATMENT", 88, 97], ["the metal binding sites", "PROBLEM", 179, 202], ["Antiviral activitySchiff base", "TREATMENT", 248, 277], ["salicylaldehyde", "TREATMENT", 291, 306], ["amino-3hydroxyguanidine tosylate", "TREATMENT", 313, 345], ["the new antiviral agents", "TREATMENT", 376, 400], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["delocalization", "OBSERVATION", 53, 67], ["lipid membrane", "ANATOMY", 159, 173]]], ["Wang et al. [126] have modified some structural features of Schiff bases of hydroxyamino guanidines (SB-HAG) led to formation of new substituted salicylaldehyde Schiff bases of HAG (SSB-HAG) derivatives and three other SB-HAG derivatives.", [["hydroxyamino guanidines", "CHEMICAL", 76, 99], ["SB-HAG", "CHEMICAL", 101, 107], ["salicylaldehyde", "CHEMICAL", 145, 160], ["HAG", "CHEMICAL", 177, 180], ["SSB-HAG", "CHEMICAL", 182, 189], ["SB-HAG", "CHEMICAL", 219, 225], ["Schiff bases", "CHEMICAL", 60, 72], ["hydroxyamino guanidines", "CHEMICAL", 76, 99], ["SB-HAG", "CHEMICAL", 101, 107], ["salicylaldehyde Schiff bases", "CHEMICAL", 145, 173], ["HAG", "CHEMICAL", 177, 180], ["SSB-HAG", "CHEMICAL", 182, 189], ["SB-HAG", "CHEMICAL", 219, 225], ["Schiff", "SIMPLE_CHEMICAL", 60, 66], ["hydroxyamino guanidines", "SIMPLE_CHEMICAL", 76, 99], ["SB-HAG", "SIMPLE_CHEMICAL", 101, 107], ["salicylaldehyde Schiff bases", "SIMPLE_CHEMICAL", 145, 173], ["HAG", "SIMPLE_CHEMICAL", 177, 180], ["SSB-HAG) derivatives", "SIMPLE_CHEMICAL", 182, 202], ["SB-HAG derivatives", "SIMPLE_CHEMICAL", 219, 237], ["hydroxyamino guanidines", "TREATMENT", 76, 99], ["new substituted salicylaldehyde Schiff bases of HAG", "TREATMENT", 129, 180], ["SSB-HAG) derivatives", "TREATMENT", 182, 202], ["HAG derivatives", "TREATMENT", 222, 237], ["Schiff bases", "OBSERVATION", 60, 72], ["salicylaldehyde Schiff", "OBSERVATION", 145, 167]]], ["All these compounds were studied for the first time against infection by a coronavirus, mouse hepatitis virus (MHV).", [["infection", "DISEASE", 60, 69], ["mouse hepatitis virus", "DISEASE", 88, 109], ["coronavirus", "ORGANISM", 75, 86], ["mouse hepatitis virus", "ORGANISM", 88, 109], ["MHV", "ORGANISM", 111, 114], ["coronavirus", "SPECIES", 75, 86], ["mouse", "SPECIES", 88, 93], ["hepatitis virus", "SPECIES", 94, 109], ["mouse hepatitis virus", "SPECIES", 88, 109], ["MHV", "SPECIES", 111, 114], ["infection", "PROBLEM", 60, 69], ["a coronavirus, mouse hepatitis virus", "PROBLEM", 73, 109], ["infection", "OBSERVATION", 60, 69]]], ["When the TCIDw values are compared, it was found that [1-[(3 0 -allyl-2 0 -hydroxybenzylidene)amino]-3-hydroxyguanidine] was the most active compound against the growth of MHV about 376 times more active than hydroxylguanidine and about 564 times more effective than hydroxyaminoguanidines (HAG).Antitumor activityHodnett et al. [127] have investigated the probable antitumor action of numerous synthetic and semisynthetic compounds.", [["antitumor", "ANATOMY", 366, 375], ["1-[(3 0 -allyl-2 0 -hydroxybenzylidene)amino]-3-hydroxyguanidine", "CHEMICAL", 55, 119], ["hydroxylguanidine", "CHEMICAL", 209, 226], ["hydroxyaminoguanidines", "CHEMICAL", 267, 289], ["HAG", "CHEMICAL", 291, 294], ["[1-[(3 0 -allyl-2 0 -hydroxybenzylidene)amino]-3-hydroxyguanidine", "CHEMICAL", 54, 119], ["hydroxylguanidine", "CHEMICAL", 209, 226], ["hydroxyaminoguanidines", "CHEMICAL", 267, 289], ["HAG", "CHEMICAL", 291, 294], ["[1-[(3 0 -allyl-2 0 -hydroxybenzylidene)amino]-3-hydroxyguanidine", "SIMPLE_CHEMICAL", 54, 119], ["MHV", "ORGANISM", 172, 175], ["hydroxylguanidine", "SIMPLE_CHEMICAL", 209, 226], ["hydroxyaminoguanidines", "SIMPLE_CHEMICAL", 267, 289], ["HAG", "SIMPLE_CHEMICAL", 291, 294], ["Antitumor", "CANCER", 296, 305], ["antitumor", "CANCER", 366, 375], ["MHV", "SPECIES", 172, 175], ["the TCIDw values", "TEST", 5, 21], ["allyl", "TEST", 64, 69], ["hydroxyguanidine", "TREATMENT", 103, 119], ["hydroxylguanidine", "TREATMENT", 209, 226], ["numerous synthetic and semisynthetic compounds", "PROBLEM", 386, 432], ["probable", "UNCERTAINTY", 357, 365], ["antitumor", "OBSERVATION", 366, 375], ["semisynthetic compounds", "OBSERVATION", 409, 432]]], ["Schiff base obtained from 2-thiophene-carboxaldehyde and 2-aminobenzoic acid and its metal complexes have been developed a new line for search to new antitumor activity.", [["antitumor", "ANATOMY", 150, 159], ["2-thiophene-carboxaldehyde", "CHEMICAL", 26, 52], ["2-aminobenzoic acid", "CHEMICAL", 57, 76], ["Schiff base", "CHEMICAL", 0, 11], ["2-thiophene-carboxaldehyde", "CHEMICAL", 26, 52], ["2-aminobenzoic acid", "CHEMICAL", 57, 76], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["2-thiophene-carboxaldehyde", "SIMPLE_CHEMICAL", 26, 52], ["2-aminobenzoic acid", "SIMPLE_CHEMICAL", 57, 76], ["antitumor", "CANCER", 150, 159], ["Schiff base", "TEST", 0, 11], ["thiophene-carboxaldehyde", "TREATMENT", 28, 52], ["aminobenzoic acid", "TREATMENT", 59, 76], ["a new line", "TREATMENT", 121, 131], ["new antitumor activity", "TREATMENT", 146, 168]]], ["A large number of transition metal including Zn (II), Ni (II), and Co (II) has been reported with high antitumor activities.", [["antitumor", "ANATOMY", 103, 112], ["Zn (II", "CHEMICAL", 45, 51], ["Ni (II", "CHEMICAL", 54, 60], ["Co (II", "CHEMICAL", 67, 73], ["transition metal", "CHEMICAL", 18, 34], ["Zn (II)", "CHEMICAL", 45, 52], ["Ni (II)", "CHEMICAL", 54, 61], ["Co (II)", "CHEMICAL", 67, 74], ["Zn (II)", "SIMPLE_CHEMICAL", 45, 52], ["Ni (II)", "SIMPLE_CHEMICAL", 54, 61], ["Co (II", "SIMPLE_CHEMICAL", 67, 73], ["antitumor", "CANCER", 103, 112], ["transition metal", "PROBLEM", 18, 34], ["Zn (II)", "TREATMENT", 45, 52], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["transition metal", "OBSERVATION", 18, 34], ["high antitumor", "OBSERVATION", 98, 112]]], ["Qin et al. [128] have reported new Co (II), Ni (II), and Zn (II) complexes of oxoaporphine (Scheme 24) and their in vitro and in vivo antitumor activities.", [["antitumor", "ANATOMY", 134, 143], ["Co (II", "CHEMICAL", 35, 41], ["Ni", "CHEMICAL", 44, 46], ["Zn", "CHEMICAL", 57, 59], ["oxoaporphine", "CHEMICAL", 78, 90], ["Co (II)", "CHEMICAL", 35, 42], ["Ni (II)", "CHEMICAL", 44, 51], ["Zn (II)", "CHEMICAL", 57, 64], ["oxoaporphine", "CHEMICAL", 78, 90], ["Co (II)", "SIMPLE_CHEMICAL", 35, 42], ["Ni (II)", "SIMPLE_CHEMICAL", 44, 51], ["Zn (II)", "SIMPLE_CHEMICAL", 57, 64], ["oxoaporphine", "SIMPLE_CHEMICAL", 78, 90], ["antitumor", "CANCER", 134, 143], ["Zn (II) complexes", "PROTEIN", 57, 74], ["Zn (II)", "TREATMENT", 57, 64], ["oxoaporphine (Scheme", "TREATMENT", 78, 98]]], ["These complexes possess higher cytotoxicity against some selected human tumor cells particularly the HepG2, T-24, and SK-OV-3 cells.Antitumor activityXiao et al. [129] have reported Co (II) complexes with the two flexible Schiff base ligands of type Py 3 CoL 1 (113) and Py 3 CoL 2 (114) (where, Py \u00bc Pyridine, L 1 \u00bc 3,5-ClC 6 130e134].", [["tumor cells", "ANATOMY", 72, 83], ["HepG2", "ANATOMY", 101, 106], ["T-24", "ANATOMY", 108, 112], ["SK-OV-3 cells", "ANATOMY", 118, 131], ["tumor", "DISEASE", 72, 77], ["Co", "CHEMICAL", 182, 184], ["L 1 \u00bc 3,5-ClC 6 130e134", "CHEMICAL", 311, 334], ["Co (II)", "CHEMICAL", 182, 189], ["Schiff base", "CHEMICAL", 222, 233], ["Py 3 CoL", "CHEMICAL", 271, 279], ["Pyridine", "CHEMICAL", 301, 309], ["L 1 \u00bc 3,5-ClC", "CHEMICAL", 311, 324], ["human", "ORGANISM", 66, 71], ["tumor cells", "CELL", 72, 83], ["HepG2", "CELL", 101, 106], ["T-24", "CELL", 108, 112], ["SK-OV-3 cells", "CELL", 118, 131], ["Co (II)", "SIMPLE_CHEMICAL", 182, 189], ["type Py 3 CoL 1 (113)", "SIMPLE_CHEMICAL", 245, 266], ["Py 3 CoL 2 (114)", "SIMPLE_CHEMICAL", 271, 287], ["Py \u00bc Pyridine", "SIMPLE_CHEMICAL", 296, 309], ["L 1 \u00bc 3,5-ClC 6 130e134", "SIMPLE_CHEMICAL", 311, 334], ["human tumor cells", "CELL_TYPE", 66, 83], ["HepG2, T-24", "CELL_LINE", 101, 112], ["SK-OV-3 cells", "CELL_LINE", 118, 131], ["Co (II) complexes", "PROTEIN", 182, 199], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["higher cytotoxicity", "PROBLEM", 24, 43], ["some selected human tumor cells", "PROBLEM", 52, 83], ["the HepG2", "TEST", 97, 106], ["T", "TEST", 108, 109], ["SK", "TEST", 118, 120], ["Co (II) complexes", "PROBLEM", 182, 199], ["the two flexible Schiff base ligands", "TREATMENT", 205, 241], ["Py 3 CoL", "TEST", 271, 279], ["Pyridine", "TEST", 301, 309], ["higher cytotoxicity", "OBSERVATION_MODIFIER", 24, 43], ["tumor cells", "OBSERVATION", 72, 83], ["HepG2", "ANATOMY", 101, 106]]], ["Gambino et al. [130] have reported the bioactive gallium complexes with tridentate substituted salicylaldehyde semicarbazone of the type (115e119) (Scheme 26) and have investigated for their antitumor activity.", [["antitumor", "ANATOMY", 191, 200], ["gallium", "CHEMICAL", 49, 56], ["salicylaldehyde semicarbazone", "CHEMICAL", 95, 124], ["gallium", "CHEMICAL", 49, 56], ["salicylaldehyde semicarbazone", "CHEMICAL", 95, 124], ["gallium complexes", "SIMPLE_CHEMICAL", 49, 66], ["tridentate substituted salicylaldehyde semicarbazone", "SIMPLE_CHEMICAL", 72, 124], ["115e119", "SIMPLE_CHEMICAL", 138, 145], ["antitumor", "CANCER", 191, 200], ["the bioactive gallium complexes", "PROBLEM", 35, 66], ["tridentate substituted salicylaldehyde semicarbazone", "TREATMENT", 72, 124]]], ["They have observed that Ga (III) complex with 5-bromosalicylaldehyde semicarbazone (116) as well as 5-bromo-2-hydroxy-3methoxybenzaldehyde semicarbazone (119) showed higher activity against cis-platin sensitive A2780 ovarian cells; also complex 116 has shown moderate cytotoxicity against breast (MCF7) prostate (PC3) cells.Antitumor activityA series of thiosemicarbazones derived from 3-acylpyridazines, 4-acetyl-pyrimidines and 2-acetyl-pyrazines have reported by Easmon et al. [135] as potential antitumor agents.", [["A2780 ovarian cells", "ANATOMY", 211, 230], ["breast (MCF7) prostate (PC3) cells", "ANATOMY", 289, 323], ["antitumor", "ANATOMY", 499, 508], ["Ga", "CHEMICAL", 24, 26], ["5-bromosalicylaldehyde semicarbazone", "CHEMICAL", 46, 82], ["5-bromo-2-hydroxy-3methoxybenzaldehyde semicarbazone", "CHEMICAL", 100, 152], ["cis-platin", "CHEMICAL", 190, 200], ["A2780", "CHEMICAL", 211, 216], ["thiosemicarbazones", "CHEMICAL", 354, 372], ["3-acylpyridazines", "CHEMICAL", 386, 403], ["4-acetyl-pyrimidines", "CHEMICAL", 405, 425], ["2-acetyl-pyrazines", "CHEMICAL", 430, 448], ["Ga (III)", "CHEMICAL", 24, 32], ["5-bromosalicylaldehyde semicarbazone", "CHEMICAL", 46, 82], ["5-bromo-2-hydroxy-3methoxybenzaldehyde semicarbazone", "CHEMICAL", 100, 152], ["cis-platin", "CHEMICAL", 190, 200], ["thiosemicarbazones", "CHEMICAL", 354, 372], ["3-acylpyridazines", "CHEMICAL", 386, 403], ["4-acetyl-pyrimidines", "CHEMICAL", 405, 425], ["2-acetyl-pyrazines", "CHEMICAL", 430, 448], ["Ga (III)", "GENE_OR_GENE_PRODUCT", 24, 32], ["5-bromosalicylaldehyde semicarbazone", "SIMPLE_CHEMICAL", 46, 82], ["116)", "SIMPLE_CHEMICAL", 84, 88], ["5-bromo-2-hydroxy-3methoxybenzaldehyde semicarbazone (119)", "SIMPLE_CHEMICAL", 100, 158], ["cis-platin", "SIMPLE_CHEMICAL", 190, 200], ["A2780 ovarian cells", "CELL", 211, 230], ["breast (MCF7) prostate (PC3) cells", "CELL", 289, 323], ["thiosemicarbazones", "SIMPLE_CHEMICAL", 354, 372], ["3-acylpyridazines", "SIMPLE_CHEMICAL", 386, 403], ["4-acetyl-pyrimidines", "SIMPLE_CHEMICAL", 405, 425], ["2-acetyl-pyrazines", "SIMPLE_CHEMICAL", 430, 448], ["antitumor", "CANCER", 499, 508], ["Ga (III) complex", "PROTEIN", 24, 40], ["cis-platin sensitive A2780 ovarian cells", "CELL_LINE", 190, 230], ["breast (MCF7) prostate (PC3) cells", "CELL_LINE", 289, 323], ["Ga (III) complex", "TREATMENT", 24, 40], ["5-bromosalicylaldehyde semicarbazone", "TREATMENT", 46, 82], ["hydroxy-3methoxybenzaldehyde semicarbazone", "TREATMENT", 110, 152], ["cis-platin sensitive A2780 ovarian cells", "PROBLEM", 190, 230], ["moderate cytotoxicity against breast (MCF7) prostate (PC3) cells", "PROBLEM", 259, 323], ["thiosemicarbazones", "TREATMENT", 354, 372], ["acylpyridazines", "TREATMENT", 388, 403], ["acetyl", "TREATMENT", 407, 413], ["pyrimidines", "TREATMENT", 414, 425], ["acetyl-pyrazines", "TREATMENT", 432, 448], ["potential antitumor agents", "TREATMENT", 489, 515], ["moderate", "OBSERVATION_MODIFIER", 259, 267], ["cytotoxicity", "OBSERVATION", 268, 280], ["breast", "ANATOMY", 289, 295], ["prostate", "ANATOMY", 303, 311]]], ["Thomas et al. [136] have reported the antitumor activities of Mn (II), Ni (II), and Cu (II) complexes of anthracene-9-carboxyldehyde thiosemicarbazone as well as cytotoxic activity of phenylglyoxal bis(thiosemicarbazone) against Ehrlich ascites carcinoma cells.", [["antitumor", "ANATOMY", 38, 47], ["Ehrlich ascites carcinoma cells", "ANATOMY", 229, 260], ["Mn", "CHEMICAL", 62, 64], ["Ni", "CHEMICAL", 71, 73], ["Cu", "CHEMICAL", 84, 86], ["anthracene-9-carboxyldehyde thiosemicarbazone", "CHEMICAL", 105, 150], ["phenylglyoxal bis", "CHEMICAL", 184, 201], ["thiosemicarbazone", "CHEMICAL", 202, 219], ["Ehrlich ascites carcinoma", "DISEASE", 229, 254], ["Mn (II)", "CHEMICAL", 62, 69], ["Ni (II)", "CHEMICAL", 71, 78], ["Cu (II)", "CHEMICAL", 84, 91], ["anthracene-9-carboxyldehyde thiosemicarbazone", "CHEMICAL", 105, 150], ["phenylglyoxal bis(thiosemicarbazone)", "CHEMICAL", 184, 220], ["antitumor", "CANCER", 38, 47], ["Mn (II)", "SIMPLE_CHEMICAL", 62, 69], ["Ni (II)", "SIMPLE_CHEMICAL", 71, 78], ["Cu (II)", "SIMPLE_CHEMICAL", 84, 91], ["anthracene-9-carboxyldehyde thiosemicarbazone", "SIMPLE_CHEMICAL", 105, 150], ["phenylglyoxal bis(thiosemicarbazone", "SIMPLE_CHEMICAL", 184, 219], ["Ehrlich ascites carcinoma cells", "CELL", 229, 260], ["Ehrlich ascites carcinoma cells", "CELL_TYPE", 229, 260], ["Cu (II) complexes of anthracene", "TREATMENT", 84, 115], ["carboxyldehyde thiosemicarbazone", "TREATMENT", 118, 150], ["cytotoxic activity of phenylglyoxal bis(thiosemicarbazone)", "TREATMENT", 162, 220], ["Ehrlich ascites carcinoma cells", "PROBLEM", 229, 260], ["carcinoma cells", "OBSERVATION", 245, 260]]], ["Some mixed ligands V (IV) complexes with Schiff base and thiosemicarbazones were synthesized, and its antitumor activity has been reported by Lewis et al. [137] .", [["antitumor", "ANATOMY", 102, 111], ["Schiff", "CHEMICAL", 41, 47], ["thiosemicarbazones", "CHEMICAL", 57, 75], ["V (IV)", "CHEMICAL", 19, 25], ["Schiff base", "CHEMICAL", 41, 52], ["thiosemicarbazones", "CHEMICAL", 57, 75], ["V (IV)", "SIMPLE_CHEMICAL", 19, 25], ["Schiff base", "SIMPLE_CHEMICAL", 41, 52], ["thiosemicarbazones", "SIMPLE_CHEMICAL", 57, 75], ["antitumor", "CANCER", 102, 111], ["V (IV) complexes", "PROTEIN", 19, 35], ["Some mixed ligands V (IV) complexes", "TREATMENT", 0, 35], ["Schiff base", "TREATMENT", 41, 52], ["thiosemicarbazones", "TREATMENT", 57, 75], ["mixed", "OBSERVATION_MODIFIER", 5, 10], ["ligands V", "OBSERVATION", 11, 20]]], ["Schiff base obtained from salicylaldehyde, 2,4 dihydroxy-benzaldehyde, glycine, and L-alanine and their Cu (II), Ni (II), Zn (II), and Co (III) complexes show antitumor activity, and their order of reactivity with metal complex is Ni > Cu > Zn > Co [138] .", [["antitumor", "ANATOMY", 159, 168], ["salicylaldehyde", "CHEMICAL", 26, 41], ["2,4 dihydroxy-benzaldehyde", "CHEMICAL", 43, 69], ["glycine", "CHEMICAL", 71, 78], ["L-alanine", "CHEMICAL", 84, 93], ["Cu", "CHEMICAL", 104, 106], ["Ni", "CHEMICAL", 113, 115], ["Zn", "CHEMICAL", 122, 124], ["Co", "CHEMICAL", 135, 137], ["Ni", "CHEMICAL", 231, 233], ["Cu", "CHEMICAL", 236, 238], ["Zn", "CHEMICAL", 241, 243], ["Schiff base", "CHEMICAL", 0, 11], ["salicylaldehyde", "CHEMICAL", 26, 41], ["2,4 dihydroxy-benzaldehyde", "CHEMICAL", 43, 69], ["glycine", "CHEMICAL", 71, 78], ["L-alanine", "CHEMICAL", 84, 93], ["Cu (II)", "CHEMICAL", 104, 111], ["Ni (II)", "CHEMICAL", 113, 120], ["Zn (II)", "CHEMICAL", 122, 129], ["Co (III)", "CHEMICAL", 135, 143], ["Ni", "CHEMICAL", 231, 233], ["Cu", "CHEMICAL", 236, 238], ["Zn", "CHEMICAL", 241, 243], ["Co", "CHEMICAL", 246, 248], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["salicylaldehyde", "SIMPLE_CHEMICAL", 26, 41], ["2,4 dihydroxy-benzaldehyde", "SIMPLE_CHEMICAL", 43, 69], ["glycine", "SIMPLE_CHEMICAL", 71, 78], ["L-alanine", "SIMPLE_CHEMICAL", 84, 93], ["Cu (II)", "SIMPLE_CHEMICAL", 104, 111], ["Ni (II)", "SIMPLE_CHEMICAL", 113, 120], ["Zn (II)", "SIMPLE_CHEMICAL", 122, 129], ["Co (III) complexes", "SIMPLE_CHEMICAL", 135, 153], ["antitumor", "CANCER", 159, 168], ["metal complex", "SIMPLE_CHEMICAL", 214, 227], ["Ni > Cu > Zn", "SIMPLE_CHEMICAL", 231, 243], ["Co [138]", "SIMPLE_CHEMICAL", 246, 254], ["Co (III) complexes", "PROTEIN", 135, 153], ["Schiff base", "TEST", 0, 11], ["salicylaldehyde", "TEST", 26, 41], ["glycine", "TREATMENT", 71, 78], ["L-alanine", "TREATMENT", 84, 93], ["Zn (II)", "TREATMENT", 122, 129], ["Co (III) complexes", "TREATMENT", 135, 153], ["antitumor activity", "PROBLEM", 159, 177], ["Ni", "TEST", 231, 233], ["antitumor activity", "OBSERVATION", 159, 177]]], ["Some Mn (II), Co (II), and Zn (II) complexes were synthesized, and their antitumor activity was determined by Li et al. [139] .", [["antitumor", "ANATOMY", 73, 82], ["Mn", "CHEMICAL", 5, 7], ["Co (II", "CHEMICAL", 14, 20], ["Zn", "CHEMICAL", 27, 29], ["Li", "CHEMICAL", 110, 112], ["Mn (II)", "CHEMICAL", 5, 12], ["Co (II)", "CHEMICAL", 14, 21], ["Zn (II)", "CHEMICAL", 27, 34], ["Mn (II)", "SIMPLE_CHEMICAL", 5, 12], ["Co (II)", "SIMPLE_CHEMICAL", 14, 21], ["Zn (II) complexes", "SIMPLE_CHEMICAL", 27, 44], ["antitumor", "CANCER", 73, 82], ["Zn (II) complexes", "PROTEIN", 27, 44], ["Zn (II) complexes", "PROBLEM", 27, 44]]], ["Schiff base and its diorgano-Sn (IV) complexes exhibitScope of Schiff bases and their complexes for nanobiotechnologyMetal complexes containing the elements from group II (e.g. Zn, Cd, Hg) and group VI (e.g. S, Se, Te) of the periodic table can be considered as plausible precursors for synthesis of semiconductor nanoparticles and as well as quantum dots which have broad range of application in modern day technology development [141] .", [["Schiff base", "CHEMICAL", 0, 11], ["diorgano-Sn", "CHEMICAL", 20, 31], ["Zn", "CHEMICAL", 177, 179], ["Cd", "CHEMICAL", 181, 183], ["Hg", "CHEMICAL", 185, 187], ["Se", "CHEMICAL", 211, 213], ["Schiff base", "CHEMICAL", 0, 11], ["diorgano-Sn (IV)", "CHEMICAL", 20, 36], ["Schiff bases", "CHEMICAL", 63, 75], ["Zn", "CHEMICAL", 177, 179], ["Cd", "CHEMICAL", 181, 183], ["Hg", "CHEMICAL", 185, 187], ["S", "CHEMICAL", 208, 209], ["Se", "CHEMICAL", 211, 213], ["Te", "CHEMICAL", 215, 217], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["diorgano-Sn (IV)", "SIMPLE_CHEMICAL", 20, 36], ["Schiff bases", "SIMPLE_CHEMICAL", 63, 75], ["Zn", "SIMPLE_CHEMICAL", 177, 179], ["Cd", "SIMPLE_CHEMICAL", 181, 183], ["Se", "SIMPLE_CHEMICAL", 211, 213], ["semiconductor nanoparticles", "SIMPLE_CHEMICAL", 300, 327], ["Sn (IV) complexes", "PROTEIN", 29, 46], ["Schiff base", "TEST", 0, 11], ["synthesis of semiconductor nanoparticles", "TREATMENT", 287, 327], ["base", "ANATOMY_MODIFIER", 7, 11], ["Schiff bases", "OBSERVATION", 63, 75], ["complexes", "OBSERVATION", 123, 132]]], ["In recent years, researchers have focused on the functionalized nanoparticles and its numerous biological and biomedical applications such as fluorescent tags for detection of lymph node prostate cancer, in vivo fluorescent probes, delivery of drugs and images, etc. Some of these nanomaterials also show potential applications in nanolasers and photovoltaics [142e146] .", [["lymph node prostate cancer", "ANATOMY", 176, 202], ["prostate cancer", "DISEASE", 187, 202], ["lymph node prostate cancer", "CANCER", 176, 202], ["nanolasers", "SIMPLE_CHEMICAL", 331, 341], ["the functionalized nanoparticles", "TREATMENT", 45, 77], ["biomedical applications", "TREATMENT", 110, 133], ["fluorescent tags", "TEST", 142, 158], ["lymph node prostate cancer", "PROBLEM", 176, 202], ["vivo fluorescent probes", "TREATMENT", 207, 230], ["drugs", "TREATMENT", 244, 249], ["images", "TEST", 254, 260], ["nanolasers", "TREATMENT", 331, 341], ["photovoltaics", "TREATMENT", 346, 359], ["lymph node prostate cancer", "OBSERVATION", 176, 202]]], ["From several decades, in the biomedical field, researchers have been exploring light emitting nanocrystals (about 2e10 nm) commonly known as semiconductor Quantum dots (QDs) by virtue of their tunable optical properties as fluorescent probes particularly in cellular imaging.", [["cellular", "ANATOMY", 258, 266], ["semiconductor Quantum dots", "SIMPLE_CHEMICAL", 141, 167], ["cellular", "CELL", 258, 266], ["light emitting nanocrystals", "TREATMENT", 79, 106], ["semiconductor Quantum dots (QDs", "TREATMENT", 141, 172], ["fluorescent probes", "TEST", 223, 241], ["cellular imaging", "TEST", 258, 274]]], ["CdSe, ZnS, and CdS are most commonly used QDs because of their exceptional characteristics such as enhanced brightness, better photostability, tunable emission spectra, and simultaneous excitation of multiple fluorescence colors as compared with the conventional fluorescent proteins and organic dyes.", [["CdSe", "CHEMICAL", 0, 4], ["ZnS", "CHEMICAL", 6, 9], ["CdS", "CHEMICAL", 15, 18], ["CdSe", "CHEMICAL", 0, 4], ["ZnS", "CHEMICAL", 6, 9], ["CdS", "CHEMICAL", 15, 18], ["CdSe", "SIMPLE_CHEMICAL", 0, 4], ["ZnS", "SIMPLE_CHEMICAL", 6, 9], ["CdS", "SIMPLE_CHEMICAL", 15, 18], ["organic dyes", "SIMPLE_CHEMICAL", 288, 300], ["fluorescent proteins", "PROTEIN", 263, 283], ["CdSe", "TREATMENT", 0, 4], ["ZnS", "TREATMENT", 6, 9], ["CdS", "TREATMENT", 15, 18], ["enhanced brightness", "PROBLEM", 99, 118], ["tunable emission spectra", "TEST", 143, 167], ["multiple fluorescence colors", "PROBLEM", 200, 228], ["organic dyes", "PROBLEM", 288, 300], ["multiple", "OBSERVATION_MODIFIER", 200, 208], ["fluorescence colors", "OBSERVATION", 209, 228], ["organic dyes", "OBSERVATION", 288, 300]]], ["Xing et al. [144] have discussed the optical properties of QDs along with their in vitro diagnostic applications as well as in vivo imaging applications, also the formation of self-illuminating QDs and its in vivo sensing, imaging applications.", [["QDs", "SIMPLE_CHEMICAL", 59, 62], ["self-illuminating QDs", "TREATMENT", 176, 197], ["imaging applications", "TEST", 223, 243]]], ["Wu et al. [146a] have reported the semiconductor quantum dotsebased fluorescent labels could be very effective for cellular imaging by linking to immunoglobin G (IgG) as well as streptavidin for labeling the breast cancer marker Her2 to detect nuclear antigens inside the nucleus and to stain actin along with microtubule fibers in the cytoplasm.", [["cellular", "ANATOMY", 115, 123], ["breast cancer", "ANATOMY", 208, 221], ["nuclear", "ANATOMY", 244, 251], ["nucleus", "ANATOMY", 272, 279], ["microtubule fibers", "ANATOMY", 310, 328], ["cytoplasm", "ANATOMY", 336, 345], ["breast cancer", "DISEASE", 208, 221], ["immunoglobin G", "CHEMICAL", 146, 160], ["cellular", "CELL", 115, 123], ["immunoglobin G", "GENE_OR_GENE_PRODUCT", 146, 160], ["IgG", "GENE_OR_GENE_PRODUCT", 162, 165], ["streptavidin", "SIMPLE_CHEMICAL", 178, 190], ["breast cancer", "CANCER", 208, 221], ["Her2", "GENE_OR_GENE_PRODUCT", 229, 233], ["nuclear antigens", "GENE_OR_GENE_PRODUCT", 244, 260], ["nucleus", "CELLULAR_COMPONENT", 272, 279], ["actin", "GENE_OR_GENE_PRODUCT", 293, 298], ["microtubule fibers", "CELLULAR_COMPONENT", 310, 328], ["cytoplasm", "ORGANISM_SUBSTANCE", 336, 345], ["immunoglobin G", "PROTEIN", 146, 160], ["IgG", "PROTEIN", 162, 165], ["streptavidin", "PROTEIN", 178, 190], ["Her2", "PROTEIN", 229, 233], ["nuclear antigens", "PROTEIN", 244, 260], ["actin", "PROTEIN", 293, 298], ["the semiconductor quantum dotsebased fluorescent labels", "PROBLEM", 31, 86], ["cellular imaging", "TEST", 115, 131], ["immunoglobin G (IgG)", "TREATMENT", 146, 166], ["streptavidin", "TREATMENT", 178, 190], ["the breast cancer", "PROBLEM", 204, 221], ["nuclear antigens", "TEST", 244, 260], ["stain actin", "TEST", 287, 298], ["breast", "ANATOMY", 208, 214], ["cancer", "OBSERVATION", 215, 221], ["nucleus", "ANATOMY", 272, 279], ["microtubule fibers", "OBSERVATION", 310, 328]]], ["They have been noticed that the labeling signals shown by these QDs are more particular for the proposed objects and are considerably more photostable as compared with organic dyes.", [["organic dyes", "SIMPLE_CHEMICAL", 168, 180], ["the labeling signals", "TEST", 28, 48]]], ["Khanna et al. [146b] have studies a series of quantum dots for cytotoxic effect various cells, e.g. human embryonic kidney cells (HEK-293), breast cancer cells (MCF-7), and Enrichlish ascitices cells.", [["cells", "ANATOMY", 88, 93], ["embryonic kidney cells", "ANATOMY", 106, 128], ["HEK-293", "ANATOMY", 130, 137], ["breast cancer cells", "ANATOMY", 140, 159], ["MCF-7", "ANATOMY", 161, 166], ["Enrichlish ascitices cells", "ANATOMY", 173, 199], ["breast cancer", "DISEASE", 140, 153], ["cells", "CELL", 88, 93], ["human", "ORGANISM", 100, 105], ["embryonic kidney cells", "CELL", 106, 128], ["HEK-293", "CELL", 130, 137], ["breast cancer cells", "CELL", 140, 159], ["MCF-7", "CELL", 161, 166], ["Enrichlish ascitices cells", "CELL", 173, 199], ["human embryonic kidney cells", "CELL_LINE", 100, 128], ["HEK-293", "CELL_LINE", 130, 137], ["breast cancer cells", "CELL_TYPE", 140, 159], ["MCF-7", "CELL_LINE", 161, 166], ["Enrichlish ascitices cells", "CELL_LINE", 173, 199], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["a series of quantum dots", "TREATMENT", 34, 58], ["cytotoxic effect various cells", "PROBLEM", 63, 93], ["human embryonic kidney cells", "TEST", 100, 128], ["HEK", "TEST", 130, 133], ["breast cancer cells", "PROBLEM", 140, 159], ["MCF", "TEST", 161, 164], ["Enrichlish ascitices cells", "PROBLEM", 173, 199], ["kidney", "ANATOMY", 116, 122], ["breast", "ANATOMY", 140, 146], ["cancer", "OBSERVATION", 147, 153], ["ascitices cells", "OBSERVATION", 184, 199]]], ["65% biotoxicity was observed in MCF-7 for the CdS/CdSe core-shell QDs.Scope of Schiff bases and their complexes for nanobiotechnologySemicarbazone are used as typical starting compounds for synthesis of 1,2,3-Selenadiazole which exhibit interesting reactivity by virtue of their thermal or photochemical decomposition thus liberating either reactive free selenium or convert into respective 1,4-diselenines [147] .", [["CdS", "CHEMICAL", 46, 49], ["Semicarbazone", "CHEMICAL", 133, 146], ["1,2,3-Selenadiazole", "CHEMICAL", 203, 222], ["selenium", "CHEMICAL", 355, 363], ["1,4-diselenines", "CHEMICAL", 391, 406], ["CdS", "CHEMICAL", 46, 49], ["CdSe", "CHEMICAL", 50, 54], ["Schiff bases", "CHEMICAL", 79, 91], ["Semicarbazone", "CHEMICAL", 133, 146], ["1,2,3-Selenadiazole", "CHEMICAL", 203, 222], ["selenium", "CHEMICAL", 355, 363], ["1,4-diselenines", "CHEMICAL", 391, 406], ["MCF-7", "CELL", 32, 37], ["CdS", "SIMPLE_CHEMICAL", 46, 49], ["CdSe core-shell QDs", "SIMPLE_CHEMICAL", 50, 69], ["Schiff bases", "SIMPLE_CHEMICAL", 79, 91], ["Semicarbazone", "SIMPLE_CHEMICAL", 133, 146], ["1,2,3-Selenadiazole", "SIMPLE_CHEMICAL", 203, 222], ["selenium", "SIMPLE_CHEMICAL", 355, 363], ["1,4-diselenines [147]", "SIMPLE_CHEMICAL", 391, 412], ["the CdS/CdSe core-shell QDs", "TREATMENT", 42, 69], ["Semicarbazone", "TREATMENT", 133, 146], ["synthesis", "TREATMENT", 190, 199], ["Selenadiazole", "TREATMENT", 209, 222], ["reactive free selenium", "PROBLEM", 341, 363], ["shell QDs", "OBSERVATION", 60, 69], ["Schiff bases", "OBSERVATION", 79, 91], ["reactive", "OBSERVATION_MODIFIER", 341, 349]]], ["Owing to these properties, 1,2,3selenadiazole acts as vital precursor in material chemistry including nanotechnology as well as in ligand chemistry [148e152].", [["1,2,3selenadiazole", "CHEMICAL", 27, 45], ["1,2,3selenadiazole", "CHEMICAL", 27, 45], ["1,2,3selenadiazole", "SIMPLE_CHEMICAL", 27, 45], ["1,2,3selenadiazole acts", "TREATMENT", 27, 50], ["ligand chemistry", "TEST", 131, 147]]], ["Reaction of 1,2,3-selenadiazoles with organotransition-metal complexes yielded respective diselenolenes.", [["1,2,3-selenadiazoles", "CHEMICAL", 12, 32], ["diselenolenes", "CHEMICAL", 90, 103], ["1,2,3-selenadiazoles", "CHEMICAL", 12, 32], ["diselenolenes", "CHEMICAL", 90, 103], ["1,2,3-selenadiazoles", "SIMPLE_CHEMICAL", 12, 32], ["organotransition-metal complexes", "SIMPLE_CHEMICAL", 38, 70], ["diselenolenes", "SIMPLE_CHEMICAL", 90, 103], ["organotransition-metal complexes", "PROTEIN", 38, 70], ["Reaction", "TEST", 0, 8], ["selenadiazoles", "TREATMENT", 18, 32], ["organotransition-metal complexes", "TREATMENT", 38, 70], ["respective diselenolenes", "TREATMENT", 79, 103]]], ["Morley et al. [149] have employed 1,2,3-selenadiazoles for the synthesis of cyclopentadienylcobalt and pentamethylcyclopentadienylcobalt diselenolenes by the formation of selenaketocarbene as intermediate through the elimination of dinitrogen from 1,2,3-selenadiazole.", [["1,2,3-selenadiazoles", "CHEMICAL", 34, 54], ["cyclopentadienylcobalt", "CHEMICAL", 76, 98], ["pentamethylcyclopentadienylcobalt diselenolenes", "CHEMICAL", 103, 150], ["selenaketocarbene", "CHEMICAL", 171, 188], ["dinitrogen", "CHEMICAL", 232, 242], ["1,2,3-selenadiazole", "CHEMICAL", 248, 267], ["1,2,3-selenadiazoles", "CHEMICAL", 34, 54], ["cyclopentadienylcobalt", "CHEMICAL", 76, 98], ["pentamethylcyclopentadienylcobalt diselenolenes", "CHEMICAL", 103, 150], ["selenaketocarbene", "CHEMICAL", 171, 188], ["dinitrogen", "CHEMICAL", 232, 242], ["1,2,3-selenadiazole", "CHEMICAL", 248, 267], ["1,2,3-selenadiazoles", "SIMPLE_CHEMICAL", 34, 54], ["cyclopentadienylcobalt", "SIMPLE_CHEMICAL", 76, 98], ["pentamethylcyclopentadienylcobalt diselenolenes", "SIMPLE_CHEMICAL", 103, 150], ["selenaketocarbene", "SIMPLE_CHEMICAL", 171, 188], ["dinitrogen", "SIMPLE_CHEMICAL", 232, 242], ["1,2,3-selenadiazole", "SIMPLE_CHEMICAL", 248, 267], ["selenadiazoles", "TREATMENT", 40, 54], ["cyclopentadienylcobalt", "TREATMENT", 76, 98], ["pentamethylcyclopentadienylcobalt diselenolenes", "TREATMENT", 103, 150], ["selenaketocarbene", "TREATMENT", 171, 188], ["dinitrogen", "TREATMENT", 232, 242], ["selenadiazole", "TREATMENT", 254, 267]]], ["Such transition-metal dithiolenes or diselenolenes attracted enormous early attention because of their electrochemical and optical properties.", [["diselenolenes", "CHEMICAL", 37, 50], ["transition-metal dithiolenes", "CHEMICAL", 5, 33], ["diselenolenes", "CHEMICAL", 37, 50], ["transition-metal dithiolenes", "SIMPLE_CHEMICAL", 5, 33], ["diselenolenes", "SIMPLE_CHEMICAL", 37, 50], ["transition-metal dithiolenes", "TREATMENT", 5, 33], ["diselenolenes", "PROBLEM", 37, 50]]], ["It was reported that transition metal bis(dithiolenes) have been applied for the making of molecular superconductors, in mode locking and passive Q-switch applications.", [["dithiolenes", "CHEMICAL", 42, 53], ["transition metal bis(dithiolenes)", "CHEMICAL", 21, 54], ["metal bis(dithiolenes", "SIMPLE_CHEMICAL", 32, 53], ["transition metal bis(dithiolenes)", "TREATMENT", 21, 54], ["molecular superconductors", "TREATMENT", 91, 116], ["mode locking", "TREATMENT", 121, 133], ["passive Q-switch applications", "TREATMENT", 138, 167]]], ["Considerable attention has been paid in the study of II-VI semiconductors such as CdSe, because by changing the particle size, its band gap can be adjusted across the visible region.", [["CdSe", "CHEMICAL", 82, 86], ["CdSe", "CHEMICAL", 82, 86], ["CdSe", "SIMPLE_CHEMICAL", 82, 86], ["the study", "TEST", 40, 49], ["II-VI semiconductors", "TREATMENT", 53, 73], ["its band gap", "PROBLEM", 127, 139], ["particle", "OBSERVATION_MODIFIER", 112, 120], ["size", "OBSERVATION_MODIFIER", 121, 125]]], ["In addition to this, CdSe shows different applications such as laser diodes, blue light emitting diodes, solar cells, and biological labeling [151] .", [["cells", "ANATOMY", 111, 116], ["CdSe", "CHEMICAL", 21, 25], ["CdSe", "CHEMICAL", 21, 25], ["CdSe", "SIMPLE_CHEMICAL", 21, 25], ["solar cells", "CELL", 105, 116], ["solar cells", "CELL_TYPE", 105, 116], ["different applications", "TREATMENT", 32, 54], ["laser diodes", "TREATMENT", 63, 75], ["blue light emitting diodes", "TREATMENT", 77, 103], ["solar cells", "TREATMENT", 105, 116], ["biological labeling", "TEST", 122, 141], ["solar cells", "OBSERVATION", 105, 116]]], ["Khanna et al. [152] have used selenadiazoles as selenium source for the synthesis of range of metal selenides including CdSe, ZnSe QDs as well as ZnSe/ CdSe core shell quantum dots to promote plausibly less toxic and an eco-friendly synthetic method for development of QDs.", [["selenadiazoles", "CHEMICAL", 30, 44], ["selenium", "CHEMICAL", 48, 56], ["CdSe", "CHEMICAL", 120, 124], ["ZnSe QDs", "CHEMICAL", 126, 134], ["ZnSe", "CHEMICAL", 146, 150], ["selenadiazoles", "CHEMICAL", 30, 44], ["selenium", "CHEMICAL", 48, 56], ["metal selenides", "CHEMICAL", 94, 109], ["CdSe", "CHEMICAL", 120, 124], ["ZnSe", "CHEMICAL", 126, 130], ["ZnSe", "CHEMICAL", 146, 150], ["CdSe", "CHEMICAL", 152, 156], ["selenadiazoles", "SIMPLE_CHEMICAL", 30, 44], ["selenium", "SIMPLE_CHEMICAL", 48, 56], ["metal selenides", "SIMPLE_CHEMICAL", 94, 109], ["CdSe", "SIMPLE_CHEMICAL", 120, 124], ["ZnSe QDs", "SIMPLE_CHEMICAL", 126, 134], ["ZnSe", "SIMPLE_CHEMICAL", 146, 150], ["CdSe core shell quantum dots", "SIMPLE_CHEMICAL", 152, 180], ["QDs", "SIMPLE_CHEMICAL", 269, 272], ["selenadiazoles", "TREATMENT", 30, 44], ["selenium source", "PROBLEM", 48, 63], ["the synthesis of range of metal selenides", "TREATMENT", 68, 109], ["CdSe, ZnSe QDs", "TREATMENT", 120, 134], ["ZnSe/ CdSe core shell quantum dots", "TREATMENT", 146, 180], ["an eco-friendly synthetic method", "TREATMENT", 217, 249]]], ["Jadhav et al. [153,153a] have reported the solventless method for the preparation of heterocyclic organoselenium compounds, i.e. cycloalkano-1,2,3-selenadiazole by using their respective cycloalkane semicarbazones.", [["organoselenium", "CHEMICAL", 98, 112], ["cycloalkano-1,2,3-selenadiazole", "CHEMICAL", 129, 160], ["cycloalkane", "CHEMICAL", 187, 198], ["organoselenium", "CHEMICAL", 98, 112], ["cycloalkano-1,2,3-selenadiazole", "CHEMICAL", 129, 160], ["cycloalkane semicarbazones", "CHEMICAL", 187, 213], ["heterocyclic organoselenium compounds", "SIMPLE_CHEMICAL", 85, 122], ["cycloalkano-1,2,3-selenadiazole", "SIMPLE_CHEMICAL", 129, 160], ["cycloalkane semicarbazones", "SIMPLE_CHEMICAL", 187, 213], ["the solventless method", "TREATMENT", 39, 61], ["heterocyclic organoselenium compounds", "TREATMENT", 85, 122], ["cycloalkano", "TREATMENT", 129, 140], ["selenadiazole", "TREATMENT", 147, 160], ["their respective cycloalkane semicarbazones", "TREATMENT", 170, 213]]], ["The heterocyclic compounds containing nitrogen and selenium atom like 1,2,3-selenadiazoles have been used as vital precursors for the material chemistry including nanotechnology as they shows thermal and photochemical decomposition during the dimer formation or formation of acyclic or new heterocyclic compounds.Scope of Schiff bases and their complexes for nanobiotechnologyOverall, synthesis of CdSe quantum dots and magic-sized nanocrystals from such precursor have been reported by Jadhav et al. [153b, c] thermal and microwave method.", [["nitrogen", "CHEMICAL", 38, 46], ["selenium", "CHEMICAL", 51, 59], ["1,2,3-selenadiazoles", "CHEMICAL", 70, 90], ["nitrogen", "CHEMICAL", 38, 46], ["selenium", "CHEMICAL", 51, 59], ["1,2,3-selenadiazoles", "CHEMICAL", 70, 90], ["Schiff bases", "CHEMICAL", 322, 334], ["CdSe", "CHEMICAL", 398, 402], ["nitrogen", "SIMPLE_CHEMICAL", 38, 46], ["selenium atom", "SIMPLE_CHEMICAL", 51, 64], ["1,2,3-selenadiazoles", "SIMPLE_CHEMICAL", 70, 90], ["new heterocyclic compounds", "SIMPLE_CHEMICAL", 286, 312], ["Schiff bases", "SIMPLE_CHEMICAL", 322, 334], ["CdSe quantum dots", "SIMPLE_CHEMICAL", 398, 415], ["The heterocyclic compounds", "TREATMENT", 0, 26], ["nitrogen and selenium atom", "TREATMENT", 38, 64], ["selenadiazoles", "TREATMENT", 76, 90], ["vital precursors", "TEST", 109, 125], ["the material chemistry", "TEST", 130, 152], ["thermal and photochemical decomposition", "PROBLEM", 192, 231], ["the dimer formation", "PROBLEM", 239, 258], ["acyclic or new heterocyclic compounds", "PROBLEM", 275, 312], ["synthesis of CdSe quantum dots", "TREATMENT", 385, 415], ["magic-sized nanocrystals", "TREATMENT", 420, 444], ["such precursor", "PROBLEM", 450, 464], ["thermal and microwave method", "TREATMENT", 511, 539], ["heterocyclic compounds", "OBSERVATION", 4, 26], ["nitrogen", "OBSERVATION_MODIFIER", 38, 46], ["new", "OBSERVATION_MODIFIER", 286, 289], ["heterocyclic compounds", "OBSERVATION", 290, 312], ["Schiff bases", "OBSERVATION", 322, 334]]], ["It has been observed by the authors that these reactions can produce particles of 2e5 nm dimensions with useful optical properties (Fig. 3) .Scope of Schiff bases and their complexes for nanobiotechnologyOwing to characteristic physical and chemical properties such as facile surface modification, stable optical property, and well defined structure; a particular gold nanoclusters and gold nanomaterials with specific size have attracted the attention of many researchers [154,154aed] .", [["surface", "ANATOMY", 276, 283], ["Schiff bases", "CHEMICAL", 150, 162], ["Schiff bases", "SIMPLE_CHEMICAL", 150, 162], ["gold nanoclusters", "SIMPLE_CHEMICAL", 364, 381], ["gold nanomaterials", "SIMPLE_CHEMICAL", 386, 404], ["these reactions", "PROBLEM", 41, 56], ["Scope of Schiff bases", "TEST", 141, 162], ["facile surface modification", "TREATMENT", 269, 296], ["a particular gold nanoclusters and gold nanomaterials", "PROBLEM", 351, 404], ["chemical properties", "OBSERVATION", 241, 260], ["stable", "OBSERVATION_MODIFIER", 298, 304], ["optical property", "OBSERVATION_MODIFIER", 305, 321], ["well defined", "OBSERVATION_MODIFIER", 327, 339], ["size", "OBSERVATION_MODIFIER", 419, 423]]], ["Gold imine complexes may further boost this prospect and may offer a new precursor for synthesis of optically tuned gold nanoparticles [154e,f].", [["Gold imine", "CHEMICAL", 0, 10], ["imine", "CHEMICAL", 5, 10], ["Gold imine complexes", "SIMPLE_CHEMICAL", 0, 20], ["gold nanoparticles", "SIMPLE_CHEMICAL", 116, 134], ["Gold imine complexes", "PROBLEM", 0, 20], ["a new precursor for synthesis of optically tuned gold nanoparticles", "TREATMENT", 67, 134], ["imine complexes", "OBSERVATION", 5, 20]]], ["It is reported that gold nanoclusters with various functional groups show excellent photostability, compatibility, and greater solubility in water so they can be employed as biosensors and can also be good candidate as fluorescent nanoprobes for biomedical applications in bioimaging, tumor therapy, and high sensitivity detection [155,155aec].Scope of Schiff bases and their complexes for nanobiotechnologyAazam et al. [156] have reported the hydrothermal reduction method for the synthesis of pure face-centered cubic Ni and Cu nanoparticles by using Cu (II) and Ni (II) complexes (120 and 121) (Scheme 27) of N2O2 donor tetradentate Schiff base ligand derived from 3-ethoxy-salicylaldehyde and 2,3-diamino but-2-ene dinitrile.", [["tumor", "ANATOMY", 285, 290], ["tumor", "DISEASE", 285, 290], ["Ni", "CHEMICAL", 520, 522], ["Cu", "CHEMICAL", 527, 529], ["Cu (II", "CHEMICAL", 553, 559], ["Ni", "CHEMICAL", 565, 567], ["N2O2", "CHEMICAL", 612, 616], ["tetradentate", "CHEMICAL", 623, 635], ["3-ethoxy-salicylaldehyde", "CHEMICAL", 668, 692], ["2,3-diamino but-2-ene dinitrile", "CHEMICAL", 697, 728], ["Schiff bases", "CHEMICAL", 353, 365], ["Ni", "CHEMICAL", 520, 522], ["Cu", "CHEMICAL", 527, 529], ["Cu (II)", "CHEMICAL", 553, 560], ["Ni (II)", "CHEMICAL", 565, 572], ["N2O2", "CHEMICAL", 612, 616], ["tetradentate Schiff base", "CHEMICAL", 623, 647], ["3-ethoxy-salicylaldehyde", "CHEMICAL", 668, 692], ["2,3-diamino but-2-ene dinitrile", "CHEMICAL", 697, 728], ["gold nanoclusters", "SIMPLE_CHEMICAL", 20, 37], ["water", "SIMPLE_CHEMICAL", 141, 146], ["tumor", "CANCER", 285, 290], ["Schiff bases", "SIMPLE_CHEMICAL", 353, 365], ["cubic Ni", "SIMPLE_CHEMICAL", 514, 522], ["Cu nanoparticles", "SIMPLE_CHEMICAL", 527, 543], ["Cu (II)", "SIMPLE_CHEMICAL", 553, 560], ["Ni (II)", "SIMPLE_CHEMICAL", 565, 572], ["N2O2 donor tetradentate Schiff base ligand", "SIMPLE_CHEMICAL", 612, 654], ["3-ethoxy-salicylaldehyde", "SIMPLE_CHEMICAL", 668, 692], ["2,3-diamino but-2-ene dinitrile", "SIMPLE_CHEMICAL", 697, 728], ["Ni (II) complexes", "PROTEIN", 565, 582], ["gold nanoclusters", "PROBLEM", 20, 37], ["fluorescent nanoprobes", "TREATMENT", 219, 241], ["biomedical applications in bioimaging", "TREATMENT", 246, 283], ["tumor therapy", "TREATMENT", 285, 298], ["high sensitivity detection", "TEST", 304, 330], ["the hydrothermal reduction method", "TREATMENT", 440, 473], ["the synthesis of pure face", "TREATMENT", 478, 504], ["centered cubic Ni and Cu nanoparticles", "TREATMENT", 505, 543], ["N2O2 donor tetradentate Schiff base ligand", "TREATMENT", 612, 654], ["salicylaldehyde", "TREATMENT", 677, 692], ["diamino", "TREATMENT", 701, 708], ["excellent", "OBSERVATION_MODIFIER", 74, 83], ["photostability", "OBSERVATION", 84, 98], ["greater solubility", "OBSERVATION_MODIFIER", 119, 137], ["Schiff bases", "OBSERVATION", 353, 365]]], ["They have tested in vitro cytotoxicity of the Schiff base ligand and its Cu (II) and Ni (II) complexes against human carcinoma cell lines (HeLa and MCF-7) as well as Cu NPs were studied for their antibacterial activity.", [["carcinoma cell lines", "ANATOMY", 117, 137], ["HeLa", "ANATOMY", 139, 143], ["MCF-7", "ANATOMY", 148, 153], ["Cu", "CHEMICAL", 73, 75], ["Ni", "CHEMICAL", 85, 87], ["carcinoma", "DISEASE", 117, 126], ["Cu", "CHEMICAL", 166, 168], ["Schiff base", "CHEMICAL", 46, 57], ["Cu (II)", "CHEMICAL", 73, 80], ["Ni (II)", "CHEMICAL", 85, 92], ["Cu", "CHEMICAL", 166, 168], ["Schiff base ligand", "SIMPLE_CHEMICAL", 46, 64], ["Cu (II)", "SIMPLE_CHEMICAL", 73, 80], ["Ni (II)", "SIMPLE_CHEMICAL", 85, 92], ["human", "ORGANISM", 111, 116], ["carcinoma cell lines", "CELL", 117, 137], ["HeLa", "CELL", 139, 143], ["MCF-7", "CELL", 148, 153], ["Cu NPs", "SIMPLE_CHEMICAL", 166, 172], ["Ni (II) complexes", "PROTEIN", 85, 102], ["human carcinoma cell lines", "CELL_LINE", 111, 137], ["HeLa", "CELL_LINE", 139, 143], ["MCF-7", "CELL_LINE", 148, 153], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["the Schiff base ligand", "TEST", 42, 64], ["Ni (II) complexes", "TREATMENT", 85, 102], ["human carcinoma cell lines", "TREATMENT", 111, 137], ["HeLa", "TEST", 139, 143], ["MCF", "TEST", 148, 151], ["Cu NPs", "TREATMENT", 166, 172], ["carcinoma cell lines", "OBSERVATION", 117, 137]]], ["It is reported that Cu (II) complexes better activity against HeLa and MCF-7 cell line than the Ni (II) complex.", [["HeLa", "ANATOMY", 62, 66], ["MCF-7 cell line", "ANATOMY", 71, 86], ["Cu (II", "CHEMICAL", 20, 26], ["Ni", "CHEMICAL", 96, 98], ["Cu (II)", "CHEMICAL", 20, 27], ["Ni (II)", "CHEMICAL", 96, 103], ["Cu (II", "SIMPLE_CHEMICAL", 20, 26], ["HeLa", "CELL", 62, 66], ["MCF-7 cell line", "CELL", 71, 86], ["Ni (II) complex", "GENE_OR_GENE_PRODUCT", 96, 111], ["Cu (II) complexes", "PROTEIN", 20, 37], ["HeLa", "CELL_LINE", 62, 66], ["MCF-7 cell line", "CELL_LINE", 71, 86], ["Ni (II) complex", "PROTEIN", 96, 111], ["MCF-7", "SPECIES", 71, 76], ["HeLa", "TEST", 62, 66], ["MCF", "TEST", 71, 74], ["cell line", "OBSERVATION", 77, 86]]], ["Also it is reported that Cu nanoparticles are better antibacterial agent against E. coli.", [["Cu", "CHEMICAL", 25, 27], ["Cu", "CHEMICAL", 25, 27], ["Cu nanoparticles", "SIMPLE_CHEMICAL", 25, 41], ["E. coli", "ORGANISM", 81, 88], ["E. coli", "SPECIES", 81, 88], ["E. coli", "SPECIES", 81, 88], ["Cu nanoparticles", "TREATMENT", 25, 41], ["better antibacterial agent", "TREATMENT", 46, 72], ["E. coli", "PROBLEM", 81, 88], ["coli", "OBSERVATION", 84, 88]]], ["The catalytic activity of the synthesized Ni nanoparticles is reported to be slightly higher toward hydrogenation of nitrobenzene to aniline compared with the commercial Raney Ni.Scope of Schiff bases and their complexes for nanobiotechnologyOwing to the promising application of Ni and Zn NPs as catalysts, capacitor and magnetic materials such metal complexes have become highly attractive to researchers specially magnetic transition metal-based materials as they are used as high density magnetic recording media [157e159].", [["Ni", "CHEMICAL", 42, 44], ["nitrobenzene", "CHEMICAL", 117, 129], ["aniline", "CHEMICAL", 133, 140], ["Ni", "CHEMICAL", 280, 282], ["Zn", "CHEMICAL", 287, 289], ["Ni", "CHEMICAL", 42, 44], ["nitrobenzene", "CHEMICAL", 117, 129], ["aniline", "CHEMICAL", 133, 140], ["Schiff bases", "CHEMICAL", 188, 200], ["Ni", "CHEMICAL", 280, 282], ["Zn", "CHEMICAL", 287, 289], ["transition metal", "CHEMICAL", 426, 442], ["Ni nanoparticles", "SIMPLE_CHEMICAL", 42, 58], ["nitrobenzene", "SIMPLE_CHEMICAL", 117, 129], ["aniline", "SIMPLE_CHEMICAL", 133, 140], ["Schiff bases", "SIMPLE_CHEMICAL", 188, 200], ["Ni", "SIMPLE_CHEMICAL", 280, 282], ["Zn NPs", "SIMPLE_CHEMICAL", 287, 293], ["the synthesized Ni nanoparticles", "TREATMENT", 26, 58], ["nitrobenzene", "TREATMENT", 117, 129], ["Ni and Zn NPs", "TREATMENT", 280, 293], ["catalysts", "TREATMENT", 297, 306], ["capacitor and magnetic materials", "TREATMENT", 308, 340]]], ["For example some Ni NPs are considered as anode materials for rechargeable batteries, ethanol fuel cell, and a fine substitute for a noble metal used in the internal electrodes of multilayer ceramic capacitors [160] .", [["fuel cell", "ANATOMY", 94, 103], ["Ni", "CHEMICAL", 17, 19], ["ethanol", "CHEMICAL", 86, 93], ["Ni", "CHEMICAL", 17, 19], ["ethanol", "CHEMICAL", 86, 93], ["Ni NPs", "SIMPLE_CHEMICAL", 17, 23], ["ethanol", "SIMPLE_CHEMICAL", 86, 93], ["cell", "CELL", 99, 103], ["some Ni NPs", "PROBLEM", 12, 23], ["rechargeable batteries", "TREATMENT", 62, 84], ["ethanol fuel cell", "TREATMENT", 86, 103], ["a noble metal", "TREATMENT", 131, 144], ["the internal electrodes of multilayer ceramic capacitors", "TREATMENT", 153, 209], ["NPs", "OBSERVATION", 20, 23], ["fuel cell", "OBSERVATION", 94, 103], ["ceramic capacitors", "OBSERVATION", 191, 209]]], ["Nickel, cobalt, cadmium, and copper complexes with carbohydrazide have been attracted more attention because of its variety of applications in defense.", [["Nickel", "CHEMICAL", 0, 6], ["cobalt", "CHEMICAL", 8, 14], ["cadmium", "CHEMICAL", 16, 23], ["copper", "CHEMICAL", 29, 35], ["carbohydrazide", "CHEMICAL", 51, 65], ["Nickel", "CHEMICAL", 0, 6], ["cobalt", "CHEMICAL", 8, 14], ["cadmium", "CHEMICAL", 16, 23], ["copper", "CHEMICAL", 29, 35], ["carbohydrazide", "CHEMICAL", 51, 65], ["Nickel", "SIMPLE_CHEMICAL", 0, 6], ["cobalt", "SIMPLE_CHEMICAL", 8, 14], ["cadmium", "SIMPLE_CHEMICAL", 16, 23], ["copper complexes", "SIMPLE_CHEMICAL", 29, 45], ["carbohydrazide", "SIMPLE_CHEMICAL", 51, 65], ["cadmium", "TREATMENT", 16, 23], ["copper complexes", "TREATMENT", 29, 45], ["carbohydrazide", "TREATMENT", 51, 65]]], ["It is documented that they are used as primary explosives [161e163], burning rate modifiers [57] , and also in gas generating agents, [164e166] .", [["burning rate modifiers", "TREATMENT", 69, 91]]], ["Copper complexes with carbohydrazide are used in pyrotechnics as an alternative for barium compounds which are normally toxic in nature, to produce flame in blue and green colors.", [["Copper", "CHEMICAL", 0, 6], ["carbohydrazide", "CHEMICAL", 22, 36], ["Copper", "CHEMICAL", 0, 6], ["carbohydrazide", "CHEMICAL", 22, 36], ["Copper complexes", "SIMPLE_CHEMICAL", 0, 16], ["carbohydrazide", "SIMPLE_CHEMICAL", 22, 36], ["barium compounds", "SIMPLE_CHEMICAL", 84, 100], ["Copper complexes", "PROBLEM", 0, 16], ["carbohydrazide", "TREATMENT", 22, 36], ["pyrotechnics", "TREATMENT", 49, 61], ["barium compounds", "PROBLEM", 84, 100], ["toxic", "OBSERVATION_MODIFIER", 120, 125], ["green colors", "OBSERVATION", 166, 178]]], ["Bushuyev et al. [58] have reported the energetic compounds of type [CuX 2 (C 7 Similarly, some other transition metal complexes Co, Ni, and Zn of carbohydrazide with perchlorate salt were investigated by Talawar et al. [162] where they reported that Co and Ni complexes were superior detonants as compared with lead azide and mercuric fulminate in terms of low vulnerability.", [["Co", "CHEMICAL", 128, 130], ["Ni", "CHEMICAL", 132, 134], ["Zn", "CHEMICAL", 140, 142], ["carbohydrazide", "CHEMICAL", 146, 160], ["perchlorate salt", "CHEMICAL", 166, 182], ["Co", "CHEMICAL", 250, 252], ["Ni", "CHEMICAL", 257, 259], ["mercuric", "CHEMICAL", 326, 334], ["transition metal", "CHEMICAL", 101, 117], ["Co", "CHEMICAL", 128, 130], ["Ni", "CHEMICAL", 132, 134], ["Zn", "CHEMICAL", 140, 142], ["carbohydrazide", "CHEMICAL", 146, 160], ["perchlorate", "CHEMICAL", 166, 177], ["Co", "CHEMICAL", 250, 252], ["Ni", "CHEMICAL", 257, 259], ["azide", "CHEMICAL", 316, 321], ["mercuric", "CHEMICAL", 326, 334], ["[CuX 2 (C 7", "SIMPLE_CHEMICAL", 67, 78], ["Co, Ni,", "SIMPLE_CHEMICAL", 128, 135], ["Zn of carbohydrazide", "SIMPLE_CHEMICAL", 140, 160], ["perchlorate salt", "SIMPLE_CHEMICAL", 166, 182], ["Co", "SIMPLE_CHEMICAL", 250, 252], ["Ni complexes", "SIMPLE_CHEMICAL", 257, 269], ["lead azide", "SIMPLE_CHEMICAL", 311, 321], ["mercuric", "SIMPLE_CHEMICAL", 326, 334], ["Co and Ni complexes", "PROTEIN", 250, 269], ["carbohydrazide", "TREATMENT", 146, 160], ["perchlorate salt", "TREATMENT", 166, 182], ["Co and Ni complexes", "PROBLEM", 250, 269], ["lead azide", "TREATMENT", 311, 321], ["low vulnerability", "PROBLEM", 357, 374], ["low vulnerability", "OBSERVATION", 357, 374]]], ["Sonawane et al. [57] have reported the copper, nickel, and cobalt carbohydrazide nitrate complexes and studied their burning rate for propellant composition.", [["copper", "CHEMICAL", 39, 45], ["nickel", "CHEMICAL", 47, 53], ["cobalt", "CHEMICAL", 59, 65], ["nitrate", "CHEMICAL", 81, 88], ["copper", "CHEMICAL", 39, 45], ["nickel", "CHEMICAL", 47, 53], ["cobalt carbohydrazide nitrate", "CHEMICAL", 59, 88], ["copper", "SIMPLE_CHEMICAL", 39, 45], ["nickel", "SIMPLE_CHEMICAL", 47, 53], ["cobalt carbohydrazide nitrate complexes", "SIMPLE_CHEMICAL", 59, 98], ["cobalt carbohydrazide nitrate complexes", "TREATMENT", 59, 98]]], ["It is reported that there is great enhancement of burning rate by incorporation of nickel complex in the order of 27e72% in the pressure range of 1.9e8.8 MPa, whereas addition of Cobalt complex resulted in the enhancement of burning rate of the order of 9e19% in same pressure range.", [["nickel", "CHEMICAL", 83, 89], ["Cobalt", "CHEMICAL", 179, 185], ["nickel", "CHEMICAL", 83, 89], ["Cobalt", "CHEMICAL", 179, 185], ["nickel complex", "SIMPLE_CHEMICAL", 83, 97], ["Cobalt complex", "SIMPLE_CHEMICAL", 179, 193], ["nickel complex", "PROTEIN", 83, 97], ["Cobalt complex", "PROTEIN", 179, 193], ["great enhancement of burning rate", "PROBLEM", 29, 62], ["Cobalt complex", "PROBLEM", 179, 193], ["burning rate", "TEST", 225, 237], ["great", "OBSERVATION_MODIFIER", 29, 34], ["enhancement", "OBSERVATION_MODIFIER", 35, 46], ["burning rate", "OBSERVATION", 50, 62], ["nickel complex", "OBSERVATION", 83, 97], ["pressure", "OBSERVATION_MODIFIER", 128, 136], ["Cobalt complex", "OBSERVATION", 179, 193], ["enhancement", "OBSERVATION_MODIFIER", 210, 221], ["pressure range", "OBSERVATION", 268, 282]]], ["Some Schiff bases possess simple harmonic generation activity [167] .", [["Schiff bases", "CHEMICAL", 5, 17], ["Some Schiff bases", "PROBLEM", 0, 17], ["simple harmonic generation activity", "PROBLEM", 26, 61], ["Schiff bases", "OBSERVATION", 5, 17]]], ["Zn (II) complexes with Schiff base as chelating ligand has been reported that they can be used as an effective emitting layer [168] .", [["Zn", "CHEMICAL", 0, 2], ["Schiff base", "CHEMICAL", 23, 34], ["Zn (II)", "CHEMICAL", 0, 7], ["Schiff base", "CHEMICAL", 23, 34], ["Zn (II)", "SIMPLE_CHEMICAL", 0, 7], ["Schiff base", "SIMPLE_CHEMICAL", 23, 34], ["Zn (II) complexes", "PROTEIN", 0, 17], ["Zn (II) complexes with Schiff base as chelating ligand", "TREATMENT", 0, 54]]], ["The Schiff base derived from tetradentate precursor 1phenyl-butane-1,3-dionemono-S-methylisothio-semicarbazone with o-hydroxy-benzaldehyde or its 5-phenylazo derivatives and its metal complexes exhibited non-linear optical (NLO) properties.Scope of Schiff bases and their complexes for nanobiotechnologyA comparison between the phenylazo-substituted Schiff base ligand with its different metal complexes indicated that the NLO response strongly depends upon the electronic configuration of the metal center [169] .", [["tetradentate", "CHEMICAL", 29, 41], ["1phenyl-butane-1,3-dionemono-S-methylisothio-semicarbazone", "CHEMICAL", 52, 110], ["o-hydroxy-benzaldehyde", "CHEMICAL", 116, 138], ["5-phenylazo", "CHEMICAL", 146, 157], ["phenylazo", "CHEMICAL", 328, 337], ["Schiff base", "CHEMICAL", 4, 15], ["tetradentate", "CHEMICAL", 29, 41], ["1phenyl-butane-1,3-dionemono-S-methylisothio-semicarbazone", "CHEMICAL", 52, 110], ["o-hydroxy-benzaldehyde", "CHEMICAL", 116, 138], ["5-phenylazo", "CHEMICAL", 146, 157], ["Schiff bases", "CHEMICAL", 249, 261], ["phenylazo", "CHEMICAL", 328, 337], ["Schiff base", "CHEMICAL", 350, 361], ["Schiff", "SIMPLE_CHEMICAL", 4, 10], ["tetradentate precursor 1phenyl-butane-1,3-dionemono-S-methylisothio-semicarbazone", "SIMPLE_CHEMICAL", 29, 110], ["o-hydroxy-benzaldehyde", "SIMPLE_CHEMICAL", 116, 138], ["5-phenylazo derivatives", "SIMPLE_CHEMICAL", 146, 169], ["metal complexes", "SIMPLE_CHEMICAL", 178, 193], ["Schiff bases", "SIMPLE_CHEMICAL", 249, 261], ["phenylazo-substituted Schiff base ligand", "SIMPLE_CHEMICAL", 328, 368], ["The Schiff base", "TEST", 0, 15], ["tetradentate precursor", "TEST", 29, 51], ["dionemono", "TREATMENT", 71, 80], ["S-methylisothio", "TREATMENT", 81, 96], ["semicarbazone", "TREATMENT", 97, 110], ["o-hydroxy-benzaldehyde", "TREATMENT", 116, 138], ["its 5-phenylazo derivatives", "TREATMENT", 142, 169], ["its metal complexes", "TREATMENT", 174, 193], ["non-linear optical (NLO) properties", "TREATMENT", 204, 239], ["Scope of Schiff bases", "TEST", 240, 261], ["the phenylazo-substituted Schiff base ligand", "TREATMENT", 324, 368], ["Schiff base", "OBSERVATION", 4, 15], ["Schiff bases", "OBSERVATION", 249, 261]]], ["It has been reported that Zn (II) complexes with benzothiazoles [170] and Zn (II) and Cd (II) complexes with N 2 S 2 donor Schiff base ligands can be used as precursors for tuning of the emission wavelength [171] .Miscellaneous applicationsSchiff bases are potential candidates as catalysts for a variety of organic and inorganic transformations.", [["Zn", "CHEMICAL", 26, 28], ["benzothiazoles", "CHEMICAL", 49, 63], ["Zn", "CHEMICAL", 74, 76], ["Cd", "CHEMICAL", 86, 88], ["Zn (II)", "CHEMICAL", 26, 33], ["benzothiazoles", "CHEMICAL", 49, 63], ["Zn (II)", "CHEMICAL", 74, 81], ["Cd (II)", "CHEMICAL", 86, 93], ["Schiff base", "CHEMICAL", 123, 134], ["Schiff bases", "CHEMICAL", 240, 252], ["Zn (II)", "SIMPLE_CHEMICAL", 26, 33], ["benzothiazoles [170]", "SIMPLE_CHEMICAL", 49, 69], ["Zn (II)", "SIMPLE_CHEMICAL", 74, 81], ["Cd (II)", "SIMPLE_CHEMICAL", 86, 93], ["N 2 S 2 donor Schiff base ligands", "SIMPLE_CHEMICAL", 109, 142], ["Schiff", "SIMPLE_CHEMICAL", 240, 246], ["Zn (II) complexes", "PROTEIN", 26, 43], ["Zn (II) complexes with benzothiazoles", "TREATMENT", 26, 63], ["Zn (II)", "TREATMENT", 74, 81], ["Cd (II) complexes", "TREATMENT", 86, 103], ["N 2 S 2 donor Schiff base ligands", "TREATMENT", 109, 142], ["Miscellaneous applications", "TREATMENT", 214, 240], ["Schiff bases", "PROBLEM", 240, 252], ["catalysts", "TREATMENT", 281, 290], ["organic and inorganic transformations", "PROBLEM", 308, 345], ["bases", "ANATOMY_MODIFIER", 247, 252], ["inorganic transformations", "OBSERVATION", 320, 345]]], ["A few examples are described here in brief, e.g. Li et al. [172] have reported asymmetric cyclopropanation of styrene by using Cu (II) complexes with Schiff base of chiral amino alcohol like (S)-2-amino-1,1-di(3,5-di-tbutylphenyl)propanol and substituted salicylaldehyde as catalyst.", [["Li", "CHEMICAL", 49, 51], ["styrene", "CHEMICAL", 110, 117], ["Cu", "CHEMICAL", 127, 129], ["amino alcohol", "CHEMICAL", 172, 185], ["S)-2-amino-1,1-di(3,5-di-tbutylphenyl)propanol", "CHEMICAL", 192, 238], ["salicylaldehyde", "CHEMICAL", 255, 270], ["styrene", "CHEMICAL", 110, 117], ["Cu (II)", "CHEMICAL", 127, 134], ["Schiff base", "CHEMICAL", 150, 161], ["amino alcohol", "CHEMICAL", 172, 185], ["(S)-2-amino-1,1-di(3,5-di-tbutylphenyl)propanol", "CHEMICAL", 191, 238], ["salicylaldehyde", "CHEMICAL", 255, 270], ["styrene", "SIMPLE_CHEMICAL", 110, 117], ["Cu (II)", "SIMPLE_CHEMICAL", 127, 134], ["Schiff base", "SIMPLE_CHEMICAL", 150, 161], ["chiral amino alcohol", "SIMPLE_CHEMICAL", 165, 185], ["(S)-2-amino-1,1-di(3,5-di-tbutylphenyl)propanol", "SIMPLE_CHEMICAL", 191, 238], ["salicylaldehyde", "SIMPLE_CHEMICAL", 255, 270], ["Cu (II) complexes", "PROTEIN", 127, 144], ["asymmetric cyclopropanation of styrene", "TREATMENT", 79, 117], ["chiral amino alcohol", "TEST", 165, 185], ["amino", "TEST", 197, 202], ["di", "PROBLEM", 207, 209], ["tbutylphenyl", "TREATMENT", 217, 229], ["propanol", "TREATMENT", 230, 238], ["substituted salicylaldehyde as catalyst", "TREATMENT", 243, 282]]], ["It is reported that these Cu (II) complexes of chiral amino alcohol are effective for the asymmetric cyclopropanation of styrene.", [["Cu", "CHEMICAL", 26, 28], ["amino alcohol", "CHEMICAL", 54, 67], ["styrene", "CHEMICAL", 121, 128], ["Cu (II)", "CHEMICAL", 26, 33], ["amino alcohol", "CHEMICAL", 54, 67], ["styrene", "CHEMICAL", 121, 128], ["Cu (II)", "SIMPLE_CHEMICAL", 26, 33], ["chiral amino alcohol", "SIMPLE_CHEMICAL", 47, 67], ["styrene", "SIMPLE_CHEMICAL", 121, 128], ["Cu (II) complexes", "PROTEIN", 26, 43], ["chiral amino alcohol", "TREATMENT", 47, 67], ["the asymmetric cyclopropanation of styrene", "TREATMENT", 86, 128], ["asymmetric cyclopropanation", "OBSERVATION", 90, 117]]], ["It has been reported [173] that many of the Cu (I) complexes having mixed ligands including the with Schiff base [2-methoxy-(5trifluoromethylphenyl)-pyridine-2yl-methylene-amine] and PPh 3 / dppe shows great catalytic activity for the amination of iodobenzene.Miscellaneous applicationsA series of Cu (I) complexes (125e128) attributing N-(2pyridylmethylene)-1,5-dimethyl-2-pyrazole-3-(2H)-one and triphenylphosphine have been reported and tested for efficient catalytic activity (Scheme 29), and it is reported that these complexes act as effective catalyst in the Sonogashira cross-coupling reaction of phenylacetylene with aryl halides [174] .", [["Cu", "CHEMICAL", 44, 46], ["Schiff", "CHEMICAL", 101, 107], ["2-methoxy-(5trifluoromethylphenyl)-pyridine-2yl-methylene-amine", "CHEMICAL", 114, 177], ["PPh 3 / dppe", "CHEMICAL", 183, 195], ["iodobenzene", "CHEMICAL", 248, 259], ["Cu", "CHEMICAL", 298, 300], ["125e128", "CHEMICAL", 316, 323], ["N-(2pyridylmethylene)-1,5-dimethyl-2-pyrazole-3-(2H)-one", "CHEMICAL", 337, 393], ["triphenylphosphine", "CHEMICAL", 398, 416], ["phenylacetylene", "CHEMICAL", 605, 620], ["aryl halides", "CHEMICAL", 626, 638], ["Cu (I)", "CHEMICAL", 44, 50], ["Schiff base", "CHEMICAL", 101, 112], ["2-methoxy-(5trifluoromethylphenyl)-pyridine-2yl-methylene-amine", "CHEMICAL", 114, 177], ["PPh 3 / dppe", "CHEMICAL", 183, 195], ["iodobenzene", "CHEMICAL", 248, 259], ["Cu (I)", "CHEMICAL", 298, 304], ["N-(2pyridylmethylene)-1,5-dimethyl-2-pyrazole-3-(2H)-one", "CHEMICAL", 337, 393], ["triphenylphosphine", "CHEMICAL", 398, 416], ["phenylacetylene", "CHEMICAL", 605, 620], ["aryl halides", "CHEMICAL", 626, 638], ["Cu (I)", "SIMPLE_CHEMICAL", 44, 50], ["Schiff base [2-methoxy-(5trifluoromethylphenyl)-pyridine-2yl-methylene-amine]", "SIMPLE_CHEMICAL", 101, 178], ["PPh 3 / dppe", "SIMPLE_CHEMICAL", 183, 195], ["iodobenzene", "SIMPLE_CHEMICAL", 248, 259], ["Cu (I)", "SIMPLE_CHEMICAL", 298, 304], ["N-(2pyridylmethylene)-1,5-dimethyl-2-pyrazole-3-(2H)-one", "SIMPLE_CHEMICAL", 337, 393], ["triphenylphosphine", "SIMPLE_CHEMICAL", 398, 416], ["Sonogashira", "SIMPLE_CHEMICAL", 566, 577], ["phenylacetylene", "SIMPLE_CHEMICAL", 605, 620], ["aryl halides [174]", "SIMPLE_CHEMICAL", 626, 644], ["Cu (I) complexes", "PROTEIN", 44, 60], ["Cu (I) complexes", "PROTEIN", 298, 314], ["mixed ligands", "PROBLEM", 68, 81], ["Schiff base", "TEST", 101, 112], ["methoxy-(5trifluoromethylphenyl)", "TREATMENT", 116, 148], ["pyridine", "TREATMENT", 149, 157], ["methylene-amine", "TREATMENT", 162, 177], ["PPh", "TREATMENT", 183, 186], ["the amination of iodobenzene", "TREATMENT", 231, 259], ["N-(2pyridylmethylene)", "TREATMENT", 337, 358], ["dimethyl", "TREATMENT", 363, 371], ["triphenylphosphine", "TREATMENT", 398, 416], ["the Sonogashira cross-coupling reaction of phenylacetylene with aryl halides", "TREATMENT", 562, 638]]], ["Many Cu (II) Schiff base complexes have also been used as catalyst for oxidation with specific focus on the DNA-binding and DNA-cleaving properties and mimic of galactose oxidase [175, 176] .Miscellaneous applicationsSimilarly other metal complexes also are reported for various catalytic activities.", [["Cu (II", "CHEMICAL", 5, 11], ["galactose", "CHEMICAL", 161, 170], ["Cu (II)", "CHEMICAL", 5, 12], ["Schiff base", "CHEMICAL", 13, 24], ["galactose", "CHEMICAL", 161, 170], ["Cu (II", "SIMPLE_CHEMICAL", 5, 11], ["DNA", "CELLULAR_COMPONENT", 108, 111], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["galactose oxidase", "GENE_OR_GENE_PRODUCT", 161, 178], ["galactose oxidase", "PROTEIN", 161, 178], ["Many Cu (II) Schiff base complexes", "PROBLEM", 0, 34], ["the DNA", "TEST", 104, 111], ["galactose oxidase", "TEST", 161, 178], ["Miscellaneous applications", "TREATMENT", 191, 217], ["metal complexes", "OBSERVATION", 233, 248]]], ["Aromatic Schiff base and their Co (II), Fe (III), and Ru (II) complexes are employed in oxidation of cyclohexane in presence of hydrogen peroxide into cyclohexanol and cyclohexanone [177, 178] .", [["Co", "CHEMICAL", 31, 33], ["Fe", "CHEMICAL", 40, 42], ["Ru", "CHEMICAL", 54, 56], ["cyclohexane", "CHEMICAL", 101, 112], ["hydrogen peroxide", "CHEMICAL", 128, 145], ["cyclohexanol", "CHEMICAL", 151, 163], ["cyclohexanone", "CHEMICAL", 168, 181], ["Schiff base", "CHEMICAL", 9, 20], ["Co (II)", "CHEMICAL", 31, 38], ["Fe (III)", "CHEMICAL", 40, 48], ["Ru (II)", "CHEMICAL", 54, 61], ["cyclohexane", "CHEMICAL", 101, 112], ["hydrogen peroxide", "CHEMICAL", 128, 145], ["cyclohexanol", "CHEMICAL", 151, 163], ["cyclohexanone", "CHEMICAL", 168, 181], ["Aromatic Schiff base", "SIMPLE_CHEMICAL", 0, 20], ["Co (II)", "SIMPLE_CHEMICAL", 31, 38], ["Fe (III)", "SIMPLE_CHEMICAL", 40, 48], ["Ru (II)", "SIMPLE_CHEMICAL", 54, 61], ["cyclohexane", "SIMPLE_CHEMICAL", 101, 112], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 128, 145], ["cyclohexanol", "SIMPLE_CHEMICAL", 151, 163], ["cyclohexanone [177, 178]", "SIMPLE_CHEMICAL", 168, 192], ["Ru (II) complexes", "PROTEIN", 54, 71], ["Aromatic Schiff base", "PROBLEM", 0, 20], ["cyclohexane", "TREATMENT", 101, 112], ["hydrogen peroxide into cyclohexanol", "TREATMENT", 128, 163], ["Schiff base", "OBSERVATION", 9, 20]]], ["These metal Schiff base complexes are also used to catalyze reaction on hydrolysis [179] , carbonylation [180] , decomposition, and electroreduction.", [["Schiff base", "CHEMICAL", 12, 23], ["[179]", "SIMPLE_CHEMICAL", 83, 88], ["These metal Schiff base complexes", "PROBLEM", 0, 33], ["hydrolysis", "TEST", 72, 82], ["carbonylation", "TREATMENT", 91, 104], ["electroreduction", "TREATMENT", 132, 148], ["metal Schiff", "OBSERVATION", 6, 18]]], ["It is observed that Co (II) Schiff base complexes show high catalytic activity in alkane oxidation reaction as compared with Fe (III) complexes [181] .", [["Co (II", "CHEMICAL", 20, 26], ["Schiff", "CHEMICAL", 28, 34], ["alkane", "CHEMICAL", 82, 88], ["Fe", "CHEMICAL", 125, 127], ["Co (II)", "CHEMICAL", 20, 27], ["Schiff base", "CHEMICAL", 28, 39], ["alkane", "CHEMICAL", 82, 88], ["Fe (III)", "CHEMICAL", 125, 133], ["Co (II", "SIMPLE_CHEMICAL", 20, 26], ["alkane", "SIMPLE_CHEMICAL", 82, 88], ["Fe (III)", "SIMPLE_CHEMICAL", 125, 133], ["Fe (III) complexes", "PROTEIN", 125, 143], ["Co (II) Schiff base complexes", "TEST", 20, 49], ["high catalytic activity in alkane oxidation reaction", "PROBLEM", 55, 107], ["high", "OBSERVATION_MODIFIER", 55, 59], ["catalytic activity", "OBSERVATION", 60, 78], ["alkane oxidation", "OBSERVATION", 82, 98]]], ["Fe (III) Schiff base complex shows catalytic activity toward electroreduction of oxygen [182] .", [["Fe", "CHEMICAL", 0, 2], ["Schiff", "CHEMICAL", 9, 15], ["oxygen", "CHEMICAL", 81, 87], ["Fe (III)", "CHEMICAL", 0, 8], ["Schiff base", "CHEMICAL", 9, 20], ["oxygen", "CHEMICAL", 81, 87], ["Fe (III) Schiff base", "SIMPLE_CHEMICAL", 0, 20], ["oxygen", "SIMPLE_CHEMICAL", 81, 87], ["Fe (III) Schiff base complex", "PROTEIN", 0, 28], ["Schiff base complex", "TEST", 9, 28], ["electroreduction of oxygen", "TREATMENT", 61, 87], ["catalytic activity", "OBSERVATION", 35, 53]]], ["Some Cr (III) salen complexes are renowned catalyst for homogeneous as well as heterogeneous reaction [183] .", [["Cr", "CHEMICAL", 5, 7], ["Cr (III)", "CHEMICAL", 5, 13], ["Cr (III) salen", "SIMPLE_CHEMICAL", 5, 19], ["Cr (III) salen complexes", "PROTEIN", 5, 29], ["Some Cr (III) salen complexes", "PROBLEM", 0, 29], ["heterogeneous reaction", "PROBLEM", 79, 101], ["heterogeneous", "OBSERVATION_MODIFIER", 79, 92]]], ["A number of Schiff base complexes exhibit important applications in reduction of alkylation of allylic substrates and ketones to alcohols [184] .", [["Schiff", "CHEMICAL", 12, 18], ["ketones", "CHEMICAL", 118, 125], ["Schiff base", "CHEMICAL", 12, 23], ["ketones", "CHEMICAL", 118, 125], ["alcohols", "CHEMICAL", 129, 137], ["allylic substrates", "SIMPLE_CHEMICAL", 95, 113], ["ketones", "SIMPLE_CHEMICAL", 118, 125], ["alcohols [184]", "SIMPLE_CHEMICAL", 129, 143], ["Schiff base complexes", "TREATMENT", 12, 33], ["important applications", "TREATMENT", 42, 64], ["alkylation of allylic substrates", "TREATMENT", 81, 113], ["Schiff base complexes", "OBSERVATION", 12, 33]]], ["The complexes of Fe, Co, Ni, and Zn with Schiff bases play the significant role in the oligomerization of ethylene [185] .", [["Fe", "CHEMICAL", 17, 19], ["Co", "CHEMICAL", 21, 23], ["Ni", "CHEMICAL", 25, 27], ["Zn", "CHEMICAL", 33, 35], ["Schiff", "CHEMICAL", 41, 47], ["ethylene", "CHEMICAL", 106, 114], ["Fe", "CHEMICAL", 17, 19], ["Co", "CHEMICAL", 21, 23], ["Ni", "CHEMICAL", 25, 27], ["Zn", "CHEMICAL", 33, 35], ["Schiff bases", "CHEMICAL", 41, 53], ["ethylene", "CHEMICAL", 106, 114], ["Fe", "SIMPLE_CHEMICAL", 17, 19], ["Co, Ni,", "SIMPLE_CHEMICAL", 21, 28], ["Zn", "SIMPLE_CHEMICAL", 33, 35], ["Schiff bases", "SIMPLE_CHEMICAL", 41, 53], ["ethylene [185]", "SIMPLE_CHEMICAL", 106, 120], ["Schiff bases", "TREATMENT", 41, 53], ["Schiff bases", "OBSERVATION", 41, 53], ["significant", "OBSERVATION_MODIFIER", 63, 74]]], ["The metal salen complexes were used as catalyst efficiently in Michael addition reaction [186] .Miscellaneous applicationsSome metal complexes exhibit catalytic activity on oxidation of ascorbic acid and decomposition of hydrogen peroxide [187] .", [["ascorbic acid", "CHEMICAL", 186, 199], ["hydrogen peroxide", "CHEMICAL", 221, 238], ["metal salen", "CHEMICAL", 4, 15], ["ascorbic acid", "CHEMICAL", 186, 199], ["hydrogen peroxide", "CHEMICAL", 221, 238], ["metal salen complexes", "SIMPLE_CHEMICAL", 4, 25], ["ascorbic acid", "SIMPLE_CHEMICAL", 186, 199], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 221, 238], ["The metal salen complexes", "TREATMENT", 0, 25], ["Miscellaneous applications", "TREATMENT", 96, 122], ["Some metal complexes", "PROBLEM", 122, 142], ["ascorbic acid", "TREATMENT", 186, 199], ["hydrogen peroxide", "TREATMENT", 221, 238], ["metal complexes", "OBSERVATION", 127, 142], ["catalytic activity", "OBSERVATION", 151, 169]]], ["The heteroannulation reaction by using the Schiff base metal complexes as catalyst has been an area of current research [188] .", [["Schiff base", "CHEMICAL", 43, 54], ["The heteroannulation reaction", "PROBLEM", 0, 29], ["the Schiff base metal complexes", "TREATMENT", 39, 70], ["area", "OBSERVATION_MODIFIER", 95, 99]]], ["Usually the ring opening of large cycloalkane is a very difficult process, but in this reaction, Co (II) and Cr (III) Schiff base complexes were effective with considerable enantioselectivity [189, 190] .", [["cycloalkane", "CHEMICAL", 34, 45], ["Co (II", "CHEMICAL", 97, 103], ["Cr", "CHEMICAL", 109, 111], ["cycloalkane", "CHEMICAL", 34, 45], ["Co (II)", "CHEMICAL", 97, 104], ["Cr (III)", "CHEMICAL", 109, 117], ["Schiff base", "CHEMICAL", 118, 129], ["cycloalkane", "SIMPLE_CHEMICAL", 34, 45], ["Co (II)", "SIMPLE_CHEMICAL", 97, 104], ["Cr (III) Schiff base complexes", "SIMPLE_CHEMICAL", 109, 139], ["large cycloalkane", "PROBLEM", 28, 45], ["a very difficult process", "PROBLEM", 49, 73], ["this reaction", "PROBLEM", 82, 95], ["Cr (III) Schiff base complexes", "PROBLEM", 109, 139], ["ring", "OBSERVATION_MODIFIER", 12, 16], ["large", "OBSERVATION_MODIFIER", 28, 33], ["cycloalkane", "OBSERVATION", 34, 45]]], ["Schiff bases act as an electrical conductor and having various applications as they are used as catalysts in photoelectrochemical processes, microelectronic equipment and electrode materials, organic batteries, or electrochromic display device [48] .Miscellaneous applicationsN,N-bis(3-methylsalicylidene)-ortho-phenylenediamine (MSOPD) acts as a chromogenic reagent for the spectrophotometric determination of Nickel in some food and other natural samples [191] .", [["N-bis(3-methylsalicylidene)-ortho-phenylenediamine", "CHEMICAL", 278, 328], ["MSOPD", "CHEMICAL", 330, 335], ["Nickel", "CHEMICAL", 411, 417], ["Schiff bases", "CHEMICAL", 0, 12], ["N-bis(3-methylsalicylidene)-ortho-phenylenediamine", "CHEMICAL", 278, 328], ["MSOPD", "CHEMICAL", 330, 335], ["Nickel", "CHEMICAL", 411, 417], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["N-bis(3-methylsalicylidene)-ortho-phenylenediamine", "SIMPLE_CHEMICAL", 278, 328], ["MSOPD", "SIMPLE_CHEMICAL", 330, 335], ["Nickel", "SIMPLE_CHEMICAL", 411, 417], ["an electrical conductor", "TREATMENT", 20, 43], ["various applications", "TREATMENT", 55, 75], ["microelectronic equipment and electrode materials", "TREATMENT", 141, 190], ["organic batteries", "TREATMENT", 192, 209], ["electrochromic display device", "TREATMENT", 214, 243], ["Miscellaneous applicationsN", "TREATMENT", 250, 277], ["bis", "TEST", 280, 283], ["methylsalicylidene", "TREATMENT", 286, 304], ["ortho-phenylenediamine (MSOPD)", "TREATMENT", 306, 336], ["a chromogenic reagent", "TREATMENT", 345, 366], ["the spectrophotometric determination", "TEST", 371, 407]]], ["Schiff base derived from salicylaldehyde and diamine, and its cobalt complexes have been shown to be light resistance as well as have storage ability and such complexes do not degrade even in acidic gases (CO 2 ) [192] .", [["salicylaldehyde", "CHEMICAL", 25, 40], ["diamine", "CHEMICAL", 45, 52], ["cobalt", "CHEMICAL", 62, 68], ["Schiff base", "CHEMICAL", 0, 11], ["salicylaldehyde", "CHEMICAL", 25, 40], ["diamine", "CHEMICAL", 45, 52], ["cobalt", "CHEMICAL", 62, 68], ["CO 2 )", "CHEMICAL", 206, 212], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["salicylaldehyde", "SIMPLE_CHEMICAL", 25, 40], ["diamine", "SIMPLE_CHEMICAL", 45, 52], ["cobalt complexes", "SIMPLE_CHEMICAL", 62, 78], ["Schiff base", "TEST", 0, 11], ["salicylaldehyde", "TREATMENT", 25, 40], ["diamine", "TREATMENT", 45, 52], ["its cobalt complexes", "TREATMENT", 58, 78], ["acidic gases", "TEST", 192, 204], ["light resistance", "OBSERVATION", 101, 117]]], ["Metal complexes containing azo groups are used for dying cellulose polyester textiles [193] , e.g. chromium azomethine complexes and un-symmetrical chromium complexes act as dyes, and they give fast color to wools, leathers, food packages, etc [194, 195] .", [["azo", "CHEMICAL", 27, 30], ["cellulose polyester textiles [193", "CHEMICAL", 57, 90], ["chromium", "CHEMICAL", 99, 107], ["chromium", "CHEMICAL", 148, 156], ["azo", "CHEMICAL", 27, 30], ["polyester", "CHEMICAL", 67, 76], ["chromium azomethine", "CHEMICAL", 99, 118], ["chromium", "CHEMICAL", 148, 156], ["azo groups", "SIMPLE_CHEMICAL", 27, 37], ["cellulose", "SIMPLE_CHEMICAL", 57, 66], ["[193]", "SIMPLE_CHEMICAL", 86, 91], ["chromium azomethine complexes", "SIMPLE_CHEMICAL", 99, 128], ["un-symmetrical chromium complexes", "SIMPLE_CHEMICAL", 133, 166], ["Metal complexes containing azo groups", "TREATMENT", 0, 37], ["dying cellulose polyester textiles", "TREATMENT", 51, 85], ["chromium azomethine complexes", "TREATMENT", 99, 128], ["un-symmetrical chromium complexes", "TREATMENT", 133, 166], ["azo groups", "OBSERVATION", 27, 37]]], ["There are reports that some thio and phenylthiosemicarbazones can be used as analytical reagents for the detection of variety of metal ions in different environmental samples, such as water, soil, human blood, leafy vegetables, medicinal leaves, etc., as well as in pharmaceutical samples.", [["samples", "ANATOMY", 167, 174], ["blood", "ANATOMY", 203, 208], ["leafy vegetables", "ANATOMY", 210, 226], ["leaves", "ANATOMY", 238, 244], ["phenylthiosemicarbazones", "CHEMICAL", 37, 61], ["thio and phenylthiosemicarbazones", "CHEMICAL", 28, 61], ["thio", "SIMPLE_CHEMICAL", 28, 32], ["phenylthiosemicarbazones", "SIMPLE_CHEMICAL", 37, 61], ["metal ions", "SIMPLE_CHEMICAL", 129, 139], ["human", "ORGANISM", 197, 202], ["blood", "ORGANISM_SUBSTANCE", 203, 208], ["leafy", "ORGANISM_SUBDIVISION", 210, 215], ["vegetables", "ORGANISM_SUBDIVISION", 216, 226], ["leaves", "ORGANISM_SUBDIVISION", 238, 244], ["human", "SPECIES", 197, 202], ["human", "SPECIES", 197, 202], ["some thio and phenylthiosemicarbazones", "TREATMENT", 23, 61], ["analytical reagents", "TREATMENT", 77, 96], ["the detection", "TEST", 101, 114], ["metal ions", "TREATMENT", 129, 139]]], ["Narayan et al. [196] have used benzyloxybenzaldehydethio-semicarbazone (BBTSC) as a complexing agent for the selective and sensitive determination of Cu (II) in food and water samples.", [["benzyloxybenzaldehydethio-semicarbazone", "CHEMICAL", 31, 70], ["BBTSC", "CHEMICAL", 72, 77], ["Cu (II", "CHEMICAL", 150, 156], ["benzyloxybenzaldehydethio-semicarbazone", "CHEMICAL", 31, 70], ["BBTSC", "CHEMICAL", 72, 77], ["Cu (II)", "CHEMICAL", 150, 157], ["benzyloxybenzaldehydethio-semicarbazone", "SIMPLE_CHEMICAL", 31, 70], ["BBTSC", "SIMPLE_CHEMICAL", 72, 77], ["Cu (II", "SIMPLE_CHEMICAL", 150, 156], ["benzyloxybenzaldehydethio", "TREATMENT", 31, 56], ["semicarbazone (BBTSC)", "TREATMENT", 57, 78], ["a complexing agent", "TREATMENT", 82, 100]]], ["It was reported that BBTSC is the best reagent for the extractive spectrophotometric determination of Cu (II) as compared with other spectrophotometric techniques reported earlier.", [["BBTSC", "CHEMICAL", 21, 26], ["Cu (II", "CHEMICAL", 102, 108], ["Cu (II)", "CHEMICAL", 102, 109], ["BBTSC", "SIMPLE_CHEMICAL", 21, 26], ["Cu (II", "SIMPLE_CHEMICAL", 102, 108], ["the extractive spectrophotometric determination", "TEST", 51, 98], ["other spectrophotometric techniques", "TEST", 127, 162]]], ["Similarly, Rao et al. [197] have reported 2-acetylthiophene thiosemicarbazone (ATT) which act as a ligand for the spectrophotometric determination of Cu (II) from edible oils and alloys.", [["oils", "ANATOMY", 170, 174], ["2-acetylthiophene thiosemicarbazone", "CHEMICAL", 42, 77], ["Cu (II", "CHEMICAL", 150, 156], ["2-acetylthiophene thiosemicarbazone", "CHEMICAL", 42, 77], ["ATT", "CHEMICAL", 79, 82], ["Cu (II)", "CHEMICAL", 150, 157], ["2-acetylthiophene thiosemicarbazone", "SIMPLE_CHEMICAL", 42, 77], ["ATT", "SIMPLE_CHEMICAL", 79, 82], ["Cu (II", "SIMPLE_CHEMICAL", 150, 156], ["2-acetylthiophene thiosemicarbazone", "TREATMENT", 42, 77], ["the spectrophotometric determination", "TEST", 110, 146]]], ["Extractive spectrophotometric method has been reported based on benzyldithiosemicarbazone (BDT) for determination of micro amounts of Ni (II) in nichrome wire and chromium steel owing to formation of yellowish-orange complex with Ni (II) salt at pH 9 [198] .", [["benzyldithiosemicarbazone", "CHEMICAL", 64, 89], ["BDT", "CHEMICAL", 91, 94], ["Ni (II", "CHEMICAL", 134, 140], ["chromium", "CHEMICAL", 163, 171], ["Ni (II", "CHEMICAL", 230, 236], ["benzyldithiosemicarbazone", "CHEMICAL", 64, 89], ["BDT", "CHEMICAL", 91, 94], ["Ni (II)", "CHEMICAL", 134, 141], ["chromium", "CHEMICAL", 163, 171], ["Ni (II)", "CHEMICAL", 230, 237], ["benzyldithiosemicarbazone", "SIMPLE_CHEMICAL", 64, 89], ["BDT", "SIMPLE_CHEMICAL", 91, 94], ["Ni (II", "SIMPLE_CHEMICAL", 134, 140], ["nichrome wire", "SIMPLE_CHEMICAL", 145, 158], ["chromium steel", "SIMPLE_CHEMICAL", 163, 177], ["Ni (II) salt", "SIMPLE_CHEMICAL", 230, 242], ["Extractive spectrophotometric method", "TEST", 0, 36], ["benzyldithiosemicarbazone", "TREATMENT", 64, 89], ["Ni (II) in nichrome wire and chromium steel", "TREATMENT", 134, 177], ["yellowish-orange complex", "PROBLEM", 200, 224], ["salt at pH", "TEST", 238, 248], ["chromium steel", "OBSERVATION", 163, 177], ["yellowish", "OBSERVATION_MODIFIER", 200, 209]]], ["Similarly, Reddy et al. [199] have studied 2,6-diacetylpyridine bis-4-phenyl-3-thiosemicarbazone (2,6-DAPBPTSC) (129) (Scheme 30) for the extractive spectrophotometric determination of Co (II) in vegetable, water, soil and standard alloy samples.", [["vegetable", "ANATOMY", 196, 205], ["2,6-diacetylpyridine bis-4-phenyl-3-thiosemicarbazone", "CHEMICAL", 43, 96], ["2,6-DAPBPTSC", "CHEMICAL", 98, 110], ["Co (II", "CHEMICAL", 185, 191], ["2,6-diacetylpyridine bis-4-phenyl-3-thiosemicarbazone", "CHEMICAL", 43, 96], ["2,6-DAPBPTSC", "CHEMICAL", 98, 110], ["Co (II)", "CHEMICAL", 185, 192], ["2,6-diacetylpyridine bis-4-phenyl-3-thiosemicarbazone", "SIMPLE_CHEMICAL", 43, 96], ["2,6-DAPBPTSC", "SIMPLE_CHEMICAL", 98, 110], ["Co (II", "SIMPLE_CHEMICAL", 185, 191], ["vegetable", "ORGANISM_SUBDIVISION", 196, 205], ["water", "SIMPLE_CHEMICAL", 207, 212], ["diacetylpyridine bis", "TREATMENT", 47, 67], ["phenyl", "TREATMENT", 70, 76], ["thiosemicarbazone", "TREATMENT", 79, 96], ["the extractive spectrophotometric determination", "TEST", 134, 181], ["standard alloy samples", "TREATMENT", 223, 245]]], ["2,6-DAPBPTSC forms reddish brown complex with Co (II) which is easily extracted into isoamylalcohol.", [["2,6-DAPBPTSC", "CHEMICAL", 0, 12], ["Co (II", "CHEMICAL", 46, 52], ["isoamylalcohol", "CHEMICAL", 85, 99], ["2,6-DAPBPTSC", "CHEMICAL", 0, 12], ["Co (II)", "CHEMICAL", 46, 53], ["isoamylalcohol", "CHEMICAL", 85, 99], ["2,6-DAPBPTSC", "SIMPLE_CHEMICAL", 0, 12], ["Co (II)", "SIMPLE_CHEMICAL", 46, 53], ["isoamylalcohol", "SIMPLE_CHEMICAL", 85, 99], ["isoamylalcohol", "TREATMENT", 85, 99], ["reddish", "OBSERVATION_MODIFIER", 19, 26], ["brown complex", "OBSERVATION_MODIFIER", 27, 40]]], ["Imine derivatives can be exerted to obtain conductive polymers.", [["Imine", "CHEMICAL", 0, 5], ["Imine", "CHEMICAL", 0, 5], ["Imine derivatives", "SIMPLE_CHEMICAL", 0, 17], ["Imine derivatives", "TREATMENT", 0, 17], ["conductive polymers", "TREATMENT", 43, 62]]], ["Tridentate Schiff base and their organo-cobalt complexes act as initiator of emulsion polymerization and co-polymerization of dienyl and vinyl monomers [200] .", [["Tridentate Schiff", "CHEMICAL", 0, 17], ["cobalt", "CHEMICAL", 40, 46], ["dienyl", "CHEMICAL", 126, 132], ["Schiff base", "CHEMICAL", 11, 22], ["organo-cobalt", "CHEMICAL", 33, 46], ["dienyl", "CHEMICAL", 126, 132], ["vinyl", "CHEMICAL", 137, 142], ["Tridentate Schiff base", "SIMPLE_CHEMICAL", 0, 22], ["organo-cobalt complexes", "SIMPLE_CHEMICAL", 33, 56], ["emulsion", "SIMPLE_CHEMICAL", 77, 85], ["dienyl", "SIMPLE_CHEMICAL", 126, 132], ["vinyl monomers [200]", "SIMPLE_CHEMICAL", 137, 157], ["Tridentate Schiff base", "TREATMENT", 0, 22], ["their organo-cobalt complexes act", "TREATMENT", 27, 60], ["emulsion polymerization", "TREATMENT", 77, 100], ["dienyl and vinyl monomers", "TREATMENT", 126, 151]]], ["The amine terminated liquid natural rubber (ATNR) is synthesized when photochemical degradation of natural rubber is carried out in solution in presence of ethylenediamine.", [["amine", "CHEMICAL", 4, 9], ["ATNR", "CHEMICAL", 44, 48], ["ethylenediamine", "CHEMICAL", 156, 171], ["amine", "CHEMICAL", 4, 9], ["ethylenediamine", "CHEMICAL", 156, 171], ["amine", "SIMPLE_CHEMICAL", 4, 9], ["ATNR", "SIMPLE_CHEMICAL", 44, 48], ["ethylenediamine", "SIMPLE_CHEMICAL", 156, 171], ["photochemical degradation of natural rubber", "TREATMENT", 70, 113], ["ethylenediamine", "TREATMENT", 156, 171], ["liquid", "OBSERVATION_MODIFIER", 21, 27], ["natural rubber", "OBSERVATION", 28, 42], ["natural rubber", "OBSERVATION", 99, 113]]], ["The poly Schiff base derived by the reaction of ATNR with glyoxal, improves aging resistance as they act as metal deactivator [201] .", [["poly Schiff", "CHEMICAL", 4, 15], ["ATNR", "CHEMICAL", 48, 52], ["glyoxal", "CHEMICAL", 58, 65], ["poly Schiff base", "CHEMICAL", 4, 20], ["ATNR", "CHEMICAL", 48, 52], ["glyoxal", "CHEMICAL", 58, 65], ["poly Schiff", "SIMPLE_CHEMICAL", 4, 15], ["ATNR", "SIMPLE_CHEMICAL", 48, 52], ["glyoxal", "SIMPLE_CHEMICAL", 58, 65], ["The poly Schiff base", "PROBLEM", 0, 20], ["ATNR", "PROBLEM", 48, 52], ["glyoxal", "TREATMENT", 58, 65], ["poly", "OBSERVATION", 4, 8], ["Schiff base", "OBSERVATION", 9, 20]]], ["Transition metal complexes with 1, 10phenanthroline and 2, 2-bipyridine are used in petroleum refining [202] .", [["1, 10phenanthroline", "CHEMICAL", 32, 51], ["2, 2-bipyridine", "CHEMICAL", 56, 71], ["1, 10phenanthroline", "CHEMICAL", 32, 51], ["2, 2-bipyridine", "CHEMICAL", 56, 71], ["1, 10phenanthroline", "SIMPLE_CHEMICAL", 32, 51], ["2, 2-bipyridine", "SIMPLE_CHEMICAL", 56, 71], ["petroleum", "SIMPLE_CHEMICAL", 84, 93], ["Transition metal complexes", "TREATMENT", 0, 26], ["phenanthroline", "TREATMENT", 37, 51], ["bipyridine", "TREATMENT", 61, 71]]], ["The chemistry of primary amines, thiols induced the separation of mammalian sperm head, and the similar action by pyridoxal shows that head and tail of sperm are connected by Schiff base which is formed between proteins inside the nuclear membrane [203] .", [["sperm head", "ANATOMY", 76, 86], ["head", "ANATOMY", 135, 139], ["sperm", "ANATOMY", 152, 157], ["nuclear membrane", "ANATOMY", 231, 247], ["amines", "CHEMICAL", 25, 31], ["thiols", "CHEMICAL", 33, 39], ["pyridoxal", "CHEMICAL", 114, 123], ["primary amines", "CHEMICAL", 17, 31], ["thiols", "CHEMICAL", 33, 39], ["pyridoxal", "CHEMICAL", 114, 123], ["Schiff base", "CHEMICAL", 175, 186], ["primary amines", "SIMPLE_CHEMICAL", 17, 31], ["thiols", "SIMPLE_CHEMICAL", 33, 39], ["sperm head", "MULTI-TISSUE_STRUCTURE", 76, 86], ["pyridoxal", "SIMPLE_CHEMICAL", 114, 123], ["head", "ORGANISM_SUBDIVISION", 135, 139], ["sperm", "ORGANISM_SUBSTANCE", 152, 157], ["nuclear membrane", "CELLULAR_COMPONENT", 231, 247], ["sperm", "CELL_TYPE", 152, 157], ["thiols", "TREATMENT", 33, 39], ["mammalian sperm head", "PROBLEM", 66, 86], ["pyridoxal", "TEST", 114, 123], ["head and tail of sperm", "PROBLEM", 135, 157], ["mammalian sperm", "OBSERVATION", 66, 81], ["head", "ANATOMY", 135, 139], ["tail", "ANATOMY", 144, 148], ["Schiff base", "OBSERVATION", 175, 186], ["nuclear membrane", "ANATOMY", 231, 247]]], ["Popova and Berova [204] have reported that copper is good for liver function as well as its level in blood and urine has influence in pregnancy disorders, nephritis hepatitis, leprosy, anemia, and leukemia in children.", [["liver", "ANATOMY", 62, 67], ["blood", "ANATOMY", 101, 106], ["urine", "ANATOMY", 111, 116], ["leukemia", "ANATOMY", 197, 205], ["copper", "CHEMICAL", 43, 49], ["pregnancy disorders", "DISEASE", 134, 153], ["nephritis hepatitis", "DISEASE", 155, 174], ["leprosy", "DISEASE", 176, 183], ["anemia", "DISEASE", 185, 191], ["leukemia", "DISEASE", 197, 205], ["copper", "CHEMICAL", 43, 49], ["copper", "SIMPLE_CHEMICAL", 43, 49], ["liver", "ORGAN", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["urine", "ORGANISM_SUBSTANCE", 111, 116], ["leukemia", "CANCER", 197, 205], ["children", "ORGANISM", 209, 217], ["children", "SPECIES", 209, 217], ["blood and urine", "TEST", 101, 116], ["pregnancy disorders", "PROBLEM", 134, 153], ["nephritis hepatitis", "PROBLEM", 155, 174], ["leprosy", "PROBLEM", 176, 183], ["anemia", "PROBLEM", 185, 191], ["leukemia", "PROBLEM", 197, 205], ["liver", "ANATOMY", 62, 67], ["nephritis", "OBSERVATION", 155, 164], ["leprosy", "OBSERVATION", 176, 183], ["anemia", "OBSERVATION", 185, 191], ["leukemia", "OBSERVATION", 197, 205]]], ["The effect of Cu (II) and Zn (II) complex with Schiff base, N-salicylaldehyde amino glucose inhibit synthesis of O 2 noticeably [205] .Miscellaneous applicationsMacrocyclic Schiff bases of dithiocarbazic acid have several essential biological functions such as transport of oxygen in mammalian and other respiratory systems and photosynthesis [206] .", [["Cu (II", "CHEMICAL", 14, 20], ["Zn", "CHEMICAL", 26, 28], ["N-salicylaldehyde amino glucose", "CHEMICAL", 60, 91], ["dithiocarbazic acid", "CHEMICAL", 189, 208], ["oxygen", "CHEMICAL", 274, 280], ["Cu (II)", "CHEMICAL", 14, 21], ["Zn (II)", "CHEMICAL", 26, 33], ["Schiff base", "CHEMICAL", 47, 58], ["N-salicylaldehyde amino glucose", "CHEMICAL", 60, 91], ["O 2", "CHEMICAL", 113, 116], ["Schiff bases", "CHEMICAL", 173, 185], ["dithiocarbazic acid", "CHEMICAL", 189, 208], ["oxygen", "CHEMICAL", 274, 280], ["Cu (II)", "SIMPLE_CHEMICAL", 14, 21], ["Zn (II)", "SIMPLE_CHEMICAL", 26, 33], ["Schiff base", "SIMPLE_CHEMICAL", 47, 58], ["N-salicylaldehyde amino glucose", "SIMPLE_CHEMICAL", 60, 91], ["O 2", "SIMPLE_CHEMICAL", 113, 116], ["dithiocarbazic acid", "SIMPLE_CHEMICAL", 189, 208], ["oxygen", "SIMPLE_CHEMICAL", 274, 280], ["Zn (II) complex", "PROTEIN", 26, 41], ["Cu (II) and Zn (II) complex with Schiff base", "TREATMENT", 14, 58], ["N-salicylaldehyde amino glucose inhibit synthesis", "TREATMENT", 60, 109], ["Miscellaneous applications", "TREATMENT", 135, 161], ["Macrocyclic Schiff bases of dithiocarbazic acid", "PROBLEM", 161, 208], ["transport of oxygen", "TREATMENT", 261, 280], ["Schiff bases", "OBSERVATION", 173, 185], ["essential", "OBSERVATION_MODIFIER", 222, 231], ["biological functions", "OBSERVATION", 232, 252]]], ["Cu (II) and Fe (II) forms chelates with amido Schiff bases which acts as a thrombin inhibitor [207] .", [["Cu (II", "CHEMICAL", 0, 6], ["Fe", "CHEMICAL", 12, 14], ["amido Schiff bases", "CHEMICAL", 40, 58], ["Cu (II)", "CHEMICAL", 0, 7], ["Fe (II)", "CHEMICAL", 12, 19], ["amido Schiff bases", "CHEMICAL", 40, 58], ["Cu (II)", "SIMPLE_CHEMICAL", 0, 7], ["Fe (II)", "SIMPLE_CHEMICAL", 12, 19], ["amido Schiff bases", "SIMPLE_CHEMICAL", 40, 58], ["thrombin", "GENE_OR_GENE_PRODUCT", 75, 83], ["thrombin", "PROTEIN", 75, 83], ["amido Schiff bases", "TREATMENT", 40, 58], ["a thrombin inhibitor", "TREATMENT", 73, 93]]], ["Transition metal (Mn (II), Ni (II), Cu (II), and Zn (II)) complexes with tetradentate Schiff base ligands exhibit miscellaneous effect on membrane in amylase productions.", [["membrane", "ANATOMY", 138, 146], ["Mn", "CHEMICAL", 18, 20], ["Ni", "CHEMICAL", 27, 29], ["Cu", "CHEMICAL", 36, 38], ["Zn", "CHEMICAL", 49, 51], ["tetradentate", "CHEMICAL", 73, 85], ["Transition metal", "CHEMICAL", 0, 16], ["Mn (II)", "CHEMICAL", 18, 25], ["Ni (II)", "CHEMICAL", 27, 34], ["Cu (II)", "CHEMICAL", 36, 43], ["Zn (II)", "CHEMICAL", 49, 56], ["Schiff base", "CHEMICAL", 86, 97], ["Mn (II)", "SIMPLE_CHEMICAL", 18, 25], ["Ni (II)", "SIMPLE_CHEMICAL", 27, 34], ["Cu (II)", "SIMPLE_CHEMICAL", 36, 43], ["Zn (II)", "SIMPLE_CHEMICAL", 49, 56], ["tetradentate Schiff base ligands", "SIMPLE_CHEMICAL", 73, 105], ["membrane", "CELLULAR_COMPONENT", 138, 146], ["amylase", "GENE_OR_GENE_PRODUCT", 150, 157], ["Zn (II)) complexes", "PROTEIN", 49, 67], ["amylase", "PROTEIN", 150, 157], ["Transition metal (Mn (II), Ni (II), Cu (II), and Zn (II)", "TREATMENT", 0, 56], ["tetradentate Schiff base ligands", "TREATMENT", 73, 105], ["miscellaneous effect", "PROBLEM", 114, 134], ["membrane in amylase productions", "PROBLEM", 138, 169], ["miscellaneous effect", "OBSERVATION", 114, 134]]], ["Mn (II) and Zn (II) complexes stimulated amylase transportation through membrane, while Ni (II) and Cu (II) complexes inhibited it.SummarySchiff bases have been reported for a long time and their applications have been mainly limited to chemistry of pharmaceutical importance (biological importance) and catalysis.", [["membrane", "ANATOMY", 72, 80], ["Mn", "CHEMICAL", 0, 2], ["Zn", "CHEMICAL", 12, 14], ["Ni", "CHEMICAL", 88, 90], ["Cu", "CHEMICAL", 100, 102], ["Mn (II)", "CHEMICAL", 0, 7], ["Zn (II)", "CHEMICAL", 12, 19], ["Ni (II)", "CHEMICAL", 88, 95], ["Cu (II)", "CHEMICAL", 100, 107], ["Mn (II)", "SIMPLE_CHEMICAL", 0, 7], ["Zn (II)", "SIMPLE_CHEMICAL", 12, 19], ["amylase", "GENE_OR_GENE_PRODUCT", 41, 48], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["Ni (II)", "SIMPLE_CHEMICAL", 88, 95], ["Cu (II)", "SIMPLE_CHEMICAL", 100, 107], ["Mn (II) and Zn (II) complexes", "PROTEIN", 0, 29], ["amylase", "PROTEIN", 41, 48], ["Ni (II) and Cu (II) complexes", "PROTEIN", 88, 117], ["Zn (II) complexes stimulated amylase transportation through membrane", "PROBLEM", 12, 80], ["Cu (II) complexes", "PROBLEM", 100, 117]]], ["In recent years, the scope of such compounds has broadened, and their new synthetic methodology has been evolved that are based on normal chemical reactions as well as by solid state reaction.", [["solid state reaction", "PROBLEM", 171, 191]]], ["Schiff bases and semicarbazones offer a variety in their coordination of vast majority of transition metals and therefore offer great potential as precursors for new generation nanomaterials of respective metal or their compound semiconductors.", [["semicarbazones", "CHEMICAL", 17, 31], ["Schiff bases", "CHEMICAL", 0, 12], ["semicarbazones", "CHEMICAL", 17, 31], ["Schiff bases", "SIMPLE_CHEMICAL", 0, 12], ["semicarbazones", "SIMPLE_CHEMICAL", 17, 31], ["metal", "SIMPLE_CHEMICAL", 205, 210], ["Schiff bases", "TREATMENT", 0, 12], ["semicarbazones", "TREATMENT", 17, 31], ["new generation nanomaterials of respective metal", "TREATMENT", 162, 210], ["bases", "ANATOMY_MODIFIER", 7, 12], ["compound semiconductors", "OBSERVATION", 220, 243]]], ["Imine ligands such as Schiff base, semicarbazones, and their derivatives have therefore been widely explored for catalytic, pharmacological, industrial, etc. applications.", [["Imine", "CHEMICAL", 0, 5], ["semicarbazones", "CHEMICAL", 35, 49], ["Imine", "CHEMICAL", 0, 5], ["Schiff base", "CHEMICAL", 22, 33], ["semicarbazones", "CHEMICAL", 35, 49], ["Schiff base", "SIMPLE_CHEMICAL", 22, 33], ["semicarbazones", "SIMPLE_CHEMICAL", 35, 49], ["Imine ligands", "PROBLEM", 0, 13], ["Schiff base", "TREATMENT", 22, 33], ["semicarbazones", "TREATMENT", 35, 49], ["Schiff base", "OBSERVATION", 22, 33]]], ["Schiff base ligands are considered as interesting ligand because of the ease of preparation with versatility and variable denticity.", [["Schiff base", "CHEMICAL", 0, 11], ["Schiff base ligands", "PROBLEM", 0, 19], ["variable denticity", "PROBLEM", 113, 131]]], ["Nowadays, Schiff base and their metal complexes are fascinating research topic that continuously provides us with new information about newly synthesized compounds.", [["Schiff base", "CHEMICAL", 10, 21], ["Schiff base", "CHEMICAL", 10, 21], ["Schiff base", "SIMPLE_CHEMICAL", 10, 21], ["newly synthesized compounds", "PROBLEM", 136, 163], ["Schiff base", "OBSERVATION", 10, 21]]], ["In this review, the biological, catalytic activity along with some miscellaneous applications of imine ligands and its metal complexes have been summarized taking the scope into materials chemistry directly or indirectly.", [["imine", "CHEMICAL", 97, 102], ["imine", "CHEMICAL", 97, 102], ["imine ligands", "SIMPLE_CHEMICAL", 97, 110], ["some miscellaneous applications of imine ligands", "TREATMENT", 62, 110], ["imine ligands", "OBSERVATION", 97, 110]]]]}